<SEC-DOCUMENT>0000950170-25-038751.txt : 20250313
<SEC-HEADER>0000950170-25-038751.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313161356
ACCESSION NUMBER:		0000950170-25-038751
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001327273
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39273
		FILM NUMBER:		25735918

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-373-4600

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	480 Biomedical, Inc.
		DATE OF NAME CHANGE:	20120927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Vascular, Inc.
		DATE OF NAME CHANGE:	20110826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Medical, Inc.
		DATE OF NAME CHANGE:	20090414
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lyra-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-13T15:31:03.8324+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:lyra="http://lyratherapeutics.com/20241231" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_16068dac-d0e7-4be3-8b2f-a9aa30ceff5e" name="dei:AmendmentFlag" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367">false</ix:nonNumeric><ix:nonNumeric id="F_d0a29375-54d1-4720-8e50-c58732727f53" name="dei:DocumentFiscalPeriodFocus" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367">FY</ix:nonNumeric><ix:nonNumeric id="F_19335553-f48f-4a14-a18e-87c61cff5766" name="dei:EntityCentralIndexKey" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367">0001327273</ix:nonNumeric><ix:nonFraction id="F_3f0045f0-3fff-4e61-b86a-d3810d5684d8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_05ec1fb1-1dd3-4023-b23a-af84bcab4881" name="us-gaap:CommitmentsAndContingencies" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_2511519b-36bc-46ee-8366-ebaa53d26f96" name="us-gaap:PreferredStockValue" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b343ec9f-148d-44d4-9d08-7d94b8644011" name="us-gaap:PreferredStockValue" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_9ae5f059-46cf-4fcf-b57c-b976764721ac" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_075aff53-3972-401b-9e57-6d6327e23180">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_12091721-daa6-4615-9374-7423de9475e8" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627">http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric id="F_d1514240-d93f-4827-833a-208926ab2d2a" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric id="F_37e2bd47-4207-458b-957f-6e4048e1644e" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627">http://fasb.org/us-gaap/2024#Liabilities</ix:nonNumeric><ix:nonNumeric id="F_88da49e1-0053-471c-838d-493a47149bc4" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_7574a635-981a-4973-932d-d749f0f65056" name="us-gaap:NumberOfOperatingSegments" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_97b57973-2894-41e7-86a2-433229fcba95" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_f8426778-65fb-4dfb-9474-719fbdef584a" format="ixt:date-monthname-day-year-en">April 30, 2027</ix:nonNumeric><ix:nonNumeric id="F_3543bcc5-79e8-4350-8931-cc3cab71a166" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_d910c3ca-d394-46d2-b9b9-f20df1877ad1" format="ixt:date-monthname-day-year-en">May 31, 2028</ix:nonNumeric><ix:nonNumeric id="F_8e41f92a-aad6-47ad-8661-51315d4fb579" name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="C_9efeb578-258e-4154-b77e-f69b4276c86d">2026-02-28</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lyra-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_81555852-032a-405b-bea2-d1c6de8074a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_852d2d00-74ce-4a20-9603-0c6650379dd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProfessionalConsultingAndPublicCompanyCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8550b4b7-6090-4399-a279-2b5260027481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lyra:DirectorsOrOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87370fcb-d580-4410-a3e9-579a2b1905ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_878fce79-96fc-484b-9c23-1738cf8a0491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8902a605-b72c-4739-9074-c30c2e4cb614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8952cd7b-48b7-4b53-b987-499c3555124b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lyra:CorporateBondsAndUSGovernmentAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89f8a662-2ae4-4167-b545-3e7a39f90636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8aa217c6-fd0c-4938-960a-3d90887e55a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bdf4601-233d-4b5c-9cfd-097e16ea264c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d8c6d11-dc4c-4661-b6b8-cede22d16893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ee2d39b-2034-44ea-b1f5-705ee63ae9c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ee3e41f-03f7-4449-99b7-ef89d56d7c11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fdbc5a2-8bc0-4cc9-afb3-fd47c4ae421c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90ccd445-a844-45e9-b76b-f02a4964792a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91222020-6393-4cde-8a28-5ea0bed8fcc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_912b5ea1-01e3-4044-a2e8-d7c9eccbc5d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92a8bd8f-ce57-4c0b-b9ef-52a50d85cf30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_940df23c-7acd-4b4c-a6d5-71d0b545b62d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_975bc4bf-e956-4689-baa6-6102f1379b64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9780270b-2928-4f2c-b42b-5d857b4e3091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98b8817f-6678-4071-a244-b8d90ff8d269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9927410f-0750-4aef-8f2e-4c0203df94da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_998603de-c72b-41d7-8c9d-fb71a4c5e1ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b8e7f3e-8fcd-405a-b6ca-6a57fd5e4161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c633c20-1b3c-4fcd-b70d-356063ad8dac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cce6eb7-717c-4284-9f9d-cca47171b6d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d4d7017-c77e-41be-bd4b-9129608b3d28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dafe4ac-e499-43b9-b4cf-d9a535621146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e1ba78d-a7e7-44eb-af47-1f204e97c03c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e7ffac5-3543-48db-a285-11bbd13c936d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9eeb8171-b971-4290-a284-8d735eff90bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9efb24d1-b674-4307-b0ea-d333f2bc6075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9efeb578-258e-4154-b77e-f69b4276c86d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-10</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0d4bd0f-380a-404f-bad2-a0ba8fbdde35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1b363ff-1904-4c03-9f49-1ead948fba72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a26c186e-cfe1-4434-9835-0bc963d20468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:FacilitiesSupportCostsAndDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2fba259-de87-46a2-af48-98b719cf4dc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a43bd8f3-4538-44af-b61c-9114bcf4aa13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a48e6107-bffc-483d-bc1d-dc2f272feed2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a797757c-a0d8-4b41-bca5-e4ece3661b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ClinicalRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8a81857-3883-412f-b823-244b5789543e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a98e409f-d6f8-4b16-b04c-f09c481c5882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa987057-5b50-4f91-90e6-77882dbd1aa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab9d9d05-16a2-48db-a97a-38ad01878ef2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac38a720-8b0c-448e-b389-9c66f5e57c87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac5f170e-0fde-48cb-9c0b-b5694cb0083b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adb4e732-d095-4cf9-b014-91975b0e1ae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aee49c45-4ce0-46b0-9eab-9386fa9c46b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afa65958-5848-4204-a888-f0ed623910ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0c1652c-3b2c-4e34-a9b2-16cba734c265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b279e47d-9fb2-49d6-8595-a8c376f75802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3a5054d-64cd-44f8-a695-70cc465ba03f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5cd3428-6f7e-489b-acb9-7fc886586ef5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b66b293d-ec8e-437b-afad-20466ee88490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b738c303-1ab5-4ff7-a680-7afbc47dc33f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProductDevelopmentAndManufacturingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b75ec916-9f93-4a03-9cb4-7b9f5bdceb2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7855080-4b7e-4605-886c-ba8da30b5934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7f4b320-3537-4193-801c-2cf634165bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-14</xbrli:startDate><xbrli:endDate>2025-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8f88f49-0e89-489b-92ff-51d33224124a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9710e1e-df0a-491d-918a-4327c625d8b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b980fa59-4978-4912-9bfb-143801b491d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b98307c7-4168-47d7-8b20-2ca01548fdde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bae57fb9-3c5f-471b-8356-fd251e1c7251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd367419-34c7-4e6d-83a8-87b37d35c96d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bed6c948-c9d7-4d57-84ac-6b989ca8e7ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf0500da-2915-422d-95b0-080c64f50c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf748116-4ebf-40ac-bff9-35c1fb5ed691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c244cff9-72f9-43c0-88c4-5e6a576e390e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3eef231-3463-425d-ba3f-d63c4ce2d6c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5d324f4-4968-4ffb-aaf4-47d647da0f16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c78c329e-4f11-4535-afbf-fbe8ac79582c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c83768e3-f530-46bd-8293-57a4d5a51a00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c83cc782-1381-485a-9d57-319e02ec88af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8d88912-cb32-4c79-b82d-9539702398aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9a482dc-f5d4-4994-8462-78e8c22a8165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-16</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9aae08b-647b-4917-91f5-0e67b5b4eb3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc81d85d-e11e-47ff-961c-df0bcedd5b2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d20093d0-99e7-48dd-9fa7-66b19c3ada23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2768b5c-c610-479e-8af2-6fa1c6059d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d72020a2-3023-4259-93b5-fa4a7d8ad386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d910c3ca-d394-46d2-b9b9-f20df1877ad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db5a6c2b-f92c-47a4-ab60-53c0ab05b473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lyra:ExecutiveChairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc75a67e-1185-42e1-9806-ae25f1f18a50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_def1fd73-fa5d-4a76-865c-950530caac65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0489a50-b282-48d4-b174-d58246a172cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e06c0d9f-3e71-41ea-b315-fd20df7409c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e09c71d4-5382-4588-a92f-344a3170a726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2a3c196-b3fe-487a-9820-f84bfac368b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4300f24-db1f-4970-b3ac-f88865d19c63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4a10c0f-30eb-47c6-8e2d-589710e6957f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lyra:RetentionCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4f2d1ea-5751-43a3-bf6a-e61453470a6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e71c57da-121c-464c-96b3-6536e9e26bf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7c9223a-fe0f-484a-a091-15fcc055e486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-15</xbrli:startDate><xbrli:endDate>2023-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8ac4fa7-d460-485e-ae33-045deec8d365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea185583-d49f-485e-8484-bcaef81144b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-21</xbrli:startDate><xbrli:endDate>2023-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed18e4b7-9e3c-4404-ad65-960cbb74cdd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed6610c5-7cef-4bd0-969d-825c8bae251e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef0c2d84-5760-4d06-a7b6-be126708a7ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eff1908e-cf95-479e-8a29-8ae67fd4d38a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f24af48f-4786-4931-9dfc-97f5f94468c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3bee2ff-cc2b-4188-9e55-bdfb437d68be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f60732e7-7b49-4546-becf-89f740a96713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f67b2471-5de2-454c-9767-81619473f71a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6b0dc2d-d4c0-4391-b0ee-c716dc85497d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8426778-65fb-4dfb-9474-719fbdef584a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f87955f6-4893-487d-8bee-6137b9aa2886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8c3db8c-4348-48f7-88f6-6a511886b8fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">lyra:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f932f338-d1f5-448c-91af-c2103ea85652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa285bde-8794-43cc-8482-2a6c0a625a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa9efc50-d605-4083-8ab3-4094e47aab16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb455e7c-310e-4d3f-9d79-4891ad9dd188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb525548-f539-4b57-ad61-75d734fd08a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPerformanceOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc7e6c54-5f68-4b31-8c26-243187e6b327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcf36a73-5344-415f-b95c-0bbadc656fc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feffa18a-b969-4f5f-82cd-f03ad737e8a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00c29fcf-7ef3-41c1-8925-61f5bbf063ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00ea0f69-39f1-4cdd-88c1-1015ba40c9e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_027852d4-18db-4239-a7cd-a51806d8be2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03789e9c-f8d7-4c13-837e-8c8982eaf153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05ee597b-300a-4f1d-950d-07a44282f29e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06ac994e-b8ce-41c9-80a2-2431128712fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProductDevelopmentAndManufacturingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_075aff53-3972-401b-9e57-6d6327e23180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_087ed0ac-1d0a-422c-a84f-3b93f915fd09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:OptionToExerciseStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0898fa9d-b760-4363-9f56-f980685e0512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09a0cae9-fe57-4508-94a6-ac09c28407d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a039f52-1a66-4979-9a5e-3989a5131b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a16c01a-3d42-4b14-9dcc-312ac1b87eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a1ce932-422a-495f-ae97-fa5f565abba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b25fafa-9dbd-4d21-b6f2-54c2f0bc249a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cf2e5c8-0ff5-4308-a0e2-b02e0055df23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0db4beff-330a-45de-8b43-98f81b33e6dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e5ac7b0-8d8f-42a9-ae36-22c91da28b12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10cb439a-3f2a-42fe-9173-724723bcd311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_114bbe38-9e67-4a2b-8b86-6fa6b5de33e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13349549-b2ec-4e54-b662-5d13b5935fbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lyra:MariaPalasisPhDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_194bf10a-3e96-4e60-85a1-7fac540a46ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1afebb99-1342-4fb9-b854-e7c6117b6e01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b2977bb-aa44-4677-a4ee-e38cdd9f5f8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b6f6f65-0092-4f48-84e8-9f5ef718920d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b70f3eb-a7d2-4546-8d83-3cc0e6a2bdef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cdb38d7-d16f-4ad8-9875-be4af848c0cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d3cffed-7156-4809-98e0-2a0d5179fc6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1db39547-aa48-42b8-8c47-2ef94db71901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e1030b6-cab3-4405-83f8-f89b4d6c3751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eedc30a-cbfb-49da-8177-e51404827448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ff01a7e-0054-4803-8549-b1cb6948ee4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2053b9ce-487a-41c5-8660-4c6a0ff5d60c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_234874bf-c13c-4027-9389-b0792e0ac2ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:FacilitiesSupportCostsAndDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_240704ca-648b-4cb8-8da2-42d785c931ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_251f3b55-1dd2-4781-ac6d-0744e7ac38e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2660b123-4ea6-43ac-8972-4157c6a3c040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-21</xbrli:startDate><xbrli:endDate>2023-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2801a74a-99e4-4308-a905-51778ab0e93c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:FinancingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_280682ef-880f-4702-8298-d09656436400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:LegalSettlementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_281acdc8-b177-4854-8880-10164275dc04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2908a678-6f00-4335-9ad2-8248e7e3b60b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ea1e700-e522-466c-b768-f653aab494c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f8edc3c-5429-4955-94db-7cf00859aeda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31f58a76-705e-4546-91b9-77d2761bcc2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32d5f8cc-4a3c-458b-8470-64a2b106b53b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_333d0a42-02ed-432e-82bf-5297563b9a25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3468569a-416b-4f26-96d4-911b0ce51a8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_346d080b-939c-4205-b5bb-6f8ce864f627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37068379-d31d-4d98-a4d1-2e6f4f1ef031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_372a66a4-61dd-407b-a6a2-2b15c95d67ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37541621-a0f6-46b9-a350-96d677fcfc2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3921f74d-c549-48e7-9cfe-f514102c6219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_397e0276-799b-4130-992e-a0f2da30c71c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a120243-ed89-4f6b-be0c-34e7f9595719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a371107-2d9a-4f5c-8c37-b98e3086c62c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c311591-1876-4a38-97cd-e253457c022f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lyra:ImpairmentOfRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cfae322-7814-406b-94d8-6c27a76311a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d311cd5-55b8-42d3-8218-5c0087ca6b10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3db47ea0-1f9a-4383-be26-a1363ba1cbea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3db95ee5-7b8d-409d-bb0f-d7092ea5f6f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_403a3ca8-bf23-400e-b0db-4d041b2b8b46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40f95a2d-f39f-40de-84f9-da9cf7468367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4175d822-423f-49b4-b933-6156169f74f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_420d91c9-ecfc-4744-a255-788637fcb6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_433f45f3-222a-4c22-aadf-b142c5221803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4489b4bf-2198-4ebe-a1bf-695353f66282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45126bd5-3587-4e96-98ac-59bdd46c63ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45156f90-0a3a-42c8-9a1d-54c60279f926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_473aaaff-01e3-4509-bda8-ca01929294c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_478d5703-d418-4d23-b8de-ef04cf2df0c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47fa54a6-2356-4b08-84c8-0df296adece4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_488bc5f4-10ce-45bb-95b7-d15c658c6b6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4969eb83-d672-422a-8e4f-a3bcb59d12f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49c96c91-10ba-4114-a86d-ac6dc268373f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a249401-3b7d-46fd-80ef-cb608151b1c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b8292bd-93d8-4684-8cfe-8f2b9dd35c42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce73bf9-81de-427b-88a0-9148395b04ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d2b77e5-3c41-49f6-87a3-e99ca4394a5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dc62508-709f-473e-ba30-98fa0a06a2b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e3aa3ed-daf5-453c-8203-7ffec41710a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ClinicalRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fa89b2f-0fcf-42bb-8c6c-336ddd1b20ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5422cf85-ab34-4c8d-83a9-3f689e53bb52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57cb61d3-40d3-48d2-9f7a-c577d8ec047d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:EmployeeRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57fb40b9-1300-49dd-abdb-a8199037cd9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5813d5de-532a-4e0e-af8e-993c31bd435f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5958571f-14a8-4ff8-a57a-1abe43eab75e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a610f2d-1ed4-4ce1-9e6a-09068ac8d582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_605136ee-faca-4595-aa05-236b9cffe793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6137d41a-fa82-43b5-b6fb-bc98341150d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61649002-24c3-41d8-9ae0-4fc54a732edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61c081e9-803b-4a01-830c-fe9cae97644d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_626e5a02-1411-4526-aa75-ce7297c15f35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62e1129c-aef1-4103-970b-5c338ee35c24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6418a52e-c88f-4b7e-b4d3-3e67f8c4d58d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67686643-4752-4ca8-a5d1-4b5b2a07cb16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68ef0c58-1c01-442d-9687-3c37bfae23d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lyra:MariaPalasisPhDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69975709-688b-4d92-8cdc-d1d390a6e165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c6217df-e212-4852-b745-042bc4d04033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cd8d3f0-2e97-4106-9cea-1f0c4afe5e89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProfessionalConsultingAndPublicCompanyCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cf8ced9-80e4-4607-86de-cb5d54cf5d13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e329cfb-354c-4c3b-b489-59580eb7b3fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e6920b6-a5cd-4c38-83d1-289485f945cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e6ff448-8d27-4434-ba19-87a416e47d57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7179b286-9afd-4afa-b79c-9e3a7b080f4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71badc65-a44f-452a-aa75-c16093a3462e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_730f05ff-8e87-4546-b39e-fa70f5bfc2d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73b2f5f2-5a24-429a-97e0-73eea6990ad7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73dd090c-1ed2-47b8-9a90-b7e929765864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74f98c49-91bf-4f2d-9c5b-151230a7e6b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:EmployeeRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7610c97e-2aed-4d93-8ea6-f8005b036844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lyra:RetentionCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_763123a3-30dd-4427-b10e-b4e51ac7debc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76dcfeb5-6b92-4328-8676-8ad9414800c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_772f9e37-d7a0-4ed6-b29c-901e928669b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_776bd276-c2c1-4b3d-bf69-ffc77fd2d52e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_788a6a79-f3bb-44f9-a6a5-ec8d29c9b846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:MarketBasedConditionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_789b1913-2263-46dd-834b-d5389e9dab08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-15</xbrli:startDate><xbrli:endDate>2023-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78cb6b9c-1c43-4ef8-965e-5c3e825546d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPerformanceOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>lyra:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>lyra:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>lyra:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employee"><xbrli:measure>lyra:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>lyra:Vote</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c052b22-1166-4212-bd51-c09eba22f45f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0d0c4abb-dfaf-4d09-81e7-47c1b52bf2fb" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d14a0e82-cebe-493d-b787-537dbd1f9731" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2a1a42c-cae8-42ee-909b-4ed29a98b363" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb6ce677-c4a9-4331-97b5-a2b6570d5e79" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="font-size:8pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0250c05b-d86d-4075-ad0d-baf9f9bf5ce9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f861b0af-82b9-43f7-a87f-c5ae1f447b31" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39273</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c</span><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5ee8211-999c-4d9c-a5d3-293002f6aff9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.08%;box-sizing:content-box;"/>
    <td style="width:49.92%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_6927425e-e8e6-46a4-bc7c-e88eca410c6e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9d5638be-86e3-4cc7-9afa-512030b61c73" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-1700838</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_940c9184-a368-4abf-8932-13771445a6f7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">480 Arsenal Way</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_40d53846-298c-4b28-93a4-5d75d782741f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_eef99c3d-a00b-49ac-b58a-03da9b1dda93" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_39e913e6-9b6a-466e-b8ce-1dc619638e75" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_315784c8-86be-49cd-aa36-2a4b94bb7b5f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_710e1c55-bdcd-4006-a88e-fac0fb41bfa6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">393-4600</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:38%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_c444e7a1-12c4-4787-a41a-14fd6e62329c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_74119fab-8abb-4476-9c94-b2c3f45ddc93" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LYRA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_a9434aed-4425-464f-ba93-859113210e7c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to section 12(g) of the Act: None</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_047e1de6-a0ad-49ed-8382-8c5fd16a228c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a729ea7-2068-4b45-9b22-0aa8886f5b7c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2c307d8-4b94-471a-b33d-3082be6269d8" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3d89a1e-257f-4f88-bf8f-40b2e0b352dc" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.689%;box-sizing:content-box;"/>
    <td style="width:1.14%;box-sizing:content-box;"/>
    <td style="width:2.281%;box-sizing:content-box;"/>
    <td style="width:45.778%;box-sizing:content-box;"/>
    <td style="width:23.689%;box-sizing:content-box;"/>
    <td style="width:1.14%;box-sizing:content-box;"/>
    <td style="width:2.281%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_e9e85876-b2fe-42f1-83be-6e6d3bd03e58" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ab484881-a587-4c8d-8c15-22c2838fd057" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0763eb1b-ab65-4d72-982a-201675d43bd3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d082fbfc-f342-4c25-8fbf-1be729373caf" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9c56ed74-ebc2-4ca1-9049-d1eb3c734bd9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_710c584e-9f14-4a96-8131-111038717fc0" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1e52d876-8624-4935-a3f2-a5e7447dfb2a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of outstanding shares of common stock held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Global Market on June 28, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19220a2f-f258-46f2-bb18-43359ec7bdd1" contextRef="C_251f3b55-1dd2-4781-ac6d-0744e7ac38e3" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,803,194</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For purposes of this disclosure, shares of common stock held by officers and directors of the registrant and by persons who hold more than 10% of the registrant&#8217;s outstanding common shares have been excluded because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily conclusive.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of the registrant&#8217;s Common Stock, $0.001 par value per share, outstanding as of February 28, 2025 was </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c7d7f2a-a86b-4095-8bee-30c23e338885" contextRef="C_3db47ea0-1f9a-4383-be26-a1363ba1cbea" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,561</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_f961fd6f-9fac-4662-b0df-796c4ca48ea2" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;box-sizing:content-box;"/>
    <td style="width:82%;box-sizing:content-box;"/>
    <td style="width:7.9%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cybersecurity2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_consolidated_financial_d"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this Annual Report on Form 10-K are forward-looking statements, including but not limited to statements regarding:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our restructuring initiatives and our ability to continue as a going concern;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our evaluation of strategic transactions, if any, to maximize shareholder value;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates and statements regarding our future revenue, future results of operations, and financial position;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sufficiency of our cash and cash equivalents to fund our operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plans to develop, manufacture, and commercialize LYR-210; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of our ongoing or planned clinical trials for LYR-210, and any future product candidates, as well as the timing for any results;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and our ability to obtain and maintain regulatory approvals for LYR-210, and any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical utility of LYR-210; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing, and manufacturing capabilities and strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations about the willingness of healthcare professionals to use LYR-210, and any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the development and commercialization of LYR-210 pursuant to the terms of the LianBio License Agreement (as defined below);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intellectual property position; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive position and developments and projections relating to our competitors or our industry; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of laws and regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks associated with the COVID-19 pandemic and related macroeconomic factors, which may adversely impact our business and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or the JOBS Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our business strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our projected research and development costs; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the plans and objectives of management for future operations.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;would&#8221; or &#8220;continue&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words or expressions. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any potential financial or strategic option we pursue in order to maximize shareholder value may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are attempting to sublease or assign our three leaseholds, which represent significant operating costs, and there can be no assurance that we will accomplish this effort on favorable terms, or at all, which would adversely affect our business, results of operations and financial condition; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we need significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved. The failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint has made it more difficult for the Company to raise capital. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, and/or discontinue operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following the failure of our ENLIGHTEN 1 Phase 3 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS) to meet its primary endpoint, which was announced in May 2024, there is significant uncertainty about the Company&#8217;s ability to complete development of LYR-210 and our ability to obtain regulatory approval for LYR-210 is at least significantly delayed and may not be possible; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our common stock may be delisted from The Nasdaq Capital Market if we cannot regain compliance with Nasdaq&#8217;s continued listing requirements, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in connection with a cost reduction initiative following the failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint, we implemented a reduction in force impacting approximately 87 employees, which was effected during May and June 2024, and this loss of key personnel significantly and adversely affects our ability to manufacture our product candidates, among other activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are no longer engaged in the manufacturing of our product candidates in-house;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our business is highly dependent on the success of our most advanced product candidate, LYR-210, which requires on-going clinical testing before we can seek regulatory approval and potentially launch our product. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials required for our lead product candidate and any future product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any failure by a third party to conduct our pre-clinical or clinical trials according to good clinical practices and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">even if LYR-210 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are party to a collaboration, and may enter into other collaborations, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if LianBio is unable to find a third party to acquire its rights under the LianBio License Agreement, it may materially harm our business, financial condition, results of operations and prospects;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our obligations under our license and other strategic agreements may divert management time and our limited resources, causing delays or disruptions to our business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our market; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of international terrorism, political unrest and wars on our business; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of other events may adversely impact our business and operations, including our clinical trials.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:-3.884%;padding-left:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T I</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unless the context requires otherwise, we use the terms &#8220;Lyra,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar designations in this Annual Report on Form 10-K to refer to Lyra Therapeutics, Inc. and its wholly-owned subsidiary.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">siness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the development and commercialization of innovative, anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our primary product candidate, LYR-210, is a bioabsorbable nasal insert designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. The drug embedded within LYR-210 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of CRS. ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. Following this announcement, we reported a reduction in force of approximately 75% of our workforce, impacting 87 employees, in addition to other cost-saving measures in order to preserve capital, including the stoppage of manufacturing and commercialization efforts for LYR-210 and pausing development efforts for LYR-220. LYR-220, our second product candidate, is substantially similar to LYR-210 and also directed at patients living with CRS, but employs a larger implant designed for patients whose nasal cavity is larger including those patients who have undergone extensive ethmoid sinus surgery.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Phase 3 ENLIGHTEN 2 clinical trial evaluating LYR-210 for the treatment of CRS is expected to read out in the second quarter of 2025 at which time the Company plans to evaluate how the data affects the potential development path for LYR-210 for patients with and without nasal polyps and to further assess the Company&#8217;s strategic options.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 is designed to treat CRS patients who have failed previous medical management. LYR-210 has a smaller dimension and is intended for patients with and without nasal polyps. In May 2024, we announced topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of CRS. ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At 24 weeks, the ENLIGHTEN 1 trial demonstrated the following results compared to baseline, which did not achieve statistical significance:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the primary efficacy analysis, treatment with LYR-210 resulted in a mean (standard deviation; SD) improvement in the 3CS score of 2.13 (2.17) points, compared to 2.06 (2.14) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the intent-to-treat (ITT) population, treatment with LYR-210 resulted in a mean (SD) improvement in the 3CS score of 2.35 (2.28) points, compared to 1.89 (2.07) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ITT population, treatment with LYR-210 resulted in a mean (SD) improvement in the Sino-Nasal Outcome Test (SNOT-22) score of 20.2 (21.38) points, compared to 15.70 (18.55) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ethmoid sinus opacification (evaluated by computed tomography (CT) scans) did not achieve statistically significant improvement after treatment with LYR-210 compared to sham control.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data showed that LYR-210 was generally well tolerated, with no product-related serious adverse events ("AEs"). The most commonly reported AEs in the study population were epistaxis, nasal odor, upper respiratory tract infection and sinusitis. Further post-hoc analyses of the ENLIGHTEN 1 data showed that LYR-210 had a positive effect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compared to sham control in 3CS, nasal congestion, and nasal polyp scores at 24 weeks in the subgroup of 35 CRS patients with nasal polyps.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in least squares (LS) LS mean (SE) improvement in the 3CS score of 3.69 (0.470) points, compared to 0.75 (0.685) points in sham control for a difference of 2.94 points (p-value 0.0017). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For patients with nasal congestion score equal to or greater than 2 (that is moderate to severe symptom) at baseline in the CRS patient subgroup with nasal polyps, treatment with LYR-210 resulted in aLS mean (SE) improvement in the 3CS score of 3.69 (0.470) points, compared to 0.75 (0.685) points in sham control for a difference of 2.94 points (p-value 0.0017). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in aLS mean (SE) improvement in the nasal congestion score of 1.20 (0.159) points, compared to 0.42 (0.243) points in sham control for a difference of 0.73 points (p-value 0.0216) in the CRS patient subgroup with nasal polyps and nasal congestion score equal to or greater than 2 at baseline. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in aLS mean (SE) improvement in the nasal polyp score of 0.62 (0.161) points, compared to 0.01 (0.237) points in sham control for a difference of 0.61 points (p-value 0.0471) in the CRS patient subgroup with nasal polyps. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 52-week extension stage of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension stage was generally consistent with the 24-week primary treatment stage, including for those patients that received a repeat dosing resulting in a 12-month treatment period. In the extension stage, LYR-210 was generally well tolerated, with no product-related serious AEs. The most commonly reported extension stage AEs in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results from the ENLIGHTEN 2 trial are expected in the second quarter of 2025.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-220</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the cost-saving efforts announced in May 2024, we paused development efforts for LYR-220, our second pipeline product candidate. LYR-220 is designed for use in CRS patients who have failed previous medical management and who continue to require treatment to manage CRS symptoms despite having had ethmoid sinus surgery. LYR-220 employs a larger implant designed for patients whose nasal cavity is larger including those patients who have undergone extensive ethmoid sinus surgery. We conducted a Phase 2 clinical trial of LYR-220, called BEACON. The BEACON trial was a controlled parallel-group study to evaluate safety, tolerability, pharmacokinetics ("PK"), and efficacy comparing two designs of the LYR-220 (7500&#181;g MF) matrix to control, over a 24-week period, in approximately 50 symptomatic adult CRS subjects who have had a prior bilateral sinus surgery. In September 2023, we reported positive topline results from BEACON, demonstrating statistically significant and clinically relevant improvements in the 3CS and SNOT-22 scores at 24 weeks.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. The technology is comprised of three interrelated components:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a bioabsorbable mesh scaffold, which is designed to maximize surface area for drug release while maintaining underlying tissue function; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an engineered elastomeric matrix composed of polymers having elastic characteristics, which has advanced physical properties resulting in implants with &#8220;shape memory&#8221; that dynamically adapt to nasal anatomy; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a versatile polymer-drug complex, which is designed to deliver six months of continuous local drug therapy with a single treatment.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mission is to transform the ear, nose and throat ("ENT") treatment paradigm by utilizing our proprietary technology to develop safe and effective therapies for the treatment of CRS. We intend to achieve this through the following strategies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete the Phase 3 ENLIGHTEN 2 clinical study. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the results of ENLIGHTEN 2, we believe LYR-210 could be further developed to treat patients living with CRS with or without nasal polyps. After we receive the topline results for ENLIGHTEN 2 in the second quarter of 2025, we will decide whether and how to proceed with further development of LYR-210 in patients with or without nasal polyps.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete the development and secure FDA approval of LYR-210 for the treatment of CRS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We believe LYR-210, if approved, could be well positioned in the CRS treatment paradigm. LYR-210, which is being studied in the ongoing Phase 3 ENLIGHTEN clinical program, utilizes MF, the active ingredient in various FDA-approved drugs. Subject to the data read-out for ENLIGHTEN 2 and potentially an additional Phase 3 trial, we intend to seek marketing approval for LYR-210 through a 505(b)(2) New Drug Application ("NDA"</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> submitted to the FDA.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluate Strategic Options. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company continues to evaluate potential strategic options to maximize shareholder value. There can be no assurance that the evaluation of strategic options will result in any transaction, or that any transaction, if pursued, will be completed on attractive terms, if at all. The Company has not set a timetable for the completion of this strategic review.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chronic Rhinosinusitis: A Disease with High Unmet Medical Needs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRS is an inflammatory disease of the paranasal sinuses causing the soft, moist layer of mucus-producing tissue, or mucosa, that lines the sinuses to become swollen and inflamed, leading to significant patient morbidities. The inflammation may be caused by infections, allergies, or environmental factors, as well as structural issues such as blockages of an ostium.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRS has been described in the literature as an &#8220;unrecognized epidemic&#8221; due to its high prevalence, its substantial impact on patient quality of life, and the significant limitations of currently available treatment options. We estimate that sinusitis, which includes both CRS and acute rhinosinusitis, impacts approximately 12% of the adult population in the United States, or approximately 30 million people, making it the fifth most common condition in people under the age of 65 and more prevalent than diabetes or heart disease. Of this population, we estimate that approximately 14 million people are affected by CRS. We estimate that approximately 8 million people are treated for CRS by physicians annually, of whom approximately 4 million fail medical management every year.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRS is grouped into two phenotypes for regulatory purposes: CRS without nasal polyps and CRS with nasal polyps. The non-polyp form of CRS represents approximately 70% of CRS patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Treatments and Their Limitations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The goals of therapy for CRS are to reduce mucosal swelling resulting from underlying inflammation, promote sinus drainage, and eradicate infections that may be present. The treatment of CRS is progressive in nature and typically begins with medical management, primarily with topical intranasal steroids, oral steroids and monoclonal antibodies. Topical intranasal steroids typically do not reach the epicenter of the disease deep in the sinuses, have fast clearance and poor compliance. The systemic complications of oral steroids limit their use. Physicians are reluctant to use monoclonal antibodies in all but their most severe polyp patients given their systemic exposure and relatively high cost. If this treatment is unsuccessful, an ENT physician may perform sinus surgery. Sinus surgery is costly, does not address the underlying inflammation, and is invasive with significant post-operative pain.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Solution for CRS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 is an implantable drug matrix that is designed to consistently and locally elute MF to the inflamed mucosal tissue for six months in CRS patients who fail medical management. MF, the active ingredient in various FDA-approved drugs, has a well-established efficacy and safety profile, which we believe will support the development process for LYR-210. LYR-210 is designed to enable continuous drug delivery at difficult-to-access nasal inflammation sites without the need for patient compliance, while avoiding the systemic side effects associated with oral steroids. LYR-210 is designed to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be administered in a simple, in-office procedure by an ENT physician under endoscopic visualization via a single-use applicator. Prior to May 2024, we were developing our second pipeline product candidate, LYR-220, for use in CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms despite having had ethmoid sinus surgery. LYR-220 is also designed to utilize MF, and employs a larger matrix designed for patients whose nasal cavity is larger, including those patients who have undergone ethmoid sinus surgery. In connection with the cost-saving efforts announced in May 2024, we paused development efforts for LYR-220.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the key potential benefits of LYR-210 include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cli</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nical Activity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: We believe LYR-210 has the potential to significantly improve symptoms by maintaining a steady, high dose of MF at the site of inflammation for six months with a single administration.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient Compliance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Because drug delivery for LYR-210 is designed to be sustained for six months with a single administration, the efficacy of LYR-210 is not dependent on patient compliance within the treatment period, unlike other CRS treatment options that require repeated daily administrations, such as topical intranasal steroids and oral steroids. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient Experience</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: LYR-210 is designed to be administered via a simple, in-office procedure every six months, which is intended to enhance convenience for patients, unlike the repeated daily medical management and/or time-consuming and painful surgery required by certain other CRS treatment options. Moreover, we believe patients may also benefit from the bioabsorbable, flexible structure of LYR-210 that is designed to maximize comfort over the therapy period. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Physician Experience</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: LYR-210 is designed to enable physicians to perform the placement of LYR-210 in-office in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for physicians to schedule separate surgical time. Moreover, the elastomeric matrix encapsulates the underlying mesh fibers to facilitate removal. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Localized Delivery</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: LYR-210 is designed to benefit from our technology, which is intended to provide localized delivery to avoid systemic side effects that are common with certain other CRS treatment options, such as oral steroids and biologics.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient Applicability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: LYR-210 is designed to benefit CRS patients who have failed medical management, including pre- and post-surgical patients. Lyra intends to address the needs of up to 4 million CRS</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients in the United States who fail current medical management.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmacoeconomic Impact</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: LYR-210 is designed as preferred treatment options for CRS, and as such has the potential to provide significant savings to the healthcare industry by reducing the number and frequency of expensive surgical and treatment options.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe LYR-210, if approved, would be the only product able to deliver six months of continuous anti-inflammatory treatment in a single administration to treat the broad spectrum of CRS patients who fail medical management, including pre- and post-surgical patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Clinical Pipeline</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current status of our clinical product candidates is summarized below.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224190320_0.jpg" alt="img224190320_0.jpg" style="width:672px;height:318px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure 1. Summary of Clinical Studies</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 for the Treatment of CRS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe LYR-210, if successfully developed and approved, has the potential to become a preferred therapy for the treatment of CRS. It is the only product candidate that we are aware of that is designed to provide six months of continuous local delivery of anti-inflammatory medication with a single administration. The simple, in-office procedure allows for its implantation without the need for general anesthesia or surgery. We believe LYR-210 has the potential to be a safe, effective, and broadly applicable CRS treatment, designed to enhance patient comfort and physician experience and eliminate patient compliance issues associated with other CRS treatments, such as intranasal steroid sprays, while achieving reduced costs compared to other CRS treatments, such as sinus surgery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224190320_1.jpg" alt="img224190320_1.jpg" style="width:430px;height:344px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure 2. Illustration of Placement of LYR-210</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 is an investigational local drug delivery system designed to fit within, and conform to, the confined space of a surgically na&#239;ve patient&#8217;s middle meatus, an air-containing space that plays a fundamental role in drainage of the paranasal sinuses (see Figure 2, above). LYR-210 consists of MF, the active ingredient in various FDA-approved drugs, embedded in bioabsorbable polymers to aid in the controlled and sustained delivery of MF to the sinonasal mucosal tissue from a single drug administration. LYR-210 has a tubular braid configuration with a uniform diamond pattern throughout and is 13 mm in diameter and 10 mm in length in the unconstrained state. It has elastic properties to promote patient comfort and is designed to be self-retaining against the mucosal tissue to allow effective drug transfer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 is intended to be administered bilaterally into the middle meatus by an ENT physician under endoscopic visualization via a provided, single use applicator. It is designed for office-based administration performed with topical anesthesia. Once administered, LYR-210 is designed to gradually release MF to the inflamed mucosal tissue for six months from a single administration. LYR-210 can be removed at six months or earlier at the physician&#8217;s discretion using standard instruments and, if needed, replaced with a new LYR-210. LYR-210 is made with bioabsorbable polymers that, if left in place, would gradually dissolve over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Our Clinical Development for LYR-210</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes our completed and ongoing clinical trials for LYR-210 for CRS in patients who have failed medical management and have not undergone ethmoid sinus surgery.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:15.46%;box-sizing:content-box;"/>
    <td style="width:14.44%;box-sizing:content-box;"/>
    <td style="width:17.52%;box-sizing:content-box;"/>
    <td style="width:28.86%;box-sizing:content-box;"/>
    <td style="width:23.72%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Status</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial Design</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial Objectives</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial Results</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Phase 1</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Completed</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Prospective, multi-center, non-randomized, single-arm, open-label clinical trial</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 25-week trial, including 24 week treatment period, plus one week post-removal</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Bilateral 2,500 &#181;g dose</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 20 patients</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 5 study sites</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Study objective: Evaluate the safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Primary endpoint: Product-related serious AEs from baseline to 4 weeks post-procedure</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Additional data collected: Morning serum cortisol, change in intraocular pressure, plasma PK, quality of life by SNOT-22 (secondary endpoint), endoscopy and MRI</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Primary safety endpoint achieved / 2,500 &#181;g was well tolerated during entire duration of treatment</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Significant improvement from baseline in SNOT-22 scores was observed from week 1 through week 25</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Average change in baseline SNOT-22 score at week 1 was -13.0 points (P= 0.008 to pre-treatment)</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Symptom relief, as measured by SNOT-22 score, was observed through the entire duration of study, achieving an average change from baseline of -20.5 points at week 24 (p &lt; 0.0001 to pre-treatment), which was the end of the treatment period, and -20.0 (p &lt; 0.0001) at week 25, which was the end of the study</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Phase 2</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(LANTERN)</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Completed</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Randomized, blinded, sham-controlled, dose-ranging, parallel-group clinical trial</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 24-week treatment period, plus 24 week safety follow up post-removal</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Bilateral 2,500 &#181;g or 7,500 &#181;g dose</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 99 evaluable patients with the option to increase to up to 150 patients. Enrollment discontinued at 67 patients due to the COVID-19 pandemic ("COVID-19")</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Up to 50 study sites globally</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Primary endpoint: Change from baseline in composite score of 7-day average of 4 cardinal symptoms (4CSS) at week 4</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Secondary objectives: Symptom improvement at week 24, sinus imaging to assess reduction in inflammation, SNOT-22, time to treatment failure, reduction in inflammation, frequency of exacerbations, PK pharmacodynamics</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; At the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012) and week 24 (-1.64) (p=0.016).</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; At the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm as measured by the change from baseline at week 8 (-12.2) (p=0.039), week 16 (-15.0) (p=0.008), week 20 (-18.4) (p=0.001) and week 24 (-19.0) (p=0.001).</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose (-0.36) (p=0.306) or 2,500 &#181;g dose (0.04) (p=0.525). We believe this was due</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:15.46%;box-sizing:content-box;"/>
    <td style="width:14.44%;box-sizing:content-box;"/>
    <td style="width:17.52%;box-sizing:content-box;"/>
    <td style="width:28.86%;box-sizing:content-box;"/>
    <td style="width:23.72%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Status</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial Design</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial Objectives</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trial Results</span></p><p style="border-top:1pt solid #000000;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">primarily to the discontinuation of enrollment related to COVID-19.</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PK Characterization Study</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Completed</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 24 patients in the United States with bilateral 2,500 &#181;g or 7,500 &#181;g dose</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; PK timepoints through 56 days, safety, SNOT-22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; LYR-210 delivered a constant daily dose of MF over 56 days without a drug burst</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Steady state plasma concentrations were 41.2 pg/mL and 12.2 pg/mL in the 7,500 &#181;g and 2,500 &#181;g dose groups respectively</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Clinically relevant improvement from baseline in SNOT-22 observed within 2 weeks</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; LYR-210 safe and well tolerated with no serious AEs</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Phase 3</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(ENLIGHTEN 1)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initiated February 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Randomized, blinded, sham-controlled, parallel-group clinical trial</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 52-week trial duration: 24-week treatment period, followed by a safety extension period involving crossover treatment for control patients and 1:1 re-randomization to control or repeat treatment for LYR-210 patients</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Approximately 180 adult CRS patients who have failed prior medical management and 2:1 randomization (bilateral LYR-210 7,500 &#181;g): sham procedure</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Up to 60 sites worldwide</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Primary endpoint: Change from baseline in composite score of 7-day average of 3 cardinal symptoms at week 24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Secondary objectives: Change from baseline in individual cardinal symptoms at week 24, CFBL in CT sinus opacification score at week 24, CFBL in SNOT-22 at week 24, rescue treatment use through week 24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;LYR-210 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks.</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; In the primary efficacy analysis, treatment with LYR-210 resulted in a mean (standard deviation; SD) improvement in the 3CS score of 2.13 (2.17) points, compared to 2.06 (2.14) points in sham control.</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">There were no meaningful differences between groups in the key secondary endpoints.</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; LYR-210 was generally well tolerated with no product-related serious AEs reported in both the 24-week treatment period as well as the extension period.</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Phase 3</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(ENLIGHTEN 2)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initiated September 2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Randomized, blinded, sham-controlled, parallel-group clinical trial</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; 24-week treatment period</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Approximately 180 adult CRS patients who have failed prior medical management 2:1 randomization (bilateral LYR-210 (7,500 &#181;g)): sham procedure</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Up to 60 sites worldwide</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Primary endpoint: Change from baseline in composite score of 7-day average of 3 cardinal symptoms at week 24</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Secondary objectives: Change from baseline in individual cardinal symptoms at week 24, CFBL in CT sinus opacification score at week 24, CFBL in SNOT-22 at week 24, rescue treatment use through week 24</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149; Enrollment was completed in October 2024. Trial is ongoing.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The LYR-210 Phase 3 program consists of two pivotal trials &#8211; ENLIGHTEN 1 and ENLIGHTEN 2. ENLIGHTEN 1 was a 52-week, multi-center, randomized, blinded, sham-controlled trial designed to evaluate the efficacy and safety of LYR-210 in approximately 180 surgically na&#239;ve CRS who have failed prior medical management. The trial consisted of three stages &#8211; a 2- to 4-week screening and run-in stage, a 24-week treatment stage followed by a 28-week safety extension stage. In the treatment stage, patients were randomized 2:1 to receive LYR-210 (7,500 &#181;g) or sham-procedure. At the end of the treatment stage, patients in the control group received crossover LYR-210 treatment while patients in the LYR-210 group were re-randomized 1:1 to either receive a crossover sham-procedure or a repeat treatment with LYR-210 (7,500 &#181;g). The ENLIGHTEN 1 trial was initiated in February 2022, and enrollment was completed in September 2023. In May 2024, we announced topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of CRS. ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At 24 weeks, the ENLIGHTEN 1 trial demonstrated the following results compared to baseline, which did not achieve statistical significance:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the primary efficacy analysis, treatment with LYR-210 resulted in a mean (standard deviation; SD) improvement in the 3CS score of 2.13 (2.17) points, compared to 2.06 (2.14) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the intent-to-treat (ITT) population, treatment with LYR-210 resulted in a mean (SD) improvement in the 3CS score of 2.35 (2.28) points, compared to 1.89 (2.07) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ITT population, treatment with LYR-210 resulted in a mean (SD) improvement in the Sino-Nasal Outcome Test (SNOT-22) score of 20.2 (21.38) points, compared to 15.70 (18.55) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ethmoid sinus opacification (evaluated by computed tomography (CT) scans), did not achieve statistically significant improvement after treatment with LYR-210 compared to sham control.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At 24 weeks, in the subset of 35 patients with nasal polyps, treatment with LYR-210 resulted in a mean (SD) improvement in the 3CS score of -3.26 (2.54) points, compared to -1.05 (1.56) points in the sham control.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 was generally well tolerated, with no product-related serious AEs reported. The most commonly reported AEs in the study population were epistaxis, nasal odor, upper respiratory tract infection and sinusitis. Further post-hoc analyses of the ENLIGHTEN 1 data showed that LYR-210 had a positive effect compared to sham control in 3CS, nasal congestion, and nasal polyp scores at 24 weeks in the subgroup of 35 CRS patients with nasal polyps.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in least squares (LS) mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2.25 points (p-value 0.0058) in the CRS patient subgroup with nasal polyps. This improvement was demonstrated despite the inclusion of only grade 1 nasal polyps in the study and without a threshold for nasal congestion score.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For patients with nasal congestion score equal to or greater than 2 (that is moderate to severe symptom) at baseline in the CRS patient subgroup with nasal polyps, treatment with LYR-210 resulted in LS mean (SE) improvement in the 3CS score of 3.69 (0.470) points, compared to 0.75 (0.685) points in sham control for a difference of 2.94 points (p-value 0.0017). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in LS mean (SE) improvement in the nasal congestion score of 1.20 (0.159) points, compared to 0.42 (0.243) points in sham control for a difference of 0.73 points (p-value 0.0216) in the CRS patient subgroup with nasal polyps and nasal congestion score equal to or greater than 2 at baseline. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in LS mean (SE) improvement in the nasal polyp score of 0.62 (0.161) points, compared to 0.01 (0.237) points in sham control for a difference of 0.61 points (p-value 0.0471) in the CRS patient subgroup with nasal polyps. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 52-week extension stage of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients who received a repeat dosing resulting in a 12-month treatment period. In the extension stage, LYR-210 was generally well tolerated, with no product-related serious AEs. The most commonly reported extension stage AEs in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENLIGHTEN 2 is a 24-week, multi-center, randomized, blinded, sham-controlled trial designed to evaluate the efficacy and safety of LYR-210 in approximately 180 surgically na&#239;ve CRS patients who have failed prior medical management. The trial consists of two stages &#8211; a 2- to 4-week screening and run-in stage and a 24-week treatment stage. Patients are randomized 2:1 to receive LYR-210 (7,500 &#181;g) or sham-procedure. ENLIGHTEN 2 was initiated in September 2022, and enrollment was completed in October 2024. Topline results from the ENLIGHTEN 2 trial are expected in the second quarter of 2025.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint of both ENLIGHTEN 1 and ENLIGHTEN 2 is change from baseline (CFBL) at week 24 in the composite score of 3 cardinal symptoms (3CS) score. Secondary endpoints include CFBL in CT sinus opacification score at week 24, CFBL in SNOT-22 at week 24, rescue treatment use through week 24.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 2 LANTERN clinical trial for LYR-210 was designed as a multi-center, randomized, controlled, patient and sponsor blinded trial. The study was designed to enroll 99 evaluable patients with the option to expand to up to 150 patients at up to 30 sites in the United States, Australia, Austria, Czech Republic, New Zealand, and Poland. Due to COVID-19, we discontinued enrollment at 67 patients and did not open any sites in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224190320_2.jpg" alt="img224190320_2.jpg" style="width:511px;height:186px;"/></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure 3. Design of Phase 2 LANTERN Clinical Trial for LYR-210.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trial consisted of three arms with a 1:1:1 randomization: (1) an experimental arm with bilateral placement of 2,500 &#181;g of LYR-210, with 23 patients; (2) an experimental arm with bilateral placement of 7,500 &#181;g of LYR-210, with 21 patients; and (3) a control arm with a bilateral sham procedure only, with 23 patients (see Figure 3, above). In addition, subjects were supplied with saline for daily nasal irrigation treatment during the course of the treatment period and were permitted to use rescue medication if deemed medically necessary by their physician.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint of the trial was a change from baseline in the 7-day average scores of the 4CSS at week 4. Because the FDA prefers a composite score of the cardinal symptoms of CRS for patients with CRS, we utilized the 4CSS for the trial. The 4CSS is comprised of four domains that are scored 0-3 with a total score of 12. The four domains are: (1) nasal obstruction and congestion; (2) facial pain and pressure; (3) nasal discharge; and (4) olfactory loss (loss of sense of smell).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key secondary endpoints for the trial were the change from baseline in 7-day average 4CSS at week 24, time to treatment failure, and percentage of subjects with at least 1-point decrease in the bilateral Zinreich score (a measure of inflammation) in at least one pair of the anterior ethmoid, maxillary, posterior ethmoid, frontal, or sphenoid sinuses at Week 24.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, we reported positive topline results from our Phase 2 LANTERN clinical trial. At the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012), and week 24 (-1.64) (p=0.016) (see Figure 4, below). However, although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose (-0.36) (p=0.306) or 2,500 &#181;g dose (0.04) (p=0.525). We believe this was due primarily to the discontinuation of enrollment related to COVID-19. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order to achieve statistical significance for the primary endpoint.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><img src="img224190320_3.jpg" alt="img224190320_3.jpg" style="width:605px;height:308px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure 4. Total Symptom Improvement by 4CSS for Phase 2 LANTERN Clinical Trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 was observed to be safe and well-tolerated at all doses in the trial. There was one serious AE, which was deemed to be unrelated to LYR-210. No treatment-related serious AEs were reported. Treatment-related AEs included epistaxis, rhinitis, rhinorrhea, and headache. All treatment-related AEs were generally mild to moderate in nature, other than one incident of increased viscosity of upper respiratory secretion in the 2,500 &#181;g dose treatment arm, and in line with the known safety profile of MF.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After 24 weeks, LYR-210 drug matrices were removed, and patients then underwent a 24-week post-treatment follow-up. The main objective of the post-treatment period was to assess long-term safety post-removal. LYR-210 continued to show strong safety through 24 weeks post-treatment with no increased incidence of treatment-related AEs. Approximately 50% of patients experienced a durable response post-removal of LYR-210 (7,500&#956;g), with no worsening of 4CSS from the Week 24 baseline, compared to approximately 90% of control patients who either experienced a worsening of 4CSS from the Week 24 baseline or required a rescue treatment.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PK characterization study</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PK study was a 56-day open label, multi-center, U.S. study of the PK and safety of LYR-210 in adult subjects with chronic rhinosinusitis. The primary objective of the study was to establish the PK profile of LYR-210 (see Figure 6, below). The study enrolled 24 patients, half of whom received LYR-210 2,500 &#181;g and the other half received LYR-210 7,500 &#181;g. The study indicated that both doses were safe and well tolerated, with the mean maximum plasma concentration, or Cmax, observed with the 7,500 &#181;g dose well below the Cmax established for FDA-approved formulations of mometasone furoate, or MF. MF blood plasma levels observed during the PK study support LYR-210&#8217;s ability to deliver consistent and steady dosing over the entire treatment period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><img src="img224190320_4.jpg" alt="img224190320_4.jpg" style="width:534px;height:236px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure 5. Plasma MF Concentration for PK Characterization Study.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Phase 1 clinical trial for LYR-210 was a prospective, multi-center, non-randomized, single-arm, open-label clinical trial with adult surgically na&#239;ve CRS patients who have failed medical management. The objective of the trial was to evaluate safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210 with an additional measurement taken one week post-removal. The trial was conducted across five sites in New Zealand and Australia. Forty LYR-210 matrices were placed bilaterally in 20 patients with and without nasal polyps. Each matrix contained 2,500 &#181;g of MF. LYR-210 met its primary safety endpoint, and significant and rapid, clinically meaningful and durable improvement on a patient symptom severity scale was observed through 25 weeks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 trial achieved its primary safety endpoint at week 4. LYR-210 at 2,500 &#181;g was well tolerated by patients during the entire duration of treatment and also gave insight into the successful office-based placement of the matrix and clinical outcomes in non-polyp and polyp patients. There were no reports of unexpected AEs, or local nasal AEs, including epistaxis, nasal burning, nasal dryness, nasal irritation, and nasal septal perforation during the 24-week MF local dosing treatment duration. Additionally, no change in morning serum cortisol levels or intraocular pressures were noted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most common reported AEs were nasopharyngitis, upper respiratory tract infection, sinusitis, nasal odor, procedural headache, nasal discomfort, and facial pain. There was one serious AE reported, an acute myocardial infarction, which was deemed to be unrelated to LYR-210.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant reduction in SNOT-22 scores was observed at week 1 and this reduction persisted through week 25, the end of the trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar efficacy was observed in both polyp and non-polyp patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-220 for the Treatment of CRS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the cost-saving efforts announced in May 2024, the Company paused development efforts for LYR-220, our second pipeline product candidate. Prior to May 2024, we were developing LYR-220 for use in CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms including patients who had ethmoid sinus surgery. LYR-220 is also designed to utilize MF, and employs a larger matrix designed for patients whose nasal cavity is enlarged, including those patients who have undergone ethmoid sinus surgery. We estimate that 40% of patients who present to an ENT physician with CRS have had a prior surgery. The majority of these patients represent the addressable market for LYR-220.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A nasal spray was recently approved by the FDA to treat CRS in adults without nasal polyps, a three-month steroid-eluting sinus implant was approved to treat CRS in adults with nasal polyps and three subcutaneously-administered monoclonal antibodies (mAbs) were recently approved as add-on maintenance therapy for uncontrolled disease in post-surgical adult patients with recurrent nasal polyps. We believe LYR-220 is meaningfully differentiated from currently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approved products because, if successfully developed and approved, it would be the only product able to deliver six months of topical treatment in a single administration to treat both polyp and non-polyp post-surgery CRS patients. Further, with respect to the mAbs, LYR-220 is differentiated because it would provide localized delivery so as to avoid systemic side effects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. Our technology platform, developed over the past decade, was first patented in 2009 by members of our team who have extensive experience in drug formulation and delivery, materials science, and biotechnology. This expertise has allowed us to significantly improve upon polymer drug delivery technology and add shape-memory properties to bioabsorbable polymeric implants, one of our key innovations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224190320_5.jpg" alt="img224190320_5.jpg" style="width:672px;height:310px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure 6. Lyra&#8217;s Proprietary Drug-Eluting Matrix.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug-eluting bioabsorbable technology is comprised of three polymeric components, which are designed to work together to enable highly efficient, localized drug delivery (see Figure 6, above). This proprietary technology is designed to enable sustained delivery of medications for six months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches. The components of our technology include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bioabsorbable Mesh Scaffold</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;our bioabsorbable mesh scaffold is designed to maximize surface area for drug release while maintaining underlying tissue function. The mesh scaffold is comprised of bioabsorbable polymers and is pliable to maximize patient comfort. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Engineered Elastomeric Matrix</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212; our engineered elastomeric matrix, which means a polymeric matrix composed of polymers having elastic characteristics, has advanced physical properties resulting in implants with &#8220;shape memory&#8221; that dynamically adapt to nasal anatomy and ensure persistent positioning in the target location. The matrix works in conjunction with the underlying mesh to exert outward retention force, keeping it in place as tissue remodels. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Versatile Polymer-Drug Complex</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212; our versatile polymer-drug complex can be customized for the treatment of various chronic diseases treatable with ENT delivery to achieve the desired drug dose and drug elution rate.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three integrated components are fundamental to the successful function and versatility of the technology. For application to a targeted tissue, the implant is compressed into a narrow applicator, which allows non-invasive placement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deep within cavities of the ear, nose, and throat. The shape-memory properties ensure the implant self-expands as it is administered through the applicator to comfortably fit within and adapt to the target anatomy. The implant is designed to be oversized for the target anatomy and therefore will push outwards to stay fixed at the target location. Over time, as inflammation recedes due to the local drug therapy, the shape-memory properties are intended to allow the implant to actively adapt to the anatomy and continue to stay in place to elute drug locally for a prolonged period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond CRS, we believe our technology has potential application in other disease areas, which we could further explore if and when we have sufficient resources.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property and Barriers to Entry</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own all the material intellectual property rights related to our technology and product candidate portfolio. As of December 31, 2024, our product candidate portfolio is protected by issued patents and pending applications in the U.S. and major foreign countries with claims directed to devices, systems, and method of use, which, exclusive of possible patent term adjustments or extensions or other forms of exclusivity, provide coverage through at least 2030, with many providing coverage through 2036 and some providing coverage through 2038. We recently filed patent applications that have the potential to provide coverage through 2042.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely upon know-how, continuing technological innovation, and technical barriers to entry, including manufacturing and drug delivery complexities, to develop and maintain our competitive intellectual property position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management Team</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team has extensive drug development</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience across a broad spectrum of disease areas, for both drug and drug-device combination products, with a successful track record in large pharmaceutical, medical device, and biotech companies. Additionally, our management team has been involved in the development of successfully approved and commercialized products including Avonex, Eylea, Taxus (drug-eluting stent), Velcade, and XenMatrix.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Approval Commercialization Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LYR-210 is successfully developed and approved, we intend to engage in targeted outreach to our key physician, payor, and patient audiences. ENT physicians are the primary treaters of CRS patients who have failed medical management and thus represent our target physician base. Given the requirement for endoscopic placement of our products, we plan to build a targeted in-house sales force that will target ENT physicians who perform 80% of the CRS procedural volume. Given that LYR-210 can be administered in a simple, in-office procedure requiring no additional equipment, we anticipate that our sales representatives&#8217; time will primarily be directed at educating the ENT physicians around product attributes and patient selection. We plan to supplement our direct physician outreach with appropriate medical education and marketing efforts to further penetrate our physician base and encourage adoption of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring physician and patient market access to our products will be critical to our success, and we plan to execute a holistic reimbursement strategy, consisting of a reimbursement support hub and field-based reimbursement experts, that will integrate payor coverage and physician practice management initiatives. We believe that the primary decision makers from a payor perspective are private payors, which represent approximately 80% of the payor mix for our products. We intend to deploy a market access team to educate payors on the clinical and pharmacoeconomic attributes of our products and to secure favorable coverage policies and to maximize the covered lives that have reimbursement for our products. To maximize access to LYR-210, we plan to develop a reimbursement support model which aims to reduce physician financial risk associated with physician-administered products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to our initial ENT physician and payor efforts, we also plan to selectively use cost-effective, patient-directed marketing strategies to further increase awareness among the CRS patient community of our products with the goal of increasing ENT physician visits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 26, 2022, we entered into an amended License and Collaboration Agreement, or the LianBio License Agreement with LianBio Inflammatory Limited, or LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. Under the terms of the LianBio License Agreement, we received an upfront payment of $12.0 million and are eligible to receive up to $135.0 million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. In February 2022, the Company achieved a development milestone of $5.0 million for dosing the first patient in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S., and the related cash amount was received in April 2022. Upon commercialization on a region-by-region basis, we will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and we will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to our LYR-220 product candidate.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company&#8217;s collaboration with LianBio is highly uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBio&#8217;s rights under the LianBio License Agreement. In November 2024 we entered into a novation agreement which substituted LianBio Cayman for LianBio HK. For more information, please see &#8220;Risk Factors &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If LianBio HK, as defined below, is unable to find a third party to acquire its rights under the LianBio License Agreement, as defined below, it may materially harm our business, financial condition, results of operations and prospects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our scientific knowledge, technology, and development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical, and, to a lesser degree, medical device companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel, in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe LYR-210 could be positioned for CRS patients with or without nasal polyps, with or without prior ethmoid sinus surgery, following the failure of medical management and therefore are not anticipated to compete directly with branded, generic, or over-the-counter inhaled corticosteroids. The primary competitive treatment is surgical procedures, including ethmoid sinus surgery with and without balloon sinus dilation (BSD) and BSD as a standalone procedure. In this space, LYR-210 would be the only product we are aware of that may deliver six months of local treatment with a single administration. Key competitive factors affecting the commercial success of LYR-210 and any other product candidates we may develop are likely to be efficacy, safety, and tolerability profile, reliability, convenience of administration, price, and reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the suspension of our manufacturing activities for LYR-210 and LYR-220 in May 2024, we would perform inspections and testing when specified of the components we receive from third parties before using them in our manufacturing operations. Using these components, we would manufacture, assemble, inspect, and package our implants, and send them to a third-party sterilization vendor. After sterilization, we would inspect the product and test via third-party laboratories to determine compliance with our specifications. Upon release of the lot to inventory, the product would be labeled and distributed via a third-party vendor to clinical sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The active pharmaceutical ingredient (&#8220;API&#8221;) and a number of the components used in our implants would be currently supplied to us from single source suppliers. We would source our supplies from manufacturers with a track record of compliance with current good manufacturing practices, or cGMP. At this stage, when engaged in manufacturing we would rely on single source suppliers for some of our polymer materials, some extrusions, and molded components, and for finished</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">goods testing, labeling, and distribution. Our ability to supply our products and to develop our product candidates depends, in part, on our ability to obtain successfully the API and polymer materials used in these products in accordance with regulatory requirements and in sufficient quantities. We would generally acquire our single source components pursuant to purchase orders placed in the ordinary course of business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively seek to protect the intellectual property and proprietary technology platform that we believe is important to our business, which includes seeking and maintaining patents covering our technology platform and products, and any other inventions that are commercially or strategically important to the development of our business. We also rely upon trademarks to build and maintain the integrity of our brand, and we seek to protect the confidentiality of trade secrets that may be important to the development of our business. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patents and Patent Applications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we own 27 issued U.S. patents, 41 foreign issued patents, 12 U.S. pending applications, and 34 foreign pending applications, out of which 21 issued U.S. patents, 39 foreign issued patents, 12 U.S. pending applications, and 34 foreign pending applications are directed to our technology.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All technology to our business has been developed in-house and is protected with patents and patent applications in three major lineages, along with the beginning of a fourth, more recent lineage of patent applications. The first lineage dates from 2009 and provides protection potentially until 2030, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This first lineage includes issued patents in the U.S., Europe, Japan, Canada, and Great Britain that are not limited to any particular drug, site of delivery, or patient condition, but specify features of the implant, delivery system, method, and polymers. The second lineage dates from 2015 and provides protection potentially until 2036, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This second lineage includes issued patents with ENT-specific method claims directed to the specific drug, site of delivery (i.e., middle meatus), and patient condition, with allowed and issued cases in the U.S., China, and Japan along with numerous pending applications in the U.S., Europe, Japan, Canada, China, and Great Britain. The third lineage dates from 2017 with the prospect of patent protection potentially until 2038, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This third lineage attempts to capture the products&#8217; drug release features and patient results from the recent clinical trial. It includes allowed cases in Australia, Singapore, Korea, and Great Britain, along with pending applications in the U.S., Canada, Australia, Europe, China, and Japan. The fourth lineage dates from 2021 and provides protection potentially until 2042, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. The fourth lineage is directed to a higher drug load (7500 ug). The lineage stems from a patent application filed under the Patent Cooperation Treaty that entered the National Phase in September of 2023. There are pending applications in this fourth lineage in the U.S., Canada, Australia, Great Britain, Europe, Korea, Singapore, China, and Japan.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks and Trade Secrets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely upon trade secrets, know-how, and continuing technological innovation, and may pursue licensing opportunities in the future, to develop and maintain our competitive position. We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements, invention assignment agreements, and non-solicitation and non-compete agreements with suppliers, employees, consultants, and others who may have access to proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation and Product Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state, and local levels, and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of pharmaceutical products such as those we are developing. We will be required to navigate the various preclinical, clinical, and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The processes for obtaining regulatory approvals in the United States and other countries, as appropriate, along with subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations, require the expenditure of substantial time and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, we are subject to extensive regulation by the FDA, which regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations, and other federal, state, and local regulatory authorities. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an Investigational New Drug ("IND") Application which must become effective before human clinical trials may begin; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility at which the drug is produced and selected clinical sites to assess compliance with current Good Manufacturing Practice, or cGMP, regulations; GCPs; and the integrity of the clinical data;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of user fees; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing LYR-210 using an innovative drug delivery technology comprised of a mesh scaffold, an elastomeric matrix, and a polymer-drug complex delivered through a narrow applicator. In the United States, products composed of components that would normally be regulated by different centers at the FDA are known as combination products. Typically, the FDA&#8217;s Office of Combination Products assigns a combination product to a specific Agency Center as the lead reviewer. The FDA determines which Center will lead a product&#8217;s review based upon the product&#8217;s primary mode of action. Depending on the type of combination product, its approval, clearance, or licensure may usually be obtained through the submission of a single marketing application. We anticipate that LYR-210 will be regulated as a drug, and the FDA will permit a single regulatory submission seeking approval. However, the FDA sometimes will require separate marketing applications for individual constituent parts of the combination product which may require additional time, effort, and information. Even when a single marketing application is required for a combination product, such as an NDA for a combination pharmaceutical and device product, both the FDA&#8217;s Center for Drug Evaluation and Research and the FDA&#8217;s Center for Devices and Radiological Health may participate in the review. An applicant will also need to discuss with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agency how to apply certain premarket requirements and post-marketing regulatory requirements, including conduct of clinical trials, AE reporting, and cGMPs, to their combination product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective, and a clinical trial proposed in the IND may begin 30 days after the FDA receives the IND, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three or four sequential phases, which may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 4: In some cases, the FDA may conditionally approve an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post-approval trials are typically referred to as Phase 4 clinical trials. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious AEs occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of 10 months to review and act on a standard NDA and 6 months to review and act on a priority NDA, measured from the &#8220;filing&#8221; date for an NDA for a new molecular entity, or NME, or from the receipt date for an NDA for a non-NME product. Measuring from the &#8220;filing&#8221; date typically adds approximately two months to the timeline for review and decision because the FDA has sixty days from receipt to make a &#8220;filing&#8221; decision, as described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&#8217;s continued safety, quality, and purity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical studies, the FDA may accept foreign data as the sole basis for marketing approval if (1) the foreign data are applicable to the U.S. population and U.S. medical practice, (2) the studies were performed by clinical investigators with recognized competence, and (3) the data may be considered valid without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The testing and approval process for an NDA requires substantial time, effort, and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit, or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met to secure final approval of the NDA and may require additional clinical testing, preclinical testing, manufacturing, or formulation modifications or other changes in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Hatch-Waxman Amendments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current regulatory strategy is to pursue development of LYR-210 as a Section 505(b)(2) NDA. As an alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments. A Section 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness, or both for an approved drug product. As such, under Section 505(b)(2), the FDA may rely, for approval of an NDA, on data not developed by the applicant. Therefore, if we can satisfy the conditions required for a Section 505(b)(2) NDA submission, it may eliminate the need for us to conduct some of the preclinical studies or clinical trials for the new product candidate that might otherwise have been required, although the review time is not shortened. The FDA may then approve the new product candidate for the new indication sought by the 505(b)(2) applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orange Book Listing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. Any applicant who files an Abbreviated New Drug Application, or ANDA, seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify, for each patent listed in the Orange Book for the referenced drug, to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the date on which such patent expires, or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. The fourth certification described above is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA refers. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. This section viii statement does not require notice to the patent holder or NDA owner. There might also be no relevant patent certification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the reference NDA holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant. Even if the 45 days expire, a patent infringement lawsuit can be brought and could delay market entry, but it would not extend the FDA-related 30-month stay of approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired. Specifically, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of an NCE, which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug, except that FDA may accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification. This exclusivity period may be extended by an additional six months if certain requirements are met to qualify the product for pediatric exclusivity, including the receipt of a written request from the FDA that the NDA holder conduct certain pediatric studies, the submission of study reports from such studies to the FDA after receipt of the written request, and satisfaction of the conditions specified in the written request.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Review and Approval Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. If and when we have sufficient resources, we may explore some of these opportunities for our product candidates as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA and other government authorities, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes, or other labeling claims, are subject to prior FDA review and approval. There also are continuing annual program fee requirements for any marketed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state authorities, and are subject to periodic unannounced inspections by the FDA and these state authorities for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters, or holds on post-approval clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.708690330477356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. The FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and other authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare and Data Privacy and Security Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical and medical device manufacturers are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, data privacy and security, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers, and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health-related and other personal information. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting obligation, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged and examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at Centers for Medicare &amp; Medicaid Services ("CMS") to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers and reduced payments to several types of Medicare providers, which will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020, through March 31, 2022, absent additional congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. In August 2022, the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new manufacturer discounting program (which began in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure, drug price reporting and other transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 30 full-time employees. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. Additionally, as of December 31, 2024, we had nine consultants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the state of Delaware in November 2005 under the name WMR Biomedical, Inc. In July 2018, we changed our name to Lyra Therapeutics, Inc. Our principal executive offices are located at 480 Arsenal Way, Watertown, MA 02472 and our telephone number is (617) 393-4600. Our website address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.lyratx.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The information contained in, or accessible through, our website does not constitute a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Internet address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.lyratx.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, are filed with the U.S. Securities and Exchange Commission, or the SEC, and are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. Our filings with the SEC may be accessed through the SEC&#8217;s website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://www.sec.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information contained in this Annual Report on Form 10-K before making an investment in our common stock. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Exploration of Strategic Options</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any potential financial or strategic option we pursue in an effort to maximize shareholder value may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, in connection with the Company&#8217;s announcement that we failed to meet the primary endpoint of our ENLIGHTEN 1 Phase 3 clinical trial, we announced our interest in potential strategic alternatives. We have not yet engaged a financial adviser to assist us in this effort. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of continuing to evaluate these strategic options may be costly, time-consuming and complex and we may incur significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges. Moreover, any potential financial or strategic option we pursue may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all. There can be no assurance of completion of any particular course of action or a defined timeline for completion, and we can provide no assurance that any strategic alternative we pursue will have a positive impact on our results of operations or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are attempting to sublease or assign our three leaseholds, which represent significant operating costs, and there can be no assurance that we will accomplish this effort on favorable terms, or at all, which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has three leaseholds including two in Waltham, Massachusetts and one in Watertown, Massachusetts. These leaseholds represent significant operating costs for the Company. The Company has retained a broker to sublease or assign all three of the leaseholds in connection with the Company&#8217;s capital preservation efforts. There can be no assurance that the Company will find third parties to enter into a sublease or assignment of these leaseholds at terms that are favorable to the Company, on a timetable that is advantageous to the Company, or at all.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The operating lease, as amended, for office and laboratory space in Watertown expires in April 2027 and comprises approximately 27,311 square feet. The lease provides for base rent of $2.0 million per year. The Company maintains a letter of credit of approximately $0.3 million securing its obligations under the Watertown operating lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has two leases for space at 880 Winter Street in Waltham. The first lease comprises approximately 29,000 square feet of office and lab space, and the lease provides for base rent of $2.2 million per year, which will increase 3% per year over the noncancellable term ending on June 30, 2033. In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $1.1 million of deposits with the financial institution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company executed a sublease agreement for additional laboratory and office space located at 880 Winter Street in Waltham. The subleased premises comprise approximately 24,000 square feet, and the sublease provides for base rent of $1.8 million per year, which will increase 3% per year over the noncancellable term ending on November 30, 2032. The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of approximately $0.6 million.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under all three leases, the Company is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the respective leased premises. An inability to successfully sublease or assign all three of the leaseholds will negatively impact our capital preservation efforts and could materially and adversely affect our business, financial condition and the results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In the future, we may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may enter into transactions to acquire other businesses, products, or technologies or enter into strategic partnerships, including licensing. If we do identify suitable acquisition or partnership candidates, we may not be able to make such acquisitions or partnerships on favorable terms, or at all. Any acquisitions or partnerships we make may not strengthen our competitive position, and these transactions may be viewed negatively by employees, customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business or partnership that are not covered by the indemnification we may obtain from the seller or our partner. In addition, we may not be able to successfully integrate any acquired personnel, technologies, and operations into our existing business in an effective, timely, and non-disruptive manner. Acquisitions or partnerships may also divert management attention from day-to-day responsibilities, lead to a loss of key personnel, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing, or size of future acquisitions or partnerships or the effect that any such transactions might have on our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future. We may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses in each year since our inception, including operating losses of approximately $93.4 million and $62.7 million for the years ended December 31, 2024 and 2023 respectively. In addition, we have not commercialized any products and have never generated any revenue from product sales. We have devoted almost all of our financial resources to research and development, including our pre-clinical development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, our Board approved a reduction in force by up to 87 employees, effective on or about May 21, 2024 with respect to approximately 80 employees and effective on or about June 20, 2024 with respect to approximately seven employees (the &#8220;May 2024 RIF&#8221;). The Board&#8217;s decision was based on the need to implement cost-reduction initiatives intended to reduce the Company&#8217;s ongoing operating expenses and maximize shareholder value. The Company incurred charges of approximately $10.9 million in connection with this workforce reduction, primarily consisting of severance payments, employee benefits and related costs. Certain of these expenses have been paid to former employees as of the date of these consolidated financial statements and relate to the May 2024 RIF. The remaining expenses are included within accrued restructuring with anticipated payout at a later date, primarily pertaining to current employees.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur significant additional operating losses for the foreseeable future and we may not achieve or maintain profitability in the future. In order to obtain FDA approval of any product candidate, we must submit to the FDA an NDA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as non-clinical or pre-clinical studies, as well as human tests, which are referred to as clinical trials. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with CRS treatment product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially if we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our ENLIGHTEN 2 Phase 3 clinical trial of our most advanced product candidate, LYR-210;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct another Phase 3 trial for LYR-210 since our ENLIGHTEN 1 Phase 3 clinical trial failed to meet its primary endpoint, as we announced in May 2024;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory and marketing approvals for LYR-210 if it successfully completes the requisite clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utilize external vendors for support with respect to research, development, commercialization, regulatory, pharmacovigilance, and other functions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other commercial products, product candidates, and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make royalty, milestone, or other payments under any future in-license agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implement additional internal manufacturing capabilities, systems and infrastructure; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operate as a public company. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our ability to successfully develop, commercialize, and license our products and generate product revenue is subject to substantial additional risks and uncertainties. Each of our product candidates will require additional pre-clinical and/or clinical development, potential regulatory approval in multiple jurisdictions, the development of or securing of manufacturing supply, capacity, and expertise, the use of external vendors, the building of a manufacturing and commercial organization, substantial investment, and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount of future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the foreseeable future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the clinical development of our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; establishing cost-effective manufacturing, generating sales, and achieving market acceptance of our products and marketing infrastructure to commercialize our product candidates for which we obtain approval; and raising sufficient funds to finance our activities. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to operate with limited resources. We have incurred significant losses since our inception and have never generated revenue or profit, and it is possible we will never generate revenue or profit. Based on our current operating plans, and without additional funding, there is substantial doubt about our ability to continue as a going concern. See Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Annual Report on Form 10-K for a discussion of our expected cash runway. This cash runway estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Until such time as the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements, but there can be no assurances that such financing will be available to us on satisfactory terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize any of our product candidates. If we are unable to obtain funding, we would be forced to delay, reduce or eliminate our research and development programs, which would adversely affect our business prospects. In addition, if we are unable to raise capital, we will also need to implement additional cost reduction measures, and any failure to effectively do so will harm our business, results of operations and future prospects. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations. If we are unable to continue as a going concern, investors could lose all or part of their investment in our Company.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We need significant additional funding in order to complete development of, manufacture, and obtain regulatory approval for our product candidates and commercialize our products, if approved. Moreover, the failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint has made it more difficult for us to raise capital. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, and/or discontinue operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to need additional capital, which we may raise through equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements or other sources. The failure to meet the primary endpoint of our ENLIGHTEN 1 Phase 3 clinical trial has made it significantly more difficult for us to raise more capital. Accordingly, we may be required to obtain further funding through public or private equity offerings, debt financings, royalty-based financing arrangements, collaborations and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned clinical trials or obtain approval of any of our product candidates from the FDA, or any foreign regulatory authorities, and could be forced to discontinue product development or reduce our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial funds to further develop, manufacture, obtain approval for, and commercialize our product candidates, including LYR-210, for which we initiated two Phase 3 clinical trials. In May 2024 we suspended further development of LYR-220. We would also require substantial additional funds to further develop, obtain approval for, and commercialize, LYR-220.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and results of our clinical trials, including any unforeseen costs we may incur as a result of clinical trial delays; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and results of our clinical trials, including any unforeseen costs we may incur as a result of clinical trial delays; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for LYR-210; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of changes in the regulatory environment and enforcement rules; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing in changes in pharmaceutical pricing and reimbursement infrastructure; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other patent-related costs, including any litigation costs and the results of such litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we in-license or acquire other products and technologies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing sales, marketing, manufacturing, and distribution capabilities for our product candidates in regions where we choose to commercialize our products.</span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on our business performance, the economic climate, and market conditions, we may be unable to raise additional funds through any sources. Market volatility could also adversely impact our ability to access capital as and when needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and U.S. treasury bills and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our operations and our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, redeeming our stock, making certain investments, and engaging in certain merger, consolidation, or asset sale transactions, among other restrictions. If we raise additional funds through additional collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have no approved products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have no approved product on the market and have generated no product revenues. Unless we receive approval from the FDA or other regulatory authorities for our product candidates, we will not have product revenues. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand and licensing fees and grants, if any.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LYR-210 is at a development stage and we have suspended further efforts on LYR-220.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biotechnology company focused on the development and commercialization of novel integrated drug and drug delivery solutions for the localized treatment of patients with CRS. Our product candidates are in clinical development, and favorable results in early-stage clinical trials may not be predictive of success in later clinical trials and may not lead to commercially viable products for any of several reasons. For example, we failed to meet the primary endpoint in our ENLIGHTEN 1 Phase 3 trial for LYR-210 which has a material adverse effect on our development plans for LYR-210. In May 2024 we also suspended further development of LYR-220. LYR-210, as well as LYR-220, if in the future we decide to advance it, will require significant additional development, clinical trials, regulatory authorizations, and additional investment by us before it can be commercialized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is highly dependent on the success of our most advanced product candidate, LYR-210, which requires on-going clinical testing before we can seek regulatory approval and potentially launch our product. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for, and successfully commercialize our most advanced product candidate, LYR-210. We currently have no products that are approved for commercial sale and have not completed the development of any product candidates, and may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures will be devoted to LYR-210, which will each require continued clinical development and potential additional pre-clinical development, management of clinical and medical affairs and manufacturing activities, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, the building of a manufacturing and commercial organization, substantial investment, and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that LYR-210 will be successful in ongoing or future clinical trials, receive regulatory approval, or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market LYR-210 from the FDA or other regulatory bodies, we cannot be certain that our product candidates will be successfully commercialized, profitable,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">widely accepted in the marketplace, or more effective than other commercially available alternatives. Nor can we be certain that, if and when approved, the safety and efficacy profile of LYR-210 and will be consistent with the profiles observed in clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We advanced LYR-210 through our Phase 2 randomized, controlled, patient blinded LANTERN clinical trial, evaluating the safety and efficacy in surgically-na&#239;ve CRS patients who have failed previous medical management. The trial was designed to enroll 99 evaluable patients with the potential to increase to up to 150 patients and was initiated in May 2019 at sites in Australia, Austria, Czech Republic, New Zealand, and Poland. In December 2019, the FDA authorized our investigational new drug application, and, prior to COVID-19, we planned to enroll patients in the United States. However, in light of developments relating to COVID-19, as described below, we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 7, 2020, we reported top-line results from our Phase 2 LANTERN clinical trial, including that LYR-210 failed to meet the primary endpoint of the trial. We believe this was primarily due to the discontinuation of enrollment related to COVID-19. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67) patients in our Phase 2 LANTERN clinical trial, a greater magnitude of change in composite score of the seven-day average of four cardinal symptoms from baseline at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order for the trial to achieve statistical significance for the primary endpoint.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 6, 2024, we reported top-line results from our Phase 3 ENLIGHTEN 1 clinical trial, including that LYR-210 failed to meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. The 52-week extension phase of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients that received a repeat dosing, resulting in a 12-month treatment period.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENLIGHTEN 2, the second Phase 3 trial of LYR-210 in CRS, is ongoing and topline data is expected in the second quarter of 2025. There can be no assurance that we will achieve the primary endpoint or any other endpoints in the ENLIGHTEN 2 Phase 3 clinical trial for LYR-210.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the required regulatory approvals for LYR-210 are not obtained or are significantly delayed, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed. For example, the Company may need to revise its regulatory strategy for LYR-210 since the Company failed to meet the primary endpoint of the ENLIGHTEN 1 Phase 3 clinical trial.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our competitors may be developing products with similar mechanisms of action and may experience problems with their products that could identify problems that would potentially harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If LianBio HK, as defined below, is unable to find a third party to acquire its rights under the LianBio License Agreement, as defined below, it may materially harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio Development (HK) Limited (as successor-in-interest to LianBio Inflammatory Limited), a private company limited by shares organized under the laws of Hong Kong, or LianBio HK, announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio HK Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio HK reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, was expected to be completed by the end of 2024. LianBio HK announced in 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio HK stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company&#8217;s collaboration with LianBio HK is uncertain as LianBio HK announced it was winding down, while seeking a third party to acquire LianBio HK&#8217;s rights under the License and Collaboration Agreement dated May 31, 2021, by and among us, LianBio HK and LianBio, a corporation organized under the laws of the Cayman Islands, or LianBio Cayman, as amended September 26, 2022, or the LianBio License Agreement. If LianBio HK is unable to find a third party to acquire LianBio HK&#8217;s rights under the LianBio License Agreement, it may materially harm our business, financial condition, results of operations and prospects. In November 2024 we entered into a novation agreement which substituted LianBio Cayman for LianBio HK.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing our obligations under our license and other strategic agreements may divert management time and attention, causing delays or disruptions to our business.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to the LianBio License Agreement. The LianBio License Agreement grants an exclusive license to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Macau, and Taiwan), Singapore, South Korea, and Thailand, or the Territory. Furthermore, under the LianBio License Agreement, LianBio HK has the first right to obtain a license to develop and commercialize LYR-220.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the LianBio License Agreement, both parties agreed to negotiate prior to December 31, 2022 a clinical supply agreement to support clinical trials to be conducted by LianBio HK in the territory, i.e., PRC, Hong Kong, Macau, Taiwan, Singapore, South Korea, and Thailand. Subsequently, there was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement. Payments made by LianBio HK to the Company that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheet. The Company anticipated that the payments treated as a contract liability would be recognized as revenue as the clinical supply of LYR-210 was delivered and over the remaining time it takes to conduct the applicable trials. As of December 31, 2024, the parties are not actively engaged in negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also may in the future enter into license and strategic agreements, which, subject us to various obligations, including diligence obligations, reporting and notification obligations, payment obligations for achievement of certain milestone as well as other material obligations. We may need to devote substantial time and attention to ensuring that we successfully integrate these transactions into our existing operations and are compliant with our obligations under these agreements, which may divert management&#8217;s time and attention away from our research and development programs or other day-to-day activities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our license and strategic agreements are also complex and certain provisions in those agreements may be susceptible to multiple interpretations. In the event of any disagreement about the interpretation of these provisions, our management may need to devote a disproportionate amount of its attention to resolving these disagreements. Such disruptions may cause delays in our research and development programs and other business objectives.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our license and strategic agreements, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to the LianBio License Agreement, we made certain covenants to not commercialize a competing product anywhere in the Territory, nor collaborate with, enable, or otherwise authorize, license, or grant any right to any third party to commercialize a competing product anywhere in the Territory, subject to certain carve-outs. We also made certain covenants to grant an exclusive option to LianBio HK for the development and commercialization of LYR-220 in the Territory. These provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other product candidates and may materially harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market and sell our products in jurisdictions outside of the United States, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Additionally, we may be dependent on third-party collaborators to develop and commercialize our product candidates in certain international jurisdictions, such as in the case of our exclusive license agreement with LianBio HK for the development and commercialization of LYR-210 in the Territory. In the agreement with LianBio HK, while we have agreed that we must use commercially reasonable efforts to complete a global Phase 3 clinical trial for LR-210 and seek regulatory approval in the United States, LianBio HK must also use commercially reasonable efforts to develop, seek</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory approval for, and commercialize LYR-210 in the Territory. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in other jurisdictions. We and our third-party collaborators may not be able to file for marketing approvals, and even if we do, we may not obtain necessary approvals to commercialize our medicines in any market.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are party to a collaboration agreement, and may enter into other collaborations, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug development programs and the potential commercialization of our drug candidates will require substantial additional cash to fund expenses. For some of our drug candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those drug candidates in selected geographic territories or for selected patient populations. For example, we are party to the LianBio License Agreement to develop and commercialize LYR-210 in the Territory. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration or successfully maintain a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed or existing collaboration and the proposed or existing collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing therapies, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate. The terms of any existing or additional collaborations or other arrangements that we may establish may not be favorable to us.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may in the future expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trials required for our lead product candidate and any future product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We initiated Phase 3 clinical trials for our most advanced product candidate, LYR-210. In May 2024 we suspended further clinical development on our other product candidate, LYR-220, in order to preserve capital following our failure to meet our primary endpoint in the ENLIGHTEN 1 Phase 3 clinical trial for LYR-210. It is impossible to predict if LYR-210 will prove effective and safe in humans or if we will receive regulatory approval, and the risk of failure through the development process is high. Given the similarities in the design of the ENLIGHTEN 1 and ENLIGHTEN 2 Phase 3 clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial, the risk that we fail to meet the primary endpoint in the ENLIGHTEN 2 Phase 3 clinical trial has increased since we failed to meet our primary endpoint in the ENLIGHTEN 1 Phase 3 clinical trial. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we may need to complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical development is a long, expensive, and uncertain process that is subject to significant delays. Due to known or unknown circumstances beyond our control, it may take us several years to complete our testing, and failure can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. We cannot assure you that any clinical trial that we are conducting, or may conduct in the future, will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analysis, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays associated with products for which we are directly conducting clinical trials may cause us to incur additional operating expenses. The commencement and rate of completion of clinical trials may be delayed by, or terminated because of, many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our pre-clinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain regulatory approval to commence a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to reach, or delays in reaching, an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">slower than expected rates of recruitment of patients or failure to recruit a sufficient number of patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modification of pre-clinical studies or clinical trial protocols; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements for pre-clinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of unusual placebo effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of effectiveness during pre-clinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the emergence of unforeseen safety issues or undesirable side effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain institutional review board, or the IRB, approval at each site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays, suspension, or termination of clinical trials by the IRB responsible for overseeing the trial at a particular trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of patients in completing a trial or returning for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from trial protocol, dropping out of a trial, or failing to comply with regulatory requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to address patient safety concerns that arise during the course of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to manufacture sufficient quantities of product candidate for use in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government, IRB, or other regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of the trials; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from pandemics. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical power to detect any statistically significant treatment effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, IRBs, or independent ethics committees, or IECs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience delays in reaching or fail to reach agreement on acceptable pre-clinical study or clinical trial contracts or pre-clinical study or clinical trial protocols with prospective trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of pre-clinical studies or clinical trials of our product candidates may be greater than we anticipate and we may not have funds to cover the costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct pre-clinical studies or clinical trials of our product candidates, or commercialize our products, may be insufficient or inadequate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment for our clinical trials may be adversely affected by recruiting for competing trials or the approval of products competitive with our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any current or future collaborators that conduct pre-clinical studies or clinical trials may face any of the above issues, and may conduct pre-clinical studies or clinical trials in ways they view as advantageous to them but that are suboptimal for us. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to extend the duration of current clinical trials or to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials, studies, or tests are not positive or are only modestly positive, if there are safety concerns, or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur unplanned costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval in some countries and not in others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could encounter delays if a clinical trial is materially modified, suspended, or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial, or by the FDA or other regulatory authorities. Such authorities may impose a material modification, suspension, or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects for our product candidates, or other products or product candidates in the same drug class, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Furthermore, we may rely on CROs and clinical trial sites to ensure the proper and timely conduct of clinical trials and while we would have agreements governing their committed activities, we would have limited influence over their actual performance, as described in &#8220;&#8212;Risks Related to Our Dependence on Third Parties.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our most advanced product candidate, LYR-210, is in clinical development and will require the completion of clinical testing before we are prepared to submit an NDA for regulatory approval. We cannot predict if or when we might complete the development of LYR-210 and submit an NDA or whether any such NDA will be approved by the FDA. We may also seek feedback from the FDA or other regulatory authorities on our clinical development programs, and the FDA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. If the results of ongoing and future clinical trials for LYR-210 are positive, we plan to submit an NDA in the United States. However, no assurance can be given that we will be successful in the near term, obtain regulatory approval, or have any commercial sales of LYR-210.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways by different reviewers and regulators, which could delay, limit, or prevent regulatory approval. Drug-related adverse events ("AEs") during a pre-clinical study or clinical trial could cause us to repeat a trial or study, perform an additional trial or study, expand the size and/or duration of a trial or study, terminate a trial or study, or even cancel a pre-clinical or clinical program. The failure of pre-clinical studies or clinical trials to demonstrate safety and effectiveness for the desired indications could harm the development of that product candidate and other product candidates. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials would delay the filing of our NDAs with the FDA and, ultimately, our ability to commercialize our product candidates and generate product revenues. A number of companies in the biotechnology and pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our future and ongoing pre-clinical studies and clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of LYR-210, and/or any future product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in the commencement or completion of, or have to extend or expand, our pre-clinical studies or clinical trials, or if we terminate a pre-clinical study or clinical trial prior to completion, the commercial prospects of LYR-210, or any future product candidate could be harmed, and our ability to generate revenues from LYR-210, or any future product candidate may be delayed. In addition, any delays in our pre-clinical studies or clinical trials could increase our costs, slow down the development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of pre-clinical studies or clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are no longer engaged in manufacturing our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously transitioned most of our clinical manufacturing from a contract manufacturing organization, or CMO, to an in-house manufacturing facility at our Watertown headquarters to produce LYR-210and LYR-220, the latter of which we have since deprioritized. We never previously completed a technical transfer process to an in-house facility, built, owned or operated a commercial manufacturing facility, and there is no guarantee that we will be successful doing so. Since the May 2024 RIF, we are no longer engaged in the manufacture of our product candidates and we no longer intend to build out a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercial manufacturing capability. We are also engaged in an effort to sublease or assign our three leaseholds which include manufacturing space. Throughout Item 1A, we refer to manufacturers, CMOs and suppliers interchangeably.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parts of our manufacturing process are still outsourced and we expect them to remain outsourced. Our CMOs provide multiple different types of services to us. For example, some CMOs provide raw materials for our in-house manufacturing effort; some CMOs perform analytical testing for our starting materials, intermediates, drug product, and stability studies; and some CMOs provide services like sterilizing, packaging, and labeling. Currently, our manufacturing activities are suspended and that suspension applies to third party CMOs that provide materials and services related to our manufacturing.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we restart our in-house manufacturing, it is common that various aspects of the development program, such as manufacturing methods and equipment, are altered along the way in an effort to optimize cost of goods, processes and results. Such changes carry the risk that these manufacturing efforts will not achieve these successfully or in a cost-efficient manner, or that we will be subject to additional requirements by the FDA or other regulatory bodies. Slight deviations resulting from technology transfer, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. Problems with our in-house manufacturing process could restrict our ability to meet our clinical and regulatory timelines, and market demand for our products.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the May 2024 RIF, we no longer have a sufficient number of experienced scientific, quality and manufacturing personnel needed to operate our manufacturing processes, which in the event we restart our manufacturing efforts, could result in delays in production.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any problems in our manufacturing process or facilities, or that of our CMOs, licensees and suppliers, could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional capital or capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our pre-clinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates and the development of our product candidates may be delayed or unsuccessful, which could prevent or delay regulatory approval and commercialization.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently LYR-210 is our only product candidate still in clinical development. Notwithstanding the data obtained to date with respect to LYR-210 and LYR-220 in CRS, LYR-210 will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate any revenue from our product sales. In addition, if we encounter safety or efficacy problems, developmental delays or regulatory issues, or other problems, our developmental plans and business could be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the development of LYR-210, or any other future product candidate is unsuccessful, our ability to generate revenues will be significantly and adversely affected. Our development of current and future product candidates is subject to the risks of failure and delay inherent in the development of new products and product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in product development, pre-clinical, or clinical testing or manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unplanned expenditures in product development, pre-clinical, or clinical testing or manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to receive regulatory approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to secure rights from third parties for new technology; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to achieve market acceptance; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">emergence of superior or equivalent products. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, product candidates in later stages of clinical trials may fail to show the desired safety profiles and efficacy results despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have not conducted, nor do we believe we are required to conduct, any head-to-head trials comparing LYR-210 to other approved or experimental treatments for CRS. Any such head-to-head trial, if conducted, may show that LYR-210 is not more effective than any of such other drugs. Material adverse differences in the relative efficacy of LYR-210 could significantly harm the adoption of LYR-210 and our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of these risks, our research and development efforts may not result in any commercially viable products. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Success in pre-clinical or earlier clinical trials may not be indicative of results in future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Pre-clinical studies and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, study pharmacokinetics and pharmacodynamics, and understand the side effects of product candidates at various doses and schedules. Success in pre-clinical studies and early clinical trials does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced, or later. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical studies and earlier-stage clinical trials. Data obtained from pre-clinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the FDA does not conclude that LYR-210 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for LYR-210 under Section 505(b)(2) are not as we expect, the approval pathway for LYR-210 may take significantly longer, cost significantly more, and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to seek FDA approval for LYR-210 through the Section 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act, or FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as we anticipate, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates, and complications and risks associated with the development of our product candidates, would likely substantially increase. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in competitive products reaching the market before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization, or that a competitor would not obtain approval first along with subsequent market exclusivity from the FDA, thereby delaying potential approval of our product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, even if our product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have conducted, are conducting, and, in the future, may conduct clinical trials for our product candidates in sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted and are conducting clinical trials for LYR-210 outside the United States, primarily in Europe, and we may in the future choose to conduct other clinical trials outside the United States for LYR-210, or any of our other future product candidates. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP, including review and approval by an IEC and receipt of informed consent from subjects. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for which we intend to seek approval for the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign exchange fluctuations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing, customs, shipment, and storage requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural differences in medical practice and clinical research; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between interim or preliminary data and final data could significantly harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LYR-210 will be regulated as a drug-device combination products, which may result in additional regulatory and other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 is expected to be regulated as a drug-device combination products. We may experience delays in obtaining regulatory approval of LYR-210 given the increased complexity of the review process when approval of a combination product is sought under a single marketing application. LYR-210 will be regulated as drug-device combination products, which require coordination within the FDA and similar foreign regulatory agencies for review of the product candidates&#8217; device and drug components. The determination whether a combination product requires a single marketing application or two separate marketing applications for each component is made by the FDA on a case-by-case basis. Although we believe a single marketing application for the approval of a combination product would be successful, there can be no assurance that the FDA will not determine that separate marketing applications are necessary. This determination could significantly increase the resources and time required to bring a particular combination product to market. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process, as well as coordination between two different centers within FDA responsible for review of the different components of the combination product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to successfully develop or supply the device component, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or third-party providers to obtain or maintain regulatory approval or clearance of the device component of LYR-210, as appropriate, could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in these product candidates reaching the market. Further, failure to successfully develop or supply the device, or to gain or maintain its approval, could adversely affect sales of LYR-210.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to obtain the necessary U.S. regulatory approvals to commercialize any product candidate, we will not be able to generate revenue in the U.S. market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that we will receive the approvals necessary to commercialize our product candidates, or any product candidate we acquire or develop in the future. We will need FDA approval to commercialize our product candidates in the United States and approvals from equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity, and novelty of the product candidate, and requires substantial resources for research, development, and testing. We cannot predict whether our research and clinical efforts will result in drugs that the FDA will determine are safe for humans and effective for their intended uses. The FDA has substantial discretion in the drug approval process and may require us to conduct additional pre-clinical and clinical testing, perform post-marketing studies, address manufacturing concerns, or otherwise limit or impose conditions on any approval we obtain. The approval process may also be delayed by changes in government regulation, future legislation or administrative action, or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay commercialization of, and our ability to derive product revenues from, our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose costly procedures on us; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminish any competitive advantages that we may otherwise enjoy. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive approval of an NDA or comparable foreign regulatory filing for our product candidates, the FDA or the applicable foreign regulatory body may approve our product candidates for a more limited indication than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of our product candidates will severely undermine our business by leaving us without a commercially available product, and therefore without any source of revenues, until another product candidate can be developed or obtained and ultimately approved. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will be able to obtain FDA approval to commercialize such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend, either on our own or through collaborations or partnerships, to market our products in international markets. In order to market any products in the European Union and many other foreign jurisdictions, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional pre-clinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, costly, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We cannot predict when or if, and in which territories, we, or any of our potential future collaborators, will obtain marketing approval to commercialize a product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that neither LYR-210, nor any future product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses in patients. Results from non-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the non-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy and costly approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development activities and receipt of regulatory approvals could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. For example, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data due to COVID-19, and, as a result, we initiated a separate characterization study in September 2020 as a follow-on to our Phase 2 LANTERN clinical trial in order to collect such data. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may encounter delays in enrolling, or be unable to enroll, a sufficient number or diversity of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. We cannot predict how successful we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate in the trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of alternative therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of geopolitical or other global events.</span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays, or both, which could have a harmful effect on our ability to develop LYR-210 and/or any other future product candidates, or could render further development impossible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause serious AEs or undesirable side effects including injury and death or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval. If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any potential future collaborators, to market the drug could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive pre-clinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Serious AEs, or SAEs, or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our clinical trials or pre-clinical studies could reveal a high and unacceptable severity and prevalence of side effects, toxicities, or unexpected characteristics, including death. For example, in our Phase 1 clinical trial for our most advanced product candidate, LYR-210, there was one SAE in the active group (acute myocardial infarction), which was considered not related to LYR-210.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, subjects treated with LYR-210 have experienced AEs, including epistaxis, rhinitis, rhinorrhea, facial pain, nasopharyngitis, sinusitis, upper respiratory tract infection, procedural headache, nasal discomfort, and nasal odor, among others. In our Phase 2 LANTERN clinical trial, treatment-related AEs were reported in 16 patients, and all treatment-related AEs except one (increased viscosity of upper respiratory secretion) were mild or moderate in nature. In addition, there was one patient in the LYR-210 (2,500 &#181;g) group who had a serious AE of acarodermatitis in our Phase 2 LANTERN clinical trial, which was deemed to be not related to treatment. In the 24-week treatment phase of the Phase 3 ENLIGHTEN 1 clinical trial, the most commonly reported AEs in the study population were epistaxis, nasal odor, upper respiratory tract infection and sinusitis.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients that received a repeat dosing, resulting in a 12-month treatment period.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most commonly reported adverse events in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, could materially modify, suspend, or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease pre-clinical studies or clinical trials, require us to conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated, or deny approval of our product candidates for any or all targeted indications. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We have historically trained and may in the future have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw approvals of such product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require long-term patient registries for the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product could become less competitive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will resolve any issues related to any product-related AEs to the satisfaction of the FDA or any regulatory agency in a timely manner or at all. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization, could include intentional, reckless, or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, the European Medicines Agency, or the EMA, and other similar regulatory authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; (ii) manufacturing standards; or (iii) data privacy, security, fraud and abuse, and other healthcare laws and regulations. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of pre-clinical studies or clinical trials, creation of fraudulent data in pre-clinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations would suffer in the event of system failures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our computer systems, as well as those of our CROs and other contractors, vendors, suppliers, and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including the impacts of climate change), international terrorism and conflicts, and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs and our business. For example, the loss of pre-clinical studies or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information or information that relates to individuals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and/or constitutes &#8220;personal data,&#8221; &#8220;personal information,&#8221; &#8220;personally identifiable information,&#8221; or similar terms under applicable data privacy laws (collectively, &#8220;Personal Information&#8221;), we could incur liability and the further development of LYR-210, or any other product candidate could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we directly or indirectly collect and store sensitive data, including intellectual property, confidential information, pre-clinical and clinical trial data, proprietary business information, personal data, and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third parties. The secure processing, maintenance, and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure has been and, from time to time, may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance, or other disruptions. For example, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with increased remote work during and after COVID-19. Although, to our knowledge, we have not experienced any material security breach, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings (including class actions), liability under laws that protect the privacy of personal information, or significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our business reputation and delay our clinical development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to extensive and costly government regulation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product candidates employing our technology will be subject to extensive and rigorous domestic government regulation including regulation by the FDA, the CMS, other divisions of the United States Department of Health and Human Services or HHS, the United States Department of Justice, state and local governments, and their respective equivalents outside of the United States. The FDA regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products. If products employing our technologies are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding United States regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The regulatory review and approval process, which includes pre-clinical testing and clinical trials of each product candidate, is lengthy, expensive, and uncertain. We or our collaborators must obtain and maintain regulatory authorization to conduct pre-clinical studies and clinical trials. We or our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product&#8217;s safety and efficacy, potency, and purity, for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the approval of a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we, our collaborators, consultants, CMOs, CROs, or other vendors fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things, delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the EU, and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could prevent or delay marketing approval of our products in development, restrict or regulate post-approval activities involving any product candidates for which we obtain marketing approval, impact pricing and reimbursement, and impact our ability to sell any such products profitably. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. In addition, new regulations are frequently adopted and interpretations of existing healthcare statutes may change over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. For instance, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, which was previously capped at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In August 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. The IRA includes several provisions that may impact our business to varying degrees, including provisions that establish a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on many drugs reimbursed under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, and require companies to pay rebates to Medicare for drug prices that increase faster than inflation (first due in 2023). The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic, and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA&#8217;s regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU, or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, AE reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA, the EMA, and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. In addition, the sponsor of an approved NDA is subject to periodic inspections and other FDA monitoring and reporting obligations, including obligations to monitor and report AEs and other information such as the failure of a product to meet the specifications in the NDA. NDA sponsors must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. The FDA may require changes in the labeling of already approved drug products and require that sponsors conduct post-marketing studies. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a medication guide, physician communication plans, or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk mitigation tools. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. In addition, advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDA&#8217;s restrictions relating to the promotion of prescription products may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The distribution of product samples to physicians must comply with the requirements of the FDCA. NDA sponsors must obtain FDA approval for product, manufacturing, and labeling changes, depending on the nature of the change. Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, consent decrees of permanent injunction, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown AEs or other problems with our products, or manufacturing processes, including AEs of unanticipated severity or frequency, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on manufacturing such products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of a product; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters or holds on clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution, or disgorgement of profits or revenues;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is withheld or withdrawn, the value of our Company and our operating results will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of LYR-210 and/or any other future product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects, and ability to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Further, three decisions from the U.S. Supreme Court in July 2024 may lead to an increase in litigation against regulatory agencies that could create uncertainty and thus negatively impact our business. The first decision overturned established precedent that required courts to defer to regulatory agencies&#8217; interpretations of ambiguous statutory language. The second decision overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. The third decision extended the statute of limitations within which entities may challenge agency actions. These cases may result in increased litigation by industry against regulatory agencies and impact how such agencies choose to pursue enforcement and compliance actions. However, the specific, lasting effects of these decisions, which may vary within different judicial districts and circuits, is unknown. We also cannot predict the extent to which FDA and SEC regulations, policies, and decisions may become subject to increasing legal challenges, delays, and changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed, approved, or commercialized in a timely manner, or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the government agency&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business, financial condition, and results of operations may suffer in the event of information technology system failures, cyberattacks, data security incidents or deficiencies in our cybersecurity.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on our information technology systems and those of our third-party service providers for both internal and external operations that are critical to our business. We face numerous and evolving cybersecurity risks that threaten the confidentiality, integrity and availability of our information technology systems and data we and our third-party providers maintain, including Personal Information, clinical trial data, confidential and proprietary intellectual property, financial information, trade secrets, and other business information (together, &#8220;Confidential Information&#8221;). Our information technology systems and Confidential Information, and those of our third-party service providers, contractors and consultants are vulnerable to attack, interruption and damage from computer viruses and malware (e.g. ransomware), bugs, misconfigurations, malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems and Confidential Information are increasing in their frequency, levels of persistence, sophistication and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intensity - including attacks conducted using artificial intelligence - and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems and data change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security incidents that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can also be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with, or effective in protecting our information technology systems and data. While we do not believe that we have experienced any material system failure or incident, from time to time, we and our third party providers have been the target of cybersecurity attacks, and we expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and number. While we do not believe that any incidents have had a material impact on our operations or financial results to date, we cannot guarantee that material incidents will not occur in the future. If such an incident were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We could also incur liabilities and the further development of our product candidates could be delayed. Further, any adverse impact to the availability, integrity or confidentiality of our information technology systems or data could expose us to legal claims or proceedings (including class actions), enforcement actions and investigations by regulatory authorities, and potentially result in penalties, fines and significant legal liability. We could also experience negative reputational impacts that cause an erosion of trust, and/or significant incident response, system restoration or remediation and future compliance costs. Any or all of the foregoing could materially adversely affect our business, results of operations, and financial condition. Finally, cyber insurance we maintain may not be sufficient to cover the financial, legal, business or reputational losses that may result from an incident, and we cannot guarantee that applicable insurance will be available to us in the future on economically reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection, and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, and third parties on our behalf, receive, store, handle, transmit, use and otherwise process business information and information related to individuals, including from and about trial patients as well as our employees, business contacts, and service providers. We and our partners are subject to diverse state, federal, and international laws and regulations relating to data privacy and security, including, in the United States, the California Consumer Privacy Act, or the CCPA, and, in the EU and the European Economic Area, or EEA, the General Data Protection Regulation, or the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened, creating an ever evolving patchwork of privacy laws. For example, the CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches. Complying with these numerous, complex, and often changing laws and regulations is expensive and difficult, and failure or perceived failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss, or other unauthorized use or disclosure of personal information, whether by us or another third-party, could adversely affect our business, financial condition, and results of operations, including but not limited to: damage to our reputation, an erosion of trust, and negative media attention; investigation costs; material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services, and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, the GDPR requires us, among other things, to make detailed disclosures to data subjects, to disclose the legal basis on which we can process Personal Information, to obtain valid consent for processing, to appoint data protection officers when sensitive Personal Information, such as health data, is processed on a large scale, and provides robust rights for data subjects, introduces mandatory data breach notification, imposes additional obligations on us when contracting with service providers, and requires us to adopt appropriate privacy governance including policies, procedures, training, and data audit. In addition, the GDPR increases the scrutiny of transfers of Personal Information from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws, which could increase our costs and our ability to efficiently process personal data from the EEA. If we do</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not comply with our obligations under the GDPR, we could be exposed to fines of up to the greater of &#8364;20.0 million or up to 4% of our total global annual revenue in the event of a significant breach. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations, and financial condition. Additionally, following the United Kingdom&#8217;s withdrawal from the EEA and the EU, companies have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217;, and employees&#8217; Personal Information and other Confidential Information will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations, and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage, and transmission of such information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act. We are not currently classified as a &#8220;covered entity&#8221; or &#8220;business associate&#8221; under HIPAA. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive protected health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of protected health information. In addition, we may maintain sensitive Personal Information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the protected health information under HIPAA. Our clinical trial programs outside the United States may implicate international data protection laws, including the GDPR and legislation of the EU and EEA member states implementing it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our activities outside the United States impose additional compliance requirements and generate additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply with the strict rules on the transfer of Personal Information outside of the European Union into the United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws, and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals&#8217; health information. The GDPR provides that EU and EEA member states may establish their own laws and regulations limiting the processing of Personal Information, including genetic, biometric, or health data, which could limit our ability to use and share Personal Information or could cause our costs to increase. Moreover, patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we, our CROs, or other contractors or consultants fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing, and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to environmental, health, and safety laws and regulations, as well as regulations regarding our employees or other social considerations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations, including our development, testing, and manufacturing activities, are subject to numerous environmental, health, and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures, and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Moreover, certain environmental laws may impose liability without regard to fault or legality of the action at the time of its occurrence. Environmental, health, and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our development efforts may be interrupted or delayed. There is also increasing scrutiny from various stakeholders, including policymakers, on environmental and social matters, including climate change and human capital; this may result in additional regulations (or changes to interpretation of existing regulations)</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or other stakeholder engagement, which if we fail to successfully navigate may result in various adverse impacts on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our policies and other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image, and goodwill, regardless of the truthfulness of such posts. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry has been characterized by extensive research and development efforts, rapid developments in technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies either marketing or developing therapeutics to treat CRS. Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors may have or may develop superior technologies or approaches, which may provide them with competitive advantages. Our potential products may not compete successfully. If these competitors access the marketplace before we do with better or less expensive therapeutics, our product candidates, if approved for commercialization, may not be profitable to sell or worthwhile to continue to develop. Technology in the pharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products, or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development. The success of our product candidates will depend upon factors such as product efficacy, safety, reliability, availability, timing, scope of regulatory approval, acceptance, and price, among other things. Other important factors to our success include speed in developing product candidates, completing clinical development and laboratory testing, obtaining regulatory approvals, and manufacturing and selling commercial quantities of potential products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are intended to compete directly or indirectly with existing products and treatments. Even if approved and commercialized, our product candidates may fail to achieve market acceptance with hospitals, physicians, or patients. Hospitals, physicians, or patients may conclude that our potential products are less safe or effective or otherwise less</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attractive than these existing treatments. If our product candidates do not receive market acceptance for any reason, our revenue potential would be diminished, which would materially adversely affect our ability to become profitable. In addition, physicians may prefer to treat patients with CRS by performing ethmoid sinus surgeries which may reduce demand for our product candidates, once approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a number of companies developing or marketing therapies for the treatment and management of CRS that may compete with our current product candidates, including many major pharmaceutical and biotechnology companies. These companies include, among others: Sanofi, GlaxoSmithKline, Regeneron, Optinose, Medtronic, Genentech and Novartis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most of our competitors, including many of those listed above, have substantially greater capital resources, robust product candidate pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. As a result, our competitors may achieve product commercialization or patent protection earlier than we can. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or noncompetitive.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers, and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Similarly, our product candidates are physician-administered treatments and as such, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. To the extent separate coverage and reimbursement should become available for LYR-210, we anticipate that it will be sold to physicians on a &#8220;buy and bill&#8221; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. We do not know if, or at what level, physicians may receive reimbursement for treating patients with CRS with our product candidates, or for performing the procedure to insert our product candidates, or if such reimbursement will be deemed adequate by such physicians.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the status of reimbursement codes for any of our product candidates, if approved, could also affect reimbursement. J-Codes are reimbursement codes maintained by the CMS that are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">currently do not have a specific J-Code for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a J-Code will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific J-Code is not available, physicians would need to use a non-specific miscellaneous J-Code to bill third-party payors for these physician-administered drugs. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulty determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can delay claims processing times as well as increase the likelihood for claim denials and claim errors. We cannot be sure that coverage and reimbursement in the United States, the EU, or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs and biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU and other jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our clinical studies were designed to demonstrate the safety and efficacy of LYR-210 based on FDA requirements and may not be seen as compelling to physicians or patients.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends on the medical community&#8217;s acceptance of LYR-210, if approved, as a treatment for CRS patients. LYR-210 was previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia, which achieved its primary endpoint of safety at week 4. In the Phase 1 trial, we also observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in SNOT-22 scores was observed at week 1, and this reduction persisted through week 25, which was the end of the trial. In our Phase 2 LANTERN clinical trial, we reported positive top-line results but failed to achieve the primary endpoint. Although not statistically significant at week 4 (the primary endpoint), at the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. Furthermore, at the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm at weeks 8, 16, 20, and 24. Even if the results of these clinical trials suggest a favorable safety and efficacy profile, the study designs and results, and the designs and results of future clinical trials we conduct, may not be viewed as compelling to our physician customers or patients. If physicians do not find our data compelling, even if LYR-210 receives marketing approval they may choose not to use our products or limit their use. Our Phase 3 ENLIGHTEN 1 clinical trial failed to meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 52-week extension phase of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients that received a repeat dosing, resulting in a 12-month treatment period. LYR-210 was generally well tolerated, with no product-related serious adverse events. The most commonly reported adverse events in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENLIGHTEN 2, the second Phase 3 trial of LYR-210 in CRS, is ongoing and topline data is expected in the second quarter of 2025.</span><span style="color:#555657;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will achieve the primary endpoint or any other endpoints in the ENLIGHTEN 2 Phase 3 clinical trial for LYR-210. We also cannot assure you that any data that may be collected will be compelling to the medical community because the data may not be clinically meaningful and may not demonstrate that LYR-210 is an attractive procedure when compared against data from alternative treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if LYR-210 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LYR-210 ever receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an adequate level of acceptance, or if we are unable to achieve an optimal cost of goods, we may not generate significant product revenues or become profitable. The degree of market acceptance of LYR-210, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our technology; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perception by members of the healthcare community, including physicians, or patients that the process of administering LYR-210 is not unduly cumbersome; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectiveness of sales and marketing efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to offer our products for sale at competitive prices; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product implant requirements of the FDA, the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our product together with other medications. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are approved, but do not achieve an adequate cost of goods or level of acceptance by physicians, healthcare payors, and patients, we may not generate sufficient revenue from these products, and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. In addition, our ability to successfully commercialize our product candidates will depend on our ability to manufacture our products at commercial scale, differentiate our products from competing products, and defend the intellectual property of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we expect sales of LYR-210, if approved, to generate substantially all of our product revenues for a substantial period, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If physicians or patients are not willing to change current practices and adopt our office-based administration procedure for LYR-210 may fail to gain market acceptance, and our business will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we believe ear, nose and throat ("ENT") physicians will be able to administer LYR-210, if successfully developed and approved, in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for ENT physicians to schedule separate surgical time, ENT physicians may not adopt our in-office procedure for a number of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of significant experience with the placement procedure via a single-use applicator; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of availability of adequate insurance coverage or reimbursement for the placement procedure; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness of the placement procedure and/or our products in general over existing alternatives; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a perception that patients may be unable to tolerate the placement procedure in the physician office setting; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liability risks generally associated with the use of new products and procedures. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If ENT physicians do not adopt the placement procedure for any reason, including those listed above, our ability to grow our business would be impaired, even if LYR-210 receives marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe recommendations and support of our products by notable ENT physicians could influence market acceptance and adoption. If we do not receive support from influential ENT physicians, our ability to achieve broad market acceptance for our products may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if patient receptivity toward treatment in an ENT physician office setting becomes less favorable in the future, this shift could negatively impact market acceptance of our products. Any negative change due to patient receptivity could also be compounded by patients reporting to physicians or other patients through word-of-mouth or social media.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, while it is currently more cost-effective to the healthcare system for providers to perform the placement procedure in an ENT physician&#8217;s office than endoscopic sinus surgery in an operating room, healthcare economics are subject to change. If the use of our products were to cease being more cost-effective than endoscopic sinus surgery due to changes in reimbursement economics, our products may fail to gain market acceptance, and our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully establish manufacturing, sales, marketing, and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing LYR-210, if approved, and we may not be able to generate any revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have commercial infrastructure for the manufacturing, sales, marketing, or distribution of all of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. The failure to meet our primary endpoint in the ENLIGHTEN 1 Phase 3 trial has also adversely affected the Company&#8217;s commercialization plans for LYR-210.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure to meet the primary endpoint of our ENLIGHTEN 1 Phase 3 trial and its effects on our ability to pursue a development strategy for LYR-210 and to raise capital to operate the business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the loss of skilled personnel as a result of the May 2024 RIF;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manufacture sufficient quantities of our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to equip medical and sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to develop or obtain sufficient operational functions to support our commercial activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to set a suitable price or establish reasonable reimbursement rates for our product candidates. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of LYR-210, or any future product candidates in markets outside of the United States. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in the product, and such collaborator&#8217;s ability to successfully market and sell the product. We intend to selectively pursue collaborative arrangements regarding the sale and marketing of LYR-210, if approved, for certain markets outside of the United States; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, in the future we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of LYR-210, we may be forced to delay the potential commercialization of LYR-210 or reduce the scope of our sales or marketing activities for LYR-210. If we elect to increase our expenditures to fund commercialization activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LYR-210 or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing, and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing LYR-210 and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing, and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our customers&#8217; ability to obtain reimbursement for our product candidates in foreign markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to directly control commercial activities if we are relying on third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting, and legal requirements; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries, among others.</span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions, and changes in tariffs, including under the new U.S. Presidential administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The sizes of the patient populations that our product candidates are intended to treat have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population than we anticipate, our revenue and ability to achieve profitability may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The precise incidence and prevalence of the conditions we aim to address with our programs is unknown and cannot be precisely determined. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases, and the incidence or prevalence of these diseases is subject to change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indications and conditions of use for which the product candidates are approved and may be marketed, acceptance by the medical community, and patient access, drug pricing, and reimbursement. The sizes of the patient populations that our product candidates are intended to treat in the United States and other major markets and elsewhere may turn out to be smaller than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, we may never achieve profitability despite obtaining such significant market share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we cannot compete for market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates receive FDA approval, they will compete with a number of existing and future drugs and therapies developed, manufactured, and marketed by other companies. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost. If our products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies, and other public and private research organizations. Many of these competitors may have compounds already approved or in development in the therapeutic categories that we are targeting with our current and future product candidates. In addition, many of these competitors, either alone or together with their collaborative partners, may operate larger research and development programs or have substantially greater financial resources than we do, as well as greater experience in developing product candidates; formulating and manufacturing products; and launching, marketing, and selling products, among others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If in the future we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If LYR-210 is approved for commercialization, we may partner with third parties to market it in certain jurisdictions outside the United States. We expect that we will be subject to additional risks related to international pharmaceutical operations, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing, and insurance regimes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010, and similar anti-bribery and anticorruption laws in other jurisdictions; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor, and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biotechnology companies have found the process of marketing their own products in Europe to be very challenging.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of LYR-210, in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. For example, complications arising from the placement procedure for LYR-210, or from the degradation or dislodgment of the LYR-210 implant within the sinuses after placement, or from foreign growth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurring in the sinus after placement, could give rise to product liability claims against us. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance. In addition, regardless of merit or eventual outcome, product liability claims may result in significant consequences including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of our business reputation and significant negative media attention; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing, or promotional restrictions, among others.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We suspended the manufacture of our clinical materials in-house. If we restart our manufacturing, we may rely on third parties for certain development and manufacturing-related services and we do not currently have long-term contracts with any of these parties. Our continued reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have previously relied on third parties for certain development and manufacturing-related services during clinical development of our product candidates, and may rely on third parties for certain manufacturing-related services if any of our product candidates receive marketing approval. Certain of these manufacturers are critical to our production and the loss of these manufacturers to one of our competitors or otherwise, or an inability to obtain quantities at an acceptable cost or quality, could delay, prevent, or impair our ability to timely conduct pre-clinical studies or clinical trials, and would materially and adversely affect our development and commercialization efforts.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The facilities used by certain third-parties involved in the production of our product candidates or components of our product candidates may require FDA clearance pursuant to inspections that may be conducted after we submit an NDA to the FDA. While we may be able to mitigate risks through our diligence and contracting processes, when we utilize third parties for manufacturing, we are dependent on them for compliance with cGMP requirements for manufacture of drug products and other laws and regulations. If these third-party manufacturers cannot successfully manufacture or supply material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Some of our CMOs may not have produced a commercially-approved product and therefore may not have obtained the requisite FDA approvals to do so. In addition, we are limited in our ability to ensure third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, we may be unable to establish any agreements with third-party manufacturers, or to do so on acceptable terms, or to do so on a timely schedule.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers or suppliers entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">breach of the manufacturing agreement by the third party; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. The extent to which geopolitical or other global events impact our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the event, and the actions undertaken to contain its negative effects and may cause delays. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on third parties to conduct our pre-clinical studies and clinical trials, including our planned and ongoing clinical trials for LYR-210. If we decide to conduct future clinical trials for LYR-210 or other product candidates, we expect to rely on third parties to conduct those future clinical trials and pre-clinical studies. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs, and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators, and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that any such CROs, investigators, or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols, or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our relationships with these third-parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding CROs, investigators, and other third parties involve additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Our relationships with these third parties may also be adversely affected by geopolitical or other global events. For instance, COVID-19 and government measures taken in response had a significant impact on our CROs, and we expect that they could face further disruption which may affect our ability to initiate and complete our pre-clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies and clinical trials. Though we carefully manage our relationships with our CROs, investigators, and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may collaborate with third parties for the development and commercialization of LYR-210, and any of our future product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize LYR-210, or our future product candidates successfully, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional collaborative relationships for the development and commercialization of LYR-210, or any future product candidates. Failure to obtain a collaborative relationship for LYR-210, or any future product candidates may significantly impair the potential for these product candidates. We also may need to enter into collaborative relationships to provide funding to support our other research and development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we seek, but are not able to establish, collaborations, we may have to alter our development and commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital. We may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party vendors, such as CROs, scientists, and collaborators to provide us with significant data and other information related to our projects, pre-clinical studies, or clinical trials and our business. If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and results of operations could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not have multiple sources of supply for some of the components used in LYR-210, nor long-term supply contracts, and certain of our suppliers are critical to our production. If we were to lose a supplier, it could have a material adverse effect on our ability to complete the development of LYR-210. If we obtain regulatory approval for LYR-210, we would need to expand the supply of their components in order to commercialize them.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have multiple sources of supply for the components used in the manufacturing of LYR-210. We also do not have long-term supply agreements with any of our suppliers. We may not be able to establish additional sources of supply for our product candidates, or may be unable to do so on acceptable terms. Suppliers are subject to cGMP quality and regulatory requirements covering manufacturing, testing, quality control, and record keeping relating to our product candidates and are subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions in supply. Manufacturing suppliers are also subject to local, state, and federal regulations and licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of suppliers of the raw material components of our product candidates is limited. In the event it is necessary or desirable to acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. Additionally, certain of our suppliers are critical to our production and the loss of these suppliers to one of our competitors or otherwise would materially and adversely affect our development and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of any marketing approval, regulatory authorities conduct inspections that must be successful prior to the approval of the product. Failure of manufacturing suppliers to successfully complete these regulatory inspections will result in delays. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA amendment or supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our ability to complete the development of LYR-210 or, if we obtain regulatory approval for LYR-210, to commercialize them.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect our intellectual property and prevent others from duplicating LYR-210, and any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal, factual, and scientific questions and can be uncertain. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge the inventorship, ownership, validity, enforceability, or scope of such patents, which may result in such patents being narrowed or invalidated, or being held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. In addition, no assurances can be given that third parties will not create new products or methods that achieve similar results without infringing upon our patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patent applications we hold with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, or whether any issued patents will be found invalid or unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications before enactment of the Leahy-Smith Act on March 16, 2013, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for the patent covering a product, we may be open to competition from generic competing products.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevent us from marketing our product candidate, if approved, or practicing our own patented technology. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is either not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Once disclosed, we are likely to lose trade secret protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we require all of our employees and consultants to assign their inventions to us, to the extent that employees or consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Further, although we require that all of our employees, consultants, collaborators, advisors, and any third parties who have access to our proprietary know-how, information, or technology enter into confidentiality agreements, we cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently discover our trade secrets or develop substantially equivalent information and techniques. Any of these parties may breach these agreements and we may not have adequate remedies for any specific breach. Misappropriation or unauthorized disclosure of our trade secrets or other confidential proprietary information could impair our competitive position and may have a material adverse effect on our business. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets or other confidential proprietary information are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret or other confidential proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement, or allegations of infringement, of the patents and other proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, and inter partes review proceedings before the United States Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. Many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to composition of matter, drug delivery, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We cannot guarantee that our technologies, products, compositions, and their uses do not or will not infringe third party patent or other intellectual property rights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Pending patent applications that have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent, and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. If any third-party patents were held by a court of competent jurisdiction to cover the composition of matter of any of our product candidates, the manufacturing process of any of our product candidates, or the method of use for any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, which may not be available or may not be available on commercially reasonable terms, or until such patents expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates and/or harm our reputation and financial results. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, in the case of claims concerning registered trademarks, rename our product candidates, or obtain one or more licenses from third parties, which may require substantial time and monetary expenditure, and which might be impossible or technically infeasible. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents, trademarks, copyrights, or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. To counter infringement or unauthorized use, we may be required to file infringement claims on a country-by-country basis, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid, is unenforceable and/or is not infringed, or may construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or held unenforceable, could put our patent applications at risk of not issuing, and could limit our ability to assert those patents against those parties or other competitors and curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent patent reform legislation has increased the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, and may diminish the value of patents in general.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biotechnology companies, our commercial success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legal complexity and is therefore costly, time consuming, and inherently uncertain. Recent wide-ranging patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted and may also affect patent litigation. Under the Leahy-Smith Act, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, and it expanded the scope of procedures that a third party may use to challenge a U.S. patent, including post grant review and inter partes review procedures. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, recent court rulings in cases such as Association for Molecular Pathology v. Myriad Genetics, Inc., BRCA1- &amp;BRCA2-Based Hereditary Cancer Test Patent Litigation, and Promega Corp. v. Life Technologies Corp. have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO, and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or our ability to hire personnel, which, in any case of the foregoing, could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO, European, and other patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business. A defendant could also challenge our ownership of patents assigned to us. We cannot be certain that a third party would not challenge our rights to these patents and patent applications. Any legal proceeding or enforcement action can also be expensive and time-consuming.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For patents that are eligible for extension of patent term, we expect to seek extensions of patent terms in the United States and, if available, in other countries. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional equivalent indications approved during the period of extension). We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise, or failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and pre-clinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, and defending our intellectual property in countries throughout the world could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Therefore, we may choose not to pursue or maintain protection for certain intellectual property in certain jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent such competitors from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuit that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country, or the third party has patented improvements) or limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we seek to protect the trademarks we use in the United States and in other countries, we may be unsuccessful in obtaining registrations and/or otherwise protecting these trademarks. If that were to happen, we may be prevented from using our names, brands, and trademarks unless we enter into appropriate royalty, license, or coexistence agreements, which may not be available or may not be available on commercially reasonable terms. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, service marks, and domain names, then we may not be able to compete effectively, resulting in a material adverse effect on our business. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted, or declared generic, or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, then we may not be able to compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our proprietary rights may not adequately protect our technologies and product candidates, and do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others, including inventors or developers of our patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to conceive and reduce to practice the inventions covered by our patents or patent applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to file patent applications covering certain of our patents or patent applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents, or; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that there are prior public disclosures that could invalidate our patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our issued patents may not provide us with any commercially viable products or competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Supreme Court of the United States, other U.S. federal courts, Congress, the USPTO, or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our collaboration partners&#8217; patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ownership, validity, or enforceability of our patents or patent applications may be challenged by third parties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The May 2024 RIF was undertaken to significantly reduce our ongoing operating expenses but it may not result in our intended outcomes and may yield unintended consequences and additional costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the May 2024 RIF, we incurred charges of approximately $4.1 million in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs. We incurred an additional $6.8 million in charges for the restructuring subsequent to the May 2024 RIF. This amount primarily relates to ongoing retention efforts for current employees and have been reflected within the financial statements as of December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The May 2024 RIF may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the May 2024 RIF. In addition, while positions have been eliminated certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. If we are unable to realize the anticipated benefits from the May 2024 RIF, or if we experience significant adverse consequences from the May 2024 RIF, our business, financial condition, and results of operations may be materially adversely affected</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our common stock may be delisted from Nasdaq if we cannot regain compliance with Nasdaq&#8217;s continued listing requirements, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 19, 2024, we received a Notice from Nasdaq notifying us that for the last 30 consecutive business days, the bid price for our common stock, par value $0.001 per share, had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (&#8220;the Minimum Bid Price Requirement&#8221;). The Notice had no effect at the time on the listing of our common stock, which continues to trade on Nasdaq under the symbol &#8220;LYRA.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we had a period of 180 calendar days, or until January 15, 2025 (the &#8220;Compliance Date&#8221;) to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date. The Notice also specified that, in the event we do not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, we may be eligible for a second 180 calendar day compliance period. To qualify, we submitted an application to transfer the listing of the common stock to The Nasdaq Capital Market, which requires us to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and paid an application fee to Nasdaq and provided written notice of our intention to cure the deficiency during the additional compliance period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Compliance Date, we notified Nasdaq that we intend to cure our bid price deficiency under Nasdaq Listing Rule 5450(a)(1) during the second 180-day compliance period. In connection with this effort, we also submitted a timely application with Nasdaq to change our listing tier from the Nasdaq Global Market to the Nasdaq Capital Market and we paid the requisite fee to Nasdaq. We were notified by Nasdaq on January 31, 2025 that Nasdaq had granted our request to transfer the listing of our common stock from The Nasdaq Global Market tier to The Nasdaq Capital Market tier, effective February 4, 2025. The transfer of the listing of our common stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect with the open of business on February 4, 2025.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 31, 2025, Nasdaq granted our request for a second 180-calendar day period, or until July 14, 2025 to regain compliance with the Minimum Bid Price Requirement. To regain compliance, we must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of its review process, Nasdaq will make a determination of whether it believes we will be able to cure this deficiency. If the Company does not qualify for or fails to regain compliance during the additional compliance period, then Nasdaq will notify us of its determination to delist our common stock, at which point we would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel. There can be no assurance that, if we decide to appeal any delisting determination, such appeal would be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with any other listing requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delisting from any Nasdaq market could make trading our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. In addition, without a Nasdaq market listing, stockholders may have a difficult time getting a quote for the sale or purchase of our common stock, the sale or purchase of our common stock would likely be made more difficult and the trading volume and liquidity of our common stock could decline. Delisting from Nasdaq could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties. If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB market, where an investor may find it more difficult to sell our common stock or obtain accurate quotations as to the market value of our common stock. We cannot assure you that our common stock, if delisted from Nasdaq, will be listed on another national securities exchange or quoted on an over-the counter quotation system.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price may be volatile. The stock market in general and the market for smaller biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above your purchase price. The market price for our common stock may be influenced by many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or expected changes in our growth rate relative to our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials of our product candidates or those of our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments related to our existing or any future collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development of new product candidates that may address our markets and make our product candidates less attractive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in physician, hospital, or healthcare provider practices that may make our product candidates less useful or appealing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us, our partners, or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or expected changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment or reimbursement systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">short selling activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry, and market conditions; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K.</span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the trading prices for common stock of other biotechnology companies may become highly volatile as a result of geopolitical events such as the current conflicts between Russia and Ukraine and in the Middle East. The extent to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which such events may impact our business, pre-clinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Holders of approximately 14.6 million shares of our common stock and certain accompanying warrants have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 or until the rights terminate pursuant to the terms of the ninth amended and restated investor rights agreement between us and such holders. We have also registered all shares of common stock that we may issue under our equity compensation plans, which can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and may remain an emerging growth company until December 31, 2025. However, if certain events occur prior to such date, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.235 billion, or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to such date. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have taken advantage of reduced reporting burdens in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q including by providing only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property, or our stock performance, or if our target pre-clinical studies or clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are considered a &#8220;smaller reporting company.&#8221; We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from disclosing certain executive compensation information and three years of financial statements. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions include those establishing:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a classified Board of Directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our Board of Directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exclusive right of our Board of Directors to elect a director to fill a vacancy created by the expansion of the Board of Directors or the resignation, death, or removal of a director, which prevents stockholders from filling vacancies on our Board of Directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our Board of Directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our Board of Directors to alter our bylaws without obtaining stockholder approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend, or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the chairman of the Board of Directors, the chief executive officer, the president, or the Board of Directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our Board of Directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable, efficient administration of cases on a more expedited schedule relative to other forums, and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees, and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees, or agents. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred and expect to continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we incur significant legal, accounting, and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Capital Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to evaluate these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. We may discover significant deficiencies or material weaknesses, which we may not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. The identification of one or more material weaknesses could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, par value $0.001, which we refer to as the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain future earnings for the development, and operation of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common shares would be your sole source of gain on an investment in our common shares for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation could be costly and time-consuming and could result in additional liabilities.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims brought by us against vendors or collaborators, and/or claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients, or vendors of our customers, or stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert management&#8217;s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or under insured could result in unanticipated costs, thereby adversely impacting our results of operations and resulting in a reduction in the trading price of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be subject to securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, and property, auto, workers&#8217; compensation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">umbrella, and directors&#8217; and officers&#8217; insurance. Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If we obtain marketing approval for LYR-210, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating as a public company has made it more difficult and more expensive for us to obtain director and officer liability insurance, and in the future we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board of Directors, our board committees, or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. The Company maintains the majority of its cash and cash equivalents in accounts with major U.S. institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our current and projected business operations, our financial condition and results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating losses and research and development credits to offset future taxable income may be subject to certain limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had net operating loss carryforwards, or NOLs, of $171.5 million for federal income tax purposes and $84.2 million for state income tax purposes, which may be available to offset our future taxable income, if any. Our federal net operating loss carryforwards begin to expire at various dates through 2037, and our state net operating loss carryforwards begin to expire at various dates through 2044. As of December 31, 2024, we also had federal research and development credit carryforwards of $6.4 million, which begin to expire at various dates through 2044, and state research and development credit carryforwards of $2.0 million, which begin to expire at various dates through 2039. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, or IRC, as amended, or the Code, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and its research and development credit carryforwards to offset future taxable income. The Company had performed an IRC 382 study in 2022 which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. We performed an update assessment to our IRC 382 analysis in conjunction with the May 2023 financing noting no additional ownership change. Also, as a result of the IRC 382 study performed in 2022, we wrote off $125.8 million of state net operating losses and $2.8 million of state research and development credits. We updated our IRC 382 study in 2023 given the changes to the Massachusetts apportionment to single sales resulting in a reduced amount of $121.2 million. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New tax legislation may impact our results of operations and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 introduced, among other changes, a 15% corporate minimum tax on certain United States corporations and a 1% excise tax on certain stock redemptions by United States corporations. The U.S. government may enact further significant changes to the taxation of business entities. In particular, presidential, congressional, state and local elections in the United States could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting our business or indirectly affecting us because of impacts on our suppliers and vendors. The likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict the ultimate impact of the Inflation Reduction Act or any such further changes on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable global, political or economic conditions may have serious adverse consequences on our business, financial condition and share price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If the equity and credit markets continue to deteriorate, or the United States enters a recession, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, international terrorism and conflicts could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business, results of operations and price of our common stock may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. Climate change is expected to increase the frequency and intensity of such events, as well as contribute to various chronic changes in meteorological and hydrological patterns, and may also adversely impact our access to or cost of any insurance. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our third-party manufacturers could materially delay our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">International terrorism, political unrest, and wars, or other events such as COVID-19 have previously and could in the future adversely impact our business and operations, including our clinical trials.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International terrorism, political unrest and wars could delay or disrupt our business activity, and if any conflict escalates or spills over to or otherwise impacts additional regions, it could heighten many of the other risk factors described in this Item 1A. In addition, the COVID-19 global pandemic and government measures taken in response have had a significant impact, both direct and indirect, on our businesses and commerce, as worker shortages occurred; supply chains were disrupted; facilities and production were suspended; and demand for certain goods and services, such as medical services and supplies, spiked, while demand for other goods and services, fell. If another pandemic unfolds or if a geopolitical crisis escalates, our business and operations could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="cybersecurity2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_8f217861-4071-4df8-abe8-cc0c7b3c1f5b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_8f217861-4071-4df8-abe8-cc0c7b3c1f5b_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We design and assess our program based on the core principles of the National Institute of Standards and Technology Cybersecurity Framework, or NIST CSF. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0233e157-4a50-4649-a03b-d37d12ce88b7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00bf8bf0-432b-4ddb-a01d-40efafcbc9bf" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is integrated into our overall enterprise risk management program</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></ix:nonNumeric></span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a lead IT person principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel, and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0c515cf-0144-41a5-9d23-88fcf4d3c4b6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86871cf6-f960-4e3d-8ce6-0c717f46e08a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> process for service providers, suppliers, and vendors.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_999216cf-f680-4675-bf7c-f458b4d9d18f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See &#8220;Risk Factors &#8211; Our business, financial condition, and results of operations may suffer in the event of information technology system failures, cyberattacks, data security incidents, or deficiencies in our cybersecurity.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_0ff9674c-81e6-4086-b438-11e5e08ddb83" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_0ff9674c-81e6-4086-b438-11e5e08ddb83_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44c1fdf2-9014-4672-889b-ba222b76b0a7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_36b478a9-3fdb-4dc8-a863-fb254baad514" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_8f217861-4071-4df8-abe8-cc0c7b3c1f5b_1"><div><ix:continuation id="F_0ff9674c-81e6-4086-b438-11e5e08ddb83_1"><div><ix:nonNumeric id="F_8a8e5372-c498-4611-8e89-bc30d99bf9ab" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_887f710e-b826-4ce8-b419-1f90cb575e68" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52b86cf8-caad-44b6-af67-571764ecf58d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95040a32-56e9-459f-86fd-74833ed98e0c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true" continuedAt="F_95040a32-56e9-459f-86fd-74833ed98e0c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team&#8217;s cybersecurity experience is limited.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_95040a32-56e9-459f-86fd-74833ed98e0c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></span></p><div><ix:nonNumeric id="F_90c28e3a-993a-42c1-b360-22629996b6aa" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a92416b-667d-4882-a99b-a5b13eadf340" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alerts and reports produced by security tools deployed in our IT environment</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We occupy one leasehold in Watertown, Massachusetts and two leaseholds in Waltham, Massachusetts. The Watertown lease, as amended, is for office and laboratory space which terminates in April 2027. In Waltham, Massachusetts we have a lease for laboratory, manufacturing and office space, which terminates in July 2033, and a sublease for laboratory and office space, which terminates in November 2032. We do not own any real property. Since the May 2024 RIF, we have been utilizing these leaseholds only partially and we have been attempting to sublease all three to preserve capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;LYRA.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 28, 2025, there were approximately 56 holders of record of our common stock. However, because many of our outstanding shares are held in accounts with brokers and other institutions, we believe we have more beneficial owners.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors after considering our financial condition, results of operations, capital requirements, contractual requirements, business prospects, and other factors the Board of Directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities; Purchases of Equity Securities by the Issuer or Affiliated Purchaser</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the quarter ended December 31, 2024, we did not repurchase any of our equity securities or issue any securities that were not registered under the Securities Act of 1933, as amended (the "Securities Act").</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds from Initial Public Offering of Common Stock</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 5, 2020, we completed the sale of 4,025,000 shares of our common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $16.00 per share. The offer and sale of the shares in our initial public offering, or IPO, was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-236962), which was declared effective by the Securities and Exchange Commission on April 30, 2020.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus for our IPO dated April 30, 2020 and filed pursuant to Rule 424(b)(4) under the Securities Act on May 1, 2020. We invested the funds received in cash equivalents and other short-term investments in accordance with our investment policy.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_consolidated_financial_d"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report on Form 10-K. In addition, even if our results of operations, financial condition, and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report on Form 10-K, they may not be predictive of results or developments in future periods.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Annual Report on Form 10-K, including those risks identified under Part I, Item 1A. Risk Factors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the development and commercialization of innovative, anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our primary product candidate, LYR-210, is a bioabsorbable nasal insert designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. The drug embedded within LYR-210 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of CRS. ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks in patients without nasal polyps. Following this announcement, we reported a reduction in force of approximately 75% of our workforce, impacting 87 employees, in addition to other cost-saving measures in order to preserve capital, including the stoppage of manufacturing and commercialization efforts for LYR-210 and pausing development efforts for LYR-220. LYR-220, our second product candidate, is substantially similar to LYR-210 and also directed at patients living with CRS, but employs a larger implant designed for patients whose nasal cavity is larger including those patients who have undergone extensive ethmoid sinus surgery.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Phase 3 ENLIGHTEN 2 clinical trial evaluating LYR-210 for the treatment of CRS is expected to read out in the second quarter of 2025 at which time the Company plans to evaluate how the data affects the potential development path for LYR-210 for patients with and without nasal polyps and to further assess the Company&#8217;s strategic options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-210 is designed to treat CRS patients who have failed previous medical management. LYR-210 has a smaller dimension and is intended for patients with and without nasal polyps. In May 2024, we announced topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of CRS. ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks in patients without nasal polyps.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At 24 weeks, the ENLIGHTEN 1 trial demonstrated the following results compared to baseline, which did not achieve statistical significance:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the primary efficacy analysis, treatment with LYR-210 resulted in a mean (standard deviation; SD) improvement in the 3CS score of 2.13 (2.17) points, compared to 2.06 (2.14) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the intent-to-treat (ITT) population, treatment with LYR-210 resulted in a mean (SD) improvement in the 3CS score of 2.35 (2.28) points, compared to 1.89 (2.07) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ITT population, treatment with LYR-210 resulted in a mean (SD) improvement in the Sino-Nasal Outcome Test (SNOT-22) score of 20.2 (21.38) points, compared to 15.70 (18.55) points in sham control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ethmoid sinus opacification (evaluated by computed tomography (CT) scans), did not achieve statistically significant improvement after treatment with LYR-210 compared to sham control.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data showed that LYR-210 was generally well tolerated, with no product-related serious adverse events ("AEs"). The most commonly reported AEs in the study population were epistaxis, nasal odor, upper respiratory tract infection and sinusitis. Further post-hoc analyses of the ENLIGHTEN 1 data showed that LYR-210 had a positive effect compared to sham control in 3CS, nasal congestion, and nasal polyp scores at 24 weeks in the subgroup of 35 CRS patients with nasal polyps.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in least squares (LS) mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2.25 points (p-value 0.0058) in the CRS patient subgroup with nasal polyps. This improvement was demonstrated despite the inclusion of only grade 1 nasal polyps in the study and without a threshold for nasal congestion score. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For patients with nasal congestion score equal to or greater than 2 (that is moderate to severe symptom) at baseline in the CRS patient subgroup with nasal polyps, treatment with LYR-210 resulted in LS mean (SE) improvement in the 3CS score of 3.69 (0.470) points, compared to 0.75 (0.685) points in sham control for a difference of 2.94 points (p-value 0.0017). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in LS mean (SE) improvement in the nasal congestion score of 1.20 (0.159) points, compared to 0.42 (0.243) points in sham control for a difference of 0.73 points (p-value 0.0216) in the CRS patient subgroup with nasal polyps and nasal congestion score equal to or greater than 2 at baseline. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with LYR-210 resulted in LS mean (SE) improvement in the nasal polyp score of 0.62 (0.161) points, compared to 0.01 (0.237) points in sham control for a difference of 0.61 points (p-value 0.0471) in the CRS patient subgroup with nasal polyps. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 52-week extension stage of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension stage was generally consistent with the 24-week primary treatment stage, including for those patients that received a repeat dosing resulting in a 12-month treatment period. In the extension stage, LYR-210 was generally well tolerated, with no product-related serious AEs. The most commonly reported extension stage AEs in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results from the ENLIGHTEN 2 trial are expected in the second quarter of 2025.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYR-220</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the cost-saving efforts announced in May 2024, the Company paused development efforts for LYR-220, our second pipeline product candidate. LYR-220 is designed for use in CRS patients who have failed previous medical management and who continue to require treatment to manage CRS symptoms despite having had ethmoid sinus surgery. LYR-220 employs a larger implant designed for patients whose nasal cavity is larger including those patients who have undergone extensive ethmoid sinus surgery. We conducted a Phase 2 clinical trial of LYR-220, called BEACON. The BEACON trial was a controlled parallel-group study to evaluate safety, tolerability, pharmacokinetics ("PK"), and efficacy comparing two designs of the LYR-220 (7500&#181;g MF) matrix to control, over a 24-week period, in approximately 50 symptomatic adult CRS subjects who have had a prior bilateral sinus surgery. In September 2023, we reported positive topline results from BEACON, demonstrating statistically significant and clinically relevant improvements in the 3CS and SNOT-22 scores at 24 weeks.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. The technology is comprised of three interrelated components:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a bioabsorbable mesh scaffold, which is designed to maximize surface area for drug release while maintaining underlying tissue function; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an engineered elastomeric matrix, a polymeric matrix composed of polymers having elastic characteristics, which has advanced physical properties resulting in implants with &#8220;shape memory&#8221; that dynamically adapt to nasal anatomy; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a versatile polymer-drug complex, which is designed to deliver six months of continuous local drug therapy with a single treatment. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations to date have been limited to organizing and staffing our Company, business planning, raising capital, developing our technology, building our intellectual property portfolio and conducting research and development activities, including clinical manufacturing for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 5, 2020, we completed our IPO in which we issued and sold 4,025,000 shares of our common stock (including shares issued upon the underwriters&#8217; exercise in full of their option to purchase additional shares of our common stock) at a public offering price of $16.00 per share, par value $0.001, for aggregate gross proceeds of $64.4 million. We received approximately $57.3 million in net proceeds after deducting underwriting discounts and commissions and offering expenses paid by us. The shares began trading on The Nasdaq Global Market on May 1, 2020. Upon completion of our IPO, all of our outstanding shares of convertible preferred stock converted into 8,335,248 shares of our common stock, par value $0.001.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From inception through December 31, 2024, we have raised an aggregate of $424.8 million to fund our operations, of which $162.1 million were gross proceeds from sales of our redeemable convertible preferred stock, $96.3 million were net proceeds from our April 2022 Financing (as defined below), $46.5 million were net proceeds from our May 2023 Financing, $57.3 million were net proceeds from our initial public offering, $23.9 million were net proceeds related to our Controlled Equity Offering Agreement (the &#8220;Original Sales Agreement&#8221;) dated September 1, 2023, $16.8 million were gross proceeds from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants. Further, we currently have an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (&#8220;Form S-3&#8221;), under which we may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $300.0 million in the aggregate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred recurring net operating losses every year since inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our net losses inception to date were $404.8 million at December 31, 2024. As of December 31, 2024, we had approximately $40.6 million of cash and cash equivalents. These conditions raise substantial doubt about our ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced a reduction in force of approximately 75% of our workforce, impacting 87 employees ("May 2024 RIF"), in addition to other cost-saving measures in order to preserve capital, including the stoppage of manufacturing and commercialization efforts for LYR-210 and pausing development efforts for LYR-220. Nevertheless, we anticipate that we will continue to incur expenses as we continue the ongoing ENLIGHTEN 2 Phase 3 clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of LYR-210.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. In the future, in the event we obtain financing and decide to restart our manufacturing activities, we may engage third party contract manufacturers ("CMOs") to manufacture our products. We do not yet have a sales organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. As a result, we need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial additional funding to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources, including strategic collaborations and licensing arrangements. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidate or any additional product candidates, if developed.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, management has concluded that there is substantial doubt regarding our ability to continue as a going concern. As of December 31, 2024, we had cash and cash equivalents totaling $40.6 million. Management believes that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2026. We have based these estimates on assumptions that may prove to be imprecise or incorrect, and we may use our available capital resources sooner than we currently expect. See &#8220;Liquidity and Capital Resources.&#8221; Because of the numerous risks and uncertainties associated with the development of our product candidates and any future product candidates and technology, and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research, development and manufacturing of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq Listing Notification</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 19, 2024, we received a written notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) notifying us that for the last 30 consecutive business days, the bid price for our common stock, par value $0.001 per share, had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (&#8220;the Minimum Bid Price Requirement&#8221;). The Notice had no effect at the time on the listing of our common stock, which continued to trade on The Nasdaq Global Market under the symbol &#8220;LYRA.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we had a period of 180 calendar days, or until January 15, 2025 (the &#8220;Compliance Date&#8221;) to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To qualify for a second 180 calendar day compliance period, we were required to submit an application to transfer the listing of our common stock to The Nasdaq Capital Market, which requires us to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. We also paid an application fee to Nasdaq and provided written notice of our intention to cure the deficiency during the additional compliance period. We were notified by Nasdaq on January 31, 2025 that Nasdaq had granted our request to transfer the listing of our common stock from The Nasdaq Global Market tier to The Nasdaq Capital Market tier, effective February 4, 2025. The transfer of the listing of our common stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect with the open of business on February 4, 2025.On January 31, 2025, Nasdaq granted our request for a second 180-calendar day period, or until July 14, 2025 to regain compliance with the Minimum Bid Price Requirement. To regain compliance, we must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to actively monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that we will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with any other listing requirements. For more information, see &#8220;Risk Factors&#8212;Our common stock may be delisted from The Nasdaq Capital Market if we cannot regain compliance with Nasdaq&#8217;s continued listing requirements, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Developments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board approved a reduction in the Company&#8217;s workforce impacting 87 employees, which occurred during May and June 2024. Moreover, we stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. Furthermore, we are currently in the process of marketing all of our leased properties for sub-leasing arrangements, and we may also seek to negotiate an early termination of our leases with our landlords.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. As of December 31, 2024, we have recognized $4.7 million of collaboration revenue from our LianBio License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization efforts, or additional collaboration agreements, we may generate revenue in the future from product sales, payments from additional collaboration or license agreements that we may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that any revenue over the next several years would be derived primarily from our collaboration agreement with LianBio. We cannot provide assurance as to the timing of future milestones or royalty payments from LianBio or that we will receive any of these payments at all, especially in view of LianBio&#8217;s wind down activities.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreement</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 26, 2022, we entered into an amended LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. Under the terms of the LianBio License Agreement, we received an upfront payment of $12.0 million. In February 2022, the Company achieved a development milestone of $5.0 million for dosing the first patient in the U.S., and the related cash amount was achieved in April 2022. The Company is eligible to receive up to $135.0 million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, we will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and we will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to our LYR-220 product candidate.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, we identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial. We determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, we determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (2) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, we determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations. The potential milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we determined that LianBio&#8217;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#8217;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will recognize the revenue associated with the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure combined performance obligation as the clinical supply of LYR-210 is delivered. We recognize revenue associated with the development activities related to the global Phase 3 clinical trial performance obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on our consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in February 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company&#8217;s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBio&#8217;s rights under the LianBio License Agreement. In November 2024 we entered into a novation agreement which substituted LianBio Cayman for LianBio HK. For more information, please see &#8220;Risk Factors &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If LianBio HK, as defined below, is unable to find a third party to acquire its rights under the LianBio License Agreement, as defined below, it may materially harm our business, financial condition, results of operations and prospects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including the development of and pursuit of regulatory approval of our most advanced product candidate, LYR-210, for the treatment of CRS, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with the clinical development of our product candidates, including under agreements with contract research organizations ("CROs"), investigative sites, and consultants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs of manufacturing our product candidates for use in our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consulting and professional fees related to research and development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to compliance with clinical regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to the termination of an agreement with a former CMO.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as clinical site activations, patient enrollment, or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and may be reflected in our consolidated financial statements as prepaid or accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses consist primarily of costs such as employee compensation, consulting fees, fees paid to CMOs and CRO expenses in connection with our clinical development activities, which have largely been suspended following the restructuring we implemented in May 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We typically use our employee and infrastructure resources across our development programs and we do not allocate personnel costs and other internal costs to specific product candidates or development programs with the exception of the costs to manufacture our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will decrease for the foreseeable future as we implemented a layoff of 75% of our workforce in May 2024 and ceased most manufacturing and CMC-related activities. Research and development expenses will be primarily focused on continuing the ongoing ENLIGHTEN 2 Phase 3 clinical trial of LYR-210.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development of LYR-210, and other potential future product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the development of these product candidates. We are also unable to predict when, if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we may obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs, and timing of preclinical studies, clinical trials, and development of our product candidates will depend on a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of clinical trials with safety, tolerability, and efficacy profiles for LYR-210, and any potential future product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval of an Investigational New Drug Application ("IND") for any potential future product candidate to commence planned or future clinical trials in the United States or foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation and regulatory guidance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements with CMOs for third-party clinical and commercial manufacturing to obtain sufficient supply of our product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and other intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competition with other therapies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from global events such as pandemics. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development, manufacture, or commercialization enabling activities of any of our product candidates would significantly change the costs, timing, and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we may be required to expend significant additional financial resources and time on the completion of clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services, and insurance costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will remain stable in the future to support existing research and development activities. Additionally, we will continue to incur expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income consists of interest income earned on our cash and cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income tax consists of income tax related to the Company's Massachusetts Security Corporation. The Company has not recorded any benefits related to its operating losses due to uncertainty regarding future taxable income.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods and estimates used to assess our ability to continue as a going concern. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern Evaluation and Presentation</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our current cash, cash equivalents, and short-term investments will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2026. Significant assumptions exist surrounding the use of our capital resources which could give rise to the use of available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities associated with successful development of LYR-210 and LYR-220 is highly uncertain, we are unable to estimate the actual funds we will require for development, approval, and any approved marketing and commercialization activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets. Management continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. We also assess our right-of-use assets for impairment based on triggering events.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, we consider factors such as the research, manufacturing and commercialization capabilities of the collaboration partner, and the availability of the associated expertise in the general marketplace. We also consider the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, we consider applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. We validate the SSP for performance obligations by evaluating whether</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the key assumptions used to determine the SSP will have a material effect on the allocation of arrangement consideration between multiple performance obligations.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the transaction price, we adjust consideration for the effects of the time value of money if the timing of payments provides us with a significant benefit of financing. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. We assessed our revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative arrangement revenue</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into the LianBio License Agreement with LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. See Note 13 to the consolidated financial statements included in this Annual Report on Form 10-K for further discussion of the arrangement.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the accounting for this arrangement, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. For example, a proportion of the stand-alone selling price is related to research and clinical trial work and development performed whereby revenue is recognized as the underlying services are performed using a cost-to-cost model. We measure the extent of progress towards completion based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing purchase orders and open contracts, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant estimates in our accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which we have not yet been invoiced:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with preclinical development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with the testing of preclinical and clinical trial materials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with preclinical and clinical studies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigative sites in connection with clinical trials. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to implementing our restructuring in May 2024, our practice was to contract with CROs to conduct clinical and other research and development services on our behalf. We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply the fair value recognition provisions of ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASC 718, for stock-based awards granted to employees and directors for their services on the Board of Directors. Determining the amount of stock-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their grant date. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based awards requires that we make subjective assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to ASC 718, we measure stock-based awards granted to employees and members of the Board of Directors at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for stock-based awards to non-employees in accordance with ASU No. 2018-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASU No. 2018-07, which simplifies the accounting for stock-based payments granted to non-employees for goods and services. Under ASU No. 2018-07, most of the guidance on such payments to non-employees would be aligned with the requirements for stock-based payments granted to employees. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield. We utilize historical volatility to approximate expected volatility. Prior to our IPO in 2020, we have historically been a private company and lack company-specific historical and implied volatility data. Therefore, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, we utilize the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends and has no current plans to pay any cash dividends on its common stock. Our policy is to recognize forfeitures as they occur.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dollar</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,766</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,029</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,263</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,501</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,057</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(556</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property and equipment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">291</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,836</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,836</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring and other related charges</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,896</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,896</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,882</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,678</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,204</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(96,348</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,120</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,228</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,547</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,547</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(93,396</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(62,621</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(30,775</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(93,435</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(62,680</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(30,755</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease in collaboration revenue was a result of a decrease in revenue recognized under the LianBio License Agreement.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense decreased by $4.3 million to $43.8 million for the year ended December 31, 2024 from $48.0 million for the year ended December 31, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease in research and development expenses for the year ended December 31, 2024 was primarily attributable to a decrease in clinical related costs of $5.5 million as we completed both the BEACON trial for LYR-220 and the ENLIGHTEN 1 trial for LYR-210, a decrease of $3.5 million in employee related costs primarily driven by the May 2024 RIF, and a decrease in product development and manufacturing costs of $1.0 million. This decrease in costs was partially offset by increases in allocation and support costs and depreciation of $4.7 million, an increase in professional and consulting costs of $0.4 million and a $0.6 million gain recorded in 2023 related to our legal settlement with a former contract manufacturer.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expense decreased by $0.6 million to $18.5 million for the year ended December 31, 2024 from $19.1 million for the year ended December 31, 2023.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease in general and administrative expenses for the year ended December 31, 2024 was primarily driven by a decrease in professional, consulting and public company fees of $0.7 million as we scaled back activities subsequent to announcing in May 2024 that the ENLIGHTEN 1 trial did not meet its primary endpoint, in addition to a decrease in employee related costs of $0.8 million primarily due to the May 2024 RIF and $0.4 million incurred in 2023 related to our financing efforts. This decrease in costs was partially offset by a net increase in allocation, support, depreciation and financing costs of $1.3 million primarily due to the increased rent and facilities expenses for the Company&#8217;s three leased facilities for the year ended December 31, 2024 compared to the year ended December 31, 2023.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment &amp; Restructuring and Other Related Charges</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8.25pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incurred impairment costs related to property and equipment of $1.9 million for the year ended December 31, 2024 compared to $1.6 million for the year ended December 31, 2023. During the second quarter of 2024 and as a result of our Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, we performed a recoverability test for property and equipment and concluded that the undiscounted cash flows associated with our property and equipment was less than its carrying value. We then compared the fair value of the property and equipment to the carrying value and recorded an impairment charge in the amount of $1.9 million which is included as an impairment of property and equipment in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8.25pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incurred impairment costs related to our right-of-use assets of $22.8 million for the year ended December 31, 2024 compared to no such charges in 2023. In connection with our Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, we engaged a commercial real estate broker to market the Company&#8217;s three leased properties for sublease arrangements. As of December 31, 2024, we have not sublet any of our leased properties. Based upon these impairment indicators, we performed a recoverability test over our right-of-use assets and concluded that the right-of-use assets are impaired. As a result, we recorded an impairment charge in the amount of $22.8 million, which is included as an impairment of right-of-use assets in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8.25pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company incurred a restructuring charge in the amount of $10.9 million primarily related to severance and retention costs for the year ended December 31, 2024 compared to no such charges in 2023. In connection with our ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, our Board of Directors approved a reduction in our workforce, impacting 87 employees, which occurred during May and June 2024. We incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through May 1, 2025. These amounts are recorded as restructuring and other related charges within our consolidated statements of operations and comprehensive loss as they are incurred. For the year ended December 31, 2024, restructuring and other related charges consisted of $6.7 million of severance costs, $3.2 million of retention costs, and $1.0 million of other costs.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income decreased by $1.5 million to $3.0 million for the year ended December 31, 2024 from $4.5 million for the year ended December 31, 2023. Interest income for both periods was primarily attributable to interest earned on the Company&#8217;s cash equivalents and short-term investments and the decrease was largely due to the net decrease in the combined balance of short-term investments and cash equivalents for the year ended December 31, 2024 compared to the year ended December 31, 2023.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Expense</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024 we recorded an income tax expense of $39,000 related to investment income, which was related to our cash equivalents and short-term investments held by our Massachusetts Securities Corporation. During the year ended December 31, 2023, we recorded an income tax expense of $59,000 related to our money market funds and short-term investments held by the Massachusetts Securities Corporation. The increase in income tax expense was primarily attributable to the balance held within our short-term investments.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From inception through December 31, 2024 we have raised an aggregate of $424.8 million to fund our operations, of which $162.1 million were gross proceeds from sales of our redeemable convertible preferred stock, $96.3 million were net proceeds from our April 2022 Financing (defined below), $46.5 million were net proceeds from our May 2023 Financing, $57.3 million were net proceeds from our initial public offering, $23.9 million were net proceeds related to our Original Sales Agreement dated September 1, 2023, $16.8 million were gross proceeds from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information regarding our total cash, cash equivalents and short-term investments at December 31, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,577</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,353</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Total</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,577</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,753</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain the majority of our cash and cash equivalents in accounts with major highly rated multi-national and local financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions, and any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the shelf registration statement on Form S-3 (No. 333-256020) filed with the SEC on May 11, 2021, or the Form S-3, under which we may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $250.0 million in the aggregate. See Note 10 for additional details.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 11, 2021, we entered into an Open Market Sales Agreement, or 2021 ATM Agreement, or Sales Agreement, with Jefferies LLC, or Jefferies, to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million, through an at-the-market equity offering program under which Jefferies will act as our sales agent. As of December 31, 2022, we had received no proceeds from the sale of shares of common stock pursuant to the 2021 ATM Agreement. As of March 27, 2023 we terminated the 2021 ATM agreement with Jefferies.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2022, we announced the closing of the private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million (&#8220;April 2022 Financing&#8221;). We received approximately $96.3 million in net proceeds after deducting estimated offering costs of $4.2 million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of 18,815,159 shares of common stock at $4.22 per share for gross proceeds to the Company of $79.4 million and (ii) certain investors purchased pre-funded warrants to purchase an aggregate of 5,000,000 shares of common stock, with the exercise price of $0.001 per share for gross proceeds of $21.1 million to the Company. The warrants are exercisable on and after April 13, 2022 and expire on April 12, 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 25, 2023, we entered into a Securities Purchase Agreement (the "Purchase Agreement"), with the purchasers named therein (the "Investors"), pursuant to which the Company agreed to sell securities to the Investors in a private placement (the "Private Placement"). The Purchase Agreement provided for the sale and issuance by the Company of: (i) an aggregate of 17,652,962 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), and pre-funded warrants to purchase up to 2,408,188 shares of Common Stock (the "Pre-Funded Warrants"), with an exercise price of $0.001 per share, and (ii) accompanying warrants to purchase up to 10,030,575 shares of Common Stock (the "Purchase Warrants"), with an exercise price of $2.673 per share, for aggregate gross proceeds of approximately $50.0 million, before deducting private placement expenses. Each Share (or Pre-Funded Warrant to purchase one share) was issued with an accompanying Purchase Warrant to purchase one-half of one share, and the combined effective purchase price per share (or Pre-Funded Warrant to purchase one share) and accompanying Purchase Warrant to purchase one-half of one share was $2.4925 (less the exercise price of the Pre-Funded Warrant, if applicable). Each Pre-Funded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant was exercisable immediately and will expire on May 31, 2028. Each Purchase Warrant will be exercisable at any time on or after November 30, 2023 and will expire on November 30, 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The closing of the Private Placement occurred on May 31, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, we entered into a Controlled Equity Offering Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $50.0 million. The offering and sale of up to $50.0 million of the common shares has been registered under the Securities Act, pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the SEC on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell any of the shares under the Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Sales Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Sales Agreement, the Company has agreed to pay Cantor a commission equal to 3.0% of the aggregate gross proceeds from any shares sold through it pursuant to the Sales Agreement. In addition, we have agreed to reimburse certain expenses incurred by Cantor in connection with the Sales Agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 2, 2023, we sold an aggregate of 3,017,568 shares of common stock under the Sales Agreement, at a weighted average price of $3.71 per share, which generated net proceeds of $10.9 million. On November 15, 2023, the Company sold an aggregate of 3,000,000 shares of common stock under the Sales Agreement, at a weighted average price of $2.88 per share, which generated net proceeds of $8.2 million. On February 12, 2024, the Company sold an aggregate of 1,041,666 shares of common stock under the Sales Agreement, at a weighted average price of $4.80 per share, which generated net proceeds of $4.8 million.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sales Agreement entered into on September 1, 2023 was amended on March 22, 2024, as we entered into an Amended and Restated Controlled Equity Offering Agreement (the &#8220;Amended Sales Agreement&#8221;) with Cantor pursuant to which we may offer and sell, from time to time through Cantor, shares of our common stock for aggregate gross proceeds of up to $75.0 million. As of December 31, 2024, there was $23.9 million in proceeds net of issuance costs of $0.9 million generated from these agreements with $50.2 million still available for future sale under the Amended Sales Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information regarding our cash flows for the years ended December 31, 2024 and 2023 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.28%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.940000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70,011</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(63,304</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,305</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,584</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,531</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,691</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,825</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,197</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Net cash used in operating activities was $70.0 million for the year ended December 31, 2024, primarily resulting from our net loss of $93.4 million, partially offset by non-cash adjustments of $29.8 million and cash used from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in our operating assets and liabilities of $6.3 million. Our net loss was primarily attributed to research and development activities and our general and administrative expenses. Our net non-cash charges during the year ended December 31, 2024 consisted of a $22.8 million impairment of right-of-use assets, $6.7 million of share-based compensation expense, $1.9 million impairment of long-lived assets, $0.5 million of depreciation expense and other charges of $0.2 million, which were partially offset by $2.3 million of net amortization of premiums on short-term investments. Net cash used in our operating assets and liabilities during the year ended December 31, 2024 consisted of a $7.9 million decrease in accrued expenses and accounts payable, a decrease of $3.4 million in operating lease liabilities and a decrease of $1.5 million in deferred revenue, partially offset by a $4.3 million increase in the restructuring liability, a $1.4 million increase in operating right-of-use assets and a $0.8 million increase in other assets, net of a $0.4 million decrease in prepaid expenses and other current assets. Increases and decreases in operating assets and liabilities were affected by the timing of payments.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $63.3 million for the year ended December 31, 2023, primarily resulting from our net loss of $62.7 million, partially offset by non-cash adjustments of $4.3 million and cash used from changes in our operating assets and liabilities of $4.9 million. Our net loss was primarily attributed to research and development activities and our general and administrative expenses. Our net non-cash charges during the year ended December 31, 2023 primarily consisted of $5.9 million of share-based compensation expense, $1.6 million of non-cash loss on impairment of long-lived assets and $0.3 million of depreciation expense, which were partially offset by $3.5 million of net amortization of premiums on short-term investments. Net cash used in our operating assets and liabilities during the year ended December 31, 2023 consisted primarily of a decrease of $1.6 million of deferred revenue, as well as an increase in right-of-use assets of $5.1 million, a decrease in operating lease liabilities, of $1.2 million, both of which were partially offset by an increase in accrued expenses and accounts payable of $1.9 million and a decrease in prepaid expenses and other assets of $1.1 million due to the timing of payments.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by and Used in Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities was $80.3 million for the year ended December 31, 2024 compared to net cash used in investing activities of $12.6 million for the year ended December 31, 2023. The increase in net cash provided by and the decrease in net cash used in investing activities was attributable to changes in the net purchases and sales of short-term investments.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $8.5 million for the year ended December 31, 2024 compared to $65.7 million for the year ended December 31, 2023. The decrease in cash provided by financing activities of $57.2 million was primarily attributable to the change in net proceeds from our equity financings. See Note 10 to the consolidated financial statements included in this Annual Report on Form 10-K for a further discussion of the Company's equity financings.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur expenses in connection with our ongoing activities, primarily the ongoing ENLIGHTEN 2 Phase 3 trial</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating LYR-210. To the extent we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although management has concluded that there is substantial doubt regarding our ability to continue as a going concern, this conclusion is based on our analysis under applicable accounting standards. Based on our current business plan, we anticipate that our cash, cash equivalents and short-term investment balance is sufficient to fund our operating expenses and capital expenditures into the first quarter of 2026. However, we have based this estimate on assumptions that may prove to be wrong. If, for any reason, our expenses differ materially from our assumptions or we utilize our cash more quickly than anticipated, or if we are unable to obtain funding on a timely basis we may be required to revise our business plan and strategy, which may result in us further curtailing, delaying or discontinuing one or more of our research or development programs. As a result, our business, financial condition, and results of operations could be materially adversely affected.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s plans to obtain resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements and short-term borrowings from banks, stockholders or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related parties, if needed, and other strategic alternatives or transactions. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of conducting current and future clinical trial of LYR-210;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing and testing additional material for one or more pivotal Phase 3 clinical trials of LYR-210 as well as potential future clinical studies we might conduct;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of scaling up our supply chain capacity to meet commercial demand;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of hiring personnel as needed after our restructuring, as well as obtaining additional resources that may be needed depending on our ability to continue as a going concern;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including cost of goods, product sales, marketing, manufacturing, and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, obtaining, maintaining, and enforcing our intellectual property rights, and defending intellectual property-related claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.9328641337218886%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of potential business interruptions resulting from global events such as pandemics.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the global economy, including credit and financial markets, has periodically experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. All of these factors could impact our liquidity and future funding requirements, including but not limited to our ability to raise additional capital when needed on acceptable terms, if at all. The duration of any economic slowdown is uncertain and the impact on our business is difficult to predict. See &#8220;Risk Factors&#8212; Unstable global political or economic conditions may have serious adverse consequences on our business, financial condition and share price".</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. We may have access to additional funds to be earned in connection with our LianBio License Agreement, if development activities are successful under that agreement. However, the future of this collaboration is uncertain in view of LianBio&#8217;s major restructuring, as discussed herein. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, that could adversely impact our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The JOBS Act permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, or December 31, 2025, (b) in which we have total annual gross revenues of $1.235 billion or more, or (c) in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our outstanding common stock held by non-affiliates exceeds $700 million as of last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K and are incorporated herein by reference. An index to those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Acco</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">untants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Limitations on Effectiveness of Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December 31, 2024, our internal control over financial reporting was effective.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Attestation Report of the Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been no change in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(f) and 15d-15(f) of the Exchange Act during the quarter ended December 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6256b293-b445-4a78-ae5e-4d8bbe77d68a" contextRef="C_fcf36a73-5344-415f-b95c-0bbadc656fc2" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a) On March 6, 2025, the Company&#8217;s Board of Directors approved amendments to the employment agreements with each of Dr. Palasis, Dr. Waksal and Mr. Cavalier that modify the form of payment of any cash severance that such named executive officer becomes entitled to in the event of a qualifying termination of employment, in accordance with the terms of his or her respective employment agreement, from installments to a lump sum (and, in the case of Dr. Palasis, such modification is only to the extent permitted under Section 409A of the Internal Revenue Code).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b) During the fiscal quarter ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of our directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) informed us of the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3f5be70-36e2-4b00-9f26-f5955c42124d" contextRef="C_8550b4b7-6090-4399-a279-2b5260027481" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_409dbf14-dbe9-4a87-97b4-0aace3e8b7f3" contextRef="C_8550b4b7-6090-4399-a279-2b5260027481" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14429c5a-b227-4464-aa4a-87de54a9e9c5" contextRef="C_8550b4b7-6090-4399-a279-2b5260027481" name="lyra:Rule10B51Arrmodifiedflag" format="ixt:fixed-false"><ix:nonNumeric id="F_3f3af547-0c31-4c31-a97e-a50d567076ce" contextRef="C_8550b4b7-6090-4399-a279-2b5260027481" name="lyra:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modification</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a1dc695-81bf-4636-ac1c-89a56324d412" contextRef="C_8550b4b7-6090-4399-a279-2b5260027481" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_e06650b9-1322-4d29-917c-90b8a486fd3d" contextRef="C_8550b4b7-6090-4399-a279-2b5260027481" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item 408.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our Directors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information concerning our Board of Directors as of December 31, 2024.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.735%;box-sizing:content-box;"/>
    <td style="width:2.14%;box-sizing:content-box;"/>
    <td style="width:8.538%;box-sizing:content-box;"/>
    <td style="width:2.14%;box-sizing:content-box;"/>
    <td style="width:40.252%;box-sizing:content-box;"/>
    <td style="width:2.14%;box-sizing:content-box;"/>
    <td style="width:19.056%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">In Current Position Since</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Chair and Chairperson of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 2022</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2015</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 2019</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 2019</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy Snyderman, M.D., FACS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 2020</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Tobin</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2022</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are brief biographies describing the backgrounds of our directors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Chair since February 2022 and was elected to our Board of Directors in February 2022. Prior to his role with us as Executive Chair, Dr. Waksal served as President and Chief Executive Officer of Kadmon Holdings, Inc., or Kadmon, a biopharmaceutical company, from August 2014 and a director since 2013 until its acquisition by Sanofi in November 2021. Prior to joining Kadmon as an employee, Dr. Waksal served as President and Sole Proprietor of Waksal Consulting LLC from 2003 to 2014. From 2011 to 2014, Dr. Waksal served as Executive Vice President, Business and Scientific Affairs at Acasti Pharma, Inc., a publicly traded biopharmaceutical company, and as a consultant to Neptune Technologies &amp; Bioresources, Inc., a publicly traded life sciences company and the parent company of Acasti. Dr. Waksal co&#8209;founded ImClone Systems (&#8220;ImClone&#8221;) in 1987, a publicly traded biopharmaceutical company acquired by Eli Lilly and Company in 2008. Dr. Waksal served in senior roles at ImClone, including: President (1987 to 1994); Executive Vice President and Chief Operating Officer (1994 to 2002); and President, Chief Executive Officer and Chief Operating Officer (2002 to 2003). Dr. Waksal also served as a Director of ImClone from 1987 to 2005. Dr. Waksal served on the boards of Oberlin College and Sevion Therapeutics through March 2016 and the boards of Acasti and Neptune through February 2016 and July 2015, respectively. Since April 2024, Dr. Waksal has served as a member of the board of directors of Perceptive Capital Solutions Corp. Dr. Waksal&#8217;s additional roles include serving as a member of the board of directors of Perceptive Discovery Fund and a member of the Technology Advisory Board at the New Jersey Edison Innovation Fund. Dr. Waksal received his B.A. from Oberlin College and his M.D. from Tufts University School of Medicine. He completed his training in internal medicine at New England Medical Center and in pathology at Kings County Hospital Center in Brooklyn. We believe Dr. Waksal&#8217;s extensive management experience in the life science industry and drug development experience provides him with the qualifications and skills to serve on our Board of Directors.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="palasis_bio"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our President and Chief Executive Officer and a member of our Board of Directors since January 2015. Prior to her role with us as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis has also served as a member of the board of directors of Beta Bionics, Inc. since January 2025. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine. We believe that Dr. Palasis&#8217; experience in the industry and knowledge of our Company qualifies her to serve on our Board of Directors.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C. Ann Merrifield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as a member of our Board of Directors since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector, which include InVivo Therapeutics Holdings Corp., from November 2014 until January 2025, and Flexion Therapeutics, Inc., from June 2014 to November 2021 until it was acquired by Pacira BioSciences. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, the Huntington Theatre Company, the YMCA of Greater Boston, and the International Institute of New England. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College. We believe that Ms. Merrifield&#8217;s extensive industry experience qualifies her to serve on our Board of Directors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">W. Bradford Smith</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as a member of our Board of Directors since November 2019. Since December 2024, Mr. Smith has served as the Chief Financial Officer of Incendia Therapeutics, Inc. From November 2023 to March 2024, Mr. Smith served as a consultant to Homology Medicines, Inc. (NASDAQ: FIXX), where he served as Chief Financial Officer, Chief Business Officer and Treasurer from March 2022 until November 2023, when the company announced it signed a merger agreement with Q32 Bio, Inc. He also served as Homology&#8217;s Chief Financial Officer and Treasurer from April 2017 to March 2022 and as Secretary from July 2017 to June 2020. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical company, where he led the company's strategic financings, including an IPO and subsequent follow-on offerings, and completed a development and commercialization deal with a major biopharmaceutical company. Prior to joining Ocular Therapeutix, Mr. Smith served as Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Since May 2021, Mr. Smith has served on the board of directors of eGenesis, a private gene editing company. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire. We believe that Mr. Smith&#8217;s extensive financial and industry experience qualify him to serve on our Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nancy Snyderman, M.D., FACS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as a member of our Board of Directors since October 2020. Dr. Snyderman has also served on the board of directors of Alkermes plc, a biopharmaceutical company, since May 2016. From April 2019 to November 2024, Dr. Snyderman has served on the board of directors of Axonics Inc., a medical device company. From 2006 to 2018, Dr. Snyderman served as an advisory board member to GE's Healthymagination, General Electric Company&#8217;s healthcare initiative. From 2003 to 2008, Dr. Snyderman also served as a senior vice president for corporate communications at Johnson &amp; Johnson. Dr. Snyderman is a board-certified Otolaryngologist-Head and Neck surgeon and clinical researcher and has had academic appointments at the University of Pennsylvania and the University of California-San Francisco. From 2016 to 2018, she served as a consulting professor at the Center for Innovation for Global Health at Stanford University. Dr. Snyderman is an Emmy award winning medical correspondent, having worked at ABC News from 1987 to 2003 and later as chief medical editor at NBC News from 2004 to 2015. Dr. Snyderman holds a B.A. in Microbiology from Indiana University and a M.D. from the University of Nebraska Medical Center and has completed residencies in Pediatrics and Otolaryngology Head and Neck Surgery at the University of Pittsburgh. We believe that Dr. Snyderman's extensive experience as an executive at a pharmaceutical company, as well as her roles in academia and as an advisor to policy organizations, qualifies her to serve on our Board of Directors.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">James R. Tobin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as a member of our Board of Directors since March 2022. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997, its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as Chairman of the Board at TransMedics, Inc. and as a director of Globus Medical Inc., each of which are public companies, and as a director at Xenter, Inc., a private company. Mr. Tobin has also served on the boards of Oxford Immunotec, Inc., from 2014 to 2021, Corindus Vascular Robotics, from 2018 to 2019, Curis, Inc., from 1995 to 2015, Medical Simulation Corp, from 2012 to 2018, CardioDX, Inc., from 2014 to 2017, Chiasma, Inc., from 2015 to 2016, and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an M.B.A. from Harvard Business School. Mr. Tobin also served as a Lieutenant in the U.S. Navy. We believe Mr. Tobin is qualified to serve on our Board of Directors because of his decades of experience as President and Chief Executive Officer or Chief Operating Officer of three large biotechnology and medical device companies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our Executive Officers</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information concerning our executive officers as of February 28, 2025.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.14%;box-sizing:content-box;"/>
    <td style="width:2.1%;box-sizing:content-box;"/>
    <td style="width:8.4%;box-sizing:content-box;"/>
    <td style="width:2.1%;box-sizing:content-box;"/>
    <td style="width:42%;box-sizing:content-box;"/>
    <td style="width:2.1%;box-sizing:content-box;"/>
    <td style="width:19.16%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">In Current Position Since</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Chair and Chairperson of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 2022</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2015</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 2021</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are brief biographies describing the backgrounds of our executive officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biography for Dr. Waksal appears above.</span></p>
  <p style="text-indent:9.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biography for Dr. Palasis appears above.</span></p>
  <p style="text-indent:9.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Jason Cavalier</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Financial Officer, and Treasurer since September 2021. He also served as our Secretary from September 2021 to March 2024. Prior to joining our Company, Mr. Cavalier served as a Managing Director and the Head of Life Sciences Mergers and Acquisitions at Cantor Fitzgerald &amp; Co., where he led transactions across the medical technology, diagnostics and biopharma sectors, from 2017 to 2021. Prior to that, Mr. Cavalier served as a Director, Mergers and Acquisitions, at RBC Capital Markets LLC from 2009 to 2017, where he primarily focused on advising senior management and boards of directors on a range of strategic advisory assignments including mergers, acquisitions, divestitures and leveraged buyouts. Mr. Cavalier has also held positions of increasing responsibility within the investment banking divisions of Barclays Capital Inc., Bear Stearns &amp; Co. Inc., and Lehman Brothers Inc. Mr. Cavalier received a B.S. in Applied Economics and Business Management from Cornell University and an M.B.A. from Columbia University Business School.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Family Relationships</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no family relationships among any of our executive officers or directors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board has adopted a written code of business conduct (the &#8220;Code of Business Conduct and Ethics&#8221;) that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. A copy of the Code of Business Conduct and Ethics is available on our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.lyratx.com </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the &#8220;Governance&#8221; section of the &#8220;Investors &amp; News&#8221; page. In addition, we intend to post on our website all disclosures that are required by law or The Nasdaq Stock Market LLC concerning any amendments to, or waivers from, any provision of our Code of Business Conduct and Ethics. We granted no waivers under our Code of Business Conduct and Ethics during the fiscal year 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Policy</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board has </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68ebaf2b-7579-4bad-8102-790c58fbf20e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an insider trading policy governing the purchase, sale and other dispositions of the Company&#8217;s securities that applies to all Company personnel, including directors, officers, employees, and other covered persons. The Company believes that its insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of the Company&#8217;s insider trading policy is filed as Exhibit 19.1 to this Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee and Audit Committee Financial Expert</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a separately-designated standing audit committee (&#8220;Audit Committee&#8221;) that consists of James R. Tobin, W. Bradford Smith and Nancy Snyderman. Mr. Smith serves as the Chair of the Audit Committee. Our Board of Directors has determined that each of the current members of the audit committee (James R. Tobin, W. Bradford Smith and Nancy Snyderman), as well as Edward Anderson who served on the audit committee in 2024, qualifies as an independent director under the Nasdaq rules and the additional independence standards applicable to audit committee members established pursuant to Rule 10A-3 under the Exchange Act. Our Board of Directors has also determined that each of James R. Tobin, W. Bradford Smith and Nancy Snyderman meets the &#8220;financial literacy&#8221; requirement for audit committee members under the Nasdaq Stock Market rules and W. Bradford Smith as well as James R. Tobin are &#8220;audit committee financial experts&#8221; within the meaning of the SEC rules.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delinquent Section 16(a) Reports</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the Exchange Act requires our executive officers, directors, and persons who beneficially own more than 10% of our common stock to file with the SEC reports of their ownership and changes in their ownership of our common stock. To our knowledge, based solely on review of the copies of such reports and amendments to such reports with respect to the year ended December 31, 2024 filed with the SEC and on written representations by our directors and executive officers, all required Section 16 reports under the Exchange Act for our directors, executive officers, principal accounting officer and beneficial owners of greater than 10% of our common stock were filed on a timely basis during the year ended December 31, 2024 other than one late Form 4 reporting one transaction for Dr. Palasis.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Compensation.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;2024 Summary Compensation Table&#8221; below. In 2024, our &#8220;named executive officers&#8221; and their positions were as follows:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D., President and Chief Executive Officer; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D., Executive Chair and Chairperson of the Board;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jason Cavalier, Chief Financial Officer and Treasurer; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Richard Nieman, M.D, Former Chief Medical Officer</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 Summary Compensation Table</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information concerning the compensation of our named executive officers for the years shown.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.08%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:7.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.46%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.56%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Principal Position</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary<br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Bonus </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock<br/>Awards</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Awards</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Equity<br/>Incentive Plan<br/>Compensation</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other Compensation</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total <br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D. <br/>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">625,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,060</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,783,149</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,488</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,732,197</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">583,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">842,675</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">349,800</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,900</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,785,375</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Executive Chairman</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,365,731</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,878</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,796,609</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">415,003</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,060</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">625,063</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer and Treasurer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,444</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,020</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">633,239</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,924</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,303,960</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">441,141</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,502</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,530</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">943,173</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Nieman, M.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Former Chief Medical Officer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,613</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,503</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">633,239</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,836</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,354,191</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">476,579</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,240</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,834</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">817,653</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts represent cash retention bonuses awarded in 2024 and earned based on continued service through October 1, 2024, or, in the case of Dr. Nieman, upon his termination without cause on June 26, 2024. Upon his departure from the Company, Dr. Nieman received the first installment of the retention bonus, as reported in the Summary Compensation Table, and forfeited the right to receive the second and third installments of the retention bonus.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts represent the full grant date fair value of restricted stock units ("RSUs"), including performance-based RSUs, granted during 2024 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. The amount included for performance-based RSUs is based on the probable outcome of the applicable performance conditions as of the date of grant. This amount also represents the potential value of the award assuming maximum achievement of the performance conditions. We provide information </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regarding the assumptions used to calculate the value of all RSU awards, including performance-based RSU awards, made to named executive officers in Note 12 to the consolidated financial statements included in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts represent the full grant date fair value of stock options, including performance-based stock options, granted during 2024 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. The amount included for performance-based stock options is based on the probable outcome of the applicable performance conditions as of the date of grant. This amount also represents the potential value of the award assuming maximum achievement of the performance conditions. We provide information regarding the assumptions used to calculate the value of all option awards made to named executive officers in Note 12 to the consolidated financial statements included in this Annual Report on Form 10-K. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts represent performance-based annual cash bonuses for fiscal year 2023, determined by our Board of Directors for the named executive officers. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts for fiscal year 2024 represent company 401(k) matching contributions, taxable fringe benefits, personal time off payouts and in the case of Dr. Waksal, travel expenses and related tax gross-ups, and in the case of Dr. Nieman, severance payments paid or accrued for fiscal year 2024 in conjunction with our restructuring program implemented in 2024, as described in Note 5 to the consolidated financial statements included in this Annual Report on Form 10-K.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.237505514913352%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Nieman's active employment ceased effective June 26, 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Narrative to Summary Compensation Table</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Salaries</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The named executive officers receive a base salary to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. For 2024, the base salaries for Dr. Palasis, Dr. Waksal, Mr. Cavalier and Dr. Nieman were $625,000, $400,000, $444,444 and $483,351, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Retention Bonuses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we entered into retention bonus letter agreements with Dr. Palasis, Mr. Cavalier and Dr. Nieman that provide for retention bonuses to be paid in three installments, with the first installment (representing 50% of the total retention bonus in the case of Dr. Palasis and Mr. Cavalier and 25% in the case of Dr. Nieman) earned based on continued service through October 1, 2024; the second installment (representing 25% of the total retention bonus) earned based on continued service through January 1, 2025; and the final installment (representing 25% of the total retention bonus in the case of Dr. Palasis and Mr. Cavalier and 50% in the case of Dr. Nieman) earned based on continued service through May 1, 2025. In the event that such named executive officer is terminated by the Company without &#8220;cause&#8221; prior to any retention date, he or she is entitled to the retention bonus installment payment that would otherwise be paid in respect of such retention date (subject to signing a release of claims in favor of the Company).</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total retention bonus amounts are set forth in the following table:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.56%;box-sizing:content-box;"/>
    <td style="width:4.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:26.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Named Executive Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Retention Bonus</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">375,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,666</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Nieman, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290,011</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer stock awards and stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation program. Our stock awards allow employees to receive shares of common stock upon their respective vesting dates and options generally allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant. With respect to grants made in connection with the commencement of employment, our stock options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in equal monthly installments over the following three years, subject to the holder&#8217;s continued service with us. From time to time, our Board of Directors may also construct alternate vesting schedules as it determines are appropriate to motivate particular employees. Historically, our stock options have been intended to qualify as &#8220;incentive stock options&#8221; to the extent permitted under the Internal Revenue Code.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the stock awards and options granted to our named executive officers in 2024.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.88%;box-sizing:content-box;"/>
    <td style="width:3.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19.8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19.8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Named Executive Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Stock Awards Granted</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Stock Options Granted</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">660,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Nieman, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our annual performance review, in March 2024 Dr. Palasis was granted an option to purchase 1,050,000 shares of our common stock, with 550,000 option shares subject to vesting based on achievement of performance goals, and 500,000 option shares subject to time vesting conditions. In addition, in October 2024, Dr. Palasis was granted 300,000 restricted stock units subject to time vesting conditions. In March 2024, Dr. Waksal was granted 660,000 restricted stock units, 275,000 of which are subject to time vesting conditions and 385,000 of which are subject to achievement of performance goals. In January 2024 Mr. Cavalier was granted an option to purchase 200,000 shares of common stock subject to time vesting conditions, and in October 2024 Mr. Cavalier was granted 100,000 restricted stock units subject to time vesting conditions. In January 2024 Dr. Nieman was granted an option to purchase 200,000 shares of common stock subject to time vesting conditions. This option was forfeited upon his termination of employment with the Company in June 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Elements of Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Retirement Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. For 2024, we made matching contributions of 50% of the first 6% of eligible compensation contributed under our 401(k) plan.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Benefits and Perquisites</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our full-time employees, including our named executive officers, are eligible to participate in our employee benefit plans and programs, including medical, dental, and vision benefits, health spending accounts, and short- and long-term disability, accidental death and dismemberment, and life insurance and personal time off ("PTO") pay-outs to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at 2024 Fiscal Year-End</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.96%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="20" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards (1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock Awards</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vesting<br/>Commencement<br/>Date</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity<br/>Incentive Plan<br/>Awards:<br/>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Unearned<br/>Options (#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Exercise<br/>Price<br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option <br/>Expiration <br/>Date</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of shares or units of stock that have not vested (#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market value of shares or units of stock that have not vested ($)(8)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) (8)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/23/2015</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,287</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.76</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/23/2025</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/13/2017</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,429</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,429</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.73</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/13/2027</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/6/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,455</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.76</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/6/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/30/2020</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326,303</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/29/2030</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/8/2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/8/2031</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/12/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90,241</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,159</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.78</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/11/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/16/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,667</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/16/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,791</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,209</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.85</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/15/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,750</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.99</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/15/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/18/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,583</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,417</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.77</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/18/2034</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/21/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">550,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/21/2034</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/16/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,800</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/16/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">520,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/15/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/16/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">953,002</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.09</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/15/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,833</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,167</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.85</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/18/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">275,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,650</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/21/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,310</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/13/2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.22</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/12/2031</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/12/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,053</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,552</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.78</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/11/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,083</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,917</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.85</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,833</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,167</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/31/2034</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/16/2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,600</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise indicated, options vest and become exercisable in equal monthly installments over four years following the vesting commencement date, subject to the named executive officer&#8217;s continued service with us on each applicable vesting date. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options were eligible to vest and become exercisable at the end of any given three-month period occurring prior to six years from the vesting commencement date in which we recognize revenue from the commercial sale of an FDA-approved product each month and in amounts, with respect to the second and third months of such period that increase from the revenue recognized from such product sales in the immediately preceding month, subject to Dr. Palasis&#8217; continued employment with us on each applicable vesting date. Such milestone was not achieved during the six-year performance period; however, the options remain eligible to vest, in full or in part, in the event of certain terminations of Dr. Palasis' employment with us or upon a change in control transaction.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options vest and become exercisable as to one-third of the shares underlying the option, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option may not become fully vested prior to the third anniversary of the date of grant, subject to the named executive officer&#8217;s continued service on each applicable vesting date.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option is eligible to vest as to 100% of the shares underlying the option on January 31, 2028, subject to the achievement by the Company of certain specified strategic milestones within specified timeframes.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs vest in three substantially equal installments on each of April 1, 2025, October 1, 2025 and April 1, 2026, subject to the named executive officer&#8217;s continued service on each applicable vesting date.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs vest as to 100% of the underlying shares on January 31, 2025, subject to Dr. Waksal&#8217;s continued service on such vesting date.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance-based RSUs are eligible to vest as to 100% of the underlying shares on January 31, 2028, subject to the achievement by the Company of certain specified strategic milestones within specified timeframes. The amount shown is the target number of RSUs, which is also the maximum number or RSUs that may vest.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts are based on per share value of $0.206, the closing stock price of our common stock on December 31, 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Employment Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into employment agreements with each of our named executive officers. The employment agreements provide for the annual base salaries described above under the headings &#8220;2024 Salaries.&#8221; Each of our named executive officers, other than Dr. Waksal, is eligible for an annual target bonus opportunity, however, each such named executive officer waived such opportunity in respect of the 2024 fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our named executive officers is also entitled to reimbursement of reasonable travel and other business expenses incurred in the performance of such individual's duties to the Company in accordance with the Company's expense reimbursement policy.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, Dr. Palasis and Dr. Waksal are each entitled to receive a cash bonus upon a change in control transaction in which our market capitalization equals or exceeds $750,000,000 (each, a &#8220;Transaction Bonus&#8221;), in an amount equal to 1.0% of our market capitalization at the time of the change in control transaction, subject to the named executive officer&#8217;s continued service through the completion of the change in control transaction and execution of a release of claims.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the employment agreements, if we terminate the employment of Dr. Palasis, Dr. Waksal or Mr. Cavalier without &#8220;cause&#8221; or the executive resigns for &#8220;good reason&#8221; (each as defined below), subject to the executive&#8217;s timely execution of a release of claims and continued compliance with a separate restrictive covenant agreement (described below), the executive is entitled to receive (i) base salary continuation for a period of 12 months for Dr. Palasis and Dr. Waksal, and 9 months for Mr. Cavalier, (ii) in the case of Dr. Palasis and Mr. Cavalier, payment of any annual bonus for the prior year earned but unpaid as of the date of termination, (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 12 months for Dr. Palasis and Dr. Waksal, and 9 months for Mr. Cavalier, less the amount each named executive officer would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the named executive officer&#8217;s termination date, and (iv) in the case of Dr. Palasis and Dr. Waksal, any vested and exercisable options will remain outstanding and exercisable for 15 months or 12 months, respectively, following termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we terminate Dr. Palasis, Dr. Waksal, or Mr. Cavalier without &#8220;cause&#8221; or the executive resigns for &#8220;good reason,&#8221; in either case, on or within three months prior to or 12 months following a change in control, then, in lieu of the severance benefits described above, subject to the executive&#8217;s timely execution of a release of claims, the executive is entitled to receive (i) an amount equal in cash equal to 1.5 times for Dr. Palasis and Dr. Waksal, and 1.0 times for Mr. Cavalier the sum of the named executive officer&#8217;s annual base salary plus target annual bonus for the year of termination, (ii) in the case of Dr. Palasis and Mr. Cavalier, payment of any annual bonus for the prior year earned but unpaid as of the date of termination, (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 18 months for Dr. Palasis and Dr. Waksal and 12 months for Mr. Cavalier, less the amount each named executive officer would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the named executive officer&#8217;s termination date, (iv) accelerated vesting of all unvested equity or equity-based awards held by the named executive officer that vest solely based on the passage of time, with any such awards that vest based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement, (v) in the case of Dr. Palasis and Dr. Waksal, any vested and exercisable options will remain outstanding and exercisable for 15 months or 12 months, respectively, following termination, and (vi) in the case of Dr. Palasis and Dr. Waksal, payment of the Transaction Bonus, provided that the conditions for payment are otherwise satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our named executive officers has agreed to refrain from competing with us while employed and following his or her termination of employment for any reason for a period of one year and to refrain from soliciting our employees or customers while employed and following his or her termination of employment for any reason for a period of two years in the case of Dr. Palasis and one year in the case of Dr. Waksal and Mr. Cavalier.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of the employment agreements, &#8220;cause&#8221; generally means the named executive officer&#8217;s refusal to substantially perform the duties associated with his or her position with our Company or to carry out the reasonable and lawful instructions of our Board of Directors concerning duties or actions consistent with his or her position, his or her breach of a material provision of the employment agreement which remains uncured (to the extent capable of cure) for a period of 30 days following written notice from our Company, his or her conviction, plea of no contest or nolo contendere or imposition of unadjudicated probation for any felony or crime involving moral turpitude, his or her unlawful use (including being under the influence) or possession of illegal drugs on our premises or while performing his or her duties and responsibilities under the employment agreement, or his or her commission of any act of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty against us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of the employment agreements, &#8220;good reason&#8221; generally means, subject to certain cure rights, the named executive officer&#8217;s termination of employment due to a reduction in salary or target bonus (other than a reduction of 20% or less of the named executive officer&#8217;s base salary implemented as part of an across the board, proportionate reduction of base salaries for other members of our management team), a material decrease in authority or areas of responsibility, our Company&#8217;s breach of any one or more of the material provisions of the employment agreement, or a relocation by our Company of the named executive officer&#8217;s primary office to a location more than 50 miles from the named executive officer&#8217;s primary office on the date of the agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Agreement with Dr. Nieman</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Nieman ceased employment with us in June 2024 and, upon his execution of a release of claims in favor of the Company, commenced receiving severance payments and benefits pursuant to his employment agreement with us, which consist of base salary continuation for a period of nine months; and payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to nine months, less the amount Dr. Nieman would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on his termination date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback Policy</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a compensation recovery policy that is compliant with the listing requirements of Nasdaq.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> Equity Award Timing Policies and Practices</span></p>
  <div><ix:nonNumeric id="F_50d0b083-68f5-47ed-ac5e-913770341204" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="ecd:AwardTmgMnpiDiscTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not grant option awards in anticipation of the release of material nonpublic information and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d991940-623e-4369-98e1-4c22f28b9338" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="ecd:MnpiDiscTimedForCompValFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we do not time the release of material nonpublic information based on option award grant dates or for the purpose of affecting the value of executive compensation.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition,</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c70129b2-8fa4-4b72-95d0-2276a524b643" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="ecd:AwardTmgMnpiCnsdrdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> we do not take material nonpublic information into account when determining the timing and terms of such awards.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In fiscal 2024, we granted stock options to Dr. Palasis within four business days before the filing of our Annual Report on Form 10-K for the year ended December 31, 2023. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2052ed7b-3003-4fed-94f5-90ef8baac295" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="ecd:AwardsCloseToMnpiDiscTableTextBlock" escape="true" continuedAt="F_2052ed7b-3003-4fed-94f5-90ef8baac295_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is being provided pursuant to Item 402(x) of Regulation S-K regarding such stock option grants.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2052ed7b-3003-4fed-94f5-90ef8baac295_1">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:19.24%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.58%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.18%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities underlying the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise price of the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date fair value of the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_37560b1c-ebc6-48db-a351-71e649d751c3" contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc" name="ecd:AwardsCloseToMnpiDiscIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 18, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a5010cd-7f64-4ed0-a4a4-32a601c28bb9" contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc" name="ecd:AwardUndrlygSecuritiesAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3992648-1d6b-4e05-af5c-f43560dbfdc7" contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc" name="ecd:AwardExrcPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.77</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f23ec4b5-d0fa-4040-b2a0-00f5a5cd4390" contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc" name="ecd:AwardGrantDateFairValue" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">4.02</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab771e3c-767b-42a9-be63-6406956d9ae4" contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc" name="ecd:UndrlygSecurityMktPriceChngPct" unitRef="U_Rate" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_15ba66d5-09cb-4421-9493-1c6a303b3183" contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0" name="ecd:AwardsCloseToMnpiDiscIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 21, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58003a3b-81cc-4cc6-822f-3e2be09632a8" contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0" name="ecd:AwardUndrlygSecuritiesAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">550,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdc8e692-0565-4c97-8506-f105a18ce303" contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0" name="ecd:AwardExrcPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.07</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fae145d9-8ccd-4f2f-bc6f-01a3a83b944a" contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0" name="ecd:AwardGrantDateFairValue" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dcf4682-6ade-458d-9e7d-ea85fd0755b0" contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0" name="ecd:UndrlygSecurityMktPriceChngPct" unitRef="U_Rate" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 Director Compensation Table</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.669%;box-sizing:content-box;"/>
    <td style="width:2.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.343%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.583%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.583%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees Earned or Paid in Cash<br/>($)</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>($)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Altman</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,935</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,169</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,104</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,250</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,169</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,419</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Edward Anderson</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,875</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,169</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,169</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Tobin</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,500</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,169</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,669</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Konstantin Poukalov</span></p></td>
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,935</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,169</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,104</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy Snyderman, M.D.</span></p></td>
    <td style="background-color:#cceeff;padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,563</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,169</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,732</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts reflect the full grant-date fair value of stock awards and stock options granted during 2024 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all stock awards and option awards made to our directors in Note 12 to the consolidated financial statements included in this Annual Report on Form 10-K.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) held as of December 31, 2024 by each non-employee director. None of our non-employee directors held unvested stock awards as of December 31, 2024.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.867%;box-sizing:content-box;"/>
    <td style="width:6.019%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:26.115%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options Outstanding at Fiscal Year End</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Altman</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,000</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,788</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,789</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Konstantin Poukalov</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Tobin</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,500</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy Snyderman, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation received by our non-employee directors for their services on our Board of Directors under our non-employee director compensation program consisted of the following amounts for fiscal year 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the director&#8217;s initial election or appointment to our Board of Directors, an option to purchase 60,000 shares of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the director has served on our Board of Directors for at least six months as of the date of an annual meeting of stockholders and will continue to serve as a director immediately following such meeting, an option to purchase 30,000 shares of our common stock on the date of the annual meeting; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An annual director fee of $40,000; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7367350305163027%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the director serves as lead independent director or chair or on a committee of our Board of Directors, an additional annual fee as follows: </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chair of the board or lead independent director: $30,000; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chair of the audit committee: $20,000; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit committee member other than the chair, $10,000; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chair of the compensation committee, $15,000; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation committee member other than the chair, $7,500; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chair of the nominating and corporate governance committee, $10,000; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:12.435%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.8805458802032775%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and corporate governance committee member other than the chair, $5,000. </span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment is prorated for any portion of a quarter that a director is not serving on our Board of Directors and no fee was payable in respect of any period prior to the effective date of the registration statement relating to our initial public offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted to our non-employee directors under the program have an exercise price equal to the fair market value of our common stock on the date of grant and expire not later than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vest in 36 substantially equal monthly installments following the date of grant. The stock options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vest in full upon the occurrence of a change in control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information (As of December 31, 2024)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan category:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities to<br/>be Issued Upon<br/>Exercise<br/>of Outstanding<br/>Options,<br/>Warrants, and<br/>Rights</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise Price of<br/>Outstanding<br/>Options,<br/>Warrants, and<br/>Rights</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Available for<br/>Future<br/>Issuance Under<br/>Equity<br/>Compensation<br/>Plans<br/>(excludes<br/>securities<br/>Reflected in<br/>first column) </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by<br/>&#160;&#160;&#160;security holders</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,414,559</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.19</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,420,831</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by<br/>&#160;&#160;&#160;security holders</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,900,002</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.44</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,283,831</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of the Lyra Therapeutics, Inc. 2020 Stock Incentive Plan, as amended (the &#8220;2020 Plan&#8221;), 2016 Equity Incentive Plan, as amended (&#8220;2016 Plan&#8221;), 2005 Equity Incentive Plan, as amended (&#8220;2005 Plan&#8221;), and 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of the Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan (the &#8220;Inducement Award Plan&#8221;), which was adopted without stockholder approval in reliance on the exception for &#8220;inducement awards&#8221; provided by Nasdaq Rule 5635(c)(4). The material terms of the Inducement Award Plan are described in Note 12 to the consolidated financial statements in this Annual Report on Form 10-K.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes 96,533 shares of common stock issuable upon exercise of stock options under the 2005 Plan, 283,233 shares of common stock issuable upon exercise of stock options under the 2016 Plan, and 4,034,793 shares of common stock issuable upon exercise of stock options under the 2020 Plan.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the weighted-average exercise price of outstanding options under the 2005 Plan was $22.76, the weighted-average exercise price of outstanding options under the 2016 Plan was $3.10, and the weighted-average exercise price of outstanding options under the 2020 Plan was $6.01. RSUs do not have an exercise price and were not taken into account when calculating weighted average exercise prices.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes 696,925 shares available for future issuance under the 2020 Plan and 723,906 shares available for issuance under the 2020 ESPP. The Company suspended offerings under the 2020 ESPP in June 2024. The 2020 Plan provides for an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including January 1, 2030, equal to the lesser of (A) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year, and (B) such smaller number of shares as is determined by the Board of Directors. In addition, any shares that were subject to awards outstanding under the 2005 Plan and the 2016 Plan as of the effective date of the 2020 Plan which are forfeited, expire, lapse for any reason or are settled for cash without the issuance of shares will be added to the number of shares available for issuance under the 2020 Plan. The 2020 ESPP provides for an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 0.5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year, and (B) such smaller number of shares as is determined by the Board of Directors, provided that no more than 987,500 shares of our common stock may be issued under the 2020 ESPP.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information with respect to the beneficial ownership of our common stock by (i) each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock and (ii) each of our named executive officers, each of our directors and all of our current executive officers and directors as a group as of February 28, 2025, unless otherwise indicated.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on 65,880,561 shares of common stock outstanding as of February 28, 2025. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options held by such person that are currently exercisable or will become exercisable within 60 days of February 28, 2025 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Beneficial Owner</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of Common Stock Beneficially Owned</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">5% or Greater Stockholders</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities Affiliated with Perceptive Advisors, LLC</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,757,562</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.36</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities Affiliated with North Bridge Venture Partners</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,888,416</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.94</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Named Executive Officers and Directors</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">670,450</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.01</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Harlan W. Waksal, M.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,140,466</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.72</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,936</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Nieman, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C. Ann Merrifield </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,116</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">W. Bradford Smith </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,789</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy L. Snyderman, M.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,025</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Tobin</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(9)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All current executive officers and directors as a group (8 Persons)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(10)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,189,282</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.24</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Less than 1% ownership as of February 28, 2025.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless noted otherwise, the address of all listed stockholders is 480 Arsenal Way, Watertown, MA 02472. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">________</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to a Schedule 13D/A filed with the SEC on December 16, 2024, Perceptive Life Sciences Master Fund, Ltd. (&#8220;Perceptive Life&#8221;) reported shared voting power and shared dispositive power over 11,469,116 shares of common stock; Perceptive LS (A), LLC (&#8220;Perceptive LS&#8221;) reported shared voting power and shared dispositive power over 1,288,446</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of common stock; Joseph Edelman reported shared voting power and shared dispositive power over 12,757,562 shares of common stock; and Perceptive Advisors LLC reported shared voting power and shared dispositive power over 12,757,562 shares of common stock. Perceptive Advisors LLC serves as the investment advisor to Perceptive Life. Perceptive LS GP, LLC is the manager of Perceptive LS. Joseph Edelman is the managing member of Perceptive Advisors LLC and the sole member of Perceptive LS GP, LLC. On December 12, 2024, each of </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Konstantin Poukalov and Michael Altman, Managing Directors at Perceptive Advisors, resigned from our Board of Directors. The address of the aforementioned individuals and entities is c/o Perceptive Advisors, LLC, 51 Astor Place, 10th Floor, New York, New York 10003.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to a Schedule 13D/A filed with the SEC on June 9, 2023, North Bridge Venture Partners V-A, L.P. (&#8220;NBVP V-A&#8221;) reported shared voting power and shared dispositive power over 2,259,301 shares of common stock; North Bridge Venture Partners V-B, L.P. (&#8220;NBVP V-B&#8221;) reported shared voting power and shared dispositive power over 1,107,370 shares of common stock; and North Bridge Venture Partners VI, L.P. (&#8220;NBVP VI&#8221;) reported shared voting power and shared dispositive power over 2,521,745 shares of common stock. North Bridge Venture Management V, L.P. (&#8220;NBVM V&#8221;), is the sole General Partner of NBVP V-A and NBVP V-B and may be deemed to have voting and dispositive power with respect to the shares held by those entities. NBVM GP, LLC, the General Partner of NBVM V, may be deemed to have voting and dispositive power over the shares held of record by NBVP VA and NBVP V-B. Shared voting and dispositive power of such shares are vested in Edward T. Anderson and Richard A. D&#8217;Amore. North Bridge Venture Management VI, L.P. (&#8220;NBVM VI&#8221;), is the sole General Partner of NBVP VI. NBVM GP, LLC, the General Partner of NBVM VI, and may be deemed to have voting and dispositive power over the shares held of record by NBVP VI. Shared voting and dispositive power of such shares are vested in Edward T. Anderson and Richard A. D&#8217;Amore. Mr. Anderson, a former member of our Board of Directors, and a manager of NBVM GP, LLC, disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein. Mr. Anderson has sole voting power and sole dispositive power over 118,483 shares of common stock. The address of all entities affiliated with North Bridge Venture Partners is 150 A Street, Suite 102 Needham, MA 02492. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of options to purchase 570,450 shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025 and 100,000 shares of common stock underlying restricted stock units that will vest within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 536,966 shares of common stock and options to purchase 603,500 shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of options to purchase 153,603 shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025 and 33,333 shares of common stock underlying restricted stock units that will vest within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 11,328 shares of common stock and 47,788 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of options to purchase 47,789 shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 1,025 shares of common stock and 49,000 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of options to purchase 34,500 shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of 549,319 shares of common stock, 1,506,630 shares of common stock that are or will be immediately exercisable within 60 days of February 28, 2025 and 133,333 shares of common stock underlying restricted stock units that will vest within 60 days of February 28, 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and Procedures for Approval of Related Person Transactions</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests (or the perception thereof) and has adopted a written related person transactions policy to comply with Section 404 of the Exchange Act. Under the policy, our finance team is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. In addition, any potential related person transaction that is proposed to be entered into by the Company must be reported to the Company&#8217;s Chief Financial Officer, by both the related person and the person at the Company responsible for such potential related person transaction.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our finance team determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our Chief Financial Officer is required to present to the Audit Committee all relevant facts and circumstances relating to the related person transaction. Our Audit Committee must review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm's length dealings with an unrelated third party and the extent of the related person's interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of our Code of Business Conduct and Ethics, and either approve or disapprove the related person transaction. If advance Audit Committee approval of a related person transaction requiring the Audit Committee's approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the chair of the Audit Committee subject to ratification of the transaction by the Audit Committee at the Audit Committee's next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person transaction, then upon such recognition the transaction will be presented to the Audit Committee for ratification at the Audit Committee's next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management will update the Audit Committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director may participate in approval of a related person transaction for which he or she is a related person.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio License Agreement</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Perceptive Advisors, LLC are shareholders of both us and LianBio. Additionally, our former directors, Konstantin Poukalov and Michael Altman are each a Managing Director at Perceptive Advisors, LLC and Mr. Poukalov served as the Executive Chairman of LianBio&#8217;s board of directors. See &#8220;Management&#8217;s Discussion and Analysis&#8212;Financial Operations Overview&#8221; for a description of the LianBio License Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Private Placement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	On May 25, 2023, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (the &#8220;Investors&#8221;), including Perceptive Advisers, LLC and, North Bridge Venture Partners, which are 5% or greater holders of our common stock and entities with which certain of our directors are related, pursuant to which we agreed to sell securities to the Investors in a private placement (the &#8220;Private Placement&#8221;). The Purchase Agreement provided for the sale and issuance by us of: (i) an aggregate of 17,652,962 shares of our common stock, and pre-funded warrants to purchase up to 2,408,188 shares of common stock, with an exercise price of $0.001 per share, and (ii) accompanying warrants to purchase up to 10,030,575 shares of common stock, with an exercise price of $2.673 per share, for aggregate gross proceeds of approximately $50.0 million, before deducting private placement expenses. See &#8220;Management&#8217;s Discussion and Analysis &#8211; Liquidity and Capital Resources&#8221; for a description of the Private Placement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Rights Agreement</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 7, 2022, we entered into a Ninth Amended and Restated Investor Rights Agreement ("Investor Rights Agreement") with the holders of our then-outstanding preferred stock, including Perceptive Advisers, LLC and, North Bridge Venture Partners, which are 5% or greater holders of our common stock and entities with which certain of our directors are related. The agreement provides for certain rights relating to the registration of such holders&#8217; common stock. On May 25, 2023, in connection with the Purchase Agreement, the Company entered into an Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement (&#8220;Amendment No. 1&#8221;) with certain Investors affiliated with Perceptive Advisors and North Bridge Venture Partners (the &#8220;IRA Covered Investors&#8221;). Pursuant to Amendment No. 1, the definition of &#8220;Registrable Shares&#8221; in the Investor Rights Agreement was amended to include all shares of common stock purchased by the IRA Covered Investors in the Private Placement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independence of the Board of Directors</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors has determined that each of C. Ann Merrifield, W. Bradford Smith, Nancy Snyderman, M.D., FACS and James R. Tobin qualify as &#8220;independent&#8221; in accordance with the listing requirements of Nasdaq. In addition, our Board of Directors determined that each of Michael Altman, Edward Anderson, and Konstantine Poukalov qualified as &#8220;independent&#8221; for the duration of their service on our Board of Directors during the year ended December 31, 2024. The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our Board of Directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management. Harlan W. Waksal, M.D. and Maria Palasis, Ph.D. are not independent. There are no family relationships among any of our directors or executive officers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tant Fees and Services.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the fees of BDO USA, P.C., our independent registered public accounting firm, billed to us for each of the last two fiscal years.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fee Category</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Fees</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">484,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">520,770</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">484,250</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">520,770</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">________</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For 2024 and 2023, audit fees consist of fees for the audit of our financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approval Policies and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee has adopted a policy (the &#8220;Pre-Approval Policy&#8221;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage our independent auditor, BDO USA, P.C. to render any audit, audit-related, tax or permissible non-audit services unless the service is either (i) explicitly approved by the Audit Committee (&#8220;specific pre-approval&#8221;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#8220;general pre-approval&#8221;). Unless a type of service to be provided by BDO USA, P.C. has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC's rules on auditor independence. The Audit Committee will also consider whether the independent auditor is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company's business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company's ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. The Audit Committee periodically reviews and generally pre-approves any services (and related fee levels or budgeted amounts) that may be provided by BDO USA, P.C. without first obtaining specific pre-approvals from the Audit Committee or the Chair of the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits and Finan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents filed as part of this report:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following documents are included on pages F-1 through F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto and are filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (BDO USA, P.C., Boston, Massachusetts, PCAOB ID: </span><span><ix:nonNumeric id="F_c4304478-0686-4aa3-9d2a-5f1a3346f949" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">243</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Statements:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statement Schedules.</span></div></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the financial statements or the notes thereto.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of Exhibits.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.738%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:44.851%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:8.098%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:6.219%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.277%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.498%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form or</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">with SEC</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SEC File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312524163395/d614069dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Restated Certificate of Incorporation of Lyra Therapeutics, Inc., dated May 5, 2020 and the Certificate of Amendment to the Restated Certificate of Incorporation of Lyra Therapeutics, Inc., dated June 13, 2024</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 18, 2024</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/lyra-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Ninth Amended and Restated Investor Rights Agreement, dated as of April 7, 2022, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement, dated as of May 25, 2023, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant, together with a schedule of Pre-Funded Warrants, each dated as of May 31, 2023, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Purchase Warrant, together with a schedule of Purchase Warrants, each dated as of May 31, 2023, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.738%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:44.851%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:8.098%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:6.219%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.277%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.498%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form or</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">with SEC</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SEC File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Stock Certificate evidencing the shares of Common Stock of the Registrant</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312520120337/d805799dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrants to Purchase Common Stock, dated various dates, issued by the Registrant to various investors, together with a schedule of warrants and warrantholders</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex42.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Purchase Warrant, together with a schedule of Warrants, each dated April 12, 2022, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8*</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex4_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2005 Equity Incentive Plan, as amended, and form of agreements thereunder</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2016 Equity Incentive Plan, as amended, and form of agreements thereunder</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2020 Incentive Award Plan and form of agreements thereunder</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. 2022 Inducement Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Harlan Waksal, M.D. on February 16, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4.1#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. 2020 Incentive Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Maria Palasis, Ph.D. on February 16, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-ex10_46.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan as Amended and Restated, Effective December 9, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4.6</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 29, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4.3#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017023060298/lyra-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan, as Amended and Restated Effective December 12, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4.4#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017024050535/lyra-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. 2020 Incentive Award Plan Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement issued to Harlan Waksal, M.D. on March 21, 2024</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 30, 2024</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4.5#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017024050535/lyra-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. 2020 Incentive Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Maria Palasis, Ph.D. on March 21, 2024</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 30, 2024</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Program</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement for directors and officers of the Registrant</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement between the Registrant and ARE-480 Arsenal St, LLC, dated August 14, 2007, as amended</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.738%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:44.851%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:8.098%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:6.219%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.277%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.498%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form or</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">with SEC</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SEC File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Maria Palasis, Ph.D., dated as of April 27, 2020</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10+</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459021042711/lyra-ex101_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Collaboration Agreement dated May 31, 2021, by and between the Registrant and LianBio Inflammatory Limited and LianBio.</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2021</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11+</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017022023266/lyra-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to License and Collaboration Agreement, dated September 26, 2022, between Registrant and LianBio Inflammatory Limited and LianBio</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 8, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459021055778/lyra-ex102_83.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Jason Cavalier dated as of September 13, 2021</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 9, 2021</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to the Employment Agreement between the Registrant and Maria Palasis, Ph.D. dated as of February 16, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Harlan Waksal, M.D. dated as of February 16, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15#</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex103_69.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Richard Nieman, M.D. dated as of June 30, 2022</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated as of April 7, 2022, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex102.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated as of April 7, 2022, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017022025323/lyra-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sixth Amendment to Lease, dated November 14, 2022, by and between Lyra Therapeutics, Inc. and ARE-480 Arsenal Street, LLC</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 16, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017023032992/lyra-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Seventh Amendment to Lease, dated July 12, 2023, by and between Lyra Therapeutics, Inc. and ARE-480 Arsenal Street, LLC</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;July 14, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex42_66.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement, dated May 31, 2022, between the Registrant, as the tenant, and BXP Waltham Woods LLC, as the landlord</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;4.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;August 9, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex43_65.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease Agreement, dated July 20, 2022, between Registrant, as the tenant, and BXP Waltham Woods LLC, as the landlord</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-ex10_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease Agreement (Notice and Acknowledgement thereof), dated March 3, 2023, between Registrant, as the tenant, and BXP Waltham woods LLC, as the landlord</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 29, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-ex10_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sublease dated as of December 21, 2023, by and between RVAC Medicines (US), Inc. and Lyra Therapeutics, Inc</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 22, 2024</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017023060298/lyra-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Lyra Therapeutics, Inc. 2022 Employee Inducement Award Plan, as Amended and Restated Effective December 12, 2022.</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.738%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:44.851%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:8.098%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:6.219%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.277%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.498%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form or</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">with SEC</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SEC File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated as of May 25, 2023, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated as of May 25, 2023, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2023</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27*</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Novation Agreement, dated as of November 15, 2024, by and among Lyra Therapeutics, Inc., LianBio, an exempted company organized under the laws of the Cayman Islands, and LianBio Development (HK) Limited (as successor-in-interest to LianBio Inflammatory Limited), a private company limited by shares organized under the laws of Hong Kong</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1*</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="lyra-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Policy</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of BDO USA, P.C. Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2**</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lyra-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation</span></a></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 22, 2024</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; this instance document appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.738%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:44.851%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:8.098%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:6.219%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.277%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.498%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form or</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Schedule</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">with SEC</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SEC File</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Date File (embedded within the Inline XBRL document)</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:8.4pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:8.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Certain portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.111%;box-sizing:content-box;"/>
    <td style="width:4.979%;box-sizing:content-box;"/>
    <td style="width:3.259%;box-sizing:content-box;"/>
    <td style="width:46.651%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:30%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director (principal executive officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jason Cavalier</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:21.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Harlan Waksal, M.D.</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Harlan Waksal, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Chair and Chairperson of the Board</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ C. Ann Merrifield</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ W. Bradford Smith</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Nancy Snyderman, M.D., FACS</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy Snyderman, M.D., FACS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James R. Tobin</span></p><p style="border-top:0.25pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Tobin</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:12.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2025</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.68%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:6.94%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (BDO USA, P.C., Boston, Massachusetts, PCAOB ID: 243)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGIST</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders and Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Watertown, MA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88944a0f-b0f5-4218-9082-649c092ee129" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern Uncertainty</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and continued outflows of cash from operating activities resulting in an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-1.695%;padding-left:1.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4074f077-bf5f-4137-846f-8a105c2d0fb1" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BDO USA, P.C.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2013.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a118b544-91cc-4701-b8fc-69b015bb221a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 13, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED BA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.353%;box-sizing:content-box;"/>
    <td style="width:1.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.723%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.723%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd7a42c-c4c3-4100-93c6-3f3d810db604" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,577</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46335d74-6fce-486c-94c1-622d21192f58" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,353</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35d72988-19eb-4645-9d6e-39c530e12c4f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c868ddef-5d12-4b71-b7b4-f2198d6282af" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a80c7a3-7b49-4eae-bf03-f43535b456ee" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a04a936-fa67-42b4-9f70-1b411803ab89" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,068</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a14cfee1-46f1-4fce-bb6f-d3f149aba020" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,025</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40554d04-a63b-4614-b32d-2791712e29db" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,821</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28d74e78-5238-4bfd-9c86-5f8817438aa5" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,404</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54f3c9a9-04c0-4894-a91a-16e18b46d639" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,043</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83a7ba89-0694-4a11-b9a9-535b28863f93" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,924</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7fe00a8-bc9f-4381-8caf-b6d88dfe4cb8" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,233</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94e36d90-da31-4a9c-b9a3-73074ccafa16" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08a5eb1e-5818-4874-a748-31df611acf64" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16438f2f-8b54-4850-81de-1c6e7a87ad4b" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5be97b0-16a7-4466-881b-fe9aacd16739" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cbdc23c-f8fd-4a40-ba5f-28c883c41f97" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,346</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35cf8ea6-3394-40bf-9324-fcfad54e813c" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b1afbef-b8a1-4859-ad6d-8f6a9535fd27" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c7c55af-86e2-40ce-b1ef-95ed4ef75c47" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,131</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66d51420-e4df-4dfc-ab77-fbe69db53c14" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:RestructuringReserveCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,347</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10333a18-f501-4d39-a2f5-908d51f1d791" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,586</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f48f3460-7e06-44e5-8370-b884dede9881" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31ca1f96-3024-4262-b56f-a5ab3f110642" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fdcd5f2-a126-4054-8ca5-d7583a7e9f5a" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,434</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6306ab77-21fb-4444-8e47-c1688abe635f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ca420f-e48b-4c83-9db9-6018f25947ac" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af135b73-eff2-4273-b307-53be9b69bc7b" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,631</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c0924f3-9d4d-4f1d-b760-5756ee7b7d17" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,597</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abfec8d6-8037-4902-a6d1-84d698cdeb90" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,259</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_071e11bb-e11f-4e6d-8cfe-5e71e066f9ed" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5370f6aa-83e4-4f87-a53d-271b5685e702" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,862</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08c247f4-4514-48ed-a651-6e0d16c04597" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,136</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c033499-005a-4830-becf-c8e2b3f8cf58" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,752</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e3551d9-52e6-4ddf-a1a8-aa611227adf0" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,180</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_3f0045f0-3fff-4e61-b86a-d3810d5684d8;"><span style="-sec-ix-hidden:F_05ec1fb1-1dd3-4023-b23a-af84bcab4881;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 17)</span></span></span></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3ba7100-9d0d-42ef-82e3-71315b81ae20" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_219661ae-d571-4b75-a7d5-17f36cc8e281" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2edb7341-8fc8-4878-b016-9e25087d35d9" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e06e9fa-8a79-4c6d-97be-148f6b61ab60" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at<br/>&#160;&#160;&#160;&#160;December 31, 2024 and 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af521c56-f61e-4c5f-8f8b-7248a6518d6c" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_40581430-cbe4-43e9-bf50-0e2ad8ffe713" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_990c9b70-4234-4b57-8bf1-8cec5ab096d2" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_56a8abdb-2faa-4162-a148-aabf74aa19ef" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding <br/>&#160;&#160;&#160;&#160;at December 31, 2024 and 2023</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_2511519b-36bc-46ee-8366-ebaa53d26f96;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b343ec9f-148d-44d4-9d08-7d94b8644011;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_444c2379-f2e7-4179-a1b8-a590381ae6d0" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c916148a-32f6-4224-b2da-eae6f077acc2" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50c28ddd-cfb9-481b-a7b2-9ae4ac543dc5" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eb58f0a7-cf15-4b44-983f-69d2b97ce1e1" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at<br/>&#160;&#160;&#160;&#160;December 31, 2024 and 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66674cd2-ce5a-420b-86e2-c2edb0b9b793" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_43debed6-9e26-4e29-87ae-2a9de7318901" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,515,440</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87a9684b-cec4-4523-97c9-246b573ed73c" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cf1a1154-a3a1-4c18-9d35-6b84ef5cb2e3" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,214,550</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and<br/>&#160;&#160;&#160;&#160;outstanding as of December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce1fcef-c6d7-4fcb-be2d-3153ada87d2f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48e60a13-4b20-41fc-86a3-529003b49931" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eb79b7d-78a6-46ff-9925-87ee388c845f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416,319</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3ccfe2e-597c-44c9-b08f-81389e84311a" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income, net of tax</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5158de1c-6c07-4042-b5d5-aff4fb5fe463" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5596692-a67c-4f63-9dc7-76303e836176" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_059e5cf8-67fb-4b85-b447-d52bd41f5c21" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">404,790</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e490c277-cb74-43e4-a442-adf7da01015a" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">311,355</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a636f06-b2fd-4b21-9920-f66a7da999b0" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,594</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e7f8be3-7abc-4f7c-a56b-a912db317c6b" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,420</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stock and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d5f954b-b61b-495c-8ae8-bf2abee2585a" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,346</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_079eded6-67ea-4abe-8c12-ebe2059b4c53" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATIONS AND COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebfa6d88-ce3c-4878-b161-deeebd3a05e5" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,534</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e1fa0dd-9e56-414d-a023-b49728d95c09" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,558</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a37d2218-b59a-4b45-82ce-5cad58568193" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,766</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8fe171-e565-48d5-8ef2-f219c7f2b181" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,029</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59c70c3f-6ade-457f-a202-eac3fbc83db0" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,501</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb6969bd-60e1-41fd-a79a-f66416d01855" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,057</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property and equipment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94691ff6-8241-430c-aff8-97637f7bd004" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46817996-a44e-49e0-a96f-0f67a24a1d45" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3076e161-2cde-41a7-b6c1-5fa0ca6660af" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,836</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring and other related charges</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5820370f-9c26-4844-981d-274d17b4c112" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,896</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6656054-3c7a-43c9-a032-da439ee81c8c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,882</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0aed609d-75af-48fa-8ac8-d2e9ec3ba12c" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,678</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fb785f1-cefa-4a5b-8083-684d9c724e69" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">96,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a837204-c0cd-4c98-9ab3-00ef37887136" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,120</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_127a00e3-4694-4343-a2cf-a20b4ca95003" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3716386-7d37-4f06-9258-3383e7ed4ec9" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,499</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8f2ff59-f4e7-4428-8d4a-5cf67dc67b67" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7fbba6f-4fb1-4ec8-baa5-eaed91af977c" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,499</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34005d64-6e39-4490-a9fd-eb63038b68c7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,396</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b97eb18f-4b09-4a94-bd72-9d360fabc38a" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,621</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ead9301-79a0-4321-9f62-25e0aecb3a5b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_605dccb5-2ce6-485b-b338-c336b6cdaa4c" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7adde3e9-6434-4a4a-84c1-cc867b6c222a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f766c6c-87a6-4c5f-bdbc-8bcad77e2e0e" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive (loss) income:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized holding (loss) gain on short-term investments, net of tax</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a8ef1ae-d936-41ed-8b9a-5e1fd43b08d4" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba704365-b50d-4c85-9f81-ad89feb8bdae" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7a0d4af-0d4a-42bd-92df-18770caf14d6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,468</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30dfc59c-2c40-4b87-8a3c-c749852e27da" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,657</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share &#8212;basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4f5ab55-89e7-4258-a03b-8c56daebb24e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eeae575b-b47f-472b-a070-17011e294f7c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.43</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e10b7aa-7312-469e-bb75-e44167c2003d" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fae4b434-a5a5-48a3-8e5b-b2f2898fa01a" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.26</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding&#8212;basic and diluted</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3193d47d-255f-4a16-9ca1-5d1a0a82591d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f5dea936-c6d3-4dba-9508-6b8b451e44c4" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,113,859</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b8b8745-da9b-492b-aff7-ebab5646ccd5" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_82647092-93fa-44c7-bac0-890564d585c8" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,804,283</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_redeemable_conve"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30.825%;box-sizing:content-box;"/>
    <td style="width:1.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.629000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.148%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.148%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.148%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.148%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.361%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.148%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income, net of tax</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_045219b4-57a1-4b2c-b209-19371daa136d" contextRef="C_bf748116-4ebf-40ac-bff9-35c1fb5ed691" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">31,827,659</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9250e099-508a-4de6-ab91-b6984b9a20df" contextRef="C_bf748116-4ebf-40ac-bff9-35c1fb5ed691" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bf15ccf-ff25-45e6-9df2-b99d5e94bc4b" contextRef="C_61649002-24c3-41d8-9ae0-4fc54a732edd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,387</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec5401c-b3d8-4123-94d2-ecce87719c10" contextRef="C_5a610f2d-1ed4-4ce1-9e6a-09068ac8d582" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67b7b14f-2dea-4152-9bed-de0ee755d422" contextRef="C_57fb40b9-1300-49dd-abdb-a8199037cd9a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">248,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b971ed35-2911-4bde-9a84-90bfacac1936" contextRef="C_194bf10a-3e96-4e60-85a1-7fac540a46ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,754</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0444bb47-8198-4951-b10c-97529f51cea1" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,897</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31e872de-9f7f-49a3-9f43-e71c773a9a6f" contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0d8ba8b-2828-4cf3-9a1f-9067b3cadb82" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock and pre-funded<br/>&#160;&#160;warrants, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da16dc8-0d43-48b1-bb9f-662f90143eaf" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,482</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7865dc44-2048-4600-be0c-eff2eee11105" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,652,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_345288c3-f55e-4b95-b596-42f176fd5824" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3a812d6-61bb-4724-8488-06e33257215f" contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45d02e3f-4cc2-4666-960e-465b1c7c543d" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon RSU vesting</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dc27005-3ed9-401f-b6fe-bd5185c656fc" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,041</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issued under ATM, net of issuance costs<br/>&#160;of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c9db127-bb33-445e-b096-a948ea6586c6" contextRef="C_c9aae08b-647b-4917-91f5-0e67b5b4eb3a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_264b5e2f-6304-4b38-a708-062ca524375d" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,017,568</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cfc204e-5209-4576-9e9c-d364801ac065" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074a52c6-4ad0-42df-9ab6-6791b0087fe2" contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b60240-104c-4890-8216-e9895e3b4239" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,068</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbbdafe6-b8d7-4dd1-b82b-42a0e04e270d" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="lyra:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,651,423</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efad70ed-14ce-4e18-accd-257cf8f1882c" contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091" name="lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ebd8097-a67c-472b-a37f-31b99e3a2117" contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd" name="lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ff732bb-3450-4dc8-a94b-363c21bd9e0e" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b9a7494-23f5-4d63-9830-290b5ecaee15" contextRef="C_69975709-688b-4d92-8cdc-d1d390a6e165" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_107e7d85-47e8-4274-bec1-cf13bd295710" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae1d5370-b461-46b2-92b1-0ba22aa60c28" contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_547b0232-c34a-4d72-935a-f7bd9247e6c0" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08b2684e-12a3-4655-aa54-9bd75c167055" contextRef="C_4175d822-423f-49b4-b933-6156169f74f7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67519a8d-9be1-442e-8bc7-12c90826f4dc" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0053508b-82b8-4242-9be1-662da3a53dd5" contextRef="C_f932f338-d1f5-448c-91af-c2103ea85652" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,214,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f3105a6-cf42-4ddd-bd41-305098a0a3b8" contextRef="C_f932f338-d1f5-448c-91af-c2103ea85652" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d9905c4-b2ef-4819-8f2d-c34acdd28d03" contextRef="C_45126bd5-3587-4e96-98ac-59bdd46c63ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,685</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fd41176-3cef-46d7-aac4-6146f349150b" contextRef="C_3921f74d-c549-48e7-9cfe-f514102c6219" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ad9fc27-000c-4262-9ae8-ef06110ff971" contextRef="C_2ea1e700-e522-466c-b768-f653aab494c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">311,355</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_193f02bf-9523-46af-ab64-963882d43523" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,420</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f41bed95-801d-4b03-be86-cf202c4e01bb" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42bcdca0-20ae-4fdb-a06d-151af547439b" contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1786513-d627-4c40-b319-245131c7946f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock and pre-funded<br/>&#160;&#160;warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d22cf200-5fa4-4797-953d-b4e86ac973d2" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,746,376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b988732-aeab-4165-a093-c3ed46cbf36a" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e37524b2-3aba-47a9-9fc7-d2e1641ada40" contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3c57bac-5782-4be3-8284-53dc4b3f0748" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issued under ATM, net of issuance costs<br/>&#160;&#160;&#160;of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9855dd27-0928-42c3-b87e-1135291ad5e1" contextRef="C_b0c1652c-3b2c-4e34-a9b2-16cba734c265" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_436a7b21-bd31-4f8e-a979-a71147742eb0" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,041,666</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c21ca04b-8ac5-48e2-a480-b481dbb5f430" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a351ad4d-3729-42ec-9d58-5dbb3d8a4488" contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,849</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3830e396-7d9d-4925-a174-5da802c045b6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,850</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under ESPP</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcb6fcd9-7a70-4538-b61d-233c6f23bf79" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of common stock warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a377bd-ae18-40d8-9b6b-9e21aa9c72c4" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="lyra:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,424,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7df2a4b-4130-4d14-a913-931db9624926" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46a124fe-9545-4747-8d4a-70f7ecb915ce" contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e" name="lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,806</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2690be80-6fef-43a4-bcdf-614bf7edf4d7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,808</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon RSU vesting</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90202df3-b91b-4ca5-94f2-762966f851b6" contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,574</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b268c465-309f-4d3c-821a-97e1d8f2e5fe" contextRef="C_6e6920b6-a5cd-4c38-83d1-289485f945cd" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1f0533d-dd9e-48e0-b865-b1b26883a645" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e81e8c-75ef-473f-a3c6-a90ac0ff2034" contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,971</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871d9efe-d776-4644-ac93-01484e00116e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,971</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25ebda63-c5b6-4720-9ff0-434d5a9da56a" contextRef="C_0898fa9d-b760-4363-9f56-f980685e0512" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5abf9fa-70b5-4781-86ec-f0a5d0b3b55c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4244a66-016b-4b54-b2bc-0fe87660ca94" contextRef="C_a1b363ff-1904-4c03-9f49-1ead948fba72" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,515,440</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a753d58d-7b15-40d5-8f6e-c5e92da38230" contextRef="C_a1b363ff-1904-4c03-9f49-1ead948fba72" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1e97372-fcde-4772-acee-0839072b62ad" contextRef="C_f87955f6-4893-487d-8bee-6137b9aa2886" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416,319</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0647f41-c4fb-47b2-a6e0-378d33a1d214" contextRef="C_397e0276-799b-4130-992e-a0f2da30c71c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">404,790</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_257ca228-5f1d-4b5d-99c7-0f9757a45454" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,594</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.886%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.478%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.478%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3eda5b0-d26a-44a2-b8bd-8f14a525e11f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fff4a2ed-2e25-440b-9155-4a26540f4ad3" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe02415c-befe-4608-9e32-f10cb3ccfa9f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,716</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dfc3cfa-1b22-442f-af15-19a5476d4540" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,887</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eeb518d-e0fb-4f69-b64e-b5f17238e0de" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">471</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774e46c4-ecd3-4479-88eb-f7869fb1fc9a" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property and equipment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20ad923c-edbf-4ef1-8310-9aecea0f3e30" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9a086e1-6d78-4389-b94e-e7e81a6ef95c" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Write-off of deferred financing costs</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50fa1a97-ff5b-49b2-b31b-37d17e5d0dba" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4ddf9a-265e-4b57-ab2d-3e23d0d7e260" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,836</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net amortization of discount on short-term investments</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac2aad75-89ca-4ab0-9258-63c2333d11e7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,276</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b4164ae-127d-4951-ad49-a1ff2a868034" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e623f9e5-c404-42c6-90e7-59bfa79848cf" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a40ce7-299c-495b-8b65-2f73f0eb358f" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">867</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58defadb-0c7f-4fb7-83aa-447a0a880103" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,353</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc2ec3a9-e2a6-467f-b025-05a336bdbabb" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,137</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c3836e-1ad2-4310-be2f-c6edde76384a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,111</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0cde70-25ac-4490-b1ff-8a319f921323" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ea982b7-5136-4c0f-9885-bc194dd14495" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,887</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e74629fc-900d-40fc-b03d-0e5bf7c7face" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab680baf-a87a-49b5-94cb-2593eb320336" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,975</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ad5bfcf-2384-4816-97b2-e3c852df73bd" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd026c66-f314-4e61-ab23-043fdca29336" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,347</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3d7d2cf-cdb9-47fa-b97f-a0a3e35dbc07" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,381</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f6801cb-e105-40bf-aef7-702e47d0fc96" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,208</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d796d7a-c357-46d5-b750-c6961e0e9b96" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,534</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_294f773d-3e69-4bc2-9efa-650c90198566" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,558</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_906caf6d-3c76-434e-81fe-c642a8d8d31c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,011</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d5a9cb9-c60b-45a6-98b9-8bc309e54e06" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63,304</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5db2110d-cd1a-4c53-be39-1d1e799c2981" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,338</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22af9bf-9a02-4f7c-9846-321f3829b243" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,047</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of short-term investments</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_914ed25b-7cfe-4fec-a4a4-82d40c6abe07" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_959e764b-4218-4fad-af3e-66fef170b35f" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturity of short-term investments</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599cfe6a-7d60-49af-a38e-9aa6474b6bde" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_383998c9-180b-4f65-b329-2b4389d0ddfd" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,886</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d099fed-915b-48be-9c46-08eeacfbad4b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,305</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4d8b89f-840e-4d24-a020-baf684ba4223" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,584</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of common stock, warrants and pre-funded warrants</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33a72ef8-4e8a-43a0-92cf-64fb65d4f1a2" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_543403bd-2079-406a-aa97-7d3b9c1616d8" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,242</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of deferred offering costs</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ab151e7-c329-4353-9cb0-8a411364f9bc" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_267caf31-596a-406d-938b-6244ab63a854" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,654</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a9e0539-7743-4f9e-b176-f2e9ae849e18" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cccd4f6-daf3-42bb-9b26-8b44203e74be" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2068171-a8fa-45d8-b7f5-1fd6d68e08e8" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbd33cf1-df5e-43b2-a93d-300ba591724b" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,691</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27e84aa3-e887-4add-b0e1-9ef02592b606" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,825</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2e4585b-2917-46a4-967a-f2c0a0b8a361" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,197</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5f582e6-1eb9-4834-a164-6005208bc670" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,745</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4b3127c-1546-4cf2-8c8d-a5f46442af05" contextRef="C_194bf10a-3e96-4e60-85a1-7fac540a46ce" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,942</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents and restricted cash, end of period</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a335cb45-d5c6-45da-b5a7-6e2032fe814f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,570</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb36637-3be6-4250-acc5-7416920604ee" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,745</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash financing and investing activities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71ae9aab-7345-40a0-b252-2e842c2bd675" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">623</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses for right-of-use asset included in operating lease liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74bc068f-d33f-4ddb-9470-a0697b1508ff" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,786</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Modification of lease agreement</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec84e127-28ee-4b52-a313-5f9de351020e" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:ModificationOfLeaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,931</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets included in accounts payable and other current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_722d5188-0c83-412a-a9cb-9c1446ff97cf" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,667</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset in exchange for lease liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a74ed570-ebd7-490a-bd4c-3ab1af113296" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,156</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ca5bad57-9a4f-4605-bc34-8ac1ab3c7e58" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_ca5bad57-9a4f-4605-bc34-8ac1ab3c7e58_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization, Restructuring, Going Concern and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company&#8217;s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#8217;s product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1c5ec60-0f6e-4fe8-a5d1-ea0022fde5d3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 21, 2005</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 16, 2024, the Company reported that topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant (7500&#181;g mometasone furoate), as a six-month treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210. The 52-week extension stage of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients who received a repeat dosing resulting in a 12-month treatment period. In the extension stage, LYR-210 was generally well tolerated, with no product-related serious AEs. The most commonly reported extension stage AEs in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results are expected in the second quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors of the Company (the &#8220;Board of Directors&#8221;) approved a reduction in the Company&#8217;s workforce impacting </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_786f523d-eeec-462c-afd8-9019b4855808" contextRef="C_c9a482dc-f5d4-4994-8462-78e8c22a8165" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Employee" decimals="INF" format="ixt:num-dot-decimal">87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> employees, which occurred during May and June 2024. In connection with the reduction in force, the Company stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. Furthermore, the Company is currently in the process of marketing all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_225c378b-e626-46d0-b884-9960506db706" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of its leased properties for sub-leasing arrangements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded a restructuring charge in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_ba1a1da5-73e6-4247-ba87-676697d9fe0c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, primarily related to severance and retention costs as further discussed in Note 5. The Company has also recorded an impairment charge for the write-down of property and equipment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77aef211-4027-4e1e-bbab-8852517c0c95" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and right-of-use assets in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf9b0a05-b53c-4e08-ad18-d7b9224267ef" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as further discussed in Notes 6 and 7, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure of the Company&#8217;s Phase 3 ENLIGHTEN 1 trial to meet its primary endpoint, which resulted in the Company&#8217;s restructuring during the second quarter of 2024, provides significant uncertainty regarding the Company&#8217;s ability to meet its business plans and conduct its future operations. The Company has incurred recurring net operating losses every year since inception and has an accumulated deficit of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd8cdd1-b400-431e-b934-9958c49614c2" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">404.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at December 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2024, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c0bd11-fa15-422f-8c7f-66143caa7b4e" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:216pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ca5bad57-9a4f-4605-bc34-8ac1ab3c7e58_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From inception through December 31, 2024, the Company has raised an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8b3c5b2-a399-4a71-b2dc-d662280dc49b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:CashProvidedByFinancingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">424.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to fund its operations, primarily from the issuance of equity securities and to a lesser extent, government contracts and a license agreement.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) assuming the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board of Directors has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. The Company is attempting to sublease all of its leased locations, and, may also seek to negotiate an early termination of its leases with its landlords. The Company may be unable to sublease its locations on favorable terms or at all. In addition, the Company may not be able to obtain an early termination of its leases with its landlords on favorable terms or at all.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will continue to evaluate its headcount of employees and may further reduce its workforce, which will result in additional severance and retention costs, which may impact the Company&#8217;s ability to meet objectives. If the Company decides to pursue any form of growth strategy in the future, it will need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to obtain funding as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e726661-e9ed-4dff-bb99-8d76500c6708" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_645d6d02-e695-419d-a381-fac330a2284f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6722a48-2ede-40d2-a557-77705eec8bcb" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1364333-dfb9-4a32-9a07-33eec12d1a9c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_1" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e25c50e5-cbb8-4e4a-b4e5-28ce03e1c8d9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, other comprehensive loss consisted of unrealized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gains and losses, net of taxes from its short-term investments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_110dabb9-5af6-4805-9ccc-0b23508dea73" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_fddb8b94-dbcb-4216-a1ba-a10a1afcc33d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had restricted cash of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fa02699-6bc0-4ec6-afd3-041549583043" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc4920e2-0215-4237-9d7b-8f959942398a" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively. These balances were held as restricted at the Company&#8217;s financial institution to secure the Company&#8217;s letters of credit for its facility leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ginning-of-period and end-of-period total amounts shown on such statements. </span><span><ix:nonNumeric id="F_b267ab55-9f9e-468c-a5e4-158f96b4aa0d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true" continuedAt="F_b267ab55-9f9e-468c-a5e4-158f96b4aa0d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b267ab55-9f9e-468c-a5e4-158f96b4aa0d_1" continuedAt="F_b267ab55-9f9e-468c-a5e4-158f96b4aa0d_2">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"/>
          <td style="width:1.5%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.843%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.5%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.843%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72e3d370-132f-4e4b-85e5-3425d20a008d" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,577</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb5746f3-9119-49be-9fb9-ae41a8d91f80" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,353</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c19da42-818b-4b6a-9b82-77c3679a05e7" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61e497cf-63a3-49c4-83b7-69477f1aa210" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,392</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_683a3747-5d67-4f98-ac8b-0cf9ddf9a518" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,570</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33e6c1bb-a2d7-4f67-ba71-08f0c8becb89" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,745</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div><ix:continuation id="F_b267ab55-9f9e-468c-a5e4-158f96b4aa0d_2"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73aa1341-3310-4e39-8cb3-f2cdff47b47c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#8217; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_2" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d75f72c7-121e-43b3-a8f5-c21e0c2bd622" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:OtherAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Assets</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company includes certain items within other assets on the consolidated balance sheets. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fb12bd0-23bb-4998-8886-a59ead14dc81" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OtherAssets" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> balance in other assets as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had other assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fedd6300-a454-49e7-87c3-df850db2c163" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OtherAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, primarily composed of long-term deposits for the Company's clinical trial agreements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57c881f1-2b2d-49a3-9b80-09c65c592d78" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f08affeb-e719-4ba3-b4c5-db9ef457874a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:SignificantSuppliersPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2054b7e-584b-47f8-9afe-de3f7e201273" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_3" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_4"><div><ix:nonNumeric id="F_9188c270-f11d-439b-a343-c4069e227b85" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc964cb4-a6f7-4786-8850-78cf0c340114" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_bc964cb4-a6f7-4786-8850-78cf0c340114_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_bc964cb4-a6f7-4786-8850-78cf0c340114_1" continuedAt="F_bc964cb4-a6f7-4786-8850-78cf0c340114_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:50%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_41598fb9-b21c-4e2f-95e0-c15c06f2a074" contextRef="C_87370fcb-d580-4410-a3e9-579a2b1905ac" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a06d04af-bf9c-49bb-a43e-db62f012c19a" contextRef="C_4fa89b2f-0fcf-42bb-8c6c-336ddd1b20ad" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fd490a88-7ef4-49c7-956a-99781c99d57e" contextRef="C_6137d41a-fa82-43b5-b6fb-bc98341150d3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the consolidated balance sheets and related gains or losses are reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_171885c0-2fb9-4ece-8bf2-1e4bf8762823" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90910216-5c28-4f18-8f08-9416cf0e8b8a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e35f840d-9567-41bb-ad40-91cf75114e04" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to loss on impairment of property and equipment for the periods ended December 31, 2024 and 2023, respectively, both related to specific facts and circumstances in the respective periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also assesses its right-of-use assets for impairment based on triggering events, and recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc938a7-cd10-450d-b445-99a797636dd4" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:ImpairmentOfTheRightOfUseAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to impairment of right-of-use assets as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e9e7681-f1f7-4fcf-8302-2837279de5fe" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="lyra:ImpairmentOfTheRightOfUseAssets" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> indicators of impairment of the right-of-use assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d5e47d4-9f5d-4422-8da9-c2051ace5293" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_379481e7-f87f-4444-90aa-0b2a32afb324" contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6ced48be-4525-4c70-8a47-39971cae9da1" contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_12091721-daa6-4615-9374-7423de9475e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right-of-use asse</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1514240-d93f-4827-833a-208926ab2d2a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lease liability</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d192a821-3bff-428c-a9b1-4f8c28ed9517" contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_37e2bd47-4207-458b-957f-6e4048e1644e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finance leases</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_654c424b-9c36-4f40-943d-e16a8cea5471" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" escape="true" continuedAt="F_654c424b-9c36-4f40-943d-e16a8cea5471_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing the Company's consolidated financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing purchase orders and open contracts,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_4" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_654c424b-9c36-4f40-943d-e16a8cea5471_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicating with the Company's personnel to identify services that have been performed on its behalf, and estimating the level of service performed and the associated cost incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company's service providers generally invoice the Company monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to the Company at that time. The Company confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company's accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which the Company has not yet been invoiced:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with preclinical development activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with the testing of preclinical and clinical trial materials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with preclinical and clinical studies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigative sites in connection with clinical trials. </span></div></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contracts with CROs to conduct clinical and other research and development services on its behalf. The Company bases its expenses related to CROs on its estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company's CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div><ix:nonNumeric id="F_32f08600-c733-4839-89db-757ebf0e12c4" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true" continuedAt="F_32f08600-c733-4839-89db-757ebf0e12c4_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_5" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_6"><div><ix:continuation id="F_32f08600-c733-4839-89db-757ebf0e12c4_1" continuedAt="F_32f08600-c733-4839-89db-757ebf0e12c4_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not recognized any product revenue to date since its product candidates are in development.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_6" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_32f08600-c733-4839-89db-757ebf0e12c4_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 13 for further discussion of the arrangement.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eacd5950-d4f9-4a98-ae95-ee64ad1bc7a9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cca8e6a-864a-47f5-bf41-74e2bd05498e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_899cf828-a4bf-4ad0-ba9c-94f80bc0969d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true" continuedAt="F_899cf828-a4bf-4ad0-ba9c-94f80bc0969d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#8217;s policy is to recognize forfeitures as they occur.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_7" continuedAt="F_645d6d02-e695-419d-a381-fac330a2284f_8"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_899cf828-a4bf-4ad0-ba9c-94f80bc0969d_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses the fair value of its stoc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41225e0e-7449-4bb9-b5a6-72b9684db5fc" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccb79c7f-0869-429e-b5d6-330c6857f608" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares and equivalents outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b29a161-1dbe-4773-af40-6875fa883598" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.034%;box-sizing:content-box;"/>
          <td style="width:1.72%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.762%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.72%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:10.762%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c551985-0d3f-48d1-9633-147804aa2613" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_619cfd4e-c401-4010-8bdd-3289ee7959d9" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86207ac8-5929-4086-affa-94580e1cca09" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54542ab2-3e8e-47b9-a269-b8ba090b38a8" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9907c7f3-b0ee-416c-a4e3-cbc6a5e3e624" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b94a290f-dbad-451d-a2a2-a5f9a49d079d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,113,859</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab4c2f56-a4c8-41df-8d08-04435e72d855" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_02c5a839-a6ac-41b9-899e-2fd38d6b3d35" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,804,283</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f2d3b75-538b-4101-bc93-cffea85b9e4b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f376d29a-9998-40f3-816e-f04838d7a10a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.43</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c470f42-745e-4939-8d0b-3e7a5eb9f849" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3d48c74c-76fd-4768-a57d-918f92c0e838" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.26</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1260150-1b49-4dd6-9b1e-d48a47137d18" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.357%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.357%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd3c106a-a859-42ff-a9b1-a0e562732fe8" contextRef="C_2908a678-6f00-4335-9ad2-8248e7e3b60b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,314,561</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cc38400-5215-494c-bf95-80be3ea4acc4" contextRef="C_adb4e732-d095-4cf9-b014-91975b0e1ae3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,709,980</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51ed72f8-809c-4d36-9387-562a6f0ccd9d" contextRef="C_91222020-6393-4cde-8a28-5ea0bed8fcc4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,143,802</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c15564-ff1b-4e13-a832-cd3a07a259fc" contextRef="C_6e6ff448-8d27-4434-ba19-87a416e47d57" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">105,048</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock warrants</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33aa2525-f402-43ef-816c-ce029e99116f" contextRef="C_c244cff9-72f9-43c0-88c4-5e6a576e390e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,606,303</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b9e33c3-608d-4fe8-b1b6-b058b30f1879" contextRef="C_9c633c20-1b3c-4fcd-b70d-356063ad8dac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,030,575</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3638c667-0499-427f-a2c7-9137310b6eb9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,064,666</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20e8f443-a1f8-4491-be5b-4c04fc1a7f16" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,845,603</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:nonNumeric id="F_a0d62c19-1632-4ca4-a35f-74ee9d19b58c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_a0d62c19-1632-4ca4-a35f-74ee9d19b58c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_645d6d02-e695-419d-a381-fac330a2284f_8"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a0d62c19-1632-4ca4-a35f-74ee9d19b58c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements and are required to be applied on a retrospective basis. The Company adopted ASU 2023-07 on January 1, 2024 for its annual reporting, and the adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. This ASU should be applied prospectively with the option to apply the standard retrospectively. In January 2025, the FASB issued ASU 2025-01: Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures - Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03. ASU 2024-03 is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of these standards on our disclosure of income statement expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_b76729d4-a7ec-48ac-86a0-e7049c6e94c7" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_b76729d4-a7ec-48ac-86a0-e7049c6e94c7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_36cad7e4-69e5-4b12-9b79-19de7eea8739" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true" continuedAt="F_36cad7e4-69e5-4b12-9b79-19de7eea8739_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.609%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.502%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.702%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.502%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea83bf7b-de9d-4f8f-854e-96fe5973145e" contextRef="C_4ce73bf9-81de-427b-88a0-9148395b04ab" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e14bea7a-9753-4401-98b6-c7f6fcae5300" contextRef="C_b3a5054d-64cd-44f8-a695-70cc465ba03f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66735e31-f145-4e86-9e27-677c598789e7" contextRef="C_e4300f24-db1f-4970-b3ac-f88865d19c63" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fafa8bc5-ba0b-48a7-b2ec-5406278247d0" contextRef="C_ac38a720-8b0c-448e-b389-9c66f5e57c87" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61bf8f16-d2dd-45c8-9567-702b73fc9534" contextRef="C_2053b9ce-487a-41c5-8660-4c6a0ff5d60c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,209</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16b5e25a-7b60-4f48-8917-937027ab2a3d" contextRef="C_4dc62508-709f-473e-ba30-98fa0a06a2b4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400b7516-4113-4b12-8d18-1ce506e6013b" contextRef="C_9dafe4ac-e499-43b9-b4cf-d9a535621146" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b76729d4-a7ec-48ac-86a0-e7049c6e94c7_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_36cad7e4-69e5-4b12-9b79-19de7eea8739_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:46.609%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.502%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.702%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.502%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d7a5c04-e01a-4ee9-9c7a-dc5349c515ab" contextRef="C_03789e9c-f8d7-4c13-837e-8c8982eaf153" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa2e2329-2ecd-42b9-b33c-f776ce526bee" contextRef="C_9cce6eb7-717c-4284-9f9d-cca47171b6d2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57676be-fdef-496a-a03d-9176200cdb11" contextRef="C_98b8817f-6678-4071-a244-b8d90ff8d269" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,980</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eeb5e9e-4c32-4aa7-9359-cb6ac2619ddd" contextRef="C_5813d5de-532a-4e0e-af8e-993c31bd435f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b8ad8f-671c-438e-b2ec-de1bcff134dc" contextRef="C_3cfae322-7814-406b-94d8-6c27a76311a8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,980</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea5fab3c-d916-4797-b6de-4b90433e1198" contextRef="C_b66b293d-ec8e-437b-afad-20466ee88490" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dce4e97-aeef-4c41-bfd7-f4dee93a5709" contextRef="C_05ee597b-300a-4f1d-950d-07a44282f29e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c508b2d2-276f-4800-a6ad-c330166ef570" contextRef="C_31f58a76-705e-4546-91b9-77d2761bcc2c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,980</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;US treasury bills</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96efba7d-e5c9-47bb-8b06-18e7695c76cf" contextRef="C_e09c71d4-5382-4588-a92f-344a3170a726" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4308b6da-b07e-4a93-9258-d48438489d4e" contextRef="C_6e329cfb-354c-4c3b-b489-59580eb7b3fb" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1284d12c-97db-4b59-91c3-36198ae23f8c" contextRef="C_8bdf4601-233d-4b5c-9cfd-097e16ea264c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4410090c-bf93-4312-94c6-7d6651bb902b" contextRef="C_e0489a50-b282-48d4-b174-d58246a172cf" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,482</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7fbea2-c506-45a3-b6a8-fa6dd7799dc4" contextRef="C_0a16c01a-3d42-4b14-9dcc-312ac1b87eeb" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efbed6e0-3e97-42e4-9b86-e6f0903dc5bf" contextRef="C_dc75a67e-1185-42e1-9806-ae25f1f18a50" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,482</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f78c0b3-d4b6-4f08-a75b-8eb39e998c21" contextRef="C_b66b293d-ec8e-437b-afad-20466ee88490" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c7fb26e-d0d2-48a6-b3cc-0dd5342e5823" contextRef="C_05ee597b-300a-4f1d-950d-07a44282f29e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c37c650-38ce-4683-b127-26a078493c7a" contextRef="C_31f58a76-705e-4546-91b9-77d2761bcc2c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s cash equivalents were invested in money market funds and U.S. treasury bills with maturity dates of less than 90 days, which were valued based on Level 1 inputs. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_595b0935-7158-417b-a09d-9f119d8a5494" contextRef="C_2053b9ce-487a-41c5-8660-4c6a0ff5d60c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> short-term investments at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2023, the Company&#8217;s cash equivalents were invested in money market funds and U.S. treasury bills, which were valued based on Level 1 and Level 2 inputs, respectively. As of December 31, 2023, the Company's short-term investments consisted of U.S. treasury bills which were valued based on Level 2 inputs and U.S. Government Agency Securities and foreign national bank securities, which were valued based on Level 2 inputs.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of its short-term investments at December 31, 2023, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities had contractual maturities of less than one year. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff73a11c-a1de-4dd0-8ab4-ecdb2d230b2e" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f9628151-a7c7-404f-a26f-0cec7fcf3465" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_3d7a3781-d86c-44b8-b2ee-6422cf0471ff" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_3d7a3781-d86c-44b8-b2ee-6422cf0471ff_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44d0643b-875b-4c52-a3b4-f8aa586f95b4" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShortTermInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> short-term investments and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62b0df74-a297-4f90-b0b1-a96295780b16" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ea89b4f1-159e-4874-a43e-323766b39c57" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net accumulated unrealized gains or losses at December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_0e8af174-97ea-4344-af05-6a09ff5e9e6b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows at December 31, 2023 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.04%;box-sizing:content-box;"/>
        <td style="width:1.001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.009999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.01%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.01%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.928%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc34edb8-d804-443c-917c-4b96264611a6" contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,881</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65d1c20c-5b2e-46be-8f46-b9bbac833db6" contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45bb77f7-098e-427a-a8b2-78852bd3f530" contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8caec86f-6274-4f75-a9ae-9c783de5a5fa" contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,918</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51eaeca8-dad3-4685-a48f-65ceae2eddf4" contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,486</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7777dcec-323a-41f3-9b26-79c7ded85bd6" contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d74418f-ccf2-4559-a5a6-bfff4129deab" contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70aa0ad7-9f4c-4436-8705-c021efafee19" contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,482</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c79f70c1-d6d2-4bd9-b2da-5c60c9371e3a" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,367</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d60080b-f939-495b-aa56-aff7745fc04c" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b9f63cd-af0c-4b74-8f05-5998e62f7a80" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a1867eb-65ed-4fa3-bab7-60d24ab81c22" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3d7a3781-d86c-44b8-b2ee-6422cf0471ff_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afa61780-c2d0-4fac-8624-4cf3688fb6de" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> debt securities that were in an unrealized loss position as of December 31, 2023. The aggregated fair value of debt securities in an unrealized loss position was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af86234-178e-4515-bde1-58100f830374" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_783520cf-922e-4bc7-b353-d134b3f7d66e" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t hold debt securities in a continuous unrealized loss position for more than 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. The unrealized losses at December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were attributable to changes in interest rates.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26e8541b-164b-4b06-87ce-236e7b2fb7b1" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Restructuring and Other Related Charges</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors approved a reduction in the Company&#8217;s workforce, impacting </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90ce3301-1635-4b17-a016-890f439c48d9" contextRef="C_c9a482dc-f5d4-4994-8462-78e8c22a8165" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Employee" decimals="INF" format="ixt:num-dot-decimal">87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> employees, which occurred during May and June 2024. The Company incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through May 1, 2025. These amounts are recorded as restructuring and other related charges within our consolidated statements of operations and comprehensive loss as they are incurred. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, restructuring and other related charges were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e0aac90-104f-4648-857a-835e52460c82" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RestructuringAndRelatedCostIncurredCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee754130-a599-473e-9070-af61e76d6174" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of severance costs, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e328a6a0-e63a-41d8-8eec-fa1647c2084a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:RetentionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of retention costs, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_194d879c-aa99-4afd-8ab8-74be2d407f63" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OtherRestructuringCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other costs.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22a9f3ae-b0cf-4e51-9e50-dad5bc9635ee" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restructuring liability activities du</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ring the year ended December 31, 2024 consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.826%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.383000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.383000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.383000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.383000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">January 1,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accruals</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash Payments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Restructuring Plan</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severance Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b73f90f2-a6d6-41d7-9116-3148c5c25790" contextRef="C_c78c329e-4f11-4535-afbf-fbe8ac79582c" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,713</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45de6dfd-62ec-40e4-a0c5-708827722265" contextRef="C_c78c329e-4f11-4535-afbf-fbe8ac79582c" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,953</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8e74991-6c59-4eb9-90bb-926b678502c1" contextRef="C_b980fa59-4978-4912-9bfb-143801b491d8" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,760</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retention Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9073d2e2-7254-4abf-a522-9deeeb0be190" contextRef="C_e4a10c0f-30eb-47c6-8e2d-589710e6957f" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_689f4695-fc3b-454d-8a8b-73cf82799688" contextRef="C_e4a10c0f-30eb-47c6-8e2d-589710e6957f" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,596</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84c7da59-bea9-415d-bfd2-3d8d05cf3ae3" contextRef="C_7610c97e-2aed-4d93-8ea6-f8005b036844" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,578</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9545b195-0a41-4e3d-a12c-bcad4d72ed25" contextRef="C_488bc5f4-10ce-45bb-95b7-d15c658c6b6b" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,009</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ad3b04f-6564-444c-ba7e-cd2c635b7984" contextRef="C_488bc5f4-10ce-45bb-95b7-d15c658c6b6b" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10e2a3ec-a462-4e62-8c3a-8b5d75de90d9" contextRef="C_b7855080-4b7e-4605-886c-ba8da30b5934" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8809a427-7ff1-4b73-b046-25b0b2a29069" contextRef="C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,896</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1084b308-c7d6-4020-9ebf-7ece3c8eedb5" contextRef="C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4f20850-6f8d-4ea5-88ec-d19212a717e9" contextRef="C_49c96c91-10ba-4114-a86d-ac6dc268373f" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,347</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef8c4ab9-ab0d-4bb3-aa01-a2dc864b71d6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Property and Equipment and Related Impairment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_bc964cb4-a6f7-4786-8850-78cf0c340114_2"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.506%;box-sizing:content-box;"/>
        <td style="width:1.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.006%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1d35b1b-6656-4927-9514-f5c5aa8f210a" contextRef="C_87370fcb-d580-4410-a3e9-579a2b1905ac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,927</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f971e9af-fddf-44bd-8e94-015dfb832e39" contextRef="C_433f45f3-222a-4c22-aadf-b142c5221803" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,736</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_451a3d70-ee27-43a3-84ea-d17cc507a2fa" contextRef="C_4b8292bd-93d8-4684-8cfe-8f2b9dd35c42" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18244197-9e79-4c8b-9a56-da311b66fa65" contextRef="C_4a249401-3b7d-46fd-80ef-cb608151b1c7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">105</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f2c0af2-ea35-4133-a3a3-c19b7f60870a" contextRef="C_420d91c9-ecfc-4744-a255-788637fcb6a9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb062059-76a9-48b9-baea-d618ae746e2c" contextRef="C_c3eef231-3463-425d-ba3f-d63c4ce2d6c3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">662</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c121f36-e592-4f42-bd9c-de962a473bd3" contextRef="C_075aff53-3972-401b-9e57-6d6327e23180" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">486</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0603f75e-1e20-457b-a0af-21a1af53c7db" contextRef="C_027852d4-18db-4239-a7cd-a51806d8be2b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b24dc46f-4839-482d-aec9-21a2caa84945" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,533</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de577d6a-3400-4f4b-9ca2-d06341521126" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,964</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc30e07-bad0-4ef9-bc3e-de995f34acd8" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,129</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8a645be-fcd7-4542-885e-7eedfa8c7545" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,921</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_275472f6-82b7-4d8a-a56e-914915c44742" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1682eaa4-c7f5-42df-87ce-ee616a6d938b" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated depreciation includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef14ac1-89c4-4277-b932-bb0130b7b3e9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_475dad54-1752-40de-ba22-aba43b0c9416" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to loss on impairment of property and equipment described below for the years ended December 31, 2024 and 2023, respectively. In addition, the Company recognized approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fec8c5d-2eb3-4932-83d6-adc7ee8b563a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4368893-3e7e-42de-85c2-f008615bf90b" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of depreciation expense for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024 and as a result of the Company&#8217;s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, the Company performed a recoverability test for its property and equipment. The Company concluded that the undiscounted cash flows associated with its property and equipment was less than the carrying value of the property and equipment. The Company compared the fair value of the property and equipment to the carrying value and recorded an impairment charge in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdbf22d8-163c-4eae-aa10-4213a1497056" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which is included as an impairment of property and equipment in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The Company determined fair market value of the equipment based on a third-party appraisal of the equipment through use of publicly available used equipment quotes. The equipment was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of December 31, 2024, and determined no additional impairment indicators existed.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company recognized an impairment charge of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aaf229d-153b-4933-bb8a-3fd8e48486a0" contextRef="C_8902a605-b72c-4739-9074-c30c2e4cb614" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, related to specific facts and circumstances of a prior year agreement termination with a CMO. This impairment evaluation related to the net book value of leasehold improvement and laboratory equipment assets held at the CMO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_4199b5dd-9958-40e1-a101-e1abba928353" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AssetImpairmentChargesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Impairment of Right-of-Use Assets</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company&#8217;s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, the Company engaged a commercial real estate broker to market the Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcb4463b-9045-4a0f-baac-e94cc6d38090" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leased properties for sublease arrangements. Based upon these impairment indicators, the Company has performed a recoverability test over its right-of-use asset and concluded that the right-of-use assets are impaired. As a result, the Company has recorded an impairment charge in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_357bbe6c-62d7-4bd7-aaeb-97e76441ea3a" contextRef="C_3c311591-1876-4a38-97cd-e253457c022f" name="lyra:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the second quarter of 2024, which is included as an impairment of right-of-use asset in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The Company reassessed the need for any further impairment as of December 31, 2024, and determined no additional impairment indicators existed. As of December 31, 2024, the Company has not sublet any of its leased properties.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0a4c1f5-ac09-4741-97ad-8ca4e586a23d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" escape="true" continuedAt="F_e0a4c1f5-ac09-4741-97ad-8ca4e586a23d_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management conducted a fair value analysis of the Company's right-of-use assets using a discounted cash flow methodology as of May 15, 2024, which included the following range of assumptions:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.052%;box-sizing:content-box;"/>
        <td style="width:3.101%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:33.847%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5162e47c-cd41-477d-8936-aec75b4d98b3" contextRef="C_478d5703-d418-4d23-b8de-ef04cf2df0c7" name="lyra:DiscountedCashFlowTechniqueDiscountRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31bccdcc-d48b-4c5b-a4b0-15948810ae59" contextRef="C_9efb24d1-b674-4307-b0ea-d333f2bc6075" name="lyra:DiscountedCashFlowTechniqueDiscountRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term (years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_042e8450-1902-4ee9-83b0-34d1544b0c25" contextRef="C_478d5703-d418-4d23-b8de-ef04cf2df0c7" name="lyra:DiscountedCashFlowTechniqueTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.96</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_5636b567-1ab7-4816-8a54-4138835bf4b6" contextRef="C_9efb24d1-b674-4307-b0ea-d333f2bc6075" name="lyra:DiscountedCashFlowTechniqueTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.13</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected sublease rent increases</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8de74ff0-925c-417e-b276-f60332ab63dc" contextRef="C_62e1129c-aef1-4103-970b-5c338ee35c24" name="lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_e0a4c1f5-ac09-4741-97ad-8ca4e586a23d_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2894bee0-9d03-4a3a-8a34-ac1f756a9363" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd2f9881-e6db-44da-9b6c-37f1886fdaf6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and employee related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5936fb57-c0a3-4007-baaf-9c55af16e169" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82b4201c-8727-4103-82e2-bde6cd684777" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbbc8c6b-4b78-48a6-8417-e676c2a8d331" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,582</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_248bf63d-7b93-4b6b-9fab-e0b378d1ddab" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4189c72-188d-482c-b42d-aeff07dcedc9" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb876493-21ff-4982-9c42-67fedd86aea2" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d597c2-b458-44df-9541-2ede054598bd" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,586</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_148bc3ae-66ef-41db-ae3f-f1c32ef17b83" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_0192304b-fbe2-4d95-9921-0585d1570555" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_0192304b-fbe2-4d95-9921-0585d1570555_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Segment Reporting</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s CODM, its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_88da49e1-0053-471c-838d-493a47149bc4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, regularly review the Company&#8217;s operations and manage its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7574a635-981a-4973-932d-d749f0f65056;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases. Segment revenues represent collaboration revenue from the Company&#8217;s consolidated statements of operations and is received from a single customer.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant segment expenses consist primarily of employee-related costs, clinical, facility and professional and consulting costs in connection with preclinical and clinical development activities. Segment expenses also include impairment charges, when and as applicable.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_644064ea-ca4e-4931-8550-b6bb0abbf17a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM evaluates and allocates resources within the segment based on the Company&#8217;s net loss.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As the Company is a clinical-stage biotechnology company, the evaluation includes review of the actual and budget costs related to employee-related costs, clinical trials, facility, professional and consulting costs in connection with preclinical and clinical development activities, and the conduct of these pre-clinical and clinical trials and responses from government agencies in determining the probability of success of product candidates. Total segment assets are reported in the Company&#8217;s consolidated balance sheets as total assets.</span></p><div><ix:nonNumeric id="F_66dafd5b-ed4b-49ea-8d7f-cf434ac9ca67" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_66dafd5b-ed4b-49ea-8d7f-cf434ac9ca67_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0192304b-fbe2-4d95-9921-0585d1570555_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_66dafd5b-ed4b-49ea-8d7f-cf434ac9ca67_1">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.751%;box-sizing:content-box;"/>
        <td style="width:2.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.503%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.503%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b0d8942-9da9-4a13-9105-6b03356f4971" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,534</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d592dcb-ecf5-4e22-b3d9-c3c40ccda936" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,558</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3daa2ee-a498-4a14-8cc1-233fb01e57e7" contextRef="C_a797757c-a0d8-4b41-bca5-e4ece3661b06" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3364aa1-d6db-4b9b-84e0-6a7c5daec37a" contextRef="C_4e3aa3ed-daf5-453c-8203-7ffec41710a2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cc2f82d-85ac-427b-bfd0-531ab5efeda0" contextRef="C_74f98c49-91bf-4f2d-9c5b-151230a7e6b3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,828</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b02ebb4b-2a61-453e-bee6-a8e21eaae96c" contextRef="C_57cb61d3-40d3-48d2-9f7a-c577d8ec047d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,124</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product development and manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ca77d91-f668-42e8-b3cf-9e358c8b53b5" contextRef="C_b738c303-1ab5-4ff7-a680-7afbc47dc33f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,304</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f44d383-9827-4bff-af70-a657b7f9bdf8" contextRef="C_06ac994e-b8ce-41c9-80a2-2431128712fd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,326</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities, support costs and depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2077972e-c3da-4b73-8913-a34547c5eb97" contextRef="C_234874bf-c13c-4027-9389-b0792e0ac2ac" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_472a07fb-935c-4368-8253-0cca14d19771" contextRef="C_a26c186e-cfe1-4434-9835-0bc963d20468" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional, consulting and public company costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1dba068-6495-428a-bc0d-f0a81f7f143d" contextRef="C_6cd8d3f0-2e97-4106-9cea-1f0c4afe5e89" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,400</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17089a7a-a869-4e28-a3b1-9acfe0c55b37" contextRef="C_852d2d00-74ce-4a20-9603-0c6650379dd8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal settlement</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d285e963-c97b-418e-a52e-a795dccd7e3f" contextRef="C_280682ef-880f-4702-8298-d09656436400" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">568</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5dd44ae-1d56-4c25-9ceb-440a44ee7a5e" contextRef="C_2801a74a-99e4-4308-a905-51778ab0e93c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f45596a-12a9-4f1a-9667-a17f778d6e3c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cedfeaa0-581f-45fa-be9e-ced413cce55d" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0732172-180a-4dee-bd45-4bdd2ac1d5ce" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,836</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring and other related charges</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4ba8773-fa7e-4f4b-93b6-a419846b2207" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,896</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dc2f159-95f5-4435-b37a-200235b9aae9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,882</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5d6c6cf-d4ca-49bc-b8f4-689c25631ea2" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,678</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_965077d9-921b-4878-aeb4-ae74566a8148" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">96,348</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b898d3e-4d9f-4e2a-a74b-87409ff729ab" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,120</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc60a7d3-9a16-4947-9755-d482e4ad71c1" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb6b8d1-d519-4377-befb-bbc58109d028" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,499</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df619136-b7ac-414d-8e8e-989a00753d22" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ad775d-5fd1-4f1d-9619-236ebc59f480" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,499</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ecdd561-5e0e-4494-8c5b-fa9c323287cc" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,396</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f78a17f-5c3d-4158-994f-4b1a55ffd3f7" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,621</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9c10ec9-96db-406b-a7d9-2ac2a89e8924" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96ef8bea-868e-4c37-86a7-2015707c58b6" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb7e325c-e7f6-4d9c-a00e-c51ca49ec0d9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,435</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14598e5e-b180-41ab-b8b3-fd3da8eab928" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,680</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c966059a-2f06-4ff9-b844-5bfd9c9a1ed4" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_c966059a-2f06-4ff9-b844-5bfd9c9a1ed4_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Preferred and Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11213277-b292-4def-8b26-7cdcddf396d9" contextRef="C_bae57fb9-3c5f-471b-8356-fd251e1c7251" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of undesignated preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc3f403a-d837-4a9d-9539-f6bb759ff250" contextRef="C_bae57fb9-3c5f-471b-8356-fd251e1c7251" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c55fa726-f4d6-45c1-8fb4-09d78ecae1aa" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_da6b1245-db61-4110-a6ea-98518f573574" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_32a9445a-2e10-44b3-95f9-46c51739136e" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_023535e5-64ec-4665-8e66-c29cb8d2c52d" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued or outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33437d60-13b8-4e79-bf35-c1891686610b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_217a5207-eeef-484f-b1a7-5517b779d91b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:CommonStockVotingRightsNumberOfVotes" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share held.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently has an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (&#8220;Form S-3&#8221;), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08b9763d-d530-4930-b6a4-08da7eb87697" contextRef="C_09a0cae9-fe57-4508-94a6-ac09c28407d1" name="lyra:StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate. As of December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58af51d8-d1ff-4224-8245-e6a4de9000ae" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:StockDebtSecuritiesWarrantsAndUnitsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,059,228</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares which generated proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_751b7ef2-04db-4731-bfe2-f6326a3610bc" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net of issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a92f212b-9298-4338-a2c6-473d839692c1" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">September 2023 Financing</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_660cd571-34da-400b-a615-3c8c836f5b92" contextRef="C_281acdc8-b177-4854-8880-10164275dc04" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b86478d-00ee-4037-99f6-651fff088e2c" contextRef="C_281acdc8-b177-4854-8880-10164275dc04" name="lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission ("SEC") on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023 (the "Prospectus Supplement").</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell any of the shares under the Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Sales</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c966059a-2f06-4ff9-b844-5bfd9c9a1ed4_1" continuedAt="F_c966059a-2f06-4ff9-b844-5bfd9c9a1ed4_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Sales Agreement, the Company has agreed to pay Cantor a commission equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb15dbf5-cf2d-4290-ac7d-24c47eb11f5e" contextRef="C_912b5ea1-01e3-4044-a2e8-d7c9eccbc5d7" name="lyra:PercentageOfAggregateCommission" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross proceeds from any shares sold through it pursuant to the Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by Cantor in connection with the Sales Agreement.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 2, 2023, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e61f14eb-52c7-4114-80a0-4bbc2e6fdf18" contextRef="C_1e1030b6-cab3-4405-83f8-f89b4d6c3751" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,017,568</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock under the Sales Agreement, at a weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e20bd3b1-a3bb-4636-a815-922db53f5157" contextRef="C_605136ee-faca-4595-aa05-236b9cffe793" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20db55d5-34f7-4f4f-8bc4-ef405c15799b" contextRef="C_ab9d9d05-16a2-48db-a97a-38ad01878ef2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On November 15, 2023, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b629fb6-8d95-474f-a4f4-1fc823c247f2" contextRef="C_789b1913-2263-46dd-834b-d5389e9dab08" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock under the Sales Agreement, at a weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebb0ab1e-ad04-4237-9f0e-876d3116cb68" contextRef="C_1afebb99-1342-4fb9-b854-e7c6117b6e01" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b973fea9-5616-4944-8c21-39df5e5940b9" contextRef="C_e7c9223a-fe0f-484a-a091-15fcc055e486" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On February 12, 2024, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24073953-2406-4d69-90f7-e23683147d8d" contextRef="C_3a120243-ed89-4f6b-be0c-34e7f9595719" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,041,666</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock under the Sales Agreement, at a weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62bc1b0d-9c6c-4873-afbf-b8e558c15374" contextRef="C_1d3cffed-7156-4809-98e0-2a0d5179fc6d" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fc2da83-78bb-4095-b1a9-45c4ac68fbfe" contextRef="C_32d5f8cc-4a3c-458b-8470-64a2b106b53b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 22, 2024, the Company amended and restated the Controlled Equity Offering Sales Agreement (the &#8220;Amended Sales Agreement&#8221;) with Cantor pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fc5d7ff-3cda-4b58-9c3e-5ed052d62b0e" contextRef="C_9e7ffac5-3543-48db-a285-11bbd13c936d" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2aaabecc-3399-4a34-9b2f-f941417d81d0" contextRef="C_9e7ffac5-3543-48db-a285-11bbd13c936d" name="lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the common shares has been registered under the Securities Act, pursuant to the Company's Registration Statement on Form S-3 (File No. 333-278163) (the "2024 Registration Statement"), which was originally filed with the SEC on March 22, 2024, the base prospectus contained within the 2024 Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on March 22, 2024. As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f989d6-9897-4a1f-a8c8-87a8af48eec3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in proceeds net of issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a91196-b10a-4887-8494-1d3695dbe8c6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million generated from these agreements with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d06c1460-61a6-4aa4-bd56-653a1fd62cd5" contextRef="C_c83768e3-f530-46bd-8293-57a4d5a51a00" name="lyra:StockIssuanceAmountAvailableForFutureSale" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million still available for future sale under the Amended Sales Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2023 Financing</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 25, 2023, the Company entered into the Purchase Agreement, with the purchasers, pursuant to which the Company agreed to sell securities to the Investors in a private placement (the &#8220;Private Placement&#8221;). The Purchase Agreement provided for the sale and issuance by the Company of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b89ad25e-b82f-4061-a828-a2d08b30515d" contextRef="C_a43bd8f3-4538-44af-b61c-9114bcf4aa13" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,652,962</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock and accompanying warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dc54d81-a820-47c5-a9d1-0adad0d598f5" contextRef="C_a48e6107-bffc-483d-bc1d-dc2f272feed2" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,826,481</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (&#8220;Purchase Warrants&#8221;), with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2670d00-23e8-42c5-91e8-84da465595d9" contextRef="C_a48e6107-bffc-483d-bc1d-dc2f272feed2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4acdd2f-3279-41d7-ae4b-6808b4a7b680" contextRef="C_0db4beff-330a-45de-8b43-98f81b33e6dc" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">44.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bd3499b-e962-4836-adb4-f2513125582e" contextRef="C_1b2977bb-aa44-4677-a4ee-e38cdd9f5f8a" name="lyra:ClassOfWarrantOrRightExpirationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Purchase Warrant became exercisable on November 30, 2023, and expire on November 30, 2028.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, the Company issued pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53b46478-c0e9-4c60-b85c-0f00588d29c4" contextRef="C_00c29fcf-7ef3-41c1-8925-61f5bbf063ad" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,408,188</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (&#8220;Pre-Funded Warrants&#8221;), with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63c48a99-3e1f-4280-8cb5-dd7e6daa9caf" contextRef="C_00c29fcf-7ef3-41c1-8925-61f5bbf063ad" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and accompanying Purchase Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_658d9449-4d87-4dbe-8a0f-023e788dddfd" contextRef="C_730f05ff-8e87-4546-b39e-fa70f5bfc2d0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,204,094</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_446462a8-5da2-4d03-a89e-b4cab6f70aca" contextRef="C_730f05ff-8e87-4546-b39e-fa70f5bfc2d0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.673</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbe99683-51ed-42bb-8b16-29bb646565e2" contextRef="C_975bc4bf-e956-4689-baa6-6102f1379b64" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In total </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c12fd8a-1989-4823-94b0-2ceafea4a420" contextRef="C_626e5a02-1411-4526-aa75-ce7297c15f35" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,030,575</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Purchase Warrants were issued and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_011ee329-63ec-45ad-9238-912429cd0ce6" contextRef="C_c5d324f4-4968-4ffb-aaf4-47d647da0f16" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,408,188</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-Funded Warrants were issued. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75a8efb9-a2ee-489c-8f6e-df8be32de612" contextRef="C_0b25fafa-9dbd-4d21-b6f2-54c2f0bc249a" name="lyra:ClassOfWarrantOrRightExpirationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028.</span></ix:nonNumeric></span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The closing of the Private Placement occurred on May 31, 2023. The Company filed a shelf registration statement on Form S-3 with the SEC on June 28, 2023, and it was declared effective on July 7, 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3f23bb6-d532-4b8f-bde2-de03daeeb18c" contextRef="C_0db4beff-330a-45de-8b43-98f81b33e6dc" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in gross proceeds, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dddcbd13-27ca-4274-a00b-af0a0bf73c1e" contextRef="C_0db4beff-330a-45de-8b43-98f81b33e6dc" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting issuance costs. The Company has allocated the net proceeds among the common stock, the Purchase Warrants and the Pre-Funded Warrants using the relative fair value method for each of the above transactions. The Company has allocated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a6c43a-d547-4cf0-a930-07893200f7e7" contextRef="C_e06c0d9f-3e71-41ea-b315-fd20df7409c5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the shares of common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_604061f3-9b03-481c-a272-ee1e1c5b432c" contextRef="C_772f9e37-d7a0-4ed6-b29c-901e928669b6" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Pre-Funded Warrants and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db5379af-bef1-412e-877b-5d35cb3806dc" contextRef="C_fc7e6c54-5f68-4b31-8c26-243187e6b327" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Purchase Warrants. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3509507-654d-48fe-aeb4-eea611a590ae" contextRef="C_f24af48f-4786-4931-9dfc-97f5f94468c5" name="us-gaap:ImmaterialErrorCorrection"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the preparation of the Company&#8217;s 2023 annual financial statements, the Company identified an immaterial error in the Company&#8217;s historical financial statements whereby the Company omitted this disclosure in the interim financial statements for the quarter ended June 30, 2023 and incorrectly disclosed an allocation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f2dc0ba-4be3-4210-94a8-9775eea9b215" contextRef="C_b75ec916-9f93-4a03-9cb4-7b9f5bdceb2e" name="lyra:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million instead of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83571d30-97fa-4bc5-a842-6e62aa62b205" contextRef="C_4969eb83-d672-422a-8e4f-a3bcb59d12f2" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Purchase Warrants and failed to disclose the allocation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75eac002-4169-489a-b196-3fa7ff880f85" contextRef="C_1ff01a7e-0054-4803-8549-b1cb6948ee4e" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Pre-Funded Warrants in the interim financial statements for the quarter ended September 30, 2023.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These immaterial errors have been corrected within these consolidated financial statements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company has determined the fair value of the common shares based upon the Company&#8217;s common stock price on the date of the transaction applied to the number of shares of common stock issued. The fair value of the Pre-Funded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c966059a-2f06-4ff9-b844-5bfd9c9a1ed4_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was determined based on the Company&#8217;s common stock price on the date of the transaction, less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8779b46-d518-44c1-baba-5b65b6653fcd" contextRef="C_e4f2d1ea-5751-43a3-bf6a-e61453470a6c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share exercise price of the warrants, applied to the number of Pre-Funded Warrants. The fair value of the Purchase Warrants was determined using the Black-Scholes model applied to the number of Purchase Warrants. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97d57318-2825-4eea-87f2-bfaeb6f9c6c9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true" continuedAt="F_97d57318-2825-4eea-87f2-bfaeb6f9c6c9_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes model were as follows:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_97d57318-2825-4eea-87f2-bfaeb6f9c6c9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_380c52cf-00e4-4b63-a0c9-70726cc22ca0" contextRef="C_76dcfeb5-6b92-4328-8676-8ad9414800c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.67</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f153afff-8f7f-4b0c-b4fa-cd34ef791260" contextRef="C_76dcfeb5-6b92-4328-8676-8ad9414800c8" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.57</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31e7772b-f984-4d9f-a36e-bedca822bcbd" contextRef="C_9927410f-0750-4aef-8f2e-4c0203df94da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">81.93</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8d20a005-1261-4ea7-b31e-ac17091441ec" contextRef="C_9927410f-0750-4aef-8f2e-4c0203df94da" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc8aa4e5-2cc6-4cca-a1ba-738090fbd2b2" contextRef="C_9927410f-0750-4aef-8f2e-4c0203df94da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.74</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s outstanding warrants are freestanding instruments and are classified within stockholders&#8217; equity since the warrants are indexed to the Company&#8217;s common stock and meet the equity classification criteria.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b955b822-fd95-420d-b7bb-3661598c50bc" contextRef="C_1b2977bb-aa44-4677-a4ee-e38cdd9f5f8a" name="lyra:WarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,424,272</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Purchase Warrants were exercised related to the May 2023 financing as of December 31, 2024 at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cac645b0-35cf-4110-99e9-1e87fc9f5b1c" contextRef="C_626e5a02-1411-4526-aa75-ce7297c15f35" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.673</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">April 2022 Financing</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, Pre-Funded Warrants to purchase common stock), resulting in gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f62ab8ac-2d1c-422a-8a10-b19576cc05e4" contextRef="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe" name="lyra:GrossProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8220;April 2022 Financing&#8221;). The Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42406630-907a-4571-8fd8-54a1c3421140" contextRef="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net proceeds after deducting estimated offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f3a217-8287-4ca9-9524-09959c17f50a" contextRef="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe" name="lyra:EstimatedOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88078956-b4ae-4ef7-b10e-94f58b944bca" contextRef="C_89f8a662-2ae4-4167-b545-3e7a39f90636" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,815,159</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d8c51ad-4223-47b4-a339-b2fa381c46e8" contextRef="C_fa9efc50-d605-4083-8ab3-4094e47aab16" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for gross proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60822cea-798b-4dd3-a6a1-7d0fa7f1a29e" contextRef="C_89f8a662-2ae4-4167-b545-3e7a39f90636" name="lyra:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and (ii) certain investors purchased Pre-Funded Warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11833bd0-0cd4-45be-b634-55fa7aff0ac8" contextRef="C_a2fba259-de87-46a2-af48-98b719cf4dc2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, with the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a68bf6ef-98d2-4e56-93f7-e9794b7ed6a1" contextRef="C_81555852-032a-405b-bea2-d1c6de8074a4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_253926c6-fb24-4325-b199-eb55d4a9dbae" contextRef="C_a2fba259-de87-46a2-af48-98b719cf4dc2" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Company. The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Pre-Funded Warrants, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c95ea9d9-afc5-4415-91d2-6cf975cf2d4d" contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Pre-Funded Warrants and recorded as a component of additional paid-in capital. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12965119-840a-443e-b076-e1db05e573f9" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:WarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,651,423</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-Funded Warrants issued in the April 2022 Financing exercised as of December 31, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0949259e-6744-433f-a635-e4b35dea7011" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reserved for future issuances the following shares of common stock as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option to exercise stock warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0533bf7-dcba-4e72-b5c7-3746c38a5160" contextRef="C_087ed0ac-1d0a-422c-a84f-3b93f915fd09" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,606,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2d3c85a-aad0-42b6-8912-d245e8f43ecb" contextRef="C_f8c3db8c-4348-48f7-88f6-6a511886b8fe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,018,288</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_249dc928-c699-4427-8379-109d82a2f169" contextRef="C_9e1ba78d-a7e7-44eb-af47-1f204e97c03c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">723,906</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e94ca50e-8e62-4d33-9486-01579f969620" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,348,497</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_26211bdb-9013-4396-9f9a-717616265646" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:CommonStockWarrantsDisclosureTextBlock" escape="true" continuedAt="F_26211bdb-9013-4396-9f9a-717616265646_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Common Stock Warrants</span></p><div><ix:nonNumeric id="F_9a4928cd-295c-4133-af35-2aa7bb9a63d9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" continuedAt="F_9a4928cd-295c-4133-af35-2aa7bb9a63d9_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table represents a summary of the warrants outstanding and exercisable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, all of which are equity-classified:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_26211bdb-9013-4396-9f9a-717616265646_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_9a4928cd-295c-4133-af35-2aa7bb9a63d9_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.283%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.361%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:4.420999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.361%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:4.881%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.062%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.361%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:4.420999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.361%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:4.420999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.061%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate intrinsic Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate intrinsic Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_306ba07c-c95a-4109-8095-13950cfb52b8" contextRef="C_998603de-c72b-41d7-8c9d-fb71a4c5e1ae" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b786af54-010c-4cc9-b1a1-086cc89e5026" contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7b736fad-97ee-40f3-8ee7-e2193a03ca99" contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8c75325-aaeb-4e85-b49f-f2981376b6b3" contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">15.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_589d56eb-2313-4055-8b73-fe2c24d3fa2e" contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 12, 2027</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common warrants issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0f1daf7-3144-404c-b5de-93400e54e309" contextRef="C_73dd090c-1ed2-47b8-9a90-b7e929765864" name="lyra:ClassOfWarrantOrRightIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,030,575</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34cef6d4-5891-4a53-8172-6ea057c4c6c7" contextRef="C_73dd090c-1ed2-47b8-9a90-b7e929765864" name="lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.673</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d7902f-0809-4fbb-94bf-6c94bc2e8cdd" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:ClassOfWarrantOrRightIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,408,188</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a60d2e-acf2-4a03-8ea2-6f9a8774c913" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8394d63d-f174-464e-979e-b69bd2a011a2" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:WarrantsAndRightsIssuedMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2028</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85314e7c-2f63-4a02-a7b1-d3d9f74dbc4f" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:ClassOfWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,651,423</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_499faba6-4ad5-4ca1-8272-fc753a1ac576" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c04e77ed-b4e2-496f-88ee-f2c3a26a2053" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:ClassOfWarrantOrRightCancelled" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">416</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8463ddca-152b-493a-a3b3-6a2534c80458" contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9" name="lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc22ee4d-377b-4d7a-b47c-e2a213f20f7a" contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,030,575</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a104de7f-3970-4f2e-ab67-568a8cca01bd" contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.673</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1db8a4bd-78a6-41fa-a9ef-a6812e14897b" contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.90</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ae43459-7ea3-49e0-95ec-1a5c903daec7" contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,700</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_3a6ccd82-c86b-47c2-bcfd-d5df296c9ad8" contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba65fb82-36c7-40b6-8d7e-e0a3ccde7b6a" contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,756,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2078cf41-fa39-499a-aa5a-65866a58ed49" contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6fc339ce-5ba6-4bb2-9ec0-85b4eb424633" contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d90984b-9bfb-4f64-b1c7-2e14aeca0ffc" contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_97b57973-2894-41e7-86a2-433229fcba95;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="-sec-ix-hidden:F_3543bcc5-79e8-4350-8931-cc3cab71a166;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2028</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2eb5ece-7e01-47e4-83f6-810d550d0960" contextRef="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72" name="lyra:ClassOfWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,424,272</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_120d7b0b-2a1e-444c-b61d-7c27e5534532" contextRef="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72" name="lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.673</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4324e1d-a181-4eed-b0b3-bd2d0a3dcd30" contextRef="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72" name="lyra:WarrantsAndRightsExercisedIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,297</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9678911c-c682-4c30-bf7d-ad9b4fcdd83a" contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65" name="lyra:ClassOfWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,756,349</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98a2b954-8099-44b1-add8-05934a50a5af" contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65" name="lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4595640-e085-4c73-b3aa-f0ae9afe0548" contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65" name="lyra:WarrantsAndRightsExercisedIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,715</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1945060f-fc7c-422f-bd8a-eab50929824f" contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,606,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92d10ea4-7362-46da-bf11-0bd7f30cdc6d" contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.673</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_88906caf-bbc8-4896-961f-506e3819b2b8" contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_cfa7b3f2-8298-4738-8df3-49d44fec948b" contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ed44678f-ad22-4231-9ff8-c160ba90f7de" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_ed44678f-ad22-4231-9ff8-c160ba90f7de_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently grants equity-based awards under its 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;) and the 2022 Employment Inducement Award Plan (&#8220;Inducement Award Plan&#8221;). The Company previously granted equity-based awards under its 2005 Equity Incentive Plan (&#8220;2005 Plan&#8221;) and 2016 Equity Incentive Plan ("2016 Plan&#8221;).</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiary.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initial number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dcac838-a101-4be3-9ec3-50d3f1b90be3" contextRef="C_372a66a4-61dd-407b-a6a2-2b15c95d67ae" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares plus the number of shares of the Company&#8217;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a377fb-1e10-45a0-8e96-95ed02ac2499" contextRef="C_cc81d85d-e11e-47ff-961c-df0bcedd5b2b" name="lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#8217;s Board of Directors. However, no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02121687-aca4-4115-b3b8-9f95849c8289" contextRef="C_cc81d85d-e11e-47ff-961c-df0bcedd5b2b" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,800,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. On January 1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c38e6a29-e5f9-4364-a760-f9855784636c" contextRef="C_ef0c2d84-5760-4d06-a7b6-be126708a7ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,273,106</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On January 1, 2024, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_005814d6-0fef-4051-8983-3c9ab659638f" contextRef="C_c8d88912-cb32-4c79-b82d-9539702398aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,288,582</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_671847d3-82f4-47ca-b778-1f925e051447" contextRef="C_feffa18a-b969-4f5f-82cd-f03ad737e8a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">696,925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the 2020 Plan. On January 1, 2025, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e5d2abd-8868-4d06-8a1a-29a643ad768d" contextRef="C_3a371107-2d9a-4f5c-8c37-b98e3086c62c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,620,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company&#8217;s Board of Directors adopted the Inducement Award Plan (and together with the 2020 Plan, 2016 Plan and 2005 Plan, the &#8220;Plans&#8221;), which was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#8220;Rule 5635(c)(4)&#8221;), and currently allows for the granting of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9163f9a9-e963-49c8-8cc7-d33891b16e79" contextRef="C_b5cd3428-6f7e-489b-acb9-7fc886586ef5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,763,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Company's common stock. The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, performance units, restricted stock awards, restricted stock units and stock grants. In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#8217;s entering into employment with the Company or its subsidiary. In June 2022, the Inducement Award Plan was amended to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ed44678f-ad22-4231-9ff8-c160ba90f7de_1" continuedAt="F_ed44678f-ad22-4231-9ff8-c160ba90f7de_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the shares authorized for issuance thereunder to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65b7e5af-7dd7-4315-b1cc-6f3984328a9c" contextRef="C_9b8e7f3e-8fcd-405a-b6ca-6a57fd5e4161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,473,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and amended again in the same month to increase the shares authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a4ffa2b-7605-45e0-abee-fbe08b709f62" contextRef="C_0e5ac7b0-8d8f-42a9-ae36-22c91da28b12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,703,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In September 2022, the Inducement Award Plan was amended to increase the shares authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_876b7507-9098-4135-871b-bd7eb73cc97f" contextRef="C_aa987057-5b50-4f91-90e6-77882dbd1aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,813,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. On December 9, 2022, the Inducement Award Plan was amended and restated to increase the shares authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bc296fe-5cb5-4837-8c82-41fd68ebce27" contextRef="C_114bbe38-9e67-4a2b-8b86-6fa6b5de33e6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,413,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. The amended and restated Inducement Award Plan was amended in October 2023 to add another </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d39c572-513c-496e-a4b4-6cf4cb912722" contextRef="C_4d2b77e5-3c41-49f6-87a3-e99ca4394a5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares to the shares authorized for issuance, for a current overall limit of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a3a2886-8e16-4b88-b905-5a9df3166489" contextRef="C_67686643-4752-4ca8-a5d1-4b5b2a07cb16" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,763,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. During the year-ended December 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f1285eb-6732-42d3-8348-4a3da7b0d585" contextRef="C_bed6c948-c9d7-4d57-84ac-6b989ca8e7ce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t grant options to purchase shares of common stock to executives under the amended and restated Inducement Award Plan, and during the year-ended December 31, 2023 the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96b05ce4-186e-4366-bd71-08b0a6cb5fe2" contextRef="C_61c081e9-803b-4a01-830c-fe9cae97644d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">630,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under this plan. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86997916-aa4d-45d7-ae4d-6d34daafcc8b" contextRef="C_a98e409f-d6f8-4b16-b04c-f09c481c5882" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">863,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the Inducement Award Plan as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All stock option grants are nonqualified stock options except for option grants to employees granted, under the 2020 Plan, 2016 Plan or 2005 Plan intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted under the 2020 Plan at less than the fair market value of the Company&#8217;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88d7ff6c-b61c-4e67-ad71-bd74341c7261" contextRef="C_37068379-d31d-4d98-a4d1-2e6f4f1ef031" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e7fd3bb-7061-4bdc-924f-3eb8aa4e8ae6" contextRef="C_1cdb38d7-d16f-4ad8-9875-be4af848c0cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbbb8ad7-2fa8-4daa-a115-2f2fd234a8cb" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.98%;box-sizing:content-box;"/>
        <td style="width:1.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e57dc29-a7ff-48f8-aee2-1c4eb4fae63c" contextRef="C_00ea0f69-39f1-4cdd-88c1-1015ba40c9e8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,360</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_501dab1f-499d-411f-b80d-7942a46616b8" contextRef="C_1b70f3eb-a7d2-4546-8d83-3cc0e6a2bdef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,176</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8578f012-c6bc-4e7c-b7a9-71b62f597ccb" contextRef="C_e2a3c196-b3fe-487a-9820-f84bfac368b0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,356</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7878e84-3942-4772-b34f-9a241c88acf3" contextRef="C_10cb439a-3f2a-42fe-9173-724723bcd311" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,711</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_792bb737-25da-4fbd-8067-f964fa3117c9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,716</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdf76943-4ba3-4452-9b05-204c9c267835" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,887</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024 </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ecc68af-e52f-4e4d-a8f7-2e83acb90bfe" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock-based compensation expense was recorded to liabilities. For the year ended December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac5ba610-c5c1-49d8-90b4-f0cc063df9b5" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">255,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the stock-based compensation expense was recorded to liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd3e98f-8214-4ccc-8d73-1d0bf6c8b473" contextRef="C_788a6a79-f3bb-44f9-a6a5-ec8d29c9b846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,648,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock that vest as to one-third of options, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to continued service on each applicable vesting date and certain exceptions in the context of a change in control transaction. The Company has accounted for these awards as market-based condition awards and therefore, stock-based compensation recorded during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00f25969-d911-4615-9280-9cc6e4a5c384" contextRef="C_788a6a79-f3bb-44f9-a6a5-ec8d29c9b846" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8489bb54-2d3b-4c6e-a34e-5e5e6b216806" contextRef="C_78cb6b9c-1c43-4ef8-965e-5c3e825546d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">550,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ad33a3-861e-49c2-b102-88718bc9efe6" contextRef="C_78cb6b9c-1c43-4ef8-965e-5c3e825546d6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to its Chief Executive Officer (&#8220;2024 Performance Options&#8221;) and granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b0cd2e6-a7eb-4b09-9871-8d8b52fde5da" contextRef="C_db5a6c2b-f92c-47a4-ab60-53c0ab05b473" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">385,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs to its Executive Chair (&#8220;2024 PSUs&#8221;), each with performance-based vesting conditions under the 2020 Plan. Vesting of the 2024 Performance Options and the 2024 PSUs are based on the achievement of various clinical and regulatory milestones during the specified periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the 2024 PSUs, the Company measures stock compensation expense based on the fair value of the award on the grant date and then once the Company determines the performance criteria is probable of achievement, recognizes such amount over the vesting term of the award, which is approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41dcba3c-9d47-4dda-a8e0-a9f0fc7637fb" contextRef="C_fa285bde-8794-43cc-8482-2a6c0a625a7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The Company determined the fair value of the 2024 Performance Option using the Black-Scholes option-pricing model and using the following inputs: risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be7fd81-7f55-4d54-97b3-db6801261929" contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f182d2b0-0ff3-4662-8bf1-d85e2b269637" contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">76.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, expected dividend yield </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41090e18-a7d5-4b44-8094-fe3c0c2deb11" contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db9f2fa5-cf7a-4f99-847e-8fc0630f2a52" contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a2d1d130-d51d-4e85-bc3a-f8e9bf69503b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true" continuedAt="F_a2d1d130-d51d-4e85-bc3a-f8e9bf69503b_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the restricted stock unit activity, including 2024 PSUs, under the Plans for the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ed44678f-ad22-4231-9ff8-c160ba90f7de_2" continuedAt="F_ed44678f-ad22-4231-9ff8-c160ba90f7de_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a2d1d130-d51d-4e85-bc3a-f8e9bf69503b_1">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5ef9b16-bba4-424a-b158-0bdfe7995917" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">105,048</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ef9a8d1-6e26-4ed3-866a-9e2a3f55ffec" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f010b9e3-5e08-4ce9-9c6d-4e0670598909" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,332,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc714f3-5f90-418c-ad2e-c2c58effdc14" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.82</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20cd2ce1-10ac-4c3e-8b86-0781b04e1836" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c6f59c4-b7d1-4c5d-8dbb-2c111aaab36c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.26</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16abd4c4-0193-4ca3-9378-f954dc678cbc" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">207,199</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c04a1e02-410e-4e0b-960e-b483d291e68b" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.29</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_240d2b36-ba34-4e4f-8609-72da6dc79e6b" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,143,802</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ca55d96-6a99-41aa-821a-a80f569ce2fd" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.65</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_015e8801-7b03-4179-94aa-ebd2a8d9678a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s unrecognized stock-based compensation as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.843%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.323%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Expense<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period of Recognition<br/>(years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96a9c43a-f789-4d50-8a68-b1edb0dcf4e2" contextRef="C_333d0a42-02ed-432e-82bf-5297563b9a25" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,088</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e3e661f4-3bfa-466b-a98f-a73ec582cb40" contextRef="C_f3bee2ff-cc2b-4188-9e55-bdfb437d68be" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac0662c1-a82c-490e-aa4e-1a29a3a9f118" contextRef="C_37541621-a0f6-46b9-a350-96d677fcfc2a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c59adecc-34b8-4c52-b10b-e1967fd1a1ad" contextRef="C_eff1908e-cf95-479e-8a29-8ae67fd4d38a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274a624e-c108-4f08-9b66-07a7763188cd" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_1e07c509-71ad-4877-858e-416743f5b5d8" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_1e07c509-71ad-4877-858e-416743f5b5d8_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to certain executive officers with market-performance grants, with the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_1e07c509-71ad-4877-858e-416743f5b5d8_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.8%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0afd267b-0a4a-4931-b5a5-8d25db9f6530" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3">4.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08b17025-6b04-48c0-bfa7-531ed0186480" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3">3.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_55b4cf88-8d55-4508-b2bc-b64a9b31f7d3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_64983888-bb11-46e0-80e0-cb7fc9844ea4" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5abe7d-7434-4efa-9308-3c18314e6573" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3">80.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6d04c62-5171-4847-b190-5e57a163642d" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3">82.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9a4d35f-5782-4300-ae25-488e89fd7dce" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the stock option activity, including incentive options, under the Plans for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.662%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.942%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.662%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac11134a-0344-4809-abc8-7aca2e334985" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,709,980</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7263ae0c-5da5-49f3-8409-d89c1da582ff" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.68</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7f009e4a-50fd-446f-a3ae-452385bdd9ee" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd6d5100-65cf-4e4e-b2cb-48fd9602e16f" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a56d07e-e8a1-442f-9b4a-276b8bdd612a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,605,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_078ca3c1-b2c0-4e0b-a8a0-31cb7d60315d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.89</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baafa410-3bf0-402d-b35a-ba92b152e39a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b51d857-d3eb-4a3d-83cc-0ae7fe39d57c" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.96</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cbf10bb-4525-4f32-a48b-cd3fcc7aae35" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,999,419</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e40a3cc2-0088-48aa-aa5f-77ac3e8c30cb" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.69</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1796e06e-fafa-4f6b-b67f-2bb39c4caa10" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,314,561</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da63e027-46be-4933-b459-e563973a63a2" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_24d794c6-19d5-43e1-9306-9df643e938d3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abf60443-2801-417b-99f3-c2e487b79eb2" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,822,175</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8941beac-1795-4b3c-81fb-14e2d4a82c4e" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.06</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_73d03c9a-4c5b-4c40-a1f4-ce791c1449fd" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868f18e2-fece-4870-ae05-314516fa78d1" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,314,561</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88aa7676-399e-495f-b78d-ebf742cc9d30" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8148eaa0-d84d-4ecb-b9a0-4c73311ecf26" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d206e23-0898-4a67-964a-bb403e3400cb" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_796ddd70-e585-470e-8c47-021fd1115bd4" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024 and 2023 was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdd8f270-6cd0-4ef9-9a68-32d8af987fb3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_04b6c08f-8af4-4b77-9783-0a01485be0bf" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ed44678f-ad22-4231-9ff8-c160ba90f7de_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_359ed3ac-8b45-4cae-9294-a4d5c4f66fcc" contextRef="C_71badc65-a44f-452a-aa75-c16093a3462e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for issuance under the 2020 ESPP. In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3b93797-da03-48c6-821e-180239c5662e" contextRef="C_d72020a2-3023-4259-93b5-fa4a7d8ad386" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" unitRef="U_pure" scale="-2" decimals="3">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#8217;s Board of Directors, provided that no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0219e65-3c44-454c-a31f-38a43070d5d3" contextRef="C_d72020a2-3023-4259-93b5-fa4a7d8ad386" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">987,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock may be issued under the 2020 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2023, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a1259da-0b4b-41a6-9ff7-d62b9dd0c4d9" contextRef="C_aee49c45-4ce0-46b0-9eab-9386fa9c46b5" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">159,138</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On January 1, 2024, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee5bf5dd-d7df-474d-8a28-3ce7bbe505c5" contextRef="C_8aa217c6-fd0c-4938-960a-3d90887e55a2" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">286,072</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. The purchase price of the shares, in the absence of a contrary designation, will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70eb1f3f-5b45-480c-a115-49ca118301ee" contextRef="C_d72020a2-3023-4259-93b5-fa4a7d8ad386" name="lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase date. In June 2024 the Company indefinitely suspended the offering of its 2020 ESPP. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88590010-e9a3-49a9-97e6-8f8842d0dbc6" contextRef="C_ac5f170e-0fde-48cb-9c0b-b5694cb0083b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the 2020 ESPP. As of December 31, 2024, there are a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934c7b73-3dd4-4f49-a044-066acb8cac4f" contextRef="C_9eeb8171-b971-4290-a284-8d735eff90bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">723,906</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the 2020 ESPP. On January 1, 2025, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4563781a-b4fe-4d9c-9145-fae19a7bfda4" contextRef="C_4489b4bf-2198-4ebe-a1bf-695353f66282" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">262,594</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_f17f9160-9b8f-4608-aeb9-14cede397ffd" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_f17f9160-9b8f-4608-aeb9-14cede397ffd_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Collaboration Agreement</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 31, 2021, and as amended on September 26, 2022, the Company entered into the LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the LianBio License Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a5f89da-b096-491c-87bc-fd7b78703bd1" contextRef="C_47fa54a6-2356-4b08-84c8-0df296adece4" name="lyra:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78504f9a-b9eb-4813-bdea-a180d9fd84f5" contextRef="C_6418a52e-c88f-4b7e-b4d3-3e67f8c4d58d" name="lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">135.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, the Company will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and the Company will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to the Company&#8217;s LYR-220 product candidate.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company&#8217;s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBio&#8217;s rights under the LianBio License Agreement. In November 2024 we entered into a novation agreement which substituted LianBio Cayman for LianBio HK. For more information, please see &#8220;Risk Factors &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If LianBio HK, as defined below, is unable to find a third party to acquire its rights under the LianBio License Agreement, as defined below, it may materially harm our business, financial condition, results of operations and prospects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 808&#8221;), which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities, or ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f17f9160-9b8f-4608-aeb9-14cede397ffd_1" continuedAt="F_f17f9160-9b8f-4608-aeb9-14cede397ffd_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, the Company identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial. The Company determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, the Company determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure (&#8220;Combined Performance Obligation&#8221;), and (2) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial (&#8220;Development Activities Performance Obligation&#8221;).</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18c6b74d-bd06-45bb-9813-bcf789de6d3e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DeferredRevenueDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a406014a-06a9-4214-8cba-5090ec506f6c" contextRef="C_fb455e7c-310e-4d3f-9d79-4891ad9dd188" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0675f21-b01f-44b8-bab9-4b83ee35a4e9" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6b06b79-427c-4b77-a044-1c36bf2d392d" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Development Activities Performance Obligation. In February 2022, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f3dba8c-c6f5-4718-8eb9-65c655427137" contextRef="C_1b6f6f65-0092-4f48-84e8-9f5ef718920d" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc80e123-bb33-4aae-bbfe-03c6ae05cf0e" contextRef="C_fb525548-f539-4b57-ad61-75d734fd08a5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which was allocated to the two performance obligations as follows: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_141e4dee-e1ad-4530-9232-510efef190f5" contextRef="C_1b6f6f65-0092-4f48-84e8-9f5ef718920d" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7c056dc-cc0d-4fa7-890d-a63f99234c34" contextRef="C_afa65958-5848-4204-a888-f0ed623910ca" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as all milestone amounts were fully constrained based on the probability of achievement. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022. There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement until March 31, 2023. The amendment did not result in any change in the Company&#8217;s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company determined that LianBio&#8217;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#8217;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheets and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company achieved a development milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e048e1f8-b524-43d2-af17-6f1686f678df" contextRef="C_fb525548-f539-4b57-ad61-75d734fd08a5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for dosing the first patient in the U.S., and the related cash amount was received in April 2022. In accordance with ASC 606, the Company has updated its determination of the transaction price for this previously constrained amount from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55292e8d-69de-4fad-893e-9d179992bb51" contextRef="C_ed6610c5-7cef-4bd0-969d-825c8bae251e" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d2f8243-ed0a-4c30-8a74-60af9019b73a" contextRef="C_bd367419-34c7-4e6d-83a8-87b37d35c96d" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated the development milestones to each of the performance obligations previously identified in the agreement in accordance with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f17f9160-9b8f-4608-aeb9-14cede397ffd_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">original revenue allocation percentages, and is recognizing the revenue under the revenue recognition model previously developed for each performance obligation. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_677da7e8-31cb-4e4b-811b-6c1ab85310e9" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock" escape="true" continuedAt="F_677da7e8-31cb-4e4b-811b-6c1ab85310e9_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects the change in the transaction price (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_677da7e8-31cb-4e4b-811b-6c1ab85310e9_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.517%;box-sizing:content-box;"/>
        <td style="width:1.259%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.975%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.299%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.737%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.299%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.916%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pre-Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Post-Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_757f1f72-224e-468a-986a-de85c004235e" contextRef="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,373</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27dd3fb1-8e34-4670-9a28-dc4cb18cbff4" contextRef="C_afa65958-5848-4204-a888-f0ed623910ca" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,489</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ff8f9d-a0f3-4378-92dd-3b5499412060" contextRef="C_e8ac4fa7-d460-485e-ae33-045deec8d365" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,862</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca171f01-e5f7-4a68-952e-7b19420ef94b" contextRef="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,627</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a943511e-9070-4a50-a8a3-4d4f4ee48c0e" contextRef="C_afa65958-5848-4204-a888-f0ed623910ca" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,511</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b8542c1-c689-4712-8f1d-cf5ba8c6deb4" contextRef="C_e8ac4fa7-d460-485e-ae33-045deec8d365" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,138</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90cede52-6268-4cb7-9c8e-41114eb1fa8a" contextRef="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e2ecd9-c239-4601-b1a1-b63b3cba4fb0" contextRef="C_afa65958-5848-4204-a888-f0ed623910ca" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f523232d-4a76-4764-a681-16d61d8ab0ce" contextRef="C_e8ac4fa7-d460-485e-ae33-045deec8d365" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ae87ce1-ed49-4950-a7bb-ded6d39a2dfa" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.517%;box-sizing:content-box;"/>
        <td style="width:1.259%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.975%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.299%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.737%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.299%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.916%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_161784dc-b5af-4707-a508-540ce543258f" contextRef="C_f6b0dc2d-d4c0-4391-b0ee-c716dc85497d" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c971d78-7bba-4119-be7c-f697cde0e934" contextRef="C_f67b2471-5de2-454c-9767-81619473f71a" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,604</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63befe6b-cb48-4b95-af7a-985714f5fb98" contextRef="C_194bf10a-3e96-4e60-85a1-7fac540a46ce" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5f468a7-535f-410a-b22e-5b18dbd57df6" contextRef="C_b98307c7-4168-47d7-8b20-2ca01548fdde" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,558</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e5e03c8-f595-4e11-ac65-ca669fd25609" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,558</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8f98cbc-a342-4ea6-a2e7-99cffc1f93d6" contextRef="C_2f8edc3c-5429-4955-94db-7cf00859aeda" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef57d73f-5384-45de-95d6-cd0fe6d7d5a8" contextRef="C_d20093d0-99e7-48dd-9fa7-66b19c3ada23" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,046</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f99570b7-816f-4290-aae8-95b74780def1" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,794</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5283a1-2e72-4d66-88b8-959d4903498e" contextRef="C_d2768b5c-c610-479e-8af2-6fa1c6059d7b" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,534</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41635548-b29f-4f82-a89e-ac3aa468fd00" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,534</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4966f9ad-cc82-4c7a-a84e-833da2d0a687" contextRef="C_bf0500da-2915-422d-95b0-080c64f50c71" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6dbebaa-3173-4394-a495-7f9e5f457560" contextRef="C_0cf2e5c8-0ff5-4308-a0e2-b02e0055df23" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">512</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6573bdda-52f4-4b59-8d07-0c5ec10f81ea" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,260</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months. As of December 31, 2024, the parties are not actively engaged in negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25511893-ee73-45f8-8b93-daa901ab7b1b" contextRef="C_90ccd445-a844-45e9-b76b-f02a4964792a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7fcb8461-29c8-41fc-99a2-616d261e80f4" contextRef="C_3468569a-416b-4f26-96d4-911b0ce51a8e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestones achieved during the years ended December 31, 2024 or 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. No royalty revenue has been earned as of December 31, 2024.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company&#8217;s former directors are Managing Directors at Perceptive Advisors, LLC and one of these former directors is also the Executive Chairman of LianBio&#8217;s board of directors.</span></p></ix:continuation></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_454bd050-13f0-461a-81dd-06a7c70a1020" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_454bd050-13f0-461a-81dd-06a7c70a1020_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Income Taxes</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2024 and 2023, the Company recorded net operating losses of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e13f44d-9d1e-4ee1-9cb2-7fbe03748f54" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">93.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_31e2fe3b-078b-4f78-aa0d-dc538f2c92a0" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">62.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa07f29-8936-46ab-824c-e2fe1ce47782" contextRef="C_776bd276-c2c1-4b3d-bf69-ffc77fd2d52e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cc9875c3-b6f5-4095-bd5d-0bda8457c29a" contextRef="C_b8f88f49-0e89-489b-92ff-51d33224124a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an income tax benefit for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_04a540d8-93fc-4494-af8d-8a300258a36a" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_04a540d8-93fc-4494-af8d-8a300258a36a_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_454bd050-13f0-461a-81dd-06a7c70a1020_1" continuedAt="F_454bd050-13f0-461a-81dd-06a7c70a1020_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_04a540d8-93fc-4494-af8d-8a300258a36a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.358%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.358%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ef6dd34-d92f-4c99-b5c1-0b2b9304795e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2762fe5b-542c-44a4-897b-2494bafd2bee" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19dcb2d5-4c33-42a4-a69a-57ec7d8c2616" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32de7a8f-97d8-4ae4-b915-2862ef1cd380" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05b799fb-6b85-4915-ac5d-298b80ec5d86" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e00da095-afee-4e7a-90cb-66a5c8d261b7" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6babc708-5bde-403d-8676-40110314c3fd" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c379912-a976-4963-8c5f-260c9ef7e1a9" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd0691e2-f190-4a4e-b436-d87b36f3d32f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">26.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39c8ec8a-a5e3-4346-8474-388cf2a40420" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">31.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_557c173d-e12f-4aa3-af62-a33d3d666df6" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ba4b0d-67f0-47ed-af36-a46d0c725203" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfbe1407-efd6-4fd4-a3aa-81f0129d6d2e" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4675544-0830-43d6-82bc-6cb090b76cac" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e89f5d1a-89a1-40da-b4b4-0f762d3b8563" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.123000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.123000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_568595a8-adf5-47c2-8274-2c50e951e152" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcc8ddef-ac6c-4499-bad6-5892f7eb4d56" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,999</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c36f665d-ce0e-4201-ad5c-aaab522f4ece" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ad206ca-6788-469a-922b-c72cb13627dd" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,026</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_627295e1-4f48-43f8-923f-3183ed014aec" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,062</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e40e833-d5b1-4203-87fb-81638f43924b" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3357fda8-4222-41e6-8b8e-5b1f0e432f28" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,184</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc78a52-829d-4658-953e-0f1fb32858be" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="lyra:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,466</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c415e256-a63f-4d42-88c7-25d50a24194a" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850b951c-7e6e-46e4-9857-50c312b54d85" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,036</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11d14317-c244-45ae-9b4c-d03ccda3275b" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,234</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab76105f-d365-493a-9b97-20ac06359c03" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,768</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9066a12d-b76b-4561-adf6-395c13422356" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">785</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b52a1809-5efe-48fe-9ccf-bdd18becf8db" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">920</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08120976-98ba-4487-a6b7-d42c9dc8008b" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,548</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f59422da-d202-40e9-9c81-5733fc4dca17" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,347</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61bd3e18-d5be-4609-9195-7b9cbc44b4a7" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,810</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4219dbc-6a0c-40d6-a9b8-bb6241bf9d2d" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,956</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ab31ad-76d3-4480-b91f-9c6e2ffab47f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ef92d4c-72f9-4b5f-800b-d93af10cf94f" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,391</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_456f969b-c992-44dd-93f1-430588c2af11" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a3b256-8fdb-4f39-8c8f-3ddc07bb5ac0" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,391</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_193989b5-0207-4e1f-88a7-6576718d8dc3" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fae1a246-3a62-4f1a-9b44-8001102028f4" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,391</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had U.S. federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf361e0-d5de-4f2c-949d-1179b42b23d1" contextRef="C_1eedc30a-cbfb-49da-8177-e51404827448" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">23.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which may be able to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_867c0b86-c2e8-470a-9450-fa9994d7d8b7" contextRef="C_92a8bd8f-ce57-4c0b-b9ef-52a50d85cf30" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70994e53-b509-4d6e-8798-75570049677f" contextRef="C_b279e47d-9fb2-49d6-8595-a8c376f75802" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">147.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal net operating loss carryforwards that may be carried forward indefinitely. As a result of the IRC 382 study performed in 2022 the Company wrote off $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e257fd-3fc7-49cf-8bde-343620831848" contextRef="C_6cf8ced9-80e4-4607-86de-cb5d54cf5d13" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566e6904-ca94-4134-bff9-56ec294380ef" contextRef="C_6cf8ced9-80e4-4607-86de-cb5d54cf5d13" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state research and development credits. The Company updated their IRC 382 study in 2023 given the changes to the Massachusetts apportionment to single sales resulting in a reduced amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d06bb7-4545-45c9-afa6-7bf8f23bb0a1" contextRef="C_73b2f5f2-5a24-429a-97e0-73eea6990ad7" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">121.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76eda843-b182-4a06-ae33-b0b1b1b9d845" contextRef="C_ed18e4b7-9e3c-4404-ad65-960cbb74cdd5" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">84.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which may be available to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6c606bb-3daf-47cf-a508-3bca7f8b376e" contextRef="C_878fce79-96fc-484b-9c23-1738cf8a0491" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2044</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b026d5-2349-4847-a3bf-ba071f0db361" contextRef="C_1eedc30a-cbfb-49da-8177-e51404827448" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee67d311-bec3-45b0-abf3-3fad74fb2e67" contextRef="C_240704ca-648b-4cb8-8da2-42d785c931ba" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2044. As of December 31, 2024 and 2023, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2328807-c495-48bf-ae4b-f39969ead80b" contextRef="C_ed18e4b7-9e3c-4404-ad65-960cbb74cdd5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2a016ed-b329-43d7-88b5-011ede95dac3" contextRef="C_3d311cd5-55b8-42d3-8218-5c0087ca6b10" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8047659-dc9d-404f-ae30-4dbccf47ec7a" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_454bd050-13f0-461a-81dd-06a7c70a1020_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company had performed an IRC 382 study during 2022 which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. The Company performed an update assessment to our IRC 382 analysis in conjunction with the December 31, 2023 annual audit noting no additional ownership change. For these reasons, in the event the Company experiences a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2024 and 2023 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0346fc9a-efb6-479c-bfbc-71f54e77d42f" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">84.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8688ff1d-859f-4191-9901-4ff6e015da58" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, has been established at December 31, 2024 and 2023. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a24cce7d-0ebb-4bf9-81ea-c7c821e05542" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during the year ended December 31, 2024 due primarily to the generation of net operating losses compared to the increase by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd818e4-9289-49e9-ba16-ec17d2719ee3" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2023 due primarily to an increase in capitalized research and experimental expenditures and an increase in operating lease liabilities.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2024 and 2023. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2024 and 2023, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2021. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_a225bde0-bee3-4e08-9cf5-c098a3bf2b98" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_a225bde0-bee3-4e08-9cf5-c098a3bf2b98_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Watertown Lease</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. The lease includes certain rent escalations. In July 2023, the Company amended the lease to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae3de6b1-0997-48c1-9931-41d54c8919cb" contextRef="C_0a039f52-1a66-4979-9a5e-3989a5131b95" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend the expiration of the lease term</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from April 2024 to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f62ebe9-cce7-43cd-bb70-1bfc731c56cd" contextRef="C_8ee2d39b-2034-44ea-b1f5-705ee63ae9c2" name="lyra:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the terms of the amended lease, the Company no longer has the right to terminate the lease after January 1, 2024. The Company has accounted for the amendment as a lease modification and changes to the right of use asset and liability was reflected within the consolidated balance sheets as of December 31, 2023. The impact to the right of use asset as of the lease amendment date was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b518d4f0-0a72-4c78-876d-3fb4eec680dd" contextRef="C_3db95ee5-7b8d-409d-bb0f-d7092ea5f6f0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a letter of credit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1e74759-f8a9-4e00-857a-127c8fe628ae" contextRef="C_403a3ca8-bf23-400e-b0db-4d041b2b8b46" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million securing its obligations under the operating lease which is secured by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_948e01b4-c593-422e-92e7-4c5c4c3d47b3" contextRef="C_940df23c-7acd-4b4c-a6d5-71d0b545b62d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waltham Lease</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2022, the Company executed a lease agreement located at 880 Winter Street in Waltham, Massachusetts. The leased premises comprise approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7207173-0575-4381-b68d-e5d6b563ea9c" contextRef="C_8fdbc5a2-8bc0-4cc9-afb3-fd47c4ae421c" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">29,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and lab space, and the lease provides for base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eef8a256-0a3f-4ef3-ac44-639dd0424b7a" contextRef="C_7179b286-9afd-4afa-b79c-9e3a7b080f4b" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year, which will increase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30a79ff5-c656-49e1-a126-4361509816d6" contextRef="C_8fdbc5a2-8bc0-4cc9-afb3-fd47c4ae421c" name="lyra:PercentageOfAnnualRentIncrement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year over the noncancellable term ending on June 30, 2033. The Company has the option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_848453b4-6732-4d78-bcc2-56cd070a6de1" contextRef="C_0a1ce932-422a-495f-ae97-fa5f565abba0" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one additional five-year term</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company did not include the option to extend the lease for the additional five-year term in its evaluation of the right-of-use asset and lease liability.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a225bde0-bee3-4e08-9cf5-c098a3bf2b98_1" continuedAt="F_a225bde0-bee3-4e08-9cf5-c098a3bf2b98_2"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Upon lease commencement on December 21, 2023, following substantial completion of construction to prepare the premises for the Company&#8217;s use, the Company recorded the lease as a component of its operating lease right-of-use asset and operating lease liabilities. The improvements to prepare the leased premises for the Company&#8217;s intended use were funded by (i) the landlord, through a tenant allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a9d048c-5d67-40db-b44d-76f1fee45e48" contextRef="C_ea185583-d49f-485e-8484-bcaef81144b1" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and (ii) approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0b50057-348a-40ed-9093-cbd939e9b853" contextRef="C_2660b123-4ea6-43ac-8972-4157c6a3c040" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million funded by the Company. The Company recorded a right-of-use asset upon lease commencement in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c242370-537b-49a7-ae67-280cb8ddef4e" contextRef="C_8d8c6d11-dc4c-4661-b6b8-cede22d16893" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8231d45-3b2b-4302-8da2-279a2146603b" contextRef="C_e71c57da-121c-464c-96b3-6536e9e26bf6" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deposits with the financial institution which is recorded as restricted cash.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1468a7a6-b6c9-4e6c-a8ee-dbc880c9447a" contextRef="C_5422cf85-ab34-4c8d-83a9-3f689e53bb52" name="lyra:NumberOfLeases" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases for two separate spaces in the same building at 880 Winter Street in Waltham, Massachusetts. The Company refers to the first lease as the &#8220;Waltham Lease&#8221; and the second lease arrangement as the &#8220;Waltham Sublease&#8221; as the Company, as a tenant, is subleasing space from under an existing lease arrangement whereby the lessee to the headlease has agreed to sublease the space to the Company under a sublease agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waltham Sublease</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company executed a sublease agreement for additional laboratory and office space located at 880 Winter Street in Waltham, Massachusetts. The subleased premises comprise approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e60b0046-94e1-4edf-9917-c57a6752cdd6" contextRef="C_6c6217df-e212-4852-b745-042bc4d04033" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">24,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet, and the sublease provides for base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a71a68a-0e19-4755-8072-4c660dafd420" contextRef="C_a0d4bd0f-380a-404f-bad2-a0ba8fbdde35" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year, which will increase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_489eae48-bad0-4835-983f-712ffbf9bb12" contextRef="C_6c6217df-e212-4852-b745-042bc4d04033" name="lyra:PercentageOfAnnualRentIncrement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year over the noncancellable term ending on November 30, 2032. The Company is also responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the subleased premises.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon sublease commencement on January 3, 2024, the Company recorded the sublease as a component of its operating lease right-of-use asset and operating lease liabilities. In connection with the sublease, a security deposit was delivered to the sublandlord in the form of an irrevocable standby letter of credit collateralized by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b00d793-1e76-49e6-a109-dd38136a8117" contextRef="C_8ee3e41f-03f7-4449-99b7-ef89d56d7c11" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deposits with the financial institution which is recorded as restricted cash.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a0f1ff6-f7cb-4903-a28f-803442454974" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.034%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.762%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.762%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc754ff7-321c-432f-8418-26be1cc5290d" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,410</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5fdf26d-5073-4e0a-bd54-dd10a87b90a2" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,966</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecb200ae-e134-48d7-9097-f8feafcadbbd" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d1e01ef-8591-457f-8ae3-a41bdf71cec7" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c4884b4-94cf-462a-904b-7d1eabf40068" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,924</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c29ed6d8-e4aa-445b-892c-ff8305ff3c98" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,168</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff0a3092-c559-4d21-868d-b19ba0a1e322" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.174%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:24.265%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_dfb9a898-afe4-49cc-bc05-1c614eb10547" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27cb38ad-1ed2-42fd-acd2-be42a45ab85b" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:71.342%;box-sizing:content-box;"/>
        <td style="width:2.01%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:24.648%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cb378a50-9ce5-42fd-a2d3-fecce4141d02" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba95b972-d3e6-4427-87d8-604bbf5d97fb" contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_1873a4af-ebbe-4012-ad4d-82d7afc5c45f" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_1873a4af-ebbe-4012-ad4d-82d7afc5c45f_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 were as follows (in thousands):</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a225bde0-bee3-4e08-9cf5-c098a3bf2b98_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_1873a4af-ebbe-4012-ad4d-82d7afc5c45f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.3%;box-sizing:content-box;"/>
        <td style="width:2.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:24.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ccd18cb-50b2-465c-9f4a-0dfe418e8232" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,121</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f5e96c6-916d-4e2a-9d21-e2db1fbed3a1" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,494</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5889010a-2333-4136-a7d3-ece0bc592387" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_015bd54c-df68-48c0-9e79-0c0428d7f807" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,507</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad365340-6042-4d29-b76a-0d84942228be" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8052d86-ddcb-43b2-b20f-c69f17a4c161" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,010</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5ac45cf-1395-4c7f-bb50-1a137a952ac5" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,905</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bb7fd69-b862-4ea2-a1c0-8598ae540a59" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fff89bca-0871-4b74-b5dc-2bb4ee1b207d" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,380</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion of operating lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b86769f2-b870-4f04-b29f-c9b05e16382c" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liability, net of current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bf0cecf-af0a-4826-91c3-eae9c47119bd" contextRef="C_f60732e7-7b49-4546-becf-89f740a96713" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,259</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total rent expense under the Company's leases amounted to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92380d17-67e3-4685-97fb-5bd8905326e3" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a1dd639-0862-421a-a45f-f2753f607599" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluated the above leases for impairment indicators and determined that the right-of-use assets were impaired. Additional details are included within Note 7 above.</span></p></ix:continuation></div>
  <p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="final_fpage">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df4e974c-70bb-4f72-a0dc-edca33084f01" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Retirement Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made a discretionary match that matches 50%, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0050c29-a90c-44da-879d-cc0d815aa679" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_18de8fe1-d751-43a8-b792-7b6a8b7b29fd" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% employee contribution, and therefore a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d540d60-60de-49d8-9316-8e5350fa9157" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b47847a3-9e81-431e-93f9-42be4d28ad94" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employees&#8217; salary. Matching contributions are fully vested at the time of contribution. The Company matched </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_7b0886a7-1c4e-4f8e-9cfe-de56e84264a2" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c3f8783-297c-4713-bc47-5257e37ccac6" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of employee 401(k) contributions for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, which is included in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_987cc757-ac7d-4783-a7e4-89474752d3ef" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Commitment and Contingencies</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2023, the Company filed a complaint in the Superior Court of the State of Delaware against a former CMO alleging breach of contract. The Company alleged in its complaint that the former CMO breached the Master Clinical Supply Agreement (&#8220;MCSA&#8221;). The Company&#8217;s complaint sought monetary damages and the return of equipment and materials that the Company owned. On July 20, 2023, the same former CMO filed an answer and amended counterclaims to the Company&#8217;s May 10, 2023 complaint (the &#8220;Litigation&#8221;). Due to the legal proceeding and termination of agreement with this manufacturer, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a3bb8ec-47d2-46d1-b47e-c70be8567c54" contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million loss on impairment of long-lived assets during the year-ended December 31, 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 2, 2023, the Company entered into a settlement and release agreement, related to the Litigation, pursuant to which each of the Company and the former CMO provided broad mutual releases of all claims relating to or arising out of the MCSA, including without limitation, all claims brought in the Litigation or that could have been brought in the Litigation. The Company and the former CMO agreed to jointly file a Stipulation of Dismissal with prejudice relating to the Litigation. In the fourth quarter of 2024, the Company paid the remaining liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fdc135d-b17e-4a9b-b1a8-349e4cc422e4" contextRef="C_fcf36a73-5344-415f-b95c-0bbadc656fc2" name="us-gaap:PaymentsForLegalSettlements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Stipulation of Dismissal with prejudice to the former CMO.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_78ade5ea-4088-4d16-850b-28ab95720b27" contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_78ade5ea-4088-4d16-850b-28ab95720b27_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2025, the Company replaced its letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daf4dad9-38c7-427a-9f91-411ba8598758" contextRef="C_a8a81857-3883-412f-b823-244b5789543e" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to its Waltham lease, which is discussed in Note 15, with a new letter of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b49e990-492c-4acb-b7ad-576a8b24cd5c" contextRef="C_a8a81857-3883-412f-b823-244b5789543e" name="us-gaap:LinesOfCreditCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8e41f92a-aad6-47ad-8661-51315d4fb579;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_78ade5ea-4088-4d16-850b-28ab95720b27_1"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 14, 2025, options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c707d5c-ebe5-4677-ba31-c483a5d3fba8" contextRef="C_b7f4b320-3537-4193-801c-2cf634165bb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,694,590</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an average per share price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f4b7fbd-5a3b-4f09-9130-ebb911e60966" contextRef="C_b7f4b320-3537-4193-801c-2cf634165bb1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, previously granted under the 2020 Stock Option Plan were voluntarily forfeited by certain executives and returned to the pool of options available for grant under the 2020 Stock Option Plan for future issuance. No replacement options were granted to those executives.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>lyra-ex4_8.htm
<DESCRIPTION>EX-4.8
<TEXT>
<html>
 <head>
  <title>EX-4.8</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.8</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). References herein to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; and the &#x201c;Company&#x201d; refer to Lyra Therapeutics, Inc. and not to any of its subsidiaries.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following description of our  securities and certain provisions of our amended and restated certificate of incorporation (our &#x201c;certificate of incorporation&#x201d;), and amended and restated bylaws (our &#x201c;bylaws&#x201d;) are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and amended and restated bylaws, each of which has been publicly filed with the SEC and applicable provisions of the General Corporation Law of the State of Delaware (the &#x201c;DGCL&#x201d;). Our authorized capital stock consists of:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">200,000,000 shares of common stock, par value $0.001 per share; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10,000,000 shares of preferred stock, par value $0.001 per share.</font></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;LYRA.&#x201d;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our certificate of incorporation and bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our certificate of incorporation. See below under &#x201c;&#x2014;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#x2014;Amendment of Charter Provisions.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights Upon Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer Agent</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, or the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have never declared or paid any cash dividends on our common stock. We do not intend to pay cash dividends for the foreseeable future. We currently expect to retain all future earnings, if any, for use in the development, operation and expansion of our business. Any determination to pay cash dividends in the future will depend upon, among other things, our results of operations, plans for expansion, tax considerations, available net profits and reserves, limitations under law, financial condition, capital requirements and other factors that our board of directors considers to be relevant.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of our certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.  There are no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain holders of shares of our common stock are entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to our ninth amended and restated investors&#x2019; rights agreement, or the investor rights agreement, until the rights otherwise terminate pursuant to the terms of the investor rights agreement. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Form S-1 Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If at any time the holders of at least 30% of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities then outstanding having an anticipated aggregate offering price that would exceed $5,000,000, we may be required to register their shares. We are obligated to effect at most (i) three registrations initiated by Perceptive Life Sciences Master Fund Ltd and Perceptive LS (A), LLC, collectively referred to as Perceptive, and (ii) three registrations covering registrable securities held by investors other than Perceptive, in each case in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Piggyback Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If at any time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities then outstanding will be entitled to notice of the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Form S-3 Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form S-3, the holders of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities having an anticipated aggregate offering price to the public in the offering of at least $2,000,000, we will be required to effect such registration; provided, however, that we will not be required to effect such a registration if, within any twelve month period, we have already effected two registrations on Form S-3 for the holders of registrable securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expenses and Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registration rights terminate upon the earlier of the date on which no stockholder holds any registrable securities, the closing of a company sale, as defined in the investor rights agreement, at such time as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of a stockholder&#x2019;s shares without limitation during a three-month period without registration, at such time a stockholder is not an affiliate (as defined under the Securities Act) of the Company, or May 5, 2028.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some provisions of Delaware law, our certificate of incorporation and our bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Undesignated Preferred Stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholder Meetings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our bylaws provide that a special meeting of stockholders may be called at any time by our board, our chairman of the board, our chief executive officer or our president (in the absence of a chief executive officer)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Elimination of Stockholder Action by Written Consent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our certificate of incorporation and bylaws eliminate the right of stockholders to act by written consent without a meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Staggered Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Removal of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders Not Entitled to Cumulative Voting</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware Anti-Takeover Statute</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Choice of Forum</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or stockholders to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; or (4) any action asserting a claim governed by the internal affairs doctrine. Under our certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Our certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice of forum provisions. It is possible that a court of law could rule that either or both of the choice of forum provisions contained in our certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment of Charter Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>3
<FILENAME>lyra-ex10_28.htm
<DESCRIPTION>EX-10.28
<TEXT>
<html>
 <head>
  <title>EX-10.28</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.59in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:2.667%;text-indent:1.404%;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.398%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.28</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                     </font></p>
  <p style="margin-left:25.373%;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:25.694%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:25.373%;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:25.694%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOVATION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.877%;font-size:10pt;margin-top:4.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS NOVATION AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made and entered into as of November 15, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novation Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) by and among LianBio, an exempted company organized under the laws of the Cayman Islands (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), LianBio Development (HK) Limited (as successor-in-interest to LianBio Inflammatory Limited), a private company limited by shares organized under the laws of Hong Kong (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio Development</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Lyra Therapeutics, Inc., a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Each of LianBio, LianBio Development and Lyra is referred to herein as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and, collectively, as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:25.373%;font-size:10pt;margin-top:4.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:25.694%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTRODUCTION</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.835%;font-size:10pt;margin-top:4.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, LianBio, LianBio Inflammatory Limited and Lyra are parties to that certain License and Collaboration Agreement dated May 31, 2021, as amended by that certain First Amendment thereto dated September 26, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novated Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to which Lyra granted to LianBio Development certain rights and licenses under intellectual property owned or controlled by Lyra to Develop, have Manufactured, and Commercialize the Licensed Products in the Field in the Territory (each as defined in the License Agreement), subject to the terms and conditions set forth in the Novated Agreement;</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.877%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, each Party hereto further desires that LianBio be substituted for LianBio Development under the Novated Agreement; and</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.809%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, (A) LianBio Development desires to transfer by novation, and effect a novation of the Novated Agreement to LianBio such that LianBio is substituted for LianBio Development as a party to the Novated Agreement in place of LianBio Development,  LianBio enjoys all rights, title, interest, liabilities, duties, and obligations of LianBio Development under and in respect of the Novated Agreement as if the original party thereto in place of LianBio Development, and LianBio Development is released from its performance, liabilities, duties, and obligations under the Novated Agreement, (B) LianBio desires to accept and agree to such novation, and (C) each of the other Parties hereto desires to consent and agree to such novation.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.877%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereto agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__novation_and_assumption_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novation and Assumption</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:4.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:6%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="width:100%;display:inline;" id="x_1__lianbio_irrevocably_novates_and_tra"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective as of the Novation Effective Date, LianBio Development irrevocably novates and transfers to LianBio all rights, licenses, title, interest, claims, demands, liabilities, duties, and obligations of LianBio Development under the Novated Agreement, and all rights, interests, claims, and demands recoverable in law or equity that LianBio Development has or may have under the Novated Agreement, as fully and entirely as if LianBio had at all times been a party to the Novated Agreement in place of LianBio Development (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.91in;min-height:1.1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.59in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:4.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="width:100%;display:inline;" id="x_2__lbl_hereby_irrevocably_accepts_the_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio hereby (a) irrevocably accepts the Novation, (b)(i) agrees to be bound by the Novated Agreement in accordance with its respective terms, (ii) assumes all liabilities, duties, and obligations of LianBio Development under the Novated Agreement, and (iii) acquires all rights, licenses, title, interest, claims, and demands of LianBio Development under the Novated Agreement, and all rights, interests, claims, and demands recoverable in law or equity that LianBio Development has or may have under the Novated Agreement, as if LianBio had at all times been a party to the Novated Agreement in place of LianBio Development.</font></div></div>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:4.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.3.</font><div style="width:100%;display:inline;" id="x_3__lbl_shall_assume_all_liability_for_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio shall assume all liability for any breach, non-observance or failure by LianBio Development to perform any performance, covenants, agreements, duties, and obligations expressed to be undertaken by LianBio Development under the Novated Agreement, irrespective of whether or not any such breach, non-observance or failure is known to any of the Parties.</font></div></div>
  <p style="margin-left:0.92%;text-indent:-7.214%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:4.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party hereby irrevocably releases, relieves, and forever discharges LianBio Development from all performance, covenants, agreements, duties, and obligations under the Novated Agreement and from all claims and demands of any kind, whether in law or at equity, which such Party or any of their respective successors or assigns now have or may in the future have, against LianBio Development arising out of or related to the Novated Agreement. LianBio Development shall be fully relieved of any liability to any other Party arising out of the Novated Agreement. All payments, obligations and duties of LianBio Development under the Novated Agreement due and payable or due to be performed on or prior to the Novation Effective Date shall be paid or performed by LianBio in accordance with the terms of the Novated Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="x__guaranty__lianbio_hereby_unconditiona">&#160;</p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__acceptance_of_novation__qed_hereby_ir"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acceptance of Novation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party hereby irrevocably consents and agrees to the Novation, assumption, and release described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, and accepts the performance and liability of LianBio under the Novated Agreement in place of the performance and liability of LianBio Development arising out of or related to the Novated Agreement and grants to LianBio the same rights, title and interest under or arising out of or related to the Novated Agreement as were granted to LianBio Development in all respects as if LianBio had at all times been a party to the Novated Agreement in place of LianBio Development.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.083%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__further_assurances__each_party_shall_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such novation, agreements, documents and instruments, as may be necessary or as the other Parties may reasonably request to effect the intent and purposes of this Novation Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__interpretation__successors__it_is_the"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation; Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is the clear intent of all Parties that the Novation will be interpreted as a novation and not an assignment. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. This Novation Agreement shall be binding upon and inure solely to the benefit of the Parties and their respective successors and permitted assigns, and shall not be construed as conferring any rights on any other person.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__governing_law__construction_and_inter"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Novation Agreement will be governed by and interpreted under the Laws of the State of New York, without regard to the conflicts of law principles thereof.</font></div></div>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__dispute_resolution_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Article 13 of the Novated Agreement is incorporated by reference herein, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutatis mutandis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.91in;min-height:1.1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.59in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="x_3__jury_waiver___each_party__to_the_ex"><font id="x_1__dispute_resolution__escalation___th">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Party hereby represents and warrants that (i) such Party has the requisite corporate or other entity power and authority to execute and deliver this Novation Agreement and to perform its obligations hereunder and (ii) this Novation Agreement has been duly executed and delivered by such Party and this Novation Agreement (assuming the due authorization, execution and delivery hereof by each other Party) constitutes its valid and legally binding obligation, enforceable against such Party in accordance with its terms.</font></div></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.963%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Novation Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart. Signatures provided in Adobe&#153; Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:25.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:25.741%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of Page Intentionally Left Blank.]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.91in;min-height:1.1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;text-indent:5.94%;font-size:10pt;margin-top:4.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, each Party has caused this Novation Agreement to be duly executed by its authorized representative as of the Novation Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIANBIO</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ Brianne Jahn    	</font></p>
  <p style="margin-left:45.107%;font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Brianne Jahn</font></p>
  <p style="margin-left:38.44%;text-indent:10.83%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Authorized Signatory</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIANBIO DEVELOPMENT (HK) LIMITED</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ Brianne Jahn    	</font></p>
  <p style="margin-left:45.107%;font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Brianne Jahn</font></p>
  <p style="margin-left:45.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Director</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.96in;min-height:1.1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, each Party has caused this Novation Agreement to be duly executed by its authorized representative as of the Novation Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LYRA THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Maria Palasis    	</font></p>
  <p style="margin-left:33.333%;text-indent:10%;font-size:10pt;margin-top:8.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">          Name: Maria Palasis</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">        Title: President &amp; Chief Executive Officer</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.96in;min-height:1.1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to Novation Agreement]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>lyra-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:53.333%;text-indent:16.764%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p>
  <p style="margin-left:25.707%;text-indent:12.305%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:24.667%;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. Insider Trading Compliance Policy</font></p>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.987%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.12%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(As of November 8, 2023)</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Compliance Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) consists of seven sections:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section I provides an overview;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section II sets forth the policies of the Company prohibiting insider trading;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section III explains insider trading;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section IV consists of procedures that have been put in place by the Company to prevent insider trading;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section V sets forth additional transactions that are prohibited by this Policy;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section VI explains Rule 10b5-1 trading plans and provides information about Section 16 and Rule 144; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section VII refers to the execution and return of a certificate of compliance.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Lyra Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as well as that of all persons affiliated with the Company. &#x201c;Insider trading&#x201d; occurs when any person purchases or sells a security while in possession of inside information relating to the security or the issuer of the security. As explained in Section III below, &#x201c;inside information&#x201d; is information that is both &#x201c;material&#x201d; and &#x201c;non-public.&#x201d; Insider trading is a crime. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines, and significant criminal fines. Insider trading is also prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including termination of employment for cause.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to all officers</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, directors and employees of the Company. Individuals subject to this Policy are responsible for ensuring that members of their households also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, limited liability companies, partnerships or trusts (such entities, together with all officers, directors and employees of the Company, are referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Covered Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and transactions by these entities should be treated for the purposes of this Policy and</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:10.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning of the term in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, which means the Company&#x2019;s president, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable securities laws as if they were for the individual&#x2019;s own account. This Policy extends to all activities within and outside an individual&#x2019;s Company duties. Every officer, director and employee must review this Policy. Questions regarding the Policy should be directed to the Company&#x2019;s Chief Legal Officer, or such person performing duties similar to those performed by a Chief Legal Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Legal Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">II.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Policies Prohibiting Insider Trading</font></div></div>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director or employee shall purchase or sell any type of security while in possession of material, non-public information relating to the security or its issuer, whether the issuer of such security is the Company or any other company. For example, if a director, officer or employee learns material, non-public information about another company with which the Company does business, including a business partner or collaborator, that person may not trade in such other company&#x2019;s securities until the information becomes public or is no longer material. Further, no Covered Person shall purchase or sell any security of any other company in the Company&#x2019;s industry or the industry of a company that is the subject of a potential strategic transaction with the Company, while in possession of material, non-public information that was obtained in the course of the Covered Person&#x2019;s employment or service with the Company.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, no officer, director or other employee designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Legal Officer as being subject to quarterly black-out periods shall purchase or sell any security of the Company during the period beginning at 11:59 p.m., Eastern time, on the seventh calendar day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company. For example, if the Company&#x2019;s fourth fiscal quarter ends at 11:59 p.m., Eastern time, on December 31, the corresponding black-out period would begin at 11:59 p.m., Eastern time, on December 24. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Policy, a &#x201c;trading day&#x201d; is a day on which national stock exchanges are open for trading. For the avoidance of doubt, any designation by the Board of Directors of the employees who are subject to quarterly black-out periods may be updated from time to time by the Chief Executive Officer or Chief Legal Officer.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These prohibitions do not apply to:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases of the Company&#x2019;s securities by a Covered Person from the Company or sales of the Company&#x2019;s securities by a Covered Person to the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or vesting of equity-based awards, that in each case do not involve a market sale of the Company&#x2019;s securities (the &#x201c;cashless exercise&#x201d; of a Company stock option through a broker </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> involve a market sale of the Company&#x2019;s securities, and therefore would not qualify under this exception);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gifts of the Company&#x2019;s securities, unless the person making the gift has reason to believe that the recipient intends to sell the securities while the donor is in possession of material, non-public information about the Company; or</font></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases or sales of the Company&#x2019;s securities made pursuant to any binding </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contract, specific instruction or written plan entered into outside of a black-out period and while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) promulgated under the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1934 Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading plans, see Section VI below.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director or employee shall directly or indirectly communicate (or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">tip</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) material, non-public information to anyone outside of the Company (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">III.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Explanation of Insider Trading</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insider trading</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refers to the purchase or sale of a security while in possession of &#x201c;material,&#x201d; &#x201c;non-public&#x201d; information relating to the security or its issuer.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">includes stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are defined broadly under the federal securities law. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Purchase&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Sale&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants or puts, calls or other derivative securities.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is generally understood that insider trading includes the following:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading by insiders while in possession of material, non-public information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading by persons other than insiders while in possession of material, non-public information, if the information either was given in breach of an insider&#x2019;s fiduciary duty to keep it confidential or was misappropriated; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What Facts are Material?</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The materiality of a fact depends upon the circumstances. A fact is considered &#x201c;material&#x201d; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&#x2019;s business or to any type of security, debt or equity.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of material information include (but are not limited to) information about:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">corporate earnings or earnings forecasts;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible mergers, acquisitions, tender offers or dispositions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major new products or product developments;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">important business developments such as trial results, developments regarding strategic collaborators or the status of regulatory submissions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">management or control changes;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant financing developments including pending public sales or offerings of debt or equity securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defaults on borrowings;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bankruptcies; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant litigation or regulatory actions.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:5.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, material information does not have to be related to a company&#x2019;s business. For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A good general rule of thumb: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When in doubt, do not trade.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is Non-Public?</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is &#x201c;non-public&#x201d; if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dow Jones</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Wire</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reuters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Associated Press</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Press International</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine or news website, a Regulation FD-compliant conference call, or public disclosure documents filed with the Securities and Exchange Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that are available on the SEC&#x2019;s website.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow two full trading days following publication as a reasonable waiting period before such information is deemed to be public. If, for example, the Company were to make an announcement on a Monday prior to 9:30 a.m. Eastern time, the information would be deemed public after the close of trading on Tuesday. If an announcement were made on a Monday after 9:30 a.m. Eastern time, the information would be deemed public after the close of trading on Wednesday. If you have any question as to whether information is publicly available, please direct an inquiry to the Chief Legal Officer.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Who is an Insider?</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.792%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Insiders&#x201d; include officers, directors and employees of a company and anyone else who has material, non-public information about a company. Insiders have independent fiduciary duties</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to their company and its stockholders not to trade on material, non-public information relating to the company&#x2019;s securities. All officers, directors and employees of the Company should consider themselves insiders with respect to material, non-public information about the Company&#x2019;s business, activities and securities. Officers, directors and employees may not trade in the Company&#x2019;s or another Company&#x2019;s securities while in possession of material, non-public</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information relating to such Company or such securities, nor may they disclose such information to anyone outside the Company (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals subject to this Policy are responsible for ensuring that members of their households also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#x2019;s own account.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Persons Other than Insiders</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders may be liable for communicating or tipping material, non-public information to a third party (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">tippee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and insider trading violations are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been misappropriated.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tippees inherit an insider&#x2019;s duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words, a tippee&#x2019;s liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for Engaging in Insider Trading</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers. The SEC and the U.S. Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities laws include:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC administrative sanctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities industry self-regulatory organization sanctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil injunctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage awards to private plaintiffs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disgorgement of all profits;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil fines for the violator of up to three times the amount of profit gained or loss avoided;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of</font></div></div>
  <p style="margin-left:14.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$2,479,282 (subject to adjustment for inflation) or three times the amount of profit gained or loss avoided by the violator;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity); and</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jail sentences of up to 20 years.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, insider trading could result in serious sanctions by the Company, including dismissal. The Company reserves the right to take whatever disciplinary or other measure(s) it determines in its sole discretion to be appropriate in any particular situation, including disclosure of wrongdoing to governmental authorities. Insider trading violations are not limited to violations of the federal securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act (RICO), also may be violated in connection with insider trading.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Size of Transaction and Reason for Transaction Do Not Matter</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The size of the transaction or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance. Brokers and dealers are required by law to inform the SEC of any possible violations by people who may have material, non-public information. The SEC aggressively investigates even small insider trading violations.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;margin-top:0.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:43.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:1.585532154375636%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">G.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of Insider Trading</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Examples of insider trading cases include:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions brought against corporate officers, directors, and employees who traded in a company&#x2019;s securities after learning of significant confidential corporate developments;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">friends, business associates, family members and other tippees of such officers, directors, and employees who traded in the securities after receiving such information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government employees who learned of such information in the course of their employment; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other persons who misappropriated, and took advantage of, confidential information from their employers.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are illustrations of insider trading violations. These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Insider</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically.  Prior to the public announcement of such earnings, the officer</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases X Corporation&#x2019;s stock. The officer, an insider, is liable for all profits as well as penalties of up to three times the amount of all profits. The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines and 20 years in jail. Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Tippee</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has signed an agreement for a major acquisition. This tip causes the friend to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchase X Corporation&#x2019;s stock in advance of the announcement. The officer is jointly liable with his friend for all of the friend&#x2019;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&#x2019;s profits. The officer and his friend are also subject to criminal prosecution and other remedies and sanctions, as described above.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">H.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition of Records Falsification and False Statements</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13(b)(2) of the 1934 Act requires companies subject to the Act to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the SEC&#x2019;s intent to discourage officers, directors and other persons with access to the Company&#x2019;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">IV.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Procedures Preventing Insider Trading</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading. Every officer, director and employee is required to follow these procedures.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance of All Trades by All Officers, Directors and Certain Employees</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.785%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company&#x2019;s securities, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all transactions in the Company&#x2019;s securities (including without limitation, acquisitions and dispositions of Company stock, gifts, the exercise of stock options and the sale of Company stock issued upon exercise of stock options) by officers, directors and such other employees as are designated from time to time by the Board of Directors, the Chief Executive Officer, the Chief Financial Officer or the Chief Legal Officer, as being subject to this pre- clearance process (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Clearance Person</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) must be pre-cleared </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Company&#x2019;s Chief Legal Officer. Pre-clearance does not relieve anyone of his or her responsibility under SEC rules. For the avoidance of doubt, any designation by the Board of Directors of the employees who are subject to pre-clearance may be updated from time to time by the Chief Executive Officer or Chief Legal Officer and reflected on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A request for pre-clearance may be oral or in writing (including without limitation by e- mail), should be made at least two business days in advance of the proposed transaction and should include the identity of the Pre-Clearance Person, the type of proposed transaction (for example, an open market purchase, a privately negotiated sale, a gift, an option exercise, etc.), the proposed date of the transaction and the number of shares, options, or other securities to be involved. In addition, unless otherwise determined by the Chief Legal Officer, the Pre-Clearance Person must execute a certification (in the form approved by the Chief Legal Officer) that he, she or it is not aware of material, non-public information about the Company. The Chief Legal Officer shall have sole discretion to decide whether to pre-clear any contemplated transaction, provided that the Chief Executive Officer shall have sole discretion to decide whether to pre-clear transactions by the Chief Legal Officer or persons or entities subject to this policy as a result of their relationship with the Chief Legal Officer. All trades that are pre-cleared must be effected within five business days of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of the pre-clearance unless a specific exception has been granted by the Chief Legal Officer (or the Chief Executive Officer, in the case of the Chief Legal Officer or persons or entities subject to this policy as a result of their relationship with the Chief Legal Officer). A pre-cleared trade (or any portion of a pre-cleared trade) that has not been effected during the five business day period must be pre-cleared again prior to execution. Notwithstanding receipt of pre-clearance, if the Pre-Clearance Person becomes aware of material, non-public information or becomes subject to a black-out period before the transaction is effected, the transaction may not be completed.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Out Periods</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, no officer, director or other employee designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Legal Officer as being subject to quarterly black-out periods shall purchase or sell any security of the Company during the period beginning at 11:59 p.m., Eastern time, on the seventh calendar day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">except for purchases and sales made pursuant to the permitted transactions described in Section II. For example, if the Company&#x2019;s fourth fiscal quarter ends at 11:59 p.m., Eastern time, on December 31, the corresponding black-out period would begin at 11:59 p.m., Eastern time, on December 24.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions to the black-out period policy may be approved only by the Company&#x2019;s Chief Legal Officer (or, in the case of an exception for the Chief Legal Officer or persons or entities subject to this policy as a result of their relationship with the Chief Legal Officer, the Chief Executive Officer or, in the case of exceptions for directors or persons or entities subject to this policy as a result of their relationship with a director, the Board of Directors).</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company, through the Board of Directors, the Company&#x2019;s disclosure committee or the Chief Legal Officer, may recommend that officers, directors, employees or others suspend trading in the Company&#x2019;s securities because of developments that have not yet been disclosed to the public. Subject to the exceptions noted above, all of those affected should not trade in the Company&#x2019;s securities while the suspension is in effect, and should not disclose to others that the Company has suspended trading.</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is required to impose a &#x201c;pension fund black-out period&#x201d; under Regulation BTR, each director and executive officer shall not, directly or indirectly sell, purchase</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or otherwise transfer during such black-out period any equity securities of the Company acquired in connection with his or her service as a director or officer of the Company, except as permitted by Regulation BTR.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an individual is in possession of material, non-public information when his or her service terminates, that individual may not trade in the Company&#x2019;s securities until that information has become public or is no longer material.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Relating to the Company</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Access to Information</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to material, non-public information about the Company, including the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business, earnings, prospects or acquisition activities, should be limited to officers, directors and employees of the Company on a need-to-know basis. In addition, such information should not be communicated to anyone outside the Company under any circumstances (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company on an other than need-to-know basis.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In communicating material, non-public information to employees of the Company, all officers, directors and employees must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#x2019;s policies with regard to confidential information.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inquiries From Third Parties</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.795%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inquiries from third parties, such as industry analysts or members of the media, about the Company should be directed to the Chief Financial Officer.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Access to Company Information</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following procedures are designed to maintain confidentiality with respect to the Company&#x2019;s business operations and activities.</font></p>
  <p style="margin-left:0.92%;text-indent:6.793%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.139%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All officers, directors and employees should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among other things:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining the confidentiality of Company-related transactions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting their business and social activities so as not to risk inadvertent disclosure of confidential information. Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting access to areas likely to contain confidential documents or material, non- public information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain confidential information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10.935%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7422107449615454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:6.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel involved with material, non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">V.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Prohibited Transactions</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that there is a heightened legal risk and/or the appearance of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions. Therefore, officers, directors and employees shall comply with the following policies with respect to certain transactions in the Company securities:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.785%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short sales of the Company&#x2019;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&#x2019;s incentive to improve the Company&#x2019;s performance. For these reasons, short sales of the Company&#x2019;s securities are prohibited by this Policy. In addition, as noted below, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons from making short sales of the Company&#x2019;s equity securities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A transaction in options is, in effect, a bet on the short-term movement of the Company&#x2019;s stock and therefore creates the appearance that an officer, director or employee is trading based on non-public information. Transactions in options, whether traded on an exchange, on any other organized market or on an over-the-counter market, also may focus an officer&#x2019;s, director&#x2019;s or employee&#x2019;s attention on short-term performance at the expense of the Company&#x2019;s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving the Company&#x2019;s equity securities, on an exchange, on or in any other organized market or on an over-the- counter market, are prohibited by this Policy.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Transactions</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchasing financial instruments, such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company&#x2019;s equity securities, may cause</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an officer, director, or employee to no longer have the same objectives as the Company&#x2019;s other stockholders. Therefore, all such transactions involving the Company&#x2019;s equity securities, whether such securities were granted as compensation or are otherwise held, directly or indirectly, are prohibited by this Policy.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:6.667%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of the Company&#x2019;s Securities on Margin; Pledging the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities to Secure Margin or Other Loans</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company&#x2019;s securities (other than in connection with a cashless exercise of stock options through a broker under the Company&#x2019;s equity plans). Margin purchases of the Company&#x2019;s securities are prohibited by this Policy. Pledging the Company&#x2019;s securities as collateral to secure loans is prohibited. This prohibition means, among other things, that you cannot hold the Company&#x2019;s securities in a &#x201c;margin account&#x201d; (which would allow you to borrow against your holdings to buy securities).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partnership Distributions</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in this Policy is intended to limit the ability of a venture capital partnership or other similar entity with which a director is affiliated to distribute Company securities to its partners, members or other similar persons. It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">VI.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans, Section 16 and Rule 144</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 will protect directors, officers and employees from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in the Company&#x2019;s stock entered into and conducted in good faith and in accordance with the terms of Rule 10b5-1 (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and will be exempt from the trading restrictions set forth in this Policy. Each such Trading Plan, and any proposed modification or termination thereof, must be submitted to and pre-approved by the Company&#x2019;s Chief Legal Officer, or such other person as the Board of Directors may designate from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorizing Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person entering into, modifying, or terminating the Trading Plan, not the Company or the Authorizing Officer.</font></p>
  <p style="margin-left:0.92%;text-indent:6.804%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Plans do not exempt individuals subject to Section 16 of the 1934 Act from complying with Section 16 reporting obligations or from short-swing profit rules or liability. Furthermore, Trading Plans only provide an &#x201c;affirmative defense&#x201d; in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows and black-out periods, even when there is undisclosed material information. A Trading Plan may also help reduce negative publicity that may result when key executives sell the Company&#x2019;s stock. Rule 10b5-1 only provides an &#x201c;affirmative defense&#x201d; in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A director, officer or employee may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading window period outside of the trading black-out period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#x2019;s filing coordinator to assist in the preparation and filing of a required Form 4. Such reporting may be oral or in writing (including by e-mail) and should include the identity of the reporting person, the type of transaction, the date of the transaction, the number of shares involved and the purchase or sale price. However, the ultimate responsibility, and liability, for timely filing remains with the Section 16 reporting person.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&#x2019;s securities, even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such suspension, discontinuation or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company&#x2019;s right to prohibit transactions in the Company&#x2019;s securities. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section VI and result in a loss of the exemption set forth herein.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers, directors and employees may adopt Trading Plans with brokers that outline a pre- set plan for trading of the Company&#x2019;s stock, including the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, the Trading Plan must include a minimum &#x201c;cooling-off period&#x201d; between the establishment of a Trading Plan and commencement of any transactions under such plan for:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16 reporting persons that extends to the later of 90 days after adoption or modification of a Trading Plan or two business days after filing the Form 10-K or Form 10-Q covering the fiscal quarter in which the Trading Plan was adopted or modified, as applicable, up to a maximum of 120 days; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employees who are not Section 16 reporting persons and any other persons, other than the Company, that extends 30 days after adoption or modification of a Trading Plan.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.793%;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals may not adopt more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 and subject to pre-approval by the Authorizing Officer.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, the requirements of this Section VI.A do not apply to any Trading Plan entered into by a venture capital partnership or other similar entity with which a director is affiliated. It is the responsibility of each such venture capital partnership or other entity, in consultation with their</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">own counsel (as appropriate), to comply with applicable securities laws in connection with any Trading Plan.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revocation of and Amendments to Trading Plans</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revocation of Trading Plans should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Trading Plan will be subject to the prior review and approval of the Authorizing Officer. Revocation is effected upon written notice to the broker.</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A person acting in good faith may modify a prior Trading Plan so long as such modifications are made outside of a quarterly trading black-out period and at a time when the Trading Plan participant does not possess material, non-public information. Modifications to a Trading Plan are subject to pre-approval by the Authorizing Officer and modifications of a Trading Plan that change the amount, price, or timing of the purchase or sale of the securities underlying a Trading Plan will trigger a new cooling-off period (as described in Section VI.A.1 above).</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain circumstances, a Trading Plan </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">must </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be revoked. This may include circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. The Authorizing Officer or administrator of the Company&#x2019;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discretionary Plans</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Authorizing Officer.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company&#x2019;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders. The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company&#x2019;s stock once the Trading Plan or other arrangement has been pre-approved.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting (if Required)</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If required, an SEC Form 144 will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote at the bottom of the Form 144 should indicate that the trades &#x201c;are in accordance with a Trading Plan that complies with Rule 10b5-1 and was adopted on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; For Section 16 reporting persons, Form 4s should be filed before the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date of such notification is not later than the third business day following the trade date. The Form 4 must indicate that the transaction was made pursuant to a Trading Plan.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Options</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercises of options for cash may be executed at any time. &#x201c;Cashless exercise&#x201d; option exercises through a broker are subject to trading windows. However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number of shares to be exercised left blank.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing and the administrator of the Company&#x2019;s stock plans will fill in the number of shares and the date of exercise on the previously signed exercise form. The insider should not be involved with this part of the exercise.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trades Outside of a Trading Plan</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During an open trading window, trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading Plan continues to be followed.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.788369430620779%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Disclosure</font></div></div>
  <p style="margin-left:1.013%;text-indent:6.735%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserves the right to publicly disclose, announce, or respond to inquiries from the media regarding the adoption, modification, or termination of a Trading Plan and non- Rule 10b5-1 trading arrangements, or the execution of transactions made under a Trading Plan.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:8.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prohibited Transactions</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.792%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&#x2019;s securities.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Limitation on Liability</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of the Company, the Chief Executive Officer, the Chief Legal Officer, the Authorizing Officer, the Company&#x2019;s other employees or any other person will have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Section VI or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a request for pre-clearance submitted pursuant to Section IV of this Policy. Notwithstanding any review of a Trading Plan pursuant to this Section VI or pre-clearance of a transaction pursuant to Section IV of this Policy, none of the Company, the Chief Legal Officer, the Authorizing Officer, the Company&#x2019;s other employees or any other person assumes any liability for the legality or consequences of such Trading Plan or transaction to the person engaging in or adopting such Trading Plan or transaction.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:10.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16: Insider Reporting Requirements, Short-Swing Profits and Short Sales</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reporting Obligations Under Section 16(a): SEC Forms 3, 4 and 5</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the 1934 Act generally requires all officers, directors and 10% stockholders (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), within 10 days after the insider becomes an officer, director or 10% stockholder, to file with the SEC an &#x201c;Initial Statement of Beneficial Ownership of Securities&#x201d; on SEC Form 3 listing the amount of the Company&#x2019;s stock, options and warrants which the insider beneficially owns. Following the initial filing on SEC Form 3, changes in beneficial ownership of the Company&#x2019;s stock, options and warrants must be reported on SEC Form 4, generally within two business days after the date on which such change occurs, or in certain cases on Form 5, within 45 days after fiscal year end. A Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings. In certain situations, purchases or sales of Company stock made within six months </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">prior </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the filing of a Form 3 must be reported on Form 4. Similarly, certain purchases or sales of Company stock made within six months </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">after </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an officer or director ceases to be an insider must be reported on Form 4.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recovery of Profits Under Section 16(b)</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of preventing the unfair use of information which may have been obtained by an insider, any profits realized by any officer, director or 10% stockholder from any &#x201c;purchase&#x201d; and &#x201c;sale&#x201d; of Company stock during a six-month period, so called &#x201c;short-swing profits,&#x201d; may be recovered by the Company. When such a purchase and sale occurs, good faith is no defense. The insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations. In addition, liabilities under Section 16(b) may require separate disclosure in the Company&#x2019;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders. No suit may be brought more than two years after the date the profit was realized. However, if the insider fails to file a report of the transaction under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed. Failure to report transactions and late filing of reports require separate disclosure in the Company&#x2019;s proxy statement.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers and directors should consult the attached &#x201c;Short-Swing Profit Rule Section 16(b) Checklist&#x201d; attached hereto as &#x201c;Attachment A&#x201d; in addition to consulting the Chief Legal Officer prior to engaging in any transactions involving the Company&#x2019;s securities, including without limitation, the Company&#x2019;s stock, options or warrants. The Company&#x2019;s employees who are not officers, directors or insiders may disregard Attachment A.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short Sales Prohibited Under Section 16(c)</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company&#x2019;s equity securities. Short sales include sales of stock which the insider does not own at the time of sale, or sales of stock against which the insider does not deliver the shares within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c). Insiders violating Section 16(c) face criminal liability.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Legal Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:6.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales of &#x201c;restricted securities&#x201d; and &#x201c;control securities.&#x201d; &#x201c;Restricted securities&#x201d; are securities acquired from an issuer, or an affiliate of an issuer, in a transaction or chain of transactions not involving a public offering. &#x201c;Control securities&#x201d; are </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">any </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities owned by directors, executive officers or other &#x201c;affiliates&#x201d; of the issuer, including stock purchased in the open market and stock received upon exercise of stock options. Sales of Company restricted and control securities must comply with the requirements of Rule 144, which are summarized below:</font></p>
  <p style="margin-left:0.92%;text-indent:6.793%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Holding Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Restricted securities must be held for at least six months before they may be sold in the market.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Public Information. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company must have filed all SEC-required reports during the last 12 months or such shorter period that the Company was required to file such reports.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Volume Limitations. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For affiliates, total sales of Company common stock for any three- month period may not exceed the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">greater </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of: (i) 1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement published by the Company, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Method of Sale. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For affiliates, the shares must be sold either in a &#x201c;broker&#x2019;s transaction&#x201d; or in a transaction directly with a &#x201c;market maker.&#x201d; A &#x201c;broker&#x2019;s transaction&#x201d; is one in which the broker does no more than execute the sale order and receive the usual and customary commission. Neither the broker nor the selling person can solicit or arrange for the sale order. In addition, the selling person or Board member must not pay any fee or commission other than to the broker. A &#x201c;market maker&#x201d; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous basis.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of Proposed Sale. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For affiliates, a notice of the sale (a Form 144) may be required to be filed with the SEC at the time of the sale. Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 and in complying with the other requirements of Rule 144.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm&#x2019;s Rule 144 compliance procedures in connection with all trades.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.729924796850553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">VII.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execution and Return of Certification of Compliance</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After reading this Policy and on an annual basis, all officers, directors and employees should execute and return to the Company&#x2019;s Chief Legal Officer the Certification of Compliance form attached hereto as &#x201c;Attachment B.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.019%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT A</font></p>
  <p style="margin-left:15.72%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHORT-SWING PROFIT RULE SECTION 16(B) CHECKLIST</font></p>
  <p style="margin-left:0.92%;text-indent:6.785%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six months of each other by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities) results in a violation of Section 16(b), and the &#x201c;profit&#x201d; must be recovered by Lyra Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). It makes no difference how long the shares being sold have been held or, for officers and directors, that you were an insider for only one of the two matching transactions. The highest priced sale will be matched with the lowest priced purchase within the six-month period.</font></p>
  <p style="margin-left:41.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales</font></p>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.508287550594301%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Have there been any purchases by the insider (or family members living in the same household or certain affiliated entities) within the past six months?</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.508287550594301%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Have there been any option grants or exercises not exempt under Rule 16b-3 within the past six months?</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.508287550594301%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Are any purchases (or non-exempt option exercises) anticipated or required within the next six months?</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Has a Form 4 been prepared?</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.715%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: If a sale is to be made by an affiliate of the Company, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144?</font></p>
  <p style="margin-left:29.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases And Option Exercises</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a purchase or option exercise for Company stock is to be made:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.508287550594301%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Have there been any sales by the insider (or family members living in the same household or certain affiliated entities) within the past six months?</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.508287550594301%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Are any sales anticipated or required within the next six months (such as tax- related or year-end transactions)?</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:14.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.776650219873791%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Has a Form 4 been prepared?</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before proceeding with a purchase or sale, consider whether you are aware of material, non-public information which could affect the price of the Company stock. All transactions in the Company&#x2019;s securities by officers and directors must be </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-cleared</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by contacting the Company&#x2019;s Chief Legal Officer, or such person performing duties similar to those performed by a Chief Legal Officer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT B</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.176%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF COMPLIANCE</font></p>
  <p style="margin-left:21.16%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RETURN BY [</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[insert return deadline]</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:35.231%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Chief Legal Officer FROM:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p>
  <p style="margin-left:0.92%;text-indent:-16.307%;padding-left:13.333%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RE:	INSIDER TRADING COMPLIANCE POLICY OF LYRA THERAPEUTICS, INC.</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have received, reviewed and understand the above-referenced Insider Trading Compliance Policy and undertake, as a condition to my present and continued employment with (or, if I am not an employee, affiliation with) Lyra Therapeutics, Inc., to comply fully with the policies and procedures contained therein.</font></p>
  <p style="margin-left:0.92%;text-indent:13.59%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby certify, to the best of my knowledge, that during the calendar year ending December 31, 20[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">], I have complied fully with all policies and procedures set forth in the above- referenced Insider Trading Compliance Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE	DATE</font></p>
  <p style="font-size:10pt;margin-top:6.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TITLE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.987%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.139%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRE-CLEARANCE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:29.68%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of Individuals Subject to Pre-clearance*:</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">All employees</font></p>
  <p style="font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:42.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective date:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">November 8, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*In addition to Section 16 reporting persons.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>lyra-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-264864, No. 333-256020, No. 272981 and No. 278163) and Form S-8 (No. 333-237973, No. 333-263402, No. 333-270949 and No. 333-278164) of Lyra Therapeutics, Inc. (the Company) of our report dated March 13, 2025, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company&#x2019;s ability to continue as a going concern.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">/s/ BDO USA, P.C.</font></p>
  <p style="margin-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">March 13, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>lyra-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Maria Palasis, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lyra Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.069%;box-sizing:content-box;"></td>
    <td style="width:4.921%;box-sizing:content-box;"></td>
    <td style="width:3.461%;box-sizing:content-box;"></td>
    <td style="width:46.549%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>lyra-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Jason Cavalier, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lyra Therapeutics, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;box-sizing:content-box;"></td>
    <td style="width:4.92%;box-sizing:content-box;"></td>
    <td style="width:3.46%;box-sizing:content-box;"></td>
    <td style="width:46.62%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>lyra-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:5%;box-sizing:content-box;"></td>
    <td style="width:44%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>lyra-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:5%;box-sizing:content-box;"></td>
    <td style="width:44%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img224190320_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224190320_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &O XT# 2(  A$! Q$!_\0
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M_0&\,_\ @+<?_'Z/^'@'Q#_Z WAG_P !;C_X_1]3JA_KME'\TO\ P$^_Z*^
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M 2/^>]0?\/ /B'_T!O#/_@+<?_'Z/J=4;XURA.W-+_P$^_Z*^ /^'@'Q#_Z
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MH_X> ?$/_H#>&?\ P%N/_C]'U.J+_7;*/YI?^ GW_17P!_P\ ^(?_0&\,_\
M@+<?_'Z/^'@'Q#_Z WAG_P !;C_X_1]3JA_KME'\TO\ P$^_Z*^ /^'@'Q#_
M .@-X9_\!;C_ ./T?\/ /B'_ - ;PS_X"W'_ ,?H^IU0_P!=LH_FE_X"??\
M17P!_P / /B'_P! ;PS_ . MQ_\ 'Z/^'@'Q#_Z WAG_ ,!;C_X_1]3JA_KM
ME'\TO_ 3[_HKX _X> ?$/_H#>&?_  %N/_C]'_#P#XA_] ;PS_X"W'_Q^CZG
M5#_7;*/YI?\ @)]_T5\ ?\/ /B'_ - ;PS_X"W'_ ,?H_P"'@'Q#_P"@-X9_
M\!;C_P"/T?4ZH?Z[91_-+_P$^_Z*^ /^'@'Q#_Z WAG_ ,!;C_X_1_P\ ^(?
M_0&\,_\ @+<?_'Z/J=4/]=LH_FE_X"??]%? '_#P#XA_] ;PS_X"W'_Q^C_A
MX!\0_P#H#>&?_ 6X_P#C]'U.J'^NV4?S2_\  3[_ **^ /\ AX!\0_\ H#>&
M?_ 6X_\ C]'_  \ ^(?_ $!O#/\ X"W'_P ?H^IU0_UVRC^:7_@)]_T5\ ?\
M/ /B'_T!O#/_ ("W'_Q^C_AX!\0_^@-X9_\  6X_^/T?4ZH?Z[91_-+_ ,!/
MO^BO@#_AX!\0_P#H#>&?_ 6X_P#C]'_#P#XA_P#0&\,_^ MQ_P#'Z/J=4/\
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M')I7=DW9=].AYS1115',%%%% !1110 5=O/^0=I_^Z__ *$:I5=O/^0=I_\
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M?A33O &C>'K/0M)EB@U33K,P3E"(OEG8<2>9PZD@$!#][)-8OP-\"^&;+1?
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MP/H;2ZMH#ZMJ6E)/_9^E[XTB8.ZK'(=@>4#8%.[*AB5#$_*=E\0=?T_P3?\
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M/X'O/ ?@K18?"GA]?$FIV;O-8^,=&G@EU5B!NDMM0*,JC#;U"+(2"H 0Y(/
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MK_\ ':/K%'^=?>@_L?,O^@:?_@$O\CR2BO6_^&3_ (J?]"M_Y4+7_P".T?\
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M^QLS_P"@6I_X!+_(\9HKV;_ACOXO?]"C_P"5*S_^/4?\,=_%[_H4?_*E9_\
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ME]X?V-F?_0+4_P# )?Y'C-%>S?\ #'?Q>_Z%'_RI6?\ \>H_X8[^+W_0H_\
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MQ>_Z%'_RI6?_ ,>H_P"&._B]_P!"C_Y4K/\ ^/4>VI_S+[P_L;,_^@6I_P"
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M*]F_X8[^+W_0H_\ E2L__CU'_#'?Q>_Z%'_RI6?_ ,>H]M3_ )E]X?V-F?\
MT"U/_ )?Y'C-*GWU^M>R_P##'?Q>_P"A1_\ *E9__'J5?V//B\&!_P"$1Z'_
M *"5G_\ 'J/;4_YE]X+)LS_Z!:G_ (!+_(\CUC_D+WW_ %W?_P!"-5*]NU']
MD'XN7.H74J>$LI)*S*?[2L^A)(_Y;57_ .&._B]_T*/_ )4K/_X]0JM/^9?>
M5+)LS<G_ +-4_P# )?Y'C-%>S?\ #'?Q>_Z%'_RI6?\ \>H_X8[^+W_0H_\
ME2L__CU'MJ?\R^\G^QLS_P"@6I_X!+_(\9HKV;_ACOXO?]"C_P"5*S_^/4?\
M,=_%[_H4?_*E9_\ QZCVU/\ F7WA_8V9_P#0+4_\ E_D>,T5[-_PQW\7O^A1
M_P#*E9__ !ZC_ACOXO?]"C_Y4K/_ ./4>VI_S+[P_L;,_P#H%J?^ 2_R/&:*
M]F_X8[^+W_0H_P#E2L__ (]1_P ,=_%[_H4?_*E9_P#QZCVU/^9?>']C9G_T
M"U/_  "7^1XS17LW_#'?Q>_Z%'_RI6?_ ,>H_P"&._B]_P!"C_Y4K/\ ^/4>
MVI_S+[P_L;,_^@6I_P" 2_R/&:*]F_X8[^+W_0H_^5*S_P#CU'_#'?Q>_P"A
M1_\ *E9__'J/;4_YE]X?V-F?_0+4_P# )?Y'C-%>S?\ #'?Q>_Z%'_RI6?\
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M6?\ \>H]M3_F7WA_8V9_] M3_P  E_D>,T5[-_PQW\7O^A1_\J5G_P#'J/\
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MOKZO&Q4E*I>+N?NO"&'K8;*XTZ\'&7-+1II_<PHHHKC/M3E****\PX@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Q/!7_)6/&'_ &"-*_\ 1M]6W7BG
MCC]H;PY\!OBQJW_"066J7G]JZ18>1_9L4;[?*EN]V[?(F/\ 6+C&>AZ5U8=-
MR:7;]4<5>I&E4I3F[)2_]MD?2U%?+_\ P\,^'/\ T!?%'_@+;?\ R11_P\,^
M'/\ T!?%'_@+;?\ R17;R2['5]?PO_/Q'U!17R__ ,/#/AS_ - 7Q1_X"VW_
M ,D4?\/#/AS_ - 7Q1_X"VW_ ,D4<DNP?7\+_P _$?4%%?+_ /P\,^'/_0%\
M4?\ @+;?_)%'_#PSX<_] 7Q1_P" MM_\D4<DNP?7\+_S\1]045\O_P##PSX<
M_P#0%\4?^ MM_P#)%'_#PSX<_P#0%\4?^ MM_P#)%')+L'U_"_\ /Q'U!17R
M_P#\/#/AS_T!?%'_ ("VW_R11_P\,^'/_0%\4?\ @+;?_)%')+L'U_"_\_$?
M4%%?+_\ P\,^'/\ T!?%'_@+;?\ R11_P\,^'/\ T!?%'_@+;?\ R11R2[!]
M?PO_ #\1]045\O\ _#PSX<_] 7Q1_P" MM_\D4?\/#/AS_T!?%'_ ("VW_R1
M1R2[!]?PO_/Q'U!17R__ ,/#/AS_ - 7Q1_X"VW_ ,D4?\/#/AS_ - 7Q1_X
M"VW_ ,D4<DNP?7\+_P _$?4%%?+_ /P\,^'/_0%\4?\ @+;?_)%'_#PSX<_]
M 7Q1_P" MM_\D4<DNP?7\+_S\1]045\O_P##PSX<_P#0%\4?^ MM_P#)%'_#
MPSX<_P#0%\4?^ MM_P#)%')+L'U_"_\ /Q'U!17S%!_P4(^'$LT:-I/B:%68
M R/:0%4&>IQ.3@>P)]J^CM#URP\3:1::II=W%?:?=QB6&XA;<KJ>A%2XN.YT
M4L12KW5.2=B_1114G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <I1117F'$%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9B2 %4$DD  DU^>?Q9?Q"GAW]H+^Q-_V$_$2V&N',WE#3O*E\WSO)_>>3O\
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M(F[S9;C;MV1OG_5MG..HZUVX1I3;?8\;-*<JM.$(*[<O_;9'P_70^&_'^O\
MA#1]=TO2;_[)8:Y +;4(O)C?SXQNPN64E?O-RI!YKW__ (=Y_$;_ *#7A?\
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M>-=$UB&XET?Q+I+V3M:1J\D-PN3!)M9E!56)R,@X/%>L_P##O/XC?]!KPO\
M^!5S_P#(]'_#O/XC?]!KPO\ ^!5S_P#(]#G!JUPA@\9"7.H.YXO;_&SQI:ZO
MX8U2+6=M]X:M/L.DR_983]FAV%-N-F'^4D9<$^]<?J%_/JE_<WMT_FW-S*TT
MKX W.Q)8X' Y)Z5],?\ #O/XC?\ 0:\+_P#@5<__ "/1_P .\_B-_P!!KPO_
M .!5S_\ (]/GAW%+!XR6DHMGE/@7]H[XB?#3P_'HGAOQ --TN.1I5@%A;2?,
MQRQ+/&S'\34VC?M-_$WP_J^LZG8>*98+O6)5GO3]E@9))%4('$;1E$;: "5
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MAT718=TAP]U>N!YMS)CEF/\ (= *[FBBN1N^K/LX0C3BHQ5D@HHHI%A1110
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M/^&S?C'_ -#A_P"4RS_^,UW^QD3_ &UA_P"67W+_ #/U HK\O_\ ALWXQ_\
M0X?^4RS_ /C-'_#9OQC_ .AP_P#*99__ !FCV,@_MK#_ ,LON7^9^H%%?E__
M ,-F_&/_ *'#_P IEG_\9H_X;-^,?_0X?^4RS_\ C-'L9!_;6'_EE]R_S/U
MHK\O_P#ALWXQ_P#0X?\ E,L__C-'_#9OQC_Z'#_RF6?_ ,9H]C(/[:P_\LON
M7^9^H%%?E_\ \-F_&/\ Z'#_ ,IEG_\ &:/^&S?C'_T.'_E,L_\ XS1[&0?V
MUA_Y9?<O\S]0**_+_P#X;-^,?_0X?^4RS_\ C-'_  V;\8_^AP_\IEG_ /&:
M/8R#^VL/_++[E_F?J!17Y?\ _#9OQC_Z'#_RF6?_ ,9H_P"&S?C'_P!#A_Y3
M+/\ ^,T>QD']M8?^67W+_,_4"BOR_P#^&S?C'_T.'_E,L_\ XS1_PV;\8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RE
M%%%>8<04444 %%%% !1110 4444 %%%% !1110 4444 %?!_[=O_ "5C2_\
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MTH>*!<@%(2%:0DJ> 1PK8R0%/M_Q9_:*\+>#?BSXAFL;"Z\5P:E':3F^\/\
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MTKRCX:^!/B'\9/@/?_#K0_!FF_\ ",:IXMGN[GQD=3CC>R\NX!<-;D>8TF$
M#ID;65<<$A\D>Y/M*G;^M#ZL\'_M,VT6H_%ZX\=7FE:!X=\%ZV--M[Q$D#R1
ME21O&YC)(2, (H)[*:K>.OVX_AGX:^$5UX[T+5/^$L@6Z_L^VL;5)()9;HJ6
M6.3S$#1+M5FWLO13M#' /C_Q)_9:^(GB[3?BK)864EG=77CJV\3:3'!J45O+
MJ-O%'*A6.4%A#)^\#*9 ,,H.*RKG]E+X@Z_\"OBFKZ%K]MXV\2RZ:!9^)_&%
MKK%Q?+:RA@YF2")$(0E5WR-D*1A %W/EAO<3G46B1]):O^V1\&]!M]"FO_'%
MK;IK< N;(&UN&8Q%MH>11&3""<X,@7(!/0$U[%;7,-[;17%O*D]O,@DCEB8,
MCJ1D,"."".<BO@GXL_ #XN^-OB3KGC,>$?$:VOC+3+:#4O#_ (;\<VFFFQ,<
M0@DM[EY(G2YC95W (N/G<'W^UOAIX2'@+X>>&O#8:1QI.G060\VX$[*(XPH7
MS!''O Q@-L3( .T=*SE&*2L:PE*3::.EHHHK,V"BBB@ HHHH **** "BBB@#
ME****\PX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^#_V[?^2L:7_V
M"(__ $;+7WA7E^J?!CP=\7?BQK__  ENC_VM_9^D:=]F_P!*FA\OS);S?_JW
M7.=B]<]..]=F%?+-M]CR<PH2Q$:=*&[EU_PR9^9]%?J!_P ,9?!S_H3_ /RI
MWG_QZC_AC+X.?]"?_P"5.\_^/5Z?MHGG?V+B/YH_>_\ (_+^BOU _P"&,O@Y
M_P!"?_Y4[S_X]1_PQE\'/^A/_P#*G>?_ !ZCVT0_L7$?S1^]_P"1^7]%?J!_
MPQE\'/\ H3__ "IWG_QZC_AC+X.?]"?_ .5.\_\ CU'MHA_8N(_FC][_ ,C\
MOZ*_4#_AC+X.?]"?_P"5.\_^/4?\,9?!S_H3_P#RIWG_ ,>H]M$/[%Q'\T?O
M?^1^:_A/Q;J7@G6X-7TEK:/4("&AEN;.&Y$; @AU65&4," 0P&1V(JOX@U_4
M?%.M7NKZM=R7VI7DK33W$I^9V/4^@'H!P!@#BOTP_P"&,O@Y_P!"?_Y4[S_X
M]1_PQE\'/^A/_P#*G>?_ !ZE[6/8K^Q\5;EYE;U?^1^9.E:I=:)JEGJ-C,UM
M>V<R7$$RXS'(C!E89[@@&IO$&O7OBC7+[5]2E2?4+Z9KBXE2)(@\C'+-M0!0
M223P!R:_3#_AC+X.?]"?_P"5.\_^/4?\,9?!S_H3_P#RIWG_ ,>H]M$/[&Q-
MK<RMZO\ R/R_HK]0/^&,O@Y_T)__ )4[S_X]1_PQE\'/^A/_ /*G>?\ QZG[
M:)/]BXC^:/WO_(_+^MGPYXPU?PE'JR:3=_9!JME)IUV1$C-);OC?&"P)4' R
M5P?>OTG_ .&,O@Y_T)__ )4[S_X]1_PQE\'/^A/_ /*G>?\ QZE[:)2R;$Q=
MU)?>_P#(_+^BOU _X8R^#G_0G_\ E3O/_CU'_#&7P<_Z$_\ \J=Y_P#'J?MH
MD_V+B/YH_>_\C\OZ*_4#_AC+X.?]"?\ ^5.\_P#CU'_#&7P<_P"A/_\ *G>?
M_'J/;1#^Q<1_-'[W_D?E_7U!^RE^RC+\1[BW\5^*[=X/"T;;[:T<%6U!@>I]
M(O?^+H.*^HX/V./@];S1RKX.4LC!@'U&[=20<\J92"/8C%>R6]O%:6\<$$:0
MPQJ$2.-0JJH&  !T J)5;JT3MPN4.G/GKM-+HOU$MK:*SMXH((DA@B4(D<:A
M550,  #H*EHHKF/IPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S- \,Z/X4L6LM
M$TJQT:S:1IFM]/MD@C,C'+.50 ;B>IZFM.B@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y2BBBO,.(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M'-M_\77Y%44>Q7</[;J?R(_77_A=_P .?^A_\+_^#FV_^+H_X7?\.?\ H?\
MPO\ ^#FV_P#BZ_(JBCV*[A_;=3^1'ZZ_\+O^'/\ T/\ X7_\'-M_\71_PN_X
M<_\ 0_\ A?\ \'-M_P#%U^15%'L5W#^VZG\B/UU_X7?\.?\ H?\ PO\ ^#FV
M_P#BZ/\ A=_PY_Z'_P +_P#@YMO_ (NOR*HH]BNX?VW4_D1^NO\ PN_X<_\
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M\77Y%44>Q7</[;J?R(_77_A=_P .?^A_\+_^#FV_^+H_X7?\.?\ H?\ PO\
M^#FV_P#BZ_(JBCV*[A_;=3^1'ZZ_\+O^'/\ T/\ X7_\'-M_\71_PN_X<_\
M0_\ A?\ \'-M_P#%U^15%'L5W#^VZG\B/UU_X7?\.?\ H?\ PO\ ^#FV_P#B
MZ/\ A=_PY_Z'_P +_P#@YMO_ (NOR*HH]BNX?VW4_D1^NO\ PN_X<_\ 0_\
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ME( 5L%(ZGUE/_CO0<YJ*CBEJ=^6PKRKIT=+;OI8^I0<@$=*6BBN$^^"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH P/B!KMQX7\!^)-9M(Q+=:=IMS>0HPR&>.)G4'\0*^/_ (;?LO\
MA#XD? [PY\3]7\7ZGI'Q'U3R=5G\>RZG()H)3*%\L*TBQ@ #REXR#CM\M?;K
MHLJ,CJ'1A@JPR"/0U\Z7/["/P^N;PP?VQXMB\(F[%Z?!,6LL-$\SJ?W&W< 6
M^;A\Y/! P*TC*QC.+D]KE/QM\</BGJGQ'\9^$_A=I7AF^@\"6-O-K5_XJDF$
MEY-+$94C@6'8H8JCY+ +GNHQGD9/VP/B%\1-9\*6OPV\/^&X%USPC+XBD3Q(
M\[?9)8;F6*9-\17S%_<E5&Q22P8D $5ZQ\2_V1_"7Q'\37&O0ZUXF\'7UY9+
MIVH#PKJ0LH]0MU4*D<Z%&#*J#: ,#'!S@8VM._9J\&Z)XNTG7M)CO-*_LKPX
MWA>TTZVE7[,EHSLY8[E+M+EC\Y<Y/)!))-7A8GEJ7W/%?AE^UM\1O%6M?";4
MM<\-^&[#P9X\EFT^$6<\[WZ7,*E9)3D[%C:53M3#,%ZMGDX5M^U]\8++X?S?
M$[4_#O@Z3X>Z=K3:5?P6S7*:G*@G\HRQ NT:@;E7#$DLK' 4C'NV@?LJ^$_#
MNB_#33+;4=9>#P#>3WNF-+/"6F>5V=A.1$ P!8XVA?J:\=^!O[$2S^'EE^(L
M_B/3WCUZXU)_"L&M(VDWN)-T,\T*%@7QM'RLIPB@CKEWAN1:KHK_ -:')?\
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MA\1O^A \4?\ @FN?_B*_7:BCVS[!_8E/^=GY$_\ "D/B-_T('BC_ ,$US_\
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M_7:BCVS[!_8E/^=GY$_\*0^(W_0@>*/_  37/_Q%'_"D/B-_T('BC_P37/\
M\17Z[44>V?8/[$I_SL^6?V4/V3X_A_#;>+O%ULLOB:1=]I8R#*V /<^LO_H/
M0<YKZFHHK&4G)W9[E"A##P5.FM HHHJ3H"BBB@ HHHH **** "BBB@ HHHH
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MK\]YH]WJT^H2VTR0NP2=G*Q),,$[(880J$#:P(8_H=13]NOY0Y/,^2?V8/\
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M&N!]IAAV!\A?]8ZYSM/3/2O3=."W/(CF.-F^6,KOT7^1]1_\/(O^J=_^5O\
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M@* .22>,"CV<.P/,\8G9S_!?Y'VA_P /(O\ JG?_ )6__N>C_AY%_P!4[_\
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M<T3")=BON:4-Y:C#+R6QE@.I I>S@BHYACI?#*_39;_<?3G_  \B_P"J=_\
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M\\MNLS')8C"JQ!Z$KD  =JP=<\1:MXGO%N]8U.\U:Z6,1+/?7#S.$'10S$G
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MBG_AV[_U43_RB?\ W11_P[=_ZJ)_Y1/_ +HK[6HH]K/N']EX3^3\7_F?%/\
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M (=N_P#51/\ RB?_ '17VM11[6?</[+PG\GXO_,^*?\ AV[_ -5$_P#*)_\
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MT>*.[U*[ALH7G)$:O(X12Q ) RPS@'Z4^6/8GGGW/4O^&P/BY_T-O_E-M/\
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M?_0I?^5*[_\ CM'_  Q_\(_^A2_\J5W_ /':]DHHYI=PY(]CQO\ X8_^$?\
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M .A2_P#*E=__ !VO9**.:7<.2/8\;_X8_P#A'_T*7_E2N_\ X[1_PQ_\(_\
MH4O_ "I7?_QVO9**.:7<.2/8\;_X8_\ A'_T*7_E2N__ ([1_P ,?_"/_H4O
M_*E=_P#QVO9**.:7<.2/8\;_ .&/_A'_ -"E_P"5*[_^.T?\,?\ PC_Z%+_R
MI7?_ ,=KV2BCFEW#DCV/&_\ AC_X1_\ 0I?^5*[_ /CM'_#'_P (_P#H4O\
MRI7?_P =KV2BCFEW#DCV/&_^&/\ X1_]"E_Y4KO_ ..T?\,?_"/_ *%+_P J
M5W_\=KV2BCFEW#DCV/&_^&/_ (1_]"E_Y4KO_P".T?\ #'_PC_Z%+_RI7?\
M\=KV2BCFEW#DCV/&_P#AC_X1_P#0I?\ E2N__CM'_#'_ ,(_^A2_\J5W_P#'
M:]DHHYI=PY(]CQO_ (8_^$?_ $*7_E2N_P#X[1_PQ_\ "/\ Z%+_ ,J5W_\
M':]DHHYI=PY(]CQO_AC_ .$?_0I?^5*[_P#CM'_#'_PC_P"A2_\ *E=__':]
MDHHYI=PY(]CQO_AC_P"$?_0I?^5*[_\ CM'_  Q_\(_^A2_\J5W_ /':]DHH
MYI=PY(]CQO\ X8_^$?\ T*7_ )4KO_X[1_PQ_P#"/_H4O_*E=_\ QVO9**.:
M7<.2/8XOX??!OP;\+&NG\+Z'%IDMU@32^;),[ =!ND9B![ XKM***5[[E)):
M(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_@SF_\ BJZS6/@/K^J>+=:L/"6@:G-I^FR1PNVIW%LL@<QJQ!<,$8\YPI)
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MW3>:R;U5\C "$[>ISP>,'-5:+5[?@;.AB%+EYOQ[:G#_ /"TO&?_ $-VO?\
M@SF_^*H_X6EXS_Z&[7O_  9S?_%5%X]TK0='\236_AS4I]3TO:"KW4+131-_
M%&X*KE@1U QS6F?@SXR&H7]B-%9KFQM%O9T6>)@L+ E6!#X;.#PI)X/%;?N[
M)M)>IS?OFW&+;MVU*/\ PM+QG_T-VO?^#.;_ .*H_P"%I>,_^ANU[_P9S?\
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M[!23U !Y'(XYK?\ "_P=DN--\=KX@AO=+U?0+19H8"Z1HSDN,L6!#(=HPRD
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M'(YY%3S4;VT-.7$6NKO[S*_X6EXS_P"ANU[_ ,&<W_Q5'_"TO&?_ $-VO?\
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MW'J"N,87'.:]'I3@X/EEN53J1JQYH[?T@HHHJ#0**** "BBB@ HHHH ****
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MZO'FYK_U>X_K<^7ELMK?A;\$_P#,[CX.^.[/X?\ B]KS4K>2YTR[M9;&[6$
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M2_MAXGO7BOMWG>:5D8;@0=C,"8QSP$*X[8KA**T]E3[&#KU;WYG^1[WIM_\
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M@K_H6=._[\BC_A3W@K_H6=._[\BNPHH]I/\ F8?4\-_SZC]R./\ ^%/>"O\
MH6=._P"_(H_X4]X*_P"A9T[_ +\BNPHH]I/^9A]3PW_/J/W(X_\ X4]X*_Z%
MG3O^_(H_X4]X*_Z%G3O^_(KL**/:3_F8?4\-_P ^H_<CC_\ A3W@K_H6=._[
M\BC_ (4]X*_Z%G3O^_(KL**/:3_F8?4\-_SZC]R./_X4]X*_Z%G3O^_(K(\(
M_";P=<_$WQ3:R^'-/>VATO39(XC"-JLTEZ&(]R$7_OD5Z/6)X*_Y*QXP_P"P
M1I7_ *-OJZ:%2=WJ]OU1A+"8>-:CRTXKWGT7\LC0_P"%*>!/^A5TS_OP*/\
MA2G@3_H5=,_[\"NVHKJ]I/\ F9['U>C_ "+[D<3_ ,*4\"?]"KIG_?@4?\*4
M\"?]"KIG_?@5VU%'M)_S,/J]'^1?<CB?^%*>!/\ H5=,_P"_ H_X4IX$_P"A
M5TS_ +\"NVHH]I/^9A]7H_R+[D<3_P *4\"?]"KIG_?@4?\ "E/ G_0JZ9_W
MX%=M11[2?\S#ZO1_D7W(XG_A2G@3_H5=,_[\"C_A2G@3_H5=,_[\"NVHH]I/
M^9A]7H_R+[D<3_PI3P)_T*NF?]^!1_PI3P)_T*NF?]^!7;44>TG_ #,/J]'^
M1?<CB?\ A2G@3_H5=,_[\"C_ (4IX$_Z%73/^_ KMJ*/:3_F8?5Z/\B^Y'$_
M\*4\"?\ 0JZ9_P!^!1_PI3P)_P!"KIG_ 'X%=M11[2?\S#ZO1_D7W(XG_A2G
M@3_H5=,_[\"C_A2G@3_H5=,_[\"NVHH]I/\ F8?5Z/\ (ON1Q/\ PI3P)_T*
MNF?]^!1_PI3P)_T*NF?]^!7;44>TG_,P^KT?Y%]R.)_X4IX$_P"A5TS_ +\"
MC_A2G@3_ *%73/\ OP*[:BCVD_YF'U>C_(ON1Q/_  I3P)_T*NF?]^!1_P *
M4\"?]"KIG_?@5VU%'M)_S,/J]'^1?<CB?^%*>!/^A5TS_OP*/^%*>!/^A5TS
M_OP*[:BCVD_YF'U>C_(ON1Q/_"E/ G_0JZ9_WX%'_"E/ G_0JZ9_WX%=M11[
M2?\ ,P^KT?Y%]R.)_P"%*>!/^A5TS_OP*/\ A2G@3_H5=,_[\"NVHH]I/^9A
M]7H_R+[D<3_PI3P)_P!"KIG_ 'X%'_"E/ G_ $*NF?\ ?@5VU%'M)_S,/J]'
M^1?<CB?^%*>!/^A5TS_OP*/^%*>!/^A5TS_OP*[:BCVD_P"9A]7H_P B^Y'$
M_P#"E/ G_0JZ9_WX%'_"E/ G_0JZ9_WX%=M11[2?\S#ZO1_D7W(XG_A2G@3_
M *%73/\ OP*/^%*>!/\ H5=,_P"_ KMJ*/:3_F8?5Z/\B^Y'$_\ "E/ G_0J
MZ9_WX%'_  I3P)_T*NF?]^!7;44>TG_,P^KT?Y%]R.)_X4IX$_Z%73/^_ H_
MX4IX$_Z%73/^_ KMJ*/:3_F8?5Z/\B^Y'$_\*4\"?]"KIG_?@4?\*4\"?]"K
MIG_?@5VU%'M)_P S#ZO1_D7W(XG_ (4IX$_Z%73/^_ H_P"%*>!/^A5TS_OP
M*[:BCVD_YF'U>C_(ON1Q/_"E/ G_ $*NF?\ ?@4?\*4\"?\ 0JZ9_P!^!7;4
M4>TG_,P^KT?Y%]R.)_X4IX$_Z%73/^_ H_X4GX$_Z%33/^_ KMJ*7M)]V3+"
MX>6DJ:?R1Q/_  I/P'_T*FF?]^!1_P *3\!_]"IIG_?@5VU%'/+N1]2PO_/J
M/W+_ ".)_P"%)^ _^A4TS_OP*/\ A2?@/_H5-,_[\"NVHHYY=P^I87_GU'[E
M_D<3_P *3\!_]"IIG_?@4?\ "D_ ?_0J:9_WX%=M11SR[A]2PO\ SZC]R_R.
M)_X4GX#_ .A4TS_OP*/^%)^ _P#H5-,_[\"NVHHYY=P^I87_ )]1^Y?Y'$_\
M*3\!_P#0J:9_WX%'_"D_ ?\ T*FF?]^!7;44<\NX?4L+_P ^H_<O\CB?^%)^
M _\ H5-,_P"_ H_X4GX#_P"A4TS_ +\"NVHHYY=P^I87_GU'[E_D<3_PI/P'
M_P!"IIG_ 'X%'_"D_ ?_ $*FF?\ ?@5VU%'/+N'U+"_\^H_<O\CB?^%)^ _^
MA4TS_OP*/^%)^ _^A4TS_OP*[:BCGEW#ZEA?^?4?N7^1Q/\ PI/P'_T*FF?]
M^!1_PI/P'_T*FF?]^!7;44<\NX?4L+_SZC]R_P CB?\ A2?@/_H5-,_[\"C_
M (4GX#_Z%33/^_ KMJ*.>7</J6%_Y]1^Y?Y'$_\ "D_ ?_0J:9_WX%'_  I/
MP'_T*FF?]^!7;44<\NX?4L+_ ,^H_<O\CB?^%)^ _P#H5-,_[\"C_A2?@/\
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M .YZ/93[!_:F$_G_  ?^1]K45\4_\/(O^J=_^5O_ .YZ/^'D7_5._P#RM_\
MW/1[*?8/[4PG\_X/_(^UJ*^*?^'D7_5._P#RM_\ W/1_P\B_ZIW_ .5O_P"Y
MZ/93[!_:F$_G_!_Y'VM17Q3_ ,/(O^J=_P#E;_\ N>C_ (>1?]4[_P#*W_\
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MI'S5X8^%_BCQEX;UW7]'TB2\T?0X_-O[H2(BPKM9C@,P+X522%!(&,XR,Q^
MOAMXF^)^L?V7X7T>XU>\"EG$6%CB&"<O(Q"(#@@;B,G &20*^O\ X9W_ (2^
M"/@WX=^'_$GC*#PU?WR/K>L:/<Z5/,+]+N-HHHY9!\L(1.#NSRH)"CKS-O\
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M#(03N((9MQY_>>@!KX&JXRYCBQ6'C0:Y>[6OD%%%%:' %%%% !1110 4444
M%%%% !1110 4444 =K\)/BWKWP;\6PZYH<WHES9R$^5=19Y1Q_(]0>17Z@?"
M3XMZ#\9?"4.N:'-Z)=6<A'FVLN.4<?R/0CD5^15>T?LFR>.T^+%E_P (.,L<
M?VDL^?LIML_-YV/_ !W'.>G>L:D%)7/:RW&SH35*UXOI_D?J'12#.!GK2UQ'
MW(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/VUE;R+Y"6S,S%CN4L9,N3N+')Y())):<3%TL4Y/WM+]^E^FFFFC[GE/@/\
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M2M'#&L:M-*TKD 8!9W)9CQRS$D]22:B3C;0[L/#$1G)U7IT)J***S.\****
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M?\.W?^JB?^43_P"Z*/:P[A_9>+_D_%?YGQ517VK_ ,.W?^JB?^43_P"Z*/\
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M_P#QVC_A O%__0ZVO_@E7_X[1[!]U^/^0>TK?\^9??'_ .2-FBL;_A O%_\
MT.MK_P""5?\ X[1_P@7B_P#Z'6U_\$J__':/8/NOQ_R#VE;_ )\R^^/_ ,D;
M-%8W_"!>+_\ H=;7_P $J_\ QVC_ (0+Q?\ ]#K:_P#@E7_X[1[!]U^/^0>T
MK?\ /F7WQ_\ DC9HK&_X0+Q?_P!#K:_^"5?_ ([1_P (%XO_ .AUM?\ P2K_
M /':/8/NOQ_R#VE;_GS+[X__ "1LT5C?\(%XO_Z'6U_\$J__ !VC_A O%_\
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MQ_T.UG_X(U_^/4<J[_G_ )!]8J?\^9??#_Y([:BN)_X1KQQ_T.UG_P""-?\
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M<?\ 0[6?_@C7_P"/4<J[_G_D'UBI_P ^9??#_P"2.VHKB?\ A&O''_0[6?\
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M7_X]1_PC7CC_ *':S_\ !&O_ ,>HY5W_ #_R#ZQ4_P"?,OOA_P#)';45Q/\
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M *':S_\ !&O_ ,>HY5W_ #_R#ZQ4_P"?,OOA_P#)';45Q/\ PC7CC_H=K/\
M\$:__'J/^$:\<?\ 0[6?_@C7_P"/4<J[_G_D'UBI_P ^9??#_P"2.VHKB?\
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MY3SB&V^##VL%DD>O2PR6VH:E?K/#!L<&[BE0!3O^4IYN0W.=O09XYZU_9K$
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M\,<29S_LX[Y#/"GPX_X1C4]#N_[1^T_V9H$6A[/(V>9L9#YN=QQG9]WGKUH
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JMV>IVRP:J;;S[6>S9V7REVG:XE4#<I/53@\\]*ZN@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img224190320_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224190320_1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (< J,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBS_PV9\>?^AGL_\ PG?#7_RFH_X;,^//_0SV?_A.^&O_ )34?ZZ93_SYQ_\
MX)H?_-/]6?E<_P!5<R_Y^8/_ ,&U?_E']6?E?]IJ*_%G_ALSX\_]#/9_^$[X
M:_\ E-1_PV9\>?\ H9[/_P )WPU_\IJ/]=,I_P"?./\ _!-#_P":?ZL_*Y_J
MKF7_ #\P?_@VK_\ */ZL_*_[345^+/\ PV9\>?\ H9[/_P )WPU_\IJ/^&S/
MCS_T,]G_ .$[X:_^4U'^NF4_\^<?_P"":'_S3_5GY7/]5<R_Y^8/_P &U?\
MY1_5GY7_ &FHK\6?^&S/CS_T,]G_ .$[X:_^4U'_  V9\>?^AGL__"=\-?\
MRFH_UTRG_GSC_P#P30_^:?ZL_*Y_JKF7_/S!_P#@VK_\H_JS\K_M-17XL_\
M#9GQY_Z&>S_\)WPU_P#*:C_ALSX\_P#0SV?_ (3OAK_Y34?ZZ93_ ,^<?_X)
MH?\ S3_5GY7/]5<R_P"?F#_\&U?_ )1_5GY7_::BOQ9_X;,^//\ T,]G_P"$
M[X:_^4U'_#9GQY_Z&>S_ /"=\-?_ "FH_P!=,I_Y\X__ ,$T/_FG^K/RN?ZJ
MYE_S\P?_ (-J_P#RC^K/RO\ M-17XL_\-F?'G_H9[/\ \)WPU_\ *:C_ (;,
M^//_ $,]G_X3OAK_ .4U'^NF4_\ /G'_ /@FA_\ -/\ 5GY7/]5<R_Y^8/\
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MG3AB)4I.K%SC[*4I)*+2=^:$+.[Z)^H4445ZIYP4444 %%%% !1110 4444
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M^?[74445\L>X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI/#<V\R[HIX)$EBD7U5T)4^A&<@\$ \5-71OL8!1110 4444 %%%% !1110
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ME(\#?^I/I=?T$5_/O\&_^2O?"K_LI'@;_P!2?2Z_H(K](X'_ -TQW_813_\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 >D?!O_DKWPJ_[*1X&_\
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MWA/X/^/;^\5=OG:AX(\37W@;Q%!O 4!_^$6\/Z,D^&),5XN_ ?G^Y*OY-/\
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M-\3>CQLC#L:S=%Q=Z4W#^Z_>A]SO;KW\K&BJJ5E5BIK^;::^:M?Y_-G :O\
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M^H05/#T%3_NSHHHKY0_L\**** "FLP16<AB%4L0JL[$*"2%1 69CCA5!9CP
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MG,)'WOX?KGK^';^M'M;]G\_1>?\ 5EZBS"]O?=M-.NR[-OMI]Q\&W7@, '$
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MM[1(+>,86.)$ %='I/@7(7]Q@\9PN3V[X_IZCI7LVB>#L[!Y6?0 ?S./7_\
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M %%%% !1110 4444 %%%% 'I'P;_ .2O?"K_ +*1X&_]2?2Z_H(K^??X-_\
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MKI[_ ":[:Z-?/0ZZ>*HJ_LIS3B[<M2SYE=*\91LEM>SBK]'I8^<? /CCXK?
M[Q$?%'PF\:Z_X*U=BGVL:5<XT_58D(*V^MZ-<I/I.M6O;R-1LKE5&3&4;##]
M2?A'_P %?M>TV.UTKX^?"Y=7\L)'-XQ^&LL=A>R8P&N+WPAK5P+&24C+2'3-
M=L(B<^38H"$'PMJ_@Y&=X]J&0+O,9QY@0G:K[,[MI8%0Y&TD%0<@BO/-1\$]
M?W(_%0?3J>P ZXS6EXSWL^G9]/\ +_-Z'D9SPWPWQ+'_ (6,LH5Z_*HPQE/F
MP^-BE;E2Q-%PJ3C'6U.K*I25_@=S^CGP'_P4#_9"^(T4,-K\8-"\-WEPJAM'
M^(EI?>#+F-WZQ23ZW;1Z)*P)P3;:K<1DYVN1@GZ%TZY^$/C6);K0]3^'OB:*
M8;UN-!UG0-2#@\Y$NDWDA.>OWOUK^0^\\"YR/(!]0.GK@@@]<>YYYQTK"_X0
M5K=_,MXWMY >)(!Y3AAT(>,JP.><@Y'7C%.'-!MTZM2F_P"[)KMNXN+_  _R
M?YMF'@=D&+;^J9SBZ$'JJ6/P>%S*,6[:)P>"]U:_$I.V[?7^Q]_AEX,F&5T!
M #R#!<Z@H.?[NRZVXYXP,=ZH3?"'P>_33M1M\\YBOKL?D)O-&/P-?R"PV?C&
MR %GXI\5V8&-JVOB#6[<#'(*B&]3!!Q@C&,#&.*Z#3_&GQIT)U?1OBW\4M+:
M/!0V/C_Q=;;2.F!'JX4\]B-OXBMHXG%JUL97[ZU*C73O)I]>^W=GSM7Z/.#D
MGR9OE4V]5SY%&E?5;SABZC3[-)_AK_6!=?!?P[(#]FU'5[5L<;VM;E0?4JUO
M$Y[<>9^/>N5O_@IJ48+:9K5G==<17D$UHY]!YD1NDS[D*/I7\W?A_P#:^_;'
M\(-&=*^/WC^[BC(*V_B*[L?%EN0N,*\?B>PU5F4C&?G!8=P>*^CO!O\ P5@_
M:@\,/#'XT\.?#CXBV2;1*]QHU[X2U>5!C)6^\/W@TU)&'1GT*10>=F.*WAF.
M80:MB%-=JD82OMHVXWOZ2N?,YE]'7,5%RPD<GQ;M[L<+C<5@ZST5DJ>(I4\*
MF_[U5J[:V/UXU7P%XLT<,]UH]S+"N<W%CB^A '<FV+R(.^9(T]ZY @J2K JR
MDAE((((Z@@\@CN#S7B?PR_X*[_ KQ(]M9?$[P?XU^%=]*5274HHHO&_AB-SP
MSO>:/%::]!",YRWAV8*OWG/6OO\ \)^+_@?\>]).L^!?%/@WQ_:; TM]X9U6
MUFU6QW#@7]O;O#J^FRCH8=4M8&!X:+/%=]+/9Q:6*P^G6=%^GV9-I^=JBL]+
M'Y'Q#X3Y_D7-+$X/'8*"=E/&4/:X24FTE&.8X13PS;OI%<\G='S717N7B#X-
M7,(DN/#E[]K09;[!?E(K@#KMANE"P2D= LT=OV'F,>OC-]I]]IER]GJ-I/97
M,?WX;B-HW [, PPZ'^%T+(W\+$5[>'QF'Q2O1J1DTKN#]VI'U@[.W3F2<6]F
MS\UQN6XW+Y<N*H3IQ;M&HK3I3_PU(WC=[\K:FEO%%.BBBNDX0HHHH **** /
M2/@W_P E>^%7_92/ W_J3Z77]!%?S[_!O_DKWPJ_[*1X&_\ 4GTNOZ"*_2.!
M_P#=,=_V$4__ $VSX7B[_>,'_P!>:G_I:"BBBON#Y$**** "BBB@ JM>V=KJ
M-G=Z??01W5E?6T]G>6LRAX;FUNHG@N()4/#1S0N\<BGAE8CO5FBC;832DG&2
M4HR34HM)IIJS33T::T:>C1_E#_\ !5;X%:QX8^&WQ\^&6IIYOB3X$?$?4XKD
M*-R2W/P^\5WWA?7;J-U# P?V++K%]!*FZ.:-8V5_*D\P?R_U_I*?\%Y?V9;+
MP3^U5XA\3S:7O^'W[4'@:36KJ-(?)L9/$-IIT?@OXC:-&YW":YN85T?Q1J4A
M!'G^,@-H7"U_G2?$WP)JOPQ^('B_P!K2.FH>%-=O])=W4+]KMH92VGZC&!QY
M&IZ>]KJ-L>-UO=1,0"<#ZCB)?6:66YK!7CBL+&G5:VC6IWDXO^]>52&FG[I]
MM?Y!^B[5?"&;^*_@SCI.GC.#N+L5F^44ZLOWN*X?S2-'#T,12B_>E1C3PV78
MV4I)-/.:-W>5H\-117U5^R#^QK\>?VW?BYI'P?\ @'X/NO$NO7CPSZWK$R26
M_A?P9HSS+%+KWBO63&T&G6,66,$ \V^U&5?LVGVUQ,=H^9C&4Y*,4VWT6K^[
MJ?U\VDFWHDFVWLDNK[+N^AY]^S_\!/B=^TM\7/ WP6^$7AK4O%/CCQ]KVFZ%
MI=CIMC=7JV*:A=Q6MQK>JO;12"PT72(I'O=3U"X,<%K;0O(T@X!_UN?V5_V>
M/ W[$?[)'P<_9J\*ZO#:Z?\ ##PEI?AO4-6LU:>7Q-XWU)!=>)-1AC1-\]WK
M>NW%P;65HGD:TBMFE V,1\(?\$O_ /@F1\+/^"6'PS73]+AL_'GQ:\?PVJ?$
M'XLO;00W^HZBBJ[Z#IL1$DVC^%]-D,BV&E+(&F;-[J,L]RP6/[ ^-_Q0U+2(
M;K4/"%_<:#J6H31::-4M@MW-HUQ<(\#:SII<K;:=+9QAY;2:]C2,72B>1961
M ?H\'7PN24YU,56I^WK\M.SDG&$)6=M+\S4N5MK1\O*E=7?B8NAB,TJ4Z=!3
M5"ES3;^S4J*UKW5VDFU&UM7S/0YWXE?$JV^%&M:F_CW7?AY\.OV5OA[X*U#5
M_&OB_P ::UJ%UX^\4_%;5;W=::*D M9O)TR"-TAG\B^N]2UJZEM[6SL4M8\C
M\]I/B&/A#\.=>\0_'7PUXM^*_C#]H3XI17O[/,F@:7IUO=:+J/BW2Y;72M9T
MVV\.^'+W6/!OAWP-X;>&5M6UF74;])-T=G:B[EV)ZCXDU:R?P_JD6A:!X7UK
MPS\+)X/$ND^'O%NJ2:[XK^*_B-D2]U;XL>*]?U07]PEO!J6^:.RMX)-2N7C:
M6.^L[=;:TC^?O$OQ&^(UQX*\7?&*_P#C5I_B'XE:M<Z79OKOB'2H-*^%/P^\
M(7PV1V/PE\+*(]/D\1Z1/-$EUKVIMK&I:C=)&VH:F8HA;I>(S"%3F<'[562O
M%1Y9*3C)N;;33BKJFK6NWKT*P^!E&,;Q4>5Q3O)J7-%K9I)QC)_'O?I8\9T;
MQ'>_!O4_^%)>-?!<&J_M&C3_ !5X)^ _C*[\<^.O%WBGX6_!_P 0V0O=7\:>
M.]<N=/N8],\3>.=2FDLO#VAZ=8G7X[:5UOM6L[5)%C\I^%/P:T>'QAXGT[QI
MIFI>&_\ @H!\8+71M(NO&"^*M>\:6WPG\!>%;L2:'X&F\<R^'Q8V=SXTTR!9
M=3T?1;>WU1(;KRY?$"JL@/OVM_$#]GKX/^%O!_C/XU?M;?#74?'VOZS!IVH_
M%WXM>(['QCXQTR:.U(LHHM&M=2LM7T>STF*4X&GV\VFV<C0RK#*B^6/$_&?_
M  61_P""7_[,6NPRQ>.?$'[2_BR]AN+S7?%OP\\+3>*=<U+5+:,6]G)<^-/%
M^L:!%IEO.F#!::==ZH((4 D2/_5CA?+*:]M*"BKQ;G[-32TY;J+<G.UDW'5]
M5<[DW%>ZIS<HQDTE)KFC:ZYIVNFVVHM+1K8^MOA_^S9XP\77'B674?B9XW\*
M?M%^(?$FA>(_'7C/PE=W-CI]MX#\)2RVWASX61>+;;PZLEIH4"PBZU9[;.LR
MI*BZAK<F$W?>L_@;P'\'_!VH_$'X]?M 0_#[0KV\3Q#XJ\;>/_B?+H<.K:@E
MHMO%I_AS4)]4\/IIVB:;:1$V6FV2',TDER()KN4M7\DGQL_X.D?BF=/\4^&/
MV5/V9?AC\([.]N[P^'_B#XP,GB[QT@G#)'KFH:3#'8^&Y=7(/GI!J,>N6<4F
MQ)C>*@S_ #D_M#_M8_M&_M8>*Y/&_P"T3\8_'GQ9\1$R+:W'BO7+F[T[2892
M&>ST+1(VBT70;'(&VQT>PLK1  $A  IK'87#17LHU*U3?5RA235M=T[]79:J
MVIA+#8C$RO4E&C!-OE<8U)RO9-7M915KI-_+O_5Y_P %"_\ @Y8L_ =UK'P7
M_P"";6G17MMIOVS1=7_:2^(&EC4I[B2.5HY3\+O#=]=7@N[(L'D3Q;XQ^UW&
MH,?-AT.*-DG?^0/XL?%KXC?''Q]XF^*GQ9\9:_X^^(?C#49-4\2>*_$=[)?:
MKJ5Y* N99G(6."*-5AMK6!(K6UA1(;>&*-54><9/J?SI*\W$XNMBI-U9:7O&
M$;QA'9:03LW9.[=VV]7T.RAAJ6'C:G'6R4IR?-.>S;E)]6ULK)*P9)ZFOU\_
MX)4^"I&O_BO\19D*Q06>B>"M-DQD2R7<TFNZVA) "F!;/P^P )W?:26"[%+_
M )!U_5E_P3@^ WAWPAX.^!/PX^(>LVO@/3/&OB;1/$/Q6\2:F9(4\-6'BG4+
M*XU^^NUMX+F8WOAWPE%;:>((89Y9[S2XX(PS2*![7#&&=7,57<6Z>#I3K2Y8
MN7ORBZ=.*2NW)\TIQ25VZ>G9_P O?2\XIAE'A8^&:->C2S3CS.<MR'"*M7I8
M>,,'A\70S',<54JUI0ITL+36'PN"Q5:;4*4<QA*;C%N4?]$[_@E]\,;CX2_L
M&?LW^&KZ P:EJW@=OB!J"NACN!+\3=9U3X@6L5TAPR7-GIGB.PT^2.0++#]C
M6&55DC8#[XK\^=+_ ."E?_!/_1-,T[1M*_:)^']CI>D6%GIFFV4%MXG$-G86
M%O':V=K"&T)B(K>WBCAC!8D(@!)/-7_^'GW[!W_1RG@3_P !_$W_ ,H:\[$8
M/,L1B*]>67X[FKU:E5KZIB-'4FYV_A].:WE;R9^I<+\:^%O#/#7#W#F'\1N!
M)4,@R3*LFHR7%W#ZYZ>68'#X*$]<P3O.-%2;:NVVWK<^]Z*^"/\ AY]^P=_T
M<IX$_P# ?Q-_\H:\9_:$_P""P7[(OPJ^#OCGQS\-/B!I'QK^(>D:1(O@KX9>
M%H-<CU#Q1XEN_P#1M*MKN]O=+L[73-"MKETO-?U-YS+::5;W1LK>\U%[.SN.
M:K@L?1IU*L\OQ_)3A*I+DP.*J3Y81YGRTX4I3G*WPPA&4Y/W8IO0^@I>)GAM
M6J4Z4/$7@/GJ3C"//QCP[3CS3:BN:<\RC"$;M<TYRC&*NY-)-KP#_@MY_P %
M1;3]B7X/2?!SX3:_"O[3OQAT.\AT:>SE22Z^%/@6[\ZPU'XAWF"1::Y>LMUI
MG@2&8*QU*&_U\AX- %K?_@'_ ,$Q?V0+KPAIB?M-?%6PGE\?>,K2>;X>:=K"
M22W_ (>\.:NK-=^+[X7(,R>(O%T,KBR>7_2+/0)FF9A/K4JP?'/PGAOOVK?V
MK?&/[3/[=OC2U@-QK\?B[4]&\0+.!XVUS>%T'PMIVF6B7T6F?#_PK9VEK:OI
MV](1IEEIGA^W62":\FB_H6^'O[3_ .RG:W":QXC^,'A"#[(RKINDO#JNQ7BP
M$N;B*/2C&L4.T"TMA\F5$C*$2-'_  K.<%Q5GF85<WQ?#?$,<+A7*CE. _L?
M,?:0A=/VU2FL.[5JS2G.36EDKN%&DW^UY1XC^$.5X2EDN#\5_#)XG%\M7-LQ
M?'?"T:+:6M&%66:QYJ-)-QA%-.>ONJ=:I%?7OPW^'0@%OXAU^#-PVV;3--E3
M_4 X,=Y=1L.9CPUM P_=#;+(/-*+'^>/_!0+_@H&WPX;5O@5\"=6CF^)$L<E
MAXZ\=6+I-#\/X9XRLVAZ%.I>*;QM+$^V[NQN3PNC87=K9"Z;2_;2_P""DOA_
M2?!8\#?LS^(1XC\8^+;2XAU;XAZ5;W4=CX$T>0O!,-)DOK>W>X\7WXWI93)$
M]OH=N3J#.]\]E&GX0Z5;1B5[B_>>2>:62>>>X,LT\\\KM)+//,Y>2::61FDF
MED9I))&9W9G8D_(5^&N+L75E7K\-<0-[4Z?]C9GRPC?1)?5MEN[ZR=V_/^I_
M"CC7Z.6$I4<VS_QN\&*>'HSYL'EF+\3^!H5\;B(-1>-S&C4SQ2C0C-6HX6I%
M>V<5*I!86,(8F?2=%FN9GN;EYKBXGFDN+B>>1Y[BYN)G:6>XN)I6:6:::5WE
MFFE=Y)969W8NQ->O:)X?)V$IUQA<<#I^9_IZ\UE:1?Z!;E?/O(D(QDLDH(Z]
M@AQV/3/KZCT[2?$_@N#;YVM6L?3.4G[8)Z0GKSQCGVK%\*<56TX9XA?;_A%S
M+R_ZA>OX][G]%UOI*?1[>D?'GP8MT4?%+@:RV[9[M_ETU;Z31= /R'9D\8&.
MF.3_ "],9[5Z_HGA_E,IG..WTZ?ER>IXP>]</I7Q ^'$&WS?$M@F,<F.Y[#N
M?LY[CV[9KTG2?BQ\)[?9YOC'2TQZQWGMU_T4^GTZ<=JPEPGQ6U?_ %8XB?9+
M),SMY?\ ,+MK^?6YY=;Z2'T?G=1\=?!MW6Z\4.!W=_+/=.G7N>IZ#H &PE.!
MCMZ?T]/S/J/2+>!+= B =!D^O_UO\^@'B\?Q[^$%JH6/QCIKYZLD-\?U^S=,
MCZY'/:G?\-#?";_H;;+_ +\7G_QBL7PCQ;+7_5?B+7_J29GM_P"$QYD_I%_1
M_D]?'3P<7E_Q$_@G3;_J>?UKYGSG\?;C4/AK\4/#WQ7T.%FNM"ND;5+:,E!J
MWAZ^ CU?39<'#B6WDD>$MD138F WHN/N;1=8T[Q#I&F:]I%PMWI>LV%KJ>GW
M*'*S6EY"D\#_ .RVQPLB'E) R, RD5\0?'7XD_#OQEIHCTG7+;49FMVB:..&
MXR3\P"D20*.00.IK*_9:^-NC^%?#.L>!/'>I'2;#0K]KOPCJ5\D[0W&EZE))
M+=Z4K11S.K:?>AKB%755,5\Z)@0 5?\ JAQ9*%GPQQ#>&W_")F=W%M:7^K=&
M]NS?8]&M](CZ/5? T*J\>/!CV]!*E*#\4>!E4G3;T:B\]YI<CULE>TI/5(_0
M@'!!'8Y_*O6/"%V&C52Q.1MY]3P/\\YQ]#7R+_POWX1?]#OI7_?%]_\ (E<U
MXN_:*TN?2[?PM\*_$=M<^*_%%V=,36X(KEH?"VF&)I=2UQ_.AB4W<%L&CTY
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M&.G7KK+P!!#C>L:X]@3]>,_J*AMO5N[[LYJN<)[2^[7MTUTLWM?\-/F;0_
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M.,HM.,HM:6>]]58^N?@5_P %6?C5\.Y+/0_C9I$'QA\+QF.%]>@^RZ%\0[&
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MC_#K^E49+0KSS^'/XG(R/RJ'"2W7]>FYT1Q-*5K2WM^G^92HI[H4.#^?^?\
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M[Q-\*=3G$<6K._B7PL)6PK7\$0BUO3H<G'F7%G%;WT4:_>%A=,,L_/U#\;/
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M5JQDW3)Y[XY_:@T'QSJOCGX??#+47N[?P9JEMX>\7>*K5P+2]U2YM7N;O1M
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M(^05X7?_  3_ ';?Z&.1QB, XYZ<#C@9S^F:\JU_X&K)O/V,AN<,(\$9S_$
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M79\)Q<FL1A$TTU1J735FO?71A1117W)\@%%%% !1110 4444 %%%% !1110
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M7W&41'"]\[OQ[5MZ?^UG^T'I+JUYH'@[5D4\^1;ZOI<I )^[)!JBQ*3V/D,
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MXN;>(P=VW:C42N]ESK1!1117W)\@%%%% !1110 4444 %%%% !1110 4444
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MQ]@1GGKW[^];M% TW%W3:?=.QY!JWP[CF#%(D<$'.T#W[=?Y&O,-7^&)._\
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M<T[ON_O9JLVQ7>[TV^7EW2^?J?!,/P"C0C;IT:_2!5Q^2#I^G6MNU^!9&/\
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MTW@?_=,=_P!A%/\ ]-L^!XN_WC!_]>:G_I:"BBBON#Y$**** "BBB@ HHHH
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M06MW?PI\*3>7=Q^#--^RW/Q"U*V;#@:I+<"XTCP?'(AP4NX]4UB,$K/IMA*
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MFV2M-,_WYI7_ -^1VS]=Q.:B(!Z@'ZT459D]=]?4, = !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &IIFM:MHLHFTK4;NQ?.2+>9EC?\
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M# 50,        # &*6BBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O=OA=X
MNANHG\&:\(;JTNH)[;3UO$2>WN()XWCNM%NHI@T<]O<0O(L,4@:-T:6U92KQ
M)7A-/CDDAD26)VCEB=9(Y$8J\<B,&1T8<JR, RL.00"*YL7A:>+HRHS6ZO"7
M6$U\,E\]&NL6UU.[+L?6RW%T\51;O%\M2%[*I2;3E!OI>R<96?+.,96=K'X\
M_ML?LSW'[*WQ>CU+PO:SI\'OB+=7FI^"IAO>'PUJB,)]8\#W$Q)*_P!F&47>
MAM*V^ZT*6*,&6XTZ]8<_\.?%Q_<?O?[O4_@?H>/7H!7[\_$[X;>&/VL_@1XD
M^&WB=H;;4[JW1M/U8QJ]QX:\9:=')-X>\3VJ_?6/S\K>11D?:M.N-4TXG9*:
M_F6T^T\2_#CQEX@\ ^,+.72O%'A#6[WP_KFGRY_<:AIT[6\C1L<>;:W 59[2
MX7Y+JTFM[B/,<JD_$U:<Z<IT:D>6K2ERR732R4K]5):WZIIK<_T(\,^,:7&?
M#L(5ZJJYIEU*E&M.3_>8S"27+A\7+6[K1<70QEW)QQ$%4FTZ\8K]3/#&KIJ5
MC&"X:1%'?DC\?2NGKYH^&?B;=Y"E\AL#!/;GMGOW]>:^E48.JNIRK $'V-<$
MH\K[+I^OW'U%>G[.;71[?\#R_KUJZC#]HL;J+&=\+C'N!D?RKX3\S_A&?VDO
MA=J7,<.LS^(?"=RV, C4].E>S1CC_G[6,J.Y Q7WN0""#T((/T-? ?[0Z/X<
MU[PEXIC&P^&?'GAK5V<94K!'J*1SY('W623:W8CKBG3UDE_,G'_P)-+\;'9E
MSYIUJ/\ S^HU(+UE%Q_.VO>VQ]]2<(Y]$;^1KY^\=R8\[G^]CV&",]/T/TKZ
M!E96CD9.49&9#V*LI*D>Q!!%?.?CUL"?URP_ <?X40W^7ZHYL+K52]-/+F5[
M_P!=SXZ\>3G]]SW]/8GL<?U_&OTB_P"".'A@3:I^T#X[DCRR+X(\&VDVT$ 2
M/K>NZ@BMVSMTMG48/"9S7YE>/Y"/.)]7Z?0^_3VK]GO^"1>F)IW[-_Q"\0[0
M)-8^+/B%V?'+0Z%X6\-6T8)[[)'G[X!<X&2U==O<=NJ@OFW'_+S9X/B?B?JO
M F9)-IXS$9?A;K3W?K=+$37SAAI+T;O=:/Z&\3WG]H>(]<O,Y$^J7K*?]A9W
MCC ]A&B@>P%85.=S([R$Y,CLY/J78L3^).:;7Z!"*A"$%M&,8KTBDE^1_F_5
MFZM2I5E\52<YR]9R<G^+"BBBJ(/2/@W_ ,E>^%7_ &4CP-_ZD^EU_017\^_P
M;_Y*]\*O^RD>!O\ U)]+K^@BOTC@?_=,=_V$4_\ TVSX7B[_ 'C!_P#7FI_Z
M6@HHHK[@^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>
MHZA9:38W>IZC<1VEC8V\MU=7$K;8XH85+NQ/4G PJ@%G8A$!9@#^;OCGQ1KG
MQH\>V]EID,CV[W)TW0-/5B1#:^829I",QK+,%-S>3 &- "'E:TM8I(_2?VB?
MBH=7O6\"^'[E7TZRGQK-Q"V1>ZC$^!:JX(0V]C(&5@=PDO%:3""UMII/6/@!
M\+!X1T=?$VLP*/$&LVZM;QR1XDTS390K*A#C<EU=C;)+D*\-N8X"L4KWB. >
MJ?#SP-IWP_\ #=KHED(Y+@@3ZI>HFQKZ_9%627GY_)C $-LCDLL*!G+3/+(_
M<T44 %%%% '\,7[8W@ZW_9Y_X+\ZDVAI]AT3XU:EI?B>6WC011S/\6?AS+'X
MC=E3 D^U_$"QU/4V8Y+7#!R0PP/U-K\\/^"KEY#XH_X+Q? K2=,(DNO"?AOX
M,V>JK&-S136-EXL\;S>: 3AAHVK6DA)QB)HSC&"?T/K^?\1"%+..(*5-6I1S
MK&N*7PQ<I\TXQ711DVDEMMT/VV,YU,LR&K4;=2>2X)2;WDH1<82;ZN44G?J%
M%%%!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444Y$:1@D:L[
MM]U$4L[>P506)]@#0 VBNGL?!?BO4@K6F@ZBR-TDF@-K%CU\RZ,*$>X)KKK/
MX/>++C!N&TRP4_\ /:[::0?\ M89ES_VT ]ZYJF,PE*_/B*,6MU[2+E_X"FY
M?@=U'+,QQ%G1P6)G%[3]C.,'?K[22C"VN_,>545[U;?!&3@WOB%!ZK::>S8]
M</-<I^&8_J*Z"U^"GA]<>=?:U=GN$-M I^@2VE8?]]Y]ZY)9Q@(WM5E-KI&G
M4U]'*,5^)Z%/AK.)VYL/"DGUJ5Z/XJ$YR_#]#YEHKZEF^'OPWT1/-U5K>U11
MEI-9U[[%'@'DL9+FS0#L3P /3.:XO5/B!^RUX4+#6_B)\&=+>,D.NI^//#$D
MRD=0T4^L33;NV-F2>.36$L]POV:6(E_V[!+S^VWIIT/4PW V=8II4HTZC=O=
MH0Q6(G=VTM3P]F]?YM3PXD#J0/K3E1W^XC/_ +JEOY UU^H?ME?L2^'=RO\
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M'^=*5DEV5@HHHH ](^#?_)7OA5_V4CP-_P"I/I=?T$5_/O\ !O\ Y*]\*O\
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M++P5X9TOP[8_,EC#FXF^;_2;V8F6[N &)*K).SF*/)\N(1QY.S)ZJ@ HHHH
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MX#SS2[H_4,0M+_PLRP:;M_@<KZ[-[*Y^@VK0FVU74[<C'D:C?0X]!'=2H/T
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MM8E,MR2PQ%^=W[1O_!1[5-2U#4/AY^RO#;WSPR26&J?&+4+-;S3HY%8Q2Q^
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MEFQWR0*^HYOBEXVFSC5D@SG_ %%A8IC/8%K=V'_?1/O6=)X_\9R_>\1:B/\
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MCMUJ'"2W7S6M_3N?6SP]2,8U$E4ISBI0J4VIPG%V<91E&ZE%IIJ46XN^C9Z
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MH'R2Q1VU]$3EDNCT !Z/#^TY\.I)?+:W\0PKG'G26FF&,<XR=FKN^._RHQ]
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M652.Q!##OZ5;?N4WVE-?=RO?_MX[L0[X?+Y]E4I_*$H26O\ V^SXG^(,',_
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MD6V-8I"DJ 'O_P"T7\6#:I-X!T"<&65,>(;R*3[BGII2%.N1\U_\P4G9:-O
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M5:HU3;7O1]G"46KM/ZF)))).2223ZD\DTE%%?-'L!1110 4444 %+D^II**
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MT^\\!7T4X:W75;G7I;FWBT^R",)KB+5K:POXH@R26#38C?\ 3K7=%;P+\%/
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MO)\S^2TC]\6UW*UE:K96EM9K+<3K;0I")[N4SW,VP8,D\S &25SRS$#)Z
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MB;H/A6Q73[3XK^$-*B-YKNOG3M.2*.+XB>%[.&374UBSB2]\2:;9W]CJ O\
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MBBBNLX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>5DCD!22-@D\+C"259N-%T:ZE:>ZTG3+F9SEYKBPM9I7. ,M))$SL< #))X
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M^?FBOZ!O^%,?![_HE'PU_P#"%\+_ /RKH_X4Q\'O^B4?#7_PA?"__P JZ/\
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MC_A3'P>_Z)1\-?\ PA?"_P#\JZ/]1\7_ -!V'_\ !=3_ ##_ %MPW_0)7_\
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M?%_]!V'_ /!=3_,/];<-_P! E?\ \#I_UW_IZ?S\T5_0-_PICX/?]$H^&O\
MX0OA?_Y5T?\ "F/@]_T2CX:_^$+X7_\ E71_J/B_^@[#_P#@NI_F'^MN&_Z!
M*_\ X'3_ *[_ -/3\3?@_>&W\6&V)PE_IMW"1ZO"8KI/Q ADQ]37Y5_MR0:C
MX%_;)U_6=!T75]7OO&?P^\$^);>QT/2K[5KN6]MK>^\+W5Q]ETZWN9L(/#\+
M/(8PI?:"V217]AUK\(_A18SI<V7PQ^'MG<Q[O+N+7P7X;MYX]RE&V2Q::DB[
MD9E;:PRK%3D$BM-/A]X!CN'NX_!'A!+J2)+>2Y3PUHJW$D$32/'"\RV0D:*-
MY972-F*(TDC*H+L3XN/\,L;B\1[:&982"=.,)*5*M=RC)^]=/^6R^7S7ZEX<
M^.F%X"Q%;$3R'%9G[7#XK#.A'&TL-"5/$RPM5*<W1K.U.MA^>RA[U[*46VU_
M#;HG[0.H:=JBZ7XCMM1TB_R&DTW7;"\TN]"]-S6FH0V]PJY_B\L ]FQ7U%X8
M\9Z1XFMTDM9XQ,R@F+>#N.,_(<\\=NOIFOZQ?&'P"^!7Q"AMK;Q]\%?A+XXM
M[*43V=OXP^''@[Q+#:3@%1-;1:UHU['!*%) DB5' )&[!KG[+]E;]F#3,?V=
M^S?\!=/VXV_8O@_\/;3;CICR/#L>,=L5Y\O";'/;-<'%_P#7FO;\S]B_XF[X
M;JTHNKP5G%#$:\ZHYG@JU+I9QE.C1D[KHX7B].:6Z_F)HK^I+_AGSX"#I\$/
MA#_X;7P9_P#*6C_AGWX"?]$0^$/_ (;7P9_\I:C_ (A)F/\ T-\%_P""*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img224190320_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224190320_2.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $7 OX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT#_$/_@)IO\ \MJ^6J*/[-PO:?\ X&_\@^OXCO#_ ,!7]?\ #ORM]2_\+O\
M"G_0/\0_^ FF_P#RVH_X7?X4_P"@?XA_\!--_P#EM7RU11_9N%[3_P# W_D'
MU_$=X?\ @*_K_AWY6^I?^%W^%/\ H'^(?_ 33?\ Y;4?\+O\*?\ 0/\ $/\
MX":;_P#+:OEJBC^S<+VG_P"!O_(/K^([P_\  5_7_#ORM]2_\+O\*?\ 0/\
M$/\ X":;_P#+:C_A=_A3_H'^(?\ P$TW_P"6U?+5%']FX7M/_P #?^0?7\1W
MA_X"OZ_X=^5OJ7_A=_A3_H'^(?\ P$TW_P"6U'_"[_"G_0/\0_\ @)IO_P M
MJ^6J*/[-PO:?_@;_ ,@^OXCO#_P%?U_P[\K?4O\ PN_PI_T#_$/_ (":;_\
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M=X?^ K^O^'?E;ZE_X7?X4_Z!_B'_ ,!--_\ EM1_PN_PI_T#_$/_ (":;_\
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M_ 33?_EM1_PN_P *?] _Q#_X":;_ /+:OEJBC^S<+VG_ .!O_(/K^([P_P#
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M\*?] _Q#_P" FF__ "VH_P"%W^%/^@?XA_\  33?_EM7RU11_9N%[3_\#?\
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MPG^VU75@O]ZH_P")_P#I,CDQW^ZU/6E_Z=@.HHHKZ8\(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /SY_P""A_B3P[X/\*?LP>*?%NO:+X6\,>'_ -MK]G75M>\1^(]4
ML=$T'1-*LM6UN>]U/5]7U.>UT_3=/M(4>:ZO;VXAMK>)6DED1%)'&?$;XM?#
MO]HC]HW]FS5/V??%&F?''1OV>K?XY_%KXL>+O@AK>C^.;#PQHOB/X(^.?A?X
M1\#67BS0KRZ\,R_$OQYXH\3Q:CX8\#KKHUN2R\'7OB#4=.M=*M['47_3FBJY
ME9*VJOK?37RMVOU_X.,J4I2D^=*,I4Y-<K<DZ;C)6ES6LW%7O%Z75^J_F5^$
M'B_X8W7[2/\ P3^^(GPHTW]E7X?7?CGXFWMGXN\$? C_ (2WXD_&SP=I/Q$^
M!GBB_P#^$4_; _:FU37-$U#QG\3/%/B^UUJ_'PW^)/PWT;Q>OB3PWJS6WB/Q
MQ<>#/$VL7>M^SE\&U_: \ _#3X0I<_8-4\8_\$L?%\7A?5,QJVA^.=&_:IA\
M1> ?$,<DD<@BE\/>-=(T#6X9D"3P2V"2VTUO<)%/'_2I6#XHT?4-?\/ZMHVE
M>*=>\$:CJ-G);6?BWPO;^&+OQ!H$SD;=1TFV\:>'/%_A6:\BP1&FN^&=:T\A
MCYMC*=I6N?LK/:]]M[=-;7]3!82WQ34E[S<8PY$U)4DTESVC?V72T5S:)):_
MFS_P3V\::[^TYXD^*O[8_C+0Y=#U76_#_P -?V>O"VC7BWD=QX>B^%GAZ+7O
MC-%9PS)%:)9ZE\=?&'B[0VFM%E%Y#X!TZ83-$L328'QU7]ERW_:<\6^)_%'[
M2?Q>_8 ^.F@VGA9[_P <3?%#P%\*?AC^T[X?M_#,EIX1UL>'_BS'XW^#_P :
M]+^&K:IK/AFZM;KPWIWC+PMJLD]KK]I'ILO@_46_1KX0?"KPM\$OAOX5^%_@
MTZE+H/A2RG@CO];NX[_7=<U34K^[UKQ#XF\07T-O9V]WX@\4^(=2U7Q%KUS:
M65A93:OJE[)96%C:M#:0^DU/-JVKVM9*_16WTL]M;K?7?4U5%NE",G%S4N><
MG%OWW=MQ<91E%IRM&2E=15MG8_ #Q=\7)/'W@W]G/0OVOM)_9KU/Q/=Z!\;]
M6\-?M,?MHZ=?^%/V:/%/@KP)\6_#W@[0/B9X5_9<N[WP[X7^('QP^,WPLU&Q
M\8:%X0UOQ?\ #/4O!WAZZG\5^!-67PWXAUWP=<?.OP;U2ZO/A)\!-(N9CM\'
M>!?^"RO@^QTUM"UWPB?#^E:1#H;Z5X=C\$>)]1U7Q!X#M-'L+JWM--\$:O>2
MZAX5TQ++1KIY9[1YYOZB:*:G;IUOOMOMIV>JVZV,WA9.2;JW]V,;N'O/EE1E
M>4N?WFW2WDG+WM9-12/Y^?@G\$_A/\9?&7Q#A^*_@#PQ\1+'P[_P2Z_8KN-#
MTKQCI%GK^D:3JNH> OBPI\1Z;INI17%I8>+-.ALC;Z%XJLHH/$.@6U_J\&CZ
MC91ZOJ*W'DGAB^M_BAIGP4UW]L+XJ?LP^&O!NN?L*?L[77P:UK]M[X2:W\6_
M 7BF\N/#-S;?'?5OAKX@O/VA/@WX9T7XVR:^G@V^\?W5P=:^+.KZ+J'@J_\
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MFV\22Z=X*N-2U6SO-,L(/$ESIDMYJ%K<V5NLES!+&FM\)_VEOV<OCW=ZU8?
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MW_!/3_UOS]F>OLBOC?\ ;L_Y(?X/_P"SOO\ @GI_ZWY^S/6E'^+2_P"OD/\
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MOV-/_HQ:K^S\;_T#U/N7^9S?ZZ\(_P#12Y)_X<L+_P#+#]8**_)__A[!X?\
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M^-]0\5V^@1Z[>>+[6T\4^)[6V\2W-_)K,%OXCUZ&*]6/5]06X^$/^'L'A_\
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M?,<<DDD_Q-TX^(OA1ID4(E17.L>.M.9V\TP),EM=/ >RJ=$I>4)0F_NA*3_
M/K%)?%)TUWJPG27I>K&"OV5]3]):^._^"B'_ "C_ /VY_P#LSO\ ::_]4KXV
MKZYT_4+#5K"RU32[VTU+3-2M+>_T[4=/N8;RPO[&\A2XM+VRN[=Y+>ZM+J"2
M.>WN8))(9X722)V1E8_(W_!1#_E'_P#MS_\ 9G?[37_JE?&U%+^+2_Z^0_\
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M'ZGXOU+XD6VKQ:9J'B2\TK4+?PU>^&;+2YM-A\2ZWKUW;00F\OXK@_;IGGU
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MJ7E8I72<)MN_+R)--/VKC&W,I<SC2E)^[RIZ<QTU.%JRI2KPQV!ITZ2C&O\
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MK4Y07NN<H2BHMU'/^IJ'_51?]<T_]!%?DIXE^)_[0'[.7[6G[5GB7PU^PO\
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M,?\ "O?%OBB&X;0M \=0Z=:W.KM!=0P7$]M;,UMA%]M_;L_Y(?X/_P"SOO\
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M^U%_T>%\ _\ Q"SXA_\ T<=:_P!JX#_G_P#^4JW_ ,K/&_XA%QO_ - &$_\
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MRG-RG)R=Y-**7R717UI_P[)_:B_Z/"^ ?_B%GQ#_ /HXZ/\ AV3^U%_T>%\
M_P#Q"SXA_P#T<=5_:N _Y_\ _E*M_P#*S#_B$7&__0!A/_#C@_\ Y;_5GY7^
M2Z*^M/\ AV3^U%_T>%\ _P#Q"SXA_P#T<='_  [)_:B_Z/"^ ?\ XA9\0_\
MZ..C^U<!_P __P#RE6_^5A_Q"+C?_H PG_AQP?\ \M_JS\K_ "717UI_P[)_
M:B_Z/"^ ?_B%GQ#_ /HXZ/\ AV3^U%_T>%\ _P#Q"SXA_P#T<=']JX#_ )__
M /E*M_\ *P_XA%QO_P! &$_\..#_ /EO]6?E?Y+KZT_X)D O^T_^V'*H+1)\
M"_V,[1I "8UNH?'G[:UU+;%P-HGBMKZRN)(<^8D-Y:RLH2>)F4?\$Q_VGG(6
M7]L3X%I$Q E:T_8Q\>0W:QD@.;:6Z_;8O[:*XVY\F2XL;R!)-K2VLZ!HG_0'
M]D_]D_PC^RIX2\2:9I?B/7OB!XZ^(&OQ^*_B7\2_%46GP:WXJUN#3[?3-/L+
M#3],@ALO#7@GPU8P-9>#O!UD]S;:%;7-]<7%_JVN:KK6M:GQ9AF&%K86I1I5
M'4G4<%I"<5%1G&;;<XQW4;*UW=]C[SPZ\.N(\@XCI9MFU+#8;#8?#8F$8PQ-
M+$5*U2O3=*,8QHN2C&*DY2E-K91BG>Z^JJ_F%_:AN3J?[=G[9M[,B>?HOC?X
M->"8)=J^:VEZ;^S%\%O&MO$9,;C#'J7Q$UF2*(L5CEGN)%53,Y;^GJOY?/VC
M_P#D^#]N?_LM?PJ_]8N_94KP(?#6_P"O:_\ 3M(_>JOQX?\ Z_2_]1ZYYU11
M169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7@OQTN3IFD:O>PHGG:S^SO^WUX)GDV
MCS1IFI_\$^OVG_&EQ$).&$,FH_#S1Y)8LE9)8+>1E+0HR>]5\^?M#?\ (N+_
M -DL_;H_]=C_ +<-=&%_WBG_ -O_ /I$CCS#_=*W_</_ -.P/[1X?]5%_P!<
MT_\ 017XK^/_ (YZ'X<_:]_:W\*^-_V"_C=^V!::!XF^#T?ACQ/\)?@1\!?B
M)I_@S3]2^!'P_P!6O_#&MZ[\0O'G@7Q"=3N=6O+O6H8)(=8MHK*^@CMK^&.,
M6-M^U$/^JB_ZYI_Z"*_)/X\?M+>+OV=_&O[>_P 6_AI\/OAC)X;^#7@CX;'Q
MK9ZV_C.[^)7QP_:>\=>!_!VB_!73=.NX?$=CX3\)?#W2M%UGX=>#M3C@T34M
M=\5:KJ%[]CO/#\NBO<:V\-=RFE'G;@DES.-FZM)+WDU)-NT5;K)7]V[2Q;2I
MTI.;A&,^>34%4;C&A6E+W91E%I).;YND7:\N6+^N/V8_VA)OC ^O^&HOV1?V
MF/V7])\)65G>:?\ \+S^'WPU\"^'M>;5KV^:YLO"4/P_^)OCU9KVSG1[[5HK
MRSTJ,"_AGBFNI99Q%G_MV?\ )#_!_P#V=]_P3T_];\_9GK#_ &:_B)^T/IGQ
M<\=?L[?M-^,/AC\2?'6A_"3X7_&[1?'/PG\ :U\-M$BTGX@^(_B+X.UOP3JO
MAO7/&_CBYGF\,Z_\/7N/#_BN*_T__A*M(U>7[;H&B7VC317>Y^W9_P D/\'_
M /9WW_!/3_UOS]F>DDEB*:2BESTFN5RE%IN+NG.TG>]]4FMN@W)RP59MR;5*
MO%\\80G%Q4XN,HTVX+EM9<K::L[L^R****YSL"OC?]NO_DB?@C_L\C_@G3_Z
M\%_9BK[(KXW_ &Z_^2)^"/\ L\C_ ()T_P#KP7]F*M*/\6E_U\A_Z4C'$?[O
M7_Z\U?\ TB1]D5^,>JP_"KQ-KWB+Q3XX_9G_ &6_B!XG\3_\%*;W]F;4_$?C
M3X#> ]8UZ7X?7GEC^T9]7&FVVH:IXQMQ'B+7]<N-567>WVZQN]L7E_LY7X(>
M._V9/V&_BWX\\:_$KXG?LX>,-4\8>-/^"A%_^SSJ-]X:_:H_:<\%Z;/XJN5A
M6+XL_P#",^%OB?HWA?2M5Q&WGZ/X>T;28]V&M]0B9I"^V%<4Y\WM+6CK347+
MXMM:E/1^3>J6G588WF:I\BI2=Y-QK2E&-K+5<M&M=K9)Q6DGKT?Z'?LTZ5X5
M\$_M#?M>?"SP!X ^&OPY\"^"+CX#WFAZ'\.?AWX,\!0O=^+/A]J>K:U=:Q+X
M3T72)]>N);R)3:SZS)>RZ? 7MK%H+=WC.S^T[_R6S_@G3_V>1XW_ /7?7[==
M>;_L8?"+X+? #XS_ +6_P;^"OP[O?!NC^%]1^"&JZMKFM?%#XN?%+Q#XOOO%
M/@+4M2ADU34_BUXX\;WNG0Z%$CV&G6>BW5C9R02O+<V\MP%D'I'[3O\ R6S_
M ()T_P#9Y'C?_P!=]?MUT2M[9VNU[#1R24G_ +)\32E))R^)^\WKJ[W"-UAX
MIJ*:Q44XP;<(VQR7+%N%-M1^%/DBM-%:Q]D4445RG:%%%% !7QOXW_Y2"_LQ
M?]F;_MU_^KL_X)TU]D5\;^-_^4@O[,7_ &9O^W7_ .KL_P""=-:4OB?_ %[K
M?^FIF-?X(_\ 7[#_ /J12/ISQ]%H4W@7QI#XIUBX\/>&9?"7B.+Q'K]IJ,FD
M7>AZ%)H]XNKZQ;:M%^]TNXTS3S<7L.HQ_O+*2!;E/FB%?@]X-_8.^(WPJ\)?
M";XC_L,^+?V;OVK_ (+6/Q6\ ?'S3[[Q'HG@SX;_ +0OQ-L?"5]J$D%H?VKO
MAGHM[X)^,$FJ6M_LFO?B5X#T;4VU'2(9K[QN;G[1 W[?_&WPUK'C/X,_%SP?
MX>MDO-?\5_#'Q]X:T.TDG@M4NM8UWPKJVEZ9;/=74D5M;)/>W4$33W$L4$(8
MR2R)&K,/S?\ !W[&_P :/V2O!O@3XE?L7PZ+I7BJ+P7X-E_:"_8U\3>((=+^
M"7QF\3V/AS2K;QCKGPZU^!;_ $WX'_&Z_O[>]D3QGI%O>?#GQSJP@?QWH0:[
MNO%D.^'J<D))5(QE*:7LZB3IRLM.:6DJ>]E--)/24HQ;DN;%T_:5*<G1G.-.
M$FZM*4E6I\THZPA9TZMDKRIR4I-:PC.7N2_0SX ?%ZW^/7P>\#_%JV\-ZCX/
M'C#3KNXN/"VJZGH6M:AH&HZ9JVH:'JNEW&K^&-0U70-3^R:GI=W%%?:5J%S:
M74(CF1D+M$GC/@C_ )2"_M._]F;_ +"G_J[/^"BU2?L ^&_&/A/]D/X,Z)X_
M\'Z[\/\ QA#IOB>_USP7XFBMX/$'ANXUOQUXHUN#3-6BM+B[M%O8+/4;<RFU
MNKBW8L'@GEB97:/P1_RD%_:=_P"S-_V%/_5V?\%%JS:498F,;<L5)1L[JRKT
MTK.[NK=;N_<U4I2C@92OS2E&4KKE?,\+6;NK*SN]596VLC[(HHHK Z@HHHH
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M_P"$0^R_;?\ A*O^$5UW_A&_L?F>3]K_ +<^P?V9]E\[]U]H^U>5YGR;]W%
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M>;T1,++"TTM&L134E:,4IK&Q4XQ47)*$9\R@E*5H**;;NS[(HHHKE.X****
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MJRQPR1R,K#^;K7? ?[7W[#?C?5/VD/VEOVO_ /@F?XE^.OC!M0TSP_\ %?\
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M'A#_ ,1&UG_Z+"C_ (AQ_'O_ $?1X0_\1&UG_P"BPK^I.BC_ %DSO_H85/\
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M_P# LP_^;?+\^[/Y;/\ B''\>_\ 1]'A#_Q$;6?_ *+"C_B''\>_]'T>$/\
MQ$;6?_HL*_J3HH_UDSO_ *&%3_P70_\ E0?\2T>!/_1M<@_\"S#_ .;?+\^[
M/Y;/^(<?Q[_T?1X0_P#$1M9_^BPH_P"(<?Q[_P!'T>$/_$1M9_\ HL*_J3HH
M_P!9,[_Z&%3_ ,%T/_E0?\2T>!/_ $;7(/\ P+,/_FWR_/NS^6S_ (AQ_'O_
M $?1X0_\1&UG_P"BPH_XAQ_'O_1]'A#_ ,1&UG_Z+"OZDZ*/]9,[_P"AA4_\
M%T/_ )4'_$M'@3_T;7(/_ LP_P#FWR_/NS^6S_B''\>_]'T>$/\ Q$;6?_HL
M*/\ B''\>_\ 1]'A#_Q$;6?_ *+"OZDZ*/\ 63._^AA4_P#!=#_Y4'_$M'@3
M_P!&UR#_ ,"S#_YM\OS[L_EL_P"(<?Q[_P!'T>$/_$1M9_\ HL*/^(<?Q[_T
M?1X0_P#$1M9_^BPK^I.BC_63._\ H85/_!=#_P"5!_Q+1X$_]&UR#_P+,/\
MYM\OS[L_EL_XAQ_'O_1]'A#_ ,1&UG_Z+"C_ (AQ_'O_ $?1X0_\1&UG_P"B
MPK^I.BC_ %DSO_H85/\ P70_^5!_Q+1X$_\ 1M<@_P# LP_^;?+\^[/Y;/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_UWU^W76E+XG_U[K?\ IJ9C7^"/_7[#_P#J12/LBBBBLS8**** "OC?QO\
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MC6?VR/\ P6?LL_\ T5E'U>KVC_X,I_\ R8?6:7:K_P"$]?\ ^5'[@45^'_\
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M4?N!17X?_P##]OX#?]&L_MD?^"S]EG_Z*RC_ (?M_ ;_ *-9_;(_\%G[+/\
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M=_%M-.3Q7XJ_X6/XFU2\T2?3-5U_4-%U2&\33]$TZS.E[4%4NM5T3W\HM_\
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M^$5_X6W\,/!/Q'_X1K^WO[-_MS_A'_\ A,=#UG^QO[9_L;1_[5_L[[-_:/\
M96F_;/.^PVOE73DHRO*]G&<79)M<T)1O9M)V;ONC*M&4X6AR\RG2FE)N*?LZ
ML)M-J,FKJ+5^5ZO8]DHKXW_X=U?\$^O^C%/V-_\ Q&+X)_\ S$4?\.ZO^"?7
M_1BG[&__ (C%\$__ )B*=J7\]3_P5'_Y<+FQ'_/JC_X/G_\ ,Y]D5\;^"/\
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MXM;B*.>"1)45A^RG_#BGXQ_]'M?#/_Q#SQ3_ /1AT?\ #BGXQ_\ 1[7PS_\
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M[7PS_P#$//%/_P!&'1_PXI^,?_1[7PS_ /$//%/_ -&'2YJ/_/VG_P" 5?\
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ML_\ H'K?^!8?_P"7GP517WK_ ,.GOVD?^CR?@A_XACX\_P#HVJ/^'3W[2/\
MT>3\$/\ Q#'QY_\ 1M4<D?\ G]3^ZK_\J#VL_P#H'K?^!8?_ .7GP517WK_P
MZ>_:1_Z/)^"'_B&/CS_Z-JC_ (=/?M(_]'D_!#_Q#'QY_P#1M4<D?^?U/[JO
M_P J#VL_^@>M_P"!8?\ ^7GP517WK_PZ>_:1_P"CR?@A_P"(8^//_HVJ/^'3
MW[2/_1Y/P0_\0Q\>?_1M4<D?^?U/[JO_ ,J#VL_^@>M_X%A__EY\%45]Z_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img224190320_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224190320_3.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" P %Y,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M :U)3J-HH 6BBB@ HHHH **** "BBB@ HHHH **** "D;I0U-H *<O2C:*6@
M I&I#UH% "4^DVBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I*6B@!E.6C:** %HHHH **** "BFGK0* '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4RGTFT4 (M.I*6@ H
MHHH **** "BD:FYH ?124M !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %,I])M% "+3J2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HIM*M "TE(U-W<T +12CFEVB@!%IU)BEH **** "BBB@ HHHH 9
M2K2X%(>* '44W-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***;0 ZD:D6EH ;3J-HI: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI
MIZT .HIHZTZ@ HHHH **** "BBB@ HHHH **** "BBFGK0 ZBFK2T +13<FE
M% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 2DW4K=*;0 ^BDI: "BBB@ HHHH **
M2C- "T444 %%%% !1110 44F110 $9I-M.HH **** &D4 4ZB@ HHI,B@!:*
M** "BBB@ HHHH **** "F[J=3* '"@T+0U ";J=3*?0 4444 %%%% !1110
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M %%%% !1110 W=2@YIM.6@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!NVE%+24 #>M,QS3STIM #EI:2EH ****0!1113
M **** "BBB@ I"*6B@!N,4;J5J;0 ^BDI: "BDHR* %HHHH **** "BBDS0
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M "BBB@ HHHH **** "BBB@ HHHH 3=0#FDI5H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
MW4M-H 4'-+2+2T %%%% !129HR* %HI,TM !1110 A.*3=2M3: 'TW;3J* $
M%!I:* &[:6EHH **** $-)MIU% !2$4M% " 8I:** "BBB@ HHI* %HI,BEH
M **** "BBB@ HHHH 0C-)MIU% !1110 4444 %%%% !1110 4444 %)NI:;0
M H-+35IU !1110 4444 (:3;3J* &[J4'--YI5H =244M #=M**6B@!":-U(
MU% #J*** "D)Q2TC4 )NIU,I] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (W2FT^DH *6BB@ HHHH **** &M
M0O6EHH 6F_Q4ZB@ I#TI:* $6EHHH 93EHI: "BBB@ HHHH **** $IM/I*
M!>E+110 4444 %%%% !1110 4444 %%%% !1128]Z %HI-M&,4 +1110 444
M4 %%%% !1110 4444 %%%% !24M1F@!^:6HP:?0 M%%% !1110 4444 %%%%
M "-TIM/I* !>E+110 4E+10 RG+THI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBF4 /I&I%IU #*=12T %%%% !1112 **** "BBBF 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2-2TAH ;3J3;3J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *:U)2K0 E%.HH *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M :U)3Z2@!:*** "BBB@!*;3Z3;0 +TI:2EH *2AJ;0 4Y:*6@ HHHH ****
M"BBB@ HHHH ***3% "T4FVEH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHI#S0 M%)MI: "BBB@ HHHH 92K2TM !1110 4444 %%%% !111
M0 44VA: '4444 %%%% !1110 4444 %%)BC% "T444 %%%% !1110 4444 %
M%%% !3*?24 (M.HHH **** "BBB@ HHHH **** "BBB@ HHHH ***1J %HIF
M:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%)CWHH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD;I3:
M 'T4B]*6@ HHHH **** "BBB@ HHHH :W6DIU% "+UIU)2T %%%% !12-24
M.HHIE #Z*:M.H **** "BH9+R*'[S8JLVM6J]9* +]%9W]O6G_/2I(]6MI.C
MT"+M%,CF23[K9I] PHHHH **** "D:D;K0.M "4^DI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BDHH 6BBB@ HI&Z4V@!]%,IPZ4 +1110 4444 %%%%
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M'_?7\Q7R$?VB#_SW_6C_ (:(/_/?]: /KWSH_P"^OYBCSD_OK^=?(8_:(/\
MSW_6KUC^T#YS &?]: /J_>I_B'YTM>#^'_B\E\R@S=?>O3M!\3)J"J=^<^]
MSJZ*:C!U!%.H$%-VTZB@!NW\*=110 4FX#J:K7UVMK$23BO/O$OCY-.W?O,8
M]Z /2?,0?Q+^=)YT?]]?S%?-&M?'(6C,!/C\:YJ;]HDK)CS_ -: /KSSD/\
M&OYT[<#W'YU\KZ3\?/M+ &?]:]$\.?%!-0V_O<Y]Z!GLM%8FCZTEZBG=G-;7
M6@0M%%(#F@!:**@NKI;:(LQQ0!-N ZG%)O7U'YUYSXF\?1Z:S#S0/QKG]/\
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MPS\1$U';^]SGWKT73=02[C!#9H OT444 %%%% !1110 4444 %%%% !1110
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M7PS\24U+;F7.?>O2M+U%;R,$-F@#0I",TM% #=M.HHH **** "BBB@ HHHH
M**** "BBB@ HHHH *2EJGJ5Q]GA+4 6]P]1^=&X>HKS?6/&GV.0C?C'O52Q^
M(2S2 &3]: /4Z6N=TG7UO OS9KH$;<H(H =1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 )2;:=10 E+110 4444 %%%% !12
M4QIT7JPH DHJ#[9'_>J19%;HP- #Z*** "BBB@ HHHH 0C-&VEHH *3;2TE
M"=*=14%U=);1EF.* )68+R2!65JWB"WL8FS(,_6N&\:?$&/2HWQ+C'O7SQXX
M^.961T6?]:M1N9N:1[;XI^(T5N7VRC\Z\ZU#XME9#B;]:\ U+XG3ZK(0)"<G
MUK,;4KNZ^;+5KR'.ZA] _P#"WWW#]]^M=!HOQ8$C+NF_6OEMI+L<_-4?_"37
M6FG)9ABGRH7,S[Y\,^/X;K;F4?G7H5CJD-[&"KC-?G3X9^,4MG,JM,1SZU]
M_#WXQ+>>6&F_6LI0:-XU$]#ZAI:Y;P[XFCU*-2'!S74*=P!'2LS86BBB@!-M
M&VEHH **** "FM3J:PH ,FG4W!IU !1110 4444 %%%% !124M "4C2*O5@/
MQK)US5!81DDXXKS77/B4EJ[+YF.?6G8ENQZTU]$O\6:='<K)TKQ"Q^)"W4P
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M&_-/%8&5'5(G YI#$:7/5*:156QOENHP0:N5X]K'T*=]4,HIPXI:0QE/HHH
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M+=J .^HID<@D7(I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,0O"[:C))A<Y->>Z7\+RUZ&,7?TKZ=U#P^MTQ)7-0V/A6.*0'9^E '->!_
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M,<TG@G7&CO$7=WH*/L_P[??;+<'.>*VJX7X<WWVBU3)SQ7=4$A1110 4444
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M)8A:D'Q,^>SD^E?(WC1<7[_6OKGXB?\ 'C)]*^2?&_\ Q_O]:YSZ-;&I\/\
M_7I]:^F_ W^ICKYC^'_^N2OISP-_J8Z9)Z5']P?2G4V/[@^E.H *;WIU,H =
MF@@,,$9%(M.H X3Q_P"'4O+20A<Y%?(/Q.\'M;SR.J8_"ONO5;475NP(SQ7@
MWQ2\*K)!*VSL>U SXQ;4I=+F*YQS6E8:A+JDJKDFH/'>F&TU!P!CYJU?AKI9
MO+Z,$9Y% SUCX;^#FN)879,]*^IO!'AU+.V3*XP*Y#X:^$TCM87V=A7KUE:B
MVB"@4$DZJ%&!P*6BB@#F?%"_N7KYF^*_RK-^-?37B?\ U+_2OF7XL#<LWT-
M'S#XAU)K6\8@]ZU_"_CJ6SP YK#\36#W%XX [U;\-^#KFZ8;48_A0!Z;'\4)
MEA'[P]/6H)/BM,G_ "T/YUE?\*^O/+ \MNGI7/ZSX,O+8-\C?E0!U%Q\6)6R
M/-/YUD7WCB;4@5\PG/O7FNJ6=S9L<AA5OPW(\MPJMZT#.OL]#FU>Z!(+9->X
M_#'X?M')&QC_ $K.^&'AE+YHB5STKZC\&^"X[6W1M@'%(#0\'Z&+.VC&W'%=
MBJA1@566-+.$8XQ6/J7BA++.6 Q3$=%17G=U\3X+<D&0?G5/_A;MOG_6K^=
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M&@DM444E "T4E+0 4444 %%%% !1110 4444 %%%% !29I::W6@!U)2TC=*
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MIZU]N7T GMW4CM7@OQ2\.K-'*=N>* /AK4+B;3;P@$C!KI?#NL2WQ1"2:?\
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M\8VXXKO>E58;5+*'Y>,5DZEXICL<Y8#% '0T5YW<_%""%B/,'YU4;XN6Z_\
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M^]04C[1^$U]OM8N>U>M*<J#7AGPAG_T:+Z5[A"VZ):"22BBB@ HHHH ****
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M'@6WN;1RD8Y'I7IU5K^U6[MV0C-8W.AH_/\ ^)WP_:UFE=(\?A7DUI=3:+?
M9*X-?=?Q0\(126TK;!T]*^*OB58C3=0?:,<UTPU..<>4]?\ AUXR::.-"^>/
M6M?XA77VK37.<\5XC\-=:*W*+N[UZCXHO?,TD\]J'N-2T/ [P?\ $Z/^]7UA
M^S\/W<'X5\G7#;M:_P"!5]9_L_\ ^KA_"B6PJ>Y]:V'_ !ZQ_2K%5['_ (]8
M_I5BN9G:%)FEIE(!]%-4TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<GUKZ\\9:;YUO)Q7RG\5+!K::0X[F@=R+P'J@6\09[U];_#BX\ZQ7_=KX/\
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MQ_\ /.G'P''C_5BC^UGW&N'5V/C_ %/X<R(IQ&?RKBM8\'R6N[Y"/PK[FO\
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M?8/PM_X]8OI7R%X6C\O5%S_>KZW^&%P!:Q#VH ]AA_U8I]16[;HA3V8*I)H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRT.?2]0<JI&#6]\-_%$]C>1JS$<U[!\3/AWYTTK+'^E>567@^;3[X$(1@^E
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M%55K&^\S^*@#ZR\,_%IM0D4>;G/O7J-KK)U73\9SFOD'X?6MVMQ'NW=:^I?
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MM8O.I.37NWPG\,M<21,R=Q7!>"/AK,UQ&S1GKZ5]4?#/P>+!(R4Q@>E(#NM
MT86=FHVX^6O+?C$NVWE^AKW<1JD> .@Q7@WQF?$<P^M,#XY\77AM]0<@]ZW_
M  )XR>VF0;N_K7->,K9I[Z3'K3?#6DSK(I -(9]9^#OB$5A3,G;UK:UKXDE+
M20"3MZUX9X?^T01*.>E:>I+<7$)'S<TP.'^*GC:2\DD 8GFO//"MY)<:FI_V
MJZWQ)X5N;R0DJQJSX-\"2QW:,4/7TH$?1GPEC,MM&".U>EZ_H/G6+';VKE_A
M?HILXH\KCI7KMU9I-9D$=J /CCXDZ*]M-(0O>N'\.:U+IU\.2 #7TO\ $3P>
MMYYA"YKPO4O!$EK=,RH1SZ4#/8/!_P 1VCL50R?K6YJ'Q&/V5_WG;UKP[3+>
MXM %YK0NGN'B(YH I?$#QR\WF#?^M>)WVM/=7G)SS7>^)-(FN-Q(-<!-HKPW
M0)'>@1Z[\*_WEQ$?>OLKP"N-/'^[7QO\*U,=Q$,=Z^RO /\ R#1_NT =37.>
M)KX1VSC/:NB<X1C[5YAXZU@0)(-U '@OQ;N/.DE />O+?#%BTFIJ<?Q5W7C:
M[^W7#@'/-1^"=!,EY&VWO0,^B?A-8E+:+(["O7$&U0*X?X=Z?]GM4XZ"NZH$
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FB@!:***
M"BBDH 6L'Q)I*7T!^7DBMW(ILD8D7!H ^9/B%X(\SS&$?KVKYX\6>&9+61\(
M17WMXD\-I>1M\N:\.\:_#GSBY$?Z4 ?'5U:RQR$;34/[P8XKVS6OAG)'(V(N
M_I7.W'@&1&_U9_*@#S;]YZ4FV1NQKT4>!9/^>9_*K=K\/9)&'[L_E0!Y[I]C
M+-(!M->F>#_"+W,D9*$\^E=#H'PQ=I%)B/Y5[1X+^'PM]A,>/PH L_#KP>+<
M1DQXZ=J]TTRU6UM551BL?0=#2SC7Y<5T2KM4"@!:**2@!:*** "BBB@# \1Z
M2MY:R?+GBOCOX[^#6;SF6/U[5]P2QB2-E/<5X_\ $OP2NJ0R_)G\*N,K,RG&
MZ/S6FAGT35=V"H#5]#_!_P"*#6(B1I<=.]87Q,^%\EK/*Z1'J>U>6VTESX?N
MA]Y=IKJ=I(Y%>+/TD\$_$"+4DCS*#D>M>E0W45Q&&5U(/O7YU>!?C!)INP/*
M1CWKV32_VB$CA4&;]:YG%G5&HK:GUJ9%7DL!^-<SXF\40:;$V)!D>]?/<_[1
M:>6?W_ZUY]XP^.IO(W"S9_&G&#"51'<?%SXIA;>9$F[>M?%OCGQ-<ZQJ3[6)
MRU=7XF\77&O2LH8L#5/PSX#FUB]5FC)R?2NE)11RRDY,UO@_H-U=WD1*MR:^
MYOA[X5=--C++V%>6_"'X8"S\EFBQT[5]4Z!I<=C8(FVL)R.FG'0\7^*_AXKI
M\F%_A]*^%OB-I\EKJLA"D?-7Z:?$#1!J-BV%ZK7QK\5OAL[3RR"/N>U$)$U(
MG%?!;Q,VGW409L<U]R_#_P 917=G$ID'3UK\[K6";PY>9P5P:]9\$_&!]-V*
MTF />KE&^I$)6/T!BF69 R'(-4->U".PL79F .*^<M'_ &@TAM0#-V]:Q/&7
MQ]6[MV59LY'K6/([F[J*Q+\7_'"I',BR>O>OD/Q9?2:OJ38^;)KK?&'CB77;
MEPK%LFJWA/P?+K%TCE"<FNF*Y4<DI.3.C^$7AN0S1N4KVCQ18_9]$88_AK5^
M&_P[^QVZ.8\<>E6?B=9_8]+E4#^&L6[LW4;(^//$_&M'_>_K7T7^S^W^I_"O
MG'Q-N;6FX_B_K7T;^S\IW09%:2V,X?$?9FA_\>"?2M&L[0_^/!/I6C7*SM.'
M^)W_ "#6_P!VOAGXI'_3I?K7W-\3O^08W^[7PQ\4E8WTN!WK6".:J8O@-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M",87&*T]0U(6L)!/:M:2V$<1P*X3QC,\4$A'I0,P_$GB*W)9685PMS):W\I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4<D"2?>7-244 5O[/@_N5*D*1_=&*DHH **** "BBB@ I,TM-;K0 N:6FKU
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %)2T4 ,V[J:UM&W5<U+10!7^P0?W*<MK$G1<5-10 @4+TI:** "BBB@ HH
MHH :R!NHS4$FG6\OWHP:LT4 9[:#9-R810-"LA_RR%:%% %2/2[:/[L8%6$A
M2/[HQ3Z* "D90W6EHH B:UC;JN::+.$?P5/10 U8U3H,4ZBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "DQ2;J44 &*6BD- "T4W=2B@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *:U.I",T -I])MI: "BBF[J '44@-
M+0 4444 -;K0O6EVT;: %HHHH **** "BBB@ HHINZ@!U%(#2T %%%% !111
M0 4444 %%%% !12&DW4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:
MW6G4FV@!%ZTZF_=HW4 .HHHH :U"]:4C-&V@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *93Z;MH %IU(!BEH **
M** "FM3J0C- #:?2;:6@ HHHH **** $VBEHHH **** "BBB@!*6F[J4&@!:
M2EHH 93EI-M+TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3-
M"TF:6FM0 NZEIE/H ;M-*M+10 4AI:* &[32BEHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IN#3J* &J*=110 4444
M%%%% !1110 4444 %%%% !3<&G44 -44ZBB@ HHI,T +1110 4444 %%%% "
M-2;33J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1J3::=10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 W!I5I:* "BBB@ I-U+3* '9I::M.H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $IM/I-M  M+24C4 .HIH-.H **9FG+0 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%-I5H 6BBB@ HHHH **** "F4^DVT "TM)2T %%%
M% !13,TY: !J;3J-M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%(U-S0 ^DHI: $I:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBDS0 M%%% !1110 444F: %HI-U+0 4TM3J:10 !J=31UIU !1
M110 A-(&IU% !1110 4444 %%%% !12;J* %HHHH **** &EJ U!ZT#K0 ZB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"*6B@!H%.HHH ;M
MI12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 -VTH&*6B@ HHHH ***
M* "BBB@ HHHH **** "BBB@!NVE Q2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 AI-M.HH 2EHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "DHJ":]B@4EFZ4 6*8TJKWKF-6\96]HI&
M]1^-<I=?$RWC8CS1^= 'J:R*W0TZO+;/XEV[L/WJ_G73:9XVM[K WJ?QH ZR
MFM5>UU"*Z4%35F@!M/I*6@ HHIK=: '44E1S7"0C+'% $M-9@O4UA:CXKM[-
M6^8#'O7*:A\2+>-C^]7\Z /1Q,I[TZO)X?B=;M(!YJ_G71Z7X\M[C'[Q3^-
M';451L]7@NU!5A5U6##(YH 6BBB@ HHHH 93EHI: "BBB@ HI-P]:;YJCO0
M^BH_.3^]2&XC'\5 $M%0_:H_6C[7'_>H%<FHJ+[5&?XJ/M$?]Z@+DM%1^>G]
MZE\Y/6@8^BF>8I[TX,&H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***90 ^B
MFK3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLPR2,&@#[_\  ?Q*%[Y8,F?QKW+0-46^@4YSD5^>/PR\:21W$2LYZCO7V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !112$T +12;J6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I-M+10 F*6BB@ HHHH ***0G%
M "T4FZEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0 M%-W4Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BF[J44 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J* &4^BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D:EHH 93J6B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EHH 93EI:* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4?;(O[U><?\ "1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4
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MD_O4 >C_ &R+^]1]LB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U>;_\
M"1R?WJ3_ (2-_4T >D_;(O[U+]KB_O5YK_PDC^IH_P"$H8?Q4 >E?:HO[U)]
MLB_O5YN/%#'^*G?\)&Y_BH ]&^V1?WJ/MD7]ZO./^$B?^]1_PD<G]Z@#T?[9
M%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R
M?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[
MU'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'^V1?WJ/MD7]Z
MO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ
M/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@
M#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_P
MD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_P"$
MCD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%
M_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7
M]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_
M>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4
M?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@#T?[9%_>H^V1?WJ\
MX_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^
MV1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /
M1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1
MR?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.
M3^]1_P )')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]
MZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?W
MJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z
M@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_
MPD<G]Z@#T?[9%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC
M_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9
M%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'
M^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')
M_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/
M[U'_  D<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ
M\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H
M^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ
M/1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"
M1R?WJ /1_MD7]ZC[9%_>KS?_ (2)_6C_ (2.3^]0!Z1]LB_O4?;(O[U>;?\
M"3./XJ3_ (2=O[U 'I7VR+^]2_:H_P"]7FR^)F/\5._X2-_6@#T;[9%_>H^V
M1?WJ\X'B)_[U+_PD3_WJ /1OMD7]ZE^UQ'^*O-CXC?\ O4+XD?U- 'I/VJ/^
M]2?;(O[U><_\)&_K2?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ
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MWJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H
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M?;(O[U><?\)')_>H_P"$CD_O4 >C_;(O[U'VR+^]7G'_  D<G]ZC_A(Y/[U
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M\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\
MA(Y/[U'_  D<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V
M1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9
M%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R
M?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[
MU'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'^V1?WJ/MD7]Z
MO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ
M/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@
M#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_P
MD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_P"$
MCD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%
M_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7
M]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_
M>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4
M?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@#T?[9%_>H^V1?WJ\
MX_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^
MV1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /
M1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1
MR?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.
M3^]2?\)$_K0!Z1]LB_O4?;(O[U><?\)')_>H_P"$CD_O4 >C_;(O[U'VR+^]
M7G'_  D<G]ZC_A(Y/[U 'H_VR+^]1]LB_O5YO_PD3^M'_"1/ZT >D?;(O[U+
M]KB_O5YM_P )$_K2_P#"2..K4 >D?:HO[U'VR+^]7FW_  E#?WJ!XF=NC4 >
MD?;(O[U'VR+^]7G/_"12?WC2'Q$_]Z@#T?[9%_>H^V1?WJ\V_P"$C?\ O&E'
MB.3^]0!Z1]LB_O4?;(O[U><?\)')_>I#XD?^\: /2/MD7]ZC[9%_>KS;_A)'
M]33O^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4 >C_ &R+^]1]LB_O
M5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U><?\ "1R?WJ/^$CD_O4 >C_;(
MO[U'VR+^]7G'_"1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4
M >C_ &R+^]1]LB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U><?\ "1R?
MWJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G
M'_"1R?WJ/^$CD_O4 >C_ &R+^]1]LB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O
M4?;(O[U><?\ "1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4
M>C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4 >C_ &R+^]1]LB_O5YQ_PD<G]ZC_
M (2.3^]0!Z/]LB_O4?;(O[U><?\ "1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'
M_"1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4 >C_ &R+^]1]
MLB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U><?\ "1R?WJ/^$CD_O4 >
MC_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$C
MD_O4 >C_ &R+^]1]LB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U><?\
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MC$QN]2&.?FKZ2^#NE$^2=OI0,^I_AW&5MX_I7HM<9X)M?)@CX[5V= @HHHH
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M^P9/2C^P9/2O2_[,B_NBC^S(O[HH \T_L&3TH_L&3TKTO^S(O[HH_LR+^Z*
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M^P9/2C^P9/2O2_[,B_NBC^S(O[HH \T_L&3TH_L&3TKTO^S(O[HH_LR+^Z*
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M^P9/2C^P9/2O2_[,B_NBC^S(O[HH \T_L&3TH_L&3TKTO^S(O[HH_LR+^Z*
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M?]FP_P!VN<\1:<D:G H \L99/,Q6MIVFR3XX-.DMU^TXQWKM/#6G)(JY% &
MN@R;1\M(=!D]#7I:Z?" !MH_LV'^[0!YB= D]*/["D]#7IITV'^[3?[+B]*
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M.H)J?Q%:+&[8%9VD_+,* /3-+DW1BM \UDZ.3Y2UK4 "TM%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!'<'$+5YSXED_>M7HMS_J6KSGQ)$S2M0!1T23]\/K7I>E-FW KS'1
MH66<?6O2M'R(10!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2?>KJ*Y3Q$A;./2@#DXY/W]=GH<GR+7%I"WG5V6AJ55: .E1LJ*=3(ONT^@
MHI#2;J '44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>];;":L55OO]2: .+U
M:3]X:IV<GSBK.K1GS&JI8Q-O% '7Z6_RBMM3E16#I:E5%;L?W!0 ^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQ*WR-71USGB1-R-B@#SV63
M_2OQKNO"LGRK7"30-]J_&NX\+(5"YH ZZBBB@ HHHH ***0F@!:*;NIU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4R8XC;Z4^H[C_ %+4 >?>)F_>-6-I3?Z0/K6QXDA+
M.V*R-+A83#ZT >BZ-_JU^E;%8NCY$:ULB@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\M?RK5M/#-M;X^1?RH \X\&^ 4L A\O&,=J]5TVS6TA  Q4T-K'" %7%34
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,E7=&17
M+:MIGG,3BNJ)J&2W$F>* .1L='\N0''>NJL8O+0"GK:*O:IU7;0 ZBBB@!":
M3=0U% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CE7=4E(>E &/>V?F9XK'
M?2<OG%=:T8:F?95ZXH RM-LO)QQ6VOW13%A"]*DH 2DW4M)M- "BEI%I: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L75+/SL\5M5&T0;K0!R"Z/\^<5MZ?
M:^4!Q6A]E7TYJ18@O2@!T8PM.I!Q2T (:3;3J* $I:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *AN%W1XJ:D8;J .:OM-\QCQ4%OI>UNE=.UN&[4BVRKVH IVE
MOY8Z5HK]T4BQA:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M65JMOYRGBM6HFCW=: .(DT7,V=O>NAT>S\C'%:/V-<YQ4L<(CQB@"6BBB@ H
MHHH *0C-+10 W;3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID@W(13Z2@#F-5TWSF/
M%4;31O+DSBNPDMP_:FK:JO:@""Q@\M0*O"D50M.H **** "BDHW4 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #6I*?24 +1110 4E+10 44F:6@ HIK4+0 ZBBB@ HI,T4 +1110 4444 %%
M%% "4M%% !1110 4444 %%%% "-3&C#CFI** *%QI$5QG<!6;-X.M9NJK^5=
M#13NT9RIQENCF!X%L^NU?RJ3_A";/;C:OY5T=%%V)4H+9'G?B#P7!'&2$'2N
M&;PO$+C&T=?2O8/$DN(2/:O/I)?]*_&D:<J1K>&?!\,BKE!^5=5_PB-GMQM'
MY5#X7F_=@5TE G%/<Y&^\"VTB-M13^%>7^-_A^GEOMC_ $KWZL77-(2\B;Y<
MT]P45'8^$/''@UK>1R$_2O+[NP:UF.1BOM7Q]X%699&$?Z5\X^-/"#6DCD)C
MFB,G%Z$U*<:D;,\[M67< :V;?3Q.HQ6#-"]K<8/'-=1X?N%9E#&O>PN82I[L
M^!S3)HU+N*&/H\D8R!3K>_GT^0<D8KOK/3HKJ$8 -9VK>%"RDJM?7X?'0K*T
MC\]Q&75</*\2UX7\?26TB!I#^=>W^#?B8C! TGZU\MW.DSV+D@$5=TGQ-/IT
MJY8C'O4XG TZRO$Z<%FU;"2M(^]]#\90WD:Y<'\:Z:VO$N0-IKX[\'_$LQ[
MTOZU[AX3\?1W"IF0?G7QN*R^5)NR/U#+\YIXA)29ZY28K,T_7H+Q!\PS6BDB
MR?=.:\=Q<=SZB,XS5XL7&#3J**DL**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 93EHI: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "DI:* &\TM+10 4444 %%)3<T /HI%I: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **92K0 ZBBB@ HHIG>@!]%(M+0 4444 %%%% "-TIM/I* "EIE*M #J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"Q&*]8\'_$QXBBM)^M?/8W*^L3ZW*^(&K1J,^U+>\CN%!5A4]>+>$?B(MTJ
MR?K7J.CZU'>(/F'-?(U</*D[,_3<-C:>)BG%FQ124M<QZ 4444 %-R:=3=M
M"K2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **;NI10 M%)2;
MJ '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
M: "FTNZC;0 J]*&H%!&: $R:=3=M.H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BDW4 YH 6BDI-U #J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BD)Q1NH 6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBD-)NH =1110 4444 %%%% !1110 44E)NH =124M !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !124FZ@!=M&,44M !1
M110 4RGTW;0 +3J0#%+0 4444 %%%% !1110 FVC&*6B@ HI"<4FZ@!U%%%
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MM+0 4444 %)2TUJ %I::M.H 3(HIM.6@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &4Y:6B@!&Z
M4VGT4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(U+10 RG4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #*5:=10 C=*;3Z* $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &M24^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&IM/HH **
M** "BBB@ HHHH **** $;I3:?10 B]*6BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z4VGT4 (O2EHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &M24^B@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#F_$O^K:O/I/^/G\:]!\2_ZMJ\^D_P"/G\: .Y\+_=6NLKD_"_W5KK*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@#F_$O^K:O/I/^/G\:]!\2_ZMJ\^D_P"/G\:
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M %;5Y])_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%%
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M@UO>'_%T^GLH+D8JL3@(5E>)GE^<5<+/EF??FA>*H;N-07!KI([A)0"K9KY
M\&?$X[D#2_K7NGA3QQ'>*F9 ?QKXO%8"=%W/U? 9Q3Q,4FST^DP*K6=_'=1@
MJPS5JO(U1](FFKH****0PHHHH **** "F&GTW;0 F*<O2DVTM Q:***!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*6@ HHHH ***;0 ZBFK3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'-.I%!112 T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#>U $QI-M.HH ;NI0:;@TY: %HHHH *;MIU% " 4M%% !1110 4444 %%%%
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M#WPZ8UC.VO<]!M?(C7CM3D989RD]3<HHHK$]8**** "BBB@ HHHH *3K2T4
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M7R6*PTJ,C](P&/AB8+4Z&DQ0#D9%+7G'LA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !37;:I-.JMJ$GEVK&@#D_&&NBUMY/FQ@5\D_&+QHV9@
M)/7O7MGQ0U\P0S#=CK7QO\3M<-U<2C=GD]Z /*/%WB"6[NW&XGFH- LWO9%X
M)S36TLW]WQSDUZS\.O +7+1GR\_A0!T'PS\+OY\3;#U%?8'@&S-CIZ$C&!7!
M?#[X=_9UC8QX_"O7OL8TO3\8Q@4 <5\3O$AM;&0!\<5\4?$SQ8TMY*-^>3WK
MZ-^,6N8CE7=7QAX\OC->OSW- %/SCJ$GKFMW1_!S7S#"9_"L?P?:F[ND'7FO
MI[X8> A?>43'G..U 'E5I\*)98@WDG\JSM7^&[V:DF(C\*^[]'^%$7V,9B'3
MTKBO'_PSCM[>0B+'X4#/@O5M/;39",8Q6SX+UY[>\0;L<UU7Q)\+&TGDPN.?
M2O/='A-M>#MS0(^VO@WXF:1807]*^J?#>H"XMTY[5\)_!_5O+>$;NXK[#\"Z
MEYUO&,^E STBEID9W1J?:GT""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O\ JVKSZ3_CY_&O0?$O
M^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K/UQMMB]:%9?B'_D'M0!\P?&*\*K/SZU\;
M^.+XO?.,]Z^M?C1(=L_XU\:>,I#_ &B_UH V?!.F_;[Q 1GFOL'X0^ UDCB;
MR_3M7RU\)XU>\BW>M??WP8M8?L<1P,XH [72?#"6-NOR8P*YGQQ?+9V<@SC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML]7 87ZU-(U/ G@/<T9,?Z5]!^$/"JV<2'9C\*;X*\)I'%&=GI7I-KIZ6\8
M'-?G>-QKJR:/VO*<JC0@I6%L8?)CQBK5(!MZ45XCU/KTK*P+2TF:6D,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6U>?2?\ 'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTG_'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%%
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MQ+\._B\9VC#39_&OI3P5XVCOHTS(#GWH$>ET5#;W*7"!E-34 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MI-U "T4F:6@ HHIDC;$)H JZE>+:P,2>U>"_%3QJ+2.4"3'7O7HGCCQ +6UD
M&['%?(/Q?\7-(TH#^O>@#S+XE>/)+B:51)W]:\<OM2GNI20Q/-6_$=])>7C<
MDY-7?#F@/J#*-N<^U S9^'DERM['G=U%?</P3ED\N#=GH*^>/AU\.'>:-O*_
M2OK?X9^%6TZ*(E<<"@#VFT.;>/Z5-45LNV%![5+0(J:DVVU:O OBG=2"&8+G
MO7O]]'YENPKR;QUX9:^C?"YS0,^"?BD]S)<2XSU->(73W4=YDEAS7VIX^^%[
MS-(WE?I7@'BSX?O8R,?+(P?2@#,\$^*)K!DRY&/>OIKX8_$HAHE,OIWKX]N0
M^FR$ 8P:[7P!XHEANHQN(YH$?IIX'\5+J,,?SYS[UZ$K;E!'>OE;X.^*C)'"
M"_I7TKI&H"XMTYSQ0,UJ*2EH$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %-W4ZFT *#2TBTM !3=M.HH 0<4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?
M\?/XUZ#XE_U;5Y])_P ?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,I<FEH 1:=24M !574I/+M'/M5J
ML[7FVV#_ $H \"^*VN&&*8;O6OC?XC:X9[J0;N]?3GQDO"JS\^M?&WC:\W7[
MC/>@9CVNG_VA=#C/->Y_#'P']H:(F//X5YCX#L1=W4>1GFOLCX1>%U\F%ME
M'<?#SX>QPQQDQC\J]CTW1HK*)0!@XJ#P_IJVD"_+CBMJ@0@&!BEHHH 1E##!
MJE=:5%=+AA5ZB@#@?$7@6&ZB;]V#^%?.WQ0^'"1K*1%^E?8LB"12#7E_Q)T%
M9H93MH&C\V/'WA@V<TGRXYKEO#I-I>+VYKZ%^+7AU8Y)2%KP9K;[->>G-(1]
M+_!_73&T(W>E?7O@G5/M%O'SVKX1^%=\4N(AGN*^R?AO>>9#%SVIC/98SE :
M=45N<PJ?:I:!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4456NKZ.U^\: +-%8,OBRVC."P_.GP>)K><X5A0!MT57M[Q;@ @U8H
M **** "BBB@ HHIK,$&30 ZBJ%QK$%OG<?UK.F\96D).67\Z .@HKF%\=6;-
MC<OYU>M_$UK<8PP_.@#9HJ"&ZCF *FIZ "BBB@ HHHH **** "BBB@ HHHH
M**** .;\2_ZMJ\^D_P"/G\:]!\2_ZMJ\^D_X^?QH [GPO]U:ZRN3\+_=6NLH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI&H ,T9IM% #Z*2EH *3-#4V@!]%%% %>[MEGA8$5XU\2/#8EBD(2O;:Y;
MQ5I(O(G^7- SX-^(7AMH9I#M[UP.GYL;D'IS7U%\2_!_^M;9^E?.?B;3383,
M<8P:N+L<U>DJD;GJ?PY\5>1)&N_%?47@?Q"+R&,;L\5\#^%=<:UNU&['-?4/
MPK\3^8(@7].];/5'@4Y.G5L?44+;HU/M3ZR]#OEN;-#GM6I7.?2Q=U=!1112
M*"DS2-24 /HHHH **** "BBB@!E*M)2K0 ZBBB@ J*YB$T+ CM4M(:8'AOQ.
MT$31RG;ZU\I^.-'-K=.=N.:^Z?&&D_:X7^7-?,7Q0\,>6TAVU]EE6*M:+/R_
MB+ \R<TCRSP;JC6MT@SCFOJWX6>(/,BC!:OCN/.GWWIS7N7PM\3",QC=7J9E
MA_:PYD?.9#BW0K<DF?85G<":)>>U6:Y#PKK NX4YSQ77#H*_/*D'!V9^V4:B
MJQYD+12-169N+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !67XAYT]ZU*S];7=8N*
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M//K7K7PMU&62:++'K0!]U>#]6-]&ASFNTKROX8R%X8L^U>J4 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6U>?2?\ 'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 0W,0FC(->>^-_#BSV\AVUZ16;K5F+FU88H ^)?B5X;\AY2$KPN\5[2^[
MC!K[,^)GA7SEE(2OF#Q?X=-K=.=O>J6AE6I^T1U'PU\0-#-$"V.17UM\/?$0
MFMXP6[5\)>']2_L^Y49Q@U]&?#/QAN\I=]:[H\3^!.Q]7V]P)E!!J8]*YKPI
MJ/VR%#G.1735@>Y3ES1N-6G44E!H&12TW::44 +1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#*!^-8W_  MJ/./.'YT ?0O]H0?WQ2_;(B.&S7SZGQ7C+#]\/SKIM#\?)>D
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MK_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4
M6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V
M@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\
M:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6*
M*K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4
M 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'
MV@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]
MH%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8H
MJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@
M4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%
M'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO
M]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8
MHJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!
M0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H
M%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJ
MO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!
M8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:
M!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@
M4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ
M_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0
M!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?
M:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V
M@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BB
MJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H%
M%BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4
M?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_
MV@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %B
MBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H%
M %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1
M]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_
M &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %
MBBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H
M% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!
M1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K
M_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6
M**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]
MH% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:
M!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**
MK_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4
M6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V
M@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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M#K$$WW3^M6TF5^E>#^#_ !Y_:&S]YG/O7KNBW_VB-3G-,1OT4B]!2T %%%%
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MC["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*>E6J*
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M6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH
MJ_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6
MJ* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^
MPK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV
M%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@
M"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U
M:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C
M["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_
M85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J*
M *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK
M5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:
M/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K
M]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:H
MH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["
MM6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85
MH^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *
MOV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5J
MB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L
M*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A
M6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH
MJ_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6
MJ* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^
MPK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV
M%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@
M"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U
M:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C
M["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_
M85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J*
M *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK
M5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:
M/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K
M]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:H
MH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["
MM6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85
MH^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *
MOV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5J
MB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L
M*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A
M6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH
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MA&U,-N@([4".T3[HIU-3[H^E.H *:6IU-/6@ #4ZFCK3J "BBB@!":3=0U%
M#J*** "BBB@ HHHH ***:>M #J*:.M.H **** *>J)OMV'M7@/Q1T%KQ9,+F
MOH6X3S(R*XSQ%X=%]NRN<T ?#^M> 7DO&/E]_2NY^'O@U[66/Y,<^E>V77PZ
M628GR_TK8T3P2MJP.S'X4#1N?#^Q-K''QBN_K%T73Q:J!C%;5 'FGQ)T]KJ.
M0 >M?)OQ$\%SW,TF$-?<&NZ:+Q6!&:\XUKP"EVS'R\_A0!\<^&O =Q%?*2C=
M1VKZI^$NC26:1;ACI5NP^&R0R@^5W]*]"\-^'Q8!<+C% CKXE'V=5/3;7!>-
MO"JZC&_R9R/2O05&% ]JCFMTG7#"@9\9>/OA/YS2,(O7M7BVM?"R:&1L1$?A
M7Z(:YX3ANU;Y <^U>>:Q\-8IF;$7Z4 CX9M_AK<--CRS^5=_X5^$\DCH6B_2
MOI"#X6QK+GRA^5=GH/@&*WVYC'Y4"/._ /PS%F$)BQ^%>\>'-)6PA4!<8%6=
M.T2&TC'R@&M-4"]!0 ZBBB@ HHHH **** "BBB@ HHHH **** .:\2C]VU>?
M2?\ 'U^->A>)?]6U>?2?\?/XT =SX7^ZM=97)^%_NK764 %)2TE ";J44VG+
M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% ";:6BB@ K'\162W5JPQGBMBHKB,2QD&@#
MY?\ B=X3\Q92$_2OF?Q)H;6-XYQC!K[X\;>'5N+=SMKY7^)7ADP32D)^E FD
MUJ<'X+UMK&Z0%L<U]2?#;Q9YD<2E_P!:^-3*]C?>G->S_#/Q*4DB!;]:U3T/
M-DG&6A]K:/>"Z@!SGBM*N#\":PMQ;IENU=TKAAD5FT>A!W0ZBBBD6%%%)NH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A
M;@C-5+O3(+N,JR#)JY10!Y5XS^'T-XKXC!_"OG/Q]\)SND*P_I7VY-;)<###
M-<IX@\%PWL;$(#GVH&?FMXH^'\UDSXC(_"O.]2TN:U+ J>*_03QQ\+$E60K%
M^E>"^*OA*^Y]L7Z4 ?+D,<ANE!!ZU[U\(K=O/AR*SU^$\RW6?*/7TKU[X<>
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MD(7')KB_#]\]G>*,D<U]'?$[PCGS6V>M?/>J:<=/O"<8YJD8R5SZ1^%'B?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O\ JVKSZ3_CY_&O0?$O
M^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"*XB$T9!KSWQMX;6XM7;;7H]4=6LUN
MK5QCG%!,E<^'?B5X<-K-(0OK7D]O?/8WP'3!KZP^*GACS%E(3U[5\N^*=(:S
MO&(7'-6C'R/:/AAXJ.Z)2_I7U/X,U-;JW7YNU?!'@;6FL[A 3CFOJ[X9^*A)
M#$"_:@I:'NE%5+&\%U&I!SQ5NH-@HI,TM !1110 A&:3;3J* "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;J;R8\T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JV
MKSZ3_CY_&O0?$O\ JVKSZ3_CY_&@#N?"_P!U:ZRN3\+_ '5KK* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3KQ7%>
M,=)2YA?*YKM3Q7)>*KY887R>U-&-62A&[/EOXG>&D4R$+7ATR?8+SCC!KZ&^
M)>K1-Y@S7SMX@N0URQ![ULXL\^GC(2E8];^&OBHV\D8WU].^#_%B30H"_:OA
M#PSK36LRG=BO:?"OQ -LB R8_&LV>C%\VJ/L&'6H6C!W#I2?VU%N^\*^>8/B
MDJQ@>;^M)_PM(;O];^M2:GTA#J4,G\0J<3QMT<5\\6?Q448_>_K6G'\5DQ_K
M?UH2N9SJ*FKL]U\Q/[P_.E\Q?[P_.O"&^+<8/^M_6M/2_B<ETP'FY_&M?9L\
M[^T:*?+<]EW#UI:Y+1_$2WBK\V:Z>WE\Q1635CT*=2-171-1112-0I*6B@ H
MHHH *R]=MQ<6Q&,\5J5%<1^8I%5%V=R)1YHM'S=\3/#/F+*0GZ5\R^)-*:QO
M6.,<U]U^.=#$UJYVYX-?)_Q)T7[/-(0N*^XRG$\RY3\DXBP/(^=&;\/=:-K<
MQ@MCFOJ[X?\ B(36\8W9XKX@T>^:ROU&<<U]%_"_Q$6\H%_2M\TPW-'F.;A[
M&NG+D9]36<WG1 U/6-X;NA<6@.<\5LU\!)<K:/V.G+FBF%%%%2:!1110 4A&
M:6B@!-M+110 44FZB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVKSZ3_ (^?QKT'Q+_JVKSZ
M3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@
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M\X?#'Q1NCB&_M7O>AWGVF%3G-?G6,HNG-G[9E>*5>DC7HHIO\5><>X.HHHH
M**** "DI:* &4Y:*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@#F_$O^K:O/I/^/G\:]!\2_P"K:O/I/^/G\: .Y\+_ '5KK*Y/PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK4W3FT?O&%K*M231+1117,=H44E&13 6DW4M-;K0 H-+35IU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\C]*5?@P!_RP_2@9\=_\(;<_W&H_X0VY_N-7V-_PID?\\/TH_P"%,C_GA^E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4
M0R6L<G45 VDVS]4S5VB@"DND6R]$J5;*)>BU8HH JMI\+=5J,Z/;-U2KU% &
M?_8=I_SSI?[#M/\ GF*OT4 4/[$M/^>8H_L2T_YYBK]% &?_ &':?\\Z/[#M
M?[E:%% &?_8=H?\ EG2KHEHO2.K]% %:/3X8_NKBIUC5>@IU% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7U#X3UD7D*?-GBOB,RP[A4;/U?(L:JM%1.RHI!2UX)]B%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4F* $&:=110 4444
M %%%% !24M% #**4BC;0,=1110(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\2_P"K:O/I/^/G\:]!
M\2_ZMJ\^D_X^?QH [GPO]U:ZRN3\+_=6NLH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=>"U9V/L(OF5PHHHI%!3=M.HH 2EI":* %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6#XO7=IK?2MZLGQ%#YUBP
M]J /B[XS6Q+3<>M?,-\ODZF2?6OL_P"+?AMYEF(7UKY)\8:.]E>2-MQS0,]5
M^$.OI9R0Y8#I7UMX:\:Q?V>@WCIZU^=WAGQ0=+N%&[&#ZU[5X;^*6VW53+V]
M:!'L_P 4M>6ZMY<-G@U\I>(YMVJ$Y_BKT;Q)XY6^MV_>9R/6O'M8U(27A;/>
M@#Z!^"NH+;R19..E?5=GXNC@TL#>!\OK7PC\/O%*V#*=^,5Z?>_%00V)42]O
M6@#I/C)XRCFCF <=Z^0O%.H"\OGP<\UU7Q ^(1OFD DSGWKS6QF;4KP'KDT#
M/5?A;9E[J(X[U]G?#&U*0Q<>E?,GPA\.L\D)V^E?87@323;V\?R]J /1K48M
MT'M4M,C&V-13Z!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!S?B7_5M7GTG_ !\_C7H/B7_5M7GTG_'S
M^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(U+24 -I5ZTNVC% [
MBTUJ=24"&TJTNVB@8M%%% AK*'7!KC?''AY+RS?"YXKM*K:A +BW92,TUHS*
MI352+BSX7^+/@@I)*PC_ $KY^GMY-)U#/(P:_0'XC^#1>0RD1YX]*^1?B-X-
M:SN9&"8YKUZ-2ZLS\?SO+I4JGM(HZ'X5^-#;RQ*7[CO7V'\/O%27EK&"^>*_
M.70]2?2;U021@U]-_"?Q[Q$ID_6LL13OJCLR+,G3DJ<F?8<<@E7(I]<WX3UI
M=0MU^;.1725YNQ^JTYJI%217N;-+E2&%><>-/!:74;GR\_A7I]5[NU6Z0@C-
M(T/BWQ]\/S$TC"/]*\CO--ETN8G!&*^[?&7@M+J)R$S^%?/'CSX?F,R%8_TH
M&>>^%?&$EE.BE\<U]!^!?&B7<:*SYKY9U#29=-N2<$8-=)X3\72:=,BE\8]Z
M6VPM'N?85Q9P:M:D@ DBO(?'OP_\[S&6/]*Z#P+XZ2[C16<?G7?W,4&J6Y/!
MR*]7"8V5*5KGS>999#$P;2/B;Q1X-DLY'^3'X5P]Q8-;R$$8KZT^('A>+:Y5
M17S]XHTD6\KX&.:_1,'C8U(ZL_&<RRN>'F[(XG[M&W=277[N0BK-G'YF*]-U
M8K6YX*H5&[6(OLYQG%:.BQA;A<^M6!9_N^E0QJ;>4'&.:S=2,U9,OV,Z4DVC
MZ ^&$<+-%NQVKZ>\)V\/V5< =*^)O _BK[#-&"^*^E? ?CQ98T4R?K7Q&:8>
M;=T?K'#V.I**C+<]P1 BX%.K.TO5([V%3N&:T*^0:<79GZ7&2DKH6BD-(.M(
MH=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!\*O*:-C%^E CI/A%X2,*0DIZ=J^E=$TX6UNG&.*Y7P9X573XH_DQ7H4:"-
MHH 6EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBDH 6BDW4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444E "T4FZB@!:*** .;\2_ZMJ\^D_X^?QKT'Q+_JVKSZ3_ (^?
MQH [GPO]U:ZRN3\+_=6NLH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2LV'7K:XQM.?QJ['.L@R*!$M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444FX>M !2TFX>M+0 4444 %%%% !1110 4444
M %%%)0 M%)N'K2T %%%% !1110 4444 %%%% !2-TI:* &4Y>E+10 4444 <
MWXE_U;5Y])_Q\_C7H/B7_5M7GTG_ !\_C0!W/A?[JUUE<GX7^ZM=90 4444
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M'>A:DH=1113 *93Z* &K3J** "F4^B@!JTZBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_"[QXXFB5I.X[U]?_#OQ(+NVBRV>*_./P;JSV-\@SCFOL+X0>)3)#""W84
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&?C"W>SC5G'(]:!'HT>DPQC&/TJ0Z?$>U/AO(;A04D4_C4OF)_>7\Z *O\
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MCZUF?97H^RO0!I_VM[T?VM[UF_97]*/LK^E S2_M;WH_M;WK-^ROZ4?97]*
M-+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-
M^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2
M_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?L
MK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[
M6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_
MI1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO
M>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4
M?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH
M_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V
M5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[
M6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?
MTH T?[5/K0-6/K6;]E>C[*] S3_M8^M)_:I]:S?LC^]+]E?T- C2_M8^M*NK
M$]ZR_LKTJVKT :EQ>":$@^E>2?$725O(9/ES7J"VSE,5C:QH)NHV!7-5%\K.
M?%456IN)\-?$3PR\,TC!/TK@-)O)=+O!R1@U];_$?P'NCD;R_P!*^8O&&@OI
MMRY"XP:]6E/F5C\;S; RPM7G1[7\+O'AA:)6D].]?37AOQHMU;1C?GCUK\[_
M  MXDDL+M5W$8-?2_P -?%K72Q*7].]8UJ?4^BR+-+I4VSZGM]46>/DYK'UJ
M)+A&&*I^'I6N8%.<\5K3632=J\[J?I<7S1N>3^)O"ZW6XA/TKS75OA^9&8^7
M^E?3,V@B8<K6?/X223^"GT ^4KGX<MN_U?Z4R#X=MN'[K]*^H)O!,;'_ %8_
M*F1^"8U/^K_2D!X)HWP_,;J3'^E>A:+X36%5!3]*](M_"*1_P5?CT 1]%H X
M2?PRK0D;.WI7GOBSP=N5R$_2OH?^QP5QBL?5/"JW"'Y<_A0(^*O$WAB6VD8A
M"*YVSNKC39N<C!KZL\5?#L3!R(_TKQSQ3X >UWD1X_"FQC/!_C^2U9 TA'XU
M[KX2^)8D1 9?UKY'O+6?2YCP1@UL^'_&4UG*H+$8]Z0[GW?H_BR.Z5<N#^-6
MM6FBOH2.#D5\U>$?B"65 9/UKUKP_P"(A?A06SFB[B[H'%37*SE_'OA5;J.0
MA,_A7SGXP\*R6LSLJ$<^E?;EQHZ:C!TSD5YGXV^' FCD81]O2OI,OS!TVHR/
MA,ZR6-:+E%'Q_;WD^FW ZC!KU?P+X\>W:,-)^M8?C+P-)93.1&1@^E<.MQ-I
M<W<8K[.2IXNF?ED9ULMK:GVKX0^("S1H#)^M>AV/B1;A0=^:^)_!OC:2-D!<
M_G7O'@_Q4;I4&_/XU\5CL"Z;;1^K9/G$<1%1;/;O[4RN<U&VJGUK#TV0W,0.
M<U?-BYYKYRSB[,^XOS*Z+?\ :I]:7^UCZUG-9N.U)]E?TIDFE_:WO1_:Q]:S
M?LK^E)]E?TH TQJQ]:/[6]ZS/LC^]+]E?TH"YI?VM[TO]K'UK,^ROZ4OV5Z8
M7-+^UCZTG]K'UK.-J^*:;1Z!7-/^UCZT?VL?6LS[(_O1]E?TI%&G_:WO1_:W
MO69]E>C[*] M33_M;WH_M;WK-^RO1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2
M_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?L
MK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[
M6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_
MI1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO
M>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4
M?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH
M_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V
M5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[
M6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?
MTH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO
M>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]*
M -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK
M-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#
M2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?
MLK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO
M[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*
M_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^U
MO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ
M4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;W
MH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'
MV5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/
M[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E
M?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^U
MO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]
M* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;W
MK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@
M#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS
M?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH T
MO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[
M*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^
MUO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^RO
MZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;
MWH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E
M'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z
M/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]
ME?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^
MUO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97
M]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;
MWK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2
M@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]Z
MS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH
MTO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW
M[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+
M^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^R
MOZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M
M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^
ME'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]
MZ/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1
M]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C
M^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?9
M7]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M
M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_
M2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]
MZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH
M TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>L
MW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -
M+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^
MROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_
MM;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK
M^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6
M]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I
M1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>
MC^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?
M97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_
MM;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5
M_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6
M]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?T
MH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>
MLW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]*
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MTH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM%
M%+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7
MTJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?
M2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?
M2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]
M*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!
M2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]
M*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7T
MH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %
M+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7T
MJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2
MC^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4
MO[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2
MKM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*
M/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2
M_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*
MNT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH
M_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+
M^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ
M[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C
M^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O
M[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2K
MM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/
M[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_
ML]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*N
MT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_
ML]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^
MSU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[
M10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^
MSU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[
M/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM
M% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[
M/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L
M]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT
M4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L
M]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^S
MU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[1
M0!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^S
MU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/
M7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM%
M %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/
M7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]
M?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]
M?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU
M]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10
M!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU
M]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7
MTH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM%
M%+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7
MTJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?
M2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?
M2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]
M*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!
M2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]
M*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7T
MH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %
M+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7T
MJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2
MC^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4
MO[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2
MKM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*
M/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2
M_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*
MNT4 4O[/7TH_L]?2KM% %$Z>/2D_L\>E7Z* *7]GKZ4?V>OI5VB@"HMDJ]JF
M2$+4M% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
MQP": %HK.NM06#))Q6+=>*8X6QO_ %H ZNFR*&4@UR<'BR.1L;_UK4@UE)%S
MNH +W1X[C.1FLB;PC!(QR@K9EUB-!RPJE+XD@CZN*!F9_P (3;Y^X/RH_P"$
M*@_N#\JMGQ9;_P!]:4>*K?\ OK0!3_X0N#^X/RH_X0N#^X/RJ[_PE5O_ 'U_
M.C_A*K?^^M %+_A"X/[@_*C_ (0N#^X/RJY_PE5O_?6C_A*K?^^M %)O!-N?
MX!^5+#X+@0YV#\JMMXLM_P"^*='XJMV. XH LV>@QVY&% K8@@$8P*SK;6(I
M\885IQ3"0<4")A2GFDQ3J $I:** "BBB@ HHHH **** $I,FEI-M "K2T@I:
M "BBB@ HHI* %K-UR\%I9L>^*TJY_P 40M-"P'I0!\Z_%WQ))Y<RJ3WKXO\
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ME6VI0:Q;@$@YKB/''@F*^A=E0'.>U?3Y?F+@U&1\#G62QJQ<X(^+[:ZGTNZ
M)(P:]>\ ^/F@:-6D_6N?\<>!WLIG94[^E<#!>SZ3= <@ U]A.,,7"Z/S"G4J
MY;6L]C[M\%>-$NH4!?.?>O3+.\6ZC!!R:^)OA]X]>%HU:3'XU])>"?&"W4:9
M?]:^%Q^!=%MH_7,GS:&(@HR9ZA15>TNEN(P0<FK%>"?8)WU0E&T4M% PI":6
MFL*  -3J:!3J "BF[J44 +1124 +12;J6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC^^_6GK\8B?^6WZU\G7'BJ;S#\Y_.GQ^*IL??/YT!<^L/^%P'_GM^M'_  N
M_P#/;]:^4O\ A*YO[Y_.C_A*IO[Y_.@=SZL_X7"?^>WZT?\ "XC_ ,]OUKY3
M_P"$JF_OG\Z1O%4W]X_G0%SZGF^,A7_EM^M6-+^,!FF \[]:^1;KQ9,!]\_G
M5[PWXJF:Z7YSUH%<_0?P7XY^WE/GSGWKV30[[[1&IS7QI\)-:DF,62>U?6/@
MR8R6\?TH$=T.@I::GW1]*=0 4444 %%%% !1110 4444 %)FBFT /HI%I: "
MBBB@ HHHH *K7EN)Q@BK-)0!R>H>%X[ICE :Q9OA]!)_RR'Y5Z+L![4;%]*
M/,_^%;6__/(?E0?AO;_\\A^5>F;%]*-H]* /,O\ A6EM_P \E_*D_P"%9VW_
M #R7\J].VCTHV#TH \WM_AO;Q,"(E_*NDTOPW'9J % KI-H]*7:/2@#*N-*6
M:/:17.:AX(ANF),8/X5W%&T>E 'G=O\ #VWADR(QU]*Z;2="2QQA<5N[1Z4N
M!0 +PH%,FA69<,*DHH P[_PS!> Y4'\*YR]^'EO(Q_=C\J[^DH \UB^&MNKY
M\H?E6[I_@>WM\'RP/PKK=H]*6@"G:Z7#:@;5Z5; "BEII- #J*1:6@ HHHH
M93EI:* "BBB@ I,TM,H ?12+TI: .:\2_P"K:O/Y/^/G\:[_ ,2?ZMJ\_?\
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M3#;QC':N6\,^ AIY7]WC'M7I6EV'V>-1CM0!JI]T?2G4@Z4M !1110 4444
M%%%)NH 6BD!I: "DVBEHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKX7"Y% %O-+35IU ";J,TVE6@!U%)FC- "TRGTR@!5IU-6G4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXE_U;5Y])_P ?/XUZ
M#XE_U;5Y])_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2
MOG[XU?ZF?\:^@9/]6WTKY^^-7^IG^AK:C\1XN;?[NSXC\??\?TGUKBXZ[3Q]
M_P ?LGUKBXZ]Q;'X%B?XK'KUIU-7K3Z9@A**6DH *1_NFEI&'RF@10;_ %P^
MM>C?#_\ U\?UKSEO]</K7HWP_P#]?']:F>QT8/\ BH^N?A=_JXOI7T+X?_U2
M_2OGOX6_ZN+Z5]#:!_J5^E>-5W/W/*/X:-BBBBN<^D"BBDS2 6BBBF 4444
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M+&#)^M>WZ#X@2]C7YLYKX/$T'3EH?L.!Q:JP5SH2*0=:56##(I:X#V HHHH
M**** "BDS2T %%%% !1110 4444 %%%% !1110 4444 %%)2T %%%% !1110
M 4444 %)2TC4 &ZEIE.H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;"/&!0!97[HI:2EH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\L&7.?>@#Z2!#<BEK T'7DOHU^;.16]0(6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVK
MSZ3_ (^?QKT'Q+_JVKSZ3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI&6S+5)M%1+=Q-T:GK(K=#2+NAU+112&%%%% !113=M #J*;M- ZT .HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN65&4=SOAB*<]F;5%017D<@X85,&#=#FLCI33V%HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH PX%-Q@ 5U7AGPR]U,AV9YK5\/^ YI)%S&:]M\"_#O;Y9:/T[4#'?#OP/\
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M"UZ$<?2GN>)4R;$4GH>A:?XXG7&9#^==5IOQ D7&9#^=>*K>>7T-6(]8:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% #6I*<1FC;0 M%%% !1110 C=*3=3J3;0(!2T44#"BBB@ HHHH **0FDW4
M&ZG4F!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBD;I0 9%+3*<O2@!:*2B@!LD*S*0PS7&>+?",5
M]"_R Y'I7;4R2-95PPXIIV,JE.-6/+(^./B9\,?EE98O7M7S5XG\-SZ1=.50
MC!K]+O%7A.*_MW^0'(KYH^)WPO#><RQ?I7HT:W1GYKG62VO.FCYG\->+I],N
M4!8C!KZ1^&OQ*+>4K2_K7SEXH\)3:7=,0A&#3_#?B:729U!8C%=4HJ:T/DL%
MC*N"J<LC]&_"/BQ+V-/GSFNZAF69 RG-?&'PW^)W^K5I?UKZ/\(^-([V-/G!
MR/6O+J4W%GZWEV90Q$4FST2BH+>Z6X4%34]<Y]"%%%% !29I::U "[J*;3Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 -;
MK0O6EQ1B@!:*** &R1B12IZ5R/B?PC%J$#G8#GVKL*1E#*01D4T[&52G&I'E
MD?(OQ*^%H;S&6+]*^;/%WA"72YW(0C!K])?$GAF/4(7^0'/M7SO\2_ACYBRE
M8OTKT*-;HS\[SC)4TYP1\H^'_$$VDSJ"Q&#7OWPY^)FUHU:7T[UXMXO\%S:9
M,Y5",&L/0]8GTFZ +$8-=DHJ:/B\-B:N J\K/T8\'^-DO(X_WF<^]>C6EVEU
M&&!KX=^'7Q(,;1*TOZU]->"O&T=W#&#)G\:\NI3<6?JV6YI#$12;/4**KVMX
MEU&&4YJQ7,?3)WV"BBB@8E+110 4444 %%%% !1110 UJ2G8I#0 ZBF9IU "
MT444 %%%% !1110 C4VG4;: %HIF:,T /HI%I: "BBB@ HHHH **** "BF9I
MRT +112-0 M%,IP- Q::RANHIU% BM)9I)VJK)HL<G85IT4 8,WA>&3^%:HS
M^!X),_(IKK**!G!W'P[A;_EF/RK'O/AK"V?W0_*O5*1E#=1FE8=SPO4/AE'S
MB(?E7+:E\-57.(OTKZ4GL8Y<_**R[KP_'+GY!18?,SY0U3X=%=V(_P!*Y6_^
M'[@G$?Z5]@7?@R.7/[L?E61<_#Q),_NQ^5&PGJ?&]YX#E&?W9_*L.Z\#S#/R
M'\J^SKKX8HP/[K]*P[[X6)SB+]*I3:V,_9QEN?&]QX-F7/R'\JSYO"<JY^0U
M]<7WPM"Y_=?I7-ZA\,]N<1?I5_6*D=F92P=&>Z/F%O#CI_"::-):/M7O6H?#
MQH\_N_TKF]0\#R)G$=;QQE5=3FGEN'?0\L6%HJE2Z,7?%=9?>$YES\AK#NO#
M<ZD_*:[(8Z:W9Y=;**4E[J*T>O-#_%5N'QE)#_RT/YUCW&@W"Y^4U1DT6<=C
M7I4\?'J>#6R:?V3MK?XA2Q_\M#^=:MI\2IE(_>G\Z\Q&DSKV-2)92IZUW1QU
M%[GE3RG$QV/9[#XGRAA^]/YUUVD_$YV(S+^M?.D/F18Y(K4L]5> CYOUK3VU
M&9BL+BJ3U/J[1_B1N"YE_6NPTWXA(V,R?K7Q[9^+GAQ^\_6MJU^(+Q8_>G\Z
MY9T*=38[:>,K4=S[0T_Q]$V,R#\ZW;7QM X^^/SKXJM?BB\>/WOZUO6/Q8;(
MS*?SKF>6J1WT\]<-&?94/BBWD_B'YU<CUBWDZ-7R=IOQ6)QF7]:ZK3?B<'VY
ME_6N6IEKCL>E3SV,CZ.6^B?HU2K,K=#7B^F_$)),9D_6NJT_QI%)CYQ7!/"R
MB>M2S&%0] I:Y^S\302 9<5IQ:M;R?QUR.G)=#THUH3V9=HJ);J)NCBG>:A_
MB%19FUT/HI-P]:6D,**** "BBB@!*6BB@ HHHH **** "BBB@ HHI#TH 6BF
M9IU "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y-Y,
M):@#.U[4UL[=CG'%>$^.OB0+"1P)<8]ZZSXC>*1:VT@#XX/>OC;XI>-9)+B4
M+(>OK0!ZK'\7#+=;?-[^M>K^!/&1OMA+Y_&O@G1_$5Q-?+\S=:^E/A7K<BK%
MN8T%'UG+KBQV1;=VKPGXI?$ 60D DQ^-=%J?B@QZ:WS_ ,/K7RS\8_%$DDDH
M#F@DRO%'Q,>:X<"7OZUQ-UXYG:3(D/7UK@[K4IKBZ/)/-68;668 X)H ]3\.
M_$2:WD7,IZ^M>\?#SXJ&1HU,OZU\>>7-:\\BNL\%>)9K6[C!<CF@#]+O!/BI
M=2BC^?/'K7H4;;T!'>OE#X.^+&F6$,_IWKZ;T?4!<6J<YXH UJ*2EH ;NI0<
MTVG+0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <WXE_U;5Y])_Q\_C7H/B7_ %;5Y])_Q\_C0!W/A?[JUUE<
MGX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:** "BBB@ HHHH **** &[:4#%+10 4A&:6B@!E. I:* $)HW4C44 .HHHH
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M10 4AI:* &[:6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTT;:6EJ#40#%(U.HH 93EI:* "D:EI",T )DTZF[33J "BBB@ HHI"P7J<4
M+15*YU*.'/S5GMKT:MC?0(W:*RK?6(Y/XJT8YDD'!H&24444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !12&EH ***:S!>2<4 .HJA<:I'%_%5!]?C4_?H WJ*R+?6HY#]ZM*&
MX25>#0!+2$9I:* $VTM%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]\P_\*(4445)T!112-TH -U&:;2KUH&*U-I]% @HHHH **** "BBB@ HHHH
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M7/[H_E7VI-X)@D_@6LJ\^'L+9_=C\J+L7+%[GQ1=?#>2/_ED?RK+N/!$L/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O\ JVKSZ3_CY_&O0?$O
M^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHIM #J*1:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQZZIRH-.J.W.Z%3[5)0(**** "DI:* &[:6EHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .;\2_P"K:O/I/^/G\:]!\2_Z
MMJ\^D_X^?QH [GPO]U:ZRN3\+_=6NLH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0TM% #=M**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HIK.%&2<55FU!(^XH N45A7'B%(<_,*R;OQI'#GYQ^
M= '9TUI%7JP%>:WGQ*CBS^\'YUS^H?%9%SB4?G0!Z]<:I%#GYA6/>>)(HL_.
M/SKQ'4OBP.<2_K7*ZE\52V<2_K0![Q?^-HX<_O/UKF[_ .)"QY_>_K7@.I?$
MAY<XDKFKWQM-,3AS0![_ *A\4PH/[W]:YK4/BL><2_K7ATVOW$_0FJYENI_[
MU 'JFH_$^1\XD/YUS-_\09ILX<_G7+PZ7=7&.&K2M?!MS<=4;\J *EYXJN+@
MGYC63-?75QW8UW=G\.9Y,9C/Y5T%C\+9&QF(_E0!Y!'I]U<-T:M.S\*W,V/E
M->YZ;\+=N,Q?I76:9\-43;F+]* /G^Q^']Q+C*&NFT_X8RMC,?Z5]#:;X!BC
MQF/]*Z:Q\&PH!\@_*@#YZT_X5N<9B_2NDL/A;MQF+]*]\M_#5O'C*BKT>DV\
M?1* /&],^'"QL,Q?I75VG@J..,#RQ^5=^MG$G1!4GEJ/X10!Y)XB\$(\+8C[
M>E>#>/O!1A+D1_I7V9>6*7$9!'->8^-O!JW<;X3- 'P=XBTR2VF8;>]<^@=6
MY%?1GC;X<MYCD1^O:O*M4\(O:,WR8_"@#CU)J09JY<::\3$;:KF%U;I0!"V:
MAD#-6C'9O*>E;6F^&I+K;\A- '/:58R33*,5[=\._"K3M&2F:J>%?AV\LB$Q
MG\J^@? /@<6JH2F/PH Z7P3X7%O#&=F*],LXO)A"U6TO3UM8%&.:OT +1110
M 4444 %%%% !1110 4444 %%-:D% #Z*** "BBB@ K(\20^=8L/:M>J]]#YT
M)6@#Y(^+WA\R+,=OK7R/XML6L;YSC&#7Z'_$;PO]JMY"$SQ7QU\4O!4D=Q*5
M3N:"CA/!?BDV-R@W8YKZG^&_BXWL,:[\_C7QO;:1/:WPX(YKZ.^#JR[H@<T"
M/:?%5B;[3V;&>*^3/B=IIL[R1MN,&OMY=)-UI?3/RU\U?&?P>^Z5@GK0(\9\
M%^*CIETOSXP:]TT?XL^39JOG8X]:^7K^RFTVZ8X(P:1?%$MNNW>1^- 'O/C?
MXE?;(7'FYX]:\1U+5OMUX3G.365?>()+P$;B:E\/Z?)?72\$Y- 'L?PKMV:X
MB(%?9/PUMV6WBR.PKYO^$7A5]T)*>E?6_@G2?LMO'QCB@L[VV_U*_2I:;&-L
M8%.H("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#F_$O^K:O/I/\ CY_&O0?$O^K:O/I/^/G\: .Y\+_=
M6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC%5I]#MYE(*C\JTJ*I2DMF9RIQENCB]8\#P3JQ"*?PKS+Q/\.4;?B+]*^@"
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M#3Z "BBB@ IK=:=24 (M.I*6@ HHHH ***:U #J*93Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MINL172CYQ^=:@(/(Y%9'J1DI*Z#FEHHH*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;MI0
M,4M% !1110 4444 %%%(U "T4RGT %%%% !1110 57N;1+A2"HS5BB@32>YR
M&J^$X[K/R9S7#:Y\,TN-Q\K]*]HICPI(,,H-==/%3I[,\VM@*59:H^4O$?PI
MVAB(OTKS'7OA_):LV(R/PK[BU;P_#<J<(*\^\0> 4N-V(P?PKZ##9K):2/C,
MPX>A*[@CXINM'GL9#\I&*FL=:FL7&217T%XA^%9;<1%^E>;ZY\-9H"Q$9_*O
MIJ6.I5E:1\)7RG$89WB4]*\?-!M!>NQT?X@K,5!>O(M4\.7-DQPK"LV"\N;%
M^=PQ3J86E65T11S'$865I'U/I.NP7V,L#746NDVU\H.%-?+_ (?\<26K*&<C
M\:]0\._%!%V!I/UKYS%93+>)]SE_$<=%-GJ,_@*WN5X0&N>U3X71OG;'^E;&
MB?$2WN%4&0?G78Z?KEK? ?,IS7SE3!SIO4^WP^:4JZT9X+K'PK*YQ%^E<7JG
MPWFAR1&?RK[$_LNUOEX"FLW4? UO<*<(/RKB=XZ,]:-IZH^)+[PA<6['"M^5
M94NGW5LW1J^O=6^&,<A;$7Z5Q^J?"4MG$/Z47!JQ\YQ:A=6O=A6K8^,+FWQE
MR*])U3X42)G$1_*N3U#X<SPYQ&?RJB2;3_B1/'C,A_.NHTWXI2+MS+^M>8W7
MA.YMS]QA5)[&ZMCT84@/HC2_BD6VYE_6NOTKXC+)C,OZU\DQZI=6IZL*T[+Q
MI<6Q&7(_&@#[3TOQK%-MS(/SKJ++Q%!*H^<?G7Q7I?Q.EAQF0_G77Z9\7&7;
MF7]: /KB/4()>CBIA*C=&'YU\W:7\6]V,R_K75Z?\3%FQ^]_6@#VC</44M>=
M6/CA)L?O!^==#8^)(YL?./SH Z2BJUM?1SKPPS5B@!:*** "D(S2T4 -VT9-
M.INV@!12T@I: $:DR:5J3:: %I:2EH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U)3Z* "BBB@ HHHH
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M)([&-CN H Z&34((OO.!5=M>LU.#**\&\6_%5;)G EQ^->:WWQR,<Q G[^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 444TM0 ZBD!I: "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-+
M4 .HI :6@ HHHH **** "BBB@ HHI": %HIH:G4 %%-W4HH 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI#0 M%-W4M "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N'K0 M%1M-&G5@*J7.K
M00J?F% %XL!U-,,R+U85RU_XHBBSAQ^=<SJ'CM(L_O/UH ]--W".KBHI-4MH
M^L@KQ+4/B8(\XE_6N:U#XK%<XE_6@#Z#NO$UM"#AQ^=8&H>-8(\_O!^=?.^H
M?%9VSB7]:Y?4OB9-)G$A_.@#Z'U+X@Q)G$@_.N3U+XE*N<2_K7@-]X\N)B?G
M/YUC7'B2YN/XFH ]KU+XG'G$OZUR^H?$R1LXE_6O+VN+JX;JU20Z7<W!'#4
M=9>?$&>3.)#^=8UWXLN9\_,U26?@^XN,?*:Z"Q^',TV,H?RH X>;4KJX[M4:
MVMU<'D-7K^G_  I=\9C_ $KI=.^$IXS%^E 'A%OX:N;@CY6K;T_P'--C*'\J
M^A-.^%87&8OTKI;#X;I%C]W^E '@&E_#5Y,9C/Y5U>F_"O=MS%^E>ZV/@N.'
M'[L?E6]:>'8X\?(/RH \5TWX3KQF+]*Z>Q^%<:X_=?I7K5OIL4(^Z*M*BKT
M% 'G5I\.(X\?N_TK6MO!<<./W?Z5V-% &);>'TAQ\HK2ALTB[59HH 3&.E+1
M10 4444 %%%% !1110 UJ*4C-&V@!:*** "BBB@ HHHH **** $:FTZC;0 M
M%%% "8HP*6B@ HHHH **** "BD-)NH =12"EH **** "BBB@ HHHH **** "
MBBB@ HHHH 92K1MI0,4 +1110 4444 %%%% !1110 4444 %0W;;;=C4U5=2
M;;9N: /'OB3JAAAEP>U?''Q3UEI)I1N]:^IOBM=%8IN?6OC/XCW1:\D&>] '
MG$ML;Z[Z9R:],\"> C?,G[O.?:N1\-68N;Q<C/-?6/P=\+1S+#E*!HQM*^#_
M )EN#Y/;TKG_ !=\*3:PN?*Q@>E?:^B>#X%LUR@Z>E<G\0O!L/V60A!T]*!'
MYR>*/#[Z;,PVXQ7%7#OYFVOHGXK>'UMII<+CDUX+?6P6[QCO0!U'@71_MUQ'
ME<Y-?6/PR^'Z7$<68_TKP+X3Z<)+B'CO7W-\)-'C$,1*]LT 5H_AS$+?'E=O
M2O+_ (C?#U(8Y"(_TKZP^R18QMKS?XGZ5&;>0[>HS0!^<GQ&\.?99I,+BN'\
M/J8+Y1TYKWGXO:>J338%>(V<?EZ@/K0!]/\ P:O#F#GTK[ \&3%[5/I7QC\&
MV^>'\*^QO!/_ !ZQ_2@#OE^Z*6FK]T4Z@ HHHH ***2@ W44VG+TH 6BDHH
M6BBB@ HHHH **** "BBB@ HHIDC;5H P_$NJ"RMF.<8KYR^)GQ$^RB51)CKW
MKU?XG:L;>SEP>QKXD^*WB:62ZF4,>IH Q_&7Q FNYG"R$_C7G%UKMY--D%CS
M5_3[&;6+KH3DUW^D_"V2[B#>43QZ4 >>6/B*[MV!+-7I/@GX@2P3(&D[^M9O
MB+X=2:?&S>61CVK@_,DTJ[QTP:!GW=\-?B!]H6,&3]:][T76A>0IAL\5\ ?"
MOQ7)YL0W^E?8/P[U=KJ&+)SQ0(]=4Y4&EID)S$I]J?0 444C<*: *.H7PME)
M)Q7COQ&\:"TCD ?%=KXUU;[+#)\V*^3_ (M>,&W2@/Z]Z .-^(7Q$DDED"R=
M_6O'M2\475U(Q5F-+JM[)JEXP!)R:Z+PWX$DU)5/EDY]J .*AUJ\CER2W6NU
M\,^.9[.5-SD<^M;U]\+9(8=WE'\JX+7-&ETF4_*1B@#ZH^&?Q(,K1J9/3O7T
M[X-\0B^@3YLY%?F[\/\ Q+):WD:EB.17V3\)_$QN(807]*"K'T;&VY0:=6=I
M-UYT*_2M&@D1O2DVFE_BI: &[J6FTY: %HHHH **** "BBB@#G/$R_NVKSV3
M_CZ_&O0_$W^K:O/)/^/H_6@#N?"_W5KK*Y/PO]U:ZR@ HHHH **3-+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>#\Z .THK M_%$4V/F%:EOJ"3 <T 6Z*0'/-+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1124 &ZDZTE.6@!%%.HHH **** "BBB@ HHHH *:PIU% #0*=110 W::
M5:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ?\ 'F]7*IZK_P >;T ?.7Q:/[N?\:^,OB$W^G/SWK[-^+7,<_XU\8_$)?\
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MU%-W#UI=P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]:
M%HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]:
M%HINX#O1Y@]: '44FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M
M "T4F:6@ HHHH ***2@!:*3</6F^8@_B% #Z*C^T1CJXJ*34((^L@H LTUI
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MB_2NKTWX7Q@#,?Z5ZY;Z'%'CY16C!9QQXX% 'F]C\-8EQ^['Y5NVO@"&,#Y
M/PKM0 O3BEH YVW\(P0XX6K\.APQ= *TZ3- $,=FD?05, %Z49HW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J>J_\ 'F]7*IZK_P >;T ?.7Q:_P!7/^-?&?Q$S]N?ZU]F?%G_ %<W
MXU\<_$*/_2I#[T 9?@J0)?)GUK['^#^H1QQ0Y85\0Z+J'V.Z4YQS7N_@/XB+
MI\<8\S'XT#/O+3=:A%NOSCI7.^--8A:SDPXZ5X):?&9(X@/._6LKQ!\7EN;=
ME\WMZT"./^,%XDDDN#ZU\[W+#[?^->B>._%@U!GP^<UY=+<;KG=GO0,][^$M
MPD<D63WK[(^&VK0I%&"PK\__  3XF&GLF6Q7O'A/XL+9JO[W'XT ?:OVZ'R]
M^\8KS'XE:O%)#)AQ7F?_  N^/[/CSAT]:X/Q9\6%O$?][G\: /._BY<+))+@
MUX=:G_B8?C7;^//$XOF<ALYK@-*F\R^!]Z 9]+?!O_60_A7V+X(_X]8OI7Q[
M\&U^:'\*^PO!'_'K%]*!'?1_<'TIU-C^X/I3J &[J4&FTY: %HHHH **** "
MBBB@ HHHH **** (+B7RU)KG=6U];4'+8K5UB;RHF/M7BGQ"\2-9QR$-C&:
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M&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT
M:G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H
M>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']
MH>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9
M>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;
M30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J
M?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[
MT?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA
M[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[
M31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M-
M &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_
M:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1
M_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O
M67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-
M&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT
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MC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC::
M-3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T
M/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^
MT/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>L
MO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-
MIH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U
M/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]
MZ/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0
M]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]
MIHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF
M@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]II=K4 :?
M]H>]']H>]9A5J3:: -3^T/>C^T/>LO::558T :?]H5(FH>]9HB:H+B7R5/-
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M533MK4 :?]H>]*NH<]:RMK4JJV: -J.]W=ZMPS;JPX-U:EKF@#1%+35^[3J
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MK['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*]J
M,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*]J
M ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*]
MJ ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*
M]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/
M*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J
M/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]
MJ/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*
M]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?
M*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU
M?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]J
MU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]
MJU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C
M]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]
MC]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1
M]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M
M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?
MM1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL
M?M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH RO
ML?M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH R
MOL?M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH
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M/)% &3]C]J/L?M6MY(H\D4 9/V/VH^Q^U:WDBCR10!D_8_:C['[5K>2*/)%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M([M5_>#GWKNM+UJ*Z4?.#7.XM'TM+$0J_"S6HI%8,,@Y%+4G2%%%% !1110
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M110 4444 %%%)0 M%-W4M "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%(: %HINZG4 %%%% !1110 4444 %%(3BC=0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !113=U #J*04M !1110 4444 %%%% !1110 4444 %%%
M)GVH 6BDS[44 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 44FX>M)O7^\/SH =13?,7^\/SIOG1C^(4 245
M%]JC'\0IIO(A_$* )Z*I2:I$O\0JM)K4:_QB@#6HK$;7HQ_&/SJ%_$4:_P 8
MH Z&DR*Y>3Q-&O\ '^M0/XJ0?QC\Z .OW#UHW#U%<1)XOC7^,?G563QJB_\
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M+$?Q8;_GK^M68_BTW'[W]: /J'^V;?\ OC\Z3^VK?^\/SKYF'Q:/_/7]:/\
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MT]/$49_C% '0T5CQZY&W\8J7^V(_[U &G167_;$?]\?G1_;$?]\4 :E%9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 C*&ZC-9NHZ)#>QD%1FM.B@#R;Q/\ #R&XW8B'Y5YOJ'PG
M1Y"?)[^E?3<UJDWWA5)]"@<Y('Y4 ?/&F_"B-&&8?TKT'P[\/(;;;^[ _"O2
M(]$@CZ ?E5N*U2'H* ,[2]!BLD7Y0*UE4+P!BEHH YKQ)I8O%88S7E'B'X>K
M>.Q\O/X5[O) LG6JLFD0R=10!\]Z;\,5AG#>5W]*]2\)>'1IX7Y<8KKUT2!3
MT'Y5:ALTAZ4 3(,*![5!>6272$,*LT4 <!XB\#PWBM^[!_"O,M<^%D<CL1%^
ME?1,D:R#!%4Y=(AESD?I0!\SVWPE19L^3^E=UX;^&T5NRYBQ^%>LKH-NIS@?
ME5N&PBAZ"@#)T?PW#91CY0*W(XUC7 %/HH **** "BBB@ HHHH **** "BBB
M@ HHHH YOQ+_ *MJ\^D_X^?QKT'Q+_JVKSZ3_CY_&@#N?"_W5KK*Y/PO]U:Z
MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM-^(D+8_>#\ZW[;QI;3?Q+0!TU%9$?B*WDZ$?G5R+4HI.AH MT4Q9%?H:?0
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M#V0?\LS^5 '%-XBN!CYFIG_"27&?O&NND^'\G_/,_E47_"OY<_ZL_E0!R_\
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M%"/_ )ZC\Z7_ (6A'_ST'YU\H?\ "8S_ -\_G1_PF4_]\_G0!]7_ /"T(_\
MGH/SH'Q0CS_K1^=?*'_"93_WS^=*OC*?/WS^= 'UI'\3HS_RU_6K*?$F(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG$O_ "T'YU5D\;QC_EH/SH ]'^T1_P!ZD^U1_P!ZO,7\<Q_\]/UJM+X]1?\
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MY?B8_/[W]:IS?$V3G]Z?SKRW[+<M_>H_LVY;LU ST2;XFR_\]3^=4Y/B9/\
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M?I5R/X0_],OTH ^:%T2Z;^%JL1>';EL?*U?3,?PAQ_RR_2K4?PF"_P#++]*
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MHO11^5 'BL?PEC7_ )9?I4J_"F/_ )Y?I7LVU?[H_*C:OH/RH \@B^%L:_\
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M]GVK_='Y4;5_NC\J /%S\*X_^>0_*FM\*8S_ ,LOTKVKRU_NC\J/+7^Z/RH
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MEINVG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?WGZU3N/B:?^>GZT ?2<GCA%_C_6J[>/4'_+3]:^9)OB4S?\M/UJLWQ%=O\
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MF?RJ6/X<S-C]V?RH Y-?$%RW=J>VKW+=VKM8/AO+_P \S^57H_AO)_SS/Y4
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M'2N[K(T:S^S1J,8K7H **** "DW4M-;K0 NZEIJ]:=0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDQ_I7TAX.T$6L*97'%5/#?@]+-5.S'X5V]I;BWCP!B@"5(P@XI]%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $)I U#4#K0 ZF[J=3* '"EI%I: "BBB@ HHHH **** "BBB@ I#2TC4
M )NI:;3J %HHHH **** "BBB@!"<4FZE:FT /HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "D-+10 W;3J** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "F[J=3: %!I::M.H **** "BBB@ HHHH ;NI0:2
ME6@!:*** "BBB@ HHHH *;MIU% ""EHHH **** "BBB@ I*6DH 3=2BFTY:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+CCTJ#PKX)2TC4^6!^%>A6-DMK&!C% $]O"(8P!4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGM7R/\(],FB,.0>U?6/@N$K;QY]*!'=)]T4ZFI]T4Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ
M+_JVKSZ3_CY_&O0?$O\ JVKSZ3_CY_&@#N?"_P!U:ZRN3\+_ '5KK* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2@G%)G- "
MTM-P:=0 5!=6J7$9##)J7FE% MSC=6\'QWF[Y <^U<!KWPK2XW?NOTKW*F/"
MDGWE!_"M%4://K8&E6W1\@>*/@WPY6+]*\>\3_"V:U9RL9_*OT)U7P_!=1G"
M#\J\Y\1_#N*[WXB_2NF%9]3Y/'9#"2O%'Y]W_ANZT^0X5ABG66L7>G,,EABO
MJGQ-\(/,WD0_I7E'B3X4RV^XK$1^%=D:BD?$5LJKX=WB86@_$J>T909"/QKT
M[PW\8&R@,Q_.O"M6\)W6GL<*PQ6-'=7FGR=6&*MTXR,:>/Q&%=F?<WAOXI)<
M;<R_K7J6@>,H+A5S(#^-?G?H/CZYLW4%R/QKU3PS\7GAV!I?UKDG0['U^ S]
M:*;/N>WU&"X4%7'YU9# ]"#7S/X;^+PE" R_K7IFA_$".\V_O <^]<<J;1]I
M0S*C66C/3:*R]-UB*Z0?.*TPP;D'(K(]6,E)70<TM%%!04444 (U)DTII-IH
M 7;2=*=33UH 4&EIJTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJUY9I<H05YJQ2T[V$TGHSB]6\'I=;OD'Y5P6O?"]9PV(OTKW&HY+>.3[R@UV
M4\5.GLSS*^7T:RU1\C^)/A*5#D1?I7EGB#X=S6K,0A_*OO#5O#L-RK80<^U>
M>>(/A['<[L1_I7T&%S:2TD?&8_AV$KN"/B.XTFYL9. PQ5RQURYL6'S,,5]!
M>(?A23N(B_2O-=?^',MN6Q&1^%?24\;2K*S/A,1E>(PKO$KZ+\1IK7;F0C\:
M]&\._%8[D!E_6O!]2\/W-BQPK"J%OJ%U8R<EABJJ8.E65T10S/$85VD?:WAW
MXB)<;<R9_&O2='\30W"+EP<^]?!N@^/)[5E!<C\:]1\._%9HP@,OZU\YBLI>
M\3[G+^(HNRFSZ_BNHIA\KBI=P/>O!]!^*"S;09/UKO\ 1_&4=UM^?]:^<J82
MI3W/MJ&94:ZT9W5%5+._CN(P0PJW7'L>JFI*Z"BBBD,*:33J:10  TZF@4Z@
M HHHH **** "BBB@ HHHH **** "BBB@ HHI&Z4 +5:ZM%N$((YJ:GT </K?
M@]+P-\GZ5P^I?"Y)G)\K]*]OP#U%,:"-NJ"@#YWF^$:EO]5^E.M_A&JD?NOT
MKZ#-E"?X!0MG"O1!0!X[I7PQ2!@?+_2NZT7PJEF%^3]*ZQ847HH%.H BM[=8
M$  J:BB@ II-.II%  M.IJBG4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A
M:DS0 NVBBEH **0FC=0 M%%% !1110 4444 %)BEHH 3%&<=:*P?$&NQV,+'
M=CBJC%R=D1.:IKFD+X@UV.QA;YL$"O!_B!\0A&LBB3]:=\0/B$(Q(HD_6OG3
MQAXN>\D?Y\_C7U>79>Y-2DC\ZSO.E!.,&/\ %'C1[J9_G[^M<Y9^*)(;@'>>
MOK7,W5T\TA)-5MSA@:^ZAAX1C8_)ZF/J2GS7/HWP#X]*M&#)Z=Z^C?!?C!+B
M- 7S^-?!/A_69+.13NQS7MO@/QZT+1J9/UKYG,<O4KN*/O\ )<Z<6HS9]I6=
M\EP@(-6Z\H\'>,DND0%_UKTRQO4N8P0:^%JTI4W9GZQ0KQKQYHENBBBL#I"B
MBB@!K4E.(S2;: '4444 %%%% !1110 4444 %%%% !1110 5SOC.0QZ<Q'I7
M15S_ (PB,NGL/:@#XS^,NI.K3<^M?+NM737-XZDYYKZK^,6BM(9CCUKYCU+3
M3%J1R/XJ )_#?A5M2D3Y<Y]J]B\-?"%KB-3Y7Z54^%.DQW$\08#J*^R?A_X,
MMYK2-BB]* /G*W^#!4#]S^E3_P#"F?\ IA^E?8*^$;)?X?TIW_")V7]W]* /
MCO\ X4S_ -,?TH_X4S_TQ_2OL/\ X1&R_N_I1_PB-E_=_2@#XVF^"V[_ )8?
MI4^E_!KR9@?)_2OL+_A$;+^[^E*OA*R4Y"_I0!XMX,\!_P!GE/W>,>U>QZ%8
M?9HP,8K1AT6W@^Z/TJY'"L?2@!Z]!2T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?\
M?/XUZ#XE_P!6U>?2?\?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 UJ04^B@ HI*3F@!U%)2T %
M%%% !4;V\<GWE!J2DH S;S0+:Z4C8,UQ7B+P#!<*V(Q^5>D5')"LHPPJE)HY
MJN'A55FCY?\ %7PK63?MA_2O(/$GPG>,N5A/Y5]WW6@07(.0/RKF=8^'UO<*
MV$!_"NJ%9H^7Q>10K7:1^>.J^!+FS9B(V'X5S]Q'=Z<W\0Q7W-XD^%,3J^(A
M^5>-^+OA,1O*Q?I77&LGN?%8S(ZE#6!X?I/C2YL64%V&#ZUZ;X4^*KPE-TOZ
MUQ.O?#N>U=ML9&/:N:?3;K3F/##%:VC(\:G6Q.$EJ?7_ (7^+Z,$!F_6O4-#
M^)T5RJCS<_C7Y]Z?XFN;&099ABN\\.?$Z2!E#2'\ZYIT.Q]3@^()1LI,^^]-
M\41W@'S@YK>AF69<@YKY(\(_%A?DW2_K7L/AOXG03*N91^=<<J31]QA<TI5E
MJSUJBN=L?&%M= ?,N?K6O!J44^-I_6L;,]F-2$]F6Z*16#<BEI&H4RGTTB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M._6@#ZQ2^AD^Z^:F616Z&O$O"OCP7^S]YG\:]3T?4/M$:G.>* -RBD7H*6@
MHIN32K0 M%%% !3:=3* %6G4U:=0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!S?B7_5M7GTG_'S^->@^)?\ 5M7GTG_'S^- '<^%
M_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !33UIU,/6@ R:4=:!S2[: %HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFE6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBDS0 M%)FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBDS0 M%%% !1110 F:!2T4 %%5KB\2 <FL>\\516V<L*N
M,)2V,IU(P^)G0=.M4+[5([93\PKAM6^)$4*M^\Q^->?>(OBHFUL2_K7=2P52
MH]CR,1FM"BMST_5O&D=J&^?'XUQ6L?%-(=P$OZUXEXC^)S2%L2G\Z\ZU;QM/
M=2'$A-?18?*+ZR1\1C.).5V@SV_Q!\6MVX"7]:\VU[XC2W&[#G\Z\_:\NKYN
MK'-7[+P[<WF,JQS7NT\'1H;GR-?-,3BW:(R\\1W%XQPQ-0VUG<WTG1CFNST;
MX=S3,"8R?PKTCPW\,L;2T7Z4ZN+I45H.AEN(Q+O(\MTGP'/>8S&3^%=EIOPC
M>903%^E>\>&_A[%&JYC'Y5Z#IOA&VMXQN0?E7SE?.))VB?:8/AJ,E>9\CZI\
M)VMXB?*_2O,O$_A-[%F^3&/:OO[7/"-O<6[%$!X]*\'^(?P_!$A6/]*Z,%FC
MG*TCDS7A]4X7IH^/KJ%H7(Q5(R-NQBO2?$WA%[>9_D[^E<Y;^&9);@#8>M?9
M0KPE&Y^9SP=2,^6Q!H>DO?.HVYS7LO@7X?M.T9,?Z5%X \"-))&3'^E?2W@7
MP7'!&A* ?A7S68YAR)J)]]DN2NHU*:*_@OP.MJD9,>/PKU/3M-CM8P M2VFG
MQVL8 %6J^$K5I57=GZUA\/'#QY4A*6BBN<ZPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "J6J0^=;E<5=IDB[UQ0!XWXN\(B^W_ "9S7EFJ?"WS
MI&/E?I7U-<Z2L_45GR>%XV.=@_*@9\I-\']S?ZG]*E'P=./]3^E?4W_"-V\?
M+**AN-/LX5.0HH&?+K?"';_RQ_2H_P#A5('_ "R_2OHG4/L4>?NUB275F'ZK
M0!XFOPE#?\LOTI__  IW=_RQ_2O=K&:S=ARM=%9V]E(H^[0(^8+CX,G'^I_2
MGZ;\(O)F!\G]*^JO[#M9APJFD3PG%G(0?E0!Y9X-\$BQV?)C'M7KVBV/V>-1
MBI;70TM\87%:<4(CH$2#H*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVKSZ3_ (^?QKT'
MQ+_JVKSZ3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\C\=?$9;??MD_6O&-:^+3QR,!+^M;QHN1XF*SN%"5KGUT?B);_\ /0?G2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBFT .HIJTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ J"YNX[6,L[8HO+@6\)8G%>3>/?'2Z?%(/,Q@>M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVKSZ3_CY_&O0?$O\
MJVKSZ3_CY_&@#N?"_P!U:ZRN3\+_ '5KK* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D-+10!&5IPS3J* "BBB@ IDD22+AE!I])S0!
MSVL>'(;I3\@.?:O._$'PUCO-V(@<^U>RXIK0HW50?PJXS<3BK82G6^)'R9XF
M^#._>1#^E>4>)/A-+:[]L6/PK[_NM'MKI2&C /TKAO$O@."X5\1C\JZ85VMS
MYC&9#3FFXH_/'5?"-U8R-A6&*S8;J[T^0<L,5]A>*?A6LF_;%^E>2^)/A/)&
MSE8OTKMC64MSX3$Y/5H.\#C_  W\1KC3]N9",>]=K_PN&1K?:9CT]:\RUOP7
M=6!;",,5Q]]'=VI(.ZKY(R.)8S$X9<K/1?%'CR34-V)"?QKS35-4FF=CN/YU
M3DO)2<,34+2>9UK2*2/(KXF=9W;*[7<V[[QJ1;V8?Q&C8*7:*U..S[B?;)O[
MQH^V3?WC^=.VBC:*D->XW[9-_>/YTHO)O[QI=HI54>E :]RK<7DW]XU;T6]F
M\Y?F/6JUPHXXJUI"CSA]:?04;\RU/=OAI>2&2+)/6OK7X<S%XH^:^1?AN/WD
M7X5];_#?_4QUYE?<_5,AOH>Q6_\ J5^E25';_P"I3Z5)7G'Z6M@HHHH&(1FD
MVTZB@ INZG4V@!0:#2#BES0 FVEI:* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3=1NH 6BDS2T %1RP),N
M&4&I** .9UCPW%<J?D'Y5P&N?#=+HMB+/X5[)33"C=5%=5/$3I['G5\#2K_$
MCY6\1?"/.\B']*\Q\0?#66UWD1D?A7W5>:+;W2G*#-<)XD\#17 ?$8_*O>PV
M;3B[2/D,?P[3DFX(^%K[P_<V+GY2,5!:ZE=6,G5ABOIKQ)\,@^XK%^E>8:[\
M-98BQ6(_E7TU+'4ZJ]X^!Q&45\,[P,/1?B%/9E<R$?C7I/AWXM,NT&7]:\5U
M;PO<V;'"$8K%6YNK&3^(5K+"4:ZNCFI9EBL)*S/M#0/B<+G:#+^M>A:-XLCN
M0OS_ *U\)Z#XTGM67<YKT_PW\4&CV@R?K7@8K*K:Q1]K@.(D[*;/LFUOH[A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **;NI0<T +1110 FVBEI-U "T4F:6@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML.K%71X MW=P=VJQ#X@N8<?,U>L:A\,V&<1?I7/7GPYD3.(_TK:.*HSW.>6
MQ-/8Y>W\93PXR[?G6M:_$26/&9"/QJM=^ YTSA#^58]QX/NH\X5JUY:%0YG+
M%TCO++XH.N,R_K706'Q8(QF7]:\5D\/W<7\+4S['=P_WJAX.A(VAF6*I[GTA
M8_%P#'[W]:W;/XNKQ^]_6OE(7%Y"?XJGBUJ[B/WFKEEE=*6QZ-/B"O#<^O[7
MXKHV/WOZUK6OQ.C?'[W]:^.H/%5S'C+-6G;>.)HR,N?SKDJ91%['JT>))]6?
M9%M\1(WQ^\_6M&'QS')_'^M?'UI\1)%QF0_G6U9_$MEQF3]:\^>4M;(]:EQ&
MGNSZTA\71R?QC\ZNP^((Y/XA7RU9_%#&,R_K6_8_%).,R_K7#/+9KH>M3SVG
M+=GTI#J:2=Q5N.59.AKP/3_BA$<?O?UKI+#XG0<9E'YUPSP52/0]6EFM"?4]
M;HKA+/XDVS*,NIK2C\>V;_Q+^=<KH5%T/0CC*$MI'4T5SB^-+5NC+4\?BJW?
MN*GV<^QK[>F]I&Y167'KT#]Q4ZZI$W0U'*UT+52+ZEVBH([I'Z&I@P;I4EII
M["T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ":\2'J:!-VW)Z*QY
M_$EO!U(K!U7X@6\", ZBMHT9RV1SSQ-*FKR9U%WJ26X.37/:AXRCML_./SKS
M/Q%\3HUW8E_6O+?$7Q.+;MLOZUZV'RZ=3='S.,SRG1^%GN.L_$R.)6_>_K7G
M?B+XL#:P$OZUX?JWCR:X+ 2'\ZYFYU:ZOF(!8U])0RF,=9'Q&+XAJ5-(,]$\
M1?$UYF;$A_.N#U'Q;<7CG#L<^]4X]%NKYAPQS73:+\/YKAEW1G\J]B,:&'1\
MS*KBL7(YF);J^/\ $<UM:;X/N+HC*$YKUCPS\,<[-T7Z5ZGX?^&D:A<Q#\J\
MW$9G"G\)[F#R&K7LYG@VC?#*21E)B_2O2/#OPQ";2T7Z5[AI?@*"% 3&H_"N
M@M_#MO;@8 _*OG:V:RGHC[;"<.PI6<D<!X>\ PPA<QC\J[BP\+V]NHR@'X5K
MPVJ0_=%35X=2O.H[MGUE'!TZ*LD5H]/@C& @J=8U7H,4ZBL+L[4DM@HHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!E*M)2K0 ZBBDH ,BC(IM% #
MJ6FK3J "BBB@ HHHH **** &4JTZB@!*,BD:DH ?1110 4444 %%%% !1110
M 4444 %%-)H!H =3)(_,7%/HH X[Q=X;6\LWPN>*^3_B[\/W8S%8_7M7V]+&
M)8RK#(-><^-_!<.I1R'RP<^U 'Y@>*?!L]K=.=A'/I6%"LVGMW&*^R_'WPI4
MM(5B_2O!/%GP\EMW?;'^E SCM.\8RV8 WD8]ZV%^),HP/,/YURFH>%;J%CA6
M%9?]@78;[K4 =Q=?$"6=2/,/YUS.I:Q-?,?F)S5:W\.W3L,JU=1HO@>>XD7*
M$_A0(YK3]!FU"8?*37M/PU^'\C31,8_3M6]X'^%[2-&6B_2OH[P%\-5M5C)B
M_2@9J_#'PG]CBBRF.!VKVZSMA!$HQVK)T/0UL8U 7'%;] @IK=:=28H !TI:
M;FE6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH YOQ+_JVKSZ3_CY_&O0?$O^K:O/I/\ CY_&@#N?"_W5KK*Y
M/PO]U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT %%%% !1110 4444 %%%% !3*?2;: !:6DI: "BBB@ HHHH **** "BBB@
MHHHH 2FT^F[: %6EI!Q0U "T4W)IU !13<FE% "T4TTE Q]%(*6@04C4C4=:
M $IU)MIU !1110 44AI,F@!U%%-:@!U%-!IU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-R: '
M44BTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4RGTW;0
M+3J0#%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E#
M4F30 E.6DVTHXH 6BBB@ IE/INV@!5I:0<4M !1110 44W)I5H 6BBB@ HHH
MH **:U&30 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD:DR: '4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?
M\?/XUZ#XE_U;5Y])_P ?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !3)(_,7%/HH R+K1TGSE:S)O"L,G\ KJJ2G=F,J,);HY ^#X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <WXE_P!6U>?2?\?/XUZ#XE_U;5Y]
M)_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM%+3 ****0!124W- #Z*1:6@ HHHH **9FG+2 6BBBF 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 -;K24[%&T4 (O6G4F*6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK=:=2
M8H 1:=28I: "BBB@ HHHH **** "BDP?6C\: %HHHH ***3'O0 M%%(2!UH
M*AEO(X?O&JVH:DENAYKAM>\4"/=AJ .X;6X%."WZT^+5H9>A_6O#[KQ@_F\/
M6EH_BXF1=ST >TI()!D&GURNB^(4F5?FKI89UF7(- $M-:G4UJ $I]-'6G4
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M.]CDZ&IE8-7GOAWQ!]L"_-FNZLY"\8- %JBBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &[:4"EHH **** &[:4#%+10 A.*3
M=0U)0 ^BBDW4 +129I: "BBB@ HHHH *0TM(U #=WO2AJ:5IR]J '4444 %%
M%% !1110 4444 %%%)0 4M(!BEH *;NI=U)UH /O4;:%%.H **3=2;J '4A&
M:3=2[J $V^].I,BEH **** "BBB@ HHHH **** "BBB@!-H]!36A1NJBGT4
M59-/BD_AJE-HD3_P"M>BJ4FB'",MT<Q<>&XGS\@K,NO!\<F?W?Z5W-&T>@K6
M-:43FEA:<NAY;>> 8Y,_N_TK#O/ABLG_ "R_2O;?+7^Z*;Y,?]P?E71'&5([
M'%/*Z,]T?/-U\) V<1?I6/=?!_K^Z_2OITVL1ZQK^512:;;R=8Q71',JL3BG
MD6'ET/D^Z^$;+G]U^E8]U\)W&<1'\J^OIO#]M(.$'Y50G\*6[9^0?E77#-IK
M<\ZIPW2>R/C>[^%TL?\ RS/Y5CW7P_GAS\A_*OLJ\\%PN#^['Y5SU_X!B?.(
MA^5=]/-F]SR*W#<5L?']QX1N(L_*U9\VAW,.?E:OJ^^^'"-G]U^E8%Y\,<YQ
M%^E>A#-(O<\2ID$X['S,UO=0GHU)]LNH>[5[W>_"QCG$/Z5B77PJDYQ%^E=<
M<=2EN>=/*<1#8\EC\0747=JT+;QA<QX^<UVEQ\*YES^Z/Y5E77PWN(\_NV_*
MMO;4)'*\+BZ?<K6OQ"N(L9<UL6OQ1FCQF0_G7,W7@>YC_@;\JS)_"]W'_"PI
M^RP]0%7QE+N>I6?Q:D7'[W]:V;7XN/\ \]?UKPEM)NX>S4FV[A_O5C+!49;&
M\<VQ4-SZ/M?BV>/WOZULV?Q5WX_>_K7RL-2NHN[5:M_$ES$W+-7/++(/8[Z?
M$%:.[/KVS^)"R8S+^M;EGX\CDQ^\'YU\?V?C:>+&7-;5G\1I8\?O#^=<,\J[
M(]BCQ'_,S[!M?%\4F/W@_.M6W\21/CYQ^=?(EG\4G3&9/UK<L_BT5Q^]_6O.
MGE4^B/9I\14NK/K&WUB&0<N*N+=1/T<?G7R[9_%\+C][^M;MG\85./WWZUQ3
MRVJMD>G2S[#RW9]$;U/\0_.EW#UKP^U^+228_??K6K;_ !.23_EK^M<LL%5C
MT/0AFV'ELSURBO-[7X@QR8_>_K6K;^-(Y,?O/UK)X>HNAUQQM&6S.SHKFX?$
MT<G\?ZU?AUJ.3^(5BZ<D=$:T);,U:*KQWD<G>I@RMT.:@V33V'4W;3J*0QO-
M*,TM% !1110 W;2BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0TFZE--P: '4M)2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444E "T54N+H1]351M85?XJ -:BL
M.;7D09W5EW'BQ8_X_P!: .PHKA4\:*S8W_K6UI_B!;G'S4 =!13(I!(H(J.Z
MF\F/- $]%<IJ/B86I/S5C2>.U1B-_P"M 'HE%><?\)\O_/2C_A/E_P">GZT
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M70C:JF5KU*W79"HH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***0G% "T57DO8XNIJ ZU;*<%OUH OUD>)L_V>V/0U<CU
M*"3[K9JOK&+BS('- 'RI\65E?S<9[U\N^*]+FFG?@U]L^/O#/VKS/ES7B.N>
M /,F8^7^E V?+5UX<D:3E33%\.NO\%?0\GPU+M_JN_I2K\+7;_ED?RH$?/0T
M61.BFI/[-F'8U] GX4N?^6)_*D_X5.__ #R/Y4 ?/_V&;T--^P3>AKZ"'PE?
M_GD?RI#\)7_YX_I0!\Z75C/CH:O^&[";[4N0>M>Z3_"-V'^I_2K>B_"9X9E/
ME'KZ4 =)\([:1?)R#VKZT\%J1;1_2O%_A_X*:Q\OY,8KWOPY9?9X4&.U '3Q
M_<'TI6Z4+]T4M "+TI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .;\2_ZMJ\^D_X^?QKT'Q+_ *MJ\^D_
MX^?QH [GPO\ =6NLKD_"_P!U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1J #-+3*=0 M(U+36H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-W)Y<+-4U9^M2>78L: .
M\5>*A8!_GQBO,=0^*8AN"OG=_6HOBMK+6XFPV.M?+_B+QA+'J##S#U]: /LC
MPK\0O[0D4>9G\:]8TZ\^V6H)YXKXG^$WBAKBZB#/GGUKZZ\+ZG'_ &:I+=J
M*OBB&/#;@*\XOH+9I2#MK<^(GBR.SC?YZ\)U+XF)'>%?,[^M 'L6FZ#;W3#"
MJ>:Z[3_A_%/&"(@?PKRKP#XZBO)HP7[U](^%=0@NK-=K#=B@#D_^%:Q_\\OT
MH_X5I'_SQ_2O2Z* /-/^%:Q_\\?TI?\ A6J?\\OTKTJB@#S-OAG&W_+']*?#
M\-8XVSY/Z5Z310!R>G^$UM,83'X5T-M:>2H&*MT4 )2T44 %%%% !24M)0 F
M32BDVTHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI":-U "T444
M%%)NH!H 6BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U !DTZF4^@ HHH
MH **** "BBB@ HHHH YOQ+_JVKSZ3_CY_&O0?$O^K:O/I/\ CY_&@#N?"_W5
MKK*Y/PO]U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *2EHH 3;2T44 %)2T4 )M%+110 4444 %%%%
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M&7!K;CG2495@:RM8].,XR5T24444BPHHHH **** "BBB@ HHHH ;DTJTFVE
MQ0 M%%% !112;J %I&H!H- "9-.INVG4 -:@&E(I * '4444 %%%% !124;J
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!-M%+10 E&T4M% !1110 4444 %%%% !28S2T4 )MHVTM% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4FVEHH 3%+110 4FT4M% "4M%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4;:6B@!-M%+10
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M+#<?O3^=<,\IFCV:/$=-[L^LX]8MY/XQ^=3K>0MTD6OF"S^+1XS+^M;=I\6
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M6I&XA&3VKGO'BE[=S[4 >-1?\A ?6O>OAK_JXOH*\'1=NH_C7O/PU9?+CR:
M/3:Q]:X1OI6Q6%X@F5$;GM0!Y+XT;+/7#V"DW@^M=CXMF$CL :Y?2X"UT#CO
M0![-X"'[M/I7H%<+X'B*QIQ7=4 %<KXU7-NWTKJJYKQA'NMS]* /G[7E/VMO
MK70>#N)%K,\06I%RQQWK0\+2".1<\4 >T:%]Q:Z&N8\.SJR+S73T <KXX_X\
MV^E?.GB,_P"G-]:^B/'<BK:,,\XKYR\0MNOFQZT ;GA[/D\5B>-I#Y;"N@\,
MPEH1Q6+XVM6VGB@#S[2+ W=\HQGFO=?!?@7[5 AV=O2O*O"-N/[07([U]5>
MH(X]-4J!NQ0!R<WPYS&W[OMZ5Q&O>!#;L3L_2OHP\\'D5R/BRUAVOP* / +>
MW.FSCMBO0_">O$;%W5R/B6(1W#;:=X7E<7"CWH ^AM&N/M%N#[5>F;;"Y]JQ
M/";$V8SZ5JZC)Y=G(?:@#RKQUK7DEP&KRN:\-]=8SGFND^)%\?.< ]ZXOPWF
MXOESSS0!Z5X1T/S&1MM>Q:#:BVA QCBN7\%Z:/LZDCM7<PQB-<"@"6BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I&I:0C- "9-.INVG4 %%%% !1110
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M10 4444 %%%% !1110 4FVEHH 3&*6BB@ HHHH **** "BBB@ HHHH ****
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M)_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "FO]T_2G4C?=- 'GWC!/E>O&=>NOL\Q.>]>U^, -CUX+XPSYK8H
MT_#OB ),HW=Z]H\)Z\&C7YNU?+NFW4D-P.3UKU'PSXC,$:Y;M0![E=:\L<+?
M,.AKQ/XA:T)V<!JU-0\5;HB _:N UJ1]1D/>@#,T-C-?+]:]P\,V)DLQ@=J\
MP\*^'7:X1BO>O>O"NEB.W4,.U '&:[H<DV["UR%QX6F9C\IKWV71X9>H%5V\
M.6[=A^5 '@?_  B<_P#<-'_")S?W#7O?_"-6W]U?RH_X1JV_NK^5 CP,^$Y_
M[IJYI_A>9) =IZU[A_PC5M_=7\J<OAVW7^$?E0!R7AW2WAC (K.\:V9-NW':
MO28=/CAZ"N<\5:;Y\;@#- 'SA?0FWOB<=Z](\"Z\+?8"V*Y_Q'X?:.9F"UD:
M?<R:?)W&* L?2%MKRR1@[NU<CXN\0"-6PU<EI_BPK#@O^M8/B;7&NU8!LT#*
M&J:Q]KN",YYK:\,Z<9Y$;%<?I=E+=78.">:]E\&:'MC0E: .O\,VGV>-.,5T
M+3!>]5(81;0@XQ63J.L" D9H Z!9PW>LS7H?M$)'7BLNQUQ9) -U;B8NH_6@
M#QGQ3I9C9VQ7(6^I_8;C&<5[+XLT;S(G(7M7B/B+39;>Z8@$<T >K>$?$0DV
M#=7?_P!N*L(.[M7SMX;U9[-ADXQ783^+?W&-_;UH U_''B(2HZALUX]< WE[
MGKDUMZKJ3ZA(0#G-3:#H37%PK%>] '2^$]))MQ\M9'CK2RL;'%>I^'=%$-LH
MVUC^--!\^%\+0!X'H\GV/4!VYKZ"\!^(PMNJ[NU>*:EH,EK=$A<<UO:!K#V&
M 6Q0!]"-K2^46R.E<!XM\2!0XW5D?\)=_HY&_MZUP_B+6'O';:<T 1:EJ/VR
MX(!SS72>$M-,DBMCO7(Z)ILMU< D$\U[/X1T+RT0E: .S\/P^1; >U-\17GE
MV3C/:M"&+R8<5S'BF8F%A[4 >%>/K@RW+?6L_P $VY:^3CO6GXHLVGN&X[U>
M\%:64ND..] 'NWA&W$=BIQVKH*R_#\?EV"BM2@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 E&T4M% !1110 44UJ : '4444 %%%% !1110
M 44W;2CB@!:*** "BBB@"*2W63J*J3:6DG85H44TVB7%2W,.7P\DG\(JK-X1
MBD_@%=-16BJ26S,G0IRW1QDO@.*3^ 51N/AO%)_RS%>@T5HL1474PE@J,MT>
M47?POC;/[H?E6)>?"J,Y_=#\J]QIC6\;=5%;QQM6/4Y9Y70ET/G>[^$R<_NO
MTK#O/A*.?W7Z5]-R:;$W\(JG/H<;Y^05U0S&HNIYU3(Z$MD?*5[\*RN<1?I6
M!>_#-USB/]*^N;CPM')GY/TK*N/!$<F?W?Z5WPS22W9Y%7AZ#V1\?W7P]E3.
M$-8]UX-GAR0A%?8EQ\.TDS^[_2L74/A:KH?W7Z5WPS9=3QZW#C^RCXXO=)N+
M?/!%8=TTL;$,2*^I?$WPL,:.1%^E>+^+O!,EFSX0C\*]S#8VG59\?CLKK8;4
M\QDG+=32+\U.U"RDMY"",5#&Q'6O:NK:'S&M[,G Q2TU6S2DT%#63=4++MJ?
M=36C,G2FA,N:3J;6L@.ZO3_"GCMK4H/,QCWKR--/E8\ UIV=K<PD'#5RUZ4*
MBU._"XFK0=XGT]HOQ.^109?UKL-/^)"$#,OZU\FV>H75N!RU:L/BBYAQ\QKP
M:F60EL?74<^J4U[Q]=6GQ$B;'[S]:V[/Q]"V/W@_.OC:'QS<QL/G-:=K\1IX
M_P#EH?SK@GE'8]>CQ+;<^TK/QO;MC+C\ZU(?%=I)C+#\Z^,+7XI3)C]X?SK7
MM?BU*N/WM>?/)Y]#V:7$]/J?82Z_:-_'4BZQ;-_'7RA:_%Q^/WOZUL6OQ7+8
MS+^M<<LKJ1/2I\0T9'TVNI6[='IXO86Z/7SU:_% -C][^M;-G\2$;_EK^M<[
MP-1'='.*,NI[<+B-OXJ>)%/0UY19^/HWQ^\'YUN6GC*)\9D'YUSRPLXG;#,*
M4^IWE+7-6WBB%L?./SK1CUZ!_P"(?G7.Z<ET.V-:$MF:E%4UU6W;^,5*M["W
M1Q469KS+N3T4P3(W1A^=+O7^\/SI%#J*3</6C(H 6BDI: "BBB@ HHHH ***
M* "FM2G/:DYH :&IZTFVDH ?12+2T %%%% !1110 44C4F30 ZBBFDT .HIN
M31DT .HIN33J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "D;[I^E+37^Z?I0!P/C!OE>O%O$%N)YF^M>R>,<X:O)M1C+7!H YB/1OFR!
M6M:V<L2\ UO:3IOV@CBNQTWP?]H4?)0!YS]GFE8 YK=T;PTUPP++7>1>!]K
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M 4444 %%%% !1110 4444 %%%% !132:,F@!U%-R:=0 4444 %%%% !1110
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MT5R-M[GHQBH[!1112+"DI:* &4Y>E)MI: !J;3CS1MH 6FTZF4 .6EIJTZ@
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M6_\ "OXO^>0_*C_A7\7_ #R'Y5ZE]GC_ +M'V>/^[0!Y6WP]A;_ED/RI]OX
MBC8'RA^5>H_9X_[M'V=/[M '):7X92UQA,?A736ML(E  JR(U7H*6@0M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A.T$GI
M7F_C_P 1+8PR?/C KK]<UA+*V?G%?,WQ>\;[8Y@)* //OB5\23#-(!+^M>::
M=\0)+B\ \T]?6O/_ (B>*Y)[J3#D\U@^$=3>:\3))YH ^X/A7X@>Z:++9KZ6
M\-S&2W0YKY#^#<I;R?PKZU\)'-M'0!UJ_=%+24M !1124 1W$PAC))Q7G/C;
MQ8NGQO\ /C'O72^)M6%K;OSBOF'XN>-C&LP#_K0!@_$/XK&)I%6;OZUX;KOQ
M/GFD;;*?SKG_ !9K\^I7;J&)R:H:;X6N=2P=K'- &M9_$:Y6?)D;\Z])\(_%
M62-XPTI_.O+;CP#<VZ[_ "R*R72XTJ8?>&#0!]X_#WXEB\\L&7/XU[[X<U=;
MZ%3NSD5^<GPS\9207,:ESU]:^S?A?XI^U6\67SQ0![915:UNA.H(-6: "BBB
M@ HI,TM !1110 4444 %%%% '-^)?]6U>?2?\?/XUZ#XE_U;5Y])_P ?/XT
M=SX7^ZM=97)^%_NK764 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** &L* *=10 4444 %%%% !
M1110 4444 %%%)F@!:*** "BBB@ HHHH 3FCFEHH **** "BBB@!*,#TI:*
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M(]2NH>I:IT\27$/\3"N665P>QZ%//ZT=SZVMOBDK8_>_K6G;_$A),?O?UKY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MONK75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP^9ABE*G&6QU8?-*]!^\?>.@_%"%U7,H_.NXT[Q];7"C+J?QK\^M-^(US:L
M96'XUVVB_%V2-E!F_6N25 ^NPO$2VD?=-OXDMI\88?G5^*^BFZ&OD[P[\6A)
MMS-^M>G>'?B1%/MS*#^-<TJ3B?3X?-J5;J>U YYI:Y;2_&-M<(,N#^-;L.K6
MTPR)!6-CVHU835TRY14:W$;]'!IX.>E(T%HHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M".!4E%<[DWN=T81CL@HHHJ2PHHHH **** "D:EHH ;M-.HHH **** "BBB@
MHHHH *2EHH ;M-&TTZB@!!0U&ZC- ";33J** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I-M.HH 2EH
MHH 0T<^E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $;2;:@EODCZFHM0F\E":\W\6>+O[/5_FQB@#T*37H8^KBH?^$F
MM_\ GH/SKY@\1?&3['(P\W&/>N7_ .%\98CSOUH ^R5\1P-_&/SJ];:G#<='
M&:^-+?XY;F'[[]:[?PO\8A<,N9?UH ^B];U2.TM6.[M7SU\3O' 3S45_7O6Q
MXB^(BS6#$2=O6OFWQYXL:\O74/D$T#,7Q->2:Q=-CYLFF:'X/>1@[)^E;G@O
M1?[6F4L,YKVG3?!,5O9ABHZ4%'@OB301;6C97'%>7^4(M2_X%7T'\2;6.UAD
M48KP"X8?VE_P*@1]%?!=LF*OKSPE_P >L?TKY ^"K+NBR:^O_"+K]ECY[4$G
M644E+0 5!>'%K)]*GJ"]YM9/I0!\T_&B8K'-7QGXUF+7S_6OLGXTQDI-^-?&
M?C*,K?O]: .F^%\6Z\C^HK[B^#\8$,'T%?$'PO.+N/ZBON#X0L/)A^@H&>M:
M@H:SE!_NU\E?'6%?W_XU];7W_'G+_NU\F?'1A^__ !H$?'VL+MU,_P"]7L_P
MAD(DA_"O&M9_Y"1_WJ]C^$:GS(?PH ^S_APQ-O%]!7I%>;?#C_CWB^@KTF@
MHHHH *3;2T4 (!BEHHH **** $I:3N*6@#FO$W^K:O/)FQ=?C7HGB;_5M7FM
MY)MN/QH [SPS, JUUWG#%>=>'[PJ!75#4/DH US,/6CSA6&U_P ]:3[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;
MOG"CSA6%]O\ >C[?[T ;OG"CSA6%]O\ >C[?[T ;OG"D\X>M8?V_WH^W^] &
MYYP]:7SA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YXH\\5A?;_>C[?[T ;OG
M"CSA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YXH\\5A?;_>C[?[T ;OG"CSA
M6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YPH\X5A?;_>C[?[T ;GG#UH\X>M8
M?V_WH^W^] &[YPH\X>M87V_WH^W^] &YYP]:/.'K6']O]Z/M_O0!N^<*//%8
M7V_WH^W^] &[]H%'V@5A?;_>C[?[T ;OV@4X7 ]:P/M_O2_V@?6@#H5D5N].
MW#UKG%U YZT_^TF]:!Z&\P1AAL&LO4--@F4_**J_VDWK2K?;NIH$XJ2LSF-8
M\(PW(;"#\JX'6OAE'<;L1?I7L_G(W6F-%#)U K15&CSJV74ZVZ/EO7/A$#NQ
M%^E>=Z]\*Y(-Q$9'X5]JWVEP3*?E%<?KGA:&X5L1C\JWA79\WB\@IRV1\+ZS
MX-N+1FPI_*N:FM[NS?\ BZU]A^(OAZDV[$7Z5YMKGPM9F)$1_*NV-9/<^+Q.
M25:;]P\4T_Q)=6;#+,,5VNA_$J>VVYD/YT:G\-9HLXB/Y5S=YX1NK0G",*N\
M9'E^SQ6%9[1H7Q@D0*#+^M>AZ'\7O,V@R_K7R&T=W9G^(5>L?$UU9N,LU0Z,
M6=]'.*U)VD?>.@_$9+K;F7]:[_2?$T-PHRX.?>O@30/B;-:LNZ0C\:],T'XS
M&-5!F_6N:5%]#[#!9]"6DV?9<=]#(,AQ4HF1NC"OFC2_C,K@ S?K74Z?\5HY
M\?O1^=<[I-'T]+,Z%39GMWF+ZTAF7UKSC3_'*7./W@/XUOVFO)-@[JR::/2A
M5A/8Z;SAZTWSJS([Y6_BIYNAZU)T<I?-P/6C[0/6LI[L9J$WOO02T;GG"CSA
M6']N]Z3[?[T"-WSA1YPK"^W^]+]O]Z -SSA1YPK#^W>]'VX^M &]YP]:1IAZ
MUB?V@::VH50&YYX]:7[0/6L+[<?6C[<?6I%J;GG"CSA6%]O]Z/M_O0,W?.%!
MF%88U#WH;4/>@HW/.%'G"L+[?[T?;_>@DW?/%'GBL+^T#1_:!H W?.'K3A,/
M6L'[>?6G#4* -SSAZTUIAZUB_P!H>]-;4#0"-OSO>E\X5A?;S1]O]Z!LW?.%
M'G"L+[?[T?;_ 'H$;OG"CSA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YPH\X
M5A?;_>C[?[T ;OG"CSA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YPH\X5A?;
M_>C[?[T ;OG"CSA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YPH\X5A?;_>C[
M?[T ;OG"CSA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YPH\X5A?;_>C[?[T
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MK7F^'LR_\LS^54)O =PO2,_E5^UP\]S%X?&4]KEVU^(<ZXRY_.MFU^)<R_\
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MU?MYBU %^EIJ_=IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%>8_#'X;LCQ,T7IVKZK\#^'5L+=/EQ@4 =5I%D+>%>.U:5(JA5 %+0 4444
M%%%% !1110 4444 %%%% '-^)?\ 5M7GS_\ 'U^->@^)?]6U>?2?\?/XT =Y
MX5/RK74UR?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 )D44VG+0 M%%% !1110 4444 <UXE_U;5Y_)_Q]?C7?^)/]6U>?O\
M\?1^M '=>%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %,I],H 5:=35IU !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !24M% #=II12T4 %%%% !1110 4444 %%%% !1110 4444
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M4%9(****184444 %%%% !3<&G44 -44ZBB@ HHHH **** "BBB@!NTTJTM%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)D4 +124M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-D<1KD
MT .JE>:7%>*0PZU#<:U';_>853;Q=:Q]67\Z .:\1?#Z&Z5CY8/X5Y9X@^%$
M<C,1%^E>WW'C&TD7&Y<?6LFZUBTN.ZF@#YPO_A*!G$7Z5EM\)_F_U7Z5]'SR
MV<F?NU7,5F?[M 'SS#\)?F_U7Z5U&B_"--RYB_2O7UCLU_NUH6M[9PX^[0!S
M?AOX7Q0[3Y0_*O2M(\)PV*CY0*I6OB>T@Q\R_G5S_A-+3^\OYT =!%"L*X45
M)7-CQI:L>'7\ZM0>*;27JX_.@#:HJI#JEO-]V058617Z,#0 ^BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#F_$O\ JVKSZ3_CY_&O0?$O^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7P=:M*K*[/V##8:&'@E%!1117.=H4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N'K0 M)
MMHW#UHW#UH ,8I:3</6DW#UH =12;AZTFX>M #J*3</6C</6@!:*3-(30 ZD
MI:90 ZEIE/H **** "BBB@ HHHH **** "BBB@ HHHH *H:Q-Y%J6J_6-XH)
M&GMCTH \@\;^-#IY?#XQ[UX[K'Q>:WE8>=C\:U/BY<RQF7&>]?+7BO5+A)Y.
M3UH&>['XV'=S/^M68_C6,#,WZU\C76O7,<A^8_G4'_"3W2_Q-^= C[#'QL7_
M )[?K3O^%VI_SV'YU\;?\)1>?WF_.G+XFO/[S4 ?8_\ PNQ/^>WZTUOC6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%%( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\[^ _B!_:4B#S,Y]Z][T*X^TV:MUK*47$]O#8J.(5XFC3:=2+WJ#N#;3J**
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M^,T$?- '>T4@Z"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#F_$O^K:O/I/^/G\:]!\2_P"K:O/I/^/G\: .Y\+_
M '5KK*Y/PO\ =6NLH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1NE+1
M0 RE7K2[:0T#N.I*1>M.H$,IR]**6@ HHHH *3-%-H ?12+2T %)FANE-H ?
M124M %34HA);-GTKYU^+]JJPR\=C7T9J#;;=OI7SO\8)/W,OXUO2W/ S>WL6
M?%7Q!7;>2?4UQ-K]ZNV^(1S>2_6N)M?O5[<?A/P;%?QF7J***#$****!A111
M3)L!4&I87:,_+5=I,5KZ-9?;)%&,TBX)R=D6K'6+F#&TM6]9>+;N'&7;\ZW-
M%\ M>1@A,_A6K/\ #&6-<B,_E63E$]NGAL1:\3+LO'UQ'C,C?G706/Q,DCQF
M0_G7-W7@.XBSA#^594_ABZAZ*U3RQ9T*MB:)ZW8_%9EQF7]:Z*Q^+@&,R_K7
MSPVFWD)Z-0&O(?[U3[.)O',\1#<^I['XOIQF;]:Z"Q^+T9Q^^_6OCE=6O(>[
M58A\47<)'S-4.BCNIY]5CN?;MC\6H6Q^]'YUO6?Q3A;'[T?G7PO:^.;F/&7;
M\ZV+7XD3QX_>'\ZS= ]2GQ');GW3;_$FWDZNI_&KT?CRWD_B6OB&S^*<JXS*
M?SK?L/BPW&9?UK-X>QZE/B%2W9]E1^+H)/XEJW'X@BD[BOD^P^+ XS+^M='I
M_P 5TXS+^M9>Q9Z=/.J<MV?2\>IQR=Q5A+A'Z&O!+'XIPMC]Z/SKHK'XG0-C
M]Z/SJ'3:/3IYC2GU/7J*X"S^(]LP&9!^=:D/CRTD_C7\ZSY6=D<32EM(ZNBL
M"/Q?:R?Q+^=6H_$5K)_%^M*S-55@]F:M%45UBW;HWZU*NH0MT:@OF3ZEFBHE
MN(VZ-4@8'H:10M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %)2TUJ %W4M,I5H&.HHHH$%)FBFT .S2TRG+0 M0RVJ3?>&
M:FHH%N4#HUN3G;^E3PV44/W1BK%%/F8E&*V0E%(U)2*'T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_2L"^^#;<_N?TK3VR9YL\EK0V/G :A>0]VJ:/Q-=PG[S5[1??!V3G]T?RK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH ;MI:6F[J
M'44@I: "DVTM% ";:*6B@ HHHH **** $Q1MI:* "BBF[J '44@I: $/2FYI
MQI-M "CI2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[VO/AG;.#B-?RKG[[X66YS^Z'Y5LL0>95X;ML?#%QX)NX\_(WY51D\.WD/\
M"U?:=]\*83G$0_*N<U#X31\XB_2K5='DU,AJ1V/DG['>0=FIRWUW!W:OHW4O
MA.!G$7Z5S&H?"IAG$7Z5:J)G!/*Z]/8\AC\274./F:K]OXUN(^K-77WGPOE7
M.(C^58UU\.IX\_NS^5:<T6<GL<538ZS^(LT>,N?SK=L?BI)'C,A_.N+N/!-S
M%GY&_*LZ7PW=Q?PM2<8LOZQB:9[+8_%UEQF7]:Z/3_C)MQF7]:^<3IMY#V:D
M\R\A_O5'LXLWIYKB*>Y]:Z?\:5&,S?K706?QHC;'[[]:^*QK5Y#W:K$/BZ[A
MZNWYU+PZ9Z$>(*T=S[DM_B_%)C]\/SK6MOBC%)C]Z/SKX8M?B!<1XS(?SK:L
M_BA+'C,I_.L_JYWT^(WU9]Q6_P 0HI,?O/UK1M_&<4O_ "T'YU\5V'Q:9<9E
M_6NET[XO=,R_K6;H,]:EQ!"6[/L&W\1QR8^8?G6A#J<<F/F%?*VF_%].,R_K
M74Z?\7HN,RC\ZR=%H]>EG%*6[/HE;A&[U(&!Z&O#[7XM0MC]Z/SK8L_BG V/
MWH_.L_9L]&.84)=3UFBN!M?B5;R8S(I_&M&+QY;R?Q+4<K.F.*I2V9UM%<]'
MXNMY.ZU9C\1P2=Q2LS15H/J;%%4(]6BD[BK,=TDG0T&BDGL344E+2*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HR*1J2@!]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E&10U-H ?1
M24M !1110 4444 %%%% !29%%-H ?12+TI: "BBB@ I,BEIE #J6FK3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3*?2;:
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M'K0 M%-WKZC\Z7(/>@!:*** "BDW#U%)YB_WA^= #J*;YB_WA^='F+_>'YT
M.I*3S%_O#\Z/,7^\/SH 6AF"\DXHW#U%9'B'4EL;<DG'% %F^U>"SB+,PR*\
MT\8?$:"V5P)0/QKA_B'\4!8QRJ)<8]Z^;?%OQ.GOKAU20GGUH ]JUGXJ;K@[
M9>,^M6O#_P 4@LR[I?UKYJL[Z\U!BV6-&HZS=:0N[+#% 'WSX3^(UO=1H#(#
MGWKT&SU&*]4%#UK\W?!/Q>G@O4C:4CGUK[#^%/CH:K!%NDSD#O0![514<,RS
M1A@>M24 %%%% #68(N2<"L'6O%EMID;9< _6G^*-833;)SNP<5\B_&#XN/8R
M2HDN/QH ]:\8?%*%2X24?G7G%Q\4BMQGS>,^M?.3?$>ZUF\*B1CD^M:,TMV\
M(D&X\4 ?5?A/XIQR.@:7]:]H\-^,(-0B4;P<^]?G!8^,+O2[@ LP ->W?#?X
MKL6B5Y>_K0!]M1SI)]ULU)7G7@SQ:NJ1I\^<^]>AJP90?:@!U07EVEG$78XI
M\MQ'"I9F 'UKS'XE^.H=,L92) ,#UH OZY\1+>RD93*!^-95E\1H;R8*LH//
MK7Q5\3OCDUOJ$BK/W]:D^%_Q8EU74(@92<D=Z /T#TG5!>*"#FNBA.4%>7_#
M74#?6<;$YR*]1B^6,4 )-.D*DL<5SFM>-K33HV!=0?K5/QSK@TZUD(;&!7R!
M\5OBU-:3R(DI')'6@#V[Q=\5(<N$E'YUYI>_$]_.)$O&?6OGR#Q]=ZS=;=['
M)KH%M[J:'?\ -0!]#^%_BD/,3=+^M>V>%/'UM>1JK2 Y]Z_/N36KO1Y,Y8 5
MV'@WXQ2VMPB-*1R.] 'Z%0ZA#< %'SFK%>%_#7XA#6%B!DSG'>O;[2036Z,.
MXH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *2EI* %I*3)I10 4M%% !1110 4444
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M(3Z"O(Q&Y^T\.?PSHZ**0=ZY#[46DI:* "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"WS8Q7'W/Q3$;$>9^M8/Q(NY8?,()KP?5M>N%N&PQH ^D/\ A; _YZ_K2_\
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MI9=Q&1CVKS;2]4FT/4%0L1@U^@?QD\(VK:7)*D8&5)Z5^?GQ&A&GZTX7CYJ
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M1DQXQCM7U!X9M_L^GJN,<5YE:7,S]6R/#RH0M(UZ0=Z6BN<^K"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M><B!F_6NTDU#SH,@YH AU#6A!GYJP;CQ<B,1OK,\22RA6QFO.]1N;GS&QNH
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M:7(F0'-9N-COIU8U-46*5:-M+4FXM%%% @HHHH **** "BBB@ HHHH ****
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ME^&4M<83%=+:6HA4#% %Q?NBEHHH **** "BBB@ I-M+10 @&*6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O^K:O/I/\
MCY_&O0?$O^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!)6;KI_T-JTJS=<&;-J /G?XA?\ 'P_UK(\&C_3%^M;/Q !^T/\ 6LGP:/\
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M:: '4444 -:D'6E848- #J3;2T4 )M]Z*6B@ HHHH **** "BBB@ HI*0YH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH ***2@!:*3=2T %%%% !1110 4444 %)BEHH **** "BDHS0
MM%%)NH 6BDI: "BBB@!NVE Q2T4 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '-^)?\ 5M7GTG_'S^->@^)?]6U>?2?\?/XT =SX
M7^ZM=97)^%_NK764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M _0.:/<MT57%]$W\5/%S&W1J0[HEHI@D5NAIU Q:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**2@ S2TRG+TH 6BBD:@ S2TRG4 +1110 4444 %%%% !1110 4444 %%%%
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M+R.V!+G% $]%8%UXTT^SSOD Q[U2_P"%E:3NQYH_[Z% '645SMOXYTVY("2
M_C6M;:I!=8V-^M %IJ6CK3: 'T4@I: "BH+B\BM_OMBJ?_"06F[&_GZT :=%
M5X+R.X^X<U8H ***CFF2%<L<4 245BW?BRQL\^8X'XUG/\2-)0X,H_[Z% '5
MT5RT/Q$TJ8X64?\ ?0K5M?$-I>8V/G\: -2F4J2"1<J<BEH %I:** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXE_U;5Y])_Q\_C7
MH/B7_5M7GTG_ !\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHVYR:]<\(_!5=4C0^5G/M6-X+T4K=)N7O7U7\,=/BCMTR@SCTH \BC_9P19
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M[H\)T_X.)'M_=?I726/PMCA_Y9#\J]=6%%Z(!^%.P/2L_:,]B&6T(=#S^S\
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MKBO6M/SY(!H =]@@'_+,4Y;6)>B 5-10 @4+T&*6BB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 -:DI6I* 'T444 %(U+10 W::=110 4444
M<GXHTO[8K#&:\DU[P ;B1CY??TKZ"DMTEZU4DT6WDSD?I0!X'HG@%K:8'R\5
MZ[X3TUK%%&,8K>30X(^@_2K<-JD/2@":BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 3\*6BB@!*6BB@ HHHH **** "BBB@ I,BEIE #J6FK3J "
MBBB@ HHHH **** "BBB@ HHHH **** $I.:=10 4444 %%%% !29%!Z4FV@!
MU%)2T %%%% !1110 45$]PB=35675HHNI%!+DEN7Z*Q)?$]O'G)'YU0N/'%O
M#_$HIV9FZU..[.JIKR",9)Q7 7GQ,MXL_O /QKG=0^+$"@_O1^=6H,Y9XZC#
MJ>I7&J)#_%65=>*HX<_/7B>K?%R(9_>C\ZXO5_BXIW8E_6M8TF>16SFE#9GT
M1=_$".'/[S]:Q+SXK10Y_>_K7R]JOQ69MV)?UKC]2^)4TC'$A_.MHX<\*MQ!
MR[,^KM2^,D:Y_>_K7(ZI\9ER<3?K7R_=>-KF=N':J,FMW=QGEJV5!(\6KQ!5
MEL>_ZI\8MV<2_K7):G\5I)-V)#^=>4;;RX_O5-#H-W<?PM6JIQ1Y4\RQ%78Z
M?4/B+--G#G\ZYV\\67-PQPS5=M? ]U.1E&_*NATWX9S2$9C/Y5=XQ.?EQ58X
M"2\O+G/+4V/3+VX[,:]OTOX4,V,Q?I78:3\(U^7,7Z5#JQ1U4\IKU7J?.5IX
M/O+C^!JWK#X;W,K#,9KZDTCX3Q+C,0_*NQTWX70+C]T/RK"6(/<H\.REN?*>
ME_"B9L9B/Y5UVE_"-N,P_I7U)8_#JWB S&H_"MFW\'6L/\*_E6+Q#/;H\.QC
MN?-NF_"<+C,/Z5U>E_#"-,9B'Y5[G'X=MH^BC\JL)I,$?0?I63JMGL4\GIPZ
M'F6E_#V&/;F(?E78:;X-MH0"8P/PKI([6./H*EZ5DY-GJ4L)3I]"C#HMI".(
M@:L"Q@7I&OY5/14'9RI;(C%O&O1 *<(U'113J*"A*6BB@ HHHH **** *FH7
MGV.$MG%>?Z]\3(M+9@9<8]ZZ7QW=&UTMG!QP:^'?C-\19=.NI@LA&#ZT ?3+
M?&Z'<1YWZUGZA\>(K=2?._6O@^Q^*EQ=7.T2L>?6MVXUR_U*'*,QS0!];-^T
MC$LF//\ UKI?#OQSBU1U'G Y]Z_/G4I-5@?=\XK>\%>-[S3[N,2.PP>YH _3
MS0?$T>IQJV_.:U;Z_6WA+YKYD^%?Q($\,2M)V'>O8[G7A?6)VMG(H H^)OB<
MNDE_WF,>]><ZG^T='9R$>?C\:YSXG6=Y<>:8]U?,?B[1]6^T/M$G7WH ^L(_
MVG(F_P"7C]:E_P"&F(_^?C]:^);?1M9W=)/UJW_8^L;>DGZT"N?9;?M.1 _\
M?'ZUI:;^T7'>,!Y^<^]?#,FCZSN'$GZUU?A/1M6\Y=P?K[T!<^[M*^+27R ^
M9G/O6?XP\;"XL9,/VKQ#PS9WUK A?=TJ[KVJ2QV[*Q/2@#QCXN7\U]>2;23D
MU6^$?AUKS5(C(N06%:.O6ZZA=G//->D_"/PZL5Y"P7N*!GTW\._ -G_8\;R1
M+T':LSXI?#ZU72Y9(XEZ'M7I/A*'R=&B6H?'%N+C09P1T% 'YC_%*Q;2]5D"
M# #&NM^!GB&6/4(59CU%6/C=HX_M*8X[FN;^%JFUU*/''- 'Z+^!=6%SI,(S
MDXKKE;<N:\@^&.HEK&%<]J];M6W1 T 35#=2>5;NWM4U9NNS>582'VH ^4_V
MA?$+VXG"MCK7R&-4EU+6MI)(W5](?M$7!D>?FOG/PG9BXUU<\_-0!]2_ [P0
MFI+ TD><X[5],1_#NS73B/*7.WTK@/@#I"QV<#;>@!KW9A\A'M0!\9?&SP''
M%YQCC Z]J^>+&&31]4[J U?=/Q2T-;N*4E<]:^1/'FCKI]X[ 8YH ]P^$'C(
M[8D+^G>OH[3]8\ZQ#9[5\)_#/7&@OHTW8YKZ^\'737FE+W^7^E '-_%#Q*T$
M,BJW8U\@?$6ZNM4EF"[C7U;\1-%FO68 $UY=_P *V:Z=B\>?PH ^&_%WAN\^
MT%V5NM=9\)+-[?480P[BO<OB-\.H;.%F\L _2O.O">FK9ZTB@8^:@#[W_9__
M ./2'Z#^5>Y$X!->&?L_G_1H?I_2O<9FVPN?]DT ?+7[07B!K'SPK8ZU\<WW
MB"34-6*ER<MZU])?M.ZCY;7//K7QE9^($CUSYF_CH ^J_A7H<<XB>10>E>_V
M2V%G9!6"]*^<OAMXLACL8\,.E=-K7CJ1$.USC'K0!N?$*SL]05Q&%)KPS4?
MS37VZ-.]=1+XX,TQ$C_G71>'=0M+Z9=Q4T 3?#'PC<6L\1VD<BOKWP!:M;V:
MAO2O,/ NG6K^65"U[7H<*PP#;0!J4E+36H 7(I:93Z "BBB@!*,BD:DH ?11
M10 4444 %%%% !1110 4444 %%%% !367<,4ZB@"G+IZ2=<56DT:+J5%:;N(
MU)8X%<WKWBJ"Q5AO Q0,LR6-M'U"U 8[5>RUYIKGQ2AMV8"4#\:Y*\^,$:L<
M3?K0(]XS:?[-&;3T6OGO_A<B?\]OUI!\9$/_ "V_6@#Z%S:>BT9M/1:^>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!4OK47*D$5S\_A9))"=@KJZ* ,"PT-;7&%Q6W%'Y:XJ2B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "DH:DR: $S3ATH
MVT4 +1110 E+110 4444 %%%% #*<M&VC&* %HHHH **** "BBB@ HHHH **
M** "BBB@ I*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *93Z3:
M* $6G4WGM2T +1110 444AS0 M%-R:=0 4444 %%%% !6#XN_P"0>WT-;U8O
MBF(R:<V!V--;F57X&?%_QL/[R;\:^6=:D'VQ_K7UG\:M)FE>;"GO7ROKF@7/
MVMOD;KZ5[5'8_!\\C+VSLC.CE7;3_-6G)H=SM^X:E70[G^XU=&A\VHS[$'FB
MCS!4_P#8-S_<-.&@W7]QJ1IRR[%;S!1Y@JU_8-U_<:F_V#<_W&_*BY/+/L4;
MB5=IYINDR#[6OUJU<:#=;3\AIND:#<B[7*'K5)HCEGS+0^C?@_(-\7X5]D>
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MSKCAZ<=D9T&CQP]A5V.%8^@J2BI-E%1V"BBB@H**2B@!:2EI* $W4J]*-M%
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MSQY*;II#0!Y.IWWV/>O<OA5"/,A..]>(*OEWV3ZU[A\*[@-)$/>@9]5^'O\
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MKX5\!QLVJ(?]K^M?>'P54KIL>?[O]* .KU#PC'>MEE!K&OO!45I"S!!T]*]
MJCK#!;)\^E 'QY\;+5;>.4 >M?.FBM_Q/5_WJ^E/CRPQ-CWKYIT7_D/+_OT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?\ 'S^-
M>@^)?]6U>?2?\?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 C4FTTZB@ HHHH **** "BBB@ HHI* %HI,B
MEH **** "BBB@ HHHH **** "BBB@!-U --I5H =1249% "T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR-6[8_"^XFP?+/Y5]/:3\+HUVYA'Y5V.F?#B!,9B'Y5DZY[M#A]R^(^5=/\
M@_-)C,1_*NITWX+/QF']*^JM/\"VT8!,:C\*VX/#5G#_ ,LP?PKGEB&>]1X=
MIQU9\TZ7\'_+QF']*Z[3/A@D>,Q?I7N*Z3;+TC%2K8PKT05BZK9Z]/**-/8\
MTTWP#%#C,8_*NEL?"4$>/D'Y5U2PHO113PH'08K-R;/0AA*<-D95OX?MX\90
M?E5Z.QACZ(*L45!V*,8[(:(U7HH'X4N!Z4M%!0E+110 4444 %%%% !1110
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MC7S/HMT?[>'^_0!]Y_L^<V\/T%>YW2[K64?[)KP;]G:3=;P_05[[(-T;#U%
M'P'^U79,TUS@>M?)_@FQV^)$WC^,?SK[S_:,\*-J!N"$SUKXUFT5M"UCS"NW
M#4 ?H+^S=#:KIMOG;NVC'Y5] 5\%?![XNC15AC,NW&!UKZ,L?CA%-:AO.!./
M6@#T7QI#;-ICF0*&P:^"_P!H)85FF\O'4U[C\0OC>GV>11-^M?)WQ!\9?\)%
M=. V[)H Y?X?^;_;T>,XWU^CGP!W?V7%N_N_TKX9^%GA5KK4HI-G\0-??_P=
MTTV.FQ@C'R_TH ]+HHHH **** "BBB@ HI*,B@!:*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <WXE_U;5Y])_Q\_C7H/B7_5M7GTG_ !\_
MC0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0>?FH ^C/@WX/$S0NR9_"OKKPSH<%KIZJ8QT]*\:^"NEI]CA..U?0%K&(H5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*:T*-U4'\*?10!5DT^&3^
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M50*?14'4HI;!11104%%%% !1249% "TF/>EHH 2EHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!R?Q"YTEOI7P[\6?W=]*3ZU]S^/%W:4WTKX9^-B^5-,?<T <GX'UV*UU!-S
M <U]>?"OQ9;-#$-X[5^<'_"4R:?J/#$8;UKVGX:_%B6W\L&0CIWH _2>WU2V
MGA5Q*HR/6N"^+GB6UM]#DA$BDX->#0_&YX;%?WO;UKS/X@?&:;5%>,2DY]Z
M/)/B](-0UJ0H<_-79? ?29/M41P>HKBXK*;Q%J 8J6R:^EO@KX%:W,+&/'3M
M0!ZG_8[R:.HQ_#7C_B[PG-)<.0IKZKMO#H^P(NWM7.:IX"6YD)\O]* /E%/!
M\_\ =-2'P?/C[IKZ97X;K_SS_2E_X5R/^>?Z4 ?,)\(3[ONFKEGX2G5A\IKZ
M0/PW7_GG^E2Q?#D*W^K_ $H \M\&^&I%D7*FO1]6T,KI+?+_  UU.C^#5M6!
MV8K:UK10=+<!>U 'Y^_&:U:"^E^IIGP5U1;758MS8^85W7QT\+NUQ,RIW/:O
M#-#OIM U+=RN&H _4+P'KEM=:! /,4%1Z^U6O%FM6]KHTQ\U22*^.?!?QKDL
M[%8C+C\:TO%7QH>ZTMD$O8]Z .:^,7BJ-[R55?N:\Y\)J=2U!2.<FN+\9>*[
MC5M2;#$@FO4/@CH<E]=0LRDY([4 ?2/PM\/M''$VWTKZ%TE1#9(I.*XSP/X=
M%K80MMQQ6UKFI_V;$0#C% '1^?'_ 'Q45XRR6LH!S\M>52^.MMQMW]_6NKT/
M7/[0AQNSN% 'SK\>-%>YDF(7/6OFNSL3I^K L,8:ONSXC>$_[2MY'V9XKY%^
M(GAV31[F1U3&#Z4 >W_!WQ5#;1PJS@=*^EM*\16MS:H3( <5^9OAWXBSZ->*
MF\C!]:]Q\/?&IQ8KF7MZT ?4'CKQA:VVG2H)!T-?$/QGU1-5NI0C9R35WQ[\
M:)9]Z"4G/O7FEGJ4WB:\YRVXT :?PO\ #SR:LC[?XJ^\/AG,FDZ2FXX^6OGK
MX6>!RGERF/WZ5ZYKVKGP_I+ ';A: +WQ*^)D.EV\P$H'![U\B>/_ (K_ -H7
M4B+-G)]:Y_XY?%B?SYXUE/4CK7@.F^(KG6-1R6)R: /=O#]F?$=XI;YMQKZ;
M^%?PSMHUBD>-?7I7SC\,V-KY3N*^D?#/Q"BTRV1=P! ]: /I;PU8VNEVBHFU
M3BMOS$/1A^=?.UO\6UD8!9?UKLO#_C@WQ7Y\_C0!ZR&!Z&EK'TN_^TJISFM>
M@"EJW_'N:\'^*1'V>7Z5[QJW_'N:\"^*F[[/-CT- 'R/XP<?VHW^]7JOP/8&
M\A^M>/>,ED_M1N/XJ]9^!8?[9#D=Z /N/P[_ ,@F'Z5IUF>'/^03#]*TZ &T
MJTFVE Q0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4C4M(: &YIU)MI: %HHHH 1J;FG&DVT +2TE+0 4444 %%%%
M !1110 4444 -H6C;2@4 +12&DW4 .HHHH *0TM(: $W&E%)MI10 M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!B^)0OV4Y'.*^:?BFJ[9>*^DO
M$Q_T=OI7S9\4C\LM=-'<^6SKX&?*7CC_ %\F/6N"7_65WOC@_OY*X%2/,KV(
M['XABOXC+RM\HHIH;@4;JHQ'449HS0 5&^>U29J-F%(3'P_>%>E?#ML747UK
MS6(_,*]'^'I_TJ/ZU,EH=^!?[U'V]\'9 (8?H*]JKPOX/G]U#]!7N:_='TKQ
M*GQ'[UEC_P!G0M%%%9'K!1110 C4VG$9I-M "[:*6B@ HHHH **** "DQFEH
MH 3;2T44 %-:G4F,T ,_BI:&'-% QPZ4M(*6@04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )MHI:* "B
MBD- "TFVDW4Z@!*6BB@ HHHH **** "BBB@ HHHH *2EHH 3;2T44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445'/*(HR30!!?7JVL9).*\_P#$WQ"33=_[
MW&/>G>-_$XLX9/GQQ7RG\4OB*\;RA9#W[T >J:]\:DC9AY_ZUQ6H?&D-G]_^
MM?*/B+XC7#7# 2M^=<^_CJ>3_EHWYT#/K:7XR9;_ %WZTU/C$?\ GM^M?)2^
M,)V_C/YT]?%L_P#>- 'UN/C!G_EM^M._X6X/^>WZU\D_\)?/_>;\Z7_A,;C^
M^U CZNG^+X7_ );?K4^E_&#S)E'G=_6OCZ\\97&#\[5>\->+IY+I<NW6@9^B
M/@GQV;_9^\SGWKVC0;[[1$ISFOBSX/ZY)<&'+'M7UQX*F,EO&2>U CO5^Z*6
MFQ_<'TIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!S?B7_ %;5Y])_Q\_C7H/B7_5M7GTG_'S^- '<
M^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4C4M% #*=2T4 %%%% !1110 4444
M %%%% !1110 4444 %%%% ";J,TC=:%H =1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MEZ]/Y%FQZ<5J5@>,,C36QZ&@#YU^+'B=H5E&[UKY%\?:XU[<2#=GFOH#XR3N
M&F_&OEG6F>:^8$]Z"CE;C1Y+Z?(!.36II_P_N+@ B-C^%>@^"/"G]I3)\F<D
M5]'^"_@VMU"A,&>/2@1\DV_PQN6_Y9-^56/^%7W&/]4WY5]X6OP-3:/W _*K
M+? ^/'^H_2@1\"_\*QN/^>3?E1_PK"X_YY-^5?>W_"CX_P#G@/RI5^!\>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZR!J '4444 %%%% !1110 4444 %%%% !1110 TBA13J* "BBB@!NTTJTM%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(I: "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I,TM% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)2T4 ,IR]*6B@ HHHH ****
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MJFX]:OV]UYF* +]%(IRM+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M6?#F/;!']*]'KB/ MJ88(\CM7;T %%%% !36ZTZB@!JTZBB@ HHHH ***1J
M,W5(/.4UR=]HY:0D+WKNFC\RH7T]&[4 <-#I[Q]!5C[._H:ZPZ6OI1_9:^E
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M^E']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E ')M;O2"W?-=;_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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M_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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M_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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M_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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MEQTH$=_X?L_L\*\8K<J&WA$2@"IJ "BD-)NH =124M !1110 4444 %)2T4
M%%%% !1132U #J*9N]Z=NH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHI": %HI-U+0 444FZ@!:*0&EH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHINZ@!U%(*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HI-U - "T444 %%-W4HH 6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI-U% "T444 %%%% !1
M110 4444 %%%)F@!:*3=2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2;
MJ '44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2;: '44E+0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !36IU% #1UIU%% !3:7-+0 U:=1
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%)10 M,I]% #0<4N:1NM"T .HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BDHH 6BBB@ HHHH **** "BBB@ HHHH **** &T+3J*
M"BBDS0 WFG+2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %)2TE #:<M-IR]* "C=0U-H ?1110 4444 %%%% !36IU
M-:@!*?3*?0 4444 )FC=2-24 /HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0TVG4M "#I1FE
MIK4 +NI::O6G4 %%)FC- "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **2DR: '44BTM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 RG+1MH
MH 6BBD:@!:*;DTM "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 UJ2G8I",4 .HIN32T %%+10 4444 %%%% !12-29- #
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!E*M+MHQ0 M%%% !1110 444AH 6BFY-**
M %HHHH **** "BBB@!&IM.HVT %+110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% !1110 4444 %
M%%% !1110 4444 %,I],H 5:6D6E- "T4W)I: %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J3&: &T
M^DVTM !24M% "4M%% #**=MHVT (M.I,8I: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2&EHH ;MI:6B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2T4 -VTM+1
M0 4444 %%%% !1110 A&:3;3J* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 0G%)NH:E H 3;2BEHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBDH 6BBDS0 M%%% !1110 4444 %%%% !3=M.HH 0#%!I:* &[:6
MEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBD:@!:*;DTM "T444 %%%% !1136ZT .HIJ]:=0 4444 %%%% !1110
M4444 %%%% !13*<M "T444 %%%% !136<+R3BLK4/$$-FIRP'XT :K2*O4U'
M]J3UKS[5?B%;P$CS1^=8R_$RWW_ZT?G0!Z\LBMT-.KSC2OB%;S,!YH_.NOT_
MQ##>*,,#F@#8HIJR*X!!S3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHIDD@C4DT .9@O)J,W*#O7.:UXFCLU.7 KD+CXA0K)CS!^= 'J0N$;H:>
MK!J\]TGQA'=$8<'\:['3;X7*@@YH TZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BH)[R.W4EFZ5S^J>,+>U!&\#\: .B>X2/J:8+R,\9KR_4OB-!&Q_
M>C\ZSX?B5 S_ .M'YT >RK(K]#3Z\XTOXA6\A'[U?SKK=/\ $D%XHPP/XT ;
M5%,CE6094YI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!K4E*U)0 ^FXZTZDH 6FLX7J:HWVJI:J<G%<CJGCB&W8CS!^=
M'<_:$]:>L@:O-K3QQ%<2 "0'\:Z_2=4%TH(.: -RBFH<K3J "BFLP7J<51OM
M9@LU)+#- %YG"]34?VJ/UKA=8\?6]N3^\7\ZYR3XF0>9CS1^= 'L"3*_0T^O
M+M-^(]O(P'FC\Z['3?%4%XH^8'\: .@HJ.*99ERII] "T4U:=0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !25!=7 A7)KD==\7)IZME\8H Z/5M8AL86)89KP
MGXE_$1+-9-LF/QK*\=?%80I(!+^M?,'Q*^)4EXT@$F?QH [+6/BTWVQ@)>_K
M79^ OB ]Y(@,F>?6OCP:U/>7>=Q/->V?"F>4S19)ZT ?=?@C5#=QH<YKT,=!
M7D/PR8F&+/M7KP^Z/I0!2U2\6TA))Q7E'C;Q\EBD@\S&/>NA^(FO?8;5\-C
MKX\^*WQ E6291)ZT =#XR^,)C=PLWZUY;J'Q>GDE.)3^=>5ZMK]SJ=RP#,<F
MI]+\.7=]AMK'- 'H<?Q8N5?/FG\ZZWP[\89%==TW?UKR&Z\&W<,>[8U8<PN=
M,DYR,&@#[F\#_%;[5Y8,OZU[OX7\1KJ"*=V<U^;_ (!\8307$8+D<BOK_P"$
M_BLW*1 OGB@#Z25MR@TM9^FW7VB!#GM6A0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6L[1+L7-JASGBM&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR3Z%^#]W(RP]>U?6_@MRUJF?2OG+X2^$WACB.WTKZ8\,VAM;=01VH&;M%%%
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M!]D_#50L,5>LC_5_A7DWPV_U$7TKUE?]6/I0!XC\7G<Q3 >]?%WQ$TZ>ZNY
M QY-?>7C[0S?K)QG->$Z]\,OM5PQ\O//I0,^8_"_@:2\NEW1DY/I7T-X'^%*
MR0QDP]O2NI\(_"L0SH?*[^E>\>%_!:6ELF4 X]*!'@FO?"J..S)$7;TKYU^)
M'@\:>\F$QBOT!\8Z;%;V;Y '%?'_ ,8Q%NFQB@#YTTF5K/4 ,X^:OJ;X+ZP[
M-"-WI7S#' 'U+Y?6OI3X*V+;X>/2@9]B>$[HS6L>3VKJ!T%<GX3@,=K']*ZQ
M>@H$+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:?"GR8P* .TTFR^SVT?&.*TJ1%VJ!Z4Z@ HHHH **** "BBB@ HHHH ****
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M"/[0D^M3?#0?\3"/ZT"/MOX8S$VL7T%>SV)S *\2^%ZG[+%]!7MNG_\ 'N*
M+-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<
MKNB->4?$F$FUEX[&O6G&Y2*\_P#B#8^98R'':@#X,^*T16\EX[FN,\'S;-13
M/K7I?QAL#'<2G'<UX]H]]]DU)<G'S4 ?<GP9F#Q0\]A7T*D:_8,^U?'WP=\7
MI L0+@=.]?1,?CB+^S_]8/N^M 'G_P 8IE2&;GM7Q7XYFWZ@_P#O5]-?%[Q<
MDT<H#YZ]Z^3_ !!>_:]2;!S\U ';_"^(M>1<=Z^W_A=;G[)%QV%?'/PCT\R7
M4)QWK[@^&]CY=E&<=A0-'H-NNU!4U(HP!2T""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2B@!:*** "BBB@ HHHH
MCN&VPL?:O)?B)K!M[>7!QQ7J]Y_Q[O\ 2O"/BD[>3-]* /ECXK>(Y9+F4;CU
M/>O.?#B-J&H+NYR:WOB9(WVR3/J:QO LRK?QY]: /JWX0^"8KN.(L@/X5[?>
M?#NV33VQ&O3TK@/@K>1>3#R.@KWB^N$.GOR/NTBKGQ=\9/"L=GYI5 .M?,>H
M7DFGZD<$C#5]B?'&9-LWXU\9^*) VIMC^]3)/=/A'XIE:6)2Y[=Z^UOAO>FZ
MM(R3GBO@'X0[OM$7U%?>'PHS]CBSZ4#/2J***!!1110 4444 %%%% !1110
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M4 P/2O28+9+=0J#%8EMKEO H"L*T(=8CFZ8H T**CCF$G2I* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M81G[5%@=Z^XOA$I6VB^@H ]F%+2+]T4M !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS1QDGM0!ZL.@I::OW1]*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MT9/X4 =[\'_"K*\)*5]@^#;'[-8IQCBO,?ASX-%G'$2F/PKVC3[<6]NJ@8H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:KBYEQNZF@#FM6\2_P!H739?//K6]X3N(UF5B:\Y@TNZ,Q)5JZ;2X[FUQP:
M/I#POXJAT^-/G Q[UVMO\74M$ $H'XU\M1ZU=1J "U5;O7KSG#-0,^P=/^,2
MW$H'G?K7IOA'QJ+_ &?O,_C7P'X9UR\:Y7+-UKZ;^%.H3R>5N)H$?7&D7GVB
M-3G-;%<CX4D9K=,UUR_=% "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%)0 M5M1_X]'^E6*KZA_QZO]* /GGX
ML,!'-^-?&OQ"E"WK_6OLOXL6[R138'K7QM\0M*G:^DPIZF@!WPZF!OH_K7W%
M\'6_T>'Z"OA_X=:5,M]%E3UK[?\ @_"T=M%D=A0![DOS(/I7)^+]+^U6TG&>
M*ZN'_5K]*@OK47$3 C/% 'Q)\8/"3-YI"=SVKYFU:QDTN]8X(P:_0SXC>#A>
M1R83/X5\H_$3X>/')*5C_2@9RO@GXB/I+(#)C'O7K5K\;-UKM\[MZU\TZGH=
MUI\IVAABJ<%U>Q_+EJ!'LWC7XC?VD&'F9S[UY7)&^J7F1DY-58;>[O) "&->
ME^ _ \MW-&60G\* .F^%?A63SHFV'K7V9\,]+-K;QY&*\T^&O@$6Z1$QXZ=J
M]]T#2Q90KQB@9M4M%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I&;:,FEJ&[;9 QH Q_$6LI9VK\XXKY?^+WC\0K,H
MD]>]>M?$75I(X)0I[5\=_%>[N;J24 L>M SRKQQXT:\NG'F9Y]:Q]!O%FF5F
M/>L'6M(NIKDG#'FK6CZ?<V^/E-)B/H#P3K4-BJ'<!7J^F_$^*QC $H&/>OE:
MRU*ZMUXW"K$OB"\VX!:F,^KO^%T*S!?._6NW\&_$A=0D0>;G/O7P?'KM[YX^
M9NM>T_"76+IKB+<6ZB@1]KW$PU6P..<BOG7XO^$VD65@E>_>!=UY8H&YXJG\
M0O""WEJYV9X]*!GYQ^(]'?3[UFVD8-;7@_Q@=*D0;]N#ZUZ5\3? +QR2LL?K
MVKP?5=)N;"X;:&'- 'T)#\7/+LPOG=O6O//&7CTZIO DSGWKS)KJ\"[<M4^F
MZ==7\H#!CS0#+-C:2:E? X)R:^E?@SX799(6*>E>??#_ , R3S1LT9//I7U?
M\-/!HLXXB4Q^% CUCP?I_P!GL4R.U=,.*JZ;;BWM57VJW0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+)-%E#U%!1ZQ\,_"K.T;;?2OJ7P/I1M(X^,<5POPM\([88R4[>E>V:?I@M5
M H$:B?=%.I!TI:!!1110 4444 %%%% !1110 4444 %%%% !1110 W;2@8I:
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]%R>#8)&R4'Y59M?#$5NP(4"@95\&:.MC ORXP*ZRJ]K;BW7 &*L4""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** $HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%%% !1110 44
MF:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $;I3:=1MH %Z4M)2T %)2T4 ,IR]*-M% "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (31NI&H'6@!U%%% !1110 4444 %%%)F@!:*2EH **** "BDS1F@!:
M*** "BBDH 6BDR*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FMUIU)B@!%IU)BEH **** &MUH7K2XHQ0 M%%% !36I
M*5: $I])@4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 FV@#%+10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M->Y^$=7^V1H=V: .XHI%^Z*6@!,BEIE/H *2EIK4 +D4M,I] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$/T%?#7PC7=<P_45]U_"2/R[>(^PH&>VKPH'M6=JFJ)9*<MBFZAK4=E Q)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#*\11^98D5\M?%[1?,68[?6OJ_5(_,M6%>#?%#2?,AE.WL: /@[QII?V>
M[<X[UCZ%=?9[I>>]>B?$O3?)N)#C'->3)/Y-X.<<T#/K_P""NK;FA&?2OJW3
M[S=I8.?X:^'O@IJ^V:'+>E?7&FZTO]CCYOX:!'D_QNU;RXIOF]:^+_%VK>=?
MR#=_%7TQ\=M8W+-AO6OCK6KQIM4(SGYJ /0_!&E_VA,G&<FO85\%?\2_=L[>
ME<5\%M,^US0Y&>:^JH?"8.D9V?P^E SXN\>Z.;%I.,5PNBW1BU!1GO7N_P 9
MM#-L\V%QUKY]MU:'4_\ @5,1]C? W4C^YY]*^M-+U3;I@Y[5\1?!34A"8<GT
MKZDM=?5=,^]_#0!QGQ?UK,<PW>M?&GQ"NOM%Q+SWKZ+^+&N>8LOS>M?+_B:X
M^T73<YYI#.>T#3_.U)>,\U]>_!#2=@A)'I7S?X,T@S7B'&>:^N_A/8BUAB)&
M* /H33;Y=.TT<XPM>.?%+XB"S651+CKWKJO$OB$66FL V/EKY"^,7C-Y)I@'
M/?O0(S?&OQ)DNI)%64G\:\YFU*XU*8X+'-8"WDFI7A&[.37JO@'P4=0DC)3.
M: .3A\.W=T,[6J27P]=VPSM85]7^%_@^DUNI,6>/2G^(_A D,#$1#IZ4 ?(\
M>I7.F-R6&*Z[PG\2)K>X13*>OK5_Q_X%-AYA5,8KR,QR6%[W&#0!]V?"OXB&
MZ\H-+G\:^F/#^K)?6:'=GBOS@^%OBQK6>$%\<U]G?#/Q8+JUC&_/% 'LSS*B
MDUQ/C+Q.MC;O\V./6M;4-4$=FS9[5\[_ !<\:FV24!\<'O0,XOXI?$LQM*JR
M_K7SAXA\=3WMPX$A.3ZU)XY\4/J%U(-^>?6N5TK2WU"Z!Y.30!?B6YU(\;CF
MK\?AB[=<[6KU7X?_  [^V;,QYKV;3_@^DEN/W0Z>E CX]FTJ[L<G#"BP\47.
MG3@%V&#ZU],^,OA*+>!R(L<>E?._C/PFVFW#D+C!H&>I_#OXG2)+$&E/4=Z^
MK?ASXX6^CB!DS^-?FWH^L/IEXHW$8-?37P>\<%FA4R>G>@#[KL[Q;F$$'/%<
MAX\7_0Y/I3O!>L?;+5#NSQ2^.CNL7/M0(^,/C%_K)OQKY<UM=U\?K7U)\8Q^
M\FKYBUA?]-;ZT >F_",B.XASZBOM;X?:PEK81G=CBOAKX>WHM9(SG&*^@M%\
M=+:V('F8X]: /8O'WQ 6UM9,28X]:^4OB%\2'GFE42]_6M'XA?$ W$<BB3]:
M\ UC4)=1O#AB<F@"]J&O37UP<,3D^M=S\/["XNYTR&-<YX.\'RZE,A*$Y-?4
M?PL^%I'E,8O3M0!VOPM\-/MB++Z5]":;8K9V(.,8%8?A/PFNFPI\F,"NDUB3
M[+8L!QQ0!YE\1?%7]GP28?'XU\D?$GXENL\JB7OZU['\9M894F ;UKXL^(&J
M/+>2?,>M %Z\\63:E,0')R?6K6FZ7<ZDP(!.:Y7PC;F\N5R<\U]._#'P;!=+
M%N4&@#RI? -Y(F[8WY5FZAX/N[7)V,*^XM-^&5I)9@^6O3TKF/%7POMUC<K&
M/RH ^(;Q;G3V/WABMGPKXJN;>Y0%V'/K7I_C/X;[9'VQ_I7%V/@">&Z!$9Z^
ME 'T!\+?&$DOE N:^GO">J&Y@3)SQ7R1\.= GM)(\J17T_X(C>.&,&@9Z7&<
MH#3JC@_U2U)0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6
ML_6H!-8R<=JOKTJ*\7=:R#VH ^0OC=I6Y9^/6OC7QAI_EWK\=Z^^/C%IOG1S
M<>M?&GC[2?+NI#MH \_TRX^ROUQ73+X@*V^-W:N1N/W+FF&[;9C- &I>:@;J
M?!.:[?P#I7VFZC..]>8V+&6Z ]Z]\^%&F^=-"2/2@I'TO\(M%\F.$[:^A]/@
MVV8'M7E_PUTORK:,X[5Z];1[85% ,\A^*FC^=;RG;G@U\4?%/2_L]Q(<=Z_0
MGQ]IXFL'..U?$_QFTG;+-QZT"/F^.\^SW)YQS6['KA\G&ZN7U:,PW3?6HENB
MJ]:!&IJNH&93S3?#,9EOT^M9>\S8KK/!&GF2^0X[T ?5GP5TK=%$<=A7O&H:
M;Y>FDX_AKS;X)Z;M@AX[5[IJNF[M-( _AH&?'WQ64QM+^-?,?BHYG?ZU]9_&
M33#&9CCUKY,\6KY=RX/K0-F)I\#22?+77Z;H=W.HV!JRO"4*7%TJGUKZ:^&W
M@>#4EBR@.:"3Q6/PGJ++PKTC>$=1[HU?<^B_!.VNK=6\H=/2I+SX'VT//DC\
MJ /A"3P1?S#!1JIO\,;N8\Q-^5?<=U\+;.USF-1^%9K>";"-L;%H&?&^G_"6
MZ693Y1_*O<_A?X#GL6C)0BO9;#P58,RX1:[OP_X-MH5!15H$<+J5JUKI)!&/
MEKY3^,DF9I?QK[8\<Z2(;&0*.QKXL^,EJ5FFX]:!GS^WS7)^M=%IEC-/MV U
MSR+B_(/K7L7P[TB*]>(,,YH Q;7PW?2K\JM5L>$]1_NM7U3X+^&-MJ$*'RP<
MCTKOK?X'V\B@^2/RH ^&_P#A$M1;C:U5IOA_?7 .8VK[NNO@K;6XR8E_*L2Z
M^'-E:D@HOY4"/A*\^$=U-(#Y1_*NV^'WPKN;2ZC)B(Y]*^J/^$+T_=C:M=-X
M=\%V*NI5%H&9/PT\.RV%O&"I& *[WQ I73R/:NDTGP_%;Q#8HK(\86_E6;_2
M@1\D_%]O]=^-?*OB1O\ 3'^M?4OQB;YIOQKY4\2'_3&^M Q=.M3<8 &:V8_"
M<DZYV58\#:;]LFC&,U]!>&?AV+RT5O+SQZ4 ?-<WAM[-LE<5/IE\UC<*.F#7
MOGC#X;-:PLPCQ^%>'Z_HKV%T>,8- 'N7PJ\9&.6$%^XK[(^''BI;BVC!?.17
MYM>#]>.GW* MC!KZN^$WCL,(E\ST[T#/L2&99ER*D90PP:Y?PGK O84.<\5T
MSR+&,DT$G.^)-!2^B;Y0<BO!?B!\-!=>81'Z]J^@=2\00P@@L!7&ZOK5G<Y!
M9: /B3QG\)9?,?;%^E>7ZA\+;B*1CY1_*OOS4-'L=28X"G-<_??#&VNU)6-3
MGVH ^#I/ \]J?N&HVL)[+L1BOLO6/@V"K%8?TKS+Q/\ "=X-V(OTH&> ?V_<
M6?1B*V]#^(EQ;RK^\(Y]:L^)_!+VA;Y,5P5U9M92'M0(^H_A[\4W:2-6E/7U
MKZE^'OC#^T8X_GSQZU^:_@_Q UO>(-V.?6OLGX(Z\UQY +9Z4RCZ_M)/,MT;
MVJ:J.C-OTZ(^U7J1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "4R?F%_I4E-<;E(H \5^)FF^=%+QZU\?_ !,TGRYI3BONOQMIOG02
M<9ZU\C_%_2#'YQ"^M 'RGK@$<S#WK,5MPZU>\7;XKIQCO6)9R.W:@#=T.WWW
MB_6OJ/X-:7N>$XKYN\)V;RWB<=Z^P/@GI)_<96@#Z>\"Z>(K-#CM7;J-J@5D
M>&[406,?':MB@#'\40^=IK\9XKX_^-&D[FF./6OLO5H_,LG'M7S1\7M'\Q93
MM]:!H^%O%&GF*Z<X[UREPWE]Z]1\?:8T-Q(=O>O(=6D>.0C% C8TT><RUZU\
M.=)\RZC..]>0>%]\TR#'>OI+X5Z.9)(CM]*!GU%\(=/\FWBX["O;YK426>W'
M\->:?#;3_)ABXQQ7K"CY0/:@#YA^-7A\M',0OK7Q!\1].>VNI>,<FOTL^*'A
M\7EM)A<Y%?$OQ<\%.LTQ$?<]J!GA'A/4#:WRY..:^L_A%XRAM_)#./SKY%NM
M,FTV\)VD8-=AX3\7S:;(OSD8H$?I_P"#_&UG-9HK.O3UK0UOQG90V[8=>GK7
MP]X9^,$EK"@,Q_.M#6OC-)-"0)CT]:!'LWCCXIV]H9,2 ?C7D=]\:HQ<$"8=
M?6O$/&GQ"N+[?MD8_C7FZ:S>75YPS')H*/M;PS\6/M<J 29Y]:]Z\#^)SJ$:
M<YKX9^%MA=W<T1.[K7VA\+]#ECMHV8'H*!'9>++7[98N0.HKXY^-7AQ]\QV^
MM?<USI_G6A4CM7@GQ:\&?:8Y2$S0(_/74-/:UOV)&.:]!^'_ (@6QFC!;&#3
M_B#X3>QN)"$QS7F\-Y-I]UQD8- S] /A;X\M_*B#.O;O7O>D^,K.2W4EUZ>M
M?FKX+^(4UALS(1^->M:;\9GC@ \X_G0!]<>*_'UI;PMAUZ>M>#>,?B[#;R/B
M4?G7DGBGXO2W43 3$_C7B7BCQI=7LS8=CGWH$?0C_&H&XP)>_K7I7@+XF_;Y
M(QOSGWKX;T5KV^NEY8\U],_![0KIFA+!NU 'VAX9U;[=;J<YXJGXX7_0G/M1
MX)T]X+1-P[4OCH;;%_I0,^-?C&WS35\L>(,-?-_O5]/?&9F\R>OEC77?[>>.
M] CT_P"$]HLEU%QGD5]K_#;P_'<6<8V \#M7Q=\(&;[5#D=Q7WI\'U$EO"#Z
M"@:*OC;P&DUBQ$?;TKY(^*/@LV<TI"8Z]J_1G5])CNK5EVYXKY<^-'A$;9B$
M]:!GPE?S/IMX>=N#7K7PG\8-%/$#)W]:\Y^(6CR6MY)A<8-4?!NI36%TF21S
M02?IC\+?%"3V\67SQZUZ7J>K 6I96[5\<?"3QPRB%2_IWKZ0T_53J>GC!SD4
M <)X^\:26!DPY'XUXAKGQG>UG8&8CGUKT_XI:'--#*R@U\=?$33[RVNI<!AS
M0,^AO#'QJ6YE4--G\:]T\&>-K;5%3<ZG/O7YKZ+K5Y87 RS#!KW'P#\3Y;$Q
MAI",>] 'Z!Q1V-Y:Y.TY%<1XN\/V4D;X5:\CT?XW*EN 9NWK4&L_&6.XC8>;
MG\: ./\ B5HMO#YN .]?-OBVW6.1PM>N^.O'HOM^'SFO&=2N'U&X.!G)H R_
M#=K*^H+C/6OLSX"VLB-!D'M7SQX!\'R75W&VSOZ5]E?!_P *M9K"2F.E 'T?
MH(QI</TK0JKID?EV<:^U6J!!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &+KUB)[=^.U?-'Q<\,&9)L)VKZLN(_,C(KS/QIX7%
M\LGR9X]* /SB\:^"I&NGQ&>OI6#IW@F7</W9_*OLCQ%\*_M$S'R<_A679?"7
M:P_<_I0!XCX,\#.+A"8SU]*^L_A+X<-HL65Q6?X=^&@MY%/E8Y]*]B\)^'A8
MJORXH [G3X_+M8U]JL4R$;8U%/H BNEWPL/:O(?B'X?^U12?+FO8F&Y2*Y_7
M-)6ZC8$9H&?!WQ(\$LTDA$?Z5X)KW@F7[0W[L]?2OT,\8> %NM_[O/X5Y/J_
MPE\R8GR?TH$?,?@WP3)]H3,9Z^E?4WPK\)&$1$IZ5)X=^%7V>53Y..?2O;/!
MOA 6:I\F/PH&==X2TW[-#'QVKL:HZ?:""->*O4",;Q%IHOK<C&>*\"^(WPZ%
MZLI$><^U?2CH)%P:R-4\/Q7L9^4$T#/SL\:?"EXI'98C^5>8WW@VXL93A"/P
MK]%_%7PWBN58^4/RKR+Q%\(U9FQ#^E CX]$-W;X #"G[;R;@[J^B+SX/GS.(
M?THMOA =W^I_2@JQ\\Q>%KB_X*,:ZGPS\*9;BY1C$?RKZ'T+X0J&7,/Z5ZIX
M7^%4,.PF$?E0!YY\+?AB+3RBT6.G:OIWPOHJ:?9J-N.*@T3PG%I\:X0"NCCC
M$:A102!C!4C%<CXN\.I?6[_+GBNQJ*>$3+@T ?''Q.^&1N/-*Q?I7SCXD^&<
MUO.Y$1'X5^E6O>#XKY&R@.?:O)O%'PIBEWD0C\J /@B3P]<6/16&*%%W&,?-
M7U-K7PA&YL0_I7/R?!\Y/[G]*!GSL;2ZNN"&-6K#P+/?3*3&Q_"OH?3_ (0?
MO!F']*[_ ,-_"%%928?TH \3\!_"=FEC9H?3M7U!\.? "6,<9\O&/:NH\,_#
MF*T5?W0'X5Z'INBQV48 4 T .TNP6U@  QQ7.^-H?-LY /2NRV[5P*PM<M/M
M$3#&:!'QA\6O#[W$DV%KYLUGP7*UX3Y9Z^E??_C+P3]N9_W><^U>77OPG\RX
M)\GOZ4#/&OA?X5DM[B(E".1VK[4^$]FUO#"",=*\Z\)_#<6<B'RL8]J]R\(:
M/]AC3Y<4 =L1N&#7D_Q.\-"^AEPN>M>LUD:UIHO(V!&<T"/SZ^)7PW:2>5A%
MW/:O)V\$RV5QD1D<^E?H)XM^'J7F\^5G/M7E>L?"D>8<0_I058\7^'L$]I<1
MC!'-?6?P[D::UC5O2O,M$^'!M9U/E8Y]*]G\%Z*UFJ#;B@1>\2>%4U&S;Y,Y
M%?-7Q(^$OVB25A#G\*^U;>Q66WPPKG=>\$0WRL=@/X4"/S9U[X7RV<C%8B/P
MKG?["NM/;A6&*^]O$WPIBFW8A'Y5YCK'P?&YL0_I0,^74O+Z'@%J<UY?2\?-
M7O4_P?.X_N?TIT/P@.X?N?TH \!_L6[OR,JQS71>&?AK/=3(6B)Y]*^@]%^$
M*[ES#^E>G>&/A3%#L)A'Y4 >:?#?X7_9S&6B].U?27A'PTMA"GRXP*N:%X/B
ML47Y ,>U=3#;+"H % A\2[(P*?110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *3(I:90 ZEIJTZ@ HHHH 3F@9[TM
M% !1110 W::5:6B@ HHHH **** "BBB@ HHHH 3(HIM*M #J*** "BBB@ HH
MHH *93Z90 X44BTZ@!.?2EHHH **** "BBB@!NTTJTM% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img224190320_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224190320_4.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %P T(# 2(  A$! Q$!_\0
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M4*Y /LJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLZQW ABCN)H:-W_P4Y_9:MOA%X>^+,%[\2M4N_%'Q'USX.Z1\&M(^%GC&_\
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MH\MYIFH:7=WFGR3)8:K:2V-YY,S1"3TZ@ HHHH **** "BBB@ HHHH ****
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MS@_2S\%_AU^S5^U9\ OVVOC+%<>*_'O[2GCCXC_ "X7]C+]LO]HE+CQ?X-^
MNGZ=XCTN\^)_[-OQ1\,_#ZS\(V%C/XCOH]-\<^&?'6EV5KJ_C2SMF\/:E<1/
MX<CBN>&_;8^,7Q]\3^(_#G[%WQO^%'QJL_AAKO@3PAK_ .V7^T3^RG^SIXU\
M9Z9^T&-0U&6/_AG;X.WD%UJ&I>#-!O\ 1(DM_BEXV\33WNK:9X?N[CPOX9AB
MN-1O+Z#^B&B@#\N?C#\$X)_VR_\ @G;\5_A?\'9=/T33;GXN'XF^,-+\*6NG
MZCX?\.#X#0^'/ASIGCW4RB:K;V]C^ZT'1M-O9IX[*[62V6-) 6/P#\'OA/\
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M&@RWT:7DWA_4VO=$GNE%Q+8/+EZ /RG_ &.T\1:Y^T=_P3;N-(N[Z\U'P?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFRUKHJ^AI_PZ?^"/_I*/QO%_[WBO^PBM_P"G)!1115G.%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_/9_P
M4ITKP'IW[<'@#QK^UC\4_P!N'X*_LL1?L[2Z/X)\5?LL^,OCAH_PT\0?&<>-
MM5DUK2OC!'\%;'5]:T#Q'IOANZT2Y^'T\UC8Z=XD:ZU."[U*>;1[?3Y?%/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M02QS0R+_ &;; -'+$SQR(<?*Z,RL.02.:Z6OH:?\.G_@C_Z2C\;Q>F+Q5_\
MH(K_ /IR044459SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%1RS16\;S3RQPPQC=)+*ZQQHN0,N[E549(&6(&2*
M!I-M))MMV26K;>R2ZMDE%0075M=!S;7$%P(R%<P31RA&(R%?RV;:2.0#@D<]
M*GH!IQ;4DXM;IIIKKJGKMJ%%%% @HHHH **** "BBB@ HHHH **** "BBB@
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M3V_:(L_B-X,^%6L^/OA3-^Q7\,_VO->_;,\)W%E;^*1\>]5\07^N:_XU\/\
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MI7K2IT,WQ="C"56K*<W"C0ITZ-*+DU3I4X4X)0A%(HHHKU3X$**** "BBB@
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MV<_BG\9-3\#S_#VV^)WQ \+>(?AAH?A+P%<?$*WEU6UM[FR\7>,]%\4^(9]
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M>U^M1P6(QV KX6&*E06'566&C*I'Z[@_;_3]%%%>\?E84444 %%%% !1110
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MX'NO"$VB>+))+;Q7J\EK#I^BS:E!H,NDK<W$U[:0AQ>M;I).BR3)\Q5?%_\
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M_5/K6;97[' 3^OY;A_K^ ]OCL+[7#4OKN$]I5C]9H\_WC7P?\%_^3\OVV?\
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M_"+]HKP!^TGX+33-%M;&Y&I7/Q'^'ZP^'[._*W4QU#0YPMYI<4,4]RWEW,9
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MLHXG$1E'C?CYQDJU12BY9%X=-N+4KIMU*EVFF_:3O\4KX-WX-\(:A:V5C?\
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MDNT7Q%]OATM=2F_M,VAAFF:W0M&JO7Z=T4 ?B[XU_P""9_[6^D?'3XP_%_\
M97_X*2^(_P!FK1_C9:?"Y_&'@,?LT?"GXJVS:]\+_AWHWPXL=;M-?\8ZDFHV
MW]IZ7HT%S=:?%$EM%<2.J%@ U?L/X9L-7TKPYH&F>(-<;Q-KVG:+I=CK7B1M
M/MM);7]6M+*"#4=:;2[-FM--;5+N.:^-A:LUO:&?R(6,<:FMNB@ HHHH *"
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M_P"2??M3?]G_ /[8?_JT+F@#M?C5_P GZ_L1?]B7^T]_ZB7A2OO2O@OXU?\
M)^O[$7_8E_M/?^HEX4K[TKR\O_WK._\ L:4__5/E)]UQ?_R)/#/_ +(7$_\
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M_2)'I9-_R.,J_P"QE@?_ %*I'D7[#G_)G7[,?_9$?AU_ZC6GU]45\K_L.?\
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MTC[7Q,_Y./Q__P!EKQ3_ .KS'!1117IGQ 4444 %%%% !1110 4444 %%%%
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M;5O%.N13:5I'E6SS70GNXG1S (5&^137YY?\$C]4\4ZY\#/C]K/CCPA'\/\
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M@L!B:\X8W,)8?-57Q"P5*-*<*GL**=2I[2I225E%RD^4^YZ***]0^%"BBB@
MHHHH **** /A3XY_\GP?L*?]@[]IO_U6NF5]UU\*_'-6_P"&WOV%6VG;_9_[
M38W8.W/_  K73."<8SR.,YK[JKR\O_WK._\ L:4__51E1]SQ=_R(_#/_ +(;
M%_\ KP^/0HHHKU#X8**** "BBB@ KS3XT?\ )'?BQ_V33QW_ .HMJM>EUX=^
MTGXBOO#?P-^)EUIG@KQS\0=3U+PEKGAW3?"OPYT >)?%.H7_ (CTVZT:S:TT
MLW=BKVMO<WD4U_</<HEI:++</N6,@\^*DH87$2E>T:%5NR;=E3ELDFV_))M]
M$>OD%&IB,]R6A2474JYKE]."E.%.+E+%TDN:I4E"G"-_BG4G&$5=RDDFSB/V
M'/\ DSK]F/\ [(C\.O\ U&M/KZHKY,_86;7X/V2_@3H7BOP+XX^''B?PA\/?
M#G@SQ!X3^(6BQZ%XBL-8\,:;;:3J$C64-Y?0R:=<W-O)-IE[%<LE[9M'.%CW
M%!]9UCE?_(MR_1K_ &'")J47&2:H4TTXR2E%IZ-22:>C29Z?',>7C7B]<U.:
M_P!9\^<9TJM.M2G&6:XJ49TJU&4Z56G.+4H5*<YPG%J4).+3"BBBNX^5"BBB
M@ HHHH *^#_@O_R?E^VS_P!B7^S)_P"HGXJK[PKX/^"__)^7[;/_ &)?[,G_
M *B?BJO+S'_><E_[&DO_ %59H?=<(?\ (D\3/^R%PW_KP> S[PHHHKU#X4**
M** "BBB@ HHHH **** "BBB@ HHHH **** "J]W_ ,>EU_U[S?\ HMJL57N_
M^/2Z_P"O>;_T6U!4/CC_ (H_FCXD_P"";7_)DWP(_P"P)XB_]3;Q-7W'7PY_
MP3:_Y,F^!'_8$\1?^IMXFK[CKS,E_P"1-E/_ &+,!_ZBTC[7Q,_Y./Q__P!E
MKQ3_ .KS'!1117IGQ 4444 %%%% !1110 4444 %%%% !1110 4444 ?GO\
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MJXBIBZF&H.$(R]E/%5:V(<)RDO;UJU56G6J2D4445N>2%%%% !1110 4444
M%%%% !1110 4444 %%%% !7YC_LX?&/X4>-/^"@W[:NA^$?B+X0\2:U+X/\
M@-#%I6C:U:7U[+)X0T/Q'I/BI(8X'99G\.ZG=6MAK20N[Z==W$,%TL4C[:_3
MBL.Q\,>&M+O)-1TSP]H>G:A-Y_G7UCI-A:7DOVF02W/F75O;QSO]HE EGW.?
M-D >3<P!KAQ>%K8BOE]2G5I0A@\7+$U8SISG*JGA<1AE"G*-6FJ;2Q,I\THU
M$W&*Y;-L^IX?SS+\IROC#!8O XW%XCB/A^CDN"K8;&T,+1P%2GGV39[+%8JC
M5P6*GC82J9+0PZH4:V"DH5JM1UFXPB;E%%%=Q\L%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIX; 95CL11JI3Q]2=&<\-.3H3A2G4I_8Y5PME>?<-9G0S7#\$XK,\ZQN#PO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^8K\R/\ AS[^P3_T3+QU_P"']^/?_P \FC_AS[^P3_T3+QU_X?WX]_\ SR:
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M  Y]_8)_Z)EXZ_\ #^_'O_YY- 'Z;Y'J/S%&1ZC\Q7YD?\.??V"?^B9>.O\
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M,CU'YBOS(_X<^_L$_P#1,O'7_A_?CW_\\FC_ (<^_L$_]$R\=?\ A_?CW_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5Y5\;OA'HOQW^%OC#X2>(_$?CGPKH'
MCC31H^M:S\-_%>H>"/&46ER7$,M]::3XHTK&HZ4NIVT<FFW\MHR32Z?=75NL
MD?F[QZK10!R?@/P-X4^&7@KPG\._ NBVGASP9X'\/:3X6\+Z%8JRVFDZ%H=E
M#I^FV,.]GD=8+6"-&EE>2:9PTLTDDKN[=9110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img224190320_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224190320_5.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'S!#@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>#H_$FGC6H?%^D77ACQ=K\GAV6\TG4Y],TG7_#WB32+FUO+J/3KV&SED-M
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MP]I&HZYJL\<,MQ)!IVE6<U]>RI!"KS3/';02.L42-)(P"(I8@5_+1^TOJ?\
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MG6D4445X)_1 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_3O_!:5(X?^">'Q8BC1(HH_$7PGCCC152.-$^)?A941$4!555 554 *
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M7Q/PQC7@<?A:F#C2P5/#Y1DV(JU*O/4E/'2C0I\])JL_SP_X+0_\H]OV1_\
ML=_A=_ZI'Q?7Z#_L( +_ ,$P/A-M 7/P#\2L=H"Y8VWB,EC@#+,<ECU)))))
M)KU_]I;]AKX/?M5?!_X>?!/XD:KX^T_PC\--3T+5O#]UX2US2-+UV>Y\/>%]
M1\)6*ZI>ZEX>UFTNHGTS4[B2Y6#3[1Y+Q8I4>*)6@?U_X4_ 7P7\'O@7X?\
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M8#+L5A,HQL<&Z<\-4S!82C.,\;4C7G+ ^SE3_P""Y7[0_P *OC-\;?A/X/\
MACXET3QH_P +?#NMVWBOQ#H%W;ZGI4&L>(-8LI(="L]5M)9;2^DLK;3OM-\;
M622&&6ZAB\UI!(J?U<?!_P#Y)+\+O^R=>"?_ %&M,K^);X\V/[-GQT^(/P%_
M9Z_X)Z_#7QO/I5M>2Z?JNN>)].F_X2_Q]XK\2ZGIL8UC5Y9&DN[?3/#NGQ21
MSW5S;Z5I&GVQFF@L[6V1Y9/[C/"&@_\ "+>$O"_A@3?:!X<\.Z)H(N.?W_\
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M-Y>_8_[9*V'J.22IV?*KN]U^&7_!0C_E-#\$_P#L??V4?_4OT:O5?^#A[/\
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M\09WO(;0Z'X$@\.W&LHDP<M>O'XF\2>%]/\ L<&P"9EU%K@&1/+MY 6*^/\
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MO)?Y\R_\,.?>7_4L\T?2E%?-?_#0?BC_ *-;_:4_\%7P>_\ GS4?\-!^*/\
MHUO]I3_P5?![_P"?-1]5K=J?_@^A_P#+ _UKR7^?,O\ PPY]Y?\ 4L\T?2E%
M?-?_  T'XH_Z-;_:4_\ !5\'O_GS4?\ #0?BC_HUO]I3_P %7P>_^?-1]5K=
MJ?\ X/H?_+ _UKR7^?,O_##GWE_U+/-'TI17S7_PT'XH_P"C6_VE/_!5\'O_
M )\U'_#0?BC_ *-;_:4_\%7P>_\ GS4?5:W:G_X/H?\ RP/]:\E_GS+_ ,,.
M?>7_ %+/-'TI17S7_P -!^*/^C6_VE/_  5?![_Y\U'_  T'XH_Z-;_:4_\
M!5\'O_GS4?5:W:G_ .#Z'_RP/]:\E_GS+_PPY]Y?]2SS1[1XW\!>"/B7X=O/
M"'Q$\(>&O'7A34);2>^\-^+M$T[Q#H5Y-8745[8RW6E:K;W5C/)9WD$-U;/+
M S07$4<T961%80^!/AWX!^%^@1^%/AMX+\+> ?#$-U<WL7A[P=H.F>&]%BO+
MUQ)=W4>F:1;6EFEQ=.H>XF6$23, TC,1FO'?^&@_%'_1K?[2G_@J^#W_ ,^:
MC_AH/Q1_T:W^TI_X*O@]_P#/FJO88GD]GS1]GS<W)]9H\G-:W-R^UY>:VE[7
MMI<Y/[<X7>-69/"UWF*P_P!46/?#&<?75A7/VGU98K^R?;K#^TES^Q]I[/G;
MER\UV?2E%?-?_#0?BC_HUO\ :4_\%7P>_P#GS4?\-!^*/^C6_P!I3_P5?![_
M .?-4_5:W:G_ .#Z'_RPZ_\ 6O)?Y\R_\,.?>7_4L\T?2E%?-?\ PT'XH_Z-
M;_:4_P#!5\'O_GS4?\-!^*/^C6_VE/\ P5?![_Y\U'U6MVI_^#Z'_P L#_6O
M)?Y\R_\ ##GWE_U+/-'TI17S7_PT'XH_Z-;_ &E/_!5\'O\ Y\U'_#0?BC_H
MUO\ :4_\%7P>_P#GS4?5:W:G_P"#Z'_RP/\ 6O)?Y\R_\,.?>7_4L\T?2E%?
M-?\ PT'XH_Z-;_:4_P#!5\'O_GS4?\-!^*/^C6_VE/\ P5?![_Y\U'U6MVI_
M^#Z'_P L#_6O)?Y\R_\ ##GWE_U+/-'TI17S7_PT'XH_Z-;_ &E/_!5\'O\
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M%'_1K?[2G_@J^#W_ ,^:C_AH/Q1_T:W^TI_X*O@]_P#/FH^JUNU/_P 'T/\
MY8'^M>2_SYE_X8<^\O\ J6>:.C\9?LR?LX_$35IM>\>_ 7X/>,];N6WW&K^)
M_AOX0US4[APNW?/?:CI%Q<ROM 7?)*S$  G %=[X'^''P]^&>E'0_ASX&\(^
M ]&9Q*VE>#_#ND>&]/>0#:)'M-(M+2!W"_*'9"P' ('%>/\ _#0?BC_HUO\
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M\,.?>7_4L\T?2E%?-?\ PT'XH_Z-;_:4_P#!5\'O_GS4?\-!^*/^C6_VE/\
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M $:W^TI_X*O@]_\ /FH_X:#\4?\ 1K?[2G_@J^#W_P ^:I^JUNU/_P 'T/\
MY8=7^M>2_P ^9?\ AAS[R_ZEGFCZ4HKYK_X:#\4?]&M_M*?^"KX/?_/FH_X:
M#\4?]&M_M*?^"KX/?_/FH^JUNU/_ ,'T/_E@?ZUY+_/F7_AAS[R_ZEGFCZ4K
MRSXC? WX,?&"72YOBO\ "?X<_$J;1$N(M'E\=^#/#WBN32H[MHVNH]/?6]/O
M6LTN6BB:=;<QB4QH7#%1CS[_ (:#\4?]&M_M*?\ @J^#W_SYJ/\ AH/Q1_T:
MW^TI_P""KX/?_/FJH4,33DITY1A)7M*&(HQDKJSLU535TVGKJG8Y<9GO#.8X
M>>$S##8C'82JX.IA<9PSG.*P]1PG&I3<Z-?*ITYN$U"<>:+Y9J,E9Q37T1IV
MGV&D:?8Z3I5E:Z;I>F6=MI^FZ=8P16ME86%E EM9V5G:P*D-M:VMO%'!;P0H
MD4,4:1QJJ* +E?-?_#0?BC_HUO\ :4_\%7P>_P#GS4?\-!^*/^C6_P!I3_P5
M?![_ .?-4O#5FVW[-MZMNO0NWW?[PZ8\4Y)&,80>8QC%*,8QR#/8QC%)*,8I
M98DDDTDDDDM%L?2E%?-?_#0?BC_HUO\ :4_\%7P>_P#GS4?\-!^*/^C6_P!I
M3_P5?![_ .?-1]5K=J?_ (/H?_+!_P"M>2_SYE_X8<^\O^I9YH^E**^:_P#A
MH/Q1_P!&M_M*?^"KX/?_ #YJ/^&@_%'_ $:W^TI_X*O@]_\ /FH^JUNU/_P?
M0_\ E@?ZUY+_ #YE_P"&'/O+_J6>:/I2BOFO_AH/Q1_T:W^TI_X*O@]_\^:C
M_AH/Q1_T:W^TI_X*O@]_\^:CZK6[4_\ P?0_^6!_K7DO\^9?^&'/O+_J6>:/
MI2BOFO\ X:#\4?\ 1K?[2G_@J^#W_P ^:C_AH/Q1_P!&M_M*?^"KX/?_ #YJ
M/JM;M3_\'T/_ )8'^M>2_P ^9?\ AAS[R_ZEGFCZ4HKYK_X:#\4?]&M_M*?^
M"KX/?_/FH_X:#\4?]&M_M*?^"KX/?_/FH^JUNU/_ ,'T/_E@?ZUY+_/F7_AA
MS[R_ZEGFCZ4HKYK_ .&@_%'_ $:W^TI_X*O@]_\ /FH_X:#\4?\ 1K?[2G_@
MJ^#W_P ^:CZK6[4__!]#_P"6!_K7DO\ /F7_ (8<^\O^I9YH^E**^:_^&@_%
M'_1K?[2G_@J^#W_SYJ/^&@_%'_1K?[2G_@J^#W_SYJ/JM;M3_P#!]#_Y8'^M
M>2_SYE_X8<^\O^I9YH^E**^:_P#AH/Q1_P!&M_M*?^"KX/?_ #YJ/^&@_%'_
M $:W^TI_X*O@]_\ /FH^JUNU/_P?0_\ E@?ZUY+_ #YE_P"&'/O+_J6>:/I2
MBOFO_AH/Q1_T:W^TI_X*O@]_\^:C_AH/Q1_T:W^TI_X*O@]_\^:CZK6[4_\
MP?0_^6!_K7DO\^9?^&'/O+_J6>:/I2BOFO\ X:#\4?\ 1K?[2G_@J^#W_P ^
M:C_AH/Q1_P!&M_M*?^"KX/?_ #YJ/JM;M3_\'T/_ )8'^M>2_P ^9?\ AAS[
MR_ZEGFCZ4HKYK_X:#\4?]&M_M*?^"KX/?_/FH_X:#\4?]&M_M*?^"KX/?_/F
MH^JUNU/_ ,'T/_E@?ZUY+_/F7_AAS[R_ZEGFCZ4HKYK_ .&@_%'_ $:W^TI_
MX*O@]_\ /FH_X:#\4?\ 1K?[2G_@J^#W_P ^:CZK6[4__!]#_P"6!_K7DO\
M/F7_ (8<^\O^I9YH^E**^:_^&@_%'_1K?[2G_@J^#W_SYJ/^&@_%'_1K?[2G
M_@J^#W_SYJ/JM;M3_P#!]#_Y8'^M>2_SYE_X8<^\O^I9YH^E**^:_P#AH/Q1
M_P!&M_M*?^"KX/?_ #YJ/^&@_%'_ $:W^TI_X*O@]_\ /FH^JUNU/_P?0_\
ME@?ZUY+_ #YE_P"&'/O+_J6>:/I2BOFO_AH/Q1_T:W^TI_X*O@]_\^:C_AH/
MQ1_T:W^TI_X*O@]_\^:CZK6[4_\ P?0_^6!_K7DO\^9?^&'/O+_J6>:/I2BO
MFO\ X:#\4?\ 1K?[2G_@J^#W_P ^:C_AH/Q1_P!&M_M*?^"KX/?_ #YJ/JM;
MM3_\'T/_ )8'^M>2_P ^9?\ AAS[R_ZEGFCZ4HKYK_X:#\4?]&M_M*?^"KX/
M?_/FH_X:#\4?]&M_M*?^"KX/?_/FH^JUNU/_ ,'T/_E@?ZUY+_/F7_AAS[R_
MZEGFCZ4HKYK_ .&@_%'_ $:W^TI_X*O@]_\ /FH_X:#\4?\ 1K?[2G_@J^#W
M_P ^:CZK6[4__!]#_P"6!_K7DO\ /F7_ (8<^\O^I9YH^E**^:_^&@_%'_1K
M?[2G_@J^#W_SYJ/^&@_%'_1K?[2G_@J^#W_SYJ/JM;M3_P#!]#_Y8'^M>2_S
MYE_X8<^\O^I9YH^E**^:_P#AH/Q1_P!&M_M*?^"KX/?_ #YJ/^&@_%'_ $:W
M^TI_X*O@]_\ /FH^JUNU/_P?0_\ E@?ZUY+_ #YE_P"&'/O+_J6>:/I2BOFO
M_AH/Q1_T:W^TI_X*O@]_\^:C_AH/Q1_T:W^TI_X*O@]_\^:CZK6[4_\ P?0_
M^6!_K7DO\^9?^&'/O+_J6>:/I2BOFO\ X:#\4?\ 1K?[2G_@J^#W_P ^:C_A
MH/Q1_P!&M_M*?^"KX/?_ #YJ/JM;M3_\'T/_ )8'^M>2_P ^9?\ AAS[R_ZE
MGFCZ4HKYK_X:#\4?]&M_M*?^"KX/?_/FH_X:#\4?]&M_M*?^"KX/?_/FH^JU
MNU/_ ,'T/_E@?ZUY+_/F7_AAS[R_ZEGFCZ4HKYK_ .&@_%'_ $:W^TI_X*O@
M]_\ /FH_X:#\4?\ 1K?[2G_@J^#W_P ^:CZK6[4__!]#_P"6!_K7DO\ /F7_
M (8<^\O^I9YH^E**^:_^&@_%'_1K?[2G_@J^#W_SYJ/^&@_%'_1K?[2G_@J^
M#W_SYJ/JM;M3_P#!]#_Y8'^M>2_SYE_X8<^\O^I9YH^E**^:_P#AH/Q1_P!&
MM_M*?^"KX/?_ #YJ/^&@_%'_ $:W^TI_X*O@]_\ /FH^JUNU/_P?0_\ E@?Z
MUY+_ #YE_P"&'/O+_J6>:/I2BOFO_AH/Q1_T:W^TI_X*O@]_\^:C_AH/Q1_T
M:W^TI_X*O@]_\^:CZK6[4_\ P?0_^6!_K7DO\^9?^&'/O+_J6>:/I2BOFO\
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M]ZI4C%=6>O4445@>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%XEUW1Y"5;=IVJZC9.@5@"(Q!<QA.YVJN #_ ,"'K>B_M,?M'^$TC71/C?\
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M2*.1]U^/^0?VKA.]3_P#_@GI]!..:\P_X3#5_P"[9?\ ?B7_ .2*/^$PU?\
MNV7_ 'XE_P#DBCD?=?C_ )!_:N$[U/\ P#_@GI]%>8?\)AJ_]VR_[\2__)%'
M_"8:O_=LO^_$O_R11R/NOQ_R#^U<)WJ?^ ?\$]/HKS#_ (3#5_[ME_WXE_\
MDBC_ (3#5_[ME_WXE_\ DBCD?=?C_D']JX3O4_\  /\ @GI]%>8?\)AJ_P#=
MLO\ OQ+_ /)%'_"8:O\ W;+_ +\2_P#R11R/NOQ_R#^U<)WJ?^ ?\$]/HKS#
M_A,-7_NV7_?B7_Y(H_X3#5_[ME_WXE_^2*.1]U^/^0?VKA.]3_P#_@GI]%>8
M?\)AJ_\ =LO^_$O_ ,D4?\)AJ_\ =LO^_$O_ ,D4<C[K\?\ (/[5PG>I_P"
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M_P )AJ_]VR_[\2__ "11R/NOQ_R#^U<)WJ?^ ?\ !/3Z*\P_X3#5_P"[9?\
M?B7_ .2*/^$PU?\ NV7_ 'XE_P#DBCD?=?C_ )!_:N$[U/\ P#_@GI]%>8?\
M)AJ_]VR_[\2__)%'_"8:O_=LO^_$O_R11R/NOQ_R#^U<)WJ?^ ?\$]/HKS#_
M (3#5_[ME_WXE_\ DBC_ (3#5_[ME_WXE_\ DBCD?=?C_D']JX3O4_\  /\
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M )(H_P"$PU?^[9?]^)?_ )(HY'W7X_Y!_:N$[U/_  #_ ()Z?17F'_"8:O\
MW;+_ +\2_P#R11_PF&K_ -VR_P"_$O\ \D4<C[K\?\@_M7"=ZG_@'_!/3Z*\
MP_X3#5_[ME_WXE_^2*/^$PU?^[9?]^)?_DBCD?=?C_D']JX3O4_\ _X)Z?17
MF'_"8:O_ ';+_OQ+_P#)%'_"8:O_ ';+_OQ+_P#)%'(^Z_'_ "#^U<)WJ?\
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MXE_^2*.1]U^/^0?VKA.]3_P#_@GI]%>8?\)AJ_\ =LO^_$O_ ,D4?\)AJ_\
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M? D=0V(VPREL@JK#%5$U259'4RXB=MP"H.5/+*XVE=[;<9?9SMZ#BG/&9(F
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MK*N\';\H( X. -$[(DWE!0\6Y"X8J!M9@I"*D@&!M4[MWRD;2&,(>>6X50X
M21ES'DX980JDR,[-Y9/+,V0C#:25^:DZ=&5V[7DO.ZT6VEKONV_)J^M1Q,TK
M*=E:[Z7L]$^]GLE\[Z'HP\1J+AU$TL2"(^7*UO( H2-HCDA@2IDX!C+,-_S#
M&&*)XDC3<J!FC$1):7='('.5)<,6*(D@WY !'WE+KTX&X>7?@N&(7<9 ",[%
MR4?.%4[P"6VNK@+SC#&)I%:,E/,E=W5-JN1(0AW._51( I*[0<H-Y)VXK)QH
M)J*6EK-V;MLV[[WWUO=Z[=+55M)N3;;O??1[7\O+RU1W+^(SF5%(+IY2;XI%
M4).007W$;9%)95QO4G )/.*SK[79)$2%8+% \RM]K=I)3''&H,RR"%PWF,Z^
M2S'89 S#>8R&KE;C?<(5&!NE50=RB,<!8\;MW0=9%R8W*\CJ:4MU&US%;A#N
MG>:*X! 6-,@B(W"W)5BTJ#<-SLJL%=,D@4*I1BDE&\M&EHG'5;M[MVNDV[VL
M[/XLJU:RNM6[7Z-+17[=+:?\$]:MM25-)B"W/VB74&DN)\RF*T6")]A+01@B
MSA9T\N.-3)(RE"@51QH6>LPHT4;?+)L>-421DFN0JLX6+8%6"SW9)8-(68%'
M^:N,@9HX$#!-A-M;1-&J;U4H4DWJK^7+L7Y@<?*,Y!R*K?;I[9!'"9K@2R)%
M(LORB=8F"Q*)'R #\S7"-M78N4*LV3JN1J^K4G=.VB6FNBZ+R\K7LR8UMM>^
MK6MG;1]]W;K9M/0]!M-2@9=C-BV1EW2Q&-))&#*S6YC=I6W!8&0G)D))8I&I
MQ3FN+69)"I,2/$UQ;QR28 6 .5-O&0D8BW9"-*WS+DAN54^;3WKJL,7VUHI9
M[P+$L($,4<RI^\E2WCRPMX5=U\LRQ&<@D,%Z.EU)2L,LP:1)DE1T"+) AB.$
M\R-I'A6*12&2"?:B@!7#ODF)TU.SB_>U6JMVY;_/7?R:-J=972TM*VG5--7M
MVTO9-]$D[63ZF[DCNXH985CEGELI5DAC41BYM[%#.UQ;LZHR1R(QW+S.)-@C
M^1\"]A;NUD@\UO,F=X['S5 D%O<6L84RQD%9Y6G&UA& 0A=V9)$Q7#S:I]J7
MR&8)++"Z--#,8UA25&RZN^(%:-<(L$9$<<9",K;%-:,.J92UFBNUMRR3F&*>
MVF^U/(P,*>;)&P5QY;F:-_*6#RP-[(JX.4J:C&-VV[]-4M$[;=7>]]M5L=$9
M7;[=._\ D= ]EIE_+%#?6*"657M9+J%HDN5N(OEAEB8(5:7*,FYEV31,FY%<
M9/(MI"6PN#YZO:%RT)*R1S0)&2;QIF5%C98V4S7&Y8/+<#8<$AM0:B)&O&AE
MM%CLDDF*$3+$4LXT7>ES,KM)#<.S*1;='W*9,@&K5S+I][#%$DT,@(!EW>8N
MH6]M*#.UY!, \86[8E)()D,C0$@,P!V8NG"3C*44VHV3:WCI?RZVNEM=;ZC:
MC+5[K2_5;:?EH<G=V2RB5$= Z.\\<<GSFZF2(R1.+C?SEPC,C11I%( P9@V3
MB/I,-W;W4B([,1LN49"92)8P\DBV[@^3)$#M\R!O+92)3* N%]'^RPO;N]P8
M5=Y9)"(O($RJT+6EL\<:>9$UNLOENX^>X8D+(BXW5STUJELZI*D:W-HEU8W(
M!86-Y-,5EMKZ%T,++A68$H[2QQHRO$!E1R5<+!-.*>_+;222:Y9*TKZ.^M^9
M.+=[IW4RI1DKZIJ2T35^BYE=WM>UWT>O8]0^$7[3'QZ^ TFFIX!\=ZE)H$VP
MR^%]>#ZWX>N;>T#.ZQVM^9/[/D>,+;%K5X$#!63YCNK]8?@Y_P %3/AKXFD@
MT?XP:!<_#[5G>&%==T@7.M>%IGD !DNU"&_TD;@Q(!U")5!=Y(E&!^)<-HBD
MRR RV\ 6WD)D)@N(YEPMPDT:2%Y(7^6%1!&3&%'S.&(9<Z=-%+;1W$,1N)(R
ML-G,S.;V+_50O9SV_P"Y6[4O'^[<+(SHZM&'9E/Y7Q;X/\'<42J5:V71R_'S
MO)9AE7)@\1*4E%7KPY)8;$N+BFYU:$JC3DO:1;T=ZT&E&2J+:S::79=)1MKI
M%VLU:-T?UT^%?%_A3QSI,6N^#/$>B^*=&F *:CH6H6VHVPW ,%D>WD<PO@C,
M<P1P>",UT5?QY>#O'7Q)^%FK1Z[\,O%?B/PCJD0F=GT:^G@@DDL)@)(]7TEI
M9K:XWNV6$L,IDA&4C*86OTZ^%_\ P5O\0:+I,&F_&?X9R^)-1MXT$GB;PA>6
MFE7%UABCK?:#=1&V6\0*6,EI<6\%TQS'"A.#_-/%7@'Q7DDI5\EG1XAP7Q*-
M-PP>8T8^[I5PM>K[*K:3<;X;$5)RY7-48PU-/K%-:5/W<NS]Y;V332Z[ZI67
M=:G[IT5\#^!_^"E'[*_C+9%>>*]7\&7C0Q2-:>+-#N[0H\B;VB,]G]LB5HQR
MQD:,%<.N5()^N?!GQ6^&7Q$6-O OC[PGXJ>6%+A+;1]:LKJ],+J&60V(E%X%
MVD$GR?E[XK\BS/AS/\FO_:V2YIET4^7GQ>!Q%"DVTFDJLZ:I2NFK<LW>^AI&
MI3F[0J0F[7M&49.W>R;T\SOZ*.G6BO&+"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M38JM&)'2)Y9F7<8F="RSL20T0!4?NWPKA S!P"''4&DE:,3(9$9%A:*)U#E
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M+PY9Z)XKU"TM;WPY=6<.IZ9?W>D:;K$.LW.D6\6I6:65I>6]M"J10!&_0O\
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MDMKZW=]5>[W6[1Z$*]HQ3OM=I6WW3[[O6UNG8]G@UVS>6!+M/*8;WEMI&G2
M;BH5HXT53;S[46.9(WE>Z,LDQVGS%&Q+K,!6Y>Y<RM<S16L*Q!(XUDCBD\FW
M>*!B@C6?8ZZA,1+(5,.,$5Y%:7;2J@C)U&<VTES-$)0WEPQ2B-9M2G6)1:B*
M5P0]JJ;U14:3YRIT6U6XC,**]O>1Q0O-.FGR7+00RM*OE*9'#^8K!VC,"*HW
MYVR+&I:IA4LHZ]U:Z;6SMT>ETDWT:[G92Q<DXW::V4=DTK?CVOML]-#T5VG:
M]57F0V=M:I-)9I:2"XN7LX65V6X@!\NSFD<Q7:1I]JG:-L% 2U9UU';1VS2Z
ME.]DDT)%S'96K+)<+-,;FWT^XGF1[FWLH$>-88P(DD262(3,"0>#_P"$DEMD
MQ)/$]O%$;:(!I&T^-Y2\Q!9))KJ2YCF,AD2&40N&1D"E&4:UMXB>1A.^EZ??
MW<DK%O-2ZCMH2(?W-Q+'<.9)GCD53'(D!2$ H6WR8+YN:49)J_V==$KJ[[:=
M7NNC6ALL3=KI?5V:=[/35ZM=[ORVM;J8]0MI(HYD7SH+=)8_*E@A@FGN$F>*
MYOF="(X(XHY([>VC96FF9%!4I\U9UW=I$B7NJ!+'SF>&VLXV@DUJ_9G$$<'V
M,F=]S6S,(9G*6@#\E6<A<1O$*W2W-Y/=RN]M:M#';6MLV;J]N3^\:(2;([2"
M#8\;&,!Q*<'!/,S7=U*TOV2P6.*?3TA>XDVV+>5&Y98VE=VU"\:9B)-ZJ,%-
MODF/8[34JN.M[7=K=;;Z?J^ESJI8B*CLM;7[Z)75^FVCVZ>3JNMQ)>%FFCMY
MYEEC;Y([Z]MT^SS-9V;JCQ6@E6T0Q7EXJHD<P*CC!KEM1D@"O+L-K"+![:14
MDDFU"%IIDBFNS!,)76.+8\9B0CRK=O,0*H JSK%SJ9+W%]/9M;2(TS6T8DMK
M>6WA9(@B70'GS7D\A<N  5!*PPD;F/&:E=R_9[646T%K$LNW[0FR:>_@ABCD
M>RN)'83+)<3%(7C<!G8,9'Z)7+*M45KR<4[.*3=E?JO-VU;[=#K]O%I24U9Z
M;>E]+;]WJM[6)]6N)C<-'=:E!',UN)5:&-9(8=-5)4\NW@A8F/[0PC8NQ,[R
M+YLPC#,*X^6\MXO*MD:Y+.MI.;.ZLXYUBACMYFGN'\LHF[SO)8F;]U SJ/,7
M><37MSY?VBYGC1'N99I9D4 -N?:(K2VGV2O-;R9\O:%BCB>.9U25$4GE+J]N
M(WEN9KTPV<-H5BABDWO?$.ZHSO*L!6&WE$D1VB1BP\XD$ICFJ5^1*[YK-OHF
MWIMMHON7W&4JS3BK\UMWM?6]DUVNK:V];AJ%\+?[7/,982X$,4SRR7%_?RRO
M$+6"1%F%O80S(?,E2(2)';QJTV\2 UY]J.HAXVB4P1VD<,J'S8;4Q74H$AN+
M.$K+]I>V>0Q-<3!E4E%6-75U2H-8O@J/M<>7%=W!N98?)WZC?W-J'N$@$PC8
MV\$:K%'.WR^8S NQ7 X/7==FN4N"9H3%#<6402.!]KS),DES;0RRX:4HS"(2
M01"",;BOW.?/KXJ3NH:QT>RUM9V5]WW_  6QM3FVTTM_M=(WVM:SU3U=[]DE
M<S-7UD6SW5RTBP36/D0V1M%%L(;A' @5;-2R?8XCB8P0P@R>6DTL?SEF^>?B
M',HN)EA>"^N4A;>[PB 27,]TLKP643QJ)X(S,&>Y,DDH78-\48*#T_6=8NIS
MJ7FQQW#7,;V\#1$M#IKPR+NL;61I!&@4+MDFF:2>-)"(X55-M?./C'49%EN;
M>7S!?>3&J;8XI!+Y<SF8^8L?F6L6QA$JQ;?.90\ISD'Y?-:\G1D[W3=WWBFM
M=-$[MO7^7IV]+"RO5C:5N71]>R37^;Z^6A_1O_P;$?%'5K#]I']H?X21I(OA
MKQ=\*=)\:S0&3?\ 9_$/A;7UTV&9E#M&J26&I7,7FIS*=@<[DK^U:OX3O^#8
M[2-2U/\ ;D^*FMV5M-!I?AWX :I'K4JDF(R:GXHTZVT^UF9<(S,Z-/"KJA;8
MSJ" <?W8U_&OB/[/_6O&2II)SP^!E4[N;PM-)RT5Y."@V];Z/F=[GI3=W>UM
M+6NF_=;BM4W?1=7>VZ3T"BBN9\;7EUIO@?QSJ5A.]K?Z9X'\8ZEI]W%M\VTO
M]/\ #6J7EE=Q;U9/-MKJ"&>+>K)OC7<K+E3\,E=I+JTOO(.D"1ABXBB61OO2
M+%&LK].'D51(XR <,QY /84ZOPA_8C^!7[8_[3G[$W[.G[1K?\%0_P!K#P[\
M7/C!\(M$\>)IFJZ3\'_$?PPLO%FH->QV]CJVA2^ K35[_P +2W-K#'J%O%JL
M6HFUDFDMKI)MB+]#_ /_ (*1Z3)^R)X>^+7[2>CZE;_&K2_C1XH_98U_X=_"
M?PS?>)?$'Q2^//@S7;[0EL?A5X1@E^U7A\86%@OBJ*RGNK>RT&QGN1?WUO;V
MC2#IJ8:47)0G&JX5%2G&*FI1D^9+245>/NM<R;2LKVNC-5$U%RC*"E!3BY.%
MG&T7]F<K-*<;IV>K6Z=OU6=4D4++'%*JDE5FBCF52>I59%8 GN0!2GD $ J!
MM"X&P*.BA,;0O^R!MQQBOC3X>?MR_"/Q@_Q9TSQQX:^*?[//C'X)> W^*OQ"
M^'_Q_P#"$/@SQ=8?"](KIV^(&D0:9JWB+2O$?AE9[*XTZ6ZT/5;Z>WU01Z=<
MVT-S/"CX'PD_;\^'WQ7\<?"[P<_P6_:9^&FG_'*TOK[X*?$+XH_"=M!^'7Q.
M@LM'/B*,:+KNDZYKMUHTFI^'U.LZ2GC#3?#GVZRP8R)66$Y>QJZ^Y+W5=]K6
MYKKH_=5]+Z*^P^>&BYE=Z6\[J-GV]YJ.MM7;<]&_; ^$?Q^^-'P4OO ?[,/[
M1#_LJ_%&Y\2:%J4/Q2L_"MIXF3_A'+-;^+Q!X6GTDQAXXO$$-W;,-2LFAO[&
M?3X'M[B+<Y/A'_!-K_@GEX?_ ."?/PS\<Z!-X_O/B]\5_BYXSF\=?%?XJ:AI
MTFES>(=6V2)9V-C9W%U>WD6G6C3WEY+-?74][?ZC>W-Y=.9"IK#^'G[</PD^
M''[/Z_$'Q!XZ_:$^.>H^+OVE?BO\&?AUX:U[P1X;U7XZ>//'^B>+M4M;CX;?
M#WP?X)N+72M1\*^$+>QNH] UG5;RPDM_"]I%?^*+ZVN9,OU'@W_@I7\&/%?B
M+X\>"]4^&G[0'PX\=?LV_!:\^.WQ8\%?$SX?Z;X6\0:-X0M1?2166GQMXHN[
M'6M8U&TT^:^TV73[V7P]<VS+C75F6:&+;EQ*I3HQC>GSWDU",92:E&*NVE4<
M5-I)/12=M'H9WHN<*C:Y^7W;S;45*/,TDFX*3BF[I7E%;M(_0W9'N\SRHO,Q
MCS?*C\['3'F[?,VXXQNQCC&* D88N(HA(>L@BC$I'3!E"B0C'8L1P/05^=O@
M'_@IE\$_'GB3X*Z;+\-/VBO G@K]HS5M+\-_!#XR_$/X6'PY\*?B'XMUO36U
M+1_"NDZTNN7NM6NJ:NL-Y;:/<:KX?L='UFXL;I]*U.\M%CNI>B^(_P#P4'^&
M/@7Q[\3O /ACX2_M'?'*;X'&"'XX>*O@7\+#XW\&?":_ET]=9GT;Q1K,^N:/
M)?:]INBN-7U;1/"MGX@U/3;'$EU;)(1$<O85K\O)*]K^5KJ.KO96DU%INZE:
M+2>AHJD&KJ2M>WS:YE_Y+[U]K:['W@$C4EDBB1F^\Z11H[_[[JH=^>?G)YYZ
MTK+&[B1XH'D&,2O!"\HQTQ*R&08[?-QVKXO^(/[>7P.\'Z#\$=4\&VGC[X^Z
M[^T?H%UXN^"W@#X#^%T\:>-O&W@_3;&VU#6O%D=E?ZEH.E:)X?T*&\MXM6O_
M !#K&E+;7LAL562[CDB7P'_@GS^T]XW_ &DOC[_P4%_MO6?B(G@3X=?%3X3^
M'_AO\./B7H">%_$/PGBO_A_>W'C#PG=:"UM'>6%X/$MG-)J N+[5;>:XB6?3
M;^:QDB=Q4*GLYU'%QC!7?-HY?O(T[);Z2>[5KQ:W5A>TAS1BG=R=E;5+W7/5
M[:Q5U:[U3V=S]3G5)?\ 6QQ38.X>=%'-ACU9?-5]K'NPP?>EK\QOC%^UQ\3_
M  /_ ,%)?V=/V;]'^&_Q@UKX6>+?@W\4=<\5+X:\)>%[W1_$_B;^VO!6G>'_
M !Y9ZU?^)K+5/^$'^%MKJFHQ>/'2VM9["_U*QFLM,UP(QBW/$G_!4#X"^'[K
MQOK-E\/_ -H7QI\%?AGXJO/!OQ"_:;\#?"J;Q#\ _">L:1?II?B*>Y\31:Q#
MX@U;0_"VH2?9?$7B+P]X6U?1=.DCDW7KJNZG]7JV@XQYE."FN5WLI2<4GM[S
M:T6[V5VG8]K#WKNW+)Q=TU=J,9-KNDI*[Z:MZ6;_ $;9$<;9(XY%Z[98TE3/
M8[)%9<CL<9':FK# A#);6B,.0R6ENC*?566(,I]P0:J:3JNF:[I6F:[HVH6>
MI:)K6FV6LZ3J]I/'+I^H:1J-I%?V&IVUT#Y4EE=64T5W%<!O+:W=9,A>:_$7
M]N3_ (*BZ5#^RM\?O$?[-FB_M'Z(="U";P'X#_:V\/?#-$^"C?$'1?%^G:)K
M&G:!XOO[J\U">WDNX]2\/0>)+GP?_P (K=ZANMX-782P3/-*C4K34()ZRC%O
MI'F:2O\ /6V[L[)V'.I"G%RD^C:2W:2N[+[M=$FU=JY^Y+ /D2*L@;[RRJLB
MM_O*X96_X$#SSUI JJ J*B*.BHJHBCT5$ 51[  5\,>+?VWO!_PYUGP'\(].
M^'7QU_:(^-U[\'_!GQ.\8>"/@'X"MO&VN^$_#6MZ/9"#Q7XXN]1UKPUH6AIX
MBU+[4VDV#:DVJZL^YM/TV2-H\^ ?&_\ ;+;XAR_\$RO'7[.'Q$\2:%X(^-_[
M?VA_!?XNZ%+IJ:%X@O=$T_X?_$Z;QA\(_B/X?UBSGU'0-2TCQ1X?LCK6E(;.
M_AO-/A:&]>UD!EJ&'JS:]UQB^:TFGRZ1<NFJYE%\K:2E;1Z.PZD5I?6\8M=4
MY2C'KI[KG'FL[J^U[(_6;:FYG\N+S&!5Y/*C\QU(P5>3;O=2.&#,002""":^
M;OVJO@'XB_:)^#^H_#SP+\:OB#^SGXTAU;3/$7A'XI_"V\^P:SH6LZ2\K1VN
MI:<CP6>O>&]4CFDMM:T>\#1W$7ES1[;B&-J^<_ '[97PR\%^*O$WAWQ3XS^.
MOCFV\>_M]?%/]EO2/$WCWP[X*M?"GPE^).EZ9::KIWPSTR^T#4[6^M_@]'Y3
MZ7\//$>LV&I>(]0U6]DL=;6!YK5C[=\0OVT?@=\+/B/\8/AUXXU+6M%_X4%\
M%-(^._Q=\;R:=;S>!O!?A7Q%K-WH?AWP_?:A#?MJUSX[U^ZLY)]*\+V&BW-Q
M<V<EK/YZF[MTD%3K4YQE&+<E:<7RWO9Q2]V2=[2:CRM.[:5G=77/"<6F]'=-
M7LUHWNGIHF[IZ)-W5G;\A_'G_!'#]N+]I2'0?A[^V7_P5)U[XS?L_:3XDTOQ
M!J'P[\.?"FQ\)ZQK!T65S8BZU* VNG7&H+;/);IJ.I6^H/9O<W%U:Q^>5)_H
M-\,^'-%\&^&O#G@_PW9)IGASPGH.C^&/#^FQLSQZ?HF@Z=;Z5I5DCN2[+:V-
MI!"K,2S!,DY)KXY^%/[>GP[^)7Q"^'?PW\1?"3]HGX#:M\9;6^NO@OJ_Q]^&
M:> _#7Q7;3M/_MJXTWPGJMOKNM>1K[:%G7+;P[XBM]#UNYTM9)X;%VBDC6'X
M%_M\_#K]HOXH>+/AG\,OA+^T'?VW@#XD_$/X2>//BAJ'P_TVS^$WA'QU\.-1
MU/3=2TK5?%:>)IYI1K,FERS:'-INF7P\NZL(M972+NZ2V&E9XFJK5()1I)RM
M"$*<(\VCE:"C%N3A9O5MJV^A%-48-N#]Z;M>4IRD^5)VO-N5DI)VV2DGLT?=
M ) (X(8892 58>C*0589P<$$9 --14C#"*.*$/\ ?$,44(?O\_E(F[D _-GD
M#T%?EG_P47_:OOO@YXR_9R^ FD?&<?L\1_'74O&NM_$#XTZ9H<?BGQYX0^'G
M@'3[-UT/X5^&9-,UL:K\1?B%XEU*R\-Z%(NB:K-I\<5Y<6UA=2G8NY_P3V^*
MGB?XAZ[\?-*L_P!J-_VI/@WX1U3P;;?#_5OB7HFH^#?VI?AUXBO]-O)O&G@O
MXV>#-1\$^")[?1O-33M1\ Z_<:9'>:K:3ZA%/$J6T3MG["?L?;.RBU=)J6JY
M^2_-;EOS7M%R4FDW:UKW[2//[/[2=GK'1\BG\/-SVLUJHM7:5]S],>S*0&5A
MAE8!E8=<,K JPSV((I%"HI2-(XD)W%(HTB0MTW%(U52V.,D9]Z^4/VC_ -L3
MX;_LR>*_A%X%\7^%?BCXT\9_'6X\6Z;\,?#'PM\(Q^,-9\0Z[X0LM.OKO04L
MO[4TZ6"_U&'4H?[/N)0-*B6&ZGU;4=,M8?/;YK'_  5@^"\VA_$+4M.^ O[7
MFLZ[\%;W5K7]H'P)I7P7@N?%WP#M](C6ZEU/XE*?%4>@1V5YI@N=9TV/POKO
MB2_N](T[4KY;)8K.2IC0K2BI1IR<9;/1)J[C?5[.2<4]G+W5KH-U(1;3DDUN
MODG;ULT[=KO9.WZA!(U)98HD9N7=(HT=SG.7=5#N<\DNQYYZT".)<[(H4W??
M\N&*/?[OL1=YY/+Y/)]37QC\1_V[_@IX'L/@I_PBNE_$GXZ^+OVB/" ^(?P@
M^&GP.\(?\)=X^\4_#U;"RU*Z\<SZ;J6HZ!IOAWPM8P:C9QW.J^(]6TN W4Z6
MEOY]QF.N/N_^"E/[.>F? ;XG_'W7K+XH>&M,^"'COP[\-_C1\-O$?@>31_B_
M\+O%?BC5=-TW2[3Q1X+N]10-:RPZK:ZU#?Z/J6JVNH:.9)](DU&X3[*14:S2
M:IS=VHK1W;<N1:;V<ERI[<RY4[JP.I!-ISBK)MW>EDE)N^VD6I/7;78]6_;:
M_9QU#]K/]E/XT?LX:#XHT?P!J?Q6\.V.AVGBS4]%N-6TK19;3Q!H^M-=7FD:
M7<:?=WR21Z6ULL<%U"ZO,DA<HC*TG[$G[.NH_LE_LF_ 7]FW6_%&D>/-8^#/
M@I_"EWXRTK1KC1M/UR=]?UK6OMVG:9J5Q?W^FQ!-62W\B:\FD\R!Y/,*NH'G
M_P .?V_/AQXY^*%G\(=7^#G[2/PR\?>(? GB'XF?#'PY\4_AG;>$[KXV>$_"
MJ0S:ROPSE7Q)?0W.N+#<6ODZ!XFE\,ZL?M<+2V\*+,T7Y57?_!1C]H#6OV#O
MB?\ &WQ ?C-\*?%/@']NBU\)W'Q!U#P?X;TVSO?A+-^T8WA2;X3^&[#0[[Q-
M=:IXB\(>#;(^$_'6F+I*73:S<2II6JZK)<"Z3>%'$3I^QTC3=6G*TDKN=6].
M,HM)N27*XM)Z.ZLW>V;J48R]KJY>SG%R5](0<)RB[M13O*,E>SMUM:_]'+HD
MG^MCBEYR/.BCEP?[P\Q6PW^T,'WIQ 92C*CQM@M'(BR1DCH2CAD)&3@D<9..
MM?$_PQ_;Q^%_Q%^*6I_"'Q)\-_CM\ _&L?P[USXO^&]/^/?P]B\$V_C?X8^&
MY /$'BKPI<V.MZ\)H]"B>.?5='U==)\06<)9I=+#0SK'R7PV_P""CWPG^)NN
M?"J+3?A'^TMX?^''QUU^'PW\&/CUXI^$SV7P9^(^H7T%Y=:)/I/B#3]<U36]
M(TGQ':V%S<Z#K/BGP[H6F7L"+*;F))%)P]A6U]R7NI-OI9IR33O9Z1;]UMZ/
MLS13@[-26KMUTUBM>RO**N[+WH]U?] ]D?EF+RH1">L(AB$+9Y.Z$((VSWW*
M<TH5%78L<2)@CRTBC2/#9W QJH0ALG=E?FSSFN(^)GQ(\$?!SX?>,OBI\2_$
M-EX3\ ^ - O_ !-XL\1:B7^RZ5I&G)NGF,<2O/<3R.T=M:6EM'+<WEW-#;6\
M4DLJ*?CKX??\%%?A7XS\:_#KP3XF^$?[2?P6N/C1#?-\$-=^-7PK7P9X9^,%
M_9:7+KD/A_PCJL.O:K]A\3:QHT+:EH>@^+X/#.HZE;%3##YFZ-9C3J33E&$I
M)7NTM-%=KS:6K2V6KLM1N<8M*4DF]D_-V3\DWHF]WHM3[Z2.*/(BBBB#')6&
M*.%2<8W%8U52V !N(S@ 9P!3Z_&7_@GA^T/\;_VHOVF_VM?&'Q)OOVF/"WA'
MX:?%+QS\,_ WPF\1Z!X#T#X"^%-#T0:18V.B^(XM+OM5\6S_ !UT]Q-JVJHV
MHW/A^.&^DDM[R=F$$7W9\??VP?AY\!/&G@CX5OX/^*OQC^,OQ#TK5O$?A?X.
M_ [PC!XS\>3>$]"FAM]7\7ZI!?ZMH.B:#X:LKJ>*T&HZSK5E]KNW%M8QW,OR
MUI.A.-14E[\^52:CLKQYFKO2T5O+;S)C5C*'/K&-[+F5FW>RLKMZO9;OL?5U
M%?!;?\%'_P!FT_!71_C);2?$+4+W7OB9J'P1TKX(V'@B]N?V@+CXVZ/<26^M
M?"9OALMPMQ#XNT98FO-4,VH1Z%9Z<8[^761:RQ2/?\)_M_?"/Q!IGQP3Q)X&
M^-/PF^(?[/OPXN_BYX^^"WQ7\#VGA;XH7/PXM[2XN8?%OA*SBU[4?"_BG1KZ
M:VETV"]TSQ0\%OJ8CM=2DL?.B=I]A6U_=RT=GIK>ZCMO;F:5]KNUQ^TINWOQ
MU5UKT:YE\VDVENTF['W+17YU> ?^"FGP.\=^(_@EI\GPZ_:%\"^!OVCM5TCP
M[\%/C7\0_A=_PC?PC\>>*==TP:II?AJPUW^W+S6;'4;Z)+R"QNM5\/V.CZE/
MI]ZVFZG=VR17$WR)HO[>GQ"\6Z'_ ,%5#\5-._:D^"O@?]G_ %'Q /!OQ+\&
M> ?AI%XL^"GA/PUX8\-QRZ1X?M=6\2ZGH^I?%O5;Z^N?%FC6WB&VO=&U+1+Z
M*XO=0L[A#I\=PPM63:<7"W+?F3^U45.R2NVU)ZQW5FK<UD2ZU-6UO?FV_NPY
M[MNR2<;--Z-.][7:_="BO@OQW^WK\._AG\2M$_9_T[X9?M%_&[XPS_ _X??&
MFU\.?"KX>:5XIUC6_ GBPZGI<?B'4KR;Q'H>B:1J5O>:#<S^(8]3NM+L#?:C
M:6>A3ZG<3_9HI-%_X*+?L]^(_A_\!?B-HMM\0[O2?V@?CG+^SEH&DS^%8=,\
M3>"/BQ927L&L^'_B5HNJZK92^'O["N;&:WU26QDUAU=X'M(;J"42B/85;)^S
ME9V:=MTTY)VW2:3:;2O9I:IEN<$W%R5XMIKLTU%KU3:371M=T?>%%?.^J?M/
M?#'0_P!HG6OV:=;?6M(\9>'?@C<_M ZWXGU&VT^U^'^F?#ZRU672;Z6\UZ35
M!>P:E9R02W=S#)I*V4=BC3&_+CRZ^9_#W_!4/X":Y/X-UN_^'O[1'@[X*_$?
MQ99>"OA_^TSXT^%$^B? 3Q9K>KWKZ9X<DM/$W]L7&OZ5HOBG4D%EX<\0>(O"
M^CZ-J4TD;1WBPL90*C5EJJ<GHGHMU)-JW=M)M)7;2=EH)U(+1R2U:^YI._9)
MM)MZ:K4_2"BOG?X>_M-?#[XE^.?VG/A]X?T_Q7;ZY^R=XFA\*?$R;5=-L+;3
MM2U.?P?%XV23P?<0:I=3ZI:#2)EA:74;;1Y!?AH1"80)S\^:9_P4I^"GB?X;
M_L_^._ 'P_\ CI\2_$7[36A>*O%/PI^#7@3P/I.L_%N]\,>"+S[%XJ\1:YI3
M^*+7PSH.CZ1.T*RWE]XJ$<S7$:6WG2),D8J-5NR@[^[?;3F@ZD;ZZ)P3E=Z6
M3;'SQTUWNEO=M24&DM[\S4;;W:2/T+HKPW]G[]H#PA^T;X+U3QCX3T#Q_P"#
MY_#GBW7? 7C#P5\4/"-]X*\<>#_&7AMX5U?0=<T>[>XMGE@2YMIX;_2-0U32
MKJ&=&MKZ5ED5/<JSE%Q;C)--.S3Z?U^(TU))IW3U304444AA7B]U_P G$Z-_
MV1G6?_4QLZ]HKQ>Z_P"3B=&_[(SK/_J8V=!K2WJ?]>JGY'M%%%%!D%%%% !1
M110 4444 %%%% !1110 445S7BKQ=H'@O2I=8\0W\=G;)E88LA[N]F RMO96
MX.^>9NF!A$!W2,J@F@<8RG)1BG*4G912NV^R2.BEEB@BDGGEC@@A0R333.L4
M,4:C+/+(Y5(T4<LS$ #J:^5OB/\ M(V6G&YTCP D.IWT8D2X\0729TNR,9(D
M>TB<I]M* ,QN96CM$ WCS5PU?#7[9/[=OP_^$7@#5_B-\:_'%C\,_A=IIDBT
M_13/]HUWQ9?HI>WTK2])MR-0\4:]=%1Y.FV,9M;;=YER\,"/<+_#Y^WA_P %
MD_CQ^U5?ZWX&^%U]JWP1_9_D9K.'PUHMX+3QSXULU,J-=^.O%.GNES%:WR.C
M?\(MHTT&FVR1I'<W%^[W+R^=C<RH8.-I2O-KW:<6N9M[7;T@GM=ZO[*=C]-X
M+\-LWXIJJI&$:&"IR2KXW$*2PM.2M>G#E7-B\0D]:-)JG#3VU6G&46_ZHOV^
M/^"B>A?LV?#+Q!\1X;BP^,'Q&$T>G:-HL_B!8M#BU">0Q ZIJEEYQ%M9$L[Z
M5HJ&=]IBDFM6#9_D'_:!_;]_:9_:JO7;XN_$6\F\."3?:> /"RMX:\!V 4@Q
MA?#]C*$U*6-@K?:M<GU&<2 O"UN',=?GUJ'Q!\5:UIUCH^K>)=;U72M- %AI
M]_JES=6=D.P@@ED:-"HX!P2.V.@]6^ .D>&/&GQ+\/>'_&%^MGHE]*XF=[A;
M59ID4-#;O<$A8ED; ))RV<#M7S.,QU;&SC"+=.G)Q7)SI)MM7<VOBUVYE:W1
M.Y^[<*<(+PVR3/L\XHJ9?GF,P$\;F6'Q.4Y35A5P64X:DI4,'@Z&(K8FM+%N
M$)3KUJ<Z?M:M1PBHT80C'U+0/'/BL:?#X<T[6->&F75Q'Y6B6MW=#3;BY+CR
ML6".(99"^W "'G!Y[?9'Q1_:C^)4OPHTWX1>*/!">'&:SM8IM6G5A-J-G; &
M(P0LNV)S@>8P<MGC [^N_$[3?#_A3X:Z;=>#OAG82ZCX/U/3[S1+K3XH)+B[
M%M*B3_OX]TMTLB$EB2^X\CIFO /C#X0^.W[0%GH5WHOA0Z6EL@DB:YC\J)4F
MC4L'GE*E0A/W2=HIK"5://!8B?-*G'W.2/+9I>[>5]M5=6M?17V_%L!X@\&^
M*.?\+9GF'AWEV&RO*<_Q^8QS#&XNV;X/.,/&C+"9BL+ECI4\0\1#V3K0QZK+
MVE-Q3E[+FE\4ZMXF=0^7<#H/F(XR!TW =SU[8]Z^I=3_ &6[J^^%6E^-?#WB
MRUU'Q3?06EVNA,T<5M-#=[3Y<=PSY6>(-N8L"#@C -<+!^P'\9-:8?\ "1>.
M/#>AH1\^W4+&1TR>05,Q((Z8QSC!KZ0^&/[$WB'P[-8CQ'^T5<7FGZ<1)::1
M%K%LEC&,89#$7SM4< ;B!U4<8K&E@H+G5:T^9)74E>+NKR2BVKZIKITMK=_J
M?B%QOG&)H9;5X'S[^R\5E^.>)QU"O@8UZ&;X912A@ZS<92A3G/6?LW3DT_XJ
M<4?E]\2(M?\ AAKHT#QE NFZ@;=;F)4F66*X@<_+)%*C,KC(*G'.<# K@+[Q
MG=6L<,]Q;7UM;W8!M9KFWFCAF4<[HI'0"53D<KP1SDU^[GC3]EK]F:YO+?Q'
M\3O''A?4;S3K9(8YM8UR K##&V_B/SQG+Y;&#G@$$$&O#/BC\6_V%_#&EQ>'
MWM[?XC+IRM#!9>'=+%S:HT:[?+7467R(AQM)W@*.I[UE+"X6"D_:S23M&+OS
M6T^?J[ZJ_8[LG\2^+\51RBA/AJCC<;4BGFE7!RK0H4YI7C/#QDZCY6^7FC4J
M/EUM)Z6^ ?V;/VD]-^"WQ3TKQSK.C_\ "1:9;VT]I=648C\^*.X()N;82?*9
MT(PHRNX$C(%:?[5G[1^E?M"_$RX\;Z#H,GABP2PM=.L[=FC6YN(H%PUS?)%E
M#.YQL&]@JY!8G%3^(/'O[&?BZ_%K<?!OQOX-M)CY:ZWHNMP%K,N<?:9=/A:5
MK@0Y,GE* 6"[3US75M^P9)XT\-KXV_9^^)^G?$+P[,-[6UU&D>JV#]3:ZA:0
MMYUM.GW&$R)R.]1'GE2="A7IR@Y*7+9*47IU>ZT6VUKWL==;"\-X;C7">(F?
M</YGEW$E'*9Y-2S"6(KRP,<#4DI3IRHT:L\/[7WI+GJ14K-NSE[R]>^#7[;7
MPI^'?[,/B3X1:YX!O-2\=WVFZOIUG>PVMF^D7[ZHDRPZG?7DCB6&:T\T,$6*
M5M\2A6&01^>%MXEU"\N4>666]E+*B(7D=RJL6CA!SN*J,I@<E>AXX^C/A9^S
MEJ_A+XL:/I_QV\-3#PEY<DX>"5GL;NX1@(X;N6/#1IPS-&S*3@ ]P>!_:BTS
MX8>'/B_JVG?!V4Q^&8;2PD>*"Y>:&RU66+=?6UO+G>$CDZ)GY#E<UG7CBU1I
MRJNFH4^6G!12YE;7FNDT[VLVI:/=7.?@7%<!9#Q_Q%@.%<+GF)S3CA5N+<XS
M:M7JXW)(8BC.-"6$HSJS_P!BG)U)5%1C3:DY<GM+QC!<U8^*[NVO$O[5S8SP
M3>9&L991$Z-G;AV+!0P^Z^X'!!]*Z-/&%_<7!O)IR9F>61I$/D[GFW%FQ$RJ
MBDL<K&,'N.M>"17;J?G9F+,2SLQ))8_Q9/.3W)ZG-=AIPG\R*">"\CGGC+V,
M8M+AY+LD?((5$>Z16Y 9 PX'K7$IN<DTGS1=N][<NOJW;U3OHKG[NYT/==1P
MA)1;5VE=12<MW?2-V^BU?5L_6K]@W1OBU<7_ (A^(7P^\,:5KVCV%K>Z1K-E
MKNH&U34YTC2XBM]/<03>3)$%?S'D4(PD4#G).-J'[=7B;3M(^(O@B^^'V@:?
MJ6J:EKEK:W$4Y1=$2ZEE@N;.:$(S7T\(>18I0T8?"L^3Q7R/\)OVG?CG^S[H
MFO\ ASP+K":)I_BE'ENK75=*2XN;>29&MVN[$7 62SG=,@MMR2JMCC!\)FU"
M^U"[GO[^>2ZO;JXENKNXD):26>XD:26:1AWD<DGH,GCI7HO&NEAZ-.C4J*2<
MO;1DHI.]G:.ETKZ-:V=[]#^>O^(,4>*_$GC'BOQ R/A?,\AQ$,BCP;C<OQF:
MTLY<,N?MI?VI&CB:6%?)-JFN6$E6@_9N]+W7]@? 'P,_Q:\4WNAKJJ:>EAIT
MFI/AU6XN29A'Y<"-P<%MS'TP>176:Y8MX*\6ZEX9:\%XVD3I&MS&X9@[+O #
MH1LEB/#@$$,."",5\?>'M?U31KN*]T>^NM,O8PZ+=65Q+;3D2E0R&2)E+(1C
M"G(')QDU]^:]^S3XJ\'_  FT[XO:MXBMK]M4CLK^]MI'>25X]3P\;)<R,S3S
M@G]X,G=\V. <9TH*M3DZ5/WH>]4?,G>"=[6;6M[NW51OWM][F^>0X2XRRZIQ
M!Q=@\'D/$\<+D7#7#D\#45>IGL8Q=2<<72A.\)1<%%U>6*=:-.3C:+?Z&_LR
M_P#!0K]H#X,66C:9>^(_^%G^ X!&DOA/QK<37UY:6B!D:UT+Q-(SZOI+H-K1
M13R7UHJPI"MO# 7!_HY_9/\ V[O!GQ1@AO?A=XLFT#Q/Y*SZU\,O$TD27_R@
M>=Y5D7%EKMFA)"ZEI++<*NU[B"UW)&W\27A'4'41*7X^7*Y.T@\<#(Y)X/UK
MZT\ ^(+S2[K3[W3+VZT_4+&2*>TO["XFM+VTGB(>.>VNK=TFMY8VPRR1R!LC
MDXKMP>;8G"\JDW5I1UY)[I)I?NYVO&VEHVE'^ZGJ1Q5X7Y'Q#"M5]G# 9C4E
M.7US"X>G3I5')WBL;A(M4L2[OWJT'2Q-[.5623B_]#+X;_'7PUXX,.F:EY?A
MWQ(PV?8;J8?8;YU &=.O)-H+N<D6D^R<'"QM,<X]S((X(P?0U_(K^S+^W7JF
MVP\*_&Z[DU2S/V>#2_'\, .J6#*$C0>)8+90VH0!@'.K6T:WL&6::*=$#)^_
M'P?_ &D9+2UTRR\3ZC'XD\*WT4+Z3XILYTOIK:UE4&&1[B$NNIZ<%('F!C=0
M*,9DVLE?6X/'T,9#FA)J2^*$K1G%Z?$K_#VFKQ;TNFG;^4N+^ <XX5Q3I8K#
MWI3<GA\11<ZN$Q,4DW]6K2C%\\4[SP]90KPWY7!P;^\J*JV-]9:G9V^H:==V
M]]8W<2S6UW:R+-!/$PR'CD4D$=B#AE(*L 015JNX^!::;35FM&GNGV84444
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M1M6@VR'/RL)+1=KMR0K[2S 8R374:1\5PSJEPUU;,SD-YL$\)0Y P(WC13(
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M5#!=^5:%00"[/\XV5UB*021QM*D20I]BB2WC6T9DE6-G!M5*A80</(SE5)*
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M0\/?$GQ/?ZM81^ K[3=3M4O;S5-9@:UO+6=YK,3R@1/\D>%/V7_B'I/[&/\
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M_._AA^TGXU\!_"'PWH^I1V.L7^L:O#I?AFYU*!YSI>DM=QV\MQ>%V*SRIOQ
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M^[S_  UX:GW8+>?X>T:;<1T+>;8ON([$Y([5K44[M;-_>P.4N/ 7@"ZW"Z\
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M5TX\_*W[MV4HSC327,G[63DHM<W(YSEH[Z/6+>M^7F6Y^0WP)_:4_:*_98^
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MM-(O?&/Q9^(GC/Q%/X:LO &C:4]]XNUZUTR&+5-(TVU.G6UYJUV0[P?LV?\
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M'^RKZQ$UFT\RR-^:W[%O[.'[6W[2G[ >G?!5OCS\*O#7[)_Q:\?_ !LTSQM
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MFE_P41_9#^'?[,4O@74O &KRO'XJ%S;7OA^[NTNIX3;(C+?P%7:00R%B'+8
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MYK?4K#S P;"J(XW49P ,XQU[&M+6[SX5_$JQ.A_$_0D6^7$5KXTT"-+75+0
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MMTOJG:^GZ V&L:3)J$4>G+&\$.Y/.C&$D8$ &,]&3C 8CD?I]%>%;@"&UE.
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M(?;=%%%>H?E@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%-Y,RYVS0^:C^5,N3MFCVR+D[6&34E%% !1110 4444 %%%% !1110 4444
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M*2C[];$5+?\ +O#4E*K);RDHQC>32?X#_P#!6O\ ;HO?VM/CA=^$_".JR2?
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MKE5K;/:S>OI<Y</0QU#,*6%PKOB754:%6$W"+;L_:*2:<;*[O96TT9VOQ/\
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MW*6ZE>#MRV11115'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBEB .,D $@9J!D=%2F"=4\TPRB,_QE&"?]]8Q^M#03(@D>&5$;[KLC*I^C$
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ME*I0=24VHP?ME[&:E*2M%233;TUV:NC\SO&=YXEUC0/#][K%SJE_%;6,$5E
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MTUE1J/VDE"?.OJ?LFE+[,:2J\JV?*DU+M9]C\:O^"H7[6_P^^*?_  4X\?\
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M1M:T'44-O=W,\]QJ>GW]KK$IN;R^&D7]E#+$(_I;_@IQ_P $\OVN?VO/@?\
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MM;TA--UG[7=3:OITUG);:1?:?937EQ/I<]YJ5O#=):K9PQ_;OQD_X)P_MT?
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M#_$H\3^'A!XMN[N;1]FMBPT\/(4F3[6GV,?9FR,R8KX!_8__ .",_P 3]/\
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M%QE*5K1E2Y9)6DG\*;:>R7-:]W8_/W]H/P)9_ 7_ (+7?\$K_@;X%\1^.)O
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MJ5Z]1]H4J49U)ORC%B;45>327=M)?>SU:E )S@$X&3@=!ZGT'N>*_'SXK_\
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M:VUAJWC32M8_XFQFGOM)8F V[?8WQ_\ VJ/C;^SO\;?^"<.F?%]-?GU'XH^
MOCUIGQT^#7[.^C7?Q(T_XE_&#1_AWX??P=I?@FTN=)TW6]2L;'Q9=W6HZ'?W
M$OAK3K.&>2XUV:&PA+KU2PDU/V:G&4TIMQ2FG[D'-VYH+F3LU&4;Q;ZI--Y*
MM%Q4[-1?):3<&O?E&*3Y92LTY)RB[22V3LT?K94<T,-Q#-;W$,5Q;W$4D%Q;
MSQI-!/!,C1S0S0R*T<L,L;-'+%(K)(C,CJRL0?B3P;_P4%_9]\1_#+X^_$_Q
M:/B!\%;;]EVYM[3X\>#/C-X.E\+>/_A]-J=A'J/ATWF@Z;?:];:K'XMMI8O^
M$7DT'4]375Y)$CA*EE)K_#+]OKX<_$'XK_#[X.>(O@_^TG\#?%/Q>TO6-6^$
M%_\ ';X5+X'\-_$^'0=/75]2LO"NK6GB#72FL1:.Z:LNBZ[;:-J;V#>9]E5U
M>-<O8U5S/DE[F^FUHJ5UW2BU*ZNE%J6SN5[2&GO+6UM>[Y5?M>5XJ]O>36Z:
M.#\0_P#!'W_@F/XI\57/C36OV,_A+-XBO+UM0N;BP/BS0].DNWD:5Y!X?T/Q
M+IOAZ-&D9F:"+2DMVR08BIQ7Z!>$O"/A7P#X9T/P7X'\.:+X1\(>&=.@TCP]
MX9\.Z=:Z3HFBZ9; B&RT[3K..*VMH$+.Y6- 9)7DFD9Y9'=OSAC_ ."L_P"S
MG/I_C'Q/;?#G]IB]^&WPQ\::YX"^+GQ=T[X.RZC\-/A/K_A_Q'>>&M1/C77K
M'7[BY33H;BT34KF_T'3M<BTS2+_3[O61ILEP;>/Z#^,7[:GPK^$_B[P+\.=#
M\,_%/X^?$[XB^$7^(?AOX<?L[^#X?B-XH/PX4P+%\0=5DEUC0] T;PE>RW,$
M.EZCJ.MP2:M+*JZ;;W0.:TG'%3Y85/;3M?E4Y2DH\J3>[:C9--[633V:(C*A
M&[A[.-[7<8J+?,[+9)RNU9+75-;W/KRBO$_@%^T#\.OVD? LOCOX<SZW;PZ7
MK^K^#_%WA/Q=HMUX7\>?#[QKX?N/LVM^#?'?A:^)O/#_ (BTUS')+:2M-#/;
M3P75G<W-O*LM>$?%W]OGX8?"3XT>)?V>XOAE\?\ XK?%[POX!\/_ !/O?"/P
M<^'%MXQGNO VNC5/.UVUO+CQ#H]A;V^@/IJ0ZTFK7&FR-<ZII5KHRZO<7$T=
MMDJ51RE!0?-%-R3T<4FDV[VLM5KMJ:.<%%2YERO9WNGZ6WV/N.BOS%T?_@K/
M^S'K^C^ O&^D>%/V@[KX/>._%?AKX?O\=V^$&HVGPC\$_$/Q3J4.AV7@7QSX
M@O-3@U/3=>L?$=Q!X8UM]*T36M(TGQ#)_9=UJBSI)L]J^+G[<?PZ^%WQ5\2?
M!30/AC\?OCW\2? GA[3?%/Q+T#]GSX:'X@K\,M$UJ*2YT2;QKJ-QK6A:=97^
MLV4,M_IFA:?<ZGKMW8JMU'IOE2Q,]?5ZR?*Z<D[-V:M91:4KW^&S:33LTVNZ
MNE5IM74XM72T=]9)N-N]TFU;=)OH[?:%%?#'CC_@HE^S=X)^%'P%^-$=[XX\
M;^"?VDO%TW@'X7CX?^#KOQ%XDO/&T%CJ%P_A35O"QN++6]-U]=3TR[\,S:4+
M2XO;+Q%$]IJ$-I;0W%Y#YK;_ /!4OX1WEYX\\+6'P _;#U#XM_"PF]^)GP*L
M/@<EW\5? WA9],35;+QSKUC#XK;PM'X4U:V=H]'N+3Q5=:IJ5W#/:6VE//$R
MT+#UFKJG*RO>ZM;EERN][62EHWLFTGNA>UIK[:V3[[KF7WQ]Y=UJM#],:*^)
M/$W_  4#_9YT3X3_  *^+'A^?QW\3XOVF8?,^!'PZ^&'@V[\3?%;XCO;VDUY
MK,.D^#Y;G3A9)X82VN8_$NH:SJ.FZ3I$T#I-J#9C+\S)_P %)_V?-/\ A+\?
MOBIXIT+XO^ K_P#9@M]%OOC=\(/'7@$>'/C-X-TKQ)<00>'];_X12ZUDZ7K.
MAZRDSW6G:QHOB*^T^Z@M+M([@W40MF7L*UK^SG\7+L[\W-R6MO\ &^2]K<WN
MWOH/VE.]N>.W-OI;EYKWV?N^]O\ #KMJ?H#17P;X._X*$?"_Q5XC^"N@ZI\)
MOVC/AK8_M"^-;OP)\(_&'Q2^&EEX1\)^*]6'A$>-?#]U;W<OBB[U2#3?&VBB
M8>$I9](6\O;VUN;6^LM-,8=OH7PW\?/!/BWX\_$_]GC0K/Q)>^,_@]X0\#^+
MO'VMKIMK_P (7H__  L5;VX\+>&/[:&HM=R^+;S2["?7)M+_ ++2"WTAH+A[
MXRRK!2=*I&]X-6BY/LHJ2BW?;2347YNP*<);23NTEZN/,E;_  Z^FI[;17YS
M_&C]HC5/A+^WO\+O#7C+XH1^!OV=K?\ 9!^./Q7^)%AK5QI]EX2CUGP?XF\,
M6FE^*M4NYK1]0%[IEG>W-I86UI> 7<MTMO'8W=U)"M=WJO[?'PAT#X'?#WXZ
M^(/!?QKT73_C+XLC\&_!'X977P[:?XU_&/5;Q9;C19O OPXT[5K[47L=?TN"
M;7M.F\0W&@S6V@H-4UFWTJWEA:2G0J6IN,7)5$G'E3W;DN7S:Y6W:]HZNP>T
MA>2;MRMIWLMN77T]Y+6S;V1]NT5\D?"C]M'X2_$V3XKZ7KVC_$;X$^,?@AX9
MA\<_%'X>_M >$T^'WC+PO\/[FTO;RW\?M:1:GK6EZKX-FBTZ_C_MS1M6U"WA
MNK6:TN!#< 1GS'P!_P %(_@IX\UOX:P7/PZ_:(^'?@+XTZ_:^%_@Y\;OBC\)
M;KP?\'/B7KNJ^:?#=AX?\3S:O=:C8OXO6%SX2D\3:'H,6OEHDLI'DFA21>QJ
M^]^[E[MF].\7)6[WBG)6O>*NM-0]I#1\R5[VOIL[._:STUMKIN?H+17YU>,O
M^"F7P9\)_$+XX?#73/A-^TW\2=<_9M\27'A_XX7_ ,+?A"?&&@?#ZV@TC3]=
M'B75=3M_$%L9]#N-,U#[5;6VGV]WXEEM[*_NO^$?6TBCN)N]\7_M[_!31XO@
M_!\.-$^*/[1WB+XZ_#R;XN?#?P=^SUX-C\<>)-5^%MK<6=C=^/;^/4M7\.:5
MHN@6NIWUOI,KZGJMO>_VMYNGI9O<Q2(HZ%96O3DN977IR\UV^B<?>3=KK5:!
M[2&OO+1V:ZWORV2ZOF:CI?WM-]#[8HKQ7X!?'KP1^T?\/8OB/X$LO%^CZ>FN
MZ]X5UCP[X_\ "VI>#/&?AGQ1X8OGTW7=!\0>']37S;6]L+R-D\VVGO+"ZC*S
MV5[<P.LA^9_&'[5'P_\ @Q\8/VSO$'C?XB?&?7_#_P"SO\$_A-\2O&WPN'A?
MP?)X \#Z!K8U95U[X7ZG%>6'B3Q!XH\3>69?%VG^)KRVTS3Q96QTB7YY0RC2
MG*4H*+YX[QL[W<HP2T6C;DDKV3=E>[5VYQ23NK2O9W5K*+DWOLE%O2[ZVLFU
M^@5%?F;#_P %5?@*=<\'Z!?_  H_:HT:^^*_AV;Q'\ 1JGP0U"+_ (:)AA6S
MF;3/A%;6VLW6H:AJYLKV/5%M_%-EX5MSI,4^IF[6SC$K=O:?\%'_ ( GX"?'
MK]H#Q#H7Q<\!Z1^S%XITGP=\=?AUXY\#P:#\5_A]K.NZKX?TW21J?ADZW<:9
M<V5_;^)-.UVVO-/\07<4^A+<7D/F3+#;3T\/75KTIZM):;N4N5)=_>?+IM+W
M7KH2JM-W]^.B;>NR24G_ .2M2_PZ[:GWW17PU\+OV^_A+\4OB'X:^%=SX%^.
MOP=\4_$SPKK_ (K^"]W\;_AE<> =#^,>CZ%I;:K?W7P\U-]3U,7=_:Z6\.MG
M0==@T+7VTEOMRZ6\*2;/EG]D#]O-_#/[$WPE^)O[2'B;XC?&'XM_%?XY?&#X
M7?#WPUX/\+P^+OBO\3=8\/\ C?Q#'I/AKPOX:T6'1K*XB\.^&=,,M[J-[)IV
MGZ;IMJ)]3U$/(C2/ZO5LWRM-2A%1L^:7.INZTLXKV<E)WT:=]G8]K#3WE9J3
MOVY>31WUN_:1Y5;7[K_L717PGX:_X*$?!S6?"_[1FM>(_ _QM^%?BG]E?P/:
M_$GXN_"7XJ^ K3PI\4+'P-J.GWVI:1XFT'2%\0ZAH6O:3K,&FW\>G7MKXB6V
M:XM7CN)(%:-WR?AW_P %(O@A\0_'?P;\'/X!_:"^'VB_M$WD6E? CXJ_$[X4
MW7A/X6?%77KC27UNTT#PSKS:K>ZM%JFH:=#=SZ4NMZ!I-IJT=C=3Z;=75JL<
M\D^PK:OV<K1U;M=?"IZ=_=:EI>\=5HF/VD+I<RN]$GH_BY=;[>][NMK2TW/T
M"HK\P/V)/VP/B9\?_P!HK]M'X=^.?AU\7M \._#+XO-H'P[O/%7@OP[X?\->
M"/#6C>&M#1O!WB"^TOQ)J=\WCCQ!J%W=>*K59+>\@O\ 0[NVN6OK.8&PC^A_
MBK\5M&\&_M6?L^^!]1^(?Q2T>[\4?"#]HOQG#\+O#>@^%[[X6^/].^'FF>&K
M_5->\?Z[J+Q^*]*\4^#8;M7\ V'AYETO5KC4=1CU]T2*V8.5"<9NF[<RI^TT
MUT]G[2VE]4M'?1:MOEU",XSBI1O9R4%?1W<^3KYOU>R5]#ZXHK\P?"G_  5G
M_9R\6:%\.O'L7P\_:4T'X,_$OQ-H/@G1OCWXD^$+Z=\']+\:>(]1&B:;X9U_
MQ+%X@N[ZTN3KV[0KC5['1M1\,PZI'- =<*032I^DGB?7K+PGX<\1>*-32XET
M[PSH>K>(-0CL4CGNY;'1K"?4;I+.)Y88IKE[>W<6\;S11R2E%:6-27$SI5*;
M2G!Q<FTD^K3LUZIM)K=7U0XSA-7C)-+JNSV?H^CV?1FU17YG?#__ (*M_LX?
M$*P^&?BR#P7^T'X2^$/Q;U_0O"'@WX_>./A3)H/P4N/&OB)HK?3?"FH^,4UR
M]ETR]EU61M"&KW.F#PM+K,%S9VVOW A:6N-^&'[8\WPV^*G_  50\5?M'_$_
M5S\%OV:?CUX"\+^ ]/NK"+4&\(Z+XD\!^&GL_!WA'3-&TY-6UG4O$WBS5HK?
M2]-E?4;^]U6_BMX)41@BW]6K6G>#BXI6BT[R;J0I\L;7]Y2FKIZK:UR?:P=K
M233W::LERN=VVU[KBFTU=/TNU^L=%?%'PJ_;H^'_ ,2/B[X=^!OB3X2?M$_
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MLZ***@H**** "BBB@ HHHH *\7NO^3B=&_[(SK/_ *F-G7M%>+W7_)Q.C?\
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M6GB"V9%;3;B]V6[F_B*,\MLA*N2AW*,C;C!'Z"Z;\ /V9/B]\5?&'C/QW>>
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MC9R20P.17S=X3\:ZE\-?'7AGQ]I#3)=^&]1L]0(B)'F6JSQI?0R[3@QRVKR
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M3$9E<P&3@[@4*E<8&.<\UZW\>KV.Z^#?P<U*/B\CMM3TF:0'YE6QN%:)?4#
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M+7+-@PQQ]LE;IV(*CD^O'/3]6/AY"3^R?^T-Y"_Z0O@*=P5P#L%Q$7SUXQU
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MK:UN]M[K4OVFGQ::K2WSLM+^71=TAI:!I[>)WN)5,JM'YD;'<T1._=N"OB)
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M_P"\A0E5WACSC/Y8_MR6L&E_M)^*-)@.Z'1]"\,:3$#QA-/T6VM0 .@VK#T
MXY'7&/5OV)KR'XH_&/X=> ?BQJ&O^+?!EHM[;^'_  W=WDMWIEM?*L;0*+6>
M81K"JAU8 '@* #@TZ=1\U:C+F?MN6"=_@:V[W2?1+TW/GO$/A:G'"<">*>$>
M$P<?#*IFO%>:X3#Y9'$X_.,!4P4OKN#P#]K1HT\77C!I5\3=0<HUE-2I)/FO
M"FJ@-"[2!>(FPK!@@(YVMWP5QD'V^OVQX+\+>,;KPZ?&-MX>U&;PU#DRZJL$
MAMU5& =]W\4<9X=P"H(()ZFN9_;B^$WAWX-_&BP@\(Z''X=\->)_#UIJ=EI\
M<JF%;V%S%J+0P+G[-%YC1A4/RG.Y>AKK/ '[67C+1/@_)\(;:QTF2PN(Y[%-
M7DB9K^"QNY"\\2\F-F(9D20KD CN!CG5&G"M45:JTHJ7)R1=G)**BG>UD[[6
M6O5)W/M<+XA\5\8<!\%\:>%/#^79S3XDQ^6U,?@N(,=# U,MR*=:I0S2NJE"
MJZ=3&X.5*5-4X5)IM<RIU;.![3X2UHLT95L*%!R!R21\HQCO]<8]*^KO".KZ
M8=*1F>0ZEYGS*1@,=QV!,?*%"]>,YS7P]\'=-U/QOK^G>'-(E47=VLCJ9F")
M'#;J'9R1N)90 0J\D]P*^F_L6H>"?$,^@:J\4E[:E&9XFW*R2 ,CX!!5CD97
MMC.>YB2G&E*K[.]-ODYGJD]&[?WEW5UW:/MLYS/AK.>)LNX*GQ)6R_BG!T:?
M$U/*,#7JTL37R^C)TN?$_NI4ZF%E*3O3=157R\Z7*FSZY\.ZID1J2=PPW)Z9
M&<'O^8]ABO8='O0X3<P4$J%5B<G&3DXP",\8(.>N:^4/#.M;QYAD4.2N "<X
M'"X['GMQC'Y^\:#J(/E$LW"[F).0H)PI4^A/3_Z_'-&_-??3F2ZVO'R_-;6M
MU/MZL=;)W:EJTM=E=V2OY_K>Y[U93LP 9@=PSP,@ DD<]1P,#G'K70PR;BI#
M*"V%"J3T.1D\G!'J,<FO/=-O%94 F)9@N2IR" .0#VQ^I],BNSM)!QLXS@CC
MH.#SC)[CID]JVC)MOM;;[CCJ):.UNCMY6U]6[OSUU/8/AC,$\1&$'B?3KD8S
MWBV2G/<_=R/<>E?LY^SR^[X5:$/^>=UJZ?\ E1G?_P!G[?SS7XR_"Z,/X@GE
MV$&'39FW#( $LD<?3 ')/(XX.3GBOV;_ &>DV?"G0#_STN=7?Z_\3.X3C_OC
M'U%?8Y'_ +H_^OM2WI:GY=[Z:]^I_*7CAR_ZQ4E'=9?@%/SESXUJV^T'!.[O
M\K'M=%%%>T?AY^3OQ-_X*R_";1$N;'X4>#?$GQ#UB-WBCN-57_A&=%1@VV.5
MS*EQ?R1R8+ >1$NW&Z52<'\_?B?^WW^U3\6B]KI6N6/PTT"7S0VE^#(WLKZ2
M-E :*?6KPS7=RR_=18W12^YEB7"UX-I'@0!(M\<<08LDG[E1% L1 C:/8#-(
M\C;0DDBK%%@J$8G=7:P>';?3F&Y47RP^Y@/,WEL,TBJRNK!"H^4HJYSR, G_
M $*X=\(O#_AKV=6ADU/-L;#_ )C,\:S&7,E;GCA:D89?3L[R@XX133?QM(ZX
MX7=3;W3NM-$TVDTVW>SBWII>R5TWXS'X1U;6M2?5]=OM3UO4+L^;/=:M/<WL
M\\LCF4L;F]D<X(!EGE!,S, =NW@]]9>$K>"-IO*$,X98W)50I0G;N1R@+Q,0
MV5+,K+@N,<5WT5K'&L7D*\1@CSYH;*R!P253<ICC:3 )1=B.F$/)8&W;"8AY
M3.,NWV=#(#M5<>8P)V!4RH<%1&1DYR.&K]1A6E)1I0ITZ=.$8PA3IQC",8II
MJ,(122BMN5)*.ZLM#5TXP^%;[R>KOTU>NEM+W6GD<I#I-O9Q26J1@EG#S3XR
MNTX.VWP#$1CY"K-N?.X%<D5I"Q++E-D6!R5B20A5?A650 -J !5RJ@]75\8V
MY(;6(DLWEQE%DC52SL#N" [F+[0^T!OD^Z1G;51&BC:13A(_+>0(TK*64?>=
MBW 8*&*[1E<#MD,VW9:/376STTUOWUVM9+56%;1=?-ZNZZOS\_NVL9ZZ4V_=
MM.XECDJ2"JG=( IW8&"@#.[_ .R@ )J":P6>(B95;:Y+-("%8(5&T[2!A,J/
MFX( /IC3DN9!L&]8@464%Y,;HCN1-N %;*9;H"."RD$BL^ZO0L4D4DK&18&R
M\/R;\,KG<=@$>UFP#@[AGDJ0 ^>>FKN[;K?9:7=K/K;=J[\LJM-.-U9.+OKU
MO9;O;R\].JMA7EM90@3 C$;81P=C><5 D!#,&8C/EAD8Q.F2% R1?BU.-K17
M""*5%*.'8K+LVCB-A\Q!)4[22R@_,K!BQYS5[V+;\HV2!"I#-QO559EVL T@
M.TAMO[OD@'E:YJ#6?,A,$DD:I(7<DR,TNXEB CL#Q'CR2IP5SM)(.1G.4Y*2
M<7+9)Q>F^M^K7KWOH9TG&$M9)IW3:N^6UGTW^Y>3?7K=6NU6%5C6***)V\V4
MDL) WSHA;*22N[%0(5(1&7+J5&:XF?5[DVUK)DQAVFBEBGD4NYB+'[0PE=BB
M$!2R>6$  48(S4E[J*.R/&'D1M@E02>6Q &5 D+$Q@D!3(Q"XR$/!K@;^]E\
MY@XM923Q&"73][(&D@,IQ(4"XWM\WF @9.*QC3G*^EK:.^FO9=_Q^_0UG-<L
M6G=2:U6W3=]/3R:9=NKJY\QV+P2-;QFX2+)\M'DPC/&%*AKAR@*K("!Q(5VD
M"JDFHMYT\B7# 2%$OA$5 CDD5?)(W#,4L:[@RC"+@%0Q8"N6N+WRF292LRO-
M/YYC  5MI6VC"AC+((RP"R1!DCQPOWL8T5Z(A-;*1#!<B9[AFVR+YL">8A,Y
M!";R&V[U5FVX(+'%5!I..U]GI9[K=?S-:K7MO>[REJFDVEWT>B>JZ77>WFM'
MH^W-X9II[:%%EA5RSPIYJVSNT8,0*R[<F1_WAD:0[ Q"(!C/)-)')=71=DV&
MY%O%,BR-91/&F^0VR8RSN 5\V1V&_)&[BHKJ^EMH@9!+#$Y1B$0/;M)A!!#'
MD>9Y;22 H%0F0D*% 4 4+QHXVDMY!)=2E?,NF,ZVSV4K*N(Q;@!_*5/F*X9\
MD"0ARIKI?*O>>EEN^EVN_6^W4Y9RM&U[;-KI_GZ6W[;%&QU"!V2.)9]3GDO+
MOR!MED:65)09VN9=Z91+=6$<@0AT 4;2ISUUOK)N'*F.&PCCNX9;FVMFD%ME
M"5B7S&\M&*$9989&2-D82!CU\YNI[J462_:HK6*V=E6.!9+>^NX9I1YD;-&J
MO:G*#<,^9)#NY._-:]CJL5\T]I:V]I;V.ER2FYF198TNI!LN&#B299##'& C
M,$(9E7YF,A"S3J)2YHZ3^%RN^5I-;+5)M;J]KWL>=B7=-J+<?=6KU6VO2RO\
MG9-VNSVZVU!;B9K2>2RN9?LH@$?E^:?*8M*98RV-LK+F)W5P(XCD(6;(PVM6
MT(WEW;0V4FE/B]FB$NYM-DE=51G$N97MEC.^4$>9O57/R_+7 17PM+N&WL)W
MEDG:>ZG<0);0V[2D&*!%8LTL2AU_>B5#MQLW@%:Z33O$<<T\UI>QPQF5GMKR
M]EN$VAFC=6MI$:,A$*ML61W"N ,@ 8KL]K3T4FHW7-OHNC3?2ZT4=+V['E.:
MCI)VOI?1+>]G=Z;7^3WZ=.VHVT)AG687,*VT<\LEU;R1+:Q7.$64K&77]XV?
M)#+EU&,J>11OM3,UE&(PHGN+NV^SV5U%+'" C&-9R&;YUE4.^54! 09&W'%5
MI"95N;FQ_LZ=)HHX6'VQI8EEM4\VW@-U&ZJYWC$=JR;4()5GC&!CWB7T 26W
M>UN+R!'1Y4M#]GMD8![F57+R/OB#;"Y 5)03Y>=Q%-JR:E=:>CLEK;;3;MIU
MU8TU+:S3ZJ_6VG;K_P /TT=2ECMPT5HK7MS#>6INKGRY=YM'B+26_F8^?:-P
MC"[EC6-1N!P#ESWJ'5!*UR;P0F%92;=3!96D</GP;[10"9@[QB3S&EWDCT.,
M.>^F2>ZTZVE>]UF^M!/;W;2M+]EV*CB0QPKY1\R(2$KMR6VX(!(JM#?EYKV^
M>XVVD4TEG,;9KFWN)O*BB_>$%!NERSI(Q9%!9?+1AFLW4C':2ON[.VCMN^GW
M=/-";M;2]^G?SZG:ZVEGKV@ZM:PQ3P@6UR%NIXXUN/,=$S';J5G<-<)N#((U
M8QE3M&":\<L[F[LKVPMIK"\M_,L#9W-^TUK8I#:0Q^9'!;"9A/!'PLLA6&5W
M< [0?E'H5O<JJSP2%K"TEFBD^U1S--?BW2, O&D:H\DUPXVRW.T[$8!B,$UY
MWXRMK=;X^(K=$6QD*64UY-)Y\*2*I.V.VC/F!I( D8F88=]X9LUSNM[TH2=D
MDFG=6;TT:TL^V[?S.?G;?*WHM%;J[KMTZ6>UK;'0132O9W"/+)]KOX)KB#[$
M3/>0:5'<;(^$&]I_*R)92I4JYD=@V!6)K,UQ):H@M)8IOM=O868=_,FN;:)8
MW+$NDI8JS#>^Z,R*A')W"J.AZL8[6*_1D%]JUJUNLT8<O%I<'G 10H HAFD9
M1_H\(^9B#,SA>63RW"PZ;%'),L]O8W<T49,C-%%;N7:3Y3M:XD 9MBF158!<
M L!7+5Q*5TEI;35Z[:O3;?W;W>C\DG/D;NE:W?5/2SV?GIOJFG<\%^-=I:OH
M6NRQ6Z37\4%J9;I)-DL,Q4M/(L2.Z>7#MB;RG"L_E@;5+9K\_O%>K.D_DI(]
MS&ZM!-F-3:Q?9\;%MHV$+RF<NT[>6"(7/EL<'=7Z4^,[.VETC7+.*%;HW5G-
M(\"S,US>>='OCN)@JO,3!B3[0%&P;%9MH''Y*:SJX$FH:8D:V\EE<73^=Y;2
MO;PH62:*WG.Y6>Y<&3ABPC5E!' /P7$U:[HU?LU(M2;LES0:LTE>]TTG=Z6?
M=GN975=53@ES>S<9/FNTN9)65W=6<;:7O=7?0] _9V^(US\,/VI/@=\1-/U"
MYL9_"GQC^'VI22,OV>:2&'Q#I\,Z,(6,2Q2Q3R)(#(0\<C(6.& _U18IEN(H
M;A""EQ##<(1R"D\22J1VP5<$8XP>*_R.],6>^\4>&[6S.^YF\5>&C;",/YTM
MS/K5B+>/:9&EWHS*P8!@>"<;@*_UH?!,-Y;>"_!MOJ)8ZA!X3\-PWY8DL;R+
M1K)+DL3R6\Y7R3SG.>:_DWQ>A3=?)JZ<?:2684I))7<(2PLX-M7TC*I-)7TO
MLNOMU-H>44M7JE:]O2][:)=>NO34445^-&84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^=?VROAEXZ\$?%C5M,\?^*/^$QU?Q!I-EJ4>MW3;IFTRRG25Q<J>()(@H"1
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M#ML0G]@^$K83*ORKYMW9M<'/3G#(<$\CKS6S\0H!X<_9Q\.2Q@6]WXE\9-J
M P'\JT>-FXZD;R?8=^U>=?':Y?6_VA]8$1+1:7-'I\: $A8K*U6U8DG@993T
M [= *]6_:>DCTGP7\#?"ZX5AX<N]8FB(&5>^N28RZ]<E0-G&5&.W%5.5TEIJ
MUY]5)K9:Z)+HM;MO0XL+1YZ]&#EHW%W:[15T[6T;?WZZW.O^%6@M\2?C7X"N
M9%::XBTS3[*YP,[XX]CYZ_-MC#Y/0#IZUYC\4?'QTG]JO6?$=A*\&GZ9XGCT
M0>7PGV&Q>.QVC'!"E-PZX(KZD_8FL%C\3ZAXGNTX\-^"]9U?>1CRSI^D3R(Q
M)!((?:>HYK\Q_%=_=:SK.N:R[L\]YK6H7;R-RS23WLTRN&[8.WD'/X5E5=I6
MVM;6_5V]6K_/O='I952]JL2IOF2@Z,=&GRR=FO\ MW=-V>NC5C[V_;0\.'Q&
MG@SXJ:5$UU)?:5;Z5KI@C,KB6!0UC=.J*6*.C,CO@G(0'BO0O^"?_P +)+CQ
M,NMWEJT=QJ%Q$JK(A#16L1WH<-@J& +DD @D ],FCX4UB;Q+\*?#@N&^TNVG
M6R," 1)(BB,[@Q89!P3BOM3]G]+/X>_#WXA^/KM4@7PMX-UK4HY  FRZ^Q20
MV@)(X)N98@N.?3M64DHKFW?_  RWMO\ ULT1+,L1/#4LI<6G3J^R=53NW%SM
M[-QM:UVNNK270\*\._M++H__  4R\+ZE;WKIX;M]>MOA:0D@^S&SG*6HX)V9
M;4I"SGC)0$D\5]E?M)_ 22__ ."H_P "_$]K;_\ $G\7Z*GBZ\F6(&%[CPO$
MUO,I;&TMLG@<EN1U^G\X$7BS4(/'-EXZ\V3^U(/%=OXE\S<WF"Y&JB]+!ADC
MYCD<Y'2O[(_#&NP?%+XG?"GQ0T-O.OA3X4S:I%?^4#<0R>(+2T22$R@$!"ML
M3C/)'/->?-)R4M>51FM]+QY7%?CHOST/>Q;_ +.K4%3BTY8!X5\NFLZ45*33
MO=WE=JSO;1W9_/Y^VQ>C4OVJ?BHL4OF"VUF*S9FY.;:WC+*#SV;"@$9S@XKV
M_P#8C\1^!O!OC!6\3W<&D>*-4N]&L?!_B&[0M;:/=2W#_:OWW"6LTR/&OGR?
M)C",0,8\@^,/PS\7?$;]I/XE:GH$<>H)J_Q!N[=8U9E-I&6BM4N)S\P\E'7+
M$<@ '%>F_M#?LN>,OV=M#\ ZCK^J:=J.G>,;>X>TN+%6AN(-3LD@ENH71W8[
M8XYX3%,C#)+<+T.?+5I3]MR<RARMN4;Q]Y*^J>^NC^RWT=D^[B'&\'\4</83
MPOS+B>.5YIQ;E]3+\!1P.(<,QJ5,+2AB:T814&I4[4[5J%:<(8J@JM)2:E)K
M]+OVAOV4]1^,7[1'@O2=,^,<?B/5/$GA.]US5HM2U&#5G\/:=IEQ!!;PZ3%!
M))'';W4LP*VY&X#]Z!M&1\(?%;X=ZI\"?BAKOPVUO4;?5+S1?LDHOK4X2:WN
M[>.Y@+1Y_=3*D@61#R&!..A/RGX7\>^,/"VMVOB30/$^MZ9KUDI@M]6@U"X^
MV16S#:8%E+DM"5&#$V4S@X)&1]/_  [^"/QT_:$M-3^)UL\NM6MUKUMI>H>(
M]<O9'N+W4)F2$LCMO=XK52JN20J!2BC(Q45)PKOEIT)NM*7->+;7+%+1WVV5
MVDN[=[)^;P)D'$O@KALL7&_BEPY+PPR/A^.3TJ6.R7#9'B?[=Q&83J86K'$4
M92A[*.'J/#4Z2JU:E:4'*5)3<JAZ/\/?&NIZ%?6NJZ1J-S87]I(K6]S;2F.6
M'("L592!A@<$'@\9'%?4.B^-KW6;U]3U:]N-0O[J0//=3R&2:8Y_B8DG(& ,
M8QVXKP'X@_LV?%#X(Z3#XFUV*#5?"OVFVL9-?T\ND,%[/A(XI8I/G$32@QQR
MYVNP[4O@[7MSQ R8 P>3W'&0?3/.#T/UK":JTE[.LI1OJHMNU]%=I:/S?5*U
MS]UX3SC@;CFC3XSX2QF1Y\W3J97'B#+Z="MBZ=*G.-6KE]3$NFL70C&<XU)8
M2KR)<\9\EIIO]'O"-V38QW<DR!G.Z.$.NU5P-LC'JQ[8P,'(XQBOH#PSJ:RH
MC"0L&P.2 !@C@#NI[8P.]?"?@G5;B[9(X"\FQ5+%22%4_>)YPO.!@CGZBOJ;
MPKJ#(J;F (7"J ?O9QDCCG&[L1@Y!!Z<TY-RC)1<4K*R6CM:]G^K6EK7[^E@
M*>)PSQ.&Q^:4\?BG7]IRJ,*-2E2GK2@Z2FVKQDK-J*LEIK<^N]"O$=8QD9(X
M8=68#&#DXQT/I7ING.3Y><@ X4<,,XQ\WN<GGG@CU%>">&M0#"(+N&%4<YVY
MQR1_]<D]_I[5I$NY5)8EF'!)**&.>>^#QQCC&.2>AOMUV[_/[]_71'35CR7M
M=K3=-;Z_AZW^:N?1WPF"C4M:9L[FTF$*3G!;[?;LQ Z!MN>.#M!X.#C]HO@C
M;?9?A9X0C(P7L;BYP>O^EWUS< _CYGY5^.'PGB9=-UF>2)LF>RBCG(&U_+@N
M7GC4^J&2!F4XQO7UX_;GP-8?V7X+\*:<5VM9^']*A88P=ZVD18D>K,2Q]22>
MN:^YR6'+@:;?VG-]OMN*?71J/ENOG_'GC+B8UN*\93C>U!8*C:]U>& HU&O*
MSKV:Z24KZG54445ZY^0'\P;.B&(,4.R&(-'%$I$9*[_G7Y0 K Q^5N.T+N9F
M; ,,A2&,3GY_-VXA&'"EB2\VU@3'&WR)P&9F!^5%-0RW,2W-S*'?<(M^TLDB
M[AAF88"$*VUF"X)SE2"3FL];HR-O=G9F4J4^5-BL" H.YE0J<"-=RAAMR<Y-
M?ZJJC):*VFF]K*V[25EZ+[K'JJ:>]U^/]?UW+4UVKK*T(+!X]EQ',WE@2PME
M7@( 3) )V-CDD#@U4\]D6&1&,Q:':WF[4,:C=DLBJ!)+(""J!O+YXSU7,D<N
MK>9(VQBI5'((#88!B"<$JFY@JL7(RQ(&#5*:\D*SPQ%7, 01,K,JL$1=QWN6
M"Y09C*G>  HW@$CIIPC!WM=]7U]/3ROZMD.3?I_7]?-FQ+*P<2AMI/[M1,1L
M5%5B%B"[E11)M;YRQSG<2169]ID#*Y:(S[A(Q?*P2/D[F8[U;9PQ\MBN6Z\*
M6K.COI)8V@EN%&07A4E=SLDA&TN-N N0"V"2=K@#:<X6H:EY!N!'F0.RMD'>
M\BIN*B-,@HQ5BNXA@=O3YB5T:NKI[=%?1=V[)7;W^_8A;O2WGW-J_P!53S4C
MWEV39$RY$FY#R/(6173: RE&C7;AN2<EJP=0U8QPA;A1%*VY55F.\C@H%'W2
M^W#,%( SDD \4;B^<;IU*J^T,HE D).P@;7\PQQI@X<$;C@C*C&>1U'49'?)
M1FE8QQOM8( NT']VK')5FP&*;/E!.0!5*FKZVZ-+JW^#5O\ @.QE6DN1Q35V
MUOOHT].[6_5*UG:Y9N=4<,PC8OE69I'.[(0C(4D^:$R%!R2IQDD#D\E'J0BG
MEC)"M*L@WL^8E1I/GP#D(5(#.-K$@[<9R*JWE[D2+(PP682?.[JCN%!#$X)"
MJORX;@D)P#@<]/>0^4CRJ58N_+*Q6&,8\L)$I)5"R[<X8%R2<4Y<L4[17O*R
MM;3;7T5NGD<4G:SM?71)V[:^?73S]+]7]O$?G!FAVL&&(I3&S@X(<X^[A.<;
M4V$@L"&P>4U741S/(RQPQ HD2LHD5RW^CC:"&8-MS))\B <N 2!5$ZB+E$Q,
M(UQ@F,*7?K\K')[ [2<[FXVC@UD7]PDK([N8UC8>9E-MPR1$,KH3C8 ^T2;S
ME<Y 8%A7-4GRKM?KZ;I>?GLC6'O:7NE=VU6K2U^ZW_ V;TNRMLR S-YZS/)<
MK&T:P1NX?;8%7*#(+1QM\S2<D-C-0WNHM-"EO"9X95^SVTJJBK'Y98&9I=\:
MJ[>0P$DY/DF4L"'(P>:-[<O.,-<?)YOE/<,OD_(N5E"Q111/",E5,>>$R&+
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M (BH4DG*MTNGZE/!!)?012%I852^N+O+/##*5=60-YK[X&'EW$$#JCY*C<<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG.5A5P]PY+!QPRR%QTF_:NTZ]27PJ,%R5%&52I*+5SUG]D?X(Z/^TK\:M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS3>EG:UKJ]O/0\W_ &:?$EQJ/@C]H&?4[@M<^)M UN4[_FWS3@W&Q2W7&W8
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MXE\(Z5K/A_P%/J$\>@6I\N2^:ZMI4N+[[3.DBK>(I\R'*F-2" .17TG\6/\
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MX&<8V([:[TBXLFU_1-1L1)+%=I:ZE:7NFS7EBQRPM?M,<1>!E! F0,,L<\#
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M9H([<(1 Q(4LR$$42:C",).7L8R4Y0324FK7NM%=KTVZ;KTJG#>'Q.+SK/\
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M>,'IR>.O;%?<_P (_#E_>>)M%M;Z 1V<1;4+T#YB\6GL+@0F5<B)WG$2QEB
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MD'S)MW%U!R%#2?*51B&&-K #%<$IMOEB]WJ^KL[W;T;?7?RW.+?KN[ON[/\
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M:6L,SV\GSE_P3+_:[_X*M?MD>#=,_:6^(_QV^"?A+]E7X(^*=?@^-\UW\*=
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M%'K.HW.JZEI6A:-8W$HLEOM06YOHYK>(QGX^_P""S$'_  4^\)? ?]G?P?\
MM^Z]\$OB9X<U_P"*?_"5^#_B%\*-'C\.ZSX4\:0Z L6K?#+Q?I>GZ5H6BW?D
M:3/]NMM8T_2Y8)KFWE@AU>Z"M"-Z>7J6)4)34:+K580BYI5IPIR<7*"Y7%\K
M5FW:]G9,RGB[4N:,7*HJ5.<FHMTX2J*+2E[RDDTW:S=KJ[/[AHW66**:,YCF
MBBGC)!!:*:-98V(/*ED=25.""<$ @T^JMA_R#M,_[!>F?^D%O5JO*.T****
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M\&>)?#WAWQ%$_P 8O$%XDN@:YK&EV6EZU&]G)'=I)IEW=(UJZ7"DPNKGS_\
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M%5:7->>&Q45%5L-5M9\]*;MK:-2#A5BG"<&_C+Q?#;E1LBG\X&07)DE5H9%
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M;Z]\0_#OBF\7P7\&O"J:C.6\J6_"QV^GV2Y*-+/,J[551SP23@UU'AX_#/\
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M#;7,A*J0$90RA'(9>GS$"L*.YA=I Q4H@D$42J61Y"V&#,NX#RVRQ1L<DY]
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MIRMHI03;LIQ;34?O?<FW-R=.-_<5H2E4CS>ZJ;::BVGI*22;Y9).)]J>"_\
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M3]+.I-+(FH6=N?QQ\1_L&?M$^,_AI\$EM_V&?B7;?M!?#OXM_!?QO\:/CO\
M&?\ :MT;XI>)/&P\,>*-)D\>7/P=T*;QM<:%#INNSM>>)I+?6K7PE-H_AVR?
M1=.M[V]6TMW_ %]_9L_9]^(_AGX[?\%/M9\?^'KGPSX(_:8^,-MJ7PQ\1KJ&
MD7[>(O"-_P#"*R\%ZEK]I9:?J%S?:<UAJ+7426FM6^FWDLD =(# Z2G:K3PT
M8RE%0;4&E%5+I-5:48R]VK)R;ISG+>*ERWY$DTU3E5E;F<DN:%WR)/E=.;E'
MWJ44O>C%-I-INRFVTSAXO^"H^D7'A.Z^.\'[,/QG?]C&R\42>'[K]K%]<\#P
MZ)'HD'B ^%[KXF+\*'O_ /A84GPPMM9!23Q0B'.G?\3A;,Z?F4>X?$[]LGQ%
MHGQ7U[X,? /]F?XE_M0>,/!7@OPEX\^(&H^$_%?@GX<>!_">C>/X+J]\#Z?'
MXQ^(-Q;:?XA\2^)M,LKC5K+1M+C"P:<(I[R]@\QUA_%;PY_P30^)'A+X$6'[
M)<__  3R\%^/_B9HLL'PYL_VO?&'[0'B6^_9U\2?#6/65'_"P?&'P<M/BCHW
MBFZ\3R>$B]M?^!++PK9Z+<^)0L\5Y%8C;7UU\<OV8/CIKW[47C^_^)_[-/Q#
M_;"^ [>"?A3X=_9F\.>"?VCH/@G\&?A;'X6\*PZ-XLT/XI^ 6\4Z'K6HMJGB
M6%=8C\36\/C"Y308QIXMI&D6WC;I852]UP:2FTI5(VG%.ER-KVZ]YJ4VTZE'
M2+?(N5QE*G7:7,[-N%WR/W;J;G'6BW9-1BFJ=9-O^([IQ_4W]EG]I#P5^UG\
M%/"GQN\"Z=K>@:1XBN]?T;4_#7B:.V7Q!X4\3^$]=OO#?B?P[JYL9)K&XN=*
MUC3KJ%+VQFDL[^V\B\MF\J=5'Y+:9\>?B1K7_!3K]JKQ!\>M+^,G@7]G[]CK
MP)X;\36*Z3\>[+0OA1X"\+6F@>)M2D^(?C_X:^&Y;)_BM)\58(X[[0]!OC?Z
MCX:ECT[3[^U>Z12?L[_@E3\!/BG^S/\ LBZ;\(?C%X,LO ?C/1/BI\7M4_L'
M2=4T[6M"&@^(O&VHZUX?O/#VHZ?>WK3Z)/IEY#'8?VE]CU<1PG^T+"VE.T^/
M>-OV*_B?\8OCG_P5,L->L'\%_#O]J_X"?"/X>?"OXBS7FDW]E?\ BCPSX?O8
MKU[C1K2^GUFVL-'UL:>FIC4+"Q-W9/<#3I)GPPSA[&%;$Q3BZ?*XPGS-M0=:
MG%N#B_>E[-R=US-I/=.2=/VDH4'9\^DIQLK.7LINTDUHN>R^S9M6M))KT;0?
M^"D\ZCX3>,OBM^R5\<O@A\ /CIXH\.^$_AG\>?&.L^!M2TE]1\<.$^'UUX_\
M"Z+?/XK^&^D^-R\']E:AK(NH[-KJVCU-;4R@CM_!/[=&O_$S]J'XT?LV?#S]
MESXG>*+']GKXM:/\+?B_\95\9>!M+\"^%TU[PWH_B73O$MKINHR1:_KF+35M
MU]X:TV)]4LK2U%^9Y5NX(!\D_$#X>_MP?M5_!;X'_L@_$K]ERS^">D^$_&OP
M:N_CG\>[GXK>"_$?@+5?"?P6U33=3EF^#7ASP]</XUNM:\<7.AV!TZ#Q+IGA
M^#P_!<W*7$DVQ%K[ _8^^#?Q+^&7[0'_  4J\:>.O#$N@>&/CS^UKX;^)7PD
MU234=)OD\7^"+#X'> _"%WKL-MIU_>7FE)%XBT;4M--GK<&G:B[6QN$M&M9(
M9W)PH1A.7+3YU!\L(U7./\2G&$[QG=R<'4;C=:14G%+1N,JDG%7DHWAS2E34
M7;V524XVE!)+GC!*5KIR<5*3U7LO[3O[37AG]F/PKX1U74?"?BOXE>-OB;X\
MT;X7?"7X4^!$L&\7_$7Q]KL5U<V6CZ?-JEQ;:;I&G6ME97>H:UX@U.5=-T:Q
M@::Y)9XHW_.+P!^U5\8=?_X*5?%*'XF_"[XO_!#1?A-_P3,\2_$/7OV?_%7C
MG2/$7A;6O%'A[XRC7(?'7A+4/#-]<>!]<U'5O"KKX77Q4MA!J>FS17>AWZB&
MT:-_KC]N7X*?%?QS??LU?'3X'>'M,\>_$S]E/XR_\+-M?A9J^M6?AJ'XF^$-
M;\/7_A;QEX9T;Q%J,4NG:)XO&GW<%_X9O=4,.F-=6LMK=7%J;B.YB^9=(\$_
MM>_&W]KWXW?';X@_LR:E\#_AQK7_  3G^)_[.?PPT?7_ !]\/O%/C35/B%KW
MC"W\00:9XK/A76[S3M*N=9N)KMM&6VGN]&M-,M(Y]2U>VO;Q[9"C&E[)M^S<
MI4YJ;E42FI>T@HQC!R5TX.]U&]V_?7*XLESNI&-YI>UIV487BXVUE*?+I:5T
MX\RT2T=[K=\-_P#!5RYUO]G+P+^U;JG['?QA\(_!3XH^+/@#X.^&_B/7_'_P
MZ%[XMU+X[_$?1?AO%=6^BV1N-2L-*\*7NKMK37]_!%'XHT>QDDTL6DUS;H?N
M/X@_M*^'OAW^U9\%/V5=5\-ZC/JWQH^%?QR^*UK\0!JVF67ACPGI/P+F\-1Z
MU8:W872_;[B;6D\21SV=];3Q6FG16-PU\&#H1^=.N_L<?'WQ'_P1V_9._9MM
M/"=C8?M$_ 'PW^R)XYU/X:ZWXATFT@U/QE^SMXQ\/>-=:^'3^*M/N-2T"VO=
M8_L>;2;768+VZTE+F1)#=F$F0;>I>!OVHOVG/V\/@5\>?BQ^S+K?[.7P*\#_
M ++_ .UI\'?$5WXB^)/P[\7>-M,UWXS:5X9\W4M4T_PGJ]_I]II$S:4]MX7D
MT^?6)I?LM_>^(!I$1M(9&Z>'DY-<D8QEB8M*IJU&"6'<5*3<W*5W>-U)W3TL
MAQG-.G&7,W-8=M\FD>>5JZ;45&/)&WQ>]'>][LL>/_\ @KG%X,^#7BG]I_2O
MV,_C_P",OV5='U6[T7PS\=M/\1> -)L?&MQ!XD_X1.VUZW\$:A=2>+= \ ZK
MKB3V>E^-=4MI+2=DMI)+&&"_MIC^L'BCQ+#X7\&>(?&<]G->6_A[PIJ?BN73
MH98HKFZ@TS1IM8>QBGD#0Q3S1PFW2:16B21@[*4!%?S"?'?XA?M#?#K_ ()"
M>+OV8[7X5_#_ ,9_#WP_H>C?"KPO^UMX-^-GPW\3_"GXJ_#_ /X6SIMIX4;X
M>>#=%U*X\>ZI\5=< T[09_"4NDI8Z??6^LZG+JTR68B;^E_XB:-J6O?"3QMX
M=TBT:ZUG6OAEKVB:98[XH7N=4U'PE<V%G9^;.\4$3S7<T</F321Q(S;I'1 6
M$UZ5.'LW&,8IUJL&U4<^:G#V7)*7O/DDU.7,O=:ZQC:PJ=2<G)-MVITW9P4>
M6<N?F2]U<T=(\KO)=I.[9^=_PT_X*DZ'XQ_9QU/]KSQQ^S5\7OA'^SFW@W3/
M$'@?QQK_ (@\%>(M<^)_BC5_$-OX2TWX?^#O FAW">(9=7UCQ+<KI7A_5KU8
M--U?RIKP+:6J%QZS\/OVW-<U?XG^"?@[\>/V9_B9^RWXG^,?AWQ1J?P8U'QQ
MXP\!^-=#\<ZEX:T5M;U?PC<:CX(O)AX0\=V6C,-5B\.ZTOF7:0W%O97<MY;F
M)OD*_P#V#/C#\3?^".OP(_9.UW1=,\+?'OX6^%_ASXE/@7Q1KL2>'M1\8_#O
MQO?^))? 7B/Q+X4OKU+33_$ND3W&EKK>A:C+_9E[>VEZD_\ HTJC"^!7['^L
MZM^TA\%/B'I?_!/#0?V2/"GPDM?%GB?QOXN^*WQNUGXW^-M?\<7OAZ32/#6C
M_!"STWXI^)=(\/V$-_<7D^M>+?%.G0W=UI#QV46E13YD%^SPK55KEBXSK1BE
M--J,$O927/53ESR;YFH5$[62AHW*E73I];PI2=X6O*37M$[4VH\BZ.4'??VF
MJ5G]B_\ ;<U+X7?L+? &^\<V?Q3_ &E/V@?CE\>_VA/A[\*/A_8Z^FK>/_'U
MYX9^*?B]YA?>+_&=^=/\.^$?!/AJTMQ?:WK=X=/T6P6QLH(=LD*+]K^#OV]_
M!QLOCW8?'?X8^.?V<OB3^S=\.XOB_P#$3X9>);_0O'VI:C\*+R*Y73?'G@'7
M_ TESI'C+2K[5;.Y\.FWM%M;ZPUX0V-]#"9B\7Y2:5_P3?\ CFG[-/[&&N>.
M/@':?%+QM^S#\9?VL=4\?_LO:C\38O ^K?$'X8?M!^.=0NX-6\(?$/PEXFL=
M*L/&>B6-CH/B+0]/U#Q)9:?=PW%W8:NT;A[0^O>#OV-OVA[#PS^VA\1/V;?V
M;?!G[#?Q#\?_ +/VG?!O]G>R\2_$?5/B/\=K_4XO$,/B?Q9JGB_XAR^.?'GA
M/PAH>K-;)8>"](TM+N;1=5<:W=7L4K3*;J4\+)SES1O*I/WE.*46Z_+%*T[\
MGLK2;5&5KMJ=ERJ82K)134K1A&T>5MO]RFVVX+WE4NN5U8MVMRW?,OLKPO\
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MOHUGX[OIE.HRSQ7AM/L9CGEJ?MZ_&W4?#_@/_@H[8?"_Q;\=O!/Q%^%7Q_\
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MM(M$FMM4#!;O7;66-KB>[MB^2\# R@)@Y%=5_P $T_V#?%O[9/CI->U^&_\
M#OP!\%:A%_PG?BR-&MI?$=[&5G7P)X0F=<3:E>*0-7U) \.@Z>Q9BU[-;Q##
MV/MZ]&.&J2KXBM[\TH."IST;;=E'D5VVWHDK]DOH. \\S3AW+N+\FXJX%PO
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M-)E1DIJZ36K33M=.+<6G9M:-/9M/=.P4445!04444 %%%% !1110 5XO=?\
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MOIIUV,OP[^Q/XF\3K%<>*X+>PTT%7(U***<J!RV%F5D1A@\CG..>E>KCX6_
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M<G/<B1C$K8.3YL> -JJ07)D9CL8MAE=F9MN!@\YBN;Z 2*6D9E4AE$K<22
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M;7\RYHK#TV_Y?956KV51GH4<OIPY74G*;717C&[MJW=R?6^J3ZIGY,_LM?\
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M"^K>%_'NEII7BGPKXJ\%ZEJFB+J%I<+%%>Z=>V6L6%YI]\GF[IEV(GS+;_\
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M-\L8+[*M=.3U;DV])IT_9\WO.7,HKJDE%.R5Y2:^*6S2VLE8_-3X4_L#^-O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>lyra-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-13T15:31:05.2544+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://lyratherapeutics.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lyra="http://lyratherapeutics.com/20241231" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" id="StatementConsolidatedStatementsOfStockholdersEquityAudited">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders' Equity (audited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" id="StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995453 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1" id="DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1">
        <link:definition>995463 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995473 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995483 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1" id="DisclosureShorttermInvestments1">
        <link:definition>995493 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges" id="DisclosureRestructuringAndOtherRelatedCharges">
        <link:definition>995503 - Disclosure - Restructuring and Other Related Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment" id="DisclosurePropertyAndEquipmentAndRelatedImpairment">
        <link:definition>995513 - Disclosure - Property and Equipment and Related Impairment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets" id="DisclosureImpairmentOfRightOfUseAssets">
        <link:definition>995523 - Disclosure - Impairment of Right of Use Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995533 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995543 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" id="Role_DisclosurePreferredAndCommonStock">
        <link:definition>995553 - Disclosure - Preferred and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants" id="DisclosureCommonStockWarrants">
        <link:definition>995563 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" id="Role_DisclosureStockBasedCompensationExpense">
        <link:definition>995573 - Disclosure - Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement" id="DisclosureCollaborationAgreement">
        <link:definition>995583 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995593 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995603 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>995613 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingencies" id="DisclosureCommitmentAndContingencies">
        <link:definition>995623 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995633 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995643 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995653 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995663 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsTables" id="DisclosureShorttermInvestmentsTables">
        <link:definition>995673 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables" id="DisclosureRestructuringAndOtherRelatedChargesTables">
        <link:definition>995683 - Disclosure - Restructuring and Other Related Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables" id="DisclosurePropertyAndEquipmentAndRelatedImpairmentTables">
        <link:definition>995693 - Disclosure - Property and Equipment and Related Impairment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables" id="DisclosureImpairmentOfRightOfUseAssetsTables">
        <link:definition>995703 - Disclosure - Impairment of Right of Use Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995713 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995723 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables" id="Role_DisclosurePreferredAndCommonStockTables">
        <link:definition>995733 - Disclosure - Preferred and Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsTables" id="DisclosureCommonStockWarrantsTables">
        <link:definition>995743 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" id="Role_DisclosureStockBasedCompensationExpenseTables">
        <link:definition>995753 - Disclosure - Stock-Based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables" id="DisclosureCollaborationAgreementTables">
        <link:definition>995763 - Disclosure - Collaboration Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995773 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995783 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanTables" id="Role_DisclosureRetirementPlanTables">
        <link:definition>995793 - Disclosure - Retirement Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" id="DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995803 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995813 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet">
        <link:definition>995823 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>995833 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>995843 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995853 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>995863 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995873 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995883 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" id="DisclosureShorttermInvestmentsAdditionalInformationDetails">
        <link:definition>995893 - Disclosure - Short-term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" id="DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails">
        <link:definition>995903 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails" id="DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails">
        <link:definition>995913 - Disclosure - Restructuring and Other Related Charges (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails" id="DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails">
        <link:definition>995923 - Disclosure - Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995933 - Disclosure - Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails">
        <link:definition>995943 - Disclosure - Property and Equipment and Related Impairment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails" id="DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails">
        <link:definition>995953 - Disclosure - Impairment of Right of Use Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails" id="DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails">
        <link:definition>995963 - Disclosure - Impairment of Right of Use Assets - Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995973 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>995983 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails" id="DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails">
        <link:definition>995993 - Disclosure - Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" id="Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
        <link:definition>996003 - Disclosure - Preferred and Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails" id="DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails">
        <link:definition>996013 - Disclosure - Preferred and Common Stock - Schedule of Assumptions Used in Black Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" id="Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
        <link:definition>996023 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails" id="DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails">
        <link:definition>996033 - Disclosure - Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails" id="DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails">
        <link:definition>996043 - Disclosure - Common Stock Warrants - Summary of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
        <link:definition>996053 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>996063 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails" id="DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails">
        <link:definition>996073 - Disclosure - Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity, Including 2024 PSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" id="DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails">
        <link:definition>996083 - Disclosure - Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC" id="DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC">
        <link:definition>996093 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails" id="DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails">
        <link:definition>996103 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity, Including Incentive Options, Under Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" id="DisclosureCollaborationAgreementAdditionalInformationDetails">
        <link:definition>996113 - Disclosure - Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" id="DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails">
        <link:definition>996123 - Disclosure - Collaboration Agreement - Summary of Change in the Transaction Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" id="DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails">
        <link:definition>996133 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>996143 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>996153 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996163 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>996173 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" id="Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
        <link:definition>996183 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails">
        <link:definition>996193 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
        <link:definition>996203 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>996213 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
        <link:definition>996223 - Disclosure - Commitment and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996233 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="lyra-20241231.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lyra-20241231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="lyra-20241231.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:href="lyra-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:href="lyra-20241231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:href="lyra-20241231.xsd#DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20241231.xsd#DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails" xlink:href="lyra-20241231.xsd#DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:href="lyra-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:href="lyra-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="lyra-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="lyra-20241231.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails" xlink:href="lyra-20241231.xsd#DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails" xlink:href="lyra-20241231.xsd#DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails" xlink:href="lyra-20241231.xsd#DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lyra-20241231.xsd#Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails" xlink:href="lyra-20241231.xsd#DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails" xlink:href="lyra-20241231.xsd#DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:href="lyra-20241231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:href="lyra-20241231.xsd#DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:href="lyra-20241231.xsd#DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lyra-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="lyra-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="lyra-20241231.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1" xlink:href="lyra-20241231.xsd#DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="lyra-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1" xlink:href="lyra-20241231.xsd#DisclosureShorttermInvestments1" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges" xlink:href="lyra-20241231.xsd#DisclosureRestructuringAndOtherRelatedCharges" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment" xlink:href="lyra-20241231.xsd#DisclosurePropertyAndEquipmentAndRelatedImpairment" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets" xlink:href="lyra-20241231.xsd#DisclosureImpairmentOfRightOfUseAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="lyra-20241231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:href="lyra-20241231.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:href="lyra-20241231.xsd#Role_DisclosurePreferredAndCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants" xlink:href="lyra-20241231.xsd#DisclosureCommonStockWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:href="lyra-20241231.xsd#Role_DisclosureStockBasedCompensationExpense" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="lyra-20241231.xsd#DisclosureCollaborationAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="lyra-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:href="lyra-20241231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:href="lyra-20241231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingencies" xlink:href="lyra-20241231.xsd#DisclosureCommitmentAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="lyra-20241231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lyra-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="lyra-20241231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:href="lyra-20241231.xsd#DisclosureShorttermInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables" xlink:href="lyra-20241231.xsd#DisclosureRestructuringAndOtherRelatedChargesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables" xlink:href="lyra-20241231.xsd#DisclosurePropertyAndEquipmentAndRelatedImpairmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables" xlink:href="lyra-20241231.xsd#DisclosureImpairmentOfRightOfUseAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="lyra-20241231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="lyra-20241231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables" xlink:href="lyra-20241231.xsd#Role_DisclosurePreferredAndCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsTables" xlink:href="lyra-20241231.xsd#DisclosureCommonStockWarrantsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" xlink:href="lyra-20241231.xsd#Role_DisclosureStockBasedCompensationExpenseTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables" xlink:href="lyra-20241231.xsd#DisclosureCollaborationAgreementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="lyra-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="lyra-20241231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanTables" xlink:href="lyra-20241231.xsd#Role_DisclosureRetirementPlanTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails" xlink:href="lyra-20241231.xsd#DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC" xlink:href="lyra-20241231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails" xlink:href="lyra-20241231.xsd#DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="lyra-20241231.xsd#DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ModificationOfLeaseAgreement" xlink:label="lyra_ModificationOfLeaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:label="lyra_OrganizationAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProductDevelopmentAndManufacturingCostsMember" xlink:label="lyra_ProductDevelopmentAndManufacturingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OtherAssetsPolicyTextBlock" xlink:label="lyra_OtherAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FinancingCosts" xlink:label="lyra_FinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AssetImpairmentChargeLineItem" xlink:label="lyra_AssetImpairmentChargeLineItem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" xlink:label="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_RetentionCosts" xlink:label="lyra_RetentionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExpirationDescription" xlink:label="lyra_ClassOfWarrantOrRightExpirationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_InducementAwardPlanMember" xlink:label="lyra_InducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionOtherMember" xlink:label="us-gaap_ErrorCorrectionOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ExecutiveChairMember" xlink:label="lyra_ExecutiveChairMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FinancingCostsMember" xlink:label="lyra_FinancingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuanceAmountAvailableForFutureSale" xlink:label="lyra_StockIssuanceAmountAvailableForFutureSale"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" xlink:label="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OptionToExerciseStockWarrantsMember" xlink:label="lyra_OptionToExerciseStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyStockOptionPlanMember" xlink:label="lyra_TwoThousandTwentyStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EmployeeRelatedCostsMember" xlink:label="lyra_EmployeeRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightIssued" xlink:label="lyra_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightCancelled" xlink:label="lyra_ClassOfWarrantOrRightCancelled"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsAndRightsIssuedMaturityDate" xlink:label="lyra_WarrantsAndRightsIssuedMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SecuritiesPurchaseAgreementMember" xlink:label="lyra_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfTheRightOfUseAssets" xlink:label="lyra_ImpairmentOfTheRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NetProceedsAfterDeductingIssuanceCosts" xlink:label="lyra_NetProceedsAfterDeductingIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalRelatedCostsMember" xlink:label="lyra_ClinicalRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantTwoMember" xlink:label="lyra_WarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OfficeAndLaboratoryMember" xlink:label="lyra_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MariaPalasisPhDMember" xlink:label="lyra_MariaPalasisPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccountingPoliciesLineItems" xlink:label="lyra_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IRC382Member" xlink:label="lyra_IRC382Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromStockIssuanceAvailableForFutureSale" xlink:label="lyra_ProceedsFromStockIssuanceAvailableForFutureSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsExercised" xlink:label="lyra_WarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImmaterialErrorCorrection" xlink:label="us-gaap_ImmaterialErrorCorrection"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyFourPsusMember" xlink:label="lyra_TwoThousandTwentyFourPsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightOutstandingExercisable" xlink:label="lyra_ClassOfWarrantOrRightOutstandingExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts" xlink:label="us-gaap_OtherRestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IssuanceOfCommonStockUnderEspp" xlink:label="lyra_IssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligationMember" xlink:label="lyra_CombinedPerformanceObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueTerm" xlink:label="lyra_DiscountedCashFlowTechniqueTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_RetentionCostsMember" xlink:label="lyra_RetentionCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyFourPerformanceOptionMember" xlink:label="lyra_TwoThousandTwentyFourPerformanceOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesTextBlock" xlink:label="us-gaap_AssetImpairmentChargesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:label="lyra_ComputerSoftwareAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember" xlink:label="us-gaap_OtherRestructuringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyTwentyFourRestructuringPlanMember" xlink:label="lyra_TwentyTwentyFourRestructuringPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" xlink:label="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfAggregateCommission" xlink:label="lyra_PercentageOfAggregateCommission"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeases" xlink:label="lyra_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PatentsCostsPolicyTextBlock" xlink:label="lyra_PatentsCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercised" xlink:label="lyra_ClassOfWarrantOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentReceived" xlink:label="lyra_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentMilestoneAchieved" xlink:label="lyra_DevelopmentMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SalesAgreementMember" xlink:label="lyra_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GoingConcernPolicyTextBlock" xlink:label="lyra_GoingConcernPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonStockWarrantsDisclosureTextBlock" xlink:label="lyra_CommonStockWarrantsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueDiscountRate" xlink:label="lyra_DiscountedCashFlowTechniqueDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_Rule10B51Arrmodifiedflag" xlink:label="lyra_Rule10B51Arrmodifiedflag"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CantorFitzgeraldCoMember" xlink:label="lyra_CantorFitzgeraldCoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsAndRightsExercisedIntrinsicValue" xlink:label="lyra_WarrantsAndRightsExercisedIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" xlink:label="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" xlink:label="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DirectorsOrOfficersMember" xlink:label="lyra_DirectorsOrOfficersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantThreeMember" xlink:label="lyra_WarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:label="lyra_GrossProceedsFromInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PerformanceObligationsMember" xlink:label="lyra_PerformanceObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NonRule10B51ArrModifiedFlag" xlink:label="lyra_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AtTheMarketMember" xlink:label="lyra_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OpenSalesAgreement2021ATMMember" xlink:label="lyra_OpenSalesAgreement2021ATMMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccountingPoliciesTable" xlink:label="lyra_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EstimatedOfferingCosts" xlink:label="lyra_EstimatedOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ControlledEquityOfferingSalesAgreementMember" xlink:label="lyra_ControlledEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CashProvidedByFinancingActivities" xlink:label="lyra_CashProvidedByFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SignificantSuppliersPolicyTextBlock" xlink:label="lyra_SignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_LegalSettlementAdjustmentMember" xlink:label="lyra_LegalSettlementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAssetMember" xlink:label="lyra_ImpairmentOfRightOfUseAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProfessionalConsultingAndPublicCompanyCostsMember" xlink:label="lyra_ProfessionalConsultingAndPublicCompanyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantOneMember" xlink:label="lyra_WarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FacilitiesSupportCostsAndDepreciationMember" xlink:label="lyra_FacilitiesSupportCostsAndDepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DocumentDocumentAndEntityInformationAbstract" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WatertownLeaseMember" xlink:label="lyra_WatertownLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamSubleaseMember" xlink:label="lyra_WalthamSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MarketBasedConditionAwardsMember" xlink:label="lyra_MarketBasedConditionAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:label="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfAnnualRentIncrement" xlink:label="lyra_PercentageOfAnnualRentIncrement"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueDescription" xlink:label="us-gaap_DeferredRevenueDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonWarrantsMember" xlink:label="lyra_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" xlink:label="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Error Correction, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Warrants Outstanding and Exercisable and Warrant Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and other related charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ModificationOfLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Modification of Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ModificationOfLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Modification of Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ModificationOfLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of lease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of issued and outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development activities performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Activities Performance Obligation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Activities Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProductDevelopmentAndManufacturingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Development and manufacturing costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProductDevelopmentAndManufacturingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product development and manufacturing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProductDevelopmentAndManufacturingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Development and Manufacturing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing and investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred and Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AssetImpairmentChargeLineItem_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charge [Line Item]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AssetImpairmentChargeLineItem_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset impairment charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Discounted Cash Flow methodology Range Of Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of discounted cash flow methodology range of assumptions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Stock Debt Securities Warrants And Units Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of Stock, debt securities, warrants and units, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of Stock, debt securities, warrants and units, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used in Black Scholes Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds to be occured from future issuance of common stock,.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds To Be Occured From Future Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds to be occured from future issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Discounted Cash Flow [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounted Cash Flow Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RetentionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retention Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RetentionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retention costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RetentionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retention costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization, Restructuring, Going Concern and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock issued during period, shares, Exercise of common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, Exercise of common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of warrant or right, expiration description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, expiration description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_InducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Award Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_InducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_InducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ErrorCorrectionOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ErrorCorrectionOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Error Correction, Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ExecutiveChairMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Chair [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ExecutiveChairMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive Chair.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ExecutiveChairMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Chair</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, unrealized loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common shares increase automatically in each year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Shares Increase Automatically In Each Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common shares increase automatically in each year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Incurred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and other related charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FinancingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FinancingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FinancingCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Achievements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Achievements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone achievements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share attributable to common stockholders-basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share -basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders-basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net accumulated unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuanceAmountAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock issuance amount available for future sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuanceAmountAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance amount available for future sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuanceAmountAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount available for future sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Waltham Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Sublease Rent Increases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounted Cash Flow Technique Expected Sublease Rent Increases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounted cash flow technique expected sublease rent increases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OptionToExerciseStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to Exercise Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OptionToExerciseStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option to Exercise Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OptionToExerciseStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to exercise stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations Of Credit Risk And Off Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Outstanding December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Outstanding at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EmployeeRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee related costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EmployeeRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee related costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EmployeeRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding (loss) gain on short-term investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand twenty employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Legal Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining liability paid to the contract manufacture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and employee related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Severance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units outstanding shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Expenses [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted stock units outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted stock units outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development and other tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Exercisable at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Match cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightCancelled_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Warrants Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right cancelled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentrations of credit risk and off-balance sheet risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations Of Credit Risk And Off Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PostMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post-milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PostMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post-Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PostMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post-Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsAndRightsIssuedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date, Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsAndRightsIssuedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Issued, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsAndRightsIssuedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants And Rights Issued, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Asset, Held-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfTheRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of the right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfTheRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of the Right-Of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfTheRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment Of the Right-Of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NetProceedsAfterDeductingIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NetProceedsAfterDeductingIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds After Deducting Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NetProceedsAfterDeductingIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds after deducting issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical related costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical related costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalRelatedCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency and foreign national bank securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. Government Agency and Foreign National Bank Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. Government agency and foreign national bank securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchases of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve, Accrual Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MariaPalasisPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maria Palasis Ph D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MariaPalasisPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maria Palasis Ph D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MariaPalasisPhDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maria Palasis, Ph.D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IRC382Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IRC 382.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IRC382Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I R C 382 Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IRC382Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRC 382</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromStockIssuanceAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount available for future sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromStockIssuanceAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from stock issuance available for future sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromStockIssuanceAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from stock issuance available for future sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongLivedAssetsHeldForSaleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Assets Held-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Expense [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity, Including 2024 PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested stock options expected to be recognized over a weighted-average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Period of recognition (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, exercise price of warrants or rights exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development activities performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Activities Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development activities performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImmaterialErrorCorrection_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Immaterial Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyFourPsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyFourPsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four PSUs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyFourPsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on impairment of long-lived research and development assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightOutstandingExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Underlying Warrants Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightOutstandingExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightOutstandingExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of warrant or right outstanding exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock units outstanding shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future milestone payments receivable upon achievement of specified development, regulatory and commercialization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Included In Accounts Payable And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets included in accounts payable and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets included in accounts payable and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherRestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherRestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments Of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock units outstanding shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units outstanding shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third-party research and development expenses current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Party Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock under ESPP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand twenty incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand Twenty Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds and U.S. government and agency securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bonds And U.S.Government And Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds and U.S. Government and Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Bonds and U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of stock, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued under ATM, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Performance Obligation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Common Stock warrants And Pre Funded Warrant Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Sale Of Common Stock warrants And Pre Funded Warrant Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock, warrants and pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds and U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge for write-down of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on impairment of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-fundedwarrants, net of issuance costs of $4,244</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounted Cash Flow Technique Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounted cash flow technique term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RetentionCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retention Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RetentionCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retention costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RetentionCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retention Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition, Milestone Method [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Change in the Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, hold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Immediately Preceding Calendar Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price of Warrants Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price of Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyFourPerformanceOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four performance option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyFourPerformanceOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PerformanceSharesMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandTwentyFourPerformanceOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2024 Performance Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Right of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Error Correction, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured debt obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Secured Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities Operating lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer Software And Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software And Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherRestructuringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Restructuring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherRestructuringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Debt Issuance Cost, Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write-off of deferred financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense recorded as liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restructuring reserve, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restructuring reserve, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue at beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue at ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Leased Properties Marketed for Sublease Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of leased properties marketed for sublease arrangements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of leased properties marketed for sublease arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyTwentyFourRestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty Four Restructuring Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyTwentyFourRestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty four restructuring plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyTwentyFourRestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Restructuring Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets, valuation allowance income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Debt Securities Warrants And Units Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock, debt securities, warrants and units issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock, debt securities, warrants and units sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Warrants Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Warrants Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Underlying Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAggregateCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate commission</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAggregateCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Commission</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAggregateCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate commission.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net accumulated unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restructuring Liability Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company match percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the patents cost policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted to employees, directors and non-employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation ownership change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Ownership Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss of Attributes - IRC 382 Ownership Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and Other Related Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stock and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share attributable to common stockholders-diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share -diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders-diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of weighted average remaining lease terms and discount rate related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued under ATM, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in deferred tax asset valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits income tax penalties accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise Of Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, Exercise of pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrants to be issued during period value preferred stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock and warrants to be issued during period value preferred stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Stock Debt Securities Warrants And Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of Stock, debt securities, warrants and units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of Stock, debt securities, warrants and units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment, Change in Valuation Technique [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alternative investment, change in valuation technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding-basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding-basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees reduced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Supply Agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockWarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price per share, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average per share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounted Cash Flow Technique Range Of Assumption [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounted cash flow technique range of assumption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Contractual Life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock voting rights, number of votes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights Number Of Votes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon RSU vesting, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vesting Of Restricted Stock Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vesting of restricted stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended lease term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares of common stock reserved for future issuances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Of Common Stock Reserved For Future Issuances Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of shares as percentage lower of fair market value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of shares as percentage lower of fair market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reduction in workforce employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity, Including Incentive Options, Under Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounted Cash Flow Technique Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounted cash flow technique discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DiscountedCashFlowTechniqueDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_Rule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_Rule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_Rule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CantorFitzgeraldCoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cantor Fitzgerald &amp; Co.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CantorFitzgeraldCoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cantor Fitzgerald &amp; Co. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CantorFitzgeraldCoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cantor Fitzgerald &amp; Co.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsAndRightsExercisedIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic Value of Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsAndRightsExercisedIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Exercised Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsAndRightsExercisedIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants and rights exercised intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses for right-of-use asset included in operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid expenses for right-of-use asset included in operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses for right-of-use asset included in operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance maximum number of common stock issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term of Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation, date of incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued and sold, public offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold, public offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and experimental expenditures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research and Experimental Expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research &amp; experimental expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Remaining Contractual Life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to additional paid in capital, sale of common stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment and Related Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DirectorsOrOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors or officers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DirectorsOrOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors or Officers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Allowance of Deferred Tax Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance initial public offering, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10b51Arr Modified Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10b51Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Rule 10b5-1Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax computed at federal statutory tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Redeemable Convertible Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contribution employee percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OpenSalesAgreement2021ATMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open sales agreement (2021 ATM) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OpenSalesAgreement2021ATMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Sales Agreement2021 A T M [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OpenSalesAgreement2021ATMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 ATM Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from warrant exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds for warrant exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Costs of Retirement Plans [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Matching contribution expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EstimatedOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EstimatedOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EstimatedOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Underwriters' Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ControlledEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Controlled Equity Offering Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ControlledEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Controlled Equity Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ControlledEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Controlled Equity Offering Sales Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CashProvidedByFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund raised for operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CashProvidedByFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CashProvidedByFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash provided by financing activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant suppliers policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Suppliers Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Termination [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LegalSettlementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Settlement Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LegalSettlementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal settlement adjustment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LegalSettlementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interim Period, Costs Not Allocable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Right Of Use Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ImpairmentOfRightOfUseAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment Of Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic Value of Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 65,515,440 and 57,214,550 shares issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProfessionalConsultingAndPublicCompanyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional, consulting and public company costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProfessionalConsultingAndPublicCompanyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Professional, consulting and public company costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProfessionalConsultingAndPublicCompanyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional, Consulting and Public Company Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Available-for-sale Investments by Type of Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 17)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding-diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding-diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue Significant Expenses and Net Loss for Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FacilitiesSupportCostsAndDepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facilities, support costs and depreciation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FacilitiesSupportCostsAndDepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facilities, support costs and depreciation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FacilitiesSupportCostsAndDepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facilities, Support Costs and Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Vested and expected to vest at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Document Document And Entity Information Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document - Document And Entity Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WatertownLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Watertown Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WatertownLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Watertown Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WatertownLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Watertown lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested share of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Bills</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Waltham Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham sublease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon RSU vesting, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment recognition in future periods to settlement of obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Recognition In Future Periods To Settlement Of Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment recognition in future periods to settlement of obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of discount on short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MarketBasedConditionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market-based condition awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MarketBasedConditionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market-Based Condition Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MarketBasedConditionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market-Based Condition Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting for Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock issued during period, value, exercise of common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, exercise of common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset in exchange for lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAnnualRentIncrement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual rent increment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAnnualRentIncrement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Rent Increment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAnnualRentIncrement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual rent increment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price of Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, exercise price of warrants or rights issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets valuation allowance income tax expense (benefit).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, valuation allowance income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price of Warrants Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Exercise Price of Warrants or Rights Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercise price of warrants or rights cancelled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of preferred stock allocated to warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right-of-use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Values Exercise Of Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, values, exercise of pre-funded warrants.</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ModificationOfLeaseAgreement" xlink:to="lyra_ModificationOfLeaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="lyra_OrganizationAndBasisOfPresentationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ImpairmentOfRightOfUseAsset" xlink:to="lyra_ImpairmentOfRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:to="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProductDevelopmentAndManufacturingCostsMember" xlink:to="lyra_ProductDevelopmentAndManufacturingCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OtherAssetsPolicyTextBlock" xlink:to="lyra_OtherAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_FinancingCosts" xlink:to="lyra_FinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_AssetImpairmentChargeLineItem_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" xlink:to="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" xlink:to="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:to="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RetentionCosts" xlink:to="lyra_RetentionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:to="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightExpirationDescription" xlink:to="lyra_ClassOfWarrantOrRightExpirationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForTenantImprovements" xlink:to="us-gaap_PaymentsForTenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_InducementAwardPlanMember" xlink:to="lyra_InducementAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionOtherMember" xlink:to="us-gaap_ErrorCorrectionOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ExecutiveChairMember" xlink:to="lyra_ExecutiveChairMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_FinancingCostsMember" xlink:to="lyra_FinancingCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_MilestoneAchievementsMember" xlink:to="lyra_MilestoneAchievementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuanceAmountAvailableForFutureSale" xlink:to="lyra_StockIssuanceAmountAvailableForFutureSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WalthamLeaseMember" xlink:to="lyra_WalthamLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" xlink:to="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OptionToExerciseStockWarrantsMember" xlink:to="lyra_OptionToExerciseStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwoThousandTwentyStockOptionPlanMember" xlink:to="lyra_TwoThousandTwentyStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_EmployeeRelatedCostsMember" xlink:to="lyra_EmployeeRelatedCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightIssued" xlink:to="lyra_ClassOfWarrantOrRightIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightCancelled" xlink:to="lyra_ClassOfWarrantOrRightCancelled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:to="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PostMilestoneMember" xlink:to="lyra_PostMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantsAndRightsIssuedMaturityDate" xlink:to="lyra_WarrantsAndRightsIssuedMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SecuritiesPurchaseAgreementMember" xlink:to="lyra_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ImpairmentOfTheRightOfUseAssets" xlink:to="lyra_ImpairmentOfTheRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_NetProceedsAfterDeductingIssuanceCosts" xlink:to="lyra_NetProceedsAfterDeductingIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClinicalRelatedCostsMember" xlink:to="lyra_ClinicalRelatedCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantTwoMember" xlink:to="lyra_WarrantTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" xlink:to="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OfficeAndLaboratoryMember" xlink:to="lyra_OfficeAndLaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:to="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_MariaPalasisPhDMember" xlink:to="lyra_MariaPalasisPhDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="lyra_AccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IRC382Member" xlink:to="lyra_IRC382Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsFromStockIssuanceAvailableForFutureSale" xlink:to="lyra_ProceedsFromStockIssuanceAvailableForFutureSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="us-gaap_LongLivedAssetsHeldForSaleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantsExercised" xlink:to="lyra_WarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DevelopmentActivitiesPerformanceObligation" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImmaterialErrorCorrection" xlink:to="us-gaap_ImmaterialErrorCorrection_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwoThousandTwentyFourPsusMember" xlink:to="lyra_TwoThousandTwentyFourPsusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightOutstandingExercisable" xlink:to="lyra_ClassOfWarrantOrRightOutstandingExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:to="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_OrganizationAndBasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" xlink:to="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestructuringCosts" xlink:to="us-gaap_OtherRestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IssuanceOfCommonStockUnderEspp" xlink:to="lyra_IssuanceOfCommonStockUnderEspp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:to="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CombinedPerformanceObligationMember" xlink:to="lyra_CombinedPerformanceObligationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" xlink:to="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DiscountedCashFlowTechniqueTerm" xlink:to="lyra_DiscountedCashFlowTechniqueTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RetentionCostsMember" xlink:to="lyra_RetentionCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwoThousandTwentyFourPerformanceOptionMember" xlink:to="lyra_TwoThousandTwentyFourPerformanceOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesTextBlock" xlink:to="us-gaap_AssetImpairmentChargesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ComputerSoftwareAndEquipmentMember" xlink:to="lyra_ComputerSoftwareAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestructuringMember" xlink:to="us-gaap_OtherRestructuringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" xlink:to="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyTwentyFourRestructuringPlanMember" xlink:to="lyra_TwentyTwentyFourRestructuringPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PreMilestoneMember" xlink:to="lyra_PreMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" xlink:to="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PercentageOfAggregateCommission" xlink:to="lyra_PercentageOfAggregateCommission_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_NumberOfLeases" xlink:to="lyra_NumberOfLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PatentsCostsPolicyTextBlock" xlink:to="lyra_PatentsCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightExercised" xlink:to="lyra_ClassOfWarrantOrRightExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" xlink:to="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_UpfrontPaymentReceived" xlink:to="lyra_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:to="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DevelopmentMilestoneAchieved" xlink:to="lyra_DevelopmentMilestoneAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:to="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SalesAgreementMember" xlink:to="lyra_SalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GoingConcernPolicyTextBlock" xlink:to="lyra_GoingConcernPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" xlink:to="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClinicalSupplyAgreementMember" xlink:to="lyra_ClinicalSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CommonStockWarrantsDisclosureTextBlock" xlink:to="lyra_CommonStockWarrantsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CommonStockVotingRightsNumberOfVotes" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:to="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:to="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CombinedPerformanceObligation" xlink:to="lyra_CombinedPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DiscountedCashFlowTechniqueDiscountRate" xlink:to="lyra_DiscountedCashFlowTechniqueDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_Rule10B51Arrmodifiedflag" xlink:to="lyra_Rule10B51Arrmodifiedflag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CantorFitzgeraldCoMember" xlink:to="lyra_CantorFitzgeraldCoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantsAndRightsExercisedIntrinsicValue" xlink:to="lyra_WarrantsAndRightsExercisedIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" xlink:to="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:to="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" xlink:to="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DirectorsOrOfficersMember" xlink:to="lyra_DirectorsOrOfficersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantThreeMember" xlink:to="lyra_WarrantThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromInitialPublicOffering" xlink:to="lyra_GrossProceedsFromInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PerformanceObligationsMember" xlink:to="lyra_PerformanceObligationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_NonRule10B51ArrModifiedFlag" xlink:to="lyra_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AtTheMarketMember" xlink:to="lyra_AtTheMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OpenSalesAgreement2021ATMMember" xlink:to="lyra_OpenSalesAgreement2021ATMMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" xlink:to="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccountingPoliciesTable" xlink:to="lyra_AccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_EstimatedOfferingCosts" xlink:to="lyra_EstimatedOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ControlledEquityOfferingSalesAgreementMember" xlink:to="lyra_ControlledEquityOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:to="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CashProvidedByFinancingActivities" xlink:to="lyra_CashProvidedByFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PreFundedWarrantsMember" xlink:to="lyra_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SignificantSuppliersPolicyTextBlock" xlink:to="lyra_SignificantSuppliersPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LegalSettlementAdjustmentMember" xlink:to="lyra_LegalSettlementAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ImpairmentOfRightOfUseAssetMember" xlink:to="lyra_ImpairmentOfRightOfUseAssetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProfessionalConsultingAndPublicCompanyCostsMember" xlink:to="lyra_ProfessionalConsultingAndPublicCompanyCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantOneMember" xlink:to="lyra_WarrantOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_FacilitiesSupportCostsAndDepreciationMember" xlink:to="lyra_FacilitiesSupportCostsAndDepreciationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="lyra_DocumentDocumentAndEntityInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WatertownLeaseMember" xlink:to="lyra_WatertownLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WalthamSubleaseMember" xlink:to="lyra_WalthamSubleaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_MarketBasedConditionAwardsMember" xlink:to="lyra_MarketBasedConditionAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:to="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PercentageOfAnnualRentIncrement" xlink:to="lyra_PercentageOfAnnualRentIncrement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:to="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDescription" xlink:to="us-gaap_DeferredRevenueDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CommonWarrantsMember" xlink:to="lyra_CommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" xlink:to="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DocumentDocumentAndEntityInformationAbstract" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentAnnualReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntitySmallBusiness" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityExTransitionPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityShellCompany" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorFirmId" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" xlink:label="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IssuanceOfCommonStockUnderEspp" xlink:label="lyra_IssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:label="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_20"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_21"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockUnderEspp" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AtTheMarketMember" xlink:label="lyra_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lyra_AtTheMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" xlink:label="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ModificationOfLeaseAgreement" xlink:label="lyra_ModificationOfLeaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_ModificationOfLeaseAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MariaPalasisPhDMember" xlink:label="lyra_MariaPalasisPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DirectorsOrOfficersMember" xlink:label="lyra_DirectorsOrOfficersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_Rule10B51Arrmodifiedflag" xlink:label="lyra_Rule10B51Arrmodifiedflag"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NonRule10B51ArrModifiedFlag" xlink:label="lyra_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lyra_MariaPalasisPhDMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lyra_DirectorsOrOfficersMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="lyra_Rule10B51Arrmodifiedflag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="lyra_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MariaPalasisPhDMember" xlink:label="lyra_MariaPalasisPhDMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lyra_MariaPalasisPhDMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesTextBlock" xlink:label="us-gaap_AssetImpairmentChargesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonStockWarrantsDisclosureTextBlock" xlink:label="lyra_CommonStockWarrantsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lyra_CommonStockWarrantsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GoingConcernPolicyTextBlock" xlink:label="lyra_GoingConcernPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OtherAssetsPolicyTextBlock" xlink:label="lyra_OtherAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SignificantSuppliersPolicyTextBlock" xlink:label="lyra_SignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PatentsCostsPolicyTextBlock" xlink:label="lyra_PatentsCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_GoingConcernPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_COVID19PandemicAndCARESActPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_OtherAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_SignificantSuppliersPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_PatentsCostsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" xlink:label="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:label="lyra_OrganizationAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CashProvidedByFinancingActivities" xlink:label="lyra_CashProvidedByFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lyra_OrganizationAndBasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="lyra_OrganizationAndBasisOfPresentationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringCharges" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_CashProvidedByFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_ShortTermInvestments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccountingPoliciesLineItems" xlink:label="lyra_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccountingPoliciesTable" xlink:label="lyra_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfTheRightOfUseAssets" xlink:label="lyra_ImpairmentOfTheRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesTable" xlink:to="lyra_AccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="lyra_ImpairmentOfTheRightOfUseAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionOtherMember" xlink:label="us-gaap_ErrorCorrectionOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_ErrorCorrectionOtherMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_RetentionCosts" xlink:label="lyra_RetentionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts" xlink:label="us-gaap_OtherRestructuringCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lyra_RetentionCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OtherRestructuringCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyTwentyFourRestructuringPlanMember" xlink:label="lyra_TwentyTwentyFourRestructuringPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_RetentionCostsMember" xlink:label="lyra_RetentionCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember" xlink:label="us-gaap_OtherRestructuringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="lyra_TwentyTwentyFourRestructuringPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="lyra_RetentionCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OtherRestructuringMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:label="lyra_ComputerSoftwareAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_ComputerSoftwareAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="us-gaap_LongLivedAssetsHeldForSaleLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AssetImpairmentChargeLineItem" xlink:label="lyra_AssetImpairmentChargeLineItem"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAssetMember" xlink:label="lyra_ImpairmentOfRightOfUseAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="lyra_ImpairmentOfRightOfUseAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="lyra_AssetImpairmentChargeLineItem" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AssetImpairmentChargeLineItem" xlink:label="lyra_AssetImpairmentChargeLineItem"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueDiscountRate" xlink:label="lyra_DiscountedCashFlowTechniqueDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueTerm" xlink:label="lyra_DiscountedCashFlowTechniqueTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" xlink:label="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueDiscountRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="lyra_AssetImpairmentChargeLineItem" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalRelatedCostsMember" xlink:label="lyra_ClinicalRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EmployeeRelatedCostsMember" xlink:label="lyra_EmployeeRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProductDevelopmentAndManufacturingCostsMember" xlink:label="lyra_ProductDevelopmentAndManufacturingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FinancingCosts" xlink:label="lyra_FinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FacilitiesSupportCostsAndDepreciationMember" xlink:label="lyra_FacilitiesSupportCostsAndDepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProfessionalConsultingAndPublicCompanyCostsMember" xlink:label="lyra_ProfessionalConsultingAndPublicCompanyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_LegalSettlementAdjustmentMember" xlink:label="lyra_LegalSettlementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FinancingCostsMember" xlink:label="lyra_FinancingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_ClinicalRelatedCostsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_EmployeeRelatedCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_ProductDevelopmentAndManufacturingCostsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="lyra_FinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_FacilitiesSupportCostsAndDepreciationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_ProfessionalConsultingAndPublicCompanyCostsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_LegalSettlementAdjustmentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestructuringCharges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_FinancingCostsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OpenSalesAgreement2021ATMMember" xlink:label="lyra_OpenSalesAgreement2021ATMMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ControlledEquityOfferingSalesAgreementMember" xlink:label="lyra_ControlledEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionOtherMember" xlink:label="us-gaap_ErrorCorrectionOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CantorFitzgeraldCoMember" xlink:label="lyra_CantorFitzgeraldCoMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SecuritiesPurchaseAgreementMember" xlink:label="lyra_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SalesAgreementMember" xlink:label="lyra_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:label="lyra_GrossProceedsFromInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromStockIssuanceAvailableForFutureSale" xlink:label="lyra_ProceedsFromStockIssuanceAvailableForFutureSale"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" xlink:label="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuanceAmountAvailableForFutureSale" xlink:label="lyra_StockIssuanceAmountAvailableForFutureSale"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfAggregateCommission" xlink:label="lyra_PercentageOfAggregateCommission"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NetProceedsAfterDeductingIssuanceCosts" xlink:label="lyra_NetProceedsAfterDeductingIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExpirationDescription" xlink:label="lyra_ClassOfWarrantOrRightExpirationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EstimatedOfferingCosts" xlink:label="lyra_EstimatedOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" xlink:label="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImmaterialErrorCorrection" xlink:label="us-gaap_ImmaterialErrorCorrection"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsExercised" xlink:label="lyra_WarrantsExercised"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_OpenSalesAgreement2021ATMMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lyra_ControlledEquityOfferingSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_ErrorCorrectionOtherMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lyra_CantorFitzgeraldCoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_SecuritiesPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_SalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsFromStockIssuanceAvailableForFutureSale" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockIssuanceAmountAvailableForFutureSale" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_PercentageOfAggregateCommission" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_NetProceedsAfterDeductingIssuanceCosts" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ClassOfWarrantOrRightExpirationDescription" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_EstimatedOfferingCosts" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfCommonStock" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ImmaterialErrorCorrection" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_WarrantsExercised" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OptionToExerciseStockWarrantsMember" xlink:label="lyra_OptionToExerciseStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lyra_StockOptionsAndRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_OptionToExerciseStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonWarrantsMember" xlink:label="lyra_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightIssued" xlink:label="lyra_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercised" xlink:label="lyra_ClassOfWarrantOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightCancelled" xlink:label="lyra_ClassOfWarrantOrRightCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsAndRightsExercisedIntrinsicValue" xlink:label="lyra_WarrantsAndRightsExercisedIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsAndRightsIssuedMaturityDate" xlink:label="lyra_WarrantsAndRightsIssuedMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_CommonWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightCancelled" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_WarrantsAndRightsExercisedIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_WarrantsAndRightsIssuedMaturityDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantOneMember" xlink:label="lyra_WarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantTwoMember" xlink:label="lyra_WarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantThreeMember" xlink:label="lyra_WarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightOutstandingExercisable" xlink:label="lyra_ClassOfWarrantOrRightOutstandingExercisable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_WarrantOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_WarrantTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_WarrantThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightOutstandingExercisable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_InducementAwardPlanMember" xlink:label="lyra_InducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ExecutiveChairMember" xlink:label="lyra_ExecutiveChairMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MarketBasedConditionAwardsMember" xlink:label="lyra_MarketBasedConditionAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyFourPerformanceOptionMember" xlink:label="lyra_TwoThousandTwentyFourPerformanceOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyFourPsusMember" xlink:label="lyra_TwoThousandTwentyFourPsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_InducementAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lyra_ExecutiveChairMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_MarketBasedConditionAwardsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_TwoThousandTwentyFourPerformanceOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_TwoThousandTwentyFourPsusMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PerformanceObligationsMember" xlink:label="lyra_PerformanceObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentReceived" xlink:label="lyra_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueDescription" xlink:label="us-gaap_DeferredRevenueDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PerformanceObligationsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligationMember" xlink:label="lyra_CombinedPerformanceObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentMilestoneAchieved" xlink:label="lyra_DevelopmentMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_CombinedPerformanceObligationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_DevelopmentActivitiesPerformanceObligationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentMilestoneAchieved" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IRC382Member" xlink:label="lyra_IRC382Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lyra_IRC382Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="stpr_MA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OfficeAndLaboratoryMember" xlink:label="lyra_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WatertownLeaseMember" xlink:label="lyra_WatertownLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamSubleaseMember" xlink:label="lyra_WalthamSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfAnnualRentIncrement" xlink:label="lyra_PercentageOfAnnualRentIncrement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeases" xlink:label="lyra_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_OfficeAndLaboratoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WatertownLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecuredDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamSubleaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_PercentageOfAnnualRentIncrement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_NumberOfLeases" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PaymentsForLegalSettlements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyStockOptionPlanMember" xlink:label="lyra_TwoThousandTwentyStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_TwoThousandTwentyStockOptionPlanMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" xlink:label="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IssuanceOfCommonStockUnderEspp" xlink:label="lyra_IssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:label="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockUnderEspp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AtTheMarketMember" xlink:label="lyra_AtTheMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lyra_AtTheMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" xlink:label="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ModificationOfLeaseAgreement" xlink:label="lyra_ModificationOfLeaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_ModificationOfLeaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lyra_ImpairmentOfRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MariaPalasisPhDMember" xlink:label="lyra_MariaPalasisPhDMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DirectorsOrOfficersMember" xlink:label="lyra_DirectorsOrOfficersMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lyra_MariaPalasisPhDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lyra_DirectorsOrOfficersMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:label="lyra_OrganizationAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CashProvidedByFinancingActivities" xlink:label="lyra_CashProvidedByFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_OrganizationAndBasisOfPresentationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_ImpairmentOfRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_CashProvidedByFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccountingPoliciesLineItems" xlink:label="lyra_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AccountingPoliciesTable" xlink:label="lyra_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfTheRightOfUseAssets" xlink:label="lyra_ImpairmentOfTheRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="lyra_AccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_AccountingPoliciesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="lyra_ImpairmentOfTheRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionOtherMember" xlink:label="us-gaap_ErrorCorrectionOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_ErrorCorrectionOtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" xlink:label="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_RetentionCosts" xlink:label="lyra_RetentionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts" xlink:label="us-gaap_OtherRestructuringCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lyra_RetentionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OtherRestructuringCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyTwentyFourRestructuringPlanMember" xlink:label="lyra_TwentyTwentyFourRestructuringPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_RetentionCostsMember" xlink:label="lyra_RetentionCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember" xlink:label="us-gaap_OtherRestructuringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="lyra_TwentyTwentyFourRestructuringPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="lyra_RetentionCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OtherRestructuringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:label="lyra_ComputerSoftwareAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_ComputerSoftwareAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AssetImpairmentChargeLineItem" xlink:label="lyra_AssetImpairmentChargeLineItem"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" xlink:label="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAssetMember" xlink:label="lyra_ImpairmentOfRightOfUseAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="lyra_ImpairmentOfRightOfUseAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_ImpairmentOfRightOfUseAsset" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails">
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AssetImpairmentChargeLineItem" xlink:label="lyra_AssetImpairmentChargeLineItem"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:label="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueDiscountRate" xlink:label="lyra_DiscountedCashFlowTechniqueDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueTerm" xlink:label="lyra_DiscountedCashFlowTechniqueTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" xlink:label="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AssetImpairmentChargeLineItem" xlink:to="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalRelatedCostsMember" xlink:label="lyra_ClinicalRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EmployeeRelatedCostsMember" xlink:label="lyra_EmployeeRelatedCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProductDevelopmentAndManufacturingCostsMember" xlink:label="lyra_ProductDevelopmentAndManufacturingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FinancingCosts" xlink:label="lyra_FinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FacilitiesSupportCostsAndDepreciationMember" xlink:label="lyra_FacilitiesSupportCostsAndDepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProfessionalConsultingAndPublicCompanyCostsMember" xlink:label="lyra_ProfessionalConsultingAndPublicCompanyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_LegalSettlementAdjustmentMember" xlink:label="lyra_LegalSettlementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FinancingCostsMember" xlink:label="lyra_FinancingCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_ClinicalRelatedCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_EmployeeRelatedCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_ProductDevelopmentAndManufacturingCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="lyra_FinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_FacilitiesSupportCostsAndDepreciationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_ProfessionalConsultingAndPublicCompanyCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="lyra_ImpairmentOfRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_LegalSettlementAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lyra_FinancingCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OpenSalesAgreement2021ATMMember" xlink:label="lyra_OpenSalesAgreement2021ATMMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ControlledEquityOfferingSalesAgreementMember" xlink:label="lyra_ControlledEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionOtherMember" xlink:label="us-gaap_ErrorCorrectionOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CantorFitzgeraldCoMember" xlink:label="lyra_CantorFitzgeraldCoMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SecuritiesPurchaseAgreementMember" xlink:label="lyra_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_SalesAgreementMember" xlink:label="lyra_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:label="lyra_GrossProceedsFromInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromStockIssuanceAvailableForFutureSale" xlink:label="lyra_ProceedsFromStockIssuanceAvailableForFutureSale"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" xlink:label="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" xlink:label="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockIssuanceAmountAvailableForFutureSale" xlink:label="lyra_StockIssuanceAmountAvailableForFutureSale"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfAggregateCommission" xlink:label="lyra_PercentageOfAggregateCommission"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NetProceedsAfterDeductingIssuanceCosts" xlink:label="lyra_NetProceedsAfterDeductingIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExpirationDescription" xlink:label="lyra_ClassOfWarrantOrRightExpirationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_EstimatedOfferingCosts" xlink:label="lyra_EstimatedOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" xlink:label="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImmaterialErrorCorrection" xlink:label="us-gaap_ImmaterialErrorCorrection"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsExercised" xlink:label="lyra_WarrantsExercised"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_OpenSalesAgreement2021ATMMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lyra_ControlledEquityOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="us-gaap_ErrorCorrectionOtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lyra_CantorFitzgeraldCoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsFromStockIssuanceAvailableForFutureSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockIssuanceAmountAvailableForFutureSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_PercentageOfAggregateCommission" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_NetProceedsAfterDeductingIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ClassOfWarrantOrRightExpirationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_EstimatedOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ImmaterialErrorCorrection" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_WarrantsExercised" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OptionToExerciseStockWarrantsMember" xlink:label="lyra_OptionToExerciseStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lyra_StockOptionsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_OptionToExerciseStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CommonWarrantsMember" xlink:label="lyra_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightIssued" xlink:label="lyra_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercised" xlink:label="lyra_ClassOfWarrantOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightCancelled" xlink:label="lyra_ClassOfWarrantOrRightCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" xlink:label="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsAndRightsExercisedIntrinsicValue" xlink:label="lyra_WarrantsAndRightsExercisedIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantsAndRightsIssuedMaturityDate" xlink:label="lyra_WarrantsAndRightsIssuedMaturityDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_CommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightCancelled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_WarrantsAndRightsExercisedIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_WarrantsAndRightsIssuedMaturityDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantOneMember" xlink:label="lyra_WarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantTwoMember" xlink:label="lyra_WarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WarrantThreeMember" xlink:label="lyra_WarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClassOfWarrantOrRightOutstandingExercisable" xlink:label="lyra_ClassOfWarrantOrRightOutstandingExercisable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_WarrantOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_WarrantTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_WarrantThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lyra_ClassOfWarrantOrRightOutstandingExercisable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_InducementAwardPlanMember" xlink:label="lyra_InducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ExecutiveChairMember" xlink:label="lyra_ExecutiveChairMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyFourPerformanceOptionMember" xlink:label="lyra_TwoThousandTwentyFourPerformanceOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MarketBasedConditionAwardsMember" xlink:label="lyra_MarketBasedConditionAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyFourPsusMember" xlink:label="lyra_TwoThousandTwentyFourPsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_InducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lyra_ExecutiveChairMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_TwoThousandTwentyFourPerformanceOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_MarketBasedConditionAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_TwoThousandTwentyFourPsusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PerformanceObligationsMember" xlink:label="lyra_PerformanceObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentReceived" xlink:label="lyra_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueDescription" xlink:label="us-gaap_DeferredRevenueDescription"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PerformanceObligationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueDescription" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_CombinedPerformanceObligationMember" xlink:label="lyra_CombinedPerformanceObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DevelopmentMilestoneAchieved" xlink:label="lyra_DevelopmentMilestoneAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_CombinedPerformanceObligationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_DevelopmentActivitiesPerformanceObligationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentMilestoneAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IRC382Member" xlink:label="lyra_IRC382Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lyra_IRC382Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_OfficeAndLaboratoryMember" xlink:label="lyra_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WatertownLeaseMember" xlink:label="lyra_WatertownLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamSubleaseMember" xlink:label="lyra_WalthamSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_PercentageOfAnnualRentIncrement" xlink:label="lyra_PercentageOfAnnualRentIncrement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_NumberOfLeases" xlink:label="lyra_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_OfficeAndLaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WatertownLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamSubleaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_PercentageOfAnnualRentIncrement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_NumberOfLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_TwoThousandTwentyStockOptionPlanMember" xlink:label="lyra_TwoThousandTwentyStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_TwoThousandTwentyStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="20" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="lyra_ImpairmentOfRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_ImpairmentOfRightOfUseAsset" xlink:label="lyra_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lyra-20241231.xsd#lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lyra_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" name="CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_RetentionCosts" name="RetentionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_WalthamSubleaseMember" name="WalthamSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" name="DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_PercentageOfAnnualRentIncrement" name="PercentageOfAnnualRentIncrement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lyra_FinancingCosts" name="FinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_GrossProceedsFromInitialPublicOffering" name="GrossProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ClinicalSupplyAgreementMember" name="ClinicalSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_WalthamLeaseMember" name="WalthamLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ClinicalRelatedCostsMember" name="ClinicalRelatedCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_WarrantOneMember" name="WarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" name="StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_TwoThousandTwentyStockOptionPlanMember" name="TwoThousandTwentyStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockDebtSecuritiesWarrantsAndUnitsIssued" name="StockDebtSecuritiesWarrantsAndUnitsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lyra_WarrantsExercised" name="WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_OtherAssetsPolicyTextBlock" name="OtherAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockOptionsAndRestrictedStockUnitsMember" name="StockOptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ControlledEquityOfferingSalesAgreementMember" name="ControlledEquityOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_EstimatedOfferingCosts" name="EstimatedOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_WarrantsAndRightsIssuedMaturityDate" name="WarrantsAndRightsIssuedMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_NumberOfLeases" name="NumberOfLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" name="ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ModificationOfLeaseAgreement" name="ModificationOfLeaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_CantorFitzgeraldCoMember" name="CantorFitzgeraldCoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwoThousandTwentyFourPerformanceOptionMember" name="TwoThousandTwentyFourPerformanceOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DiscountedCashFlowTechniqueTerm" name="DiscountedCashFlowTechniqueTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" name="ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" name="ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_AssetImpairmentChargeLineItem" name="AssetImpairmentChargeLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_OrganizationAndBasisOfPresentationTable" name="OrganizationAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DiscountedCashFlowTechniqueDiscountRate" name="DiscountedCashFlowTechniqueDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_MilestoneAchievementsMember" name="MilestoneAchievementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PerformanceObligationsMember" name="PerformanceObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_RetentionCostsMember" name="RetentionCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightExpirationDescription" name="ClassOfWarrantOrRightExpirationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_CommonStockVotingRightsNumberOfVotes" name="CommonStockVotingRightsNumberOfVotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" name="PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_TwoThousandTwentyFourPsusMember" name="TwoThousandTwentyFourPsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" name="StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" name="ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ImpairmentOfTheRightOfUseAssets" name="ImpairmentOfTheRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_DirectorsOrOfficersMember" name="DirectorsOrOfficersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_DevelopmentActivitiesPerformanceObligation" name="DevelopmentActivitiesPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_WatertownLeaseMember" name="WatertownLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ProductDevelopmentAndManufacturingCostsMember" name="ProductDevelopmentAndManufacturingCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_NetProceedsAfterDeductingIssuanceCosts" name="NetProceedsAfterDeductingIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" name="ThirdPartyResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_OpenSalesAgreement2021ATMMember" name="OpenSalesAgreement2021ATMMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ProceedsFromStockIssuanceAvailableForFutureSale" name="ProceedsFromStockIssuanceAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable" name="DiscountedCashFlowTechniqueRangeOfAssumptionTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightCancelled" name="ClassOfWarrantOrRightCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" name="DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_FacilitiesSupportCostsAndDepreciationMember" name="FacilitiesSupportCostsAndDepreciationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_SignificantSuppliersPolicyTextBlock" name="SignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" name="DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_ImpairmentOfRightOfUseAsset" name="ImpairmentOfRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_ComputerSoftwareAndEquipmentMember" name="ComputerSoftwareAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DevelopmentActivitiesPerformanceObligationMember" name="DevelopmentActivitiesPerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" name="TwentyThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" name="TwentyThousandTwentyIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" name="ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightOutstandingExercisable" name="ClassOfWarrantOrRightOutstandingExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lyra_WarrantThreeMember" name="WarrantThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_WarrantsAndRightsExercisedIntrinsicValue" name="WarrantsAndRightsExercisedIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" name="GrossProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" name="ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_DevelopmentMilestoneAchieved" name="DevelopmentMilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" name="PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" name="StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_PatentsCostsPolicyTextBlock" name="PatentsCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_OptionToExerciseStockWarrantsMember" name="OptionToExerciseStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_IRC382Member" name="IRC382Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_MariaPalasisPhDMember" name="MariaPalasisPhDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_CashProvidedByFinancingActivities" name="CashProvidedByFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_Rule10B51Arrmodifiedflag" name="Rule10B51Arrmodifiedflag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_PercentageOfAggregateCommission" name="PercentageOfAggregateCommission" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_FinancingCostsMember" name="FinancingCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_InducementAwardPlanMember" name="InducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" name="PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" name="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_EmployeeRelatedCostsMember" name="EmployeeRelatedCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_MarketBasedConditionAwardsMember" name="MarketBasedConditionAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_CombinedPerformanceObligationMember" name="CombinedPerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_WarrantTwoMember" name="WarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" name="FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_CommonStockWarrantsDisclosureTextBlock" name="CommonStockWarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ProfessionalConsultingAndPublicCompanyCostsMember" name="ProfessionalConsultingAndPublicCompanyCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_COVID19PandemicAndCARESActPolicyTextBlock" name="COVID19PandemicAndCARESActPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockIssuanceAmountAvailableForFutureSale" name="StockIssuanceAmountAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" name="EffectiveIncomeTaxRateReconciliationOwnershipChange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ImpairmentOfRightOfUseAssetMember" name="ImpairmentOfRightOfUseAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PostMilestoneMember" name="PostMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwentyTwentyFourRestructuringPlanMember" name="TwentyTwentyFourRestructuringPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_CombinedPerformanceObligation" name="CombinedPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" name="OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements" name="NumberOfLeasedPropertiesMarketedForSubleaseArrangements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" name="UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_PreMilestoneMember" name="PreMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_OrganizationAndBasisOfPresentationLineItems" name="OrganizationAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_IssuanceOfCommonStockUnderEspp" name="IssuanceOfCommonStockUnderEspp" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" name="StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_LegalSettlementAdjustmentMember" name="LegalSettlementAdjustmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" name="SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember" name="USGovernmentAgencyAndForeignNationalBankSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ExecutiveChairMember" name="ExecutiveChairMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212931312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyra Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1700838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Arsenal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">393-4600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,803,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001327273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Document Document And Entity Information Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214441888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,577,000<span></span>
</td>
<td class="nump">$ 22,353,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,448,000<span></span>
</td>
<td class="nump">2,068,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">43,025,000<span></span>
</td>
<td class="nump">104,821,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,404,000<span></span>
</td>
<td class="nump">2,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">19,924,000<span></span>
</td>
<td class="nump">33,233,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,993,000<span></span>
</td>
<td class="nump">1,392,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,111,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,346,000<span></span>
</td>
<td class="nump">142,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,179,000<span></span>
</td>
<td class="nump">3,131,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring liability</a></td>
<td class="nump">4,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,586,000<span></span>
</td>
<td class="nump">9,374,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,121,000<span></span>
</td>
<td class="nump">5,434,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">398,000<span></span>
</td>
<td class="nump">1,658,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,631,000<span></span>
</td>
<td class="nump">19,597,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total operating lease liability, net of current portion</a></td>
<td class="nump">30,259,000<span></span>
</td>
<td class="nump">21,447,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">11,862,000<span></span>
</td>
<td class="nump">12,136,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">54,752,000<span></span>
</td>
<td class="nump">53,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 65,515,440 and 57,214,550 shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">416,319,000<span></span>
</td>
<td class="nump">400,685,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(404,790,000)<span></span>
</td>
<td class="num">(311,355,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">11,594,000<span></span>
</td>
<td class="nump">89,420,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stock and stockholders&#8217; equity</a></td>
<td class="nump">$ 66,346,000<span></span>
</td>
<td class="nump">$ 142,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662352896368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">65,515,440<span></span>
</td>
<td class="nump">57,214,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">65,515,440<span></span>
</td>
<td class="nump">57,214,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212862544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,534<span></span>
</td>
<td class="nump">$ 1,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">43,766<span></span>
</td>
<td class="nump">48,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,501<span></span>
</td>
<td class="nump">19,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfRightOfUseAsset', window );">Impairment of right-of-use assets</a></td>
<td class="nump">22,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and other related charges</a></td>
<td class="nump">10,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">97,882<span></span>
</td>
<td class="nump">68,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(96,348)<span></span>
</td>
<td class="num">(67,120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(93,396)<span></span>
</td>
<td class="num">(62,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(93,435)<span></span>
</td>
<td class="num">(62,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding (loss) gain on short-term investments, net of tax</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (93,468)<span></span>
</td>
<td class="num">$ (62,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share -basic</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share -diluted</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding-basic</a></td>
<td class="nump">65,113,859<span></span>
</td>
<td class="nump">49,804,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding-diluted</a></td>
<td class="nump">65,113,859<span></span>
</td>
<td class="nump">49,804,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214457920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (audited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income, Net of Tax</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 80,754<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 329,387<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (248,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,827,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">46,518<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,652,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon RSU vesting, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under ATM, net of issuance costs</a></td>
<td class="nump">19,068<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">19,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under ATM, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,017,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(62,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">89,420<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">400,685<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(311,355)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,214,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,746,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon RSU vesting, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under ATM, net of issuance costs</a></td>
<td class="nump">4,850<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under ATM, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants', window );">Exercise of common stock warrants</a></td>
<td class="nump">3,808<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Exercise of common stock warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,424,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(93,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,435)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 11,594<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 416,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (404,790)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,515,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, Exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, Exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, values, exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211797680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) (audited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lyra_AtTheMarketMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance cost</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lyra_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lyra_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211332528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (93,435)<span></span>
</td>
<td class="num">$ (62,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,716<span></span>
</td>
<td class="nump">5,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of deferred financing costs</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfRightOfUseAsset', window );">Impairment of right-of-use assets</a></td>
<td class="nump">22,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of discount on short-term investments</a></td>
<td class="num">(2,276)<span></span>
</td>
<td class="num">(3,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(380)<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,353<span></span>
</td>
<td class="num">(5,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,887)<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(5,975)<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring liability</a></td>
<td class="nump">4,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(3,381)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(70,011)<span></span>
</td>
<td class="num">(63,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,338)<span></span>
</td>
<td class="num">(1,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(47,949)<span></span>
</td>
<td class="num">(122,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturity of short-term investments</a></td>
<td class="nump">130,592<span></span>
</td>
<td class="nump">110,886<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">80,305<span></span>
</td>
<td class="num">(12,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet', window );">Proceeds from sale of common stock, warrants and pre-funded warrants</a></td>
<td class="nump">8,818<span></span>
</td>
<td class="nump">69,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(3,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,531<span></span>
</td>
<td class="nump">65,691<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">18,825<span></span>
</td>
<td class="num">(10,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">23,745<span></span>
</td>
<td class="nump">33,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">42,570<span></span>
</td>
<td class="nump">23,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities', window );">Prepaid expenses for right-of-use asset included in operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ModificationOfLeaseAgreement', window );">Modification of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities', window );">Other assets included in accounts payable and other current liabilities</a></td>
<td class="nump">$ 13,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset in exchange for lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ModificationOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ModificationOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets included in accounts payable and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses for right-of-use asset included in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Common Stock warrants And Pre Funded Warrant Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216513904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (93,435)<span></span>
</td>
<td class="num">$ (62,680)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211737488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares </div>
<div>Rate</div>
</th>
<th class="th">
<div>Mar. 18, 2024 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares </div>
<div>Rate</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not grant option awards in anticipation of the release of material nonpublic information and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we do not time the release of material nonpublic information based on option award grant dates or for the purpose of affecting the value of executive compensation.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> we do not take material nonpublic information into account when determining the timing and terms of such awards.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In fiscal 2024, we granted stock options to Dr. Palasis within four business days before the filing of our Annual Report on Form 10-K for the year ended December 31, 2023. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is being provided pursuant to Item 402(x) of Regulation S-K regarding such stock option grants.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:19.24%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities underlying the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise price of the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date fair value of the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 18, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.77</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 21, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">550,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTableTextBlock', window );">Awards Close in Time to MNPI Disclosures, Table</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is being provided pursuant to Item 402(x) of Regulation S-K regarding such stock option grants.</span>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:19.24%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.58%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.18%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities underlying the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise price of the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date fair value of the award</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 18, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.77</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maria Palasis, Ph.D.</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 21, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">550,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=lyra_MariaPalasisPhDMember', window );">Maria Palasis, Ph.D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscIndName', window );">Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Maria Palasis, Ph.D.<span></span>
</td>
<td class="text">Maria Palasis, Ph.D.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardUndrlygSecuritiesAmt', window );">Underlying Securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardExrcPrice', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="nump">$ 5.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardGrantDateFairValue', window );">Fair Value as of Grant Date | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_UndrlygSecurityMktPriceChngPct', window );">Underlying Security Market Price Change | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardExrcPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardExrcPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardUndrlygSecuritiesAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardUndrlygSecuritiesAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_UndrlygSecurityMktPriceChngPct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_UndrlygSecurityMktPriceChngPct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=lyra_MariaPalasisPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=lyra_MariaPalasisPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662215574320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a) On March 6, 2025, the Company&#8217;s Board of Directors approved amendments to the employment agreements with each of Dr. Palasis, Dr. Waksal and Mr. Cavalier that modify the form of payment of any cash severance that such named executive officer becomes entitled to in the event of a qualifying termination of employment, in accordance with the terms of his or her respective employment agreement, from installments to a lump sum (and, in the case of Dr. Palasis, such modification is only to the extent permitted under Section 409A of the Internal Revenue Code).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b) During the fiscal quarter ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of our directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) informed us of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modification</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item 408.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=lyra_DirectorsOrOfficersMember', window );">Directors or Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_Rule10B51Arrmodifiedflag', window );">Rule 10b5-1Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_NonRule10B51ArrModifiedFlag', window );">Non Rule 10b5-1Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b51Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_Rule10B51Arrmodifiedflag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule10b51ArrModifiedFlag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_Rule10B51Arrmodifiedflag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=lyra_DirectorsOrOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=lyra_DirectorsOrOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211021376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211043120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We design and assess our program based on the core principles of the National Institute of Standards and Technology Cybersecurity Framework, or NIST CSF. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is integrated into our overall enterprise risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a lead IT person principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel, and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> process for service providers, suppliers, and vendors.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See &#8220;Risk Factors &#8211; Our business, financial condition, and results of operations may suffer in the event of information technology system failures, cyberattacks, data security incidents, or deficiencies in our cybersecurity.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div><div><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team&#8217;s cybersecurity experience is limited.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alerts and reports produced by security tools deployed in our IT environment</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is integrated into our overall enterprise risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team&#8217;s cybersecurity experience is limited.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alerts and reports produced by security tools deployed in our IT environment</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team&#8217;s cybersecurity experience is limited.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alerts and reports produced by security tools deployed in our IT environment</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team&#8217;s cybersecurity experience is limited.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team&#8217;s cybersecurity experience is limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alerts and reports produced by security tools deployed in our IT environment</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216431968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Restructuring, Going Concern and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization, Restructuring, Going Concern and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization, Restructuring, Going Concern and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company&#8217;s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#8217;s product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 21, 2005</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 16, 2024, the Company reported that topline results from the Company&#8217;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant (7500&#181;g mometasone furoate), as a six-month treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210. The 52-week extension stage of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients who received a repeat dosing resulting in a 12-month treatment period. In the extension stage, LYR-210 was generally well tolerated, with no product-related serious AEs. The most commonly reported extension stage AEs in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results are expected in the second quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors of the Company (the &#8220;Board of Directors&#8221;) approved a reduction in the Company&#8217;s workforce impacting </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> employees, which occurred during May and June 2024. In connection with the reduction in force, the Company stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. Furthermore, the Company is currently in the process of marketing all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of its leased properties for sub-leasing arrangements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded a restructuring charge in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, primarily related to severance and retention costs as further discussed in Note 5. The Company has also recorded an impairment charge for the write-down of property and equipment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and right-of-use assets in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as further discussed in Notes 6 and 7, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure of the Company&#8217;s Phase 3 ENLIGHTEN 1 trial to meet its primary endpoint, which resulted in the Company&#8217;s restructuring during the second quarter of 2024, provides significant uncertainty regarding the Company&#8217;s ability to meet its business plans and conduct its future operations. The Company has incurred recurring net operating losses every year since inception and has an accumulated deficit of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at December 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2024, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From inception through December 31, 2024, the Company has raised an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">424.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to fund its operations, primarily from the issuance of equity securities and to a lesser extent, government contracts and a license agreement.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) assuming the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board of Directors has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. The Company is attempting to sublease all of its leased locations, and, may also seek to negotiate an early termination of its leases with its landlords. The Company may be unable to sublease its locations on favorable terms or at all. In addition, the Company may not be able to obtain an early termination of its leases with its landlords on favorable terms or at all.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will continue to evaluate its headcount of employees and may further reduce its workforce, which will result in additional severance and retention costs, which may impact the Company&#8217;s ability to meet objectives. If the Company decides to pursue any form of growth strategy in the future, it will need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to obtain funding as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662318234400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, other comprehensive loss consisted of unrealized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gains and losses, net of taxes from its short-term investments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had restricted cash of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively. These balances were held as restricted at the Company&#8217;s financial institution to secure the Company&#8217;s letters of credit for its facility leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ginning-of-period and end-of-period total amounts shown on such statements. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,577</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,353</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,392</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,570</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,745</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#8217; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Assets</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company includes certain items within other assets on the consolidated balance sheets. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> balance in other assets as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had other assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, primarily composed of long-term deposits for the Company's clinical trial agreements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:50%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the consolidated balance sheets and related gains or losses are reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to loss on impairment of property and equipment for the periods ended December 31, 2024 and 2023, respectively, both related to specific facts and circumstances in the respective periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also assesses its right-of-use assets for impairment based on triggering events, and recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to impairment of right-of-use assets as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> indicators of impairment of the right-of-use assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_12091721-daa6-4615-9374-7423de9475e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right-of-use asse</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1514240-d93f-4827-833a-208926ab2d2a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lease liability</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_37e2bd47-4207-458b-957f-6e4048e1644e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finance leases</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing the Company's consolidated financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing purchase orders and open contracts,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicating with the Company's personnel to identify services that have been performed on its behalf, and estimating the level of service performed and the associated cost incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company's service providers generally invoice the Company monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to the Company at that time. The Company confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company's accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which the Company has not yet been invoiced:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with preclinical development activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with the testing of preclinical and clinical trial materials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with preclinical and clinical studies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigative sites in connection with clinical trials. </span></div></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contracts with CROs to conduct clinical and other research and development services on its behalf. The Company bases its expenses related to CROs on its estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company's CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not recognized any product revenue to date since its product candidates are in development.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 13 for further discussion of the arrangement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#8217;s policy is to recognize forfeitures as they occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses the fair value of its stoc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares and equivalents outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.034%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.762%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.762%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,113,859</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,804,283</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.43</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.26</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,709,980</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,143,802</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,048</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock warrants</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,064,666</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,845,603</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements and are required to be applied on a retrospective basis. The Company adopted ASU 2023-07 on January 1, 2024 for its annual reporting, and the adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. This ASU should be applied prospectively with the option to apply the standard retrospectively. In January 2025, the FASB issued ASU 2025-01: Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures - Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03. ASU 2024-03 is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of these standards on our disclosure of income statement expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216440208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.609%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,209</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:46.609%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;US treasury bills</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s cash equivalents were invested in money market funds and U.S. treasury bills with maturity dates of less than 90 days, which were valued based on Level 1 inputs. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> short-term investments at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2023, the Company&#8217;s cash equivalents were invested in money market funds and U.S. treasury bills, which were valued based on Level 1 and Level 2 inputs, respectively. As of December 31, 2023, the Company's short-term investments consisted of U.S. treasury bills which were valued based on Level 2 inputs and U.S. Government Agency Securities and foreign national bank securities, which were valued based on Level 2 inputs.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of its short-term investments at December 31, 2023, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities had contractual maturities of less than one year. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216535024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> short-term investments and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> net accumulated unrealized gains or losses at December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows at December 31, 2023 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.04%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.009999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.928%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,881</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,486</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> debt securities that were in an unrealized loss position as of December 31, 2023. The aggregated fair value of debt securities in an unrealized loss position was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t hold debt securities in a continuous unrealized loss position for more than 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. The unrealized losses at December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were attributable to changes in interest rates.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210522112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Other Related Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Other Related Charges</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Restructuring and Other Related Charges</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors approved a reduction in the Company&#8217;s workforce, impacting </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> employees, which occurred during May and June 2024. The Company incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through May 1, 2025. These amounts are recorded as restructuring and other related charges within our consolidated statements of operations and comprehensive loss as they are incurred. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, restructuring and other related charges were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of severance costs, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of retention costs, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other costs.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restructuring liability activities du</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ring the year ended December 31, 2024 consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.826%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">January 1,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accruals</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash Payments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Restructuring Plan</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severance Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,713</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,953</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,760</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retention Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,174</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,596</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,578</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,009</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,896</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,549</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,347</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210524736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Related Impairment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment and Related Impairment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Property and Equipment and Related Impairment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.506%;box-sizing:content-box;"></td>
        <td style="width:1.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">461</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,129</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated depreciation includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to loss on impairment of property and equipment described below for the years ended December 31, 2024 and 2023, respectively. In addition, the Company recognized approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of depreciation expense for the years ended December 31, 2024 and 2023, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024 and as a result of the Company&#8217;s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, the Company performed a recoverability test for its property and equipment. The Company concluded that the undiscounted cash flows associated with its property and equipment was less than the carrying value of the property and equipment. The Company compared the fair value of the property and equipment to the carrying value and recorded an impairment charge in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which is included as an impairment of property and equipment in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The Company determined fair market value of the equipment based on a third-party appraisal of the equipment through use of publicly available used equipment quotes. The equipment was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of December 31, 2024, and determined no additional impairment indicators existed.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company recognized an impairment charge of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, related to specific facts and circumstances of a prior year agreement termination with a CMO. This impairment evaluation related to the net book value of leasehold improvement and laboratory equipment assets held at the CMO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216353760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Right of Use Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesTextBlock', window );">Impairment of Right of Use Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Impairment of Right-of-Use Assets</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company&#8217;s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, the Company engaged a commercial real estate broker to market the Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leased properties for sublease arrangements. Based upon these impairment indicators, the Company has performed a recoverability test over its right-of-use asset and concluded that the right-of-use assets are impaired. As a result, the Company has recorded an impairment charge in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the second quarter of 2024, which is included as an impairment of right-of-use asset in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The Company reassessed the need for any further impairment as of December 31, 2024, and determined no additional impairment indicators existed. As of December 31, 2024, the Company has not sublet any of its leased properties.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management conducted a fair value analysis of the Company's right-of-use assets using a discounted cash flow methodology as of May 15, 2024, which included the following range of assumptions:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.052%;box-sizing:content-box;"></td>
        <td style="width:3.101%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:33.847%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term (years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.96</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.13</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected sublease rent increases</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210819792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and employee related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,586</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210524736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Segment Reporting</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s CODM, its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_88da49e1-0053-471c-838d-493a47149bc4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, regularly review the Company&#8217;s operations and manage its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7574a635-981a-4973-932d-d749f0f65056;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases. Segment revenues represent collaboration revenue from the Company&#8217;s consolidated statements of operations and is received from a single customer.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant segment expenses consist primarily of employee-related costs, clinical, facility and professional and consulting costs in connection with preclinical and clinical development activities. Segment expenses also include impairment charges, when and as applicable.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM evaluates and allocates resources within the segment based on the Company&#8217;s net loss.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As the Company is a clinical-stage biotechnology company, the evaluation includes review of the actual and budget costs related to employee-related costs, clinical trials, facility, professional and consulting costs in connection with preclinical and clinical development activities, and the conduct of these pre-clinical and clinical trials and responses from government agencies in determining the probability of success of product candidates. Total segment assets are reported in the Company&#8217;s consolidated balance sheets as total assets.</span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.751%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.503%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.503%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product development and manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,326</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities, support costs and depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional, consulting and public company costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal settlement</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring and other related charges</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,882</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,348</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,396</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,621</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216546368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Preferred and Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Preferred and Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of undesignated preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued or outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share held.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently has an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (&#8220;Form S-3&#8221;), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate. As of December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,059,228</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares which generated proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net of issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">September 2023 Financing</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission ("SEC") on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023 (the "Prospectus Supplement").</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell any of the shares under the Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Sales</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Sales Agreement, the Company has agreed to pay Cantor a commission equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate gross proceeds from any shares sold through it pursuant to the Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by Cantor in connection with the Sales Agreement.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 2, 2023, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,017,568</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock under the Sales Agreement, at a weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.71</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On November 15, 2023, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock under the Sales Agreement, at a weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On February 12, 2024, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,041,666</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock under the Sales Agreement, at a weighted average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 22, 2024, the Company amended and restated the Controlled Equity Offering Sales Agreement (the &#8220;Amended Sales Agreement&#8221;) with Cantor pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the common shares has been registered under the Securities Act, pursuant to the Company's Registration Statement on Form S-3 (File No. 333-278163) (the "2024 Registration Statement"), which was originally filed with the SEC on March 22, 2024, the base prospectus contained within the 2024 Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on March 22, 2024. As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in proceeds net of issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million generated from these agreements with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million still available for future sale under the Amended Sales Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2023 Financing</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 25, 2023, the Company entered into the Purchase Agreement, with the purchasers, pursuant to which the Company agreed to sell securities to the Investors in a private placement (the &#8220;Private Placement&#8221;). The Purchase Agreement provided for the sale and issuance by the Company of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,652,962</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock and accompanying warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,826,481</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (&#8220;Purchase Warrants&#8221;), with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Purchase Warrant became exercisable on November 30, 2023, and expire on November 30, 2028.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, the Company issued pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,408,188</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (&#8220;Pre-Funded Warrants&#8221;), with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and accompanying Purchase Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,204,094</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In total </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Purchase Warrants were issued and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,408,188</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-Funded Warrants were issued. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028.</span></span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The closing of the Private Placement occurred on May 31, 2023. The Company filed a shelf registration statement on Form S-3 with the SEC on June 28, 2023, and it was declared effective on July 7, 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in gross proceeds, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting issuance costs. The Company has allocated the net proceeds among the common stock, the Purchase Warrants and the Pre-Funded Warrants using the relative fair value method for each of the above transactions. The Company has allocated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the shares of common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Pre-Funded Warrants and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Purchase Warrants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the preparation of the Company&#8217;s 2023 annual financial statements, the Company identified an immaterial error in the Company&#8217;s historical financial statements whereby the Company omitted this disclosure in the interim financial statements for the quarter ended June 30, 2023 and incorrectly disclosed an allocation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million instead of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Purchase Warrants and failed to disclose the allocation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Pre-Funded Warrants in the interim financial statements for the quarter ended September 30, 2023.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These immaterial errors have been corrected within these consolidated financial statements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company has determined the fair value of the common shares based upon the Company&#8217;s common stock price on the date of the transaction applied to the number of shares of common stock issued. The fair value of the Pre-Funded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was determined based on the Company&#8217;s common stock price on the date of the transaction, less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share exercise price of the warrants, applied to the number of Pre-Funded Warrants. The fair value of the Purchase Warrants was determined using the Black-Scholes model applied to the number of Purchase Warrants. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes model were as follows:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.57</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.93</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s outstanding warrants are freestanding instruments and are classified within stockholders&#8217; equity since the warrants are indexed to the Company&#8217;s common stock and meet the equity classification criteria.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,424,272</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Purchase Warrants were exercised related to the May 2023 financing as of December 31, 2024 at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">April 2022 Financing</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, Pre-Funded Warrants to purchase common stock), resulting in gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8220;April 2022 Financing&#8221;). The Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net proceeds after deducting estimated offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,815,159</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for gross proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and (ii) certain investors purchased Pre-Funded Warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, with the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Company. The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Pre-Funded Warrants, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Pre-Funded Warrants and recorded as a component of additional paid-in capital. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,651,423</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-Funded Warrants issued in the April 2022 Financing exercised as of December 31, 2023.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reserved for future issuances the following shares of common stock as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option to exercise stock warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,018,288</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">723,906</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,348,497</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212501760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CommonStockWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Common Stock Warrants</span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table represents a summary of the warrants outstanding and exercisable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, all of which are equity-classified:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.283%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.420999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.881%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.062%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.420999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.420999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.061%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate intrinsic Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate intrinsic Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 12, 2027</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common warrants issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,408,188</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2028</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,651,423</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.90</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,700</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,756,349</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_97b57973-2894-41e7-86a2-433229fcba95;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="-sec-ix-hidden:F_3543bcc5-79e8-4350-8931-cc3cab71a166;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2028</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,424,272</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,297</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,756,349</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,715</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CommonStockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CommonStockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216539440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently grants equity-based awards under its 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;) and the 2022 Employment Inducement Award Plan (&#8220;Inducement Award Plan&#8221;). The Company previously granted equity-based awards under its 2005 Equity Incentive Plan (&#8220;2005 Plan&#8221;) and 2016 Equity Incentive Plan ("2016 Plan&#8221;).</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiary.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initial number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares plus the number of shares of the Company&#8217;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#8217;s Board of Directors. However, no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. On January 1, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273,106</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On January 1, 2024, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,288,582</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">696,925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the 2020 Plan. On January 1, 2025, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,620,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company&#8217;s Board of Directors adopted the Inducement Award Plan (and together with the 2020 Plan, 2016 Plan and 2005 Plan, the &#8220;Plans&#8221;), which was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#8220;Rule 5635(c)(4)&#8221;), and currently allows for the granting of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Company's common stock. The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, performance units, restricted stock awards, restricted stock units and stock grants. In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#8217;s entering into employment with the Company or its subsidiary. In June 2022, the Inducement Award Plan was amended to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the shares authorized for issuance thereunder to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,473,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and amended again in the same month to increase the shares authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,703,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In September 2022, the Inducement Award Plan was amended to increase the shares authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,813,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. On December 9, 2022, the Inducement Award Plan was amended and restated to increase the shares authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,413,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. The amended and restated Inducement Award Plan was amended in October 2023 to add another </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares to the shares authorized for issuance, for a current overall limit of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,763,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. During the year-ended December 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t grant options to purchase shares of common stock to executives under the amended and restated Inducement Award Plan, and during the year-ended December 31, 2023 the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">630,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under this plan. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the Inducement Award Plan as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All stock option grants are nonqualified stock options except for option grants to employees granted, under the 2020 Plan, 2016 Plan or 2005 Plan intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted under the 2020 Plan at less than the fair market value of the Company&#8217;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.98%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,360</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,356</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,711</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,887</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024 </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock-based compensation expense was recorded to liabilities. For the year ended December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the stock-based compensation expense was recorded to liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,648,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock that vest as to one-third of options, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to continued service on each applicable vesting date and certain exceptions in the context of a change in control transaction. The Company has accounted for these awards as market-based condition awards and therefore, stock-based compensation recorded during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">550,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to its Chief Executive Officer (&#8220;2024 Performance Options&#8221;) and granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs to its Executive Chair (&#8220;2024 PSUs&#8221;), each with performance-based vesting conditions under the 2020 Plan. Vesting of the 2024 Performance Options and the 2024 PSUs are based on the achievement of various clinical and regulatory milestones during the specified periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the 2024 PSUs, the Company measures stock compensation expense based on the fair value of the award on the grant date and then once the Company determines the performance criteria is probable of achievement, recognizes such amount over the vesting term of the award, which is approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The Company determined the fair value of the 2024 Performance Option using the Black-Scholes option-pricing model and using the following inputs: risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, expected dividend yield </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the restricted stock unit activity, including 2024 PSUs, under the Plans for the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,048</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,332,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,574</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,199</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,143,802</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s unrecognized stock-based compensation as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Expense<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period of Recognition<br/>(years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to certain executive officers with market-performance grants, with the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:12pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.8%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the stock option activity, including incentive options, under the Plans for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,709,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.68</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,334</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,605,002</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.96</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,999,419</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.69</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,822,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.06</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December 31, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024 and 2023 was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company initially reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock for issuance under the 2020 ESPP. In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#8217;s Board of Directors, provided that no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock may be issued under the 2020 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2023, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,138</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On January 1, 2024, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">286,072</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. The purchase price of the shares, in the absence of a contrary designation, will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase date. In June 2024 the Company indefinitely suspended the offering of its 2020 ESPP. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the 2020 ESPP. As of December 31, 2024, there are a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">723,906</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for issuance under the 2020 ESPP. On January 1, 2025, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,594</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662352336896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Collaboration Agreement</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 31, 2021, and as amended on September 26, 2022, the Company entered into the LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the LianBio License Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, the Company will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and the Company will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to the Company&#8217;s LYR-220 product candidate.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LianBio announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company&#8217;s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBio&#8217;s rights under the LianBio License Agreement. In November 2024 we entered into a novation agreement which substituted LianBio Cayman for LianBio HK. For more information, please see &#8220;Risk Factors &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If LianBio HK, as defined below, is unable to find a third party to acquire its rights under the LianBio License Agreement, as defined below, it may materially harm our business, financial condition, results of operations and prospects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 808&#8221;), which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities, or ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, the Company identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial. The Company determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, the Company determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure (&#8220;Combined Performance Obligation&#8221;), and (2) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial (&#8220;Development Activities Performance Obligation&#8221;).</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Development Activities Performance Obligation. In February 2022, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which was allocated to the two performance obligations as follows: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as all milestone amounts were fully constrained based on the probability of achievement. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022. There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement until March 31, 2023. The amendment did not result in any change in the Company&#8217;s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company determined that LianBio&#8217;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#8217;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheets and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2022, the Company achieved a development milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for dosing the first patient in the U.S., and the related cash amount was received in April 2022. In accordance with ASC 606, the Company has updated its determination of the transaction price for this previously constrained amount from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated the development milestones to each of the performance obligations previously identified in the agreement in accordance with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">original revenue allocation percentages, and is recognizing the revenue under the revenue recognition model previously developed for each performance obligation. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects the change in the transaction price (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.517%;box-sizing:content-box;"></td>
        <td style="width:1.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.975%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.916%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pre-Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Post-Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,373</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,489</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,862</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,627</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,511</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,138</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.517%;box-sizing:content-box;"></td>
        <td style="width:1.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.975%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.916%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,604</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,046</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">512</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,260</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months. As of December 31, 2024, the parties are not actively engaged in negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestones achieved during the years ended December 31, 2024 or 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. No royalty revenue has been earned as of December 31, 2024.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company&#8217;s former directors are Managing Directors at Perceptive Advisors, LLC and one of these former directors is also the Executive Chairman of LianBio&#8217;s board of directors.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662354692288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Income Taxes</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2024 and 2023, the Company recorded net operating losses of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">62.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an income tax benefit for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.358%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.358%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.6</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,333</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,999</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,062</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,184</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,466</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,036</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,234</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,768</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">785</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">920</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,548</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,347</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,810</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,956</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,738</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,738</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,738</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had U.S. federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which may be able to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal net operating loss carryforwards that may be carried forward indefinitely. As a result of the IRC 382 study performed in 2022 the Company wrote off $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state research and development credits. The Company updated their IRC 382 study in 2023 given the changes to the Massachusetts apportionment to single sales resulting in a reduced amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which may be available to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2044</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2044. As of December 31, 2024 and 2023, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company had performed an IRC 382 study during 2022 which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. The Company performed an update assessment to our IRC 382 analysis in conjunction with the December 31, 2023 annual audit noting no additional ownership change. For these reasons, in the event the Company experiences a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2024 and 2023 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, has been established at December 31, 2024 and 2023. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during the year ended December 31, 2024 due primarily to the generation of net operating losses compared to the increase by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2023 due primarily to an increase in capitalized research and experimental expenditures and an increase in operating lease liabilities.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2024 and 2023. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2024 and 2023, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2021. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216437296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Watertown Lease</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. The lease includes certain rent escalations. In July 2023, the Company amended the lease to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend the expiration of the lease term</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from April 2024 to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the terms of the amended lease, the Company no longer has the right to terminate the lease after January 1, 2024. The Company has accounted for the amendment as a lease modification and changes to the right of use asset and liability was reflected within the consolidated balance sheets as of December 31, 2023. The impact to the right of use asset as of the lease amendment date was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a letter of credit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million securing its obligations under the operating lease which is secured by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waltham Lease</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2022, the Company executed a lease agreement located at 880 Winter Street in Waltham, Massachusetts. The leased premises comprise approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and lab space, and the lease provides for base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year, which will increase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year over the noncancellable term ending on June 30, 2033. The Company has the option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one additional five-year term</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company did not include the option to extend the lease for the additional five-year term in its evaluation of the right-of-use asset and lease liability.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Upon lease commencement on December 21, 2023, following substantial completion of construction to prepare the premises for the Company&#8217;s use, the Company recorded the lease as a component of its operating lease right-of-use asset and operating lease liabilities. The improvements to prepare the leased premises for the Company&#8217;s intended use were funded by (i) the landlord, through a tenant allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and (ii) approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million funded by the Company. The Company recorded a right-of-use asset upon lease commencement in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deposits with the financial institution which is recorded as restricted cash.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases for two separate spaces in the same building at 880 Winter Street in Waltham, Massachusetts. The Company refers to the first lease as the &#8220;Waltham Lease&#8221; and the second lease arrangement as the &#8220;Waltham Sublease&#8221; as the Company, as a tenant, is subleasing space from under an existing lease arrangement whereby the lessee to the headlease has agreed to sublease the space to the Company under a sublease agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waltham Sublease</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company executed a sublease agreement for additional laboratory and office space located at 880 Winter Street in Waltham, Massachusetts. The subleased premises comprise approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet, and the sublease provides for base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year, which will increase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year over the noncancellable term ending on November 30, 2032. The Company is also responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the subleased premises.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon sublease commencement on January 3, 2024, the Company recorded the sublease as a component of its operating lease right-of-use asset and operating lease liabilities. In connection with the sublease, a security deposit was delivered to the sublandlord in the form of an irrevocable standby letter of credit collateralized by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deposits with the financial institution which is recorded as restricted cash.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.034%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.762%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.762%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,410</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,966</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,924</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,168</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.174%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.265%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:71.342%;box-sizing:content-box;"></td>
        <td style="width:2.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.648%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 were as follows (in thousands):</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.3%;box-sizing:content-box;"></td>
        <td style="width:2.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,121</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,494</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,507</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,642</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,010</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,905</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,380</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion of operating lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,121</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liability, net of current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,259</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total rent expense under the Company's leases amounted to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluated the above leases for impairment indicators and determined that the right-of-use assets were impaired. Additional details are included within Note 7 above.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662316847152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Retirement Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made a discretionary match that matches 50%, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% employee contribution, and therefore a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employees&#8217; salary. Matching contributions are fully vested at the time of contribution. The Company matched </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of employee 401(k) contributions for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, which is included in the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662354695424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Commitment and Contingencies</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2023, the Company filed a complaint in the Superior Court of the State of Delaware against a former CMO alleging breach of contract. The Company alleged in its complaint that the former CMO breached the Master Clinical Supply Agreement (&#8220;MCSA&#8221;). The Company&#8217;s complaint sought monetary damages and the return of equipment and materials that the Company owned. On July 20, 2023, the same former CMO filed an answer and amended counterclaims to the Company&#8217;s May 10, 2023 complaint (the &#8220;Litigation&#8221;). Due to the legal proceeding and termination of agreement with this manufacturer, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million loss on impairment of long-lived assets during the year-ended December 31, 2023.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 2, 2023, the Company entered into a settlement and release agreement, related to the Litigation, pursuant to which each of the Company and the former CMO provided broad mutual releases of all claims relating to or arising out of the MCSA, including without limitation, all claims brought in the Litigation or that could have been brought in the Litigation. The Company and the former CMO agreed to jointly file a Stipulation of Dismissal with prejudice relating to the Litigation. In the fourth quarter of 2024, the Company paid the remaining liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Stipulation of Dismissal with prejudice to the former CMO.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216480848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2025, the Company replaced its letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to its Waltham lease, which is discussed in Note 15, with a new letter of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8e41f92a-aad6-47ad-8661-51315d4fb579;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 14, 2025, options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,694,590</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an average per share price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, previously granted under the 2020 Stock Option Plan were voluntarily forfeited by certain executives and returned to the pool of options available for grant under the 2020 Stock Option Plan for future issuance. No replacement options were granted to those executives.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212224672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, other comprehensive loss consisted of unrealized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gains and losses, net of taxes from its short-term investments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had restricted cash of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 and 2023, respectively. These balances were held as restricted at the Company&#8217;s financial institution to secure the Company&#8217;s letters of credit for its facility leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ginning-of-period and end-of-period total amounts shown on such statements. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,577</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,353</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,392</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,570</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,745</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Short-term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#8217; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OtherAssetsPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Assets</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company includes certain items within other assets on the consolidated balance sheets. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> balance in other assets as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had other assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, primarily composed of long-term deposits for the Company's clinical trial agreements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Concentrations Of Credit Risk And Off Balance Sheet Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:50%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the consolidated balance sheets and related gains or losses are reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to loss on impairment of property and equipment for the periods ended December 31, 2024 and 2023, respectively, both related to specific facts and circumstances in the respective periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also assesses its right-of-use assets for impairment based on triggering events, and recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to impairment of right-of-use assets as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> indicators of impairment of the right-of-use assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_12091721-daa6-4615-9374-7423de9475e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right-of-use asse</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d1514240-d93f-4827-833a-208926ab2d2a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lease liability</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_37e2bd47-4207-458b-957f-6e4048e1644e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finance leases</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing the Company's consolidated financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing purchase orders and open contracts,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicating with the Company's personnel to identify services that have been performed on its behalf, and estimating the level of service performed and the associated cost incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company's service providers generally invoice the Company monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to the Company at that time. The Company confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company's accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which the Company has not yet been invoiced:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with preclinical development activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with the testing of preclinical and clinical trial materials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with preclinical and clinical studies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigative sites in connection with clinical trials. </span></div></div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contracts with CROs to conduct clinical and other research and development services on its behalf. The Company bases its expenses related to CROs on its estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company's CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not recognized any product revenue to date since its product candidates are in development.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 13 for further discussion of the arrangement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#8217;s policy is to recognize forfeitures as they occur.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses the fair value of its stoc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares and equivalents outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.034%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.762%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.762%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,113,859</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,804,283</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.43</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.26</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,709,980</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,143,802</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,048</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock warrants</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,064,666</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,845,603</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements and are required to be applied on a retrospective basis. The Company adopted ASU 2023-07 on January 1, 2024 for its annual reporting, and the adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. This ASU should be applied prospectively with the option to apply the standard retrospectively. In January 2025, the FASB issued ASU 2025-01: Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures - Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03. ASU 2024-03 is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of these standards on our disclosure of income statement expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant suppliers policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216548208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):</span>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.313%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.5%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.843%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,577</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,353</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,392</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,570</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,745</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:50%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></span></p></td>
         </tr>
        </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.506%;box-sizing:content-box;"></td>
        <td style="width:1.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">461</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,129</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.034%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.762%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:10.762%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,113,859</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,804,283</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.43</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.26</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,709,980</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,143,802</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,048</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock warrants</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,064,666</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,845,603</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216435728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.609%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,209</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:46.609%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.702%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,147</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,167</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;US treasury bills</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Short-term investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216544400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value of Available-for-sale Investments by Type of Security</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows at December 31, 2023 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.04%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.009999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.928%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,881</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,918</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,486</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,482</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total investments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,400</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216538320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Other Related Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring Liability Activities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restructuring liability activities du</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ring the year ended December 31, 2024 consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.826%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">January 1,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accruals</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash Payments</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Restructuring Plan</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severance Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,713</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,953</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,760</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retention Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,174</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,596</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,578</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,009</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,896</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,549</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,347</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662354692288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Related Impairment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:50%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></span></p></td>
         </tr>
        </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.506%;box-sizing:content-box;"></td>
        <td style="width:1.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.006%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">461</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,129</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,921</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210455664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Right of Use Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock', window );">Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management conducted a fair value analysis of the Company's right-of-use assets using a discounted cash flow methodology as of May 15, 2024, which included the following range of assumptions:</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.052%;box-sizing:content-box;"></td>
        <td style="width:3.101%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:33.847%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term (years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.96</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.13</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected sublease rent increases</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of discounted cash flow methodology range of assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210517232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and employee related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third-party research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,586</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216437296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Revenue Significant Expenses and Net Loss for Segment</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.751%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.503%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.503%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,828</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product development and manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,304</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,326</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities, support costs and depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional, consulting and public company costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,400</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal settlement</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">568</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring and other related charges</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,882</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,348</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,396</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,621</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,435</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662318189120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Assumptions Used in Black Scholes Model</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions used in the Black-Scholes model were as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.67</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.57</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.93</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s outstanding warrants are freestanding instruments and are classified within stockholders&#8217; equity since the warrants are indexed to the Company&#8217;s common stock and meet the equity classification criteria.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,424,272</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Purchase Warrants were exercised related to the May 2023 financing as of December 31, 2024 at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuances</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has reserved for future issuances the following shares of common stock as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option to exercise stock warrants</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and restricted stock units</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,018,288</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">723,906</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,348,497</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock reserved for future issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662209676624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding and Exercisable and Warrant Activity</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table represents a summary of the warrants outstanding and exercisable as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, all of which are equity-classified:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.283%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.420999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.881%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.062%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.420999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.361%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.420999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.061%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Common Warrants</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate intrinsic Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Pre-funded Warrants</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Term (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate intrinsic Value</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 12, 2027</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common warrants issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,408,188</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 31, 2028</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,651,423</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,030,575</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.90</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,700</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,756,349</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,200</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_97b57973-2894-41e7-86a2-433229fcba95;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="-sec-ix-hidden:F_3543bcc5-79e8-4350-8931-cc3cab71a166;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2028</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,424,272</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,297</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,756,349</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,715</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,606,303</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.673</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.92</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2028</span></span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216477472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.98%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,360</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,176</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,356</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,711</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,887</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity, Including 2024 PSUs</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the restricted stock unit activity, including 2024 PSUs, under the Plans for the year ended December 31, 2024 was as follows:</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,048</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,332,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,574</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,199</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,143,802</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s unrecognized stock-based compensation as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.843%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.323%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Expense<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period of Recognition<br/>(years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to certain executive officers with market-performance grants, with the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.8%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity, Including Incentive Options, Under Plans</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the stock option activity, including incentive options, under the Plans for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,709,980</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.68</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,334</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,605,002</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.96</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,999,419</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.69</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,822,175</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.06</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,314,561</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210501472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock', window );">Summary of Change in the Transaction Price</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects the change in the transaction price (in thousands):</span><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.517%;box-sizing:content-box;"></td>
        <td style="width:1.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.975%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.916%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pre-Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Post-Milestone</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,373</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,489</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,862</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,627</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,511</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,138</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,000</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.517%;box-sizing:content-box;"></td>
        <td style="width:1.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.975%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.737%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.299%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.916%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,604</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,046</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,534</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">512</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,260</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216531904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.358%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.358%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.6</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.123000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,333</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,999</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,026</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,062</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,184</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,466</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,036</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,234</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,768</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">785</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">920</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,548</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,347</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,810</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,956</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,738</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,738</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,738</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,391</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662311187760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.034%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.762%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.762%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,410</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,966</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,924</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,168</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock', window );">Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.174%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.265%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:71.342%;box-sizing:content-box;"></td>
        <td style="width:2.01%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.648%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.3%;box-sizing:content-box;"></td>
        <td style="width:2.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:24.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,121</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,494</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,507</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,642</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,010</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,905</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,380</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Current portion of operating lease liability</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,121</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liability, net of current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,259</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease terms and discount rate related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214323680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation, date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements', window );">Number of leased properties marketed for sublease arrangements | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge for write-down of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfRightOfUseAsset', window );">Impairment of right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CashProvidedByFinancingActivities', window );">Fund raised for operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,790,000)<span></span>
</td>
<td class="num">(311,355,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,577,000<span></span>
</td>
<td class="nump">22,353,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees reduced | Employee</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CashProvidedByFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash provided by financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CashProvidedByFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of leased properties marketed for sublease arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211301072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,993,000<span></span>
</td>
<td class="nump">$ 1,392,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of property and equipment</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">19,924,000<span></span>
</td>
<td class="nump">33,233,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfTheRightOfUseAssets', window );">Impairment of the right-of-use assets</a></td>
<td class="nump">22,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,121,000<span></span>
</td>
<td class="nump">$ 5,434,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating lease right-of-use assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ImpairmentOfTheRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of the Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ImpairmentOfTheRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662209388960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,577<span></span>
</td>
<td class="nump">$ 22,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 42,570<span></span>
</td>
<td class="nump">$ 23,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662209760288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211053936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (93,435)<span></span>
</td>
<td class="num">$ (62,680)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (93,435)<span></span>
</td>
<td class="num">$ (62,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding-basic</a></td>
<td class="nump">65,113,859<span></span>
</td>
<td class="nump">49,804,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding-diluted</a></td>
<td class="nump">65,113,859<span></span>
</td>
<td class="nump">49,804,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders-basic</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders-diluted</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662208810208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">17,064,666<span></span>
</td>
<td class="nump">15,845,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">6,314,561<span></span>
</td>
<td class="nump">5,709,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,143,802<span></span>
</td>
<td class="nump">105,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">8,606,303<span></span>
</td>
<td class="nump">10,030,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210095584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,209,000<span></span>
</td>
<td class="nump">20,147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">23,214,000<span></span>
</td>
<td class="nump">11,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,980,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,918,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,482,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">23,214,000<span></span>
</td>
<td class="nump">11,167,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">23,214,000<span></span>
</td>
<td class="nump">11,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,995,000<span></span>
</td>
<td class="nump">8,980,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,980,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 6,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,918,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,482,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212863888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,209,000<span></span>
</td>
<td class="nump">20,147,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,918,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">23,214,000<span></span>
</td>
<td class="nump">11,167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,995,000<span></span>
</td>
<td class="nump">8,980,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 6,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210786960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt securities, held | Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt securities, unrealized loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, hold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Net accumulated unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Net accumulated unrealized losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211152688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,367,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,881,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,918,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember', window );">Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,486,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,482,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210844432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Other Related Charges (Additional Information) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring and other related charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_RetentionCosts', window );">Retention costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees reduced | Employee</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_RetentionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retention costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_RetentionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214198928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accruals</a></td>
<td class="nump">$ 4,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember', window );">2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accruals</a></td>
<td class="nump">10,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="num">(6,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">4,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember', window );">2024 Restructuring Plan | Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accruals</a></td>
<td class="nump">6,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="num">(3,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember', window );">2024 Restructuring Plan | Retention Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accruals</a></td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="num">(1,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">1,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember', window );">2024 Restructuring Plan | Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accruals</a></td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=lyra_RetentionCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=lyra_RetentionCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662213912272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="nump">$ 3,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(4,129)<span></span>
</td>
<td class="num">(1,921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">3,927<span></span>
</td>
<td class="nump">2,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember', window );">Computer Software and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662311187760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Related Impairment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long-Lived Assets Held-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long-Lived Assets Held-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662209672656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Right of Use Assets - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AssetImpairmentChargeLineItem', window );"><strong>Asset Impairment Charge [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements', window );">Number of leased properties marketed for sublease arrangements | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfRightOfUseAsset', window );">Impairment of ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=lyra_ImpairmentOfRightOfUseAssetMember', window );">Impairment Of Right Of Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AssetImpairmentChargeLineItem', window );"><strong>Asset Impairment Charge [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfRightOfUseAsset', window );">Impairment of ROU asset</a></td>
<td class="nump">$ 22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AssetImpairmentChargeLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset impairment charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AssetImpairmentChargeLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of leased properties marketed for sublease arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=lyra_ImpairmentOfRightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=lyra_ImpairmentOfRightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662213861808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Right of Use Assets - Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology (Details) - Discounted Cash Flow Technique<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AssetImpairmentChargeLineItem', window );"><strong>Asset Impairment Charge [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases', window );">Expected Sublease Rent Increases</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AssetImpairmentChargeLineItem', window );"><strong>Asset Impairment Charge [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DiscountedCashFlowTechniqueDiscountRate', window );">Discount Rate</a></td>
<td class="nump">10.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DiscountedCashFlowTechniqueTerm', window );">Term (years)</a></td>
<td class="text">9 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AssetImpairmentChargeLineItem', window );"><strong>Asset Impairment Charge [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DiscountedCashFlowTechniqueDiscountRate', window );">Discount Rate</a></td>
<td class="nump">9.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DiscountedCashFlowTechniqueTerm', window );">Term (years)</a></td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AssetImpairmentChargeLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset impairment charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AssetImpairmentChargeLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DiscountedCashFlowTechniqueDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounted cash flow technique discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DiscountedCashFlowTechniqueDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounted cash flow technique expected sublease rent increases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DiscountedCashFlowTechniqueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounted cash flow technique term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DiscountedCashFlowTechniqueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662318241280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 4,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent', window );">Third-party research and development expenses</a></td>
<td class="nump">1,582<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,586<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Third-party research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216449872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">Chief Executive Officer [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The Company&#8217;s CODM evaluates and allocates resources within the segment based on the Company&#8217;s net loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214212688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,534<span></span>
</td>
<td class="nump">$ 1,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">43,766<span></span>
</td>
<td class="nump">48,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ImpairmentOfRightOfUseAsset', window );">Impairment of right-of-use assets</a></td>
<td class="nump">22,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and other related charges</a></td>
<td class="nump">10,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">97,882<span></span>
</td>
<td class="nump">68,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(96,348)<span></span>
</td>
<td class="num">(67,120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(93,396)<span></span>
</td>
<td class="num">(62,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(93,435)<span></span>
</td>
<td class="num">(62,680)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_ClinicalRelatedCostsMember', window );">Clinical Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">15,156<span></span>
</td>
<td class="nump">20,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_EmployeeRelatedCostsMember', window );">Employee Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">22,828<span></span>
</td>
<td class="nump">27,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_ProductDevelopmentAndManufacturingCostsMember', window );">Product Development and Manufacturing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">3,304<span></span>
</td>
<td class="nump">4,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_FacilitiesSupportCostsAndDepreciationMember', window );">Facilities, Support Costs and Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">13,579<span></span>
</td>
<td class="nump">7,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_ProfessionalConsultingAndPublicCompanyCostsMember', window );">Professional, Consulting and Public Company Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">7,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_LegalSettlementAdjustmentMember', window );">Legal Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(568)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lyra_FinancingCostsMember', window );">Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_ClinicalRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_ClinicalRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_EmployeeRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_EmployeeRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_ProductDevelopmentAndManufacturingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_ProductDevelopmentAndManufacturingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_FacilitiesSupportCostsAndDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_FacilitiesSupportCostsAndDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_ProfessionalConsultingAndPublicCompanyCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_ProfessionalConsultingAndPublicCompanyCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_LegalSettlementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_LegalSettlementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lyra_FinancingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lyra_FinancingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662203629296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 12, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 15, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 02, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 25, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 13, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 05, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of common stock are entitled to one vote for each share held.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CommonStockVotingRightsNumberOfVotes', window );">Number of common stock voting rights | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,515,440<span></span>
</td>
<td class="nump">65,515,440<span></span>
</td>
<td class="nump">57,214,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Stock and warrants to be issued during period value preferred stock and warrants</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockDebtSecuritiesWarrantsAndUnitsIssued', window );">Stock, debt securities, warrants and units sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,059,228<span></span>
</td>
<td class="nump">7,059,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits', window );">Proceeds from issuance of Stock, debt securities, warrants and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts', window );">Proceeds from issuance of Stock, debt securities, warrants and units, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,850,000<span></span>
</td>
<td class="nump">$ 19,068,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_GrossProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_EstimatedOfferingCosts', window );">Estimated offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_SecuritiesPurchaseAgreementMember', window );">Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,826,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from issuance of preferred stock allocated to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lyra_CantorFitzgeraldCoMember', window );">Cantor Fitzgerald &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PercentageOfAggregateCommission', window );">Percentage of aggregate commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_WarrantsExercised', window );">Pre-funded warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember', window );">Pre Funded Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds for warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember', window );">Pre Funded Warrants | Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,408,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,408,188<span></span>
</td>
<td class="nump">2,408,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExpirationDescription', window );">Class of warrant or right, expiration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,666<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,017,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,666<span></span>
</td>
<td class="nump">6,017,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,815,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,652,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Cantor Fitzgerald &amp; Co. | Controlled Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuanceAmountAvailableForFutureSale', window );">Amount available for future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Maximum | Cantor Fitzgerald &amp; Co. | Controlled Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock', window );">Proceeds to be occured from future issuance of common stock</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds under agreement</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Stock warrants | Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,030,575<span></span>
</td>
<td class="nump">10,030,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExpirationDescription', window );">Class of warrant or right, expiration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each Purchase Warrant became exercisable on November 30, 2023, and expire on November 30, 2028.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_WarrantsExercised', window );">Pre-funded warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,424,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember', window );">Error Correction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImmaterialErrorCorrection', window );">Immaterial Error Correction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During the preparation of the Company&#8217;s 2023 annual financial statements, the Company identified an immaterial error in the Company&#8217;s historical financial statements whereby the Company omitted this disclosure in the interim financial statements for the quarter ended June 30, 2023 and incorrectly disclosed an allocation of $11.5 million instead of $12 million to the Purchase Warrants and failed to disclose the allocation of $4.2 million to the Pre-Funded Warrants in the interim financial statements for the quarter ended September 30, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember', window );">Error Correction | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember', window );">Error Correction | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember', window );">Error Correction | Common Stock | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants', window );">Adjustments to additional paid in capital, sale of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, expiration description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock voting rights, number of votes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_EstimatedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_EstimatedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_GrossProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_GrossProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PercentageOfAggregateCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PercentageOfAggregateCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Stock, debt securities, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Stock, debt securities, warrants and units, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds to be occured from future issuance of common stock,.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants to be issued during period value preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockDebtSecuritiesWarrantsAndUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock, debt securities, warrants and units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockDebtSecuritiesWarrantsAndUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuanceAmountAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuance amount available for future sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuanceAmountAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImmaterialErrorCorrection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes nature and related effect on financial statements related to corrections of prior year errors in the current year financial statements when the effect of the prior year error was immaterial to the prior year financial statements and the current year correction is immaterial to the current year financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 1.N.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.M.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImmaterialErrorCorrection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lyra_CantorFitzgeraldCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lyra_CantorFitzgeraldCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lyra_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lyra_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=us-gaap_ErrorCorrectionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662317347216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock - Schedule of Assumptions Used in Black Scholes Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">81.93%<span></span>
</td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">82.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211147488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">19,348,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_OptionToExerciseStockWarrantsMember', window );">Option to Exercise Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">8,606,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">10,018,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">723,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_OptionToExerciseStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lyra_OptionToExerciseStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210099264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_CommonWarrantsMember', window );">Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">10,030,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightIssued', window );">Number of Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,030,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercised', window );">Number of Warrants Exercised</a></td>
<td class="num">(1,424,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">8,606,303<span></span>
</td>
<td class="nump">10,030,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued', window );">Weighted Average Exercise Price of Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Weighted Average Exercise Price of Warrants Exercised</a></td>
<td class="nump">2.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="nump">$ 2.673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted Average Remaining Contractual Term of Warrants Outstanding</a></td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Aggregate intrinsic Value of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_WarrantsAndRightsExercisedIntrinsicValue', window );">Aggregate intrinsic Value of Warrants Exercised</a></td>
<td class="nump">$ 4,297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Nov. 30,  2028<span></span>
</td>
<td class="text">Nov. 30,  2028<span></span>
</td>
<td class="text">Nov. 30,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">5,756,349<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightIssued', window );">Number of Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,408,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercised', window );">Number of Warrants Exercised</a></td>
<td class="num">(5,756,349)<span></span>
</td>
<td class="num">(1,651,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightCancelled', window );">Number of Warrants Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,756,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued', window );">Weighted Average Exercise Price of Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Weighted Average Exercise Price of Warrants Exercised</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled', window );">Weighted Average Exercise Price of Warrants Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price of Warrants Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted Average Remaining Contractual Term of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Aggregate intrinsic Value of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_WarrantsAndRightsExercisedIntrinsicValue', window );">Aggregate intrinsic Value of Warrants Exercised</a></td>
<td class="nump">$ 9,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 12,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_WarrantsAndRightsIssuedMaturityDate', window );">Expiration Date, Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercise price of warrants or rights cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, exercise price of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, exercise price of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_WarrantsAndRightsExercisedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and rights exercised intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_WarrantsAndRightsExercisedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_WarrantsAndRightsIssuedMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Issued, Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_WarrantsAndRightsIssuedMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lyra_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662203249936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Sep. 03, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 09, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,605,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,348,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Stock-based compensation expense recorded as liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,716,000<span></span>
</td>
<td class="nump">$ 5,887,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units outstanding shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">82.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPerformanceOptionMember', window );">2024 Performance Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPsusMember', window );">2024 PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear', window );">Percentage of common shares increase automatically in each year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,273,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember', window );">2020 Plan | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in Shares available for grant</a></td>
<td class="nump">2,620,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember', window );">2020 Plan | Chief Executive Officer | 2024 Performance Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember', window );">2020 Plan | Executive Chair | 2024 PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units outstanding shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember', window );">Inducement Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,763,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,413,002<span></span>
</td>
<td class="nump">2,763,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813,002<span></span>
</td>
<td class="nump">1,703,002<span></span>
</td>
<td class="nump">1,473,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember', window );">Inducement Award Plan | Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear', window );">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock', window );">Purchase price of shares as percentage lower of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="nump">262,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_MarketBasedConditionAwardsMember', window );">Market-Based Condition Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance maximum number of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common shares increase automatically in each year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of shares as percentage lower of fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPerformanceOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPerformanceOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lyra_ExecutiveChairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lyra_ExecutiveChairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_MarketBasedConditionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_MarketBasedConditionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662208399744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,716<span></span>
</td>
<td class="nump">$ 5,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,356<span></span>
</td>
<td class="nump">$ 4,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214021648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity, Including 2024 PSUs (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding, Beginning Balance | shares</a></td>
<td class="nump">105,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units outstanding shares, Granted | shares</a></td>
<td class="nump">2,332,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units outstanding shares, Vested | shares</a></td>
<td class="num">(86,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units outstanding shares, Forfeited | shares</a></td>
<td class="num">(207,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding, Ending Balance | shares</a></td>
<td class="nump">2,143,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">2.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">4.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">4.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662216266208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 7,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 2,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition (years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 5,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition (years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211561488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.93%<span></span>
</td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">82.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210789856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Summary of Stock Option Activity, Including Incentive Options, Under Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding December 31, 2023</a></td>
<td class="nump">5,709,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">2,605,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled</a></td>
<td class="num">(1,999,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding at December 31, 2024</a></td>
<td class="nump">6,314,561<span></span>
</td>
<td class="nump">5,709,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable at December 31, 2024</a></td>
<td class="nump">2,822,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest at December 31, 2024</a></td>
<td class="nump">6,314,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding December 31, 2023</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding December 31, 2024</a></td>
<td class="nump">5.66<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2024</a></td>
<td class="nump">7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2024</a></td>
<td class="nump">$ 5.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662202027392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization', window );">Future milestone payments receivable</a></td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,534,000<span></span>
</td>
<td class="nump">$ 1,558,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueDescription', window );">Deferred revenue, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, 2024, as all milestone amounts were fully constrained based on the probability of achievement. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember', window );">Milestone Achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember', window );">Pre-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember', window );">Post-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CombinedPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined performance obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CombinedPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DevelopmentActivitiesPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development activities performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DevelopmentActivitiesPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future milestone payments receivable upon achievement of specified development, regulatory and commercialization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment recognition in future periods to settlement of obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211214144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreement - Summary of Change in the Transaction Price (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember', window );">Pre-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">8,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Total</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember', window );">Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Total</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember', window );">Post-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">11,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">5,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Total</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CombinedPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined performance obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CombinedPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DevelopmentActivitiesPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development activities performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DevelopmentActivitiesPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment recognition in future periods to settlement of obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212964896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at beginning</a></td>
<td class="nump">$ 13,794<span></span>
</td>
<td class="nump">$ 15,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized</a></td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at ending</a></td>
<td class="nump">12,260<span></span>
</td>
<td class="nump">13,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember', window );">Combined Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at beginning</a></td>
<td class="nump">11,748<span></span>
</td>
<td class="nump">11,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at ending</a></td>
<td class="nump">11,748<span></span>
</td>
<td class="nump">11,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember', window );">Development Activities Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at beginning</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">3,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized</a></td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at ending</a></td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 2,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211307024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating losses</a></td>
<td class="num">$ (93,435,000)<span></span>
</td>
<td class="num">$ (62,680,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred tax assets, valuation allowance income tax expense (benefit)</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">84,810,000<span></span>
</td>
<td class="nump">59,956,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">24,800,000<span></span>
</td>
<td class="num">(19,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation Allowance of Deferred Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred tax assets, valuation allowance income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 23,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">offset future income tax liabilities and expire at various dates through 2037 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">147,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">offset future income tax liabilities and expire at various dates through 2044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State jurisdiction | IRC 382</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=stpr_MA', window );">Massachusetts | IRC 382</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lyra_IRC382Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lyra_IRC382Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211559520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development and other tax credits</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="num">(26.60%)<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange', window );">Loss of Attributes - IRC 382 Ownership Change</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662211301072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 41,333<span></span>
</td>
<td class="nump">$ 29,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">7,975<span></span>
</td>
<td class="nump">5,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">9,184<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures', window );">Capitalized research &amp; experimental expenditures</a></td>
<td class="nump">24,975<span></span>
</td>
<td class="nump">19,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3,234<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">88,548<span></span>
</td>
<td class="nump">67,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(84,810)<span></span>
</td>
<td class="num">(59,956)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,738<span></span>
</td>
<td class="nump">7,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(3,738)<span></span>
</td>
<td class="num">(7,391)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (3,738)<span></span>
</td>
<td class="num">$ (7,391)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and experimental expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662205056608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Initial base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,924<span></span>
</td>
<td class="nump">33,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one additional five-year term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,410<span></span>
</td>
<td class="nump">$ 1,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember', window );">Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_LesseeOperatingLeaseExtendedLeaseTerm', window );">Extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Payments for tenant improvements</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_NumberOfLeases', window );">Number of leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember', window );">Office and Laboratory | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Initial base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PercentageOfAnnualRentIncrement', window );">Percentage of annual rent increment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Payments for tenant improvements</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember', window );">Office and Laboratory | Waltham Sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Initial base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PercentageOfAnnualRentIncrement', window );">Percentage of annual rent increment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of Deposits | Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Waltham Sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_NumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_NumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PercentageOfAnnualRentIncrement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual rent increment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PercentageOfAnnualRentIncrement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lyra_WalthamSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662213849296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 6,410<span></span>
</td>
<td class="nump">$ 1,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,514<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 8,924<span></span>
</td>
<td class="nump">$ 3,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662212885248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662214426016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturity of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 6,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">6,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">5,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">4,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">4,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total maturities</a></td>
<td class="nump">42,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(8,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">34,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(4,121)<span></span>
</td>
<td class="num">$ (5,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total operating lease liability, net of current portion</a></td>
<td class="nump">$ 30,259<span></span>
</td>
<td class="nump">$ 21,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662210449984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Company match percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Match cost</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Maximum contribution employee percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662414773632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Remaining liability paid to the contract manufacture</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45662213430784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,605,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Average per share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember', window );">Waltham Lease | Subsequent Events | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">New letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Letter of credit expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember', window );">Waltham Lease | Subsequent Events | 2020 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase</a></td>
<td class="nump">1,694,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Average per share price</a></td>
<td class="nump">$ 9.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW1,>,S6:10@>4]H>N$-I/=:W#O;&^*[0+(DUH(TVT$;[0;N)10A]\2?!'-W
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M!W"B/KFK'Q3?F<.O%5>*E^8V8S1E0AO _QO.U?%!?Z ]/UW\"U!+ P04
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M:&H#\?]E450O%_4;3ON7[*;_ 5!+ P04    " "Z@6U:"K@LD7("  !N!@
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MDS38;MRTP \"*)N ^PLIS3:P!W2?F/0G4$L#!!0    ( +J!;5IJ70(X@@<
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M+BE)*-<"ZOL%8W+S03^@>?=E_C]02P,$%     @ NH%M6M<(VI]+ @  I 4
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M5K]:7)I>O;L>;G_R %+@&*9(PN9@ZCDG\!U,VE\1[(T6N>FKSX36(C67,:/
M+@Z ]W,A].H&'52_Y8S^!5!+ P04    " "Z@6U:6+UR0W4$  !H#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RU5U%/XS@0_BNCK+1:I-(F*90"
M;:4">SITZBT"[O;A= ]N,FTL'#MK.RW]]S=VTE"XDJZ0]J6)DYEOOOD\,W5&
M:Z6?3(9HX3D7THR#S-KBHM<S288Y,UU5H*0W"Z5S9FFIESU3:&2I=\I%+P[#
M02]G7 :3D7]VIR<C55K!)=YI,&6>,[VY0J'6XR *M@_N^3*S[D%O,BK8$A_0
M_E7<:5KU&I24YR@-5Q(T+L;!-+JXBF+GX"W^YK@V._?@4IDK]>06M^DX"!TC
M%)A8!\'HLL)K%,(A$8\?-6C0Q'2.N_=;]-]\\I3,G!F\5N([3VTV#H8!I+A@
MI;#W:OT[U@F=.KQ$">-_85W9]L\#2$IC55X[$X.<R^K*GFLA=AR&X3L.<>W@
MA>A5@3S+&V;99*35&K2S)C1WXU/UWD2.2[<K#U;36TY^=G)+^J:HX5&SE,LE
M3+5F<HFDNS6CGJ4(SJZ7U&A7%5K\#EH?9DK:S,!7F6+ZVK]'S!IZ\9;>5=P*
M>(-)%_I1!^(P/FG!ZS?I]CU>_QV\?6EV8+Z!6YGR%4]+)O9E78&>[ =UC7-A
M"I;@.*#.,*A7&$P^?XH&X64+Y9.&\DD;^F3&+&K.!#RBS@VHQ;Z]VD>Z'98=
MP3<),Z:3# 9>W],.V SA6N4%DYO/GX9Q='9IX$HQG;JP-UQ3*REM@!6%5BM,
M@5'LU(L(5GEOS NA-NX1L*7&2F&J:9L!,@KE<'07[IA@AI/T;O&=/1G*C\D4
M9K2\9BLF.-6DS9B%7*5\L?'8;@8Y@()5 >B6B$+"3 8&5TAJ)%AYF9)B2:*7
M CYC4KK6)_L%3PAWCHG*T0!A<"O(A+AS6=%?;8'A!]4"179"TP90ZS$_1NC=
M2XX=Y\>21.G4Q_9Y.AR[W:N,TT5#1F&I- KT0VBO2AU8:)43H+%,B$94!J+,
M"S<UX0LIU-DRI:SQ?VKZM+UB/*GHNO!2;)KM>;8N:.$2LI92+Z7K_H=Z1IZ$
MYU,'ZDQO)24A:5_NG2BE*XP4C[HP/X*;4GM9W)YPDY -B:7)G"2EO@?J6LSG
MM-QV+G1 *NGYJE)#VE0221/4VV("2M"XB4J5FKHT[TN!$ W8<?1E<50S=3&_
M/B>9*WR8)O:(#%U=N%3,ECI+5>'SZ;P6@Z*]V4H&KL[C\+**%<Y/CR.P=7^Q
ME_[R5M&E0Z@=*)_C TZ=K1>E93-EMF7!-+Y*$Y>EJ!@]'/_1@5N+.>W$L-LR
M/$Z;X7':VN4WNTI_JX6&?V9^>_[=-S5:\3XXZ@8-V\&OF,Z#7T#YK*%\UBKP
M;@GLT(:I*\&W?X$5W7; !1,&6X@-&V+#5IP_W]3G3Y)K!SU$[KPA=_XAU1[K
M[MS/K1WS$+<H?#D2A1^6KIWA >"#%'=.;='/"KC+;N:GW3O<VA$/<HM?N,6'
MY(./\&M'?9=?;^?PFZ->^B.^@425TE;GX.9I\QDQK0[/+^;5-PB=AI;T_PL"
M%^0:=L]H&.KJ6%\MK"K\47JN+!W,_6U&GT*HG0&]7RAEMPL7H/FXFOP'4$L#
M!!0    ( +J!;5H\I3,X$0(  -T$   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;*54VX[3,!#]%<M(/*$Z22^@DD1J=T&LQ$K5+I<'Q(,;3Q-K?0FV
MLUG^'MM)0T'="HF7V&//.7..XW'>:_-@&P"'GJ10ML"-<^V:$%LU(*F=Z1:4
MWSEH(ZGSH:F);0U0%D%2D"Q)5D12KG"9Q[6=*7/=.<$5[ RRG934_-R"T'V!
M4WQ<N.-UX\("*?.6UG /[G.[,SXB$POC$I3E6B$#AP)OTO5V$?)CPA<.O3V9
MH^!DK_5#"&Y8@9,@" 14+C!0/SS"%0@1B+R,'R,GGDH&X.G\R/X^>O=>]M3"
ME19?.7--@=]@Q.! .^'N=/\!1C_+P%=I8>,7]4/N<HY1U5FGY0CV"B17PTB?
MQG,X :2K9P#9",BB[J%05'E-'2USHWMD0K9G"Y-H-:*].*["3[EWQN]RCW/E
MC3]>!@9],I1Q5:.=%KSB8!%5#.V,KH!U!FQ.G"\6(*0:B;<#<?8,<9JA6ZU<
M8]$[Q8#]24"\RDEJ=I2ZS2XR7D,U0_/T%<J2;'&!;SY9GT>^^?]91]\^>B"Z
M<2#M]W/G,%19G*\2FFIM6UI!@7W76#"/@,N7+])5\O:"A\7D87&)_9\];)AN
MW=]_89!_N8 S'9S324ZNG 13Q\:RJ-*=<L/MFU:GWMT,5_9W^M#XM]347%DD
MX."AR>SU$B,S--,0.-W&"[S7SK=#G#;^_0$3$OS^06MW#$*!Z44K?P%02P,$
M%     @ NH%M6HX/ L"Q"0  -#$  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL[5M;;QLW%OXKA H4*:"U+.5:WP [B;L&FL:PW?8AV =JYD@B/#.<
MDAPIVE^_WR'G)GL\MN(6"P1Z2>9"GLMW[M3X:*7-K5T0.?$U33)[/%@XEQ^,
M1C9:4"KMGLXIPYN9-JETN#7SD<T-R=AO2I/19'__S2B5*AN<'/EGE^;D2!<N
M41E=&F&+-)5F?4:)7AT/QH/JP96:+QP_&)T<Y7).U^1^SR\-[D8UE5BEE%FE
M,V%H=CPX'1^<C=_Q!K_B#T4KV[H6K,I4ZUN^N8B/!_LL$244.28A\=^2WE.2
M,"7(\5=)=%#SY(WMZXKZN5<>RDREI?<Z^5/%;G$\>#<0,<UDD;@KO?HWE0J]
M9GJ13JS_5ZS*M?L#$176Z;3<# E2E87_Y=<2B*=LF)0;)E[NP,A+^4$Z>7)D
M]$H87@UJ?.%5];LAG,K8*M?.X*W"/G?R?CTE8RDJC')K<:7LK?@D,]@#R+NA
MP%+I:+X6,HO%+WI))I-91$<C!]Y,8125?,X"G\D#?,83\4EG;F'%QRRF>)/
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M5[^X4AK]+TDN6HA/R@?79:%SVI0+\8/%'W%E3:8<'&AR<2F]]L(6XJ-37IG
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M <%/28 + 2>']+-R>.?=%0-(]E*X'R3=P%*M2MQ.>#">2N9;HB+E&G#S7%^
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MRO[RYLU'P,YO0P7, E*M 36 @[.^A4]?7.8"& ABX4%U;/BD^E4!F%HN%:\
M8=OAVL4ZT!*,=ST04%T5\ZJN>D!DGKFOH,^\S-BYF@ N*[^H6S]TM'D $[&/
M@/ 4--;,DA6\*.Y6$7(_+$^!&2 J@5[AO.)VB 1<5[5 =[^ !@/L-]<M?@N*
MJ(+-3)V$0:.[*>J!T(>L$Y"9 Q=5BU7@P?D &X6M PED2.D('YV 3A3F_N=0
M7O-F .[.W;AF0%@7+5 OGDN>@;6 A (@U@Z49=:A5CQNE\<#?- #&0]*#@AH
MMQL  D5+GO$NA/C\"D ]1D4,2-P67:F(+>KJ6QB%^P7=[+H.]U)\E:5GV?<
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MZF S=' TGKED#JR/$+@(@0%N_%/@.?IAY6J2YO.B^8*$)C)!OX:UW0Y@ZKX
M9I9#4^(8F#3=1NGF?>99V55.%[=K(F^3'"I1<"U:WZL$ &W4M5]%Q,I"R&UN
MEGT"W'35 A^B"2U65P4R7/B=]H+R-LX&X/TQ.YN=@,E:UV1] ]Q_S$YG%_$;
M$B*WT10LL7%DM=<[4KQ JD$[;U'=$:8*;X$1T3R6BE$B ]GU53^0I(#S(\RY
MR6=JU_=(.J@20(Y4< A !TB4RV*!\FK'\LO/+';"XT;TXPR(I"7X0)$&QB@D
M(EP<)!VB/12V#2XNB@+([[IJ&OB(0I:5!3-]4YIO^K:'K2N! 4]M49>PJ(MP
M@GD4%TC4/0*3[X&4B^A-MQ%T'.Y'#))$.\H99N2UB"H'S:YRF6&5A7VQ=B.X
MIZ8\C&N2JTLP&O'30WJV'3S [1^]>/ /D&[LG#P@VD.Z>W"8>?^879SD3YX^
M1=H^R\^?G#_X--K[:?[\^3G\>_[\[,%GV@<\<P;/G. SY_G3BR?9591H[XT(
MLG\C\Q,W%O/:&>8F5E[4H,S 6'1$^L5-4=4X[!B(\]@#I'"*>]^-YU@#W0ZH
M&U.C!"B\J#H6 =G@D<A^&UK\:0.[9%7$?K3 YXDE/!@--6#22J%?[RWJ41;<
M"7"$$3[#CV2/.E(X("4;FNZPDIR!Q^+6U; F28[6'A,4:1F82G:,"P&M@>'U
MC85[5!'(M"V08GOC6#'6U3+8?B":75>3L1V?8%_C@+E\]X;#"&4+%;Z(<#2F
MT)X>.C):Q)X"AH!%$3]L#B3V84(V 3"?KNO#E&+XHL5 ''.]8G9D-6+UI$>T
M5$U9W50EVDEF/C250$#! 9$=@;@'[*+0VK5 #22_K"P@@WHF'J3G,XVS ;>7
MR,^E0]ZIT %$TLE02:#OE(&B!\-]J>Z5V,C1.IP@14*UR&/2N6S'R&$_%!OT
MT4%1ELJ=> XL/_:LH411H &-0:;4$('A3FG,,".JUR:A1\\6B9AQEG )=Z0#
M;A E"SZ>!2EY]IOL3-&%*[J.:)C%;<8>)BD$ (A(4=" !%;XMJ'O1,,@/55K
M.+WWY.<U$G5#=#I\+"7&Z)G AL4<!7_*+3 N@>=@MKYB!0\$C9X5<JQH8SE"
MH"H^-=#*?=O!D:O5ITK2?>W%JV2SQTR>H#%%(9+.+ACAPH7BMZAVTAC#?(=(
MX=_ :6H6.R:\H@34>2*:LF+*4'(M,(ZA#JC,KO.1+8C+V'T!:I?L^"-S>B]B
M*3U9BQO8-UC>XB92/*KI(SD9)8EDONBC/0O:DC^K@Q,W6GDBZZ*+0(\(C]AN
MC""!_5\$XRY:5TZ?V#R?0H,BK]V2I$'YF1)0Y8G(NY(ERAWV2AY\Y/E.@4%V
M(?R/N/9>@(/,!CJK *E5Q]$/G"EP7R 0 5J@!8_[FQ59$Z[7/57EGX.2?!<=
M3@+V%IRQ3A:DT4)@^]]4%*O'T0_A/PP0=)YLN4>CHR&QBNL KX!LJ8590*I7
M&'PE"R/$1?YCPO=#A!W8NKM&T$DC]*/]DJEMY=7<U17LQFO@@$F3HQ8[$<Z'
M=;JP3;/$ RY18-$"KJ*34Q,;!H+(0MEZ770E&Q,DMPB5%"33X)C'. ',N79@
M9OQ"L[QAA6WU2P@Q:)01%E@'=#+9B)Z_F^QG>QY@TX8AX^D.^7;[DZ10+,E'
M/+W#1SS/<K1'P0*MZAW3M>?X0@U"DRWK$NQ%7XE]:D[RSX -T#$H?C.PW)'R
MKL'/UZ "N#[PE](1QK:9;#]5_@N1U2_+Y?%;V?45V2STTX^)>]D-3)7$R)L6
M#[$B<0\DC?$62UG(V'NK"K-T.+4$4,R.56I.^BCXY:&8B44^)NQZMH:0EGI_
M>,[\EDG)W]ZV%+5#F)/@IW&U89*J"8X<(<9]73@<[DJ4 #72*_LD)%_W" [E
M81(G;^$H4O.1\$4^+?E\G8/1N R)-0KK8EZ' I!DG-AO@A$Q?FSERFM2ZUV'
MGP65-D-R-6!0'R,%"?>AI;K!R!G"2B'[KCP&8=PC\IL!M3ILMR/3PN,4.Y2A
MY; 0JD5-670+/I,2I$_=;D@ D ?&-C$QM<?GKKMB[<GZPB6JQ0 .66IS=2C#
M)")(FM8+\8'5PE'1#N,V;%.OD2J:@=@.Z.T0P$"D%+6H*,T19%1DN[(;KG5;
M&L1O@3C(E9-<".W5VD'>F1U]3CX#O .X 6 >B&D%0' :@!5RD9 (97JZ@4];
M5(A +E(7@U4H!@+X&OK6[?Z.7<RR'U'U_TU-FR@4WANA\&-B'I1N29Y,X<4\
M C>;V6.K&P4UZT"'E=FPP9 -ZA51."@UD7+!<F#48>07 ]-%"*FCZNJWF,22
M\!Y31P44P<Q;:"R 2(L=L#=7[[+/[09<JF=G)[G=U4]QK,\>HNMP=O(2A\-
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MY8#>OY:(Z+$A@&"2 CK;)I3P]B^S5;O%(IN<JS"%PC U2N9%E/1IYO^+,]U
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MQ*V3^J%O-S@EQL+[=DU_KEP!)(X#X/=E"W0I'W"!;=M](?!>_S]02P,$%
M  @ NH%M6H2)^8E^!0  $P\  !D   !X;"]W;W)K<VAE971S+W-H965T,34N
M>&ULU5??<]LV#'[W7X%S=]UVY]BR[";.+]\YR;KE;KUF==,][/9 2[#%BT2J
M)&7'^^L'4(HL.W::/NQA+PE) Q^ CP $7JRT>; )HH/'+%7VLITXEY_U>C9*
M,!.VJW-4],M<FTPXVII%S^8&1>R5LK07!L%Q+Q-2M<<7_NS.C"]TX5*I\,Z
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MI<KPLD,=$="OL'/U],GP=/#J$<*3AO#D,?3_D)K'<28]. X%GPJ$6U<NE=U
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M@XWH^*%JG+9G%:/7LRJ*>G-=[;+.!JE!(TL9AMZQDVE_[P)1(L60KTGL'?5
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M$2 '5+FT1%6U0K15BPR[6(K+FT^<7Q;UEBQQ+2JSUL)5NJ$27,*W"M+[CLC
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MR.[PM[<-5&\K72"=!<6LQAR(DF1*2>GY/C@U>JN4.^$>^;2^2Z& K%@Y*2A
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M+K0?!%T,L>)FUL=XLS<3@^S9-6F$'3W$\'P\:S?Q-61Y8"%O,BJ?W>)U/'&
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MAIXK59%)/B$0XB >D%[0'\;[$_>H/ZV<';CQ->)...A%WJCGCT:DYO4]S^\
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MX:!?SNR$6P(-Y.9-<FX'K H>6.C?'=2H@Q]%!.7TF"/4C6<=BR<;\2O+M=0
M93;K&CQ%?LMH$Y])D<C,0DN&]WBC$#Y8P7_F1HGL?-C>'4?Y.HTL@L\B3Y(A
MQY+E%_$2!>,]7BAZ]"[^,"_0R7L$6B?!$;M90JO8BF$TZ4 /9ZJG>0SXF_3A
M4N3 - B8B+A;S8%K/S@.Q-NJ\"B4,-:%Y>V!-)UHJK)$Z2.B*[[ HP>^QZ @
MN=,G%5<$@]K8_?$RM DA>13;HP[7OLSM8W<ZZDC;,Z:I=G$ '*CPCOZ;LP3K
MH86BMA_'JH>02K]-R'Y@!,0$S;5SBV\V4#URO,:E\@2NR3QTYW7J3">,H \
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MKI6$ F@!GB^-R:L?=$#]IQ;7_P502P,$%     @ NH%M6J^G+?X["0  EAH
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MCA7H?&UM.&S8P?"G8?$W4$L#!!0    ( +J!;5I%T23U:@0  $P*   9
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M;,E-DOL+CP(O)E'@(X 75'^<%]<T=O"3 XP?_&#4Z+@W&;),_SL!&25FV";
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M#72$KF[@R%4Y5I'MOG;BI6#MT P>@3$&(:+.WEM30H5B!ZNL5&_:8H] X=_
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M,6/W<)!X%2LRFF?W&,WG28HJ,2C!1;EGTFK95U4"WV;E/@>5M2U$13;(]&\
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M,T)W$]K.FSJORWJMRI*&,3JWW%3%'SU17!UY$/7X#6VUAIW1?'P,,6C("V1
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M!^(M(ZC@+Y?S>OQ,AXIG@)*OA;MWO:?)+P>P#880SF4T^Y'.[.R^U3Z#2_2
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MX;Q&L^&N:&98/Y9ID2:+9?DO2;*CMD A5K+W0PN'5G5,@Y)2.*+4W'IL]<Z
MD%\WH>7$8Z@.91ML8E+\J&,NE]XMC+%2+#/HR!,JZB.--8#Q/KB9IGO8CHG9
MY @;'GO71&:+0;X9&Y"& +.PDUBK&Y<?:JH>V)QQ:<H8E46A#LT%&'L0,4$)
M+%5/&6U\5Q<,6B(+3+BC%%[XX#4,_TT4"!N6/TO3#TR$[3NL>M9*\U'%4Y.:
M;*I[Y5L/!?AQ3!>.A]JH,3URF@[&L=D\XK8:5IN@&RY^R?9:MC*3AI=;]K#
MBF_P,B*J;)E?T2/S@7Y!70=0BI+Z_E[8-K6^CUQ%;]3$0][(8[POLNIM4?N7
MS"/$./3W=]6JS+9;EH[ON6\C<5AY(&5$IUT=N+)@FO_^>#*?4:.)?Z<"^":Y
M!KF=)8^QSK*DI>+G-/D/;-?Y7_"_-/F4%7=9Q>#X)5MF_9,TN8$#V\#O, A\
M +S/=K74R7[:H..K@L.[<2[Y%6^OF9T38UWU3<?]'5JP;5H3+# D.U4L- _-
MK>?3/:F/I@%?H]$\%B.?'O!HA_N)6>)<9*NX<A[@\6SQHR\>Y!>"H.6T&ZY0
M)7G2IJ8Y%$ER;O/5IO?EX(4K3V*?:/B>^FR*4H"<#KZ.2L+3N-@8#2(MUTN#
MN E!^]':3^YE&869CN?F2-U1R+P#S$2!;E(MKK6L5_/?QY-[@@8ZR 5,AQ4V
MGHFA S.Z'48D'E!O*QF"VUWI_-TQZBGJLO8++.R#S5;J.)\NSC6*V*5-O;,!
M&ZNZZH41([?$@.S&"F:^D2K*1$U]8Y_I2N[Q:X5:GZG%8;7I#!CQ6OU:5P]+
MWQHH#+9-EW;:X/0MTT?\H9E<_H8>;F]HZKE1[I@O0I[4@&:MTBO!*QH7BYP;
MYUTK433+IS@=BK=(A* 'H.[;*5!&&3A\&1CNC0I;"])KF3"$) 1UHOOVM$_=
M()'3!+#Q9$INNV,; 415+[9U[OW9T1&SLS#@85K-!V0\"#X1O7W*SR#(] \N
M%O>N3!(I.7 >21>GSX*848N=R""HLG+_IVL#_?I\-\HJIK,4?A",.J(K*<,8
M4+M6[TKN]2 E5P\O.')O1AS;[<#70-4 63Y:N:8[]!><9)%GBN$[O-;K37RY
M%#<I'#*.H4EO+IOZ-/+S!M3=NF$A(XF=80=QCMWQS$3>D2_7F,Z8FX?&P//I
MSKX?LFY:#9A\_4CS%3-FA,X>X7?\A+T6T))2Z=:Z34L;(J+EF@,QS/Q3#^DT
M?>]%@7^Y-\?4(81^OO/I?K[FNDPD\!M2*MZ2J+LV2L7H^?Q31H[M2;V84N_F
M.:KDC-RZ&C(DG\V>I]$D1 _S5[2&>':;(0FOF4M6^8L0[$+WJUV.K6+$*%*]
MITQR+(?T'YGO4M>TNC%"TQM-4</R R'_%U$B4E$*D-I-IM6UH37$P(*/?:=Q
M0S3-?J)QG.TJ]+;,  XWRTU-SJ6=MX=]:S2NJ"%XR\\T"L, 96(,HPAJO,*Q
M.4[B.7K-8@LIE]P=[>7(;L8=HMMM+7?9I8.P3(W><ILR\!=>UIX"8Z]9H(C<
MPZ[()ROLIA:URPLQ4[KUB5P=]O*Q;YU2_4,'LD3'(G76::L^3 J2@FC,M7[W
MX3=$5C"ZSV*IC5I3D#?E7IR%B!>W>DL 2W=@LW"VK7X3PK967%4YUZC'9X']
M/*7V!/M 'ZZ :8"+Y+#%5+!^QDZ6B<Y,&Q][%IH+,#M?-W6_(P]COP#Y810]
MOK%0VORAV80*18/Y"TLN=.ZLK@*4O7:21DT.$:.<I=REJET6>L%*#^($>\:"
MJ8[=P:IU1U>T@8RAP7CY<BV(+N%6RKW\W0E"5N-[I3:IE ;%]=>1936XAT7*
MXMN><-2'QF-,#''JF-]($FWH%YU1)^7.5MARG" #(8O-OPH2U]X+9]9O^PR$
MFPUP+?$I:D(9DP&[[18.K^$QMR5QWT2<.*Z3Y+!Q.G#%FH02BC*K&5/5U%F)
MTM0BQ/&(0@YR<=MWE!R'ICHU6VS[HI.>FG*(?NP["IK0A:>:?T)_$A9&F6^^
MA7*/ /C3F(^AM#X^$L]%6Z(WVI2$H]F@U&N0Q=%\\],U&BRKE;UK^VU?HKI=
M@35YFLS.GJ7)#=W.R@)?K.N$?&(>QT;0!CG>4.Q8^4HZF?'GD@IK\,1@AT]1
M)=R&04(2K[EBB$.@U&5:(AZF3/Q@?9K\:I=<2)Y*\/P>BCWA&Q0?P NUT7Z+
M8Q+#VB&,6P,&=D.%/"3>8K>NMCM1.K=YOUC(>%MP!1?*1 PH"P3AI9W'@I_'
MH1T)XT%K$$8J7\?ALTBM^+'W\FJ00K;+X/:AG4F6<4PJ6M<U'&Q##;3VIHFD
M4(N>CM[W:O-X1L5F)"8'1QV+1+Z)$);K(X!_NJ8>GBEYR>G&+7+)4+\Q'8?5
M'KDS05OP[,!:)&$!4",C<?"*;P@4%(]QLX^N,:=4/JZBD1H+@/O*%=PZD=>Z
MU]2)45OI4(E2G3P95<KE$N:'*\3W=R(A]1LKA6WS DK>D'02VQR 6+_*/:TK
M&_%I* :@WNWUU(D-F5):$Z$9!F3]U!37,<G>49X0*G$<$+>UJV$0DV1PFOPR
M=H&WJ76,QLDF%V>3%R)7ID=Q#C%)<&ND\-3FWIG.CNK&H [44S9IN'1C/GWI
MQCN^(N\37N$X:GA^PUT;=LP)DY.?XLLC@[D3&GF)7)RV/B] ,8[FBXS,B[-@
M9.)"E+>34L*17:*[0P<O*^[9U_@>M".=J ;9IA5W@,1D3W&TAKU.-;-B)3HR
M_O"-,KN3#$QS0=R@:2)K=I+U2%T!?6TX*5-AXZWDS+A3NG)!:$^OS!)7;^C3
MG@X2IXC'@18M]VP<W/4^R$4+A<>D=4G&#Q7\^J:4UOD\DJ01\A(X(\5#DJYE
M(A*A^C.*]:,L"M^3VW!L7I\OTX*Z3SETIUH&^F=\7(/!S-41K%=BQ*:+=NN[
M;$MA\^79_]'Y;4:5;-K<U69#QGC%INDX/QJC$$O!'S2I"9QX"=_Y1N$D=.YQ
M886[3N;3=YW\"B=,=]K#Y*QUCC*-;[C:Y'#D@S"![X$M/7@EU!WE8^-SGHZ0
M=I>^73:-S&K]8L^2OA"-S3\B:O>=0R'I\I,,<P$!H.%F'54(<)S6=^;4^Z8P
MY*!UXW&?3HYH8]W18>J-O10K+\J>6W:86WB'D/ [I*?AWVB/=HE)MD),7,-N
MQ0D:Y?&BHVUT]FB;UIHV_=5\*Z;8.W-'@;ENZA$+IKP/J<&,T8:7&DXHNN<)
M:XZ<<'$"&X(3ZKP5!4O%%A<[ZJ3;#)O0&9\ W=\=+J7UEAR: 0J$T^2M6V;]
MX(JR"!,5[H?8F$ID,X1Z8\P)[1!PRA.=,V6D345YX],=8&]XE33I#/L'O254
MMR^-H/U=%GD=CMWO[6$H&%3E9@RT\(Y= /XK*.G4A?SE=[_J[']+'B<OSM.+
M\\OD"7VXFJ=7S\^2)^$1,,[!Z.T[K2:SN"*76TX,\Z.K*!60IOW'D' CH(MK
M>G$ JZO+=#8[3Y]?OD@N7J3/SR[2^?/SL,"P^P<L]>@DN.K9Z<6Y;&!V.K^"
M/S]%+E6]*9QU)#&@[F$/R:!=F31.M$W.XTY_$QBR4(2/^CAN8_KPR'H$#6ZL
M;9=<I>>SB_3R:I9<IL_.7J0OGI_9V]^9G/L*V? \G5W *9S-D]G997IV\5R&
M\ASE>8H5UN=GY_! >G:.=\I?RG7QLV?IV=5%>G5UE<PNT^<7E_#H^:30"W<8
MS*?O, #- . /P'\'9B@LV;AB/C1U!7]SV\IQ!?H;KC5X\(3)SW3$Z"A$O8M2
MT2IW%U7YQB]0!AB/*K+NYS<W;\--$%R#U6 E:D?O+^I<$VVR',[4'5PX$@R4
M<$\&7Y'SN>(+4SIM3"<I4&Y0#V"N956?'_S /+M16,BJ=8&#3&QL^<6,'HG#
M%RM(78XOFM9QC^9LCV5]J Z8^GAQ'"&J&]/?G'R.O^*U")0R1_VW/9AE#V]N
M/M,O)^2[<ZRG??36W6.V;>;/SYZ\3-[92Q;@D/DQ8A/ZYH]\V1.Z&J1PVI^B
MCZCE_AG*R#$Q]]:MXS0%4^J+&>D-WW,H5<?26NJW'W]A$3RXVX@R*[UT--=(
MZ2PP$N7^\D4*J>E=PFD3Z/_<V9:DE%C:AHXB@J8R'%]<(HX7."WFRN.3A5Q=
MK%1BL:8C"P)S:1MVS((-:DV.JW)IH%>Q[YRK!;DR%:"FPY+GK-CZV0W(HZL6
M0])1J/Q<.._8E+K&KJE]3JL4-D:FM-"B025\\S\SL#V;?:+]S36VRS9I\""$
MP!0-A"#0^V.&)!/7L3V09$(TE>C!-T>_CQY>#*UY;^:/D$)XTI* \5;Y0F'C
MD7;5)O/<$#5@AHPQ^7)+3B/W<WKB(BZC'2G)S@3--2NX"BZ$2PKMU.QG(->J
M8JSVB@,V>H?W08MC,R;8R%E"'D[X/5NO,10C+/EW4 ?:O%C*:.;B>;ME:?RH
M6\#F*9YK(K+0'2^ CNNBH@P;-A_\^8%H#9<+..(-'H$*4B2V1=<-K7ET#+/;
MM=P/$Y8"IX]@&S?JSF*.<&]N7H6],.JNJCMWR) OCB+@Q<G9N4? &QV/<'WV
M*O#GZR@;@!^7AZ3=+N*CG@ZNW*!G\OBF7W3,X.=G)X38@Z=AG\,U^#Z^BMV6
ML1L\&,6:X-0*R:%FQR$>(MX#Z[)=9GJSHB]:ES/Q5WVOLJ6Y*3">\97T>$LQ
MDC2V9MFOIJ@>3$LI@4&OT&O*V&-B*#6Z@TR/WE\=-LJ72%(B'-J-UVZ%!^\"
M\RWW(9(1^E9K)-594=O9MPCME!T#I"^/8MWER=GLY3C6S1^"=?.'8-U)<HTI
MTZ$3RT^>['^D$BE&JR4]5$1N-VJU(O61!FUB'#I@)!*T7Z %CTJ@#Z]2H@4S
M7?55WL=NKJ3 0@2LOB9'OH)MPF /XUS/I+)@P+L,X_J'8V?L@QA6ZXQ"BJC<
M-P^GP3'CY"DU((8CR5Y_#\;TVEV#3* $Q0KL!\SW\]^B1Q![Y;U\,W_T%-X,
MC[_^?@>V[R]9L\9&<J5;P:MGI\_ $J&F0?H!N! .B3E"7;VE/S<N QL6'X#?
MD8[T TYP5S=?:'FO_P=02P,$%     @ NH%M6K$A0,75!0  P@X  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&ULC5=M;]LV$/[N7T&XQ=  ;*QWVVD2
M(&DR;$#:!7&[8ACV@99.,5%*=$DJ3O;K=T?)LI/9;K[8E'0OS]T]=R1/5]I\
MMPL QQXK5=NSX<*YY<EH9/,%5,(>ZR74^*74IA(.'\W]R"X-B,(K56H4!4$V
MJH2LA^>G_MVM.3_5C5.RAEO#;%-5PCQ=@M*KLV$X7+^XD_<+1R]&YZ=+<0\S
M<%^7MP:?1KV50E906ZEK9J \&UZ$)Y=CDO<"?TI8V:TUHTCF6G^GA]^+LV%
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MV;BW<2,-OK2N6N*O#2@[ <>W4II#PP;H?Y9F_P%02P,$%     @ NH%M6M;
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MP'4']7S-F#S<Z &J4\+9?U!+ P04    " "Z@6U:AB-,8Q$$   C$0  &0
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M*$A10N2B26L!T+( 9O-Y'N)>+PJ"H.\_[\IHL(MZX:[='L-6Q;#E9/B76H!
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M+^@<FKLZDBJ<H HGL'J=(WH55!U*HZDI_Z',< AC1]>W!/$*SN3K%[_G_6@
M:U=@;:O>/@)6I6Y.;7X/$OATIT^C6P6I_%<'WCX!>*<"[S1F].#.88?<0K'@
M4M;!-LMUT1:PD U@W0JLVZATS=,L5Z"_,#Q2:RS@D+ .K5'P@WGL5;B]TQ5
M[P3@_0J\_[D%T"S7?K< +BJPBT:E6:0_5H"B7#"B\O+^([(QZUJP1KD/9G%0
MP0Y.=_V#$X#[WEN'\#ZW -[1Z[]; ?Y>]_(;M>Y =^2$TQ6Z33/!7\&@U4,U
M"GTTB6]]R0].=__^*3J7_]:Z_,8&4[&W"OC68?MOH4<)44[1'8F@A7Z#2%MH
M"C(4)+.#U]/-1IDQ;DD!W; \!8'-\_I(FTER>19CG T+C\;A(N%"-X%99/S.
M(EL/,W$II1XG%:%$;>\A78*H2X2[-S:9$?0>BY@PB2A$VKMWWM?]0A137;%1
M/+.3U)(K/9?99:(G81#F@'X?<:YV&S.<5;/UY#]02P,$%     @ NH%M6JSN
M4YM8 P  V0H  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULM5;;;MLX
M$/V5@;98M$ 37:W(J2T@MK?H FT1Q$W[3$MCBXA$>DG*;O]^24I1%$=V_9"^
MV"0UYW .9SB<R9Z+!UD@*OA9E4Q.G4*I[;7KRJS BLA+OD6FOZRYJ(C24[%Q
MY58@R2VH*MW \V*W(I0YZ<2NW8ITPFM54H:W F1=543\FF')]U/'=QX7[NBF
M4&;!32=;LL$EJOOMK= SMV/):85,4LY X'KJW/C7<]\S &OQG>)>]L9@I*PX
M?S"3?_.IXQF/L,1,&0JB_W8XQ[(T3-J/_UI2I]O3 /OC1_:/5KP6LR(2Y[S\
M07-53)W$@1S7I"[5'=]_PE;0R/!EO)3V%_:MK>= 5DO%JQ:L/:@H:_[)S_8@
M>@ _/@((6D!P"(B. ,(6$%JAC6=6UH(HDDX$WX,PUIK-#.S96+160YD)XU()
M_95JG$J73?B KV%)-XRN:4:8@ILLXS53E&W@EI<THRCA GK&,R)I!H3EL*!E
MK3"'KSKG/G,I88L"E@41"#=*";JJ%5F5"(K#G%>5#MU2\>RAX&6.0L+;!2I"
M2_E.\]\O%_#VS3MX RY(PR"!,KAG5,GW>E&/OQ6\EGI7.7&55F\TN%FK=-8H
M#8XH]0/XPIDJ)/S#<LR?$[CZV+JS"Q[/;A:<9%Q@=@FA_QX"+X@&')J?#P]/
MN!-VH0PM7WB$[VM=H2"*B^NAPVFPT3#6%(MKN2493AU=#22*'3KIWW_YL?=A
M2-@KD3V3&74RHU/LJ<FS4N?9D,@&.;)(4\!VZ<4XC,+1Q-WUW1\PBX,X\3JS
M9XZ-.L=&9SD&Y"#MLR;M92_MAYP?G>?\@-D)Y^/.^?AD\BR0<5U>CJ9/_)KI
M\TIDSX1>=4*O3D;IARWLF%^0G;XM&^RBT]0;_=))I0N,KGP7*U/CA@ZCV2'N
MA2 >^7Z8C,8'L7II&(T3+PJ2<#A:22<B>2T1>5.>AV0DY\IX:7A:QKB3,3[O
MQI@GP_I^SMTY'I=FMZ1_-?S+*#Q0,V@5Q,-2?._I(?7^A)@3\6DW_)V>8;,7
M@MQ>DZ ?BHWMG238=[YY\[K5KC^[L5W)P?K,]&VV^7BB:9J^+T1L*)-0XEI3
M>I=7NDJ)IH]J)HIO;2NRXDHW-G98Z-X3A3'0W]><J\>)V:#K9M/_ 5!+ P04
M    " "Z@6U:&W3.^:D#  ###P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6S-5UUOJS@0_2L6*UWM2KO%0"!)-XG4IKVZ5[H?4:.[^[#:!Q>&Q*K!
MK&V:]M^O;2B!E**MA%9Y:; ]<YAS/$-G%@<N'N0>0*&GC.5RZ>R5*BY=5\9[
MR(B\X 7D^B3E(B-*+\7.E84 DEBGC+D^QI&;$9H[JX7=VXC5@I>*T1PV LDR
MRXAXO@;&#TO'<UXV[NANK\R&NUH49 =;4#^*C= KMT%): :YI#Q' M*E<^5=
MKKW .%B+/R@<9.L9&2KWG#^8Q>=DZ6 3$3"(E8$@^N<1UL"80=)Q_%.#.LT[
MC6/[^07]HR6OR=P3"6O._J2)VB^=F8,22$G)U!T_?(*:4&CP8LZD_8L.M2UV
M4%Q*Q;/:64>0T;SZ)4^U$"T'+WK#P:\=_%.'R1L.0>U@E7.KR"RM&Z+(:B'X
M 0ECK=',@]7&>FLV-#?7N%5"GU+MIU;;ZOH03]&6[G*:TICD"EW%,2]S1?,=
MVG!&8PH2_89:QANN0)\3QI[1#66EN0RTA;@45!GCVZ>8E0DD*!4\0VO"XI(1
M>W':V3KHLV\Z3;]P*5$! FWW1 #Z^084H4S^HE\GS8Y<N$KS--&Z<<WINN+D
MO\')\]%7GJN]CB+7(70!7"U0HY+_HM*U/XAX _$%"KQ?D8_]24] Z__N'@R$
M$S27%EB\X V\*ZU\,B3Z1RLZSXI25:)_3]$M$;F^3XDVC=A_?=' Z+."3/[=
M)W,5Q:0_"O.!N90%B6'IZ"^(!/$(SNK#3UZ$?^^3:"2PCF"31K#)$/JJG:V-
M</(H''2R->YF:U)G:ZZSE;UDJ\W-/LVJ0"(;B/F&/JZ\*8XF410MW,>V'CV&
MX6P21CAH##M<PX9K.,CU-BL8?P:=&(K'#^A[87CT13H(\][;'0FLPSAJ&$=G
M40[1F(*-!-81;-H(-CV7<IB^RO(H\'26>R?5\-HNG.+Y?(;[BV'6,)T-,KT#
MJ02-3;Q5.?S(J>K]ES*(\][+'0FL0WG>4)Z?137,QQ1L)+".8!X^]D#X7.JA
MCJ2=Z+XW"6;8/RF('D,/AW@RZR\(K]7P>8-DJSHX$"%TH]??70T"O/=JQT+K
MTO6/=/VS*(<ZC+%$&PFM*]JQO_0&N['_M2""5WD^BW 4M-J@6I+7AA[& 0ZG
MX4E)N*UQ* .QLU.B1':BJ7K^9K>91*_L_'6R?VTF5#MF'6&J\?8K$3N:2\0@
MU9#X8JK['U%-C-5"\<(.7?=<Z1'./N[UE W"&.CSE&N)ZX5Y03.WK_X%4$L#
M!!0    ( +J!;5KLD66S @8  -\U   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;,V;76_;-A2&_PKA#4,+M+'X8<?N' --@G8!FJ&HE^ZBV 5C,[%0
M271)VFF _?A1LB-*E<28%34H%XD_R%?GO.2)'A]9LP<NOLHU8PI\CZ-$G@W6
M2FW>#(=RN68QE2=\PQ+]SAT7,57ZJ;@?RHU@=)5-BJ,A"H+Q,*9A,IC/LM<^
MBOF,;U44)NRC '(;QU0\GK.(/YP-X.#IA4_A_5JE+PSGLPV]9PNF;C8?A7XV
MS%568<P2&?($"'9W-G@+WUR,@G1"-N)SR!YDX3%(4[GE_&OZY&IU-@C2B%C$
MEBJ5H/K/CEVP*$J5=!S?#J*#_)CIQ.+C)_5W6?(ZF5LJV06/_@Y7:GTVF S
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M^OT[SM73D_0>G_R>KOE_4$L#!!0    ( +J!;5IDA$WH>P0  &H=   9
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M:#QG[3#!FQ!($X#/9T+HS<2\H+Q;]?X"4$L#!!0    ( +J!;5K;5GT5\P(
M /()   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+56;6_3,!#^*Z<P
MH4V")4WZIM%&ZEH011N;-@H?$!_<YMI82^Q@.^V0^/'83AK:*8VH5+XDMG//
MXWON+F</-EP\R1A1P7.:,#ET8J6R*]>5BQA3(B]YADQ_67*1$J6G8N7*3"")
M+"A-7-_SNFY**'/"@5V[%^& YRJA#.\%R#Q-B?AUC0G?#)V6LUUXH*M8F04W
M'&1DA8^H9MF]T#.W8HEHBDQ2SD#@<NB,6E?COK&W!E\I;N3.&(R2.>=/9C*-
MAHYG',($%\HP$/U:XQB3Q!!I-WZ6G$ZUI0'NCK?L'ZQVK65.)(YY\HU&*AXZ
M?0<B7)(\40]\\Q%+/1W#M^")M$_8E+:> XM<*IZ68.U!2EGQ)L]E''8 OG\
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MKO21;X>QOI2A, ;Z^Y)SM9V8#:IK7O@'4$L#!!0    ( +J!;5J%9"1I# ,
M .X)   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+56V4[;0!3]E2M7
MJD!J\9(%0A-+0(H:J4B(K0]5'P;[)AXQBYD99_G[SMB."9+C2E!>DEGN.??<
M93PS7DGUI#-$ VO.A)YXF3'YJ>_K)$-.])',4=B=N52<&#M5"U_G"DE:@CCS
MHR 8^IQ0X<7C<NU:Q6-9&$8%7BO0!>=$;<Z1R=7$"[WMP@U=9,8M^/$X)PN\
M17.?7RL[\QN6E'(4FDH!"N<3[RP\/0\C!R@M'BBN],X87"B/4CZYR2R=>(%3
MA P3XRB(_5OB!3+FF*R.YYK4:WPZX.YXRWY9!F^#>20:+R3[15.33;P3#U*<
MDX*9&[GZ@75  \>72*;+7UC5MH$'2:&-Y#78*N!45/]D72=B!Q -]P"B&E F
MPJ\<E2JGQ)!XK.0*E+.V;&Y0AEJBK3@J7%5NC;*[U.),/.,YH<JFV8"<0UD4
M-[C7"&=:H]'P%6YM*Z0%0[=Q::WA@;#"[@O"-IKJ?<![3<4"IE0GLA &4[@@
M.H-+VP=PA2:3J61RL8&#*1I"F3ZTGEJ-[S#)!'TN<.P;&['3[2=U=.=5=-&>
MZ,((KJ0PF8;O(L7T-8%O4]7D*]KFZSSJ9)QB<@2]\ M$0=3OX.LU^>^5?+T]
M?&6N8*<*%QE1"X3?/ZTAS SR/VUA5Z3]=E)WDD]U3A*<>/:H:E1+].+/G\)A
M\*U#<K^1W.]BC[^O<WND;(ENBT>&]D3 C1,^$XER,]VFMV(,JZRZ+\4R#HZ"
MWMA?M@@9-$(&G4*NR)KR@K?YZP2^,3_#1M;P(THZ_ #)QXWDX\Y,;L\=W!#3
M>LPJ^.A5^<)@T%Z_D\;K2:?7.U0<#C9(E#YL<]J-'D&)A!"X.^(0'D-*-KHC
M&Z-&UZB[KZC8UU>=P#<6*0Q>OM7!1W16S?J?5>_<,.'[FJO&O^ZN8+2GN\+H
MQ7'TKO[Z!SS:-EC=878TV-MB_LX5S-$6Q3TT-)2!5[=QL]H\9LZJ*_S%O'H)
M7=F:4J&!X=Q"@Z-C^S%3U>.BFAB9EQ?ZHS3V>5 .,_L@0^4,[/Y<2K.=. ?-
M$R_^"U!+ P04    " "Z@6U:VXAIV\4"  !U!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6RM56MOFS 4_2L6JZ966LN;M!U!:I--F[1I4=-N'Z9]
M<. F6#68V2:/?S_;4$83&G72OH ?]QS.N5Q?QQO&'T4.(-&VH*486[F4U;5M
MBS2' HL+5D&I=I:,%UBJ*5_9HN* ,P,JJ.TY3F07F)16$INU&4]B5DM*2IAQ
M).JBP'QW"Y1MQI9K/2W<D54N]8*=Q!5>P1SD0S7C:F9W+!DIH!2$E8C#<FS=
MN->32,>;@.\$-J(W1MK)@K%'/?F<C2U'"P(*J=0,6+W6, %*-9&2\;OEM+I/
M:F!__,3^T7A77A98P(31'R23^=BZM% &2UQ3><<VGZ#U$VJ^E%%AGFC3QCH6
M2FLA6=&"E8*"E,T;;]L\] !N\ + :P'>:P%^"_"-T4:9L37%$B<Q9QO$=;1B
MTP.3&X-6;DBI_^)<<K5+%$XF-VG*:\C0AZVJ"P$"X3)#WV0.'$UJSJ&4Z O!
M"T*))&KW',U5'64U!<26Z!_!IU.0F%!QIF@>YE-T>G*&3A IT7W.:J&P(K:E
M\J25V6FK_[;1[[V@?PKI!?+==\ASO&  /GD]W'\.MU4FNW1Z73H]P^>_P#?#
M.[R@;29,>C 5Z.?-0DBN*O;7D,&&,1AFU*?X6E0XA;&ECJD O@8K>?O&C9SW
M0W;_$]DS\WYGWC_&KLUS1JGQ#D5%V0Y G72*I:H1:&MD* ,-;6AH==M9)Z%W
M%=OKOK'#F" :.5W0,\%!)S@X*O@^)SP[KS"7.Z33@7F:&_49K%5_JPI=P<>$
M-_113Y0;7GI[R@^#_&#D#RL/.^7A4>7FD TI"@\^%HS"/4&',:[GN\."HDY0
M=#R53&+UY]N& /V&P$Q#2-N&0/\VA"']T<%O]L++:,_ 8="5/PKV#-B]IJ@O
MI*^8KT@I$(6E@CD7(X7G39-O)I)5ID\NF%1=UPQS=2\"UP%J?\F8?)KHUMO=
MM,D?4$L#!!0    ( +J!;5IP<X75W0(  ,T&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;)55VV[;, S]%<(%B@WHZL1)TZ)- N2VK0]I@UZVAZ(/
MBDW'0F7)D^0D_?M1LN.U6Q9L+[8NY.$A*1WU-TJ_F S1PC87T@R"S-KB,@Q-
MG&'.S*DJ4-).JG3.+$WU*C2%1I9XIUR$4:O5"W/&93#L^[6%'O95:067N-!@
MRCQG^G6,0FT&03O8+=SQ56;=0CCL%VR%]V@?BX6F6=B@)#Q':;B2H#$=!*/V
MY;CG[+W!-XX;\V8,+I.E4B]N<IT,@I8CA )CZQ 8_=8X02$<$-'X46,&34CG
M^':\0__L<Z=<ELS@1(GO/+'9(+@((,&4E<+>J<U7K/,Y<WBQ$L9_85/;M@*(
M2V-57CL3@YS+ZL^V=1W^Q2&J'2+/NPKD64Z99<.^5AO0SIK0W,"GZKV)')>N
M*?=6TRXG/SN\QQ65V,(=%DI;+E?P"49)PEW)F(!K6?7=%?##%"WCPGSLAY8B
M._\PKJ.,JRC17Z*T(Y@K:3,#,YE@\AX@),H-[VC'>QP=1)QB? J=]@E$K:@+
M=18'<#M-/3H>M_//]7@:+8W5='J>]^5=H77WH[D;=6D*%N,@H"MC4*\Q&!X?
MM7NMJP-<NPW7[B'T/[F>P.1V.C^AKB5\S9.2&OC K4!@,H&%,KZKH#1\T:HL
MX(;E"$^SK75W;$EF,UGFJ'VW]R9[F,XDXYC";(MQZ6X:W*8ICU'#TQSS)>KG
M QF?-1F?'0QQ4SHD4"F0*CFBU!^SK_<5WPJLY\&<.JV'[7ZXWA._U\3O_6_%
M9UO21X/O;LJCP026KW4WIFABS0NWLX_DX8@/&<)$Y063K\='%U'[_,IX6, U
M$R6S:'QSF1 J]C,Z9JK4,8TVW&9<@B6$ND9>OQ)0U>+OL)*> *&,.=W7J/"-
MQ- 967DA-1"K4MI*;9K51JM'E43],J^$?L[TBDL# E-R;9V>4YMT)9[5Q*K"
M"]9269(_/\SHO4'M#&@_5<KN)BY \X(-?P)02P,$%     @ NH%M6DQZ<+ !
M!@  ZR   !D   !X;"]W;W)K<VAE971S+W-H965T-C0N>&ULM5K;;MLX$/T5
MPELL6J"I15*2Y6QBH'%:;(!V$<3M[L-B'QB9MH5*HDI2N?S]4A>+ED2Q<2"_
M))8\/#HS''*.AKYX9/R'V%$JP5,2I^)RLI,R.Y].1;BC"1$?6$93]<V&\81(
M=<FW4Y%Q2M;EH"2>(L?QIPF)TLGBHKQWRQ<7+)=QE-);#D2>)(0_7]&8/5Y.
MX&1_XR[:[F1Q8[JXR,B6KJC\GMUR=35M4-910E,1L11PNKF<?(3G2^P7 TJ+
MOR/Z* X^@\*5>\9^%!<WZ\N)4S"B,0UE 4'4OP>ZI'%<("D>/VO02?/,8N#A
MYSWZY])YY<P]$73)XG^BM=Q=3H()6-,-R6-YQQ[_I+5#7H$7LEB4?\%C;>M,
M0)@+R9)ZL&*01&GUGSS5@3@8 /V! :@>@+H#W($!N!Z 2T<K9J5;UT22Q05G
MCX 7U@JM^%#&IARMO(G28AI7DJMO(S5.+E9TJR9%@CN:,2ZC= O.P*J:4L V
MZO8#37,*5M$VC3912)3IIR>50X(*0-(U^$MEVA<F!% 9!?9@;Z^I)%$LWBFP
M[ZMK\/;-._ &1"GXMF.Y4,/$Q50J\@6%:5@3O:J(H@&B$(&O+)4[ 3ZE:[IN
M TR5UXWK:._Z%;(B7M/P \#P/4 .<@V$EB\?CBUT<#,3N,3#+YZ)F[1:ID6Z
M__M%F8,;21/QGREX%;9KQB[V@G.1D9!>3M1B%Y0_T,GB]]^@[_QA<GPDL%88
MW"8,K@U]H=9C3.X9K]SF5?Z9/*Y@O!*FV*P>%M##:AX?#CTQ&7E!8]1BZ#4,
M/2O#.^4SX>&NS/^U(ABSK)RYD EIS.P*SS]@X>*9[W>X&JP"!\W-9/V&K&\E
M>Y-D).(E/;6<,Z[V?RZ?2^KT9QZ5Q$V4_1X9& 2XP]A@Y,V1F?"L(3P[@C O
M=N$SMCG+!05$"&H.\*Q'!*$ =P-L?? KTSIHW I^E322YZ',>;&RB_ SN:-<
M)7A,)%V#<$?XEAJ="_I1=H)YUSGKXU_IW+QQ;FYU[AN3) 9%:I%RXZ)UA3!Y
M,^]Y,Y\% >IXT[?R W\VL'"AHXN=8R5:52K.DCU9EII+D=-[_MG<QV[0H6FR
M\V<0.0-$#ZHRM*^"5%(U3U(5S9 EQOVO1F@E_=SK!M)@Y;KS@4T%(LT/O63&
MRQ2V4$0OHMBWLE#4Y11:RU0UU_=4E5!:4P22/.USTT@7&V8=X]Y2,]GYR$=P
M@+(N?=!>^VY>1M/M/Q[/NQP-1MY03'7E@_;25ZB]6,752*M?OU3T7.QUF1GL
M5/2"H36C*QVTE[JENJ$4:JP45+6G+H?JL1WH6+4T%EK;;5TOX>R$NA&.5!3K
M4)RBQ$)=8^$OB^R1R@P:BJL'O=Z*[YLAQP\&I [4=1/:"^>G)(O9,Z4O2%DK
MT-'S-!):^[U+EV'DG#!ED;7&'QN*L=#:H="%'MD+_?$IBPQU'P6H*TU,9DJ9
MN.:41;KR(WOEO^5LK70LN#[@6G#_2M)\0_8"=S"/[>A'3]Y(:.U8:(F!3OG*
MCD9]9Q\+K1T*+5V07;J\(H_["@5CI_L";[!R,?('LE@+&607,I])&,61C*AX
M#U9Y5DQ?E;,E_VNJ8A1&Y30:J5O!CYZYD=#:H="R"?FG3.)1I=18:.U0:"F%
M[+V'5R1QO_, L3?KJG&#V<Q%WD 6:[V#['I'[<4;*HJ..HG?J_Q-11[+?7_A
M-K^/HU#=33*2/EMVY)$Z![6GI^A#("VHT/R4R3RJR!H+K=U-UB(+VWL=QR=S
M#>BULM1Q.KF,^SV/F>]C<RYC+82P70A]H5OUZK:B4L9TJ"EIASBZRST26MMA
M+:0P.F6_?U0=-19:.Q0')Q_V5LTK4G7<\PY#0\?S![J-6&LB;-=$GZ.4I*%5
M#ML1CO9C)+2VOUI48>^4&3VJJ!H+K1T*+:JPO1?UBHP>54C5:(=;N8N[[W[3
M@V/CA/)M>9HN%,4\E=4Q:G.W.;'_6)Y3=^Y?P?-E=>ZN8:J? 7PE?!NE L1T
MHR"=#S/%B%<GZ]6%9%EY.'W/I&1)^7%'R9KRPD!]OV%,[B^*!S2_;UC\#U!+
M P04    " "Z@6U:'/L'[O88  "UCP$ &0   'AL+W=O<FMS:&5E=',O<VAE
M970V-2YX;6S-W6MOVT:^Q_&W0GB+8@_@VB)U=9L82,W[;8/-[O;!P7G 2&.;
MIY*HDE3<%/OB#RG1ID:F1V+P[>+T09/8Y&>HR_S%(7^:>?>4Y;\6CT*4VN^K
MY;IX?_%8EIL?KZ^+^:-8)<55MA'KZC?W6;Y*RNJ?^<-UL<E%LMCMM%I>&X/!
MY'J5I.N+VW>[GWW,;]]EVW*9KL7'7"NVJU62?_U9++.G]Q?ZQ?,/_IX^/);U
M#ZYOWVV2!_%)E/_<?,RK?UV_*(MT)=9%FJVU7-R_O_B@_QC?#.L==EO\*Q5/
MQ<'?M?JA?,ZR7^M_>(OW%X/ZB,12S,N:2*H_OH@[L5S64G4<OS7HQ4N;]8Z'
M?W_6[=V#KQ[,YZ00=]GREW11/KZ_F%UH"W&?;)?EW[,G5S0/:%Q[\VQ9[/ZO
M/37;#BZT^;8HLU6S<W4$JW2]_S/YO7DB#G8PC#=V,)H=C*,=1F^U,&QV&)Z[
MPZC9873N#N-FA_&YCV'2[# YVF%X\\8.TV:'Z;F'-&MVF)U[2#?-#C?G[J /
MGE^YP;D'I;^\V,>O]MMOC^>76S_[]=:?7W#]^!4?ZF_M\OR2Z[O7_'K_]MV]
M]\VD3&[?Y=F3EM?;5U[]EUT'VNU?O>73==W7/Y5Y]=NTVJ^\_5AU+9'G8J$E
MZX5VEZU650?\5&;S7[4?M ^+15KWR&2I>>M]7:G[YU]-42;ILOBO=]=E=0@U
M=#UOFO/VS1EO-#?4HFQ=/A::M5Z(1<?^@7K_FU/[A^K]=4,!7%?/W<L3:#P_
M@3\;2C%*\BO-,"XU8V",M']^,K6_?M?UQ-RI&5M\OM+T(T;[3KO6BL<D%T7S
M1P=LJN$X^U+!XQT\[ 5;:OAO\_)*&QC? -MJ^)/85+ NPQV,<^J%^:H9W_*X
M7;7[85.]X/IP!QN]8.^,QST<G'S<OIKQM^NSF$#-F&)>,?HWO"'#;X'_E97B
M+#TZ7^_WLL>GWTZ#_=MI<,J3"LGPI1(/=PT,WVC@;ID4A?:W^Z;Z_G=8_5[S
M2K$J_J?C:'_>8Z-NK#Y#_+'8)'/Q_J(Z!2Q$_D5<W'[_%WTR^*FK-I&826(6
MB=DDYI"82V(>B?DD%I!82&(1B<40)I61T4L9&:GTV^84KM@5D:9&)=OR,<O3
M/ZJSO'^_70!_5L)]2PJ)F21FD9A-8@Z)N23FD9A/8L$>F^RP^L+&EUMCT/SW
M[OK+8;TX>\OH["UCZ*%(/7W\TM/'Y_?T39)K7Y+E5E0]O#T[Z>KE2K1O+R<Q
MD\0L$K-)S"$QE\0\$O-)+-ACTX,>.;@:#/2C'G[65M%96\70X4L]>_+2LR?*
MGMU>E-F-!2ZU3_O/\0_G?8XK\;X]G,1,$K-(S"8QA\1<$O-(S">Q8/+J,U?O
M_A@_=\/HW WC,S:4NO'TI1M/S^S&Q;X;G_\AK83[=F$2,TG,(C&;Q!P2<TG,
M(S&?Q(+I61_29VT5G;55?&HKJ=O.7KKM[.SSZDOM2U:FZP<MK^\9=G95)=:W
MJY*826(6B=DDYI"82V(>B?DD%I!8J.Y._W@4VF.V7(B\T+)[;7XX:JT^_C2Q
M+M-R67U(EIF6K47=X81VG^6:2.:/^X]([5$L%U==E^W(QQ%#F%1T;EZ*SHWR
M68JWJ\\B?_4$2=6G.FNH;Y-T%2$EWK<(D9A)8A:)V23FD)A+8AZ)^206D%AX
M\_HD_NB4@FPNAC"I5NB#-K0QZ'V1/RV*[8D+ VJU;YE -1/5+%2S4<U!-1?5
M/%3S42UHM,,N/AF/]?%H='R)X.PMHXXMQU-#'XW'QQ<)J,<B]_B#F):N[/'[
M4$"=T7I*\CQ95V<#U?G29_'<[1?;O#Y1V(@\S1;-18:-?/U!VKNS/.P/87SP
M9 R[[WO<J8^V=]\G-0O5;%1S4,U%-0_5?%0+4"U$M0C58DJ3ZXS1UAGC=)VY
MU!;B<ZD58EY5E3(5Q65;=>HBLEVGU=^*:E"G/MU0-M7[=(/43%2S4,U&-0?5
M7%3S4,U'M:#1#D\-IH/QC6',CL\VSMPP0H\OIC2Y4+1I15V98KK]F&=S(1:%
M=I]GJ]U92+*>B_H"QODEI+-HH,%&5#-1S4(U&]4<5'-1S4,U']4"5 L;[?"$
MW!C>=-WK1-N-*4TN+6V"45?&II#2<JFM15GO\K+[/"O>J#AD'NT.U4Q4LU#-
M1C4'U5Q4\U#-1[4 U<)&.SR7Z:XW9*LQI<GUILU1ZNH@I7=089[O^M874#J+
M!1J?1#43U2Q4LU'-0347U3Q4\U$M0+6PT0Y/3T:S<5>U>+VA?C.8S%Y'L:@#
ME"M!F[O4SPU>]KZU@H8N4<U$-0O5;%1S4,U%-0_5?%0+]-<1R%?W5$YN$IW>
M)*8.6^[?;2!3[Y7(?.[?V;8LRFKH4-]!479R-):):B:J6:AFHYJ#:BZJ>:CF
MHUK0:,I.?G*3Z/0F,778<B=OXYNZ.G#V,4^_)*70/BZK-E9B779V932VB6HF
MJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%E.:7$O:5*:^#W)!DS+H: X3U4Q4LU#-
M1C4'U5Q4\U#-1[4 U4)4BU MIC1YQJ@VOFFHXYN?I,L*]3V+.DMQJ6VVGY?I
M7,ONJT'*+LV5I_/3WQ53-]:WZ*":B6H6JMFHYJ":VVBSPTMK5X8AGVA[:)L^
MJ@6H%J):A&HQI<G%I$V&&NIDJ)-GU2G*1KIGNFF&0!O5$$CM]JX;:"(4U2Q4
MLU'-0377>!WAU0>#<<<M/ ]MV$>U -5"5(M0+:8TN7BT<4]#'?>,1?E-I0--
M=J*:B6H6JMFHYJ"::[R.,=Y,AIV5 TUMHEJ :B&J1:@64YI<.=K\IZ'.?UI%
MF:ZJ0K%HARMO)JS45.]R@68Z4<U"-1O5'%1SC=?9Q)'162W0N":J!:@6HEJ$
M:C&ER=6BC70:R@A7QWE&D2QW@2O5%]+4:.^Z06HFJEFH9J.:TVC2F,+H^E:@
MB[;KH9J/:@&JA:@6H5I,:7+A:+.9ACJ;^7&;SQ^30F@?'G*Q&X]H_];.NL.K
MAGL7#S2IB6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64)A>8-O)I3,@[O ::\T0U
M$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LI3:XJ;=#44 =-V^F\7KZ:UMSM+3-M
M\WQ.(TWUI0J>JEOK7770X"FJ6:AFHYICO(X^SF;&9#33C\=!:*84U7Q4"U M
M1+4(U6)*DPM*&VHUU*'67Y[+B/A=Y/.T$/MPR&4]XT\S2>+)G @:>44U$]4L
M5+-1S6FTPV2'<369'E<0-,J*:CZJ!:@6HEJ$:C&ER16DC;(:)V88?74)]O";
M]9OCN<*6RVR^N[U3G; HK]&BD5=4,U'-0C4;U9Q&D^[&3+IB'R[:KH=J/JH%
MJ!:B6H1J,:7)ZQ:V<=:A.L[ZC2$2M=JW<J":B6H6JMFHY@P[9L#LG//11=OU
M4,U'M0#50E2+4"VF-+ERM-G5H3J[^FVWA=5H[\*!!E=1S4(U&]6<X>NHZ6C4
M73C0:4I1S4>U -5"5(M0+:8TN7 8;>$X,4UI52:*]IYP9Y5 ,ZJH9J*:A6HV
MJCFHYJ*:AVH^J@6H%J):A&HQI<F5Y&#5=7;9=7;==7;A=7;E=7;I=7;M=7;Q
M=7;U=7;Y=7;]=78!=G8%=G8)]C\C[SIL\ZY#92Q.&MATEA$RHW?7:/)$;!UG
MXF;'AK.NT+;5L:$^Z)H)TD8?B8-J+JIYJ.:C6H!J(:I%J!93FMRQVSSJ\,2B
MZ\FZS'+-3LL_'D2>+!?:]\EJ\Y-VEW6M3_>S6NO=S]$0*JI9J&:CFH-J+JIY
MJ.:C6H!J(:I%J!93FEQ5VA#J$ VA#M$0*JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6DQI<E5I0ZC#$[.=BGPNUF7RL+NCDCP\Y.*AOBM;QT[3HDBS=6=Q0;.F
MJ&:BFH5J=J/5R_*4!ZN1#^7QDH,VZJ*:AVH^J@6H%J):A&HQI<E5HTV:#D]-
MGRHT>[M>B(7VB^HF+)HF1343U2Q4LU'-0347U3Q4\U$M0+40U2)4BRE-KB9M
MZG2(3J Z1-.DJ&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:5)5674)DY'ZL0I
M\&T8=0M]*PVJF:AFH9J-:DZC3>4QT^#X"W5HHQZJ^:@6H%J(:M%Y+U9,-2K7
MAC93.OHS,J5JM'<Y0#.EJ&:AFHUJSJ@C4]IU?]I%F_50S4>U -7"CB=8OYEV
MK?"(MAM3FEP3C+8FJ..B'W/QP_W^FL;3\:F#>ETW-=R[+J I4E2S4,U&-0?5
M7%3S4,U'M0#50E2+1J_GF]4G8WUD#(_/)_Z,@.BH#8B.3BUT_^IZZ+E3D*GE
MWL4##8NBFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:7)%:8-BXY&Y#72$9FGNT,U
M$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LI3:XJ;5)U=/ZJ]M)$8_NY/]9IF2;+
MXR6G+K6U*.L]7N8&V4WJ?JDU2U8IATIHUA753%2S4,U&-0?5W$;KF!W@:)9W
MM%D?U0)4"U$M0K68TN22T\981\I &W);!HVVHIJ):A:JV:CFH)K;:"?N&WAH
MHSZJ!:@6HEJ$:C&ER26DS:R.U)G5X]7LLOSYBNU+4>FN&VAJ%=5,5+-0S48U
M!]7<1CN\66'H>N?9!QI<1;4 U4)4BU MIC2Y=+3!U5'OX&I]H?:;%Y!0-]>[
MI* )5U2S4,U&-0?57%3S4,U'M0#50E2+4"VF-+GLM G7$9IP':$)5U0S4<U"
M-1O5'%1S4<U#-1_5 E0+42U"M9C2I*HR;A.NXQ-SJK(+2*A;ZUMU4,U$-0O5
M;%1SQJ_G6C5&@YD^FQW%V]!F/53S42TX]RD)S]TP0H\OIC2Y#+1AUK$ZS I<
M456WT+OKH\E65+-0S48UI]%.!=W11CU4\U$M0+40U2)4BRE-+B%&6T+4V=?]
M^*0]D="R7,O3A\?RLBHJFS1/RK0ZA5B(8IZGF_*-20'4;?0N(F@,%M4L5+-1
MS4$U%]4\5/-1+4"U\$1_^\>CT#[FXH?C2Y'U9W6Z6HE%FI1B^?7Y$SWYO!1:
MLE[L.Z/0JKX8)5^UH7ZI&0-CUC6K6(0^GIC2Y/K4YFO'ZGSMMWU?1XWV+DAH
MM!;5+%2S4<UIM,,[-)/.*>#19CU4\U$M0+40U2)4BRE-KAMM:G:LS,_=WNVO
M?>RNNG96"#+,=X=J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!93FEQ&VICL>$S>
MOAFC(5=4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K68TN2JTB9AQ^HD['\\?*\^
MGMYU:?+J8KL^&.F3R>1H0OF.#8== P"K<T-].IX<7;ZWT0?BH)J+:AZJ^:@6
MH%IX[MLIZMAPTO4NB:GCD[MWFU(=JU.JIY9W4._>NS>B:514LU#-1C5G_#H_
M.AQT+HJ+MNNAFH]J :J%J!:A6DQI<HEHTZAC=1KU\ Q@]]%_J7U)EEO162[0
MI"FJF:AFH9J-:@ZJN:CFH9J/:@&JA8TFKSST:G:BCJTFK[:*J2.32T";#!TK
M,V+2%<IS0^=JLG<I0..AJ&:AFHUJ#JJYJ.:AFH]J :J%J!:A6DQI4FF9M/'0
MR8"\:CE!XY^H9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI<E5I4V;3M1IT__X
M54OU\?2N2V@V%=4L5+-1S4$UM]&DBWVSF3[6QS='W]I%V_51+4"U$-4B5(LI
M3:XY1EMSU'&YXR_\[RK-&W6HLX2@R514,U'-0C4;U1Q4<QOM<'0_O1EU??$?
M;=='M0#50E2+4"VF-+F$M G2B3I!>GR=Y9N_\:]NIW<M04.EJ&:AFHUJ#JJY
MJ.:AFH]J :J%J!:A6DQI<KUIDZ>3$7KQA8S+W:&:B6H6JMFHYJ":BVH>JOFH
M%J!:B&H1JL64)E>5-H@Z^7\V7ZOZ>'K7)33*BFH6JMFHYDQ>S["J3R=CXV9B
M'(54T'8]5/-1+4"U$-4B5(LI3:XY;4QUHHZI'HV</B7+JF:\#)LZBP::,T4U
M$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LI32XL;4!V,D6'2&A>%M5,5+-0S48U
M!]5<5/-0S4>U -5"5(M0+:8TN:JTF=J).E/;#&J:B=#J21.*;+FX/!X4[>=(
M.CDQDKJQWD5GK^F#@Q/YT=71]Q;,9JO9P4;&U?$45E;'5L.KZ=%<039Z_ ZJ
MN:CFH9J/:@&JA:@6H5I,:7+G;].TDUYIVKMD76:Y9J?E'P\B3Y8+[?MDM?E)
MN\NNZM]FZS+/ELNJ3%B_;=/R:W4NTA2'<P8Y: @7U4Q4LU#-1C4'U5Q4\U#-
M1[4 U4)4BU MIC2I(DW;$.X4#>%.T1 NJIFH9J&:C6H.JKFHYJ&:CVH!JH6H
M%J%:3&ER56E#N%-U"/?#*MNN2RWYDJ3+W>1P]1HX]]MRFXO=S&B=I07-T:*:
MB6H6JMFHYJ":BVH>JOFH%C3:8=QO/# ZXGXAVFZ$:C&ER67#:,O&B6E>Y>%1
ME/R>KK:K/WF@I#ZFWG4'#=^BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:7)M:D-
MZ$Z'Z$ )C>&BFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E"97E3:&.U4&\FX_
M/G]GJ,RTST++YO-JB+38Q^6:\5*?+Q(UK1T&L::=:UW?J8^K=T4A-0O5[$:3
MS\R[GA,';==%-0_5?%0+4"U$M0C58DJ3JT4;KYVJX[5'WS.L)^?/M40YN!F_
M>O._51#0["NJ6:AF=SPG;Q4$=(I65/-0S4>U -5"5(M0+:8TN2"TV=>I.ONZ
M'XL\$2L%JUOJ/6!!0[&H9J&:C6H.JKFHYJ&:CVH!JH6H%J%:3&ERQ6E#L5,T
M%#M%0[&H9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI<E5I0W%3M6A6'BE8'5K
MO:L..A<MJEFH9J.:TVC2MP*-P6AP,SKZ4B#:K(=J/JH%74_)8# <C*?CX[O$
MYVX9H4<84YI<"-J [%0=D 76"E:WT+OSH\%75+-0S48UI]$.UPHVKB;3X7'7
M1Q.MJ.:C6G#>$Q*>MUF$'EM,:5*GG[49U)DRC<:L[JMNHV^W1S43U2Q4LU'-
M0347U3Q4\U$M0+7P1'^SDOEC>Z6P^<C5/HMYLA+2DKY5KXNS+V)W;CX<[!;S
M'5X>+?1[O$'W:K_HXXLI3:Y7;;IUIDZW?LS%#_?[E9&?CL]7%LJ!B1KN7:30
MC"NJ6:AFHYJ#:BZJ>:CFHUJ :N&L8X[=D3$RID=SQD1HLS&ER;7#:&N'.N)J
MY7EU=G.7Y;F8OWDJ@R924<U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DJ32TF;
M2)VAB=09FDA%-1/5+%2S4<U!-1?5/%3S42U M1#5(E2+*4VN*FTB=:;,L-UZ
MJU52BKR>I_&L<Q4R7W>':B:J6:AFHYJ#:BZJ>:CFHUJ :N&)GF5N=U])*Q_K
MFQIBDS37-;/[W8_NLM4F67_]_B\S0Y_^5.RNM6C)>KVM.N)]ND[6\[I+%F75
M.>L(5W%YN)>6+JJ?I??I;DHA+6W[L-CUX73=V<9C6I19GL[?:$)[>A2Y^/Q5
M:BE;I659WYBM=M86:3%?9L4NIKYO(EW7#:^ZO?I;P/5&OVV3O-I,$[MK*/ZV
M.F]YOKRTN[J4KN?[HK/\^MS$_H$ERV4V?WG:OM/UJ[&V2I?+^@?INBA%LMC_
MPGCY<9GMFCR^W%7L&KI/TN7^)O-S,[N-CYH97;WF<O&#O;\$] )^^S/P26Q*
M^2I;]T4T\MT:4YK\.=-FF6?J+//QA\NY.44UV_L#!TT]HYJ%:C:J.:CFHIJ'
M:CZJ!:@6HEJ$:C&ER>6E34;/)NC@&$T_HYJ):A:JV:CFH)J+:AZJ^:@6H%J(
M:A&JQ90F5Y4V_3Q3YB!O8U$>+?-6SV9SF%OL+"YH"!K53%2S4,U&-0?57%3S
M&DU:,-[H^DJ:C[8;H%J(:A&JQ90F%XXVX#Q3!YP[1SM".QI"=A8/-,N,:B:J
M6:AFHYJ#:BZJ>:CFHUJ :B&J1:@64YI<8-K@].P&'>^@(6E4,U'-0C4;U1Q4
M<U'-0S4?U0)4"U$M0K68TJ2J<M,FLV_42=%O&^^HT;[%!=5,5+-0S48U!]5<
M5/,:[7"\,^J:+--'FPU0+42U"-5B2I/K1IN0OE$GI#N&.R<7N.ZL)&A>&M5,
M5+-0S48U!]5<5/-0S4>U -5"5(M0+:8TN=P8;;DQR,'/#9JO1C43U2Q4LU'-
M0347U3Q4\U$M0+40U2)4BRE-KBIMOOI&F;2\_;#XWVU1[G,[9:8EBT5:G\O4
M"U@G:1U2TN;))BV3Y>7+J$B:H:(.&"F'26@@&]5,5+-0S48U!]5<5/-0S6\T
MZ2:3/NX8=05HNR&J1:@64]J^Q%P7CT*49E(FM^]6(G\0=V*Y+*JJL%V7]=G+
MP4^U7-Q7)4C_\8-Q<?WJYY[^HZ]W_#S4?XQV/[]N^=MWF^1!1$G^D*X+;2GN
MJZ8&5_7$A+OOT#__H\PV[R^JT[3/65EFJ]U?'T6R$'F]0?7[^RPKG_]1-_"4
MY;_N'L[M_P%02P,$%     @ NH%M6K2>K=EB P  [ H  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C8N>&ULK59MC^(V$/XKH[2J6JE+0L+;;@&)ESO=25T)
M+;KKAZH?O,D UCIQ:AM8_GW'3C8'R*1WTGX!VYGGF9EGXLF,CU*]Z!VB@==<
M%'H2[(PI'\)0ISO,F>[($@MZLI$J9X:V:AOJ4B'+'"@781Q%@S!GO BF8W>V
M4M.QW!O!"UPIT/L\9^HT1R&/DZ ;O!T\\>W.V(-P.B[9%M=HOI0K1;NP8<EX
MCH7FL@"%FTDPZSXL1];>&7SE>-1G:["9/$OY8C>?LTD0V8!08&HL Z._ RY0
M"$M$8?Q;<P:-2PL\7[^Q?W2Y4R[/3.-"BK]X9G:38!1 AANV%^9)'C]AG4_?
M\J52:/<+Q]HV"B#=:R/S&DP1Y+RH_MEKK<,9H#N\ 8AK0'P-&-P )#4@N0+$
MR0U KP;TG#)5*DZ')3-L.E;R",I:$YM=.#$=FM+GA2W[VBAZR@EGIBN2&97"
M#%B1P4+F.15C;63Z G>PII<LVPL$N8&9IC>CM+72\$63/2]@+AC9D944J.%1
M9BC@UR4:QH7^C? _0PAZQQ3J<6@H6.LR3.O %E5@\8W NC$1%F:GX4.1879)
M$%*63:KQ6ZKSN)7QD9T@[O\.<10GOGC:T4M,.Y!T';SG@2^_'YZT)),T=4L<
M7W*#;VUEO9LS6PFJ&G4!S=Q%FBG%BBW2S33P?()SNQ4[N>/9D:D,_OZ3*.&S
MP5S_X\EG7OGO^?W;;O2@2Y;B)*!VHU$=,)C^\E-W$/WAT_8]R9;O1':A>Z_1
MO=?&/OWPBBKE&J%4/$6?;A5^Y/"VZ1ZF<6<P'(>'<SU:G?RH'N]$=J%'O]&C
MWZK'1\85')C8NR:15OU#V_[ATZ;OT:9_K4VKPQ_5YIW(+K09--H,6K7Y*@7=
M2<'-R:=%A;T_TR+JC+KWR94:7K.H?VFU]%K%WY2]B'_8Q#_\GW>]I*\S-0Z#
M*O>ET [OPPF9TC" W#5R7U]H9QA4#+ZZ?A<0NI5K"B%C)]U2TE$CR:B5^(GK
ME[N-0J3/'ZF"VH!BQML'1IZ21,FP=U5?KUDOOJJOG^S^JK[AV1R0H]JZ>4K3
MK=P7IOI.-J?-R#9SD\K5^8)&N6KR^D93S8&/3&TYC0 "-T09=89TP50U6U4;
M(TLW;3Q+0[.+6^YH'$5E#>CY1DKSMK$.F@%W^A]02P,$%     @ NH%M6O/L
MNPWJ @  :0H  !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULO99=;YLP
M%(;_BL6D:9.V\I40TA&D->VT2IL:->IZ,>W"A4.P:C"S3=+^^]F&4+I2+JJT
M-XF-?5X_YQQ_G&C'^*W( 22Z*V@I%E8N975LVR+)H<#BB%50JI&,\0)+U>4;
M6U0<<&J,"FI[CA/8!2:E%4?FVXK'$:LE)26L.!)U46!^?P*4[1:6:^T_7))-
M+O4'.XXJO($UR*MJQ57/[E124D I""L1AVQA?76/3UQ/&Y@9OPCL1*^-M"LW
MC-WJSGFZL!Q-!!02J26P^MO"$BC52HKC;RMJ=6MJPWY[K_[-.*^<N<$"EHQ>
MDU3F"RNT4 H9KJF\9+OOT#HTU7H)H\+\HET[U[%04@O)BM98$12D;/[Q71N(
MGH'G/F/@M08F$':SD*$\Q1+'$6<[Q/5LI:8;QE5CK>!(J;.REER-$F4GXY4*
M G .*<)EBI:L*%2HUI(EM^@S6JL]D-84$,L>#UV" +Y51FI;H&^UK#F@<R%J
M7"8@T(=3D)A0\3&RI4+4"]E)BW/2X'C/X)Q"<H1\]Q/R'&^"1(XYB,<JMG*P
M\]+KO/2,K/^,[))B(=!%UN+__J'&T;F$0OP98FS$)L-B^IP<BPHGL+#403"!
ML.+W[]S ^3*"ZG>H_IAZO#8^ZX@G3<2%0>;]B&=-Q,D^XD,^-*L$9A5]-+>Q
M._<GX60^B^SM -^DXYN,\EU4YC1)AL[N@"=$0!O4:\PY+N4@S*CD"P,Z[8"G
MA\S]]!50@PXU>)/<!T]R'P9.X#O^<.IG'=YL',_0-!M F/M"W0.2DT0JMF;P
MJB3#.V!4^85A#3ON\) [('P%U'F'.G^3'3!_>OH=QPV],!S> J[S\%XXHX1G
M1479/4!+5M4\R=6KB"J*R\'[?E3NA>%T>\^;>\C<MVH'IGUXIMS1I^5@Z6^7
MZ>=_YOES)_@O^W:O<-!%V$_,-T2=;0J9,G2.9NHVY$U=TW0DJTPM<<.DJDQ,
M,U>U(' ]08UGC,E]1Y<G7749_P-02P,$%     @ NH%M6K][-S&A!@  OS$
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MGEXLEX(OF>3(4V2],/;FZ#OS-WMG8R-9H^XA5QN6)^EP9"7_ZO.T"V^ M3G
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MD>R@?G^*(KG]D@0HWMF8_@]02P,$%     @ NH%M6GH#[<63$P  I#P! !D
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M=TA7N2SKO;*CQ=;66"NAJ6*SS81J9)1F <VOA= O'6.@KKJG_P-02P,$%
M  @ NH%M6@E]^G,% P  ;@H  !D   !X;"]W;W)K<VAE971S+W-H965T-S(N
M>&ULQ59M;]HP$/XKIZR:6FEM7GAM!Y&@=%JE54-EW3Y,^V"2@UA-[,PV4/;K
M9SLAI5K(I(II7\!V[IY[[NZ)<X,-%X\R053PE*5,#IU$J?S*=6648$;D!<^1
MZ2<++C*B]%8L79D+)+%URE(W\+RNFQ'*G'!@SZ8B'/"52BG#J0"YRC(BMF-,
M^6;H^,[NX)XN$V4.W'"0DR7.4#WD4Z%W;H42TPR9I)R!P,70&?E78S\P#M;B
M*\6-W%N#267.^:/9W,9#QS.,,,5(&0BB_]9XC6EJD#2/GR6H4\4TCOOK'?H'
MF[Q.9DXD7O/T&XU5,G3Z#L2X(*M4W?/-1RP3ZAB\B*?2_L*FM/4<B%92\:QT
MU@PRRHI_\E068L\AZ!QP"$H'6PBW"&193H@BX4#P#0ACK=',PJ9JO34YRDQ7
M9DKHIU3[J7"F>/1X/M9YQ7#-,]UL26RY;I[,&N$<9EH)\2I%X MX8 (COF3T
ME[8_Z'LZ045H*L_@!"B#+PE?2<)B.7"5IFP"NU%);US0"P[0\P.XXTPE$FY8
MC/%+ %?G6B4<[!(>!XV($XPNH.6_@\ +VO PF\#IR5D#;JLJ9,OBM@X5,B$"
MZXHQ$H*P)6HE*YAO8=]N2K;V>+0A(H;OGS0DW"K,Y(^Z2A7QV_7QS=M[)7,2
MX=#1KZ=$L48G?/O&[WKO&[)K5]FUF]##%WW'0AIU' N4CD4Q%\(Z[/5;_L!=
MU\3N5+$[C;'O42I!([53G!8A5;5::L1Y986Z%<ON?^Y_]Q]DUZNRZQVE_[T_
M^A]X_7Y]__M5['YC["D*RF-S^Y0<BCMFBT3(LSH2S7 !6$]H0U;<+/H:B,E6
M-E3ILF)ZV0A=R/-S;@C6"K31_94M]+WGJ][[SQ(M"1PYP;UOF7\4E98P^S+M
M]-JM>IGZP7/XX+A"_0O>3JG]G5+UU_"04MV]$2!#L;2#CH2(KY@JIH'JM!JF
M1L4(\6Q>3&)W1"PIDY#B0KMZ%SU=)U$,-\5&\=P.%'.N]'ABEXD>"%$8 _U\
MP;G:;4R :L0,?P-02P,$%     @ NH%M6G6U57Y& P  ,PD  !D   !X;"]W
M;W)K<VAE971S+W-H965T-S,N>&ULK59-;]LX$/TK RU0=(%-)$NVTF1M ;'=
M[O80U(B1]%#L@9%&-A%*])*4'?_[#DE%=0S9R*$7FQ_S'F?>#(<:[Z1ZUFM$
M R^5J/4D6!NSN0E#G:^Q8OI2;K"FG5*JBAF:JE6H-PI9X4"5".,H2L.*\3K(
MQFYMH;*Q;(S@-2X4Z*:JF-I/4<C=)!@$KPOW?+4V=B',QANVPB6:A\U"T2SL
M6 I>8:VYK$%A.0EN!S?SU-H[@T>..WTP!AO)DY3/=O*UF 21=0@%YL8R,/K;
MX@R%L$3DQO\M9] =:8&'XU?V+RYVBN6):9Q)\9T79CT)/@508,D:8>[E[E]L
MXQE9OEP*[7YAU]I& >2--K)JP>1!Q6O_SUY:'0X @ZL3@+@%Q,> ] 0@:0')
M$2!.3@"&+6#HE/&A.!WFS+!LK.0.E+4F-CMP8CHTA<]KF_:E4;3+"6>RI9'Y
M\\64E"M@)BNJ)LU<0CZ_V#'"!2RIU(I&(,@2OC"NX)&)QLT<&+YM/$ ;3GD@
M'IJ0+\[B'\5J P^:URN8"D9'$9L4J%O4Q4+QW&[>R0(%2$6#FJ SIH2$):\:
MX=WA-:UIQ^F1VG/3<4;"#)6A$B>G,6]L(<&WLN0Y*@T?YTA;0O\Y#@WI9:,.
M\U:;F=<F/J'-(';>K#5\K@LLWA*$)'2G=ORJ]C0^RWC']A"/_H(XBI,^?\ZC
MYYA?0C)P\&$/?/Y^>'(FF*0KG<3Q):=*9\T4MJ6S8'OJ!09N%25EA6[\X_9)
M&T47^[\>7Z>>>]C/;9O=C=ZP'"<!=3.-:HM!]N&/01K]W:?;[R2;_R:R-YH.
M.TV'Y]BS>ZZ?+TJ%2 5OD/@-*+I*?0)ZHFM'9)O[-HLNH^2*"F-[*$VOV3!^
M:S7O)[ONK-X$,^J"&9T-QK:0W-U05!5\I/NY1Z9Z;^+T/-/((R&%REW(OAHX
MSY!ZAKY\OPL( W\TN5"PO3Z3ZK13)WV?.EMI>YS@9M\G3-J3F4^#Z^0HS;UF
MT>@HS;U6\=51FL.#YZ1"M7+/LH9<-K7QO:Y;[5[^6_?@':W/Z(O /^"_:/SG
MQ!U3*TX]7&!)E-'E%25!^2?:3XS<N$?K21IZ MUP35\UJ*P![9=2FM>)/:#[
M3LI^ E!+ P04    " "Z@6U:Q^/B2[L$  #G%0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6RUF&UOZC84Q[^*E553*[4D#B20#I" =ENE75W4KKTO
MIKTPR0&B)C&S#;3??G:2)I"DAG+;-ZT3?([/[QP__./^EK)GO@00Z"6.$CXP
MED*LKDV3^TN("6_1%23RESEE,1'RD2U,OF) @M0HCDS;LEPS)F%B#/OINRD;
M]NE:1&$"4X;X.HX)>QU#1+<# QMO+^[#Q5*H%^:POR(+> #QN)HR^6067H(P
MAH2'-$$,Y@-CA*\G=FJ0]G@*8<MWVDBAS"A]5@]WP<"P5$00@2^4"R+_;6 "
M4:0\R3C^RYT:Q9C*<+?]YOWW%%["S B'"8U^A(%8#HR>@0*8DW4D[NGV3\B!
M'.7/IQ%/_Z)MWM<RD+_F@L:YL8P@#I/L/WG)$[%C8#OO&-BY@5TQP)UW#-JY
M03L%S2)+L6Z((,,^HUO$5&_I3372W*36DB9,5!D?!)._AM).#!\$]9^OQC(1
M 9K06,X.3M+\WKZH-J K])!5&-$Y2GNC[ZNTQTA5(!2OE^@N\:-U$"8+U8)$
M%2;OQ"_18Q( 0].()!R=WX @8<0OI-O'AQMT?G:!SI")^)(PX"A,9.]02*,S
MU?Y[2=><) 'OFT*BJH!-/\<:9UCV.UC81M]H(I8<W<KA@WT'ILQ1D2C[+5%C
M6^OQ!OP6:N-+9%MVIR&@R?'F;4TX[:)N[=1?^[VZJ8SE=9N25[FP!!HQ1I(%
MI.U_1C,NF%PD_S8E+_/=:?:M=HYKOB(^# RY-7!@&S"&O_Z"7>NW)O!/<K:7
MADZ1AH[.>Y8&.5^^KP47<JJH.2A3#?%,SKGF=&<9R-RZJ5NUU6V&3M?RO)[5
M-S>[<-KA3X1S"CCG*+@_9%E%=1)G&$X-PW8MQ[+L"H9VH!,QW +#/0KC]@68
M'_)F$+<&<H7K&-J!3L3H%AC=HS F1.YQ4=2,T6W \#RO@[T*B7:L$TEZ!4GO
MPXN&B-JZ:=KEQKT:H-O&'<?%%;YZO^KZV@O=*T+W/C*7R"R"HT/WZFNE9]NX
MZU1"UT9P8FFP59['UE&$3\#EFD>R/ CD4>RK!T'11KX^FC@?ZG"U]#&=RKRC
M0;"6^4<JMB3@: -,BL=BJT!3%OIPPO:>#]C;G7\MMU?%UH9U*K9=8ML_AZW9
M^'/7N+-#V&GUJMN,/H)3"4N1@K6'_V%"[9F0.]]C;+<\M\KX%0($EPH$ZR7(
M04;M@9$[K]31K=7Q*W0(+H4(UBN1GUJ@S5N34^>6*[166T>_CO=Y2D6"]9+D
MV'GYH?,E'W,/J=NR:DA?(6)PJ6*P7L8<1/^4@Z?;5+9:)KY"!.%2!6&]#-J9
MLY>HEI9[4)<@:CY/Y(>D^I):DPC]%<X!G<MOTU<@C%\TLNM'[6:FR$5Q^H':
M]$5UP$4O<Z%+0JFGL%Y0[4ST3TV"?E0W3X*7)P'A'@K(:W,ROD*/V:4>L_5Z
M3+,</C-A!Z(X9M;H79R:J%+$V7H1-UHL&"R( '0GR<.$ASYZ(M%Z_W1H9/\D
M&9:G(?/F[(G>=J=R9)@[5V8QL$5ZD\B13]>)R"Z%BK?%;>4HO:.KO!_CZTEV
MYUBZR:Y OQ&VD&E $<RE2ZO5E2&Q[%8Q>Q!TE5[,S:@0-$Z;2R !,-5!_CZG
M5+P]J &*N]WA_U!+ P04    " "Z@6U:5>1(:' '  "C,0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970W-2YX;6S%6VUOVS80_BN$%PP=D-JF_!(W2PRDD8H5
M:+&@63<,PS[0$FUSE42-I.+FW^](R9(5,TS5,4@_-);,>T@^1_+N.4L7.RZ^
MR"VE"GW-TEQ>#K9*%>>CD8RW-"-RR N:PS=K+C*BX%)L1K(0E"3&*$M'P7@\
M'V6$Y8/EA;EW(Y87O%0IR^F-0++,,B+NW]*4[RX'>+"_\8EMMDK?&"TO"K*A
MMU1]+FX$7(T:E(1E-)>,YTC0]>7@"I]'P4(;F!:_,[J3!Y^1GLJ*\R_ZXGUR
M.1CK$=&4QDI#$/AS1Z]IFFHD&,>_->B@Z5,;'G[>H[\SDX?)K(BDUSS]@R5J
M>SE8#%!"UZ1,U2>^^X76$YIIO)BGTOR/=G7;\0#%I50\JXUA!!G+J[_D:TW$
M@0&>/F(0U ;!0X/9(P:3VF#RP.#1(4UK@^FW#FE6&YBICZJY&^)"HLCR0O =
M$KHUH.D/AGUC#7RQ7"^46R7@6P9V:@D$IV3%!3%NN]H(2F$9*/0:724)TS=)
MBM[GU8K435Z%5!&6RI^@R>?;$+TZ^>EBI& D&F\4U[U>5[T&C_2*T4>>JZU$
M49[0Q&(?/F$?. !&0$'#0[#GX6W@1/Q([M$$GZ)@'&#;?-S6[^AJB(*%,0]L
MTW&;AS0>[GN?6LRC;S>?.+B8-&MB8O F3Z^).XJNA"#YIEH5)$\ZU[^J+15(
M;4F.ND9_?0!,]%[13/YMF=#;:@!3^P#TX7@N"Q+3RP&<?I**.SI8_O@#GH]_
MMOG&)UCH$RSR!-;QXK3QXM2%OGQ7JE)0.#-2"J<(>*,@]]II$L[WF+([LDJI
MS345ZLR@ZC!SM\23V=C\NQC='?+N[+\O[S[!(D]@'=YG#>\S)^_=$U70.YJ7
M5J*=,'WW@$^P<':\!&:3Z=$"B&SM9HO#=AT&YPV#\R<8S%9P*T$%%2;PY#%%
M?)6RC>'4QJ43L"^7/L'""FQ^P-%B:ME,D:=..X2?-82?.0D/89&FO*B.>)VY
M0>"GL@?]3OB^]/L$"\^.ENAD;J/?4Z<=^A<-_8LGZ%]3(6"]UX?%*62Z,A:L
M>(QN)UQ?NGV"A=\!]ADR.)U#4/2!D?PMX_ W!B5"VVST%+$<<6':<43O2%H2
M18V-@F1$DDIT% (,$2Q95)2BX!*6,%^CJ]MK-!_/3TUS.%H*DM\#P8J*S!PR
MD+TH\UU9K 4DE?LXJ6U/<# <ZQ":&E&3)Z:AH"Q;E4+J"(IB+DU3_44,$V8Q
M),RR+(KT7M_^\.>GUP$>0[-<*J;*>MB SP15]XTE?,U@?E70@$FN*,PY3DO(
M;O7D[5,E<F\/$E#29ARD3=%.T6[+XBW:05N2ICP&XA+=@4'<\4<VN=38:XAD
M?"?/T<EB.&U8J&V;0_KF .#7!L"0=3(9SA_:'9XU5^U98T<9@O1 D%R+$D2L
M2:Z[;JPR&1C$R>S 3V5A%.B605=[3VJK-1.MKY*#<30YDLZ-TCU#"9<LWR &
M&5-E6<"8]EFPW2&&Y>0?D&T L;KO#LN'(R;#V7<Y A_;]73$;V;AZ]*#)J7@
M2B]A6.J6_++947LW,8DH(#&]7Z#WVFMH1R$_I5_K50Z;+W.N<Y Y-%O!&;!7
M2J>HXO)@#"3CI1Z"@5Z7*6Q"L_,$,13IDD*">+6?"L%79,525FW#@P4S1+:D
MTM-!V0D1;YH0\<:=$NU/EMOJ9&F.1EMX<$+U#0\^P4*?8)$GL(X_\+BMFXQ?
M6B37(_#D2*]HH5>TR!=:UY<'-3#LW%V?'T3^?5BQ.@4?BY[ *H_=G?8FW"=:
MY NM2WC0$A[T)9QO<E-NU-G.NBI=0$1D/)$Z9$!RH](FF+O%B+OOWMO&)UI8
MHSV]>B)?_78]U)8 L;,VM?S8A-2K-BY**]U>:WE>T4*O:)$OM*Y+VGH>GKYX
MQ/%9A;OVBA9Z18M\H75]V=8(L:<BH1NGMT>.*W;6TFY8-SPL6QT=4,=8C]3]
M<%OXP^[*W_/&!:]%0GQ<V'N$RF]L&/D:7Y?[M@:(W47 [ZBZNA%[,WIV1%3]
MP\-#1BT-IXLW%D:?HZJ'V[(>?JJN]S_+JF[\WOQZK?35:(=.P#.,+4YX#MV,
M6^&,W<KY1M#733)C)=FK7/:*%GI%BWRA=7]@;Q5S\.**.?"JF+VBA5[1(E]H
M75^VBCGHK9C]!6IWW[V]B(\/*JOD"K^Y9>1KA%WV6_D<N.7S=X1J-V)O3KV*
MXAJM\QOIY&QBH?TY-''0:N+ K8G_=SQWX_=V@E>I7*-UDJIY<&9QPG.HX*!5
MP8'[L98;+I4[H+L!>K/L5<1Z18M\H75=T8K88/;B =VK_/6*%GI%BWRA=7W9
M*N_@!96WN^_>7IP?UU#/[ ']6'K;6T:^1MAEO]7>@7?M[4;LS:G7AVZ"8X&.
M\6(>6'A_#H4>M H]>&:%[L;O[06O"KU&ZQ3[\&1A<8)7A3XZ>!@]HV)CW@*0
M*-8_S%?/8S=WFS<-KLSS]0_NA_@\JMX7:&&JUQ<^$K%AN40I70/D>'@&<Q35
M&P'5A>*%>>1]Q97BF?FXI22A0C> []><J_V%[J!Y+V/Y'U!+ P04    " "Z
M@6U:,STD$;<#  "3$P  &0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6S%
M6%UOTS 4_2M60 @D6.*D'^EH*XU6""00%1OP@'APV]O&(HF#[;;P[[&=+&G:
MS&,EU5[:./$YN>?$OCKR<,?X3Q$!2/0[B5,Q<B(ILTO7%8L($B(N6 :I>K)B
M/"%2#?G:%1D'LC2@)'9]S^NY":&I,QZ:>S,^'K*-C&D*,X[$)DD(__,&8K8;
M.=BYO?&9KB.I;[CC84;6< WR2S;C:N26+$N:0"HH2Q&'U<BYPI<3/-  ,^,K
MA9W8NT9:RIRQGWKP?CER/%T1Q+"0FH*HORU,((XUDZKC5T'JE._4P/WK6_:W
M1KP2,R<")BS^1I<R&CFA@Y:P(IM8?F:[=U (ZFJ^!8N%^46[8J[GH,5&2)84
M8%5!0M/\G_PNC-@#X,X= +\ ^/\*" I 8(3FE1E94R+)>,C9#G$]6['I"^.-
M02LU--6?\5IR]90JG!PK^3&9,TZ,J5=K#J ^DD2OT'7^81%;H4E$TC4@FB(9
M ;KA)!4D_PHS3A> GD]!$AJ+%PKVY7J*GC]]@9[JZ3<1VPB2+L70E:I8_4IW
M413V)B_,OZ.P*2PN4(!?(M_S.PWPB1W^%N87R \-W*_#7651Z9-?^N0;ON!^
MG[: KCC7CABGE+S:^)/RB"NC2(KJH.\?%"=Z+R$1/YK\R OH-!>@M_.ER,@"
M1H[:KP+X%ISQLR>XY[UN<J<ELII70>E58&-77B5S=6N),N"FT:1JC;!Y3-=F
ME35ISPF[AE!WGNTX['C>T-WN:[*^]41-G5)3QZII"EO5\C+SA:]TZZ&2@D"S
M/86?K IS^MZ>PJ!WI-!:PXD*NZ7"KE7AC,.KCS0&U7)2:%)@A3]T?;9$5E/:
M*Y7V'GLO]]KTJB6RFE?]TJM^VWNY?[32PZ ?'*QTZUM/U!26FL+S[N6P82_[
M_0.%UAI.5#@H%0ZL"F^8)'%3Y8.CRK$*?(=M:'#4C>NS:C5AKXH:GK4J:W>Q
M8Q^Z9=IBJRO="U7XL3M,44%;?K7$5O>K"E?8FD=.Z3(%8VT3=L+!P4INFM6]
M<R57 0?;$\Y_=Y""O[81NQ@?5G^.Q(.KR(/MF>?.+H*/PTSWN(O<-ZM>5153
M\#TYA0EI#RIV@@=OC7-$%5QE%?SH806WFE;:8JO[5>45W'I@P<>)!>.PYQ^N
MYW-D%ER%%GSFU(*/8TL7!^&ARG/D%EP%%WQB<L$-H:3?T'3NFY;7Y>Z=F.CC
MJH^$KVDJ4 PKA?,N^HJ YR= ^4"RS!RBS)F4+#&7$9 E<#U!/5\Q)F\'^ERF
M/(<;_P502P,$%     @ NH%M6JA+!G2P P  4@\  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S<N>&ULQ5=MCYLX$/XK%E>=6JE=W@+)[B5(V:2GJ]2JJ]WK
MW8?3?7!@ E;!SME.TKM??[8A!!)"&@FI7P";F8=G'H_-S'3/^%>1 4CTK<BI
MF%F9E)L'VQ9Q!@46=VP#5+U9,UY@J88\M<6& TZ,4Y';GN.$=H$)M:*IF7OB
MT91M94XH/'$DMD6!^;^/D+/]S'*MP\0S23.I)^QHNL$IO(#\LGGB:F37* DI
M@ K"*.*PGEES]V'A!MK!6/Q!8"\:STB'LF+LJQY\2&:6HQE!#K'4$%C==K"
M/-=(BL<_%:A5?U,[-I\/Z+^:X%4P*RQ@P?(_22*SF36Q4 )KO,WE,]O_!E5
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MI0OU-Z$T!J5Q*$U :1Z*9JJG]D%=NP_ZY?C[:79"9YW0QBBP\6"?0;/D4)J
MTCP4S0S_SDOFQU:6*E4^BK]/Y2)0)_8[V'?,L2^98]\RQ[YFCGW/_!S^J%O[
MH^[P3/T.TA2\A](8E,:A- &E>2B:J9[:3'7M9NJCG&]TBT,6\DF1Y"D,GHO=
M6EI==3NJLV!:7D!O=D!03Q1*$U":AZ*9.J@]4=>^8K2U SJR ,B.[*P'J!T*
MI7$H34!I'HIF"J>V0]W)F;H?J$4*I3$HC4-I DKS4#13/;65ZMJMU%.F/2UO
ME3N-9[GV?#K''[JB%$H34)J'HIGQK\U5UVZN6KH=VV-<.[5SVP$U6:$T#J4)
M*,U#T<P=MFK+=GBFI:=#J%T+I3$HC4-I DKS4#13/;5=.[0O/3VAY[$3.NL$
M:LP.FTM%&R]J<6B6 DKSCE2@C&I_9SO22*;/Q4ZS&9DGFUB56SANSVYWL_U0
M[.&Z=YXYU]QI.2^<:Z_<J[;&EUOG?O;3YR#.2"B7.JO!Y427-"UWHRT/5+(N
M-D-]2I1*HN+C2OH+F>87Z.^72:+>#_(,MGL"S_X/4$L#!!0    ( +J!;5H6
M*,A&DP(  .@&   9    >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;*U576_3
M,!3]*U:8T";!\MFPE332VH) 8F):M_'L)K>-M<0.MMN.?\^UDX9^+?# 2^-K
MWW-\SJU]G6R$?%8%@"8O5<G5R"FTKH>NJ[("*JHN10T<5Q9"5E1C*)>NJB70
MW(*JT@T\+W8KRKB3)G;N3J:)6.F2<;B31*VJBLI?8RC%9N3XSG;BGBT+;2;<
M-*GI$F:@'^L[B9';L>2L JZ8X$3"8N3<^,-);/)MPA.#C=H9$^-D+L2S";[F
M(\<S@J"$3!L&BI\U3* L#1'*^-ER.MV6!K@[WK)_MM[1RYPJF(CR!\MU,7*N
M')+#@JY*?2\V7Z#U,S!\F2B5_26;-M=S2+926E0M&!54C#=?^M+680?@QZ\
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MN=#8Z.RPP*<(I$G ]840>AN8#;K'+?T-4$L#!!0    ( +J!;5I4R9?D;P(
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MN.*;RB[4[C-V>LX<7ZXJXW]AU\5& >0;8U7=@2F#6LAVY(^=#P< =O8"@'4
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M^@5ZEOB,%'CJ1T_KIS8'G?03/<3LGW6=]*<%?A1-.D[<D^.G/OO?4K%CA43
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M-RSP?P"4-<#O2RG-=F(WZ/XPDE]02P,$%     @ NH%M6@:G%\;5 P  $!,
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M]^#.^\A?OZ?\S?]G1W\!4$L#!!0    ( +J!;5J7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ NH%M6H.=$I%8!@
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M:+ F/(CANI]?0$S,0AEU1=I@Z;I/SBOA8[CKY5+ T"/#+)21UT ?P[SR,0G
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M!$%I_B"#()L_R"'(YP_*$)3G#RH05.8/>H2@Q_F#XA)E7!(D3; FT#HBUY'
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MUMOCK\NODQ-VKCB'^XKA^2]02P,$%     @ NH%M6B';^;$Q @  S3$  !,
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "Z@6U:5RZC(NX    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "Z
M@6U:F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( +J!;5H?E@8):PD  .LX   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "Z
M@6U:C7Q;\0,&   \&@  &               @(&N$0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ NH%M6@(3T3/G @  Y0D  !@
M         ("!YQ<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( +J!;5KG@P!'0P4  $L5   8              " @00;  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "Z@6U:8<^J!70'  !P-P
M&               @(%](   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ NH%M6@JX+)%R @  ;@8  !@              ("!)R@  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +J!;5IJ70(X@@<
M  <C   8              " @<\J  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "Z@6U:UPC:GTL"  "D!0  &               @(&'
M,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ NH%M6EYJ
M6.CB!0  UQD  !@              ("!"#4  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( +J!;5I8O7)#=00  &@-   9
M  " @2 [  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MNH%M6CRE,S@1 @  W00  !D              ("!S#\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "Z@6U:C@\"P+$)   T,0  &0
M            @($40@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( +J!;5H(?P)6 @X  *@E   9              " @?Q+  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ NH%M6KAD:"3<*
MSH4  !D              ("!-5H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "Z@6U:A(GYB7X%   3#P  &0              @(%(
M@P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +J!;5I*
M='$"] 4  *L.   9              " @?V(  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ NH%M6C>-*L)5!   W D  !D
M     ("!*(\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +J!;5K3Q8#6-PX  . N   9              "
M@2^G  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ NH%M
M6OUA*Z?  P  B@D  !D              ("!G;4  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "Z@6U:]WFT-^(/   5,P  &0
M        @(&4N0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( +J!;5K'QL+.>!    TS   9              " @:W)  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ NH%M6K>RR(":"P  =B$
M !D              ("!7-H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " "Z@6U:KZ<M_CL)  "6&@  &0              @($MY@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +J!;5IF@E)Z
MK@,  $ (   9              " @9_O  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ NH%M6D71)/5J!   3 H  !D
M ("!A/,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "Z
M@6U:&&*^$C(#   B!P  &0              @($E^   >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +J!;5K=?%H5/"X  />?   9
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M970S-2YX;6Q02P$"% ,4    " "Z@6U:;BI%WV4#  "R!P  &0
M    @(%].@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M +J!;5KFRK* V@(  !,&   9              " @1D^ 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ NH%M6B>>K6J^ @  )P8  !D
M             ("!*D$! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " "Z@6U:+QI=900$  !G"   &0              @($?1 $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +J!;5KXA<4[] ,
M -<(   9              " @5I( 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ NH%M6@/)K'?3 P  J D  !D              ("!
MA4P! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "Z@6U:
MW^&?N (&   '$   &0              @(&/4 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( +J!;5J4U3P,E0,  #@)   9
M      " @<A6 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ NH%M6M; 7FZ?!   B@H  !D              ("!E%H! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "Z@6U:6IJ4W/T#  "#"@
M&0              @(%J7P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( +J!;5J*K>D8E00  #$4   9              " @9YC 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ NH%M6H8C3&,1
M!   (Q$  !D              ("!:F@! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " "Z@6U:(W3YS*<"  #J!@  &0
M@(&R; $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +J!
M;5KC+TZS#P,  &<+   9              " @9!O 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ NH%M6JSN4YM8 P  V0H  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( +J!;5I7@:P9L0,  -<1   9
M  " @3:( 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
MNH%M6H +:A,F P  8@L  !D              ("!'HP! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " "Z@6U:#*Q*;*X#  "?$   &0
M            @(%[CP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( +J!;5JB&G]:G@,  -,0   9              " @6"3 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ NH%M6BT#<M#R @
M9PD  !D              ("!-9<! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " "Z@6U:VU9]%?,"  #R"0  &0              @(%>
MF@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( +J!;5J%
M9"1I# ,  .X)   9              " @8B= 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ NH%M6MN(:=O% @  =0<  !D
M     ("!RZ ! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +J!;5KS[+L-Z@(  &D*   9              "
M@=G) 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ NH%M
M6K][-S&A!@  OS$  !D              ("!^LP! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " "Z@6U:>@/MQ9,3  "D/ $ &0
M        @('2TP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( +J!;5IB#YN-*@,  .<+   9              " @9SG 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ NH%M6IC)2!:8 P  @0L
M !D              ("!_>H! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " "Z@6U:"7WZ<P4#  !N"@  &0              @(',[@$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( +J!;5IUM55^
M1@,  #,)   9              " @0CR 0!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ NH%M6L?CXDN[!   YQ4  !D
M ("!A?4! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " "Z
M@6U:5>1(:' '  "C,0  &0              @(%W^@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( +J!;5HS/201MP,  ),3   9
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M970X,"YX;6Q02P$"% ,4    " "Z@6U:H3,4[GP(   ?6   &0
M    @(']%P( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (
M +J!;5H6*,A&DP(  .@&   9              " @; @ @!X;"]W;W)K<VAE
M971S+W-H965T.#(N>&UL4$L! A0#%     @ NH%M6E3)E^1O @  0 8  !D
M             ("!>B," 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"
M% ,4    " "Z@6U:>J-#]%P#  #@#   &0              @($@)@( >&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( +J!;5I#B)2HH (
M  P'   9              " @;,I @!X;"]W;W)K<VAE971S+W-H965T.#4N
M>&UL4$L! A0#%     @ NH%M6@76(IS6 @  ;0@  !D              ("!
MBBP" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " "Z@6U:
M!J<7QM4#   0$P  &0              @(&7+P( >&PO=V]R:W-H965T<R]S
M:&5E=#@W+GAM;%!+ 0(4 Q0    ( +J!;5K8>A\G4P,  *P5   -
M      "  :,S @!X;"]S='EL97,N>&UL4$L! A0#%     @ NH%M6I>*NQS
M    $P(   L              ( !(3<" %]R96QS+RYR96QS4$L! A0#%
M  @ NH%M6H.=$I%8!@  ECD   \              ( !"C@" 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( +J!;5I RG71C@(  $PS   :
M  "  8\^ @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M +J!;5HAV_FQ,0(  ,TQ   3              "  55! @!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !? %\ $!H  +=# @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>240</ContextCount>
  <ElementCount>424</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>85</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity (audited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (audited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995453 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1</Role>
      <ShortName>Organization, Restructuring, Going Concern and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995503 - Disclosure - Restructuring and Other Related Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges</Role>
      <ShortName>Restructuring and Other Related Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Property and Equipment and Related Impairment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment</Role>
      <ShortName>Property and Equipment and Related Impairment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Impairment of Right of Use Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets</Role>
      <ShortName>Impairment of Right of Use Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995543 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Preferred and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock</Role>
      <ShortName>Preferred and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995613 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995623 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995633 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995643 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995653 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995663 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995673 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995683 - Disclosure - Restructuring and Other Related Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables</Role>
      <ShortName>Restructuring and Other Related Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995693 - Disclosure - Property and Equipment and Related Impairment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables</Role>
      <ShortName>Property and Equipment and Related Impairment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995703 - Disclosure - Impairment of Right of Use Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables</Role>
      <ShortName>Impairment of Right of Use Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995713 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995723 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995733 - Disclosure - Preferred and Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables</Role>
      <ShortName>Preferred and Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995743 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995753 - Disclosure - Stock-Based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables</Role>
      <ShortName>Stock-Based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995763 - Disclosure - Collaboration Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables</Role>
      <ShortName>Collaboration Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995773 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995783 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995803 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995813 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995823 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995843 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995853 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995863 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995873 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995883 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995893 - Disclosure - Short-term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995903 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails</Role>
      <ShortName>Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995913 - Disclosure - Restructuring and Other Related Charges (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails</Role>
      <ShortName>Restructuring and Other Related Charges (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995923 - Disclosure - Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails</Role>
      <ShortName>Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995933 - Disclosure - Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995943 - Disclosure - Property and Equipment and Related Impairment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment and Related Impairment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995953 - Disclosure - Impairment of Right of Use Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails</Role>
      <ShortName>Impairment of Right of Use Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995963 - Disclosure - Impairment of Right of Use Assets - Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails</Role>
      <ShortName>Impairment of Right of Use Assets - Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995973 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995983 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995993 - Disclosure - Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Preferred and Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails</Role>
      <ShortName>Preferred and Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Preferred and Common Stock - Schedule of Assumptions Used in Black Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails</Role>
      <ShortName>Preferred and Common Stock - Schedule of Assumptions Used in Black Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails</Role>
      <ShortName>Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996063 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996073 - Disclosure - Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity, Including 2024 PSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity, Including 2024 PSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996083 - Disclosure - Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996093 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996103 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity, Including Incentive Options, Under Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Summary of Stock Option Activity, Including Incentive Options, Under Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996113 - Disclosure - Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996123 - Disclosure - Collaboration Agreement - Summary of Change in the Transaction Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails</Role>
      <ShortName>Collaboration Agreement - Summary of Change in the Transaction Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996133 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails</Role>
      <ShortName>Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996143 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996153 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996163 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996173 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996183 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996193 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996203 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996213 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996223 - Disclosure - Commitment and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="lyra-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996233 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lyra-20241231.htm">lyra-20241231.htm</File>
    <File>lyra-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img224190320_0.jpg</File>
    <File>img224190320_1.jpg</File>
    <File>img224190320_2.jpg</File>
    <File>img224190320_3.jpg</File>
    <File>img224190320_4.jpg</File>
    <File>img224190320_5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="700">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lyra-20241231.htm": {
   "nsprefix": "lyra",
   "nsuri": "http://lyratherapeutics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "lyra-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "lyra-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 356,
   "keyCustom": 68,
   "axisStandard": 31,
   "axisCustom": 0,
   "memberStandard": 40,
   "memberCustom": 42,
   "hidden": {
    "total": 16,
    "http://fasb.org/us-gaap/2024": 13,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 240,
   "entityCount": 1,
   "segmentCount": 85,
   "elementCount": 785,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 700,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/ecd/2024": 20,
    "http://xbrl.sec.gov/cyd/2024": 15
   },
   "report": {
    "R1": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity (audited)",
     "shortName": "Consolidated Statements of Stockholders' Equity (audited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_194bf10a-3e96-4e60-85a1-7fac540a46ce",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_194bf10a-3e96-4e60-85a1-7fac540a46ce",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_fcf36a73-5344-415f-b95c-0bbadc656fc2",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcf36a73-5344-415f-b95c-0bbadc656fc2",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995453 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1",
     "longName": "995463 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation",
     "shortName": "Organization, Restructuring, Going Concern and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995473 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995483 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1",
     "longName": "995493 - Disclosure - Short-term Investments",
     "shortName": "Short-term Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges",
     "longName": "995503 - Disclosure - Restructuring and Other Related Charges",
     "shortName": "Restructuring and Other Related Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment",
     "longName": "995513 - Disclosure - Property and Equipment and Related Impairment",
     "shortName": "Property and Equipment and Related Impairment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets",
     "longName": "995523 - Disclosure - Impairment of Right of Use Assets",
     "shortName": "Impairment of Right of Use Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995533 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995543 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock",
     "longName": "995553 - Disclosure - Preferred and Common Stock",
     "shortName": "Preferred and Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants",
     "longName": "995563 - Disclosure - Common Stock Warrants",
     "shortName": "Common Stock Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:CommonStockWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:CommonStockWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense",
     "longName": "995573 - Disclosure - Stock-Based Compensation Expense",
     "shortName": "Stock-Based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement",
     "longName": "995583 - Disclosure - Collaboration Agreement",
     "shortName": "Collaboration Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995593 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995603 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan",
     "longName": "995613 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingencies",
     "longName": "995623 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995633 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995643 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995653 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995663 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsTables",
     "longName": "995673 - Disclosure - Short-term Investments (Tables)",
     "shortName": "Short-term Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables",
     "longName": "995683 - Disclosure - Restructuring and Other Related Charges (Tables)",
     "shortName": "Restructuring and Other Related Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables",
     "longName": "995693 - Disclosure - Property and Equipment and Related Impairment (Tables)",
     "shortName": "Property and Equipment and Related Impairment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables",
     "longName": "995703 - Disclosure - Impairment of Right of Use Assets (Tables)",
     "shortName": "Impairment of Right of Use Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AssetImpairmentChargesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AssetImpairmentChargesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995713 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995723 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables",
     "longName": "995733 - Disclosure - Preferred and Common Stock (Tables)",
     "shortName": "Preferred and Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsTables",
     "longName": "995743 - Disclosure - Common Stock Warrants (Tables)",
     "shortName": "Common Stock Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "lyra:CommonStockWarrantsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "lyra:CommonStockWarrantsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables",
     "longName": "995753 - Disclosure - Stock-Based Compensation Expense (Tables)",
     "shortName": "Stock-Based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables",
     "longName": "995763 - Disclosure - Collaboration Agreement (Tables)",
     "shortName": "Collaboration Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995773 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995783 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995803 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)",
     "shortName": "Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995813 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:OtherAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "lyra:OtherAssetsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet",
     "longName": "995823 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "995843 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_87370fcb-d580-4410-a3e9-579a2b1905ac",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_87370fcb-d580-4410-a3e9-579a2b1905ac",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995853 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "995863 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995873 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4ce73bf9-81de-427b-88a0-9148395b04ab",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995883 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
     "longName": "995893 - Disclosure - Short-term Investments - Additional Information (Details)",
     "shortName": "Short-term Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "U_Security",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "U_Security",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails",
     "longName": "995903 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)",
     "shortName": "Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
     "longName": "995913 - Disclosure - Restructuring and Other Related Charges (Additional Information) (Details)",
     "shortName": "Restructuring and Other Related Charges (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails",
     "longName": "995923 - Disclosure - Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)",
     "shortName": "Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RestructuringReserveAccrualAdjustment1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457",
      "name": "us-gaap:RestructuringReserveAccrualAdjustment1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
     "longName": "995933 - Disclosure - Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
     "longName": "995943 - Disclosure - Property and Equipment and Related Impairment - Additional Information (Details)",
     "shortName": "Property and Equipment and Related Impairment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8902a605-b72c-4739-9074-c30c2e4cb614",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
     "longName": "995953 - Disclosure - Impairment of Right of Use Assets - Additional Information (Details)",
     "shortName": "Impairment of Right of Use Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements",
      "unitRef": "U_Lease",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3c311591-1876-4a38-97cd-e253457c022f",
      "name": "lyra:ImpairmentOfRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetImpairmentChargesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails",
     "longName": "995963 - Disclosure - Impairment of Right of Use Assets - Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology (Details)",
     "shortName": "Impairment of Right of Use Assets - Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_62e1129c-aef1-4103-970b-5c338ee35c24",
      "name": "lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock",
       "div",
       "us-gaap:AssetImpairmentChargesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_62e1129c-aef1-4103-970b-5c338ee35c24",
      "name": "lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock",
       "div",
       "us-gaap:AssetImpairmentChargesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995973 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "995983 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
     "longName": "995993 - Disclosure - Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details)",
     "shortName": "Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a797757c-a0d8-4b41-bca5-e4ece3661b06",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
     "longName": "996003 - Disclosure - Preferred and Common Stock - Additional Information (Details)",
     "shortName": "Preferred and Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bae57fb9-3c5f-471b-8356-fd251e1c7251",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails",
     "longName": "996013 - Disclosure - Preferred and Common Stock - Schedule of Assumptions Used in Black Scholes Model (Details)",
     "shortName": "Preferred and Common Stock - Schedule of Assumptions Used in Black Scholes Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_76dcfeb5-6b92-4328-8676-8ad9414800c8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_76dcfeb5-6b92-4328-8676-8ad9414800c8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
     "longName": "996023 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "shortName": "Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_087ed0ac-1d0a-422c-a84f-3b93f915fd09",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
     "longName": "996033 - Disclosure - Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_c83cc782-1381-485a-9d57-319e02ec88af",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_73dd090c-1ed2-47b8-9a90-b7e929765864",
      "name": "lyra:ClassOfWarrantOrRightIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
     "longName": "996053 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)",
     "shortName": "Stock-Based Compensation Expense - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails",
     "longName": "996063 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_00ea0f69-39f1-4cdd-88c1-1015ba40c9e8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails",
     "longName": "996073 - Disclosure - Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity, Including 2024 PSUs (Details)",
     "shortName": "Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity, Including 2024 PSUs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
     "longName": "996083 - Disclosure - Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC",
     "longName": "996093 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers (Details)",
     "shortName": "Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_9927410f-0750-4aef-8f2e-4c0203df94da",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails",
     "longName": "996103 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity, Including Incentive Options, Under Plans (Details)",
     "shortName": "Stock-Based Compensation Expense - Summary of Stock Option Activity, Including Incentive Options, Under Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
     "longName": "996113 - Disclosure - Collaboration Agreement - Additional Information (Details)",
     "shortName": "Collaboration Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_6418a52e-c88f-4b7e-b4d3-3e67f8c4d58d",
      "name": "lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6418a52e-c88f-4b7e-b4d3-3e67f8c4d58d",
      "name": "lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails",
     "longName": "996123 - Disclosure - Collaboration Agreement - Summary of Change in the Transaction Price (Details)",
     "shortName": "Collaboration Agreement - Summary of Change in the Transaction Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "lyra:CombinedPerformanceObligation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "us-gaap:DeferredRevenueDescription",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
     "longName": "996133 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)",
     "shortName": "Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_473aaaff-01e3-4509-bda8-ca01929294c6",
      "name": "us-gaap:DeferredRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_194bf10a-3e96-4e60-85a1-7fac540a46ce",
      "name": "us-gaap:DeferredRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "996143 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "996153 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996163 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "longName": "996173 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails",
     "longName": "996183 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)",
     "shortName": "Leases - Schedule of Components of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails",
     "longName": "996193 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)",
     "shortName": "Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
     "longName": "996203 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Summary of Maturity of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f60732e7-7b49-4546-becf-89f740a96713",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails",
     "longName": "996213 - Disclosure - Retirement Plan - Additional Information (Details)",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
     "longName": "996223 - Disclosure - Commitment and Contingencies - Additional Information (Details)",
     "shortName": "Commitment and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcf36a73-5344-415f-b95c-0bbadc656fc2",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996233 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_40f95a2d-f39f-40de-84f9-da9cf7468367",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8a81857-3883-412f-b823-244b5789543e",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lyra-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Line Items]",
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting Policies."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Table]",
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting Policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r819"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of discount on short-term investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities disclosure.",
        "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Research and Development Expenses",
        "label": "Accrued Research and Development Expenses [Policy Text Block]",
        "documentation": "Accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r178",
      "r653"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income, net of tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r88",
      "r184",
      "r649",
      "r675",
      "r679"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income, Net of Tax",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15",
      "r24",
      "r516",
      "r519",
      "r593",
      "r670",
      "r671",
      "r973",
      "r974",
      "r975",
      "r989",
      "r990",
      "r991",
      "r993"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r989",
      "r990",
      "r991",
      "r993",
      "r1069",
      "r1103"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Error Correction, Type [Domain]",
        "documentation": "Type of error correction."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r219",
      "r220",
      "r221",
      "r222",
      "r233",
      "r272",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r340",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r557",
      "r558",
      "r568",
      "r569",
      "r570",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r633",
      "r634",
      "r635",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ]
    },
    "lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to additional paid in capital, sale of common stock and warrants",
        "label": "Adjustments to Additional Paid in Capital Common Stock and Warrants",
        "documentation": "Adjustments to additional paid in capital common stock and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r411"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance cost",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r116"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r876",
      "r909"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r879",
      "r912"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r904",
      "r913",
      "r917",
      "r925"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r445"
     ]
    },
    "us-gaap_AlternativeInvestmentChangeInValuationTechnique": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentChangeInValuationTechnique",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alternative Investment, Change in Valuation Technique [true false]",
        "terseLabel": "Alternative investment, change in valuation technique",
        "documentation": "Indicates (true false) whether valuation technique or approach changed for measuring alternative investment."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.",
        "label": "Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Immediately Preceding Calendar Year",
        "terseLabel": "Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in number of shares available for issuance maximum number of common stock issued.",
        "label": "Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued",
        "terseLabel": "Maximum number of common shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "lyra_AssetImpairmentChargeLineItem": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AssetImpairmentChargeLineItem",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charge [Line Item]",
        "documentation": "Asset impairment charge."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge for write-down of property and equipment",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "verboseLabel": "Loss on impairment of property and equipment",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentChargesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentChargesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentChargesTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges [Text Block]",
        "terseLabel": "Impairment of Right of Use Assets",
        "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r145",
      "r180",
      "r207",
      "r247",
      "r252",
      "r266",
      "r267",
      "r309",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r505",
      "r509",
      "r559",
      "r645",
      "r724",
      "r784",
      "r785",
      "r819",
      "r833",
      "r1031",
      "r1032",
      "r1084"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r185",
      "r207",
      "r309",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r505",
      "r509",
      "r559",
      "r819",
      "r1031",
      "r1032",
      "r1084"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets, fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r807"
     ]
    },
    "lyra_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM",
        "label": "At The Market [Member]",
        "documentation": "At the market."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r862"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r862"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r862"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains",
        "verboseLabel": "Net accumulated unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses",
        "verboseLabel": "Net accumulated unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r326",
      "r643"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Unrealized gain on available-for-sale securities",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedLabel": "Unrealized loss on available-for-sale securities",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Fair Value",
        "terseLabel": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r326",
      "r536",
      "r637",
      "r807",
      "r811",
      "r1003",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r339",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization, Restructuring, Going Concern and Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r99",
      "r102"
     ]
    },
    "lyra_COVID19PandemicAndCARESActPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "COVID19PandemicAndCARESActPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act Policy [Text Block]",
        "terseLabel": "COVID-19 Pandemic and CARES Act"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_CantorFitzgeraldCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CantorFitzgeraldCoMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cantor Fitzgerald &amp; Co.",
        "label": "Cantor Fitzgerald &amp; Co. [Member]",
        "documentation": "Cantor Fitzgerald &amp; Co."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r176",
      "r772"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r129"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r96",
      "r204"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r96",
      "r204"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r96"
     ]
    },
    "lyra_CashProvidedByFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CashProvidedByFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund raised for operations",
        "label": "Cash Provided By Financing Activities",
        "documentation": "Cash provided by financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of Deposits",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r181",
      "r182",
      "r183",
      "r207",
      "r237",
      "r238",
      "r241",
      "r243",
      "r249",
      "r250",
      "r309",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r372",
      "r373",
      "r376",
      "r379",
      "r387",
      "r559",
      "r683",
      "r684",
      "r685",
      "r686",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r712",
      "r733",
      "r751",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r949",
      "r981",
      "r994"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r249",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r385",
      "r387",
      "r683",
      "r684",
      "r685",
      "r686",
      "r796",
      "r949",
      "r981"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue Date",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "lyra_ClassOfWarrantOrRightCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightCancelled",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants Cancelled",
        "label": "Class of Warrant or Right Cancelled",
        "documentation": "Class of warrant or right cancelled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price of Warrants Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance",
        "label": "Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price of Warrants Outstanding",
        "terseLabel": "Warrants exercise price, per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price of Warrants Cancelled",
        "label": "Class of Warrant or Right Exercise Price of Warrants or Rights Cancelled",
        "documentation": "Class of warrant or right exercise price of warrants or rights cancelled."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price of Warrants Exercised",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights Exercised",
        "documentation": "Class of warrant or right, exercise price of warrants or rights exercised."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price",
        "terseLabel": "Weighted Average Exercise Price of Warrants Issued",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights Issued",
        "documentation": "Class of warrant or right, exercise price of warrants or rights issued."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants Exercised",
        "terseLabel": "Number of Warrants Exercised",
        "label": "Class of Warrant or Right, Exercised",
        "documentation": "Class of warrant or right, exercised."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClassOfWarrantOrRightExpirationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightExpirationDescription",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right, expiration description",
        "documentation": "Class of warrant or right, expiration description."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants Issued",
        "label": "Class of Warrant or Right, Issued",
        "documentation": "Class of warrant or right, issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued to purchase common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants Outstanding, Ending Balance",
        "periodStartLabel": "Number of Warrants Outstanding, Beginning Balance",
        "terseLabel": "Number of shares Underlying Warrants Outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClassOfWarrantOrRightOutstandingExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClassOfWarrantOrRightOutstandingExercisable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares Underlying Warrants Exercisable",
        "label": "Class Of Warrant Or Right Outstanding Exercisable",
        "documentation": "Class Of warrant or right outstanding exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "lyra_ClinicalRelatedCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClinicalRelatedCostsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical related costs [Member]",
        "documentation": "Clinical related costs.",
        "terseLabel": "Clinical Related Costs"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ClinicalSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ClinicalSupplyAgreementMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Supply Agreement member.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreement",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r164"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "lyra_CombinedPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CombinedPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined performance obligation",
        "label": "Combined Performance Obligation",
        "terseLabel": "Combined performance obligation"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_CombinedPerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CombinedPerformanceObligationMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined performance obligation.",
        "label": "Combined Performance Obligation [Member]",
        "terseLabel": "Combined Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 17)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r135",
      "r646",
      "r711"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitment and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r353",
      "r354",
      "r767",
      "r1022",
      "r1030"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuances",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r989",
      "r990",
      "r993",
      "r1069",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r712"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r712",
      "r730",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 65,515,440 and 57,214,550 shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r648",
      "r819"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "lyra_CommonStockVotingRightsNumberOfVotes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CommonStockVotingRightsNumberOfVotes",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock voting rights, number of votes.",
        "label": "Common Stock Voting Rights Number Of Votes",
        "terseLabel": "Number of common stock voting rights"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_CommonStockWarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CommonStockWarrantsDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "label": "Common Stock Warrants Disclosure [Text Block]",
        "documentation": "The entire disclosure for common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrants",
        "label": "Common Warrants [Member]",
        "documentation": "Common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Retirement Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Accounting for Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r189",
      "r191",
      "r196",
      "r638",
      "r660",
      "r661"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer software and equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ComputerSoftwareAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ComputerSoftwareAndEquipmentMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Software And Equipment [Member]",
        "label": "Computer Software And Equipment [Member]",
        "terseLabel": "Computer Software and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentrations of credit risk and off-balance sheet risk.",
        "label": "Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block]",
        "terseLabel": "Concentrations Of Credit Risk And Off Balance Sheet Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r776"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractTerminationMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Termination",
        "label": "Contract Termination [Member]",
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r793"
     ]
    },
    "lyra_ControlledEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Controlled Equity Offering Sales Agreement",
        "label": "Controlled Equity Offering Sales Agreement [Member]",
        "documentation": "Controlled Equity Offering Sales Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Preferred stock converted into common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r49",
      "r81",
      "r114",
      "r382"
     ]
    },
    "lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "CorporateBondsAndUSGovernmentAndAgencySecuritiesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds and U.S. government and agency securities.",
        "label": "Corporate Bonds And U.S.Government And Agency Securities [Member]",
        "terseLabel": "Corporate Bonds and U.S. Government and Agency Securities",
        "verboseLabel": "Corporate Bonds and U.S. Government Agency Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r799",
      "r807",
      "r820",
      "r822",
      "r1101"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r368",
      "r374",
      "r594",
      "r614",
      "r642",
      "r773",
      "r775"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r940"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r934"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, hold",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r330",
      "r789"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Available-for-sale Investments by Type of Security",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Debt securities, unrealized loss position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r328",
      "r789"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Debt securities, held",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r329"
     ]
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense recorded as liability",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r133",
      "r467"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Total",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred Revenue",
        "periodStartLabel": "Deferred revenue at beginning",
        "periodEndLabel": "Deferred revenue at ending",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue",
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Current, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredRevenueDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueDescription",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Description",
        "terseLabel": "Deferred revenue, description",
        "documentation": "Description of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "negatedLabel": "Revenue recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research and experimental expenditures.",
        "label": "Deferred Tax Assets Capitalized Research and Experimental Expenditures",
        "terseLabel": "Capitalized research &amp; experimental expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Research and development credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "negatedTotalLabel": "Net deferred taxes",
        "totalLabel": "Deferred Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "lyra_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowance income tax expense (benefit).",
        "label": "Deferred Tax Assets Valuation Allowance Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax assets, valuation allowance income tax expense (benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Operating lease right-of-use assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Match cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Maximum contribution employee percentage",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Company match percentage",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43"
     ]
    },
    "lyra_DevelopmentActivitiesPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DevelopmentActivitiesPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development activities performance obligation.",
        "label": "Development Activities Performance Obligation",
        "terseLabel": "Development activities performance obligation"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DevelopmentActivitiesPerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DevelopmentActivitiesPerformanceObligationMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development activities performance obligation.",
        "label": "Development Activities Performance Obligation [Member]",
        "terseLabel": "Development Activities Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DevelopmentMilestoneAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DevelopmentMilestoneAchieved",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone achieved.",
        "label": "Development Milestone Achieved",
        "terseLabel": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DirectorsOrOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DirectorsOrOfficersMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors or officers.",
        "label": "Directors or Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r413",
      "r441",
      "r442",
      "r444",
      "r801"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Black Scholes Model",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54"
     ]
    },
    "lyra_DiscountedCashFlowTechniqueDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DiscountedCashFlowTechniqueDiscountRate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discounted Cash Flow Technique Discount Rate",
        "documentation": "Discounted cash flow technique discount rate.",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Sublease Rent Increases",
        "label": "Discounted Cash Flow Technique Expected Sublease Rent Increases",
        "documentation": "Discounted cash flow technique expected sublease rent increases."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DiscountedCashFlowTechniqueRangeOfAssumptionTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discounted Cash Flow Technique Range Of Assumption [Table]",
        "documentation": "Discounted cash flow technique range of assumption."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_DiscountedCashFlowTechniqueTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DiscountedCashFlowTechniqueTerm",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discounted Cash Flow Technique Term",
        "documentation": "Discounted cash flow technique term.",
        "terseLabel": "Term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r862"
     ]
    },
    "lyra_DocumentDocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "DocumentDocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document Document And Entity Information Abstract",
        "label": "Document Document And Entity Information [Abstract]",
        "terseLabel": "Document - Document And Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r862",
      "r905"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "U.S. federal jurisdiction",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Net loss per share attributable to common stockholders-basic",
        "terseLabel": "Net loss per share -basic",
        "verboseLabel": "Net loss per share attributable to common stockholders-basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r234",
      "r237",
      "r241",
      "r242",
      "r243",
      "r246",
      "r493",
      "r502",
      "r533",
      "r534",
      "r639",
      "r662",
      "r778"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Net loss per share attributable to common stockholders-diluted",
        "terseLabel": "Net loss per share -diluted",
        "verboseLabel": "Net loss per share attributable to common stockholders-diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r237",
      "r241",
      "r242",
      "r243",
      "r246",
      "r493",
      "r502",
      "r533",
      "r534",
      "r639",
      "r662",
      "r778"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r245"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r804"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r454",
      "r480",
      "r804"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in deferred tax asset valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r804",
      "r983",
      "r1062"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r458",
      "r804",
      "r983",
      "r1062"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationOwnershipChange",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation ownership change.",
        "label": "Effective Income Tax Rate Reconciliation Ownership Change",
        "terseLabel": "Loss of Attributes - IRC 382 Ownership Change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r804",
      "r983",
      "r1062"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development and other tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r983",
      "r1062",
      "r1064"
     ]
    },
    "lyra_EmployeeRelatedCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "EmployeeRelatedCostsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee related costs [Member]",
        "documentation": "Employee related costs.",
        "terseLabel": "Employee Related Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee related expenses",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unvested stock options expected to be recognized over a weighted-average period",
        "verboseLabel": "Period of recognition (years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "verboseLabel": "Severance Costs",
        "terseLabel": "Employee Severance",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity incorporation, date of incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r169",
      "r193",
      "r194",
      "r195",
      "r216",
      "r217",
      "r218",
      "r220",
      "r228",
      "r230",
      "r232",
      "r248",
      "r313",
      "r319",
      "r337",
      "r389",
      "r475",
      "r476",
      "r489",
      "r490",
      "r491",
      "r494",
      "r501",
      "r502",
      "r514",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r532",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r569",
      "r572",
      "r593",
      "r658",
      "r670",
      "r671",
      "r672",
      "r690",
      "r751"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Short-term Investments",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r64",
      "r308"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r876",
      "r909"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r873",
      "r906"
     ]
    },
    "us-gaap_ErrorCorrectionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ErrorCorrectionOtherMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Error Correction",
        "label": "Error Correction, Other [Member]",
        "documentation": "Error correction to previously issued financial statement classified as other."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r951",
      "r954",
      "r955",
      "r956",
      "r957",
      "r992"
     ]
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Error Correction, Type [Axis]",
        "documentation": "Information by type of error correction."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "lyra_EstimatedOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "EstimatedOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated offering costs",
        "label": "Estimated Offering Costs",
        "documentation": "Estimated offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "lyra_ExecutiveChairMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ExecutiveChairMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Chair [Member]",
        "documentation": "Executive Chair.",
        "terseLabel": "Executive Chair"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executives"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "lyra_FacilitiesSupportCostsAndDepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "FacilitiesSupportCostsAndDepreciationMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facilities, support costs and depreciation [Member]",
        "documentation": "Facilities, support costs and depreciation.",
        "terseLabel": "Facilities, Support Costs and Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r547",
      "r807"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r547",
      "r807"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r1071",
      "r1072",
      "r1077"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r546",
      "r547",
      "r549",
      "r601",
      "r602",
      "r603",
      "r794",
      "r795",
      "r797",
      "r798",
      "r799",
      "r807",
      "r811"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r540",
      "r807",
      "r1074",
      "r1078"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r544",
      "r545",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r636",
      "r807",
      "r812"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r401",
      "r406",
      "r537",
      "r547",
      "r601",
      "r797",
      "r798",
      "r799",
      "r807"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r401",
      "r406",
      "r537",
      "r538",
      "r547",
      "r602",
      "r794",
      "r795",
      "r797",
      "r798",
      "r799",
      "r807"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r537",
      "r538",
      "r539",
      "r540",
      "r547",
      "r603",
      "r794",
      "r795",
      "r797",
      "r798",
      "r799",
      "r807",
      "r811"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r540",
      "r807",
      "r1074",
      "r1078"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r546",
      "r547",
      "r549",
      "r601",
      "r602",
      "r603",
      "r794",
      "r795",
      "r797",
      "r798",
      "r799",
      "r807",
      "r811"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1078"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liability",
        "totalLabel": "Finance Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r585"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r331",
      "r332",
      "r370",
      "r385",
      "r522",
      "r554",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r659",
      "r789",
      "r807",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r820",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1070",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities, fair value",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1076"
     ]
    },
    "lyra_FinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "FinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs",
        "documentation": "Financing costs.",
        "terseLabel": "Financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_FinancingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "FinancingCostsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs [Member]",
        "documentation": "Financing costs.",
        "terseLabel": "Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future milestone payments receivable",
        "label": "Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization",
        "documentation": "Future milestone payments receivable upon achievement of specified development, regulatory and commercialization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r735"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "lyra_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern policy text block.",
        "label": "Going Concern Policy [Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ]
    },
    "lyra_GrossProceedsFromInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "GrossProceedsFromInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from initial public offering.",
        "label": "Gross Proceeds From Initial Public Offering",
        "terseLabel": "Gross proceeds from initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_GrossProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from private placement",
        "label": "Gross Proceeds From Issuance Of Private Placement",
        "documentation": "Gross proceeds from issuance of private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_IRC382Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "IRC382Member",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IRC 382.",
        "label": "I R C 382 Member",
        "terseLabel": "IRC 382"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r862"
     ]
    },
    "us-gaap_ImmaterialErrorCorrection": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImmaterialErrorCorrection",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immaterial Error Correction",
        "documentation": "Describes nature and related effect on financial statements related to corrections of prior year errors in the current year financial statements when the effect of the prior year error was immaterial to the prior year financial statements and the current year correction is immaterial to the current year financial statements."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r100",
      "r101"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on impairment of long-lived assets",
        "verboseLabel": "Loss on impairment of long-lived research and development assets",
        "label": "Impairment of property and equipment",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r105",
      "r808"
     ]
    },
    "lyra_ImpairmentOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ImpairmentOfRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of right of use asset",
        "documentation": "Impairment of right of use asset.",
        "terseLabel": "Impairment of right-of-use assets",
        "verboseLabel": "Impairment of ROU asset"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ImpairmentOfRightOfUseAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ImpairmentOfRightOfUseAssetMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Of Right Of Use Asset [Member]",
        "documentation": "Impairment of right of use asset.",
        "terseLabel": "Impairment Of Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ImpairmentOfTheRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ImpairmentOfTheRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of the right-of-use assets",
        "label": "Impairment Of the Right-Of-Use Assets",
        "documentation": "Impairment Of the Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r107"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating losses",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax expense",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r139",
      "r144",
      "r640",
      "r655",
      "r780",
      "r784",
      "r996",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r345",
      "r541",
      "r543",
      "r548",
      "r665",
      "r667",
      "r736",
      "r770",
      "r810",
      "r1100"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r345",
      "r541",
      "r543",
      "r548",
      "r665",
      "r667",
      "r736",
      "r770",
      "r810",
      "r1100"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r454",
      "r455",
      "r463",
      "r472",
      "r804",
      "r1067"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r454",
      "r455",
      "r463",
      "r472",
      "r804",
      "r1067"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r450",
      "r454",
      "r460",
      "r461",
      "r462",
      "r464",
      "r471",
      "r481",
      "r483",
      "r484",
      "r485",
      "r688",
      "r804"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "negatedTerseLabel": "Income tax expense",
        "verboseLabel": "Deferred tax assets, valuation allowance income tax expense (benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r162",
      "r231",
      "r232",
      "r247",
      "r256",
      "r267",
      "r453",
      "r454",
      "r482",
      "r663",
      "r804"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r451",
      "r452",
      "r464",
      "r465",
      "r470",
      "r474",
      "r682"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r979"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r979"
     ]
    },
    "lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease right-of-use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r904",
      "r913",
      "r917",
      "r925"
     ]
    },
    "lyra_InducementAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "InducementAwardPlanMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Award Plan",
        "label": "Inducement Award Plan [Member]",
        "documentation": "Inducement award plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r929"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r929"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r929"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r255",
      "r267",
      "r784",
      "r976"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestments1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-term Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r166",
      "r275",
      "r276",
      "r555",
      "r556",
      "r1093"
     ]
    },
    "lyra_IssuanceOfCommonStockUnderEspp": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "IssuanceOfCommonStockUnderEspp",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock under ESPP",
        "documentation": "Issuance of common stock under ESPP.",
        "terseLabel": "Issuance of common stock under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r952"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r952"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r818"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r586"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_LegalSettlementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "LegalSettlementAdjustmentMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Settlement Adjustment [Member]",
        "documentation": "Legal settlement adjustment.",
        "terseLabel": "Legal Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r587"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r587"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "lyra_LesseeOperatingLeaseExtendedLeaseTerm": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Extended lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturity of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total maturities",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r69",
      "r70",
      "r71",
      "r73",
      "r74",
      "r75",
      "r78",
      "r207",
      "r309",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r506",
      "r509",
      "r510",
      "r559",
      "r710",
      "r779",
      "r833",
      "r1031",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stock and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r136",
      "r651",
      "r819",
      "r982",
      "r1020",
      "r1079"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r175",
      "r207",
      "r309",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r506",
      "r509",
      "r510",
      "r559",
      "r819",
      "r1031",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Line of Credit",
        "totalLabel": "Long-Term Line of Credit, Total",
        "terseLabel": "Letter of credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r134",
      "r1096"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit expiration date",
        "label": "Line of Credit Facility, Expiration Date",
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r72"
     ]
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit, Current",
        "terseLabel": "New letter of credit",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r132"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsHeldForSaleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsHeldForSaleLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets Held-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MA",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_MariaPalasisPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "MariaPalasisPhDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maria Palasis Ph D.",
        "label": "Maria Palasis Ph D [Member]",
        "terseLabel": "Maria Palasis, Ph.D"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_MarketBasedConditionAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "MarketBasedConditionAwardsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market-based condition awards.",
        "label": "Market-Based Condition Awards [Member]",
        "terseLabel": "Market-Based Condition Awards"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r408",
      "r446",
      "r540",
      "r630",
      "r664",
      "r666",
      "r680",
      "r702",
      "r703",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r768",
      "r769",
      "r788",
      "r796",
      "r800",
      "r811",
      "r812",
      "r816",
      "r817",
      "r821",
      "r1033",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "lyra_MilestoneAchievementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "MilestoneAchievementsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Achievements",
        "label": "Milestone Achievements [Member]",
        "documentation": "Milestone achievements.",
        "verboseLabel": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r408",
      "r446",
      "r540",
      "r630",
      "r664",
      "r666",
      "r680",
      "r702",
      "r703",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r768",
      "r769",
      "r788",
      "r796",
      "r800",
      "r811",
      "r812",
      "r816",
      "r821",
      "r1033",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "lyra_ModificationOfLeaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ModificationOfLeaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of Lease Agreement",
        "label": "Modification of Lease Agreement",
        "terseLabel": "Modification of lease agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "netLabel": "Net operating losses",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r98",
      "r140",
      "r173",
      "r188",
      "r190",
      "r195",
      "r207",
      "r219",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r239",
      "r309",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r493",
      "r502",
      "r534",
      "r559",
      "r657",
      "r732",
      "r749",
      "r750",
      "r831",
      "r1031"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r223",
      "r224",
      "r226",
      "r227",
      "r234",
      "r235",
      "r240",
      "r243",
      "r502"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_NetProceedsAfterDeductingIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "NetProceedsAfterDeductingIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds after deducting issuance costs",
        "label": "Net Proceeds After Deducting Issuance Costs",
        "documentation": "Net proceeds after deducting issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r904",
      "r913"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "lyra_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Rule 10b51Arr Modified Flag.",
        "label": "Non Rule 10b51Arr Modified Flag",
        "terseLabel": "Non Rule 10b5-1Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "NumberOfLeasedPropertiesMarketedForSubleaseArrangements",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Leased Properties Marketed for Sublease Arrangements",
        "documentation": "Number of leased properties marketed for sublease arrangements.",
        "terseLabel": "Number of leased properties marketed for sublease arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_NumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "NumberOfLeases",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of leases",
        "documentation": "Number of leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r997"
     ]
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Concentrations Of Credit Risk And Off Balance Sheet Risk",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r324"
     ]
    },
    "lyra_OfficeAndLaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OfficeAndLaboratoryMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and fixtures",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_OpenSalesAgreement2021ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OpenSalesAgreement2021ATMMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open sales agreement (2021 ATM) [Member]",
        "label": "Open Sales Agreement2021 A T M [Member]",
        "terseLabel": "2021 ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r780",
      "r996",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r818"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Initial base rent",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease liability",
        "terseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "negatedLabel": "Less: Current portion of operating lease liability",
        "verboseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r818"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r818"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Operating loss carryforwards limitations on use",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r62",
      "r63",
      "r128"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_OptionToExerciseStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OptionToExerciseStockWarrantsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to Exercise Stock Warrants",
        "label": "Option to Exercise Stock Warrants [Member]",
        "documentation": "Option to exercise stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_OrganizationAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and basis of presentation.",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_OrganizationAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OrganizationAndBasisOfPresentationTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and basis of presentation.",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Total",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r179",
      "r644",
      "r785",
      "r833"
     ]
    },
    "lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Included In Accounts Payable And Other Current Liabilities",
        "documentation": "Other assets included in accounts payable and other current liabilities.",
        "terseLabel": "Other assets included in accounts payable and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "lyra_OtherAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "OtherAssetsPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets policy.",
        "label": "Other Assets [Policy Text Block]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding (loss) gain on short-term investments, net of tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r307"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r819"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Restructuring Costs",
        "terseLabel": "Other costs",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other Costs",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r793"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r868",
      "r878",
      "r911"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Exercise of Underwriters' Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_PatentsCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PatentsCostsPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the patents cost policy.",
        "label": "Patents Costs Policy [Text Block]",
        "terseLabel": "Patents Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Legal Settlements",
        "terseLabel": "Remaining liability paid to the contract manufacture",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "negatedLabel": "Cash Payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r978"
     ]
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForTenantImprovements",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for tenant improvements",
        "label": "Payments for Tenant Improvements",
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of deferred offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Investments, Total",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Purchase of investments",
        "negatedLabel": "Purchase of investments",
        "negatedTerseLabel": "Purchases of short-term investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "lyra_PercentageOfAggregateCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PercentageOfAggregateCommission",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of aggregate commission",
        "label": "Percentage Of Aggregate Commission",
        "documentation": "Percentage of aggregate commission."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_PercentageOfAnnualRentIncrement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PercentageOfAnnualRentIncrement",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual rent increment",
        "label": "Percentage Of Annual Rent Increment",
        "documentation": "Percentage of annual rent increment."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PercentageOfCommonSharesIncreaseAutomaticallyInEachYear",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common shares increase automatically in each year.",
        "label": "Percentage Of Common Shares Increase Automatically In Each Year",
        "terseLabel": "Percentage of common shares increase automatically in each year"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_PerformanceObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PerformanceObligationsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Obligations",
        "label": "Performance Obligations [Member]",
        "documentation": "Performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-Based Stock Awards",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "lyra_PostMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PostMilestoneMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-milestone.",
        "label": "Post-Milestone [Member]",
        "terseLabel": "Post-Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_PreMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PreMilestoneMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-milestone.",
        "label": "Pre-Milestone [Member]",
        "terseLabel": "Pre-Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r372"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r712"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r372"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r712",
      "r730",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r647",
      "r819"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "lyra_PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses for right-of-use asset included in operating lease liabilities",
        "label": "Prepaid expenses for right-of-use asset included in operating lease liabilities",
        "documentation": "Prepaid expenses for right-of-use asset included in operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from initial public offering, net of underwriting discount",
        "verboseLabel": "Net proceeds from initial public offering",
        "label": "Proceeds from issuance initial public offering, net",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Net proceeds from issuance of preferred stock allocated to warrants",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Stock Debt Securities Warrants And Units",
        "documentation": "Proceeds from issuance of Stock, debt securities, warrants and units.",
        "verboseLabel": "Proceeds from issuance of Stock, debt securities, warrants and units"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Stock Debt Securities Warrants And Units Net Of Issuance Costs",
        "documentation": "Proceeds from issuance of Stock, debt securities, warrants and units, net of issuance costs.",
        "verboseLabel": "Proceeds from issuance of Stock, debt securities, warrants and units, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of short-term investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r1004"
     ]
    },
    "lyra_ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Sale Of Common Stock warrants And Pre Funded Warrant Net",
        "documentation": "Proceeds From Sale Of Common Stock warrants And Pre Funded Warrant Net",
        "terseLabel": "Proceeds from sale of common stock, warrants and pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ProceedsFromStockIssuanceAvailableForFutureSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProceedsFromStockIssuanceAvailableForFutureSale",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount available for future sale",
        "label": "Proceeds from stock issuance available for future sale",
        "documentation": "Proceeds from stock issuance available for future sale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r19"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from warrant exercises",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross proceeds for warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProceedsToBeOccuredFromFutureIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds to be occured from future issuance of common stock,.",
        "label": "Proceeds To Be Occured From Future Issuance Of Common Stock",
        "terseLabel": "Proceeds to be occured from future issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ProductDevelopmentAndManufacturingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProductDevelopmentAndManufacturingCostsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Development and manufacturing costs [Member]",
        "documentation": "Product development and manufacturing costs.",
        "terseLabel": "Product Development and Manufacturing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ProfessionalConsultingAndPublicCompanyCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ProfessionalConsultingAndPublicCompanyCostsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional, consulting and public company costs [Member]",
        "documentation": "Professional, consulting and public company costs.",
        "terseLabel": "Professional, Consulting and Public Company Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r188",
      "r190",
      "r201",
      "r207",
      "r219",
      "r228",
      "r231",
      "r232",
      "r309",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r493",
      "r502",
      "r504",
      "r507",
      "r508",
      "r534",
      "r559",
      "r640",
      "r656",
      "r689",
      "r732",
      "r749",
      "r750",
      "r805",
      "r806",
      "r832",
      "r975",
      "r1031"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment and Related Impairment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r157",
      "r160",
      "r161"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "terseLabel": "Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r177",
      "r654"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r586",
      "r641",
      "r654",
      "r819"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r157",
      "r160",
      "r652"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property Plant And Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of shares as percentage lower of fair market value of common stock.",
        "label": "Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock",
        "terseLabel": "Purchase price of shares as percentage lower of fair market value of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r400",
      "r408",
      "r436",
      "r437",
      "r438",
      "r446",
      "r540",
      "r604",
      "r613",
      "r630",
      "r664",
      "r666",
      "r680",
      "r702",
      "r703",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r768",
      "r769",
      "r788",
      "r796",
      "r800",
      "r811",
      "r812",
      "r816",
      "r817",
      "r821",
      "r825",
      "r1026",
      "r1033",
      "r1074",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r400",
      "r408",
      "r436",
      "r437",
      "r438",
      "r446",
      "r540",
      "r604",
      "r613",
      "r630",
      "r664",
      "r666",
      "r680",
      "r702",
      "r703",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r768",
      "r769",
      "r788",
      "r796",
      "r800",
      "r811",
      "r812",
      "r816",
      "r817",
      "r821",
      "r825",
      "r1026",
      "r1033",
      "r1074",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r873",
      "r906"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r368",
      "r374",
      "r594",
      "r614",
      "r642",
      "r774",
      "r775"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r770",
      "r784",
      "r1092"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r980",
      "r1094",
      "r1097"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r966",
      "r980"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Other Related Charges",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r344",
      "r347",
      "r352"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reduction in workforce employees",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring and other related charges",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r346",
      "r349",
      "r351"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees reduced",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "terseLabel": "Restructuring and other related charges",
        "verboseLabel": "Restructuring charge",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r348",
      "r349",
      "r1027"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r349",
      "r350"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "totalLabel": "Restructuring Reserve, Total",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r350"
     ]
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAccrualAdjustment1",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Accruals",
        "verboseLabel": "Restructuring liability",
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r350"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Restructuring liability",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r116",
      "r650",
      "r674",
      "r679",
      "r687",
      "r713",
      "r819"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r216",
      "r217",
      "r218",
      "r220",
      "r228",
      "r230",
      "r232",
      "r313",
      "r319",
      "r337",
      "r475",
      "r476",
      "r489",
      "r490",
      "r491",
      "r494",
      "r501",
      "r502",
      "r514",
      "r517",
      "r518",
      "r521",
      "r532",
      "r569",
      "r572",
      "r670",
      "r672",
      "r690",
      "r1103"
     ]
    },
    "lyra_RetentionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "RetentionCosts",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retention Costs",
        "documentation": "Retention costs.",
        "terseLabel": "Retention costs"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_RetentionCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "RetentionCostsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retention Costs [Member]",
        "documentation": "Retention costs.",
        "terseLabel": "Retention Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r247",
      "r253",
      "r254",
      "r265",
      "r267",
      "r269",
      "r270",
      "r271",
      "r398",
      "r399",
      "r632"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r771"
     ]
    },
    "us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionMilestoneMethodTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Milestone Method [Table Text Block]",
        "terseLabel": "Summary of Change in the Transaction Price",
        "documentation": "Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset in exchange for lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r818"
     ]
    },
    "lyra_Rule10B51Arrmodifiedflag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "Rule10B51Arrmodifiedflag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rule10b51ArrModifiedFlag",
        "label": "Rule10b51ArrModifiedFlag",
        "terseLabel": "Rule 10b5-1Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds under agreement",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "documentation": "Sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCostsOfRetirementPlansTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureRetirementPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Costs of Retirement Plans [Table Text Block]",
        "terseLabel": "Schedule of Matching contribution expenses",
        "documentation": "Tabular disclosure of the costs related to the various types of retirement plans including defined benefit pension plan cost, defined contribution plan cost, other postretirement benefit plan cost, and net periodic benefit cost."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Discounted Cash Flow methodology Range Of Assumptions [Table Text Block]",
        "documentation": "Schedule of discounted cash flow methodology range of assumptions.",
        "terseLabel": "Schedule of Fair Value Analysis of Right of Use Assets Using Discounted Cash Flow Methodology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r804",
      "r1062"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Asset, Held-for-Sale [Table]",
        "documentation": "Disclosure of information about long-lived asset held for sale. Includes, but is not limited to, description of fact and circumstance leading to expected disposal, manner and timing of disposal, amount of asset held for sale, gain (loss) recognized in statement of income, and statement of income caption that includes gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r586"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring Liability Activities",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r108",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Revenue Significant Expenses and Net Loss for Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity, Including Incentive Options, Under Plans",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r123"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Certain Executive Officers",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity, Including 2024 PSUs",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r111",
      "r113",
      "r115",
      "r116",
      "r181",
      "r182",
      "r183",
      "r249",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r385",
      "r387",
      "r683",
      "r684",
      "r685",
      "r686",
      "r796",
      "r949",
      "r981"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Warrants Outstanding and Exercisable and Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Stock-Based Compensation",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt",
        "terseLabel": "Secured debt obligations",
        "totalLabel": "Secured Debt, Total",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r134",
      "r1096"
     ]
    },
    "lyra_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Agreement",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r783",
      "r787"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r257",
      "r267"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfRevenueSignificantExpensesAndNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r268",
      "r270",
      "r781",
      "r782",
      "r786"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r1034"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock units outstanding shares, Forfeited",
        "terseLabel": "Restricted stock units outstanding shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock units granted",
        "terseLabel": "Restricted stock units outstanding shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted stock units outstanding, Ending Balance",
        "periodStartLabel": "Restricted stock units outstanding, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock units outstanding shares, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfRestrictedStockUnitActivityIncluding2024PsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in Shares available for grant",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares available for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable at December 31, 2024",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2024",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares, Granted",
        "terseLabel": "Number of shares granted",
        "label": "Options to purchase",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted to employees, directors and non-employees",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Shares, Outstanding December 31, 2023",
        "periodEndLabel": "Shares, Outstanding at December 31, 2024",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding December 31, 2023",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding December 31, 2024",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2024",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest at December 31, 2024",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest at December 31, 2024",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Exercise price per share, granted",
        "label": "Average per share price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfAssumptionsUsedInBlackScholesModelDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackscholesOptionpricingModelOrMonteC",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted Average Remaining Contractual Life (in years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual Life (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued and sold, public offering price",
        "verboseLabel": "Shares issued and sold, public offering price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock reserved for future issuances.",
        "label": "Shares Of Common Stock Reserved For Future Issuances Table [Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r971"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r205"
     ]
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit",
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "lyra_SignificantSuppliersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "SignificantSuppliersPolicyTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant suppliers policy.",
        "label": "Significant Suppliers Policy [Text Block]",
        "terseLabel": "Significant Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State jurisdiction",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r181",
      "r182",
      "r183",
      "r207",
      "r237",
      "r238",
      "r241",
      "r243",
      "r249",
      "r250",
      "r309",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r372",
      "r373",
      "r376",
      "r379",
      "r387",
      "r559",
      "r683",
      "r684",
      "r685",
      "r686",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r712",
      "r733",
      "r751",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r949",
      "r981",
      "r994"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r85",
      "r86",
      "r169",
      "r193",
      "r194",
      "r195",
      "r216",
      "r217",
      "r218",
      "r220",
      "r228",
      "r230",
      "r232",
      "r248",
      "r313",
      "r319",
      "r337",
      "r389",
      "r475",
      "r476",
      "r489",
      "r490",
      "r491",
      "r494",
      "r501",
      "r502",
      "r514",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r532",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r569",
      "r572",
      "r593",
      "r658",
      "r670",
      "r671",
      "r672",
      "r690",
      "r751"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r248",
      "r572",
      "r632",
      "r681",
      "r701",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r712",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r731",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r751",
      "r826"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r248",
      "r274",
      "r572",
      "r632",
      "r681",
      "r701",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r712",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r731",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r751",
      "r826"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r877",
      "r910"
     ]
    },
    "lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants to be issued during period value preferred stock and warrants.",
        "label": "Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants",
        "terseLabel": "Stock and warrants to be issued during period value preferred stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockDebtSecuritiesWarrantsAndUnitsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockDebtSecuritiesWarrantsAndUnitsIssued",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Debt Securities Warrants And Units Issued",
        "documentation": "Stock, debt securities, warrants and units issued.",
        "verboseLabel": "Stock, debt securities, warrants and units sold"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockIssuanceAmountAvailableForFutureSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuanceAmountAvailableForFutureSale",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance amount available for future sale",
        "documentation": "Stock issuance amount available for future sale.",
        "terseLabel": "Amount available for future sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under ESPP",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r82",
      "r116"
     ]
    },
    "lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period, shares, Exercise of common stock warrants",
        "documentation": "Stock issued during period, shares, Exercise of common stock warrants.",
        "terseLabel": "Exercise of common stock warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants, Shares",
        "label": "Stock Issued During Period Shares Exercise Of Pre Funded Warrants",
        "documentation": "Stock issued during period, shares, Exercise of pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Shares",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs",
        "documentation": "Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.",
        "verboseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Vested share of common stock",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued under ATM, net of issuance costs, Shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r82",
      "r116",
      "r683",
      "r751",
      "r762"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "terseLabel": "Issuance of common stock upon RSU vesting, shares",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r82",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureStockbasedCompensationExpenseSummaryOfStockOptionActivityIncludingIncentiveOptionsUnderPlansDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of common stock options, Shares",
        "negatedLabel": "Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r82",
      "r116",
      "r422"
     ]
    },
    "lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon RSU vesting, shares",
        "label": "Stock Issued During Period Shares Vesting Of Restricted Stock Unit",
        "documentation": "Stock issued during period shares vesting of restricted stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock warrants",
        "label": "Stock issued during period, value, exercise of common stock warrants",
        "documentation": "Stock issued during period, value, exercise of common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs",
        "terseLabel": "Issuance of common stock and pre-fundedwarrants, net of issuance costs of $4,244",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs",
        "documentation": "Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of stock, value",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares issued under ATM, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r82",
      "r116",
      "r690",
      "r751",
      "r762",
      "r832"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r85",
      "r86",
      "r116"
     ]
    },
    "lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "label": "Stock Issued During Period Values Exercise Of Pre Funded Warrants",
        "documentation": "Stock issued during period, values, exercise of pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_StockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options and Restricted Stock Units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "documentation": "Stock options and restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r103",
      "r714",
      "r730",
      "r752",
      "r753",
      "r819",
      "r833",
      "r982",
      "r1020",
      "r1079",
      "r1103"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Preferred and Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r206",
      "r371",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r386",
      "r389",
      "r523",
      "r754",
      "r755",
      "r766"
     ]
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Classification and Accretion of Redeemable Convertible Preferred Shares",
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r79",
      "r80"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split of issued and outstanding common stock",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r597"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of weighted average remaining lease terms and discount rate related to operating leases.",
        "label": "Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Accretion of redeemable convertible preferred stock",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "ThirdPartyResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third-party research and development expenses current.",
        "label": "Third Party Research And Development Expenses Current",
        "terseLabel": "Third-party research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1083"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r370",
      "r385",
      "r522",
      "r554",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r659",
      "r807",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r820",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1070",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "TwentyThousandTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty thousand twenty employee stock purchase plan.",
        "label": "Twenty Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_TwentyThousandTwentyIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "TwentyThousandTwentyIncentiveAwardPlanMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty thousand twenty incentive award plan.",
        "label": "Twenty Thousand Twenty Incentive Award Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_TwentyTwentyFourRestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "TwentyTwentyFourRestructuringPlanMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Four Restructuring Plan [Member]",
        "documentation": "Twenty twenty four restructuring plan.",
        "terseLabel": "2024 Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_TwoThousandTwentyFourPerformanceOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "TwoThousandTwentyFourPerformanceOptionMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty four performance option.",
        "terseLabel": "PerformanceSharesMember",
        "label": "2024 Performance Option"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_TwoThousandTwentyFourPsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "TwoThousandTwentyFourPsusMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four PSUs [Member]",
        "documentation": "Two thousand twenty four PSUs.",
        "terseLabel": "2024 PSUs"
       }
      }
     },
     "auth_ref": []
    },
    "lyra_TwoThousandTwentyStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "TwoThousandTwentyStockOptionPlanMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Stock Option Plan",
        "label": "Two Thousand Twenty Stock Option Plan [Member]",
        "documentation": "Two thousand twenty stock option plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r219",
      "r220",
      "r221",
      "r222",
      "r233",
      "r272",
      "r273",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r340",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r557",
      "r558",
      "r568",
      "r569",
      "r570",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r633",
      "r634",
      "r635",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r349",
      "r350"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Corporate Bonds and U.S. Government Agency Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r797",
      "r1095"
     ]
    },
    "lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "USGovernmentAgencyAndForeignNationalBankSecuritiesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Agency and foreign national bank securities",
        "label": "U.S. Government Agency and Foreign National Bank Securities [Member]",
        "documentation": "U.S. Government agency and foreign national bank securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Bills",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r797",
      "r799",
      "r807",
      "r1095"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "terseLabel": "Unrecognized tax benefits income tax penalties accrued",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "lyra_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Upfront Payment Received",
        "documentation": "Upfront payment received."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment recognition in future periods to settlement of obligation",
        "label": "Upfront Payment Recognition In Future Periods To Settlement Of Obligation",
        "documentation": "Upfront payment recognition in future periods to settlement of obligation.",
        "verboseLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r154",
      "r156",
      "r158",
      "r159"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation Allowance of Deferred Tax Assets [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r811",
      "r1075"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Discounted Cash Flow Technique",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueAnalysisOfRightOfUseAssetsUsingDiscountedCashFlowMethodologyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r811",
      "r1075"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r818"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "lyra_WalthamLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WalthamLeaseMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waltham Lease",
        "label": "Waltham Lease [Member]",
        "documentation": "Waltham lease."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_WalthamSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WalthamSubleaseMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waltham Sublease",
        "label": "Waltham Sublease [Member]",
        "documentation": "Waltham sublease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "lyra_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant One",
        "label": "Warrant One [Member]",
        "documentation": "Warrant one."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Three",
        "label": "Warrant Three [Member]",
        "documentation": "Warrant three."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Two",
        "label": "Warrant Two [Member]",
        "documentation": "Warrant two."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_WarrantsAndRightsExercisedIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WarrantsAndRightsExercisedIntrinsicValue",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic Value of Warrants Exercised",
        "label": "Warrants and Rights Exercised Intrinsic Value",
        "documentation": "Warrants and rights exercised intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_WarrantsAndRightsIssuedMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WarrantsAndRightsIssuedMaturityDate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date, Warrants issued",
        "label": "Warrants And Rights Issued, Maturity Date",
        "documentation": "Warrants And Rights Issued, Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value",
        "terseLabel": "Aggregate intrinsic Value of Warrants Outstanding",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantActivityDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term",
        "terseLabel": "Weighted Average Remaining Contractual Term of Warrants Outstanding",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "lyra_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants exercised",
        "label": "Warrants Exercised",
        "documentation": "Warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "lyra_WatertownLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lyratherapeutics.com/20241231",
     "localname": "WatertownLeaseMember",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Watertown Lease",
        "label": "Watertown Lease [Member]",
        "documentation": "Watertown lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "terseLabel": "Weighted-average common shares outstanding-diluted",
        "label": "Weighted-average common shares outstanding-diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r243"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted-average common shares outstanding-basic",
        "label": "Weighted-average common shares outstanding-basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r243"
     ]
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://lyratherapeutics.com/20241231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "terseLabel": "Write-off of deferred financing costs",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481288/505-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.M.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 1.N.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-9"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0000950170-25-038751-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-038751-xbrl.zip
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M73.*-Q:T@1^7/DKID-+&:02"NW#DQ_')P2D:DU<&ZV/-T49)E49#RSJZ&I
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M-UAX&!HD%TPQFW1!J;T36!WQ %R@QW^XG<$_P@K:DH\PJ8KHJ:H\JPBJN%X
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MW9$OF.*7R_5CPX_QQ890LARVPS2H@#3PF=-N[_MDH;,".P=P;6-8D:930=%
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MI@8LZP452=5VF3NFS<WJ/KQ_]UJB3,19)GKE34<-W2AB(P,I@N>=6%8*7#.
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M)VPG)ENJ]_XMO<EP" TZ(NUP7[S0I=DAH:BGR!+[YEK1IVGG=/2#H[TDVBJ
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M=3915R./&P[[ 0"O'\:]6D[?-QB7QHZX>J!,2;00!VQ,'C8#.5*/@JJA&F+
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MUT$08J'C1!]T%$, +#%@ZNF#S'Y3[[4*'(6(XT9CH?\R2 _M;H3NY$$W;A(
MS<+[SH*78G+-^>NMXVQ.<^@OD\[_-RI( $1=:FSJDL&@  '@;3(_J;_ON CZ
M@LH9P'8<*PO]:5S_$JXO$0!EEVS>Z>%_PNI+\N='FZ#V"% J&KH),?SWX7P\
M1PL!8'S)2##G8LS&15^C/N<E?J@+*H D +YCB_]M6.-?M-<^G9?DHHSX1[7_
MJ/8?U?ZCVO]3J@V$?H/-SJA@E9"D,SZ4AGBZK*<@['&*Q3UBW_:*FT$;%VQ
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M8*PAR2AU41 K#=EY7 V6U9&TH(T7R4U^1$=U_U<53TJ\C<I7'469((&_F7X
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MD):=0]J0.C,E%>LDNHO<UDFBW4I)D7@;) 2@;G4Y;H]E%S,H=:Q9AM"@8#%
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M>IVT<=^7P@U 9Q%JG.#)]<7K04Z=0#A%SX. VC<M16L>@C:X((;UM* 'TX=
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M#1H256XU'C^WI?V@91GQ=)7SO=)U 63S-H0(362 ?56V[&S^T'?%(WO01?!
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MCP"X3@#\-+BL'-)6"  .V(N\YM/"Q5^GO+/H#JS='P?N?PE!-QX=$@")8P0
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MMZMA)XV]XC</_?0!S&'>_Z#N"\-5TP^*U=>@;F._SWV%\R#S?9B@<FYPN[=
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MVU=B@=%H.VX.\DT7#"[)\X+7>\F9);@YDLA:Q>SV<G[Z),S^4*E4!9'4P=
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MLO:-4G)7565$S/B4<L7%[2V=T2T=%4X7"KN[A(IXH3,U$3$UC)S+G.MOZHS
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MD$JEH/*]@%-G_DC+PP6B:QB" K5A 41H97@C>VL2C"C@^#I'QS?7!4U?6_F
MLGY(7IU*V9YUK:I5U4-0?;](ZZP#A1_F.B[E(*(*35PR++5A4^C;3#FYQ>_F
M:>)@#QZ?^7]4ZUR9XJ].(I76,TED&'KN(@3PVI5GUTUZM:+84E?:;JVYKH*8
MU735>5Z-0"& SI+ON?U*]LW+)ORY9YAX:'<'*\>:NNDU/:,X0#* J5)/:93-
M)#L3VJO4=>%)NF94>_NY<+#AQ,[#PSM1@XEK2@O\?L^(39BK1!66R-7'$N3
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M1OT+O7JE#E6[?,.& WS\F(Q/\3[*R[-3T^ _TM>FN<R^'WXAQ809POD-M6V
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MC&,V&K==B:>B0!O.Y3AW,N'<N26C QU"^V_3@G[%*?1 T5K>#H2(=%W&!$-
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M)$I.354-43E65%<+V?]@* A_A1%>+.B%$7/&X$D$-#,4Z>]6[.^HO8*TG>Z
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M!'Y*Q#;T'-%ZB(FTTKSIV<U3D)E2\0UF#Y($DOE"?(_/71C%Y :356G6>R*
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M;",LC'# -]TX /-9?@?8+XIN]2)TR6SN[^34)5ETB*2^+.IW1BZ8DK'N);A
MXZ!Q5WP5\,K_ ,*ZYIMY=:\NI6FEZ4^CV5L++R62$R1LA=]Y#,%B520J@X!P
M#G(!7\1?%PV>LV5EIFGRR6HUV+1[S4[E%^S*Y7=(B8D#[E!'S%-F01DG ITG
MQST6"W2YN--U6ULIXEN;.ZGAC5+RW,JQF>/]YG:/,1R&"OL8-M-1:A\'IKS5
MI#'K21Z'+K2ZY)I[V6Z1IL8=/-\P?(W)QLR#CG'!IZ#\ K'1[.^L'ETR2PET
M^;38C;Z+!!=&-^ \\X):5PN!E?+#$$D$] #?O?BSI\&J7.G6FEZIJU]#=2VB
M064<>9FBB229D+R*-J>8BG<02S84-6-IGQOL[_4-2D2%[S3BNFIID-K%BZN)
MKD29C;>X4$&/N5"[6R>*9-\#(I]$\/PW%]8ZMJNER74LMUK.EK=P7C7#;I6D
MA+@[MP0@A^-N.1Q26_P,%D3/;:S''>Q2:?<6L@TZ..**:V\P$M%&44HXF<%5
MV8SU)YH NGXYZ6]S%:6VB:W>:BT=R\MC###YMN;=@LJ/NE"AAD$8)!!&"20#
M#<_M :#&9'MM.U;4+-&M$:\M88S'NN8UD@ #2!B6W;<!>".<#!."OPA\3Z5X
MYL[_ $O6(DEGM;^2_P!8EM%:,7$\B':D E5E "@J=QP4Y)S@ZD'P M-/L[FR
ML=6>"T>[TRYB62WWN@LT1=K,&&XOMR6P,$]#0!KGXSZ=)!MMM&UB\U-'NDN-
M)MXH6N+86Y E9R91'C+)C:[;MX"Y.0(W^.>A-=3"VL]2O=.@:S$^JP11_9HE
MN@IA8[G#D'< <(2N.0.,Y.K? *"_U.[U)+S39KZ>\O+C&JZ.E[ L<^P[?+9Q
M\Z,@*N"/O,"I!J\_P4C&FZ_91:JL4>J?V:!LLD00_9-G\"%5^?9T4*%SP#B@
M#4\$?$.;6_#GB'5]<M/['M])O[V!V<*=L,#L,ML=\LJJ0V."0=N1BN=\3_'*
M:VT0MI>@:A::N\MCLM]4BA)$%S(%28(LZ[P<,NW>I#X#[1S74:;\.(X?#_BG
M0[^\%[INN75Y<%8X?*DA6X9F==Q9@Q!8X; Z#BN>E^"MYJ86?5O$:7E_$MA!
M#-#8>2B06LPE"E/,.7=LY;.!GA0!B@#J=1\3W^F^,?">BND#QZI;7<EU(8RK
M!XEB(V#<0H)=L@[NW/<XGBSXDZCX(UG4;'4+.*[-Y K^'A:QL#=3E@AMI,L?
MG#/&V1@;"QP-AK:\6^$-1UKQ%H.M:7JEKIUWI27,86\LFN8Y!,$!X66,@C9Z
MGK3M4\'W>NW?A:\O]1@-YHUXUW(;:U*1W!,3Q[0ID8I]_/);I[\ ' :O\5=<
MT35_$&FZGXF\(:+>:1:02K%>6LF;R5X2[B/-RIVAAM& QY'?BO2-.U76=;\#
M66HVME!8ZW>644PMK\L(X)'4$APN6(7).W@G&"5SD9UY\-++5;[Q=)J$YN+3
MQ#';H\")L: Q)M5E?)RV<,#@8('6H+KX;RS>'G\F]L;;QG):K:OXKCTQ?M+
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M]*ZN@ HHHH **** /__94$L#!!0    ( +J!;5K%E(_.O8<!  FA 0 2
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M_#Q&64A9B'V,K\@)O%N>N1H5%XJ569$3%XO21+4'Y6'<ND0!GIE-7\_ZKTX
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MG:'3<0OL+F9"J8;OF8^ $^LT%E0NRB7L961+HRO^E/_0 9OE"+(_F%4:"%)
MER$??G;'I2(96DYVL@S.*_7BWM[II^VGV@F@N68*H0&_Y1D3'OHA]QAZIW[%
M1X$HO8T5O=>TL0_-;*DO;I=QR2;L%7_UZ?@, -2<(=M^U4/H1K^M4<W:4F-'
M<_DGQ@ZUS)D"4BX-$T2\[:S$2)NP><T<']G;-O$K;J/VR6DA4NOS0L%G!:4!
M$PPON!WV'LY=)<G?NW;[!<C2?/8V<E0#8X,^ZZ1IOL+HUZ'@$0*"LL3(]*A
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M!ARQB"PX!TI\]1WZVI.?Y]CP#U8><U8Z7SYAY-/)6CTFSVEO'-X^86,0(7K
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M&\H<M^?F<8,%:LGW]#;'BC1CZ$57U))YM&*D]4IT(T.D/;8ZN5YD/$JRN%-
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M,1;^RLE3U5C^_E=2>9JTB\MS#OA'1B^2;#'(!U-Q4"?LDT2S,2G:PM[?)SW
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M=E^6K$FZ'Z;Q K]+Y9GX]XEF-L2'ELT[2ZZ5J5V^+])16S8Y\ZTRSE]VU3
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M:WFV2?0D=S_S(!BC1.<Q,*)=#01%G0#.NXW0#2G)"V$._@YRO*=\Q1 ,*8W
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MG/[Z]&D]GTQH6##9/I>B8KYM*,G+=8DO*/B5;'Z)_$:'[!O#JZPYQK1<\O@
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M&)>L, CE677,.U'Q-R&F @'7%F1_+G^.?#^19!&K(ARP-EI\ FB2;/(F$D\
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MQS$AN86A LN:@O)<:9"Y DS$37=HY -Y*YYL>A$1H3^(O]9@(3Z\<BDR3B5
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M=G/O)YAVVR?_E7/X0,:[1V-_59]DG8630<2J5%WN/U#M>SC6"/]0;[D,^;K
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MM&$MEXJ)O+<WH!)[-[F(\5FGC!4A+<$AM9-2!&*UR.&0''<PD-&#H@.UB3S
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MX<:]5A-6I4U_FV)O<D7)^%II>B7:X&N> 6W:^&JIL<Y2M9EQUT26I>==79!
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M>S;'@=:,893'GU83'[:;$J^FR84%;XU]UU)]<4% X@#<]?$*@I,4<^W>Q;*
M.5;=W >(;3W*3SH@'#0X A\&<TIIG$C#K^>6UO%G@'E>.^CP)U<93MX,4_!;
MLMB@ SK\+R]ZP*X>/ZM=F$C=0IBXS?0"R7;.@;L.BZ(;>0:P8_P LA.O4W\_
MFN.E>)F E7.*U*ID,?LR:7X1\>#]CQB)]:%5H5%U%CJ@UYYD1@<X"[7@3Y/7
M_:GG+?9W"1":WG$;BGQ7\"(=,(;41ZW=1NO,(8Z?!E+?F=(!&'>2O30= &VE
M [#IR%-K)K$?S7,GU_Z7_OE_B47:3<HC@D4;\CRT8$&[ W)]W9Z5(!->I;_+
M!BWHF)KIFUI/?YA8\!@S8S?=]T3E6K%0^-3YU(V]%1T/R;GL#:A#T.><2WV^
MGQTN:?;Y)AO'.;)/Y]U]^-F1/<.C*LF@]F4.CZ'Q.Z&[@R;&<2\S\^[J3MV/
M,\,E>P@G>=0Z%_EVJ=\G%+3CK[C1%(E#[ZL0EZ&@MGJ[V=H%T'52Q+.:T0.[
M&[H_/^0WH,?\K]3=KJVI"9<7R=;F$3%F4!%'SF_2F$+I@ M>I%]GYQM$#*T;
M7^$1_:%,_>+&5,8Z;^0$4J K90&5X&-M\/50(#3WGOX\)-+<'HQ+UAZS'\-;
M=Z1WQS%+>O@)B)ZY)@1%$K/8_F_=#C@)!]PZ)*NXIN.CT*^H5RP4@A6B1-(]
M9&6N3:UC[?4H9J0!A*<]7XCB99LLAO;K\IWY,:,VN$F;C5G1%!1P%STI<:1&
M0I"EH%9R".9'JOI$U@XV&XT%.@!H.R7^9NIPQ$DB=_T:C7B 8+&99CN2NL-C
MM<,OLE(D/SYO'DTL%UYHU I5GGQE9 *%95_W(WX-;Q1W'"45SN^Z,#^P,/&X
M:P;N6,ZEIH G*J_RM2_=R_FR4K7X?O!.CBEC6$"*ZI4 KS([B?V7MP]CK$V3
MWF1MR+CI?Z9&T@$O4%=I@\'^54,":7%P!5+ZR NB:!SG]0EEELSO]IOM-'97
MS,#/X>T$4+6\BP[J<%+HNJWDPUBW DTR/Y+P'@8D:*%0I%B+BA$Y5M9US"9<
MG/BPX#8.UPEQY0G:*?!-9=-B379VY0[*^[18&Z[D6?Y/3_-E0DI:>%402IY'
MZL>8<$U(D^.S;,N%VI_5X0]4?V9\X'D9-=@G%U2^(S#QT"EHR9O=>XL&HP,\
MAW!7CX^^$-U@]T@0A"J8@2)2_,]QZK8PF%!)T706$L.6IXD-S9<IFWG/Q_)8
M>/1[8LN?]<N_"P"G.]Z_5^0NR#E&\+,O0_1/BKHHJ2UED"!PE]TF]QSJC7ED
M]&3TC968_%M]UY<CW?OYQ J8:QD5=H9STY>A?4=^ZZ;6=W)+"TU02D&!VVYD
M$Q+RJ)$4S6=51HLE1+0%IK%!&=N2.6-LNE7F,SIIMR,O)Q@@S*)CH?SUKZW=
MXI5GTA<,'B_LQA @$5=OJQOZ)LX?'!SP"Z*C#!ZTT)@48X^%/C9ZS#%[,=8J
MB1:IKJ:?'K<V7V[K&. $M$IJ702TKN:#"HST]EWD.9RVZMU"@@,A)6 "?LH2
MILXHTN*P]Z<^[MY?56$.9;D?AY['*7I)LWG6R9[^;_3V,I?O/L1A%-KLKX :
MJ%@'"JC@]R:%EKV?MU9S"G/;*_)B]&3$8H%/F9J<'2_$Z?/KG6-([18^[C[C
M%/7Q@#KG.Y0TR/Y.4+6;7D[#2 !ZE;1>N]*G[/^C.9XD2BAU^_7D;/"RV;AH
M5J<%?'*4A=57CTEU3A>VLQ18]Z!O?S3?F0_(;&6/%2U(6OK[Y_A>3MH+AP&3
MG)4B$UVRI-JEJN*7$G)(*>4W^F1,1KRBJ%*7S)(B)L['\_P\Q>7:JG_=O;_.
MO='MK=V;2E$/<YT()&9^82I%,Y#G#;5/[KL%FU5;).^O1%."Z;S"9"JV"RY:
M-=#_#ME^:KN&&!F)<ASW7' XFUI7<^7?,8-\"K8-F<LNQ7Z@%M$>3+LVLQ.Y
MWL$$8$0[M:H:Y:-JUUL6D<[FN@<9EQ=OEB;D=A?:=N$^Z4_]V_KG3_-W8L$"
MFB(T/# /NCI]#F7;66O:'%GIYV9E2OU7LE&ZP)N/V7'EU]MW7ZQFI9  TL;%
M>L+$=T%=D<#[PDGPH_^TW5!7:4AX!?UHX>GFA7:ED'E!OJQBX0G?KQIYUGFN
M(KQ5CB:@O5-7'^QGI\6H_)S(_)-Q(Q<2:Q2,(Q/ZM:,*9DN\$Y/*Z^]J%/'[
M3:GM3RB,7;SXRU,GPB$7.>4.M9R)XW;!EP7;?3WBD6P[U7$1,JG?X>4*9H,+
MDVYO3_ T:K-$Q\CYOV2WU<_]L%6M<YN1+\_&)B,D*T)J"?<'[W\9U;2Y!^PR
MGUJ-A)D5D-#M"BR.J#7>L#$_W#?9?)U!D=HLQ7T/SP49#W\&@:1VH:[VJVX'
M1G/X+A0+!3S<V9G<G7^&D1^X.K(YLQ_)^.'>1H9D:/H([NMD/ZTN6W)H_-DV
MNZ7IE:NP7.:KJ>NGJQM0G03I+9&Q$SRKC'^M:J[;]O.<7]8KO5EL??QN[+D\
M;2O)/&W?3N4A:FOC>P*K>I;RP>YA"7%]3WGYVJ>$,T:Y16/(;D[1N#K!.+QO
M_W6^L&S73$M#]6[/6O -/!V >OL,UBS=^'.L*<=V)(&,TP]R*T#L*S)B5@T+
MVYMUMD]85\VL>;B*D?W\")F)YG=I;2&+TT*,0D( OZ&%H(/-'0ED ^'3ZK$V
M=N=8""LXN3Z5A70Y%K3CWV=1N6NEEDV>09BCIX<X6P6TQ#D4'4[@_FMIV>PI
MLL9&3Q>Y-TF^M*#R  3K=%<W6ZU BUIH"-DE 6VM7:+-$U4$#"@^;JBJU?7?
MWT9\??O?)T(;W"%AB"RGZ;74&_]87[NL^BGA 7Z_N\G?(&^F"%3O20>T^7:?
M;.OX]5=>VL,ASPSH8D7I#XR9$.2NC,3A'GGP!HW-0'YP.R=B1GL>"3&,0'&\
MD6%V-;X&^_CWD.DL8[S9NJ'3-/BOH<;!D\0A13K@3@&O%-DO$BV)4'WVO$*/
M#NB.3SL>K9E2:5Y;QNA6Q%+MJFY>U7I^ ]G!/_[),[:M(T(PYD>]QCSUZ<';
M1,IY.B!2ODK 0 L^2 <\9:-TGN_FT%S;Q$#R5FHP%BCD8=%@QFNG"R+A#TV'
M_L0$$X*Z#P><9Z 0G0;&/U6/#.%K@, MC</UT?INC$P.>6*/E73YC#CW3\9?
MU6:I'YC(C!M<(/\[LS[6M$WHV\Q+36RJPH(?]%<#H^JEAD78I4.?>0\5;B*_
M48/F(33F*1W]?S_6*IUX73[88"PXV 0_X?",-!J.H+'/?/-_!F*ZF@Z=UE2Q
MSCW8W[<Y1&!#D/=8W[%<>6&3W-/+Q$H+9_4\K'4F=.8(W7/DWO@M-)V<N(RO
MU3N]P3 ,?QS'JG'"!$+U%X W*W+^2/1KX4+MCTF!)[-XX:#0Z+"Y,.G#>.^$
M'&&_,[6LQ[37<))].>D <!H#3L!0.?"P/-E5@#VQ+;M"!^_/36.D+.+S&%5+
M^@)]?-#)!Q;HH=/A(H&R1B&VME@ZX!QC 59>2#KX!1S98[9<48]HN(+\[ZXP
MU0G&(N[<OY((_DQ#KE+$E+(L.V?-;J,[19:J&[8A[3T=>U0Z0 _*S3WH;2<.
M=7P&@V\EMM#X'4'6#5P1U8PTAA/@.DUPC'N(+UI_MN., UM2D8%#IQ7=SQZI
M/0)9[YJVU$<@Z\\ -GEH"=&M5KP%OEK-);0,]_Y+1/93J)J<H5_C?DDRJTL:
MR$- 1B20]TJ51;EHVV9+E!6^5Y-'2NC\L_MCJ:JL0P6+MJ\J"ERM'>7NSW0'
M*B<QM?P;II CFY1#5#H0+!_P+-ND!B5$.;SK&#N"!I=7I=0U93J+<,P:2 @C
M S$Y2NYOQQ9^R?_VL\D"FL1V?%P_%@22.?ZD=U@W>O7GLZ@K?MU9:M0/&W[O
M&&DW\_>?,$\3;@9;T0Y$'.)J,Q=.=58*NUVV6\-5/2RIAR>%$_:K'3"W$+(B
MOI%D@TWK*6FM]6[$$.0]'<!#"2%.O1K>VA8E1+=W?;6J>ITG4[Q9Q!<=7]W?
M<8GWFIF3G?H%?47\!1I.V'M:1(MU 9(J8>^2$^ V;U-;GHIIT!YY44DQ%"FR
M?KY^)[/$P$JX=)<%HA10DS:3L[X[*62+D5$565!C--35BL\G=7>D9;-Q:68[
M$:J/O@TY0K[*SCUN77YF1*E]"7=//AR 99!52!X'')HQ('$V]]XJEI(J40:(
MP#V0H-NFN$F:7&9#3><7L5#/DGQ<K.M,0[.;B$1S614NU,;]S*V2W__/!RK_
M2TBD$_D=ROH1E49H?O]55;C9Z,2=>M#P7[+"'AW /*RXTV2Q JM=O-2RKWP(
M\1Z.\SNBE"P;<8=?(3]@[5Y!E3:^!,@>M0K[TP%NI_ZH9)A34!HW>1!Q(#-:
M/]]P@#^E5:E'7SJ,3DE;PJ^$UM(!Y]\]I8T@;BRMWJ?<RH("979ASO,CO5M:
MK8GVH1*'!0M60_'5>%>/Z&5'=]G0H6 *ZFR8J5E_55> N39UF6/G$Y(]&K)Y
M]SLG*L]A>6X/- BR[]T?VC#J$+T.Q70((U@(1ETJT&LT&V_[%5W:B=69U<@W
MPPZJ]G$'H'C:IU]&'XHUU5Y6%E;3 7Z30\NYV-XCQ3[QU)Q"&U=SKN"4Q2_;
M[M^"5EXH/.P ^G,)^39PZ&"%?"OCXE9^?R8V%U=(+6/?4C0XO][^X%@?UNZO
M^#;*Q,K=V,2RU028VF+Z46>E.=LTSMI@XW!$P3G$;E)%HFDF;1JA4-AGX>JQ
MDM9K5X(6"0CE^M]95Q8J3%UD!/:$")EW=+48&1)&L%&87U5Y#=NW(.9%1UNO
M3_5QF@$H>6-R07-*J+54M.[<J[QWW7(8L&5!,99FA[S<V5NJQ2:'>?[&3OY5
MT^%()+LQV <69JS)#OC_"@OB5SJ \1_XWVP0B0X@_PN5H5U&$1YNN,4+/9Y0
MO>]-E,4:U26)-8*)3SHXCTY1T8UJ)0-7N(>BFH&O%0*R;XZ9/)Y8+\/;V>(?
M23=*.$@B)K,02,36KA?MK&2$H^'8;#%BA8*@.*;1GZR_$6P]"]NW>?.!^(3&
MAM4Y_U7\-# :(E/ZXDKB'8S/S>< UB%5S2YL7NJ<S]2#%+&5OT,.'XHX,5!K
M8S-Q$P/WC;[GF'4Q+;^E3!>A7<4K5[2@E !G<[8BR9*+F_-%O7:29E9D93/K
M;3WQ'"-HGW&F]><;X'S$+\:MD3G$9,A\6>);B@2SPM3R@@T>NMHE^ZBH"-K0
M(7'-JCS/A_FG*^?349O7UL\0=]IZ/!U$MCNW_] !W\"75,5_Z8K&0%Y.?U3!
MN8IOMF;^4ZL0)MBL [G-N2WTM'TE7H?P-R<H+X&[:_W.I]OQH?9:ER*(KQB(
MJ!]P:9C&*-H%^5;] >FM/[])^W]_>QYS!3Q,^AA;#'T[+EEE<W'I^E3M>Y3D
M]E*7C4='XN"HVY[[5'&;P]WYUR*L'L&NVGEBN*_2M1F?32'FF;C 0)#M/']E
MLW]FFVWB#3#N622WBI)Y]\OB8DNS\G1=!8X?<>,2UN+=R]$4]M6C7^B,9W74
M5#CO!@00$A($E]U,O9Z2\J,Q0:4$&%VSW^'+:^!.V!"4^-NZ'.4FQ?$^P<"<
MD3)(X ION7:.%2#6-=)R CT80CE0ZB#,-IOJ][#51AS0I!T/BPYUD7%4];:O
M2=W+??!&?=ET&A9KHM3[I_:&SD;..Y/";^*10'>8.B'L]C\O%Y<WSBTF#GT;
M4B6_L/BCIW=9Q#F_N<G^]%"?)D@'K"5H)\V1C$3:G14UN<0TGW>_O%Y%A$YV
MJ>/9[FR+<HGT:DG1=M[=Q1C\KCD%,D EQ3L&!-D!NA)A%]5T*-3W#.G'#3:6
M9;<M?SS[=E6'N_<,"#2>5E3&=)V/$F%@.G?S7#*-9W5ZB2IMP>>![@V0+3$W
M<\(%^]G]$R-13M".J);A=SN:DLYF]D;B-Q0Z]34++(7.2?W)^CH(:WA=R8RI
M_-:VZXQCB4+%=1BWS;L:U@BQF<@5CH8W%B@U:$I_\/?QT+JKI%N8C\WXNF+)
MG"'3]:HN7SSUBG0_X=#;\H]9D,_H]\>?;0N4Y#(S*JL<+MP=RXA7]OZ\S-W<
M,*_0;M486$(M/A&.;5>V+9R*F_NL@&%6=@T85,*+SY<O/\EP"^"^;?4#E:]^
MEZ)920K\H9&[5N*>3ITIC-#]]>%&SZBD(U@$LAS&4L)_"]9PB?N<7(]E5 R/
M@MOF*3:*Q@H5O^1Q,]YD0LCEQWI&R^]Q>4Z[7?GVMW6U2@K6\2.VX@(?HEX+
M@<Z[60_F+0B8'%N-E_-NT&BOTH-L5+2@.@Y//W$T7N(4NPU.51Q_[K2$'-]G
M-@>V4[XZG?CKF"VX]WU^\TIQ*KB10TFTG]>G,LG;T+A-8TJW;E%<3&GT'?HS
M-$3R#_RCJA.I__W/0\(LK]>$>#XP6O;I8^\$WP\%BLK)'1KZ2=Y%8J8E&6.&
M?EN%3F.BYG(5_D7#V6?&G[ZRXBHM+2V2%+3Z=4KW5;JYC'"ERO7!G2VK+TFZ
MPNG=$R^XE)V7A%W\_GV[H<7B.BH;95(JRWU-NU"5E_*A!N?QW[&#"Z[!C=<<
M>NP@[-KNYW_GUKH7*<_=QJ9W/^YE4IPC>QEWIW"27J]P4@4!U,'*%%0Y"&L,
MMR0H)^-0\,87IR&PND(HPIJP\@NR &1YHS#%V5"@XUPY[C=I?^6+3;W*G1$Y
M:75=AX^J)EU/?7)R9+$;C#&4F]+Z]=U--M[GF0FA7HJK1& \[' !>.ZZD[KN
MCK(O!=T1PYYIA_E%H:0'RR\=J.=<2(P-?[<M5MVWL(7!:2'+TFNF#C%"\T/;
M<4<O\9JDSEQ=-W'W2%77>;)Y>A?,X7Q]5^RU_3);ZKJG7(6<>T<*YH=Q.KFA
M55!U1+[!TA]_R:W>Y;U<W<.*WZ.[M^OC7)#2_O&-.*MHK:@5Q7S3CR,1Z90&
M;+-@-#X#=M@SI<1_R!]^B0Y076ELEKD"C6ZS3CQ"OZN.=VQ7SG61"/IA;^2T
M&ZYC9<+U;[:L]@#[VQR'CST:\A;O:FT3&_UC#Q,VEV8;--D^]-VS_-L_J6NR
M:G^H)!TLVU0/3N=":XVN?:+R0ET6+J:%,GO9*;<K,C'U/%):S8=Z:@O?V.P,
M_#3MFO:"/4FH83AA1DW;,)H!G8< "?)2BYOEH*;]M42ME!^DTSZI8D_[A\/^
M,SD,=W;:0!4&=Y1FI#.$XZ:KWB6#-4DV1[N$^WL_B!<*XBA\WGO1Y%?9];.9
MB7B/":20G2Q#<EW5DJ+ N86RN[EU0:_J%1O0#;H>^176)VOPT"]>%T4,S;Q\
MD@SPJ1G^#H&0Z-1QJ:5UM.GABH%XEY?7M56E+I53WX-MJU&2_?C0.6UTP4G+
M(2J* B*#*0_&'X=&+R#>369PQYHTAW+"0^2L&P.T%1?/LV5G8DLLX</I'*,2
M."BR#?O^4?L4*4W["QN>3_JO(W UQJ*V\V*#Z][D=F4-M1QV0')4:T?[-V?4
M:3:5Y8[!]?I'D!H*$=M?J..JARVK!-$8'Y+ZB*&.1B)D=0L$'$HG%,%!KXFW
M@N3QK%K?^*NR;XX::S=;;_);<)70QNTO8L9I.")CRQ&TYQ;%.$]O+LSW?=F.
MT\<Y?Z;</<"Q_>:;D61<3BC'&;:WGR3P<+&-P8HW(=6AVWG)D!'KTV"@)2KR
MH.?$)RNH%Q@-)N1Y@-HG<F3[/;_Y]HL!4XWF(X:,!^!^T(BC69*Q:Q-X0?P-
M\P-R%H/.A/\=7\P5V4FIB@/&(89I)F*HV]$J(3,O[0FAH -X0[='5_KVKU$I
M_NQWC6D6&/%LY:FH(WZF<JN=HKTCGRH+PZ/=Z4,Q+_M ^\&:VU6FM>V72[:/
MBD/D40;!ZW6G^(=E<_TF_Z:9?SOFPYSZ;:Z;L7YH9#+$^+LAC]-0ADT/Z #L
M$ >I"$%VH.@V2ZJ"" 4Z%>8@X:G9ZM!"';4KG2Z<7W)/PSK\-R12ZZBYB->;
M;09-M>%R>:J1$1J_ZYP8"P:"@OP;$K[N8E5'7#SLA-$=V4>C(Y#FYL2*#5/"
M:8FN$8^]+,;*(K_Z./C)5) KO+F(MB5R!C8RERX'N?X.O^?T*(@..*0#3AMZ
M8&KS&:U?RJ607HO,T:AA<@2R7!'5ZD!^1!L=>;@RKBIQ;_ I9#[$#.S]^5^O
MIOT&XK9-,&+;A:RQ+ET6] VJ8JZI>L)YVIQV%X!L$.;]T9%[I/X$X-W*?[VW
M:5UA ^M9:8ZA;*\LMRB2).9_Z8)_^+/O5B<'1-M1(5BCZ;O-0%=37[ZVT"A\
M(86JIC+AAV0N2] [<5'LUEA?IP,V*!)[$"UJ<Z/Q2S95?<)JA_G?EI!X!OO8
M9QK9>1[55\3X!(XRVD(X%5$6HZ"Y;VC6U;_U"66+K*P]WG7R".;&GNCO%PW$
M0Y\(X5^HMR5H%^SLUE2\L4.GH"7<3GXEP*0ZGU]_UDG60=W5_S>5-H3T)WEX
MHK]Y$)IO!VM3$>J^5-=-0AM;W'OBIV$Z0!TA&!:,[3+'UYXY820SFD-N34-
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M,$Z)N^<6H%Q8(4_6Q_?#[IKFT[@'[6.HS7 P857 B(-T)^$O;"-_JE3P*EO
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MWQQ%I4,:,Y);8\./Y?'2D)?F#GV5RFN_%C'Y>E69'_L[FH6#V:4XFD3@WDM
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M\(/*X)&GQ^@XYA0.61_'H%]LO[@82^$@HL6O (VY;?$24]O 6L-===1"_Q6
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M2-HQ[TQOE(+3I,I&(P0_K#'[>F40;Y(=%F\U2^<,R<-L@&^L#WMT2GC:SJ\
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M',@7MBV:(--7[<5\ ^XR\9.8^6L_8VSEGO63P>RF\6%5RQPH!5F%,J[AR0=
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MVNB'DNH%<<W:T*'.SB&>P,FAT05&/J'E"(!>+-^$]HL-P/NDP0"&;N\8LRL
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MFQ0WY81"[NSH.J0#DJ.+5%'#M+5Y=X)X'W.(70'4S',*9:@,>UJE":%@ARM
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MJ]6;CL5=C0]O&!AG^7Y*B AVO@CY[VG>?R5Z&(9+KN'':5> VZJ$IF=Q#'3
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M*VY$%B]EDZQRG)H]1/I5"25$O\F[>HB-*B1Q?E#=EF'7M?2^AFDRE18:)_Z
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M&"(-LY^)VWTLM1A/^LZM5>K%JUX2:YJTOMG20SE,2?+/'*SXU2__=W--X1:
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MW6\M%5+8+?H"G,([#D7J&@Q3='R!.D3_B_&H_VC1X85A1<)5;C1:"EM'^(C
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M%5\Y?VL]&&-<L^ /ZD"L)IC#M67TQ1%4),=Q/2]S,<0E3&(V9RNZW1OA .P
MF]C1\UL"5C\W\PMYW>TG-,Z.A(N/C,R<IP[@]2)Y#N/F/Z?)]L8:[#= VUK\
M7OO!6&@,A2J[H.6V1RJ.M9!6\TK7F]J2X1X\:C9;?['O= T=3?\;,3TQ'T=7
M%JGP![GTA-@#>%33D"'>@/<'MK<J2/6\()X<T)2=4AVHKLY7OE7SM>G^69\I
MS^4$FEWI-%N=:;+R+L_1ZV?:+<U<$[O23OY\USP<E.'9,C#QYM ;F$2\+]^7
M05>RM)X08N!6W'X_"Y'6 .U$U8RG(U0Y$BWM'IWTK0H*X@6;]3%2]P4?\&J[
M'M[B>JHN":N)JCO$I!Z<K_D>.,)>?H^J#[I>&=;6=;$Q4*_BS4 JF6X,_7_U
M!O4KYN\X(:N4_6':T^W!8W: 1<*M"$+%*'O<W[.^Z1RK)B4L/'C/]RF+ARSE
M"K)_QK3JC9J1B Q_UEMRV8DW1\P**SFLG2%E[\K^+7$E4.(C1.L&5U?^5NKM
M 9L[&M5E@<(DD6^5=41H.0[-8#&3PG<>U$CP6GEB8F#VY5QS\FO]I+G@C\T9
M[)'3C6G1U?X^5ZVS<6?K4S*!GFX6JA.;((7!6W7!FV.NM5".=9#6XUR[F]0*
M&N3(K<\"2D#&J:?\;0^"J[W>LP/-S@:>]0@\9!TC5U 4$Z0T\#I[.<?Y@-,7
M0<CN%;]_J9US6Y8_?8Z?B[Y^PU%;(H7U#7!"_BDR_J)^=7NVUCV>:LHA'KQ&
MT^'!MWO.Y&9UIE4\F5)!*A,=@? G%L&?%J/Z$GE,FD-QX+)G\/APO84IS4=^
M@.;ZQ+#LL4=/>)F7_Q2AZOWBCSK<_*,.7_H!1%/B/C3]T[A@\&\C 2V"R^FB
M;Q-Y]HL.\RA$59TDD>M$H3R8R?.+_V9Y9:NJ.JD,YW<6].91Y$$-]SR? 9$=
MQ;_5(+?/@^\>WQ"LP5C 81D^^W)MSA@U5,<H./R!62<TE_M1717>Z)=GWC=<
M<LB8*^7EU8Z\:HBH_=Q<.[:(^*^!)/%_(/;_)HC]'W;U?XOK:[RZ40V(]OD$
MR18^L0.M:IYX RN#DVUG[^57I)B29N.'"+5X8VZP]OQ%9H/1K%A[07BN5;@M
MQS<\7'#"K.O[V:8%6LIQKY2<-!7 8B5,P)/",@^(GZ)FF2A_N/B<Q*"\]H-^
M@&=4@X"SLB4R8?^A^YGQD\K#W+*!UJ8:UBJTI#M0)\O9O&D]?K>XZ8S&7JCA
M+IRK/RE3)"-11._MAZ!B PBM^G208 KB8Y&2,8R(%_3M F'86@J["(7(224M
M7,$ 40020 N,*&E:]U=/](SBDIT4UKQ*&.1,0R:7)3#:8G=(8?VJXB8"WX?0
MR)3"CN8.#1*P]-^9[JWJSYB6YD)G< W->1*]$8_L;S!*HC]3F4L'EMM[>93$
M OUW(MF)5-1Y?E]RZX:I5AG@@X\F/R?)!"WW'H/+Z8BR3AP.WWTA)&2O77&Z
M9)B2*H6%]*WLD\"A#KH5ZN.C"#.QL6\6>5_?.M\NT?UN?_CS>:_ .?W1M@IQ
M8%+A2,"I<+7 L(]WOKS^:E)XT*MA.*AZ+"8XIB!1N#]9MR;LB?XD88PB.5-X
M&S6[@)K(1ZT"F-'DUC__(8:^LC]VTX]&'1)S0PJ;:2-</3! X@<0F'\2ILYT
MRTOF,1+:L!0VH!F3;JWH=K4-4T"GYHB@5Y^BQ 6VB5+8TATI++A*O(72AQGK
MD=A(8>\1DCZ-#L)J.Z%Q./P7.AL*SB0I;.K(L<.<;PTG @A3[[<5)^M/D3;]
M=S=P1"O0HHE@)J,5#E3,MO$*E6=81O&TPU"RCP4)PH<;YN5!TKEG_29J"O:U
MPPTOYL-/8-R'OC0,+HXC!Q0C:RC8D'V-U"1/N\NG76QW\7?SF PZ2T.0*LXS
M18\N=ZKZ=:OM%D11P2_\(%YW2NNFH"A4VC7+P\4@:8*4%JL"VKX<\3GXCF)(
M,S;JH*OC2CKX@<B=@,5,B5=&3QNS=>_0C1GO ^QN9\)@[H$761F-5:L<1SR9
M)29,3!YPN5^Z,G"WS,GQ.E5SZODKSXLC=:'N-)\<]VGZ \P==2/0-UQX1@IK
M0[7NQ^L.$JY@B,S88V!>M!]O?CT><M@=*@_=U2<3@))';L052V$2>?38.D'Y
ML&FOPEE^84>?(MC*]*0CY"2:(O-^FD^K)L!^,L+6X'=VQUDZ/O&>B7V+V<@4
M_ [ &>@[>F$".=<N%." 4.GDQK@>KO://=9/#_P#;SV!V-ZMF?[G_AP&VW3
M1"YDUSU-P.&7C#%'[&_I:,1BY06D;O^2'(&QVIA:AJOP 6Q*'H^^"O;C<63'
MP%_G.U37O[49M[5KY%<0+3%<#\K^-OGR9FY^$'H?*<]7C^7V0JA_@A)#I3H&
M$UPWW*%VFFK-F^]DI)MJV9GDG"@A7!GHO\C2S*;GH0 T5C6(7O\E"7E \EYR
MY-VG=TO>6*@BRQ'\*++^S)1(M6YB,>C!_=HP?[??@W'$VC\[*J<;LQ/7;!5
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M1:IYG]-K0T>J:55YU?.@#9&ZQZNC*3X>QX_K_-'OXGQCFNUZ=X=]WD!XRYW
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M3)QD!]@M5!%%/N67,5-0ST2R )5'ZA#&*#!BC_"-[MPH5)QIW0:Z3E:*CI6
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MM^%M663 I?5U!ZDYA[Q*,RH^N7?U@7J83BEL=+"M=Y*3B@+0J#3U]< 8QS/
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M^ W/5U"U,G.IH<KH'(MNH>;8D^J"/2<)0L]1]FGXV1SE=_:H9%-+5P(70,I
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MB>;(=_K.N#>]^F6VNF**L%5D!Y0SN!]]#$=,8E#>H%NFO^HW(F]\-R/G&2N
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MR4JFA/8B[,+$ES[5AW_<M?P2H"?<>0X# Z=H/TD4,!O 9S37/?L_B4Q:]XS
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M8Q].3705F(E&T,"/C:\SVGG:G#-C+?9"654%(30^2 R%O PD,-(0C)QXSOG
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M?! L!_X]U&VEN8?GP<UYM;)UB;CO[%903%'54H. ([T)8AZ\MMS 7EVVW]:
M?8\4ZH?Z38*-45$]LX:,K#H61I))3$+K^(?#IH*#T"8T$R_3^C>-&^.0.OCN
MO,@@R=KOEY]\K]&P6"@J77T%*IG58MHO#Z/P'&O:'J9QFV\>37\\_.1$R;?*
M:9N<O\<&>D?! R,S*R=F;D=,UKK6_W$C;O%?MF#$E$OX-*NZ):N$F^)6MVW-
MUB 5#?V8[![O09.IQ5M-FD]>S0^X6L:MOC@Y5"[_9A0OANRW";F38??0SNGN
MO>5O-CDTHL377$Q%R=<VI8FZ% W/^].!N3XYE0%R&%SEM&QI@_X.H0#?I3^5
MO%LD*?Z*TY.!PXF1Q1HU3HX^#VC(0RB[K2V("/#(C3%;K-R2G1X@M[L"6SS;
M6D*4K)EJ'2\("3)RZSUQL/>$UK&46=F"S#H_\Q'83SSQ?X&:L%GO'*/92H0!
MY9Y>]+*&!F_934OOZQ6T!O/7 TFIBOF>BGR04\C Z\7W+?FXZ@#2HJ?='71^
M0]8L808X,2?!4_X84']OM4? 30<)BZQMZ;MR7;-:$PMCMX*T&<&$6UM[1N76
MIF8_O>(6[?6Y7/KVF]1K#>A$CZ)>]41PB[TW74QR$LC]?B*5W>78=G2,L#7=
ME7E)V8K@*5\WJGW(=O]QTUQJ9WS11['LISN0?]WZRMCF6M-3%\87&EY7,&99
M/.F)\6F$O3DU+;XFTULUU%+/ =7G,B"C.F%[U2$#%3OF\-N+51ERO^*UE73H
M[6&T+UUTERUY7!<B!>28CI%LSRSEEF94+>4&%Y=K_4U;HB+7*]=>-+9(?'SU
M\8JV\I]69R6@BZ  TKR8%!_4(4K'[@-Z5L!3.$;R<M-=$K> 17S-;69#%[2A
M ZS!6@]NWKO)VG=LK9Z<@EE[NO^.S+_^7'E_W_E<4N#@WY/MB'<QD-?S&=/=
MM,97%6BJ>\J@'IE5R=6=VCS'R!I7$1U\1E4W2PFWD_*X/%)N%_8=;W<PRXKR
M*E6DP,(%=AB>V*8R:FQ=M P]/=9B3?=0,ANGC<TS6 +.+&GVY]Z"EA<E2]E-
MR1%-)XN])1Z5!MP]9EWP]RD+9?S8JWXO:!Q%+'$;(7[+6+E$%GV1)29L2FAQ
MXIUFAO'.,CTK7@(/U\8#V03[KD/^KI)GW,[[EB[*!3_S0I:<9UE%2?L'!Q=B
M/^XT_!M(#Y_8H*A:.UAT<+++/%1G=*<2X[2F,II)<TY%#5:,Y:[RZ]4HB^'.
M=[&&5[.UKO4L;*E/L,)5'<H.TTXNQ'\JLQ>SO%HF]RK_B'*_Y"LXKG,->GPI
M'8CHR VO#3!$Q*.5 @E?'175A[>2DN3[B7N6[=P]#&+7BQY*-64;&;5>=':+
M'+F6.KKH6C)UI2F0(F?M[O"NHGS697$J_#,>&U'VE?FQL\3YXZP[W!=O&AFN
MO/K)-;RRQECZ],RLE=9,G]L)*Y/1='=+12=?F)T@-OV+\6',_$Q_,>DFZ0Y/
M*G"F47]M<;$2_ZDQUU4GMR%F]BA-:_7VZ(DL]6OGL'6O0Y+P9I)J(\G%^YXD
M3\4J/LPLP9]KDEPX9WDU"1K,6$]&>U"%M?$,7"+:G!J)3%==O\E8:RS_FNYI
MOLOH0@Z\=,9-K^/"\.4A3?RX?H3J+S[OG@(Y3(7P4J8J\(!^G68PP@?5(!"*
M&A-F=5-7"X+-GDZ])+-#_6D+CO05L]"@+Z_Z%R+OG]I>_U>Q5-$KNWZZ7'JJ
M-CC&<6K$C)LU->3'/AH7JWC<OLPFRS"@0-V>E5G>>:YX7]B21W]AOI*'F<3G
M3)RN7=9T1/-$^R8?I.#AC,)VC_\JDD<6!UB!E_4&I3V7[-P]VQ(4=I9=L_..
M()&LAN8)4G,T=-UY=$W/@C)#RODPVT7JFM!JGQC'_4NXJ-D/29DB!/OD<<>"
M7"TU>!Z+WI+IKAKB;AUMT"ZSY, _&+4">"RW@Y]JUW:V(5E^:TX>R<>[DESZ
M0N_DYQ=\&DY$* \A7/]E1C"&_:^LZV\833R$S 5=AS'HCP2DB3R&R^)9%;75
M_?3:H9^S.[:3X"\8'[21A>0Y@IE[W\SQ[I_" 2'M@E-S2X-]?-"_=8=#W(K[
M?!".#_IN*0C?&F+ 8W<D'_2[+)QS=EYP$KGENX!-7Q;0PI._0]APWH<[+[4.
MH46XR:MROPNG!+]@?EDEA&M5W]9/H-6WU;Q)/_(]072ALO*%2L(S<XX$F%5X
M1QHQ+3'O>JE+V'6$=9KYR2#P\-%S]=G+K _D^D1Z,/J9MB;RJ(5^77WM<S_<
MYAX6G)O!46*KHZRZ!(&49A)%VY/:=C20"1!IB"ZRE&E9.P&H<'L$;QC198N(
MPJX\E(>(HE0Z'4_IY3QJ4;BYK3\E11K8HE!XA*J IG%2.=/G<*QTO31>SD'!
M8O2VZX406]M\G^G0Y C;&M+,G->ZL2%C.7[C@!(^SV?T]8=;^F#1A,=>^ZTU
M32W'-$;"BF6[D]*3;Y0LJ%D3,F\4K+6](GZ68;UH-,2M3K)]9O].^/*US0#0
MFW^J/-46Z'\/N4)AN'77,P^??M.IB&=*N*2K)DFENJR=<+#7R>855GQ'_]C,
MZ1, "\:RM;#[R%M)9&]+QC'&.!]$%.3S-L.P>Q5,*A^TO$G>4FS\<LW6U.?6
MCP3[?^>0FB<K:-L\*PG8?ET4.36XLLZ.1IV,U$_3]<_%<22663@FONN"C>S%
MD\6,;^;ISC6.%G\T/,FL4^U==_CV9564#SHNR'HF-;E-L"U!6M4@&G8=.ZO&
M!TT++.I2JG$G=[B!V\D'C;R&U?U7(4. 2.>#4N^!XV"!<U-S'6T&W(<\ \P'
MZ=P]"6UB@I MP5$&Q!DRM).X^0&8'?!#\LR1S.ANJ.)<8'YY@+X0;E3@NK'N
M&BM\;%RKJ*;MH5$@X)7L/(T9O?@?\@#$7E@:N*XAB>R+E>/-\D'2/#DT%/!2
MB>6)HI2HU4Q"83U/IQG(8G:R"ID3#S@*11RID;#E-VAS+RI,&&TR7.?A2YUX
M1#H[/Z2G%4%QK7H1Q3(:%.LO:NVN9TS<R;7]$BRL_#?=9VG8:M;:0G]5*KC&
M:3MXF%)7/IR1]]@+&JDG9/NF.\;?:B;36SK=!IE7XD'4=B97P7Q@4X>0R6)$
M(  R*<-ZRLW9Q F[N,P*<C5&"P^,UF- XDB?QXC(W,_]'5<Y,""//I;+>A<6
MM>JJT6^B?@I"+52KPF>'2&-_IGH@2(E\R/&X.N@S9F@/HK9AU8 N%@L[A Y_
MP3D!()C-ILS!#BPH$"%:=[D.%P]5 I+F5Y'MAL38K4%Y@/8YLD6'R#&)2A,#
MJC2X,-XA@I)3SFK3[H3H8FNIV2\_JS#=XH9:25&.R<E&=[QT7E)3:%W!>K1=
M8/"C.W?:'8-Z298M"./KPA2*C?:9%/WYQB#OOJF =RO_4Z[\]7^77#DB^5XE
M;%^+-1&51(&>Y3[C@[S)\8HJ3!A'LG2;Y3/*,:?#[\_N&M=;Q( ]([W89M'N
M_O53L>5T^1#%XQ-;_2D.WK-SP=7-TS(Y['.(AXI&W&>PZ^0DC#&3V$5,F*N-
M2]:#RZ)&>/O$L6SC)8-9.>XKF/^@T&(M\&KANG.;IH  ZE"1"3L&,9L$)_$&
M7#$093;L-1/;,'K<Y\^V#TZ27P96M?R6K4W[:=.NF9L8ZZ7L D?969_R#76[
MB(P0@IJ9?LW8G2'"W7H+BK\*T7Q'@:V[Z"G%@*^*LCW1FHP]]Z%RG',,R$-M
MZ*Y9OWO@3EP<9C]#$A)!&XR;*B00/ (/ 7#3896)*N66!.O*G;]S:A89,O75
M?EHS="-8W3HG>Q!0@7,+S04-NS6':/"()*]<9R3--[P52^:#2.1V\D/R@76T
M?#& L 6.O5J:^DQB7J1]H4 . FUL"O3749+JS3$]6)+G66;K6L&!F$,FL06^
M13/.D[V_$;4&6AI^N:GXY.<RGT,:4;Z!I!7=.Q86 D*!ME:S4($DL >6*UH[
M#)Q1I46Y%-.S[0U[IX_D:+K%Z(]B)+\?KQMR[9D4(-.=@A<_A"$1\L#<CZZE
MT]C)/-X,]D?/4H$>RQ2-I&._7X:L4/ZA4QG.!_U#J#)L/+--A0_R7,8NEC^=
M )3X((3 (W:>7-X)[1GRLT?)=/\)E#F_86S'>C-RXFE,1;+_R]X2CZ_W)'--
M:$L[E'J"S'I8<XH.W$#F]=)IWD;?9>D%J%\,1@QEP#H I# J.A#";4J\3J@6
M-X\<(*AP'";5\@OS&[R-J9@P/QC+!]5!NJ;!PHB 0^?]L 'KL?>TUA]B3EF\
M<IU;R=VF.=W?#+(F*1P_3&P)#L8,[<+,<8(8X]5TV".8C#&8NGRS98+CQ.CI
MF95[OWJB4.1:T[C>W+ZE*<]GM[:=[$R#;F7,SIR7@(=H7KT@VZN9(%<K-L '
M[<%T\T%RL)O$W8 $S6D%<2 )CWH%$0+T$5,B+#VF0?RQ89XPVH=IDA:G6X&4
M7<8=( '2?) U &8V\7BSK$O,PB?(2,:7'L/7#S@1+W8W-S%O&E&7[ERPN);L
MK89?63JQV-=OX^^O'C5IK9LQ;)?LEOZ9,L+*4NL=RJ?;' HFJ%DXE@VH+N]U
M&:FX252_8Y?AVJ&3TPAY/W@?+$/@F: 5&3!*!5)T"2JF>&JD:DW;6.O5TCUI
MTDL_N=1G%0%RBA7XCP$\V5$]CUWV[)-E^!F*%"OKI?N4QP6E9X=%ZBSHT)]U
M_5FP00"R&RK!_9.W_VLAC(%I_C$=]N!BFPIYPEB&YD>89^Z)7=,C*Z"*W1Y=
M&2NJ>]-<Y_9!<TL^5(W4]*;A1OM\H?,SC^*?30[5S_1.2 [JEU*6-ZI0WQRN
M;6YJ<&O>UK/++'Z021Q0,[-K6D /BK@T5V@8M3IDU=?\0QEEU\O_EGTJ?TH
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M\GYEM5 Z/+!][!/APNF\NBF'<TOV!(MR,\EK ?8IZB-E-@=L:RH<0UGIGQ:
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M=M2KF\W-"U*;/;F2FTP9I/^JA# U]Q"@TXWDH:G#ZU>\'E\3KU?Q&=9L(47
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M,/GW\?OG[WI$6,%=A^JV=?M>&#"I"_5R>9&S>'Y@^713FN3[U?E($[/!"?Y
MUH>1BS]^;*[MT>G247[;GA6\;L%8_67!GA= ;OP!&23^]/<O^B<D*?/8P#AY
M3&=AZZ_/3H]5(>U2Y_OG0K?-S%:6K!TT_J$P,X/<+#K?Y/[-J]XE*\<+8)2
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M^_U-#?W[!Q2:<P4^W:KM0Q6'?WF]-[T2]K JZB6^;F7.?#S.3?B;I(2&DD%
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M;@)KDW1+/E>1M8ZGWD[0_H ;D .K-A0B38-")^T$F=R55AEDK]CPG51[QO\
MZ$W$N,$%D=1PDBI6#2BMB;"R$N_B=O_P^AIO6S*,'+Z4MRT6 Q]N32S3B-"\
M;]_O;'CCS%MC$M+9-6.ZSB1&*6N46=M;W,?HN^]S--W0K7* ]-K5M$13=.AN
M>I7'R='C]_R9=?R(<*80!2H(-@DO2JJI>EAM<)L@S4&P,;<"]Q:A@--#Q:R"
M=!XB-:+;1RXJ,!> T96F%@TRL$B>E7Z_0S]?_*W"1"VR,;3@B?'(\ONFEA?U
MCL'[A%!VK?0<_K:<Y2_0Q@H(JQQ"K=49T2EIAQJT=K(=OEOL-D +)K$"A/$
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M'U0[8K>=%'\6/C_X608A_OL.A1%0BC)(EYCS09S9:85O]]\'>):=:.!E1%T
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M:NS[:K3-E?MMT0["E1I6-[Z+I/?X;YZAZJ^^^RP0EBHI_L<')%B9_!D(*/)
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ML)1NC]]6+#LQ<K$@-?RETRI*GF9Y3"$@B_,GQ9OY^S3]I;OP[B ITU&0(S:
M+TMF4H6F)E#2G,#P%=U[E.X"6$JI-Q# V@EB<W!$J:_6:8A2=RH<.H?1/DTK
MZ;IDNF>BS3W:<Q3&,NM$,:X3]0VOWBU(2SZ^C1KRHP952._UE;<5B$H>519W
M^)P.77$.NF^7&I/H%=CH1;;4,^3Y-&\@_U.G%]Q17%#O.<-R\,+<3N%>;2-
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M'2%S*6E:2_EM>!45Y4M"W(FT]Z7]*BK6G2#%MS5#A4>AP3GLEM C]7 TE-,
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M66C-!Y0U@WH.T6A'-SSX# S[5NY'J_V(IA@CX<3>M_Z:B_AF<P*YQ%,T(2
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ME[ P3D[#1=^TG2#_,\@]VX ^I9DZM,,$V(>R-;S?</@;\_#?"%Y2S0W,\6V
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MR&[;%^>/1BB *HHT6P\#E<T638$ZJ LQ2FU['L" 7*SF4$WW2QL;G*M4Y#8
MV,'**IG=!H1CG\BMY3/A_['?9QQ-5VO:$1C 0P:&Z=@Z^#^HNVX][:NDUZA+
M*0/I6W-[@Z'?5D5Z>9*KZ^%0'\M54@I&1D\.0D0;4:5^./0H?2GR:+D86,6!
MVKFVQL2I=_>%X76X%\+]7U/2;G K&N?=WS'WDX,,2-K%;I3L>3,;CC#5)<%#
M<FFMGKD$[*L5I,(F6MVW 0B^SF%NJ1Y[RV>N VG9"R6O-Z$_@-)E2D<38BC]
M,&H+7J6/;,7NU#IBS=)Y@=/N^RLZE"5@,$V.82,(!9?%FU&]U"<KNI?Y+IY<
MQH;[B9;"K0YI#^J$!(@HQ0WFV ]_:FNVM;GP3["#M?VHJWJUGX?IX9(]U^QV
M5>$/(^//^$XVTJ.^,RWB3A3'MC"T^.1,)[WZYA0O!1\*/<Z.9RH\_Q[--VXJ
M@;GM1>X>I[YXI8V]!Y<A1RQ]TN:Y A-!?D5*]V(RT:JR0R@MAD/"C=&<6;@-
M&WM%RME**PXD3.77NW/7OG:;H\'0;'32-?4L>Z-,"^;A04)$@T+!M)T<TL_Z
MU<=O1SK1[VA L:TREZG.H*$<QLCBX<2I&<9';7H]V]0SS>?E"(G@/<+5KDW0
M>CFR3"HHW09$!$3N;N9 ;WWB:I=?EWV%/7VGA*IN1^U<S'_[LY%1N,^CIL_O
MQ5,^C<TT0T34TP;;7CY>):6#CR-WW^Q:V)E?%V[)Z&Y)N-!;8$#"]'.A:]%G
M]==("8\#T1I_#J;HSKO+4WZ_=U(?SIR2SP17;UXPZ$*TI '9*9YC=8[PUZ,N
M"6A0YUW[ZDBZJ>(2 V-"AE+AYB[;@%S<5B_<D'O<N)D-[77>!LPYSIJ=3)K9
M!DA(\TXM\VG)/<Q5K&D;L"'4SEL$H,R8^[$TOVW $A3+>+IU)_ KZ@*$J8==
M+R"S#7[$]PA5S">(?P*N(V:69-I@B[RR5<4*Q<==^$8X!/G-V*U^*%1A@MWH
MJC)$3F<_K/&(5AQ<T7\^(BW,(GWB'<UHE01T7RTD/O8+QWD/%A(?;5ER[+5G
MNJ/B,=.PC6:RFP=O#_P*ZKK_:$>W]T:+V3O^L9E%WS9 :&3K((1P'^7\FAB]
M!8),L)L+L5:][/RJ8G_"";ODHAS_18]N)K0&I?XZ"<<@"5>;;15BQTB!;%BV
M#S;BI%"O.U^S7ZNWHE3QW4 0."F>VLT"K1*C<:S#Z-/AJ#KFMPMD/Y/Y&5&P
MIV$%]P Y@3V1NH*5V^BW#<<BQ-9SU8 V7+645G]9\."?L6,45+J4? TTE6L"
MMDT0;Y5\VB)7?.6H9]DNXW3:O;)337U[?%A%\HTPG^$(SN211)?,XXF+R3YB
MQI1;C!%32XWL4R$]#G\P0@Q(ZKV8=@[T<B'R*#JI&.AOM8K?]Z?79?95$C&$
MJ*>6%3C2I7J,C:/IAW^,_'%<%.G[%Z]+7#\6A_B+?9DI'7=ER@@T#93YL]\?
MV:1AD"6*"U\YUWD(7+:&#95_D@GY38H%RUM,N9N;S"_@(NN7#\+7[PL6%2&:
MUG990\\ONNEZSCL$O?7G ]IKLCHL.NCD,6@JTIW=FI?;';PF%GO(UPO1^%@/
M5*"Y.2"!*\4<@?N716<.SEL]S**\0!W';\EI$D+"U:M/9258_;_FV=;^KQ3F
MXC]XKG<H"C0Q"5%C_<X8Z,W<HRZZ2'A3P:\3-Y^D 4KR4,XN0?M6L+ NB(P0
M'R00,_@C""CHP4_UH:J2(K=''?9"@];,,.P,:?XJOZ\U0/@OX*<UJ@+G!K8!
MBQTDYRRQ/ VPYMX8')\]C)F13?[EYA.6&9N4.+VJP(H"9]_I/./445N )<W7
M=<QFQJ#H+N:><J'K%;>JW&P)0,T>PRCS+,$3R<1S>%.1N[GT4Z?VYN0R5^R%
M@B:6Q.5ECTPWA^!?@%6WWDKLM1LBNY:]R[X5-5(V6"1NOC]+C"A-!PQ#0C@]
MXS+2_^)C)46C#I:\^7!^,%=PSH$9A)VIF#=C-]2O4%BDM]@*C?K:0?GYY)MS
M P)KBI%,!S]7,7U276 )LM#-:VG%\P39B.%7]I"R;[_?A[IQ2_);6^,[F6]$
M5H"Q<F&)75])R4MONO./[IC7U^S"3Y<3R$&5.+_LQ*VY^;C6/9?S%N%"A="N
M<'HEJ8RGV#HU.P?Y18HA'VHS_FD>$K5YL>'H[!RZX/2+@:[R*-7"JZ$?_LV0
MYA6H8 M05RH?5$Y^P,HW)/2\.-()",IIKGNZ4'Z.6MR,.LZ$-">,>A_.PK!8
M_BV=][?>WJHI)D5R';5JAC(\#;SGGIW/+\EE/_W0071_?]I%F5S']F<,2LG\
MIJTNNFMN0MA!&LKA2=TGR#3&6+1D'%ZZH^NTIT9$7UR$+_#KVMNU^6JM#6=@
M;*V8;\#]*26AJ%5^QY(<K*R,>!WU;<;B-%B,G<?@CM06Q=,9I+UO@TI-+LJ"
MGL.SZB6,58Z6E^CMA)_*LDF$6(@].ANH&V@V.I4GKUC"2&[!:31I<B@?D'.;
MBS"CC)DI4BKYR%RG DTCA%++?K;9V3."I^8EE.Q>!5NP4V63^?"Z!+5F1#9J
M/@T4'[;33:=M!@00];'I'$H-:C=CX:'Q25)P'T?6W#!SGC'>4+"&C&[]^81T
MJX3A1/K%\)!M)5A2%635?>A& <V/M\Y+MHWE/+Y=B-I@/F]XK?XFIC@N,XDQ
M@RO5]LBK<FKMA!/J)8A2ONJO@(WP_=QK_>+^A/-++OV>)M?OH8[7)XS]/:5R
ME#):?U!CSQ!>Q@])>@%6;#E>;Q,<M>E(O=ZZ$(#S3@NS 8.\M,AXM58/^"'4
MI7Z'0+6]8ZSUR";>XW:^$8@D*VER;4]N Y"#C@<^XD564R:K<: Q<A/;/ZMQ
M[?Y.Q+P=VQW2]X%#^04_"-V2@A!LS?H,T1ZV<0HF#"-H&U9QM*DD; E^A_V<
M9[:T2HHCFUA,[Z^7LQ_-KP%*>[>?&BJ"DCKA9EQQAN6 B '.H-5[656GW@@F
M"VR&>V*ZR JQ;T5(!'^5]QU7#3,C^/XWHOBD5J(TW]PI2']]<..2V-N]H+**
M_EO/=.SK]FC;C_A[-P4T/UQ1C#QM#*41^F;+K^VA[R(#V?$T-3_=_8>T6A:@
M0]L >=8U]6G FBX3^E([J/!0T$;!_:-ELH-<[9X[0QKT,X0OB 5()/"@QXT3
MGM$5!&1K ^3@R;X+5ASH<.;1/J4OQ;BI&4GMN_VOI-*I1D8A#^2T^ONJ@"\5
M]U14E3Z,C[,@! <ZUY>YU#RYH'UC],]][C: _8ZQ1;R7U&>,D9P<2G:\7]%P
MIT@436%>_"9NZ0OR43 !T4BOG)5L!X#W6W7[1:\:M+[A*Y%(]W->V;'",S@8
MA1T1N$;4[7K4C,0UNMTG?M?XRYH#J]:MZ"1V>RO2K_4PC+YN XYD\UCH6YL0
ML=]?V=!VBF@-;!L0!AW"EFP#.)78 Z<^Y_U%(W:&OXJW3C=#B_GN[ 8OZ795
MZK!$*N'3-8%5Q^O_VY;=^Y_M?[;_?[>/!+[PQLIZ3<_IRY#PM7<G[E7'\VQX
MDBS;M4P-L[;.1T_'Q*Q?&-@,Q2>KT>EGL3<L6J#UPK]'>0L\)P>,!!D[R$M:
M W&-8G&<^KX4\-'6;8!Q0?9(R?2IUY^6/"8A;"=__IGN*5ML1%$!+Y?GM";&
M!55N V;PLPZN*"-<!Z1F2VWSB>;"GI]LG"M#^&;VX10NJ%-WT?A7C0AT!'BH
M5EZ!6!NN?-ZD8++[Y5 T(N#8K-MU[T? 4^E3\P=P!BN0H*@4YZ<9QC3M,5+!
ML[*?*-<;<VKZ!_0/"$M%V7Z+_18JLU0ZN @&EIZ73-3YZD)\["[EH//'9-8D
MTGKL75S)!4:!N^^WZ1J$V O2N>=\>5%40.V.O/;'(JD3+4CM%K X ]HDCR4U
M7B/B>A[(6A$E%E _P)+D<9;G\B=\A#^>9;%,^BS46,GDD58_\NWJ4R!W90N$
M']$>Y36XX>(FV==G>#<Q21IX1AG]-1"T2B*Y4']@5SI6"3CJ@/<O/OQ;84:M
MCUF.M;Y":GX5]3KI>4\+?A%I9+>I7AWS)'<!I?AV89_5[()/<[5 #-28\ /M
M+";$"O2(9..6?_&%:3S7MRMK&P#CC-.P'9Y\57B)^3'46RR1ZQ2_D.U/7;V;
M8\7!-I1/-BJ@OC+6.*K3-I_GX79(:5C%%7J'IAUL=_"YV/P]ZJ85/6=W6]6_
M _H^YP639DQ?[2RTPF= >%=&A;B^A2.[9_>;TIZOU4?[<P6^B+R7G,:+$R^]
M?<C\22'4_]:=P1]*0<?9O<_R;!H_7,K<RE8!-L/&]RU(;U[0,(HB,D^;;;U7
M&2HCB[>!QZ4'[+47E@1<]JW^[(*\J!Z>KCWXM;2I=?WRX])_H\4>\E0A5=B=
M!X57_%8LAL@)3 M.,@?:62\A@UEG9HD)VZKYL<Z(X]/(86P'QK0\55;K.=Z;
M*:KG))>UPV-%;-##J-<]0D[;@ -O^^]O2*\676RN%\I2W;P-3 HA7 STJ]!*
MNI4&8&O25+X5>TV+2T$.++N@CVQJ;,;'R&TNT?2?7YO^W79U+&DY$H<Z/8QN
MBCDBHR/R%RP^K^52:O:25&BL67#QT>W0L[/P3/!1IN.?]7Q"^02E'RO,4R+V
MM<1JY@0#.-+7/=8>5?35^K?J.[8 _1"4,_X> S[+!Q^"4IG \):L'.&,'J4I
M[&&$=)[2/V4/\2,5F]T_QM^A@04H5>DS=LD<9TVN6GS-%G365%'E8 6V%M7I
MGCZA;O7W9O8HK/HE1G3/L0TXX3$'V,CJNZ%E<SO4""\\MU?>22/$R4X&V0(R
M\A1H:& 5FB!@N$LE_BDB!S;6:=)-B_V6,LFL+&'(H5K?4P,)9QX"NVK?%?YE
M1=?3CJ75?YH3=*W92#?077#?QW K;=&_*R'RE2'6:*"1*DM789"RN;*,-:-]
M#JF[PA:=N2H??GDQ20>TW/+=S$KWQ)MR>K3*R[6&<P^<[KR\EH+CEL*[,K^
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MBF@ER=G'.P_-!;J1W3PSXBHI@7?2<_$:_T_#9=1\#8IGX6K<*V40K]?T.D"
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M3S:]]EA#/]O2\^1"9XK)W(V9@YN,/74=C*:J?VU3[+L%NI#O$J+^,F8&.:'
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M-O!6146T2!;(IGHE?Y#_QSB!X\)"T0="U0VF$_:R[8Q=/:HWZ463\R35*1M
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MR9D9UXB661)*F>=N971\:;*",=H5&E9O/LM#W@A]US)%/M%G1/2O=-3251?
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M.XQF9?%UCDTK<BT.I&XP#7W9Q?D5<8QP'B8Y(1R#O5#)D!+V[7&-8TCT ^I
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M<7KIE-N<7$J#7^J<O9='L>';/PM]>70<^I$)1#9JL0NH0_C"&C]+*7^:59B
MMCU9O;&N50NA6T#;'RV_Z^0)GG'PA]!</\OE7KH!3;6"4)H4W)%1'QNH8%+
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MMIUN?S*_4XQ'QQ$E2^<,IN]U);/;%H0%.YXSTECJD2/JT.U;Z.5.J1@F%<4
M8JVMDKQ+&C*>PWLXM*S4-&T4XL4L33ZKGUB0VNCK3SALC[F4U#P/8R7(JUW
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M&8(PB@_@;BJJ3^&?@MYYE:FC#\QHO$Z*NQ&XT#4-)#W#V"=2:BC]O?*Y_Z&
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M)3.3$MB\A^OW+O=/\,V-Q!"Z!SP9@(A"XG\<+GM5@XPC"K6(\X^7K-4]=ML
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M@.,$<ZCU&#_IP7:@Z$4=\;=*QRQ!3S(@:3<:>Y*=QE'L42^K8S7O07/B\,*
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M:_#2-:DSU*-9W-2T@QY.<,O:Y[T4Y&!K@ /)?AL^L3$PB@2NKE6N5IVC]0C
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MW2]3M1WX\N?K/+J07K1?A7;?4JTRJO=A&>?9\,@&.2;5>KQG)&J'G?Q27O;
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M>+A<B\'C$*975%AOP2)F2D:S+8/5SHG7T5&$N]3T3Z/AZDV=J8N?*&:EP4F
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MX@0@'_SHPH^H>#5?=J9VHDOXJ:][YIB,#VPZDAY.NJ];[X=!*U>4IQM6+LK
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MW*<&T?30WY[@JN^)ACVY#]@5KIXQ'QMXXO=Q'TEKC^7_?.[*<MCT>[FG9\]
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M0HAE"CZ'!3N"NDPUDSYT>#VA^Y-\@1[??:3.+$"< UYH:BQ'M_GRI'KL[Z0
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M: 87G'JS9/KBVHKD'BS>)/=4YKJ3JZ,BVB=Z&,Y#K=N.8GYW!6/=M[*[/N9
M,"9&EX?\HL9]H(#%F8V")#M*_$39I1&B--A=CC[O GAEZBTJ1O"P&K'X9;HF
M=:2-ZT96=6T(L;>1K]+<^!J'F/LOG_/8YR!73R1DL!QS]_%PN7M\#II\#ML+
M57<J.Y6=RDYEI[)3V:GL5'8J_^:5_WYV74[.0ZP0(#T3J)KS>U?09J%BXNE
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M +:*S8)YH!9<"Y8'C_-$;D0NEC91TAQ_Q5T C\O7,.F?.)1HY[XQ?S=P:MM
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MFLD_O 7HE5R_XDU)G-@"=$DSBMG%6G//U"=3V>[.0JT9,D3INH=Z;<N"W^!
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MEIIZCRI?.5E K'H2>'$O@,63XG_G25-?)TU>%IV1G-S47O0^-9O,XDD6K5L
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M7FK(9T2"''C<UP%%-@$LWWTD]C*29@WJVCLKRK290E!JT AL:A.K &-3V7Y
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MK@2!W<YTP3U%:%_$GC:SV_1CS+9K\ HM?=35='#15IS4U@"$/J(-:#)6P3E
M2MWD%B 7MX019+8W+'N"*WRV '7];',RY"MC2\/, +X$ZRU K_\Z,0YQ$Q*B
MP7Z>)018;::^]%W_B= VI!%_F0FJ_;2@)YI4I=-KF,>W'=N8^']9%V*V-3!G
MK1 W1[8 @<7L7\I!FF9-B\/,0/^SM %U(K?N$I'0(+ITOF'J(9J/YT=-7$ F
M+R$<1*$YDZ<U^!14W<XL0$UHMHQA_6@M3!QHW_12Q_61W(%5F?MDUS=(4*I
MR*[-SY=>X-8X\3EGCUMI:*<(  ;EAMR'_B(3T/\V_I19",;\C\Q"O]*2ZXOW
M1C%GB/9.J%_%7\17_E<!+Z)NS&1]@VQ'+VD2I7,P9UD\:0O (DJW&%Z>4'[2
MY-C\3UH<;HRZ(4.HK=[H^#5.M(QR(.$;:W_".6.8"A*-G@;3ES$.\)G\IX&J
M&8$GV+EM-ZI2U6!5#RP1*RV-8N-;  ;,: 5SQI=U!/S#T7-'<9'MH:&FJ"W
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M3?%RY3RX8+7O;<D.#H ]M$[.0\Y=ZA]!3?_NY>__=)_Z&V##K#E.0\$PSRV
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MNU*@5OQ#(RTHF@ NTW0;3/R">+6((\F-.Q\.6]M%M4RSX6JV/6:F'?CP(\M
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MXO,U:FI%R\\93TT[3(4I-SU#B&;+6)S?\-!/4:TXRGIT\E\"UQ<!XJQ3E96
MRO\!D91?^(5_3NB[ 7Q9NX/_W9%L?0'?7/0]"WRJD(06L+0!E4="<,^.)GIV
M--!?Z"B6WE_>U9RCB^9(B[<B5A\ Y.H?7>E@! 1+8^U<'2S>QXVNV9T=S='G
M?:,YA7@> B0,0/=H8 [3C:>M",GOH0NPZ>E*FH7F,U4/AWO9&MT_ECF[QZI5
M!")4"$GEO!K0RU_[[F7SO@]$C,PI#3 ,PADJ7\D\3U06_;%^R$+=\W;XPR7[
M2S"N83VO-JTM1/ZYL33=X<B^&'& ,:$T^+"?\4/*09^&\-M<&'^2:1"T8Q!M
M?S*YK/C"OOLBKX.Y8@KQ4[\^[55$A.1[.\UXJSV)V61'-8X!2-<!X&AE1R*:
MOZ8Q. F[:2 YT9[PQ5!ZM!P\-P5*D=4\M!JN6:6M>NZ/R[EV-84%J4C^C:J%
MOP?^=_=P^T_#DKL_EG?+9:'?W2[*L5M$IY=X $ +MOK6QET[O[ID+QZP-TNJ
MOJ]E+J6PA1C4M]:+VZ6G4[V"8"6$8U<OY28\L22)OHZ%\'+A JL-N ?O1X&.
M/[&!RMNW778?:6#&T>NRQ\B\(+D9\)+ #Q0<;_%1/D6B5KNRZT,,]U9E!EAV
M?^W0JVV.R! QYG.JF?B*7&#4L1YR#1X15;G.I>O^T)$?5[X7^E3J+K !G.6M
M*#@XB,Q/U(?;RK<M' "RF\NER>R/#P!(S[$F \^G4J%(->(P>/8FY:=39L:8
M_+B!6,5,[B+_.":>8+E"V=-L1:2\[3!\<X#L$]KR,8D<!.R/OPF<0-;ATPG9
MS9L3>(K%$)X#WT3A$4G,;5Q@S"O2$AS[QI%RQ,C-HA_J^PU[<+L)DA[DIM+,
MV =&AH[C 3V;&!PB4N8 \-034[S);&^U?0"("+GDWL7?@\&5+6A\WKIGB:S.
MB$665>[%@RY[FZ\PM*3Q!6? W:8K..IVMA;Z6%LRH"-#PMS/;K".W\OAS(2J
MM(NS'A'*E\DL_MWEKF7SS)=S1DY;M)\%"Y7*&-+SCH51X^<.M@$@!>^-D)3Q
M(4.&%W8PD+;W7O/0VPHR>W[Z_F=2Z;A<O*KVV]!ZL(A:W>8"IN6ZPCYRR69_
MI^5>'67#WE"YS-A7U?12Y14!AF/"%OX@W1$0QP^J(S5]!,3SSH4E) 6/WPG_
MF>FYO_-H+NEGM0\3IK-FFBY5"0T>JILX !Q!\H6H$2%?:F:8S/7(ZUL5WH8$
MFS/@^GV1)-=GJEJ$[<W6&DG,@EM/IDY]_'O(&&3FZ,[I/<10W0KR29GT'GRH
M.NZ\D<+%L"<[(%=KZ^(#0"-$?+[N6:2XW50@MFJ.6A?4_H'@?\%R?PQ\;,I!
M(,[2*7G^7G508]L5XM/R%2"'/I,49K-H*@!D0;T2T8&OD$PA)A >Q^Q%J9Y;
MO''C2/2%YW,[D9OE$Q)12#YP\"[JV>3$9&<V=W$ER@B.KB@>BZE1VGT!;9T%
M9;XAU ;TSI3[C/NWQQ+V=U;LSZN^MM70%+>6 UVLB^9RL-HT<9&*.P=T6FH^
ME:I/#7;##7#S]W_*NSL5$L9<WZ:!LWRM_-NT^:GN3Q>AX0>\DBE.==N\\.C<
M). 5TDI(C^WC.Q2*:7\.>@ X_96:2KGL@XP^0]U83&'=5EQ"7^0HP<OX&VE=
M\3+VM%]G[F\*&2:+B3I099_80T__5%FJ<+FF^8K'43&[O39H,&/S@3WP0NT^
M9L5:+ELLS@:&!W6H[WLPW%)WLEQAZ8O/J'1(=^2B?Y=LXZ]XSECZB]^PQKB5
M59@1H)W?I/@/*>;"W*G/8P8..0Z7?/A#]Z%C0OEB'"7M '$V'8QQ' ]I-'M\
MR^W+C$KLN*C(C$6< ;J<<U&;@?Y1XC^Z,N 7?N&? EH_NU"Y7[;3;@<H1KWR
M>JW)@3-C0,V9['RG#8KZ7#.6]WQ_>2AB]J(=(T!72P/JFG-XXC]"P<R=&QG@
MSCVK5KX\..+;!!6@!,D4VY7B=#78?1[.N\3LX"4\$<.]SX:KB5!?:( +!&PA
MDD.$8<J!?,9O@[9S7'J\"(G67&\XHSYXS94X1GILFN/7:9",/2$_\%ME"DK\
M7A^_S*0<$M$O;BJXQ*Q0,?<QF]L]LWC"Q<M42?J;PF*Z--?*DKTZ29K@L3S(
M'CU<17LU-**)5\[/=<*K'4K8LPB6:_]XY2-""TM9]$,ZB^*3>""I)+LW7G=%
M'JG$)X $ UHL$1=MYS=M:L+-]77P1P_/C^W$*$G++N83C ,K>F;C6],=:V-C
M-!$%@ >"GYH9D^83LU/P\'"?YO?6FAU7$)($VV_#+JP*>CZK=A@GMVIL<>>5
MG(KP%$Y#8=?<Q]=^Q\*;?Q*GZ-_ J?=XVTM75_SH-+RL9%![A8]D\LN0V4T7
M Z3DXLR/KHPW&1,>S>)<9%[8W'=?!_):EE5O>-E?@%D,CW+;,%MM"77]"/&$
MWSJ?E*C9NQO;:MVK<J5X=@3.Z^9Y4JUZH:GJQC2?Z#!8,$TJ4QVYRH&7:1YG
M7G:[^,28>/[1]'4XY0447 D<&59*T$P4.O[9I%A[&=H\+E%33L^BYQIB11=X
MVL+M?G!)X+J])HRKR3^#!ZY#?-?!O)6RBQJ<H4.W#9B;W>U^4'<UK49S8IKV
M[GA0Z =;L_O9A^9N&!3X^L[V>._T@K&Y%.*F/<!JI#4E!)C2@%:6CCV*&AD/
MIE#&_V9=7JAA4!2T1F.YDA1E!7A4AO8H,=(NF.@:%5E@I4F2B+R;3V8AF@<C
MJ=4W-!494?2!^)U'LW?(/T+,^MV S'-WO\1O(6ZYCM9'/=8],E.<<PE&+(')
MFU-I8NI($^<:=6-9P>=*/O)02=>LQ04R6XY+YVYD2Z$"-=MR']/2:4/^3C;;
MSI\^^MC@&U4>Z<%QEQV'C=P?-F\?P%EM8?*)8*)CJ$A/+?;ZFP- CS01\C5M
MANGV'?+W$+.^92"C(69';2,OX]I\I,-\($E9MAF;42 F/;&+&LXH:I6,:+,O
MN,]=U"I ?,NQ9*61IW&_@&, V[QZ_*F!>5$G6O>IP;3L$F2&T=$&S4\TI\.T
MUD'(EO#NFM@'/"8MWG<<K +&T$JP>8AJ$4DEW2N=\;;^M_1<\#VRF67#525P
MRVC-F%&/V'%E:7W"\Q5J08YE 4F?GRL)CZ#;XVUO=F;%-]76K+6$VTJ!"BX$
M&^63C(VH5=R6122CV(>]>9N(F-/MWA2:S%5^W/ZI]W7-=6:,6F4DFXC+Q%CS
MJ=_TB-RM Y:%+\O']S>)O"%DG?^I2!0LCPYS=+8?R_O:GA%\6VN/?J:=PN1>
MF#]1;+COS[:QEH13XODI1R2/=G3A2L.7^"14>IUR:>J\_\[G?$%?X"4XCEVP
M<UT38\L+CYN%A6!#?&-*OBS'6J_YLT(4F&/$YSM[F[-LH]O,-_R!64[.GKWI
MY>K&\681-R+*.A6U!P:=>3XG)KP0ZLI3<GXCN^HEENN9R1HEMLP][^<6<E/2
MQN,][MA5&+7MQJ< %!KPY,HI!QR"&2??ILVMT5:TF</L/PH2%+R2AB\["A)@
M/ "LA%H1ZS<[3;0,*!? %#Q[.?DE,7+S=6.X.QQ")<)I]^BIWX8?K7?_+I\K
M:07M"H/*>( #0A67?#R?&G>LI!M@C!FFN"'1>1^.;X;9BC=V]^>$V0L&2*//
M^>D/D:O6LMEP;K;GG38[RVF53T4]'EOR.'G2+>A?/0S"PE#NAR>BK)P4?^:)
M_]XS^R_\PO]%'.YCC1T+SV'X(X<TN?A<(S^#3Q5HM="@C6:KC&VZ8T@WI=N6
M,"X*^PCA*H.IQ_&V]@*S IMCF\X&7OU(F3_9<,QMEKPSI^#]#Y4/ ,:$G,RX
MB^LK%MXP_3/-8SMX1$8%S$LF+I0R!;R>OIP,QT<\!)6^);S\$.&T[_Y^$'1!
M\Q)#!EB1D 'DUGL"PVQ6P%4)C\0\ZIZ3?6AV/-+0Q6LMI&\H-<_[[R^I(I))
M7#B.7D=&B14[S*P]J_@\=!.#RV$B1T4=?3+XF/$_5G+#)E'6/N+(DD'MU0*V
M50&O;<+=\-SN(F^(#_FG'X)T<8*?/@Y)GB2G='5AO7?@RZ$Z>T#3M^\3;EQ;
MK,N,E>JSSQV0_M0@@8V]E7 T<@OACDU[E/?NZ-X;R55K=ET7S_@/UJGCC67\
M$48JT8R%%\S;KT7A9I[Q\<CWG#V>@2?*KMS/IP=F>2NV3DQ[=-$_@HOT83].
MVK-+NL!U\/&1S4S\E4?T;H:PH;2+QM4%T.Q5/E.WQY  J2C 2J6RP%5.0P #
M6UV"30'BV?DT&@OST:QOF9PR1P:4H2,#\B>&BW]+DW@^Y/$OO^GO@'\>URVM
MKK%S5I1^9=OQ&X7[X_+&G,ON^\,W"KMV& %>?%*>6X&@E W/]@YB(<E]^0#
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ME+5M6GJ-E;O$,/80E$K0+E5*;*/,&F-DMJ3>8<.]8X0/W[8B5UE"V+8]PPX
M\Z?@JBIG_NV<*KVN'(9!K<I*@+GS!W""JW416Y$%Z%)PAC?0004()IG@3*P[
MA6;BJC; ;<PLRO,;%:1-NQ5<O*'(,.-TU<9TE;3-\@GI;%>N/ANHU/+I4S1*
M(Z7?ZJHQMTBEHPW'O\VL:G/,]P>7CF7.7F&_VI ]G7R$*-X VL;0Z8.4V?+G
MV'[8B6$]OUSP3.+<+F,4U(#4'8,T KQ8")?<'SU_,F)"8$(K)<82(2/9QPC^
M? 7<(3]X]B"6I3 .H)/8V=4E%2"C38"'UA4GV:$ :<WV<4=_A"D.U3HV;'L
M\(UY #F78[4?MZ_*^2F'N1#$M'163"D(,IK-_GYC-2EN=%/S4]WSIQKNRZ',
M*7LB<T./,EIS"G*C#LN6_*S8%1:B@28[I[$"Q!63?A\=W'\>!QZ-7M'0W9S#
M5KX"PJZ 0NT=1E"FX*0,S2?",%EY?I>;PL,F8OH(J#$[69L)[2U$8M.E<U/R
M;%.:WM\VUQ_!I0A1JMM%NZ-7+>E%.I_F@=TH'*TJ9A5A_8HP,H%QFKELU&!J
MS2B1ZJKNIMU V0ZQS+OU*B(_LYWN46&@"VNF_MF1!*T^V\JZ1 $Z?:.(4_UT
MOF0@=L*>C>BM]F4Z1>&&^3.!3+1[IG+M;3J_78:VDM4I-2W-.3/PK$WWP!I+
M=G9*OULV>]WPY/,R28N]=\HO&C3.F'QO/@*SF'HCTUS^P" ")*AZ/D<JOK^)
MYOWHI:TQH/0)B&4>2;_VO1.],9B[Q<?DRPXV<&L)*KVE:X ++T#'OW!9L1I8
M-M3?L6JZB&WN$"32ZN^BWA"LT4$V=WMGRKUTHI_M<-JL93VPA:N*TG,QR"S/
MR1APJ=XKW?L8RKTLCK]RB97-RT)F<,MTY5INO5.]<.GYFFN,BOE?_O^9<:8*
M4V["S\R7OU\I8'Y![L-3"24CR8#Q8('!?\/[+ULR\J(/( ?7KOXWS!OWLQZY
M6>H \\0.!<6HCSB.R+F,+[.JZ/JHB*7#S]^<?PBR($3//L^^==Q>B9#1^F,#
MS+8-;V,\H<_Z1!SV'L>L?KE'L"?J<"!K_+,C)7E[570C @K];A8O[N8X)H_;
MMJ067Q-G'$I-NI<O&7OM2LQBFL>R>:7_=R&=M;9NF]>+X7'5=RUNO;6-B)_K
MK!$Y_ (A_X!+TT&7YW[;U,K;6]80S72Q%LDT4="C0;( &-"SB_+*@VE-U5!U
MQ1L+B[$.B^4]8'8ESGW,BLU0@=#6U27T.2./X.@\TC6-":K.8^4,W[6/SJI$
M5-LV^&0V#[6SXQXPZKX 0T:H8G?O]P9[D]52>PZK7GK+4,6&C(6RK#-X1+S,
M>K1$YWJSU4IE<Y0&-3TR1P;T4E^#2U%6[SV_C^SLKD';Q22/G]I$,"CKPQ!L
MB$];$*^X]UB(4(2*%+IR=G1U@2RI$CUBJNM]>LO+8+KH%2M@65CXSW]]-97C
MZO)>!:R_5<L8&SL.T!;G6UD!?NL^[/SO:V%$%@#$67N'BVE<_^%6WR_\PE_C
M^58.76YZQKVE_ZJF2SKE<S(;-;WTW9^B2J, B5&E @6'@VW,1.-/6G>^O$+Z
M3FOV0L+$J&K$?00E&(S^[H!<9\#8C!7,?<Y#4EB@"E_J;CX+WJV"?+;J1AE8
M$;MO@M;I_'"*7/5Y.93MF,LI<B7-5DIGC/@Y9&]SUFTWX$EQU)7G(;Z;]*]P
M=N;] N L[QWX*4P:N!&<!0B6*(%I//-^1CF 7SE...2.[B[JH0T!O>@YY]G_
MO@!UJ4)Z4S*'V6X4=%'^2AJ^PMJ0$"OJ<BJDZI/4E$UHP,C;[_+2;V9C 7?L
M I;1=]!JQ+&+BQ]\?>'IL7<L @0")Y+!*;YRH8R.B4HOD LJ?&H!PUHW?HR9
M)F1-HMZ[ YGMIJ5@[XF0;'>KT^,*1"\5GG'<C5S?C8F,6$>N%953QK)<K'RN
M-)7KL_GH3'Z $ U7K4QJZJ)N^%RCG'3C6UMPI(QS??H1FTT5OAILQ.<RG->2
M_6V"NM^2JW(X; 9;T[IZ_+K?'!91J 3F2+F=]\60ON!O>B *J-ID\D;5B5DJ
M $X*;0.(OL25' ">N0>+YE4\Z'#_H/];+=&K3-A,+ PE-/7:>W]YUWM.MFY*
MGJ]J4Q:SYBMEL%-,^[WY<;6DSJ ';57PE?H3IZ V0GM5&RZ?]KWNYC]E[]39
MK5%%G5JY83:5+43[L4GTNRAM]S5T@WF_6?6(BA)L=&NF79?%ZT09?0 BI4&E
MSZ&$;T86$&R&=5X^'OY4[BIDL%6UNF%8=;QH80OQ#,1(*/VQ>?WX7%'0[DIK
MT^4X?5E5K^&QATKV<Q)/;L4Z.ZG:BRP/1#/JS<6Y_V".KI^49]^8?81N4L#%
M?B,/W"]JI%7N_+96RZZEL;R+:5',R1BE?P#Y!#[F*Z?[M&[=WA%V=83;/>#=
M@V.'.BM*NL-N%*_V?S?=,TW^F21'F?ASZ%<+"GZ_-,1_)A?C;Q NW]%7?#[
M< 8]X7VQX05OZ4)S5,;5[J%9[[&FIC$Q\N"9$\X-\1U\1^4GR'J8\7HH,ID8
M,W%LY5,^C W-S-CM83VO'"R2U1RQ0+L&[&XJ'2&S<!4(=N^+E(4R? GM 0XU
MTEE:D/HM+]KY_8!U'0".3#9/@E.$L//-D[);!P"2\.8!0,E@0?< < QV $">
M)AJM/C\ O'7;!MD? )[<MU\S#FU1D-]A#%:CC ANQL0O:?[VGE"=D*\,V^)V
MG3TSV+B>_6&B,3-33WRM^](!@&"R^G. *O:W-U1?([>7?B&^[FR]GYXVK^P^
M#N(A7/\\N&8P],$:_.0N3PX17!#D_[B!9EM KS/&W%=4(-Y:H@O#_:R+!0IF
M&D+W.E^:3NDAU,Q>PK:I[T*&ZC62>,OK'S>@X:&YUM/GZ.C='YE!X0^4"E-T
M_%P^DB\0(&)GNMOC6QI:K;"^H\DQURZWAT02(C_>FQ2]?=F]BV2$+1"8-N<A
MLTT<VT=&==[;L_I(:.%:E_G*,,U9T=-*!M6^%3F>0)5C39KE[^@U/TV$O'0'
MT=>]%7]RBP QD'&$5;[Y\O)"13P$BVSOC+\I!>]OM&Z%LZ?>S>G;174P;I<K
MQ$]SE@<#.]+8[P-LHOI-3;[@+W_ML[HT#%8E@>>*UT:]!4*YUWSVS47S@5<0
M80WB.,O5;OHT/.(F%MEQ422G%ZSX+8N]&H2ARQHN+A<(5CFBS 1U[_8!/TN8
MNDL5\:X>AFGS+H+NN3.PQQ<6115!9EU4U:44V,WH;D#Q#!9_RUHT\1LNSCE,
MRUIII')4NSXU\Z?.UN\K;OL?<P3+5,:J &2DUFR,Q14?*B!.0<\O3A&0;)NA
M;3/'4C>/&%CM-BVRR(CE0UX&M+8\Q@/G^P"P,VAE>MW F84*-XMIZ1C(<),,
MP<=?@65W&W$.U<"YO3;S 9P"N'?$JN"$NPY&*\![(R/W[B1?,LUQ2=GC'$BV
MD#/R?AWC7X=)<CMZ()UC&N9)#A=[XJ1MIQ.^[=0;^H6D#! T/S+SGY,DIZPV
M<1*"V&5[@QM%9O.DBQ%G^!B]L/MM@1M4A51\_-$NSP_S[<'Q7M]87;T6R"D=
MA+#9G 1K%G+*%L'J354^C,DAXG5F,G,L_CA7SFVYC.Z$0LH7DFX#'K>UC$\.
M%=G<=_@H<1<^!>]N](U\9>0*0Z(D+?Q+%K6]Y$M*[]GJ<=YWM]I1=;\=8BPJ
MF7>Y1F>^-%48)IBG!DKF+>S35;YFQK\H.PC=W7JS2D1B;!S]S[CM-RR\M6.[
M4YWOISEVR[M;5MZE $J62>2AYF1E&A">XZC%5XCS-;'S':+7SF@WKO1D\_GL
M@**R+V4YK;V?K#P 1-VA%B_9@C)Q!E>HVJ9S//XLFWU6\2;9,W5E$@Z%J"^[
M'_0)S]]14Q9&H=-R<7="-O&(N#+2+=D/S"^BEBJ;GZX?Y4K"EU[88^]L8]&/
M?VG>)I^@E\<DNJ OBJZ>I*J3KDJCAUXRR^/S&09N/?KNK6NG=@MW34%R;Y"(
M4G6:^[Q([2"JPHMG0XX3$@0[^S)&P@RU'T0!ZK2"#,O.//?653E1)/X'ETKR
MN*_ L,JQRI]W\T5Q5L!496YJD@R@TMAXX-_D8UK0WWLM^X5?^'^&FJXZ0/ZN
MT/_+[2E<-JNAW6Z6::BU1WE>U&_9!(133 )1@?6.A%;XRQ ?FJ_#5NIV972!
MY9BV8O1/(X/\"F?)<269LF\%Q9UOB%EDBP]$:^4B^\&*.%Y=]$<,Q<KH7K9G
MT_UI9:QSD.7B>,B;^ J/ P#Z6B=\FESU33&M+3+M2F)=Z<P9?<DKWBI\!X!B
MF,DQYO50J\4JYJC.EQ0+(U(?,6DPD%'A5 _?&Z%9SHAO(P*O/"?[]LZ05#/N
MS%+FKP9%V]&.*VY#5=B[?9VFGMT/1>P"7J._P5^,Z:%0$-XO*'\7[&*@),6H
ML*6+;_EZANLIV91FGF5I!\(X6'H#V5(C[; @NQ;DV3)5VVM?X)OATFJJ7Q>]
ME<,,_Q$"G-2->46= 1U$'2CS^I9<YC?.O Z'?='"M]@[0@R?P2( XHH!P1S#
M%;U5D=@ZZS'I_/^Q]RWP3.___Y.B7%/N89622\C]4C9QW!,18RXK<IU+0FYC
M))?FLH2$0KGGLN0NIER+W!FY;T((FTN&X;]UOI?SO?U^O__O?CF/AY>]WMMG
M[VWOS_OR>KZNTOT-:U/-YJ09<?&-0,/ZX!.A5SROD>^6O:%U?C^#*5[Y_5K[
MK,W.EY87QV]F0-%X3KJO&6>)&E<DHW<#(>'^NQ^T3WS5V8%\27DJYL5WV-O6
M?L:3H63<\R'U!!,D2,H:N#QS7[7>833_"NG+4"3?F[1/ &)<UTI,FZ2=N];L
MB5EL:GJ%#*ZS;6DDF5.NM1%#=<:')=,BU;N@,E_J\W/=7;#\3Y8\/QH"O$?-
M8A.O97,M3[%1Q <J[N2YYD>$"-:_/2.3V8$-([*'M;Y^*89N"E6%'29;6S7S
M?4%M="K7/],8<I<VLK+@M$]K_ ?H5J'P" #T1TO&VRMZ["_LFD<K%QLV0#[G
MG>F_HF,F@;(7VSU+$&C"&'<9UCOVUO W9(LG\][K28V35R#M,,YZKG-^)Y*O
MSSV(/_DA1$Q1253)/FTG$]\8$_==II2RKT!JJ$I0*R%.Q\._K88727T+ZSJD
MEM]J+K)KY-CFCTD$77#)ZU[3'HOEWPWP2?3-W>CIA"D@G(A!*\D/ GN%VQ \
MA.P\&^F>6/XM0R"A)]&Q:-X>#=T.W.]P5UR(/_HA!\9IX/'.+X'<RUA/GB)
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MM/9$L,1&>NL4^S+&DHCR7K:%%2!X(@ENT5?G^\,RN19"CM6EOI>IGK5M)!X
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M0C T<XD-Z1EUIU_P67V8']NZ8\SXT(KL.C>-3B[R-"(*#-B+(L5W3EXGF],
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M=#[])9^IB)=5/[V\A7>Y%V?*S=)AC-:?FT6'-DHSB2]^*IP$T4W1*< Z8#(
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M@$'5J :E7<W)<LOK8N\,3>@A5!Z]?'+)THK:KRX_;1F?713:C*OHIPRRS>W
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MU;'9[^_C%HB[NRJ<#SU4%<^B9];BO968WT?>'3^@QG.@>6,!_:63PURB,_.
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MMRJ(!PZM7 4,2%;7F?]6BPBGEE;62]0,<12CD5F7-S#;M9 C1[.^ <VW"_<
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M!W'I:^WRMUI_;7!(\ U_V>D*Z:_Z__L^+.GJ6FX@^^?QJB2,N!*M/-L,_^$
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M=5"RLS,[L,H[O'J%QS%G/_-^.5*=9>-B9..\%V<^9OSQ&\&TKL[1]\T6!\K
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MAM$ELPILRJN&4-D$R?>#2"T"_$'JVSW@<.:D<4EM9M-R4V?I4^P)7U1H=D&
M_PS*+XN[&45V4D5UX@KO4*PY:Z=B%6!O[R5-EPSK,B5*P#XW8#Y+4^H(K,HG
M(>NX.01H]E:*+52[3.OA+@T5(*B)*;_V.X9NQ0.3H"'4]Q*' F,6X<98.]?D
M +40HJ\L5]VZG6NE$;]62#JI*YHS+5G<WU_0T]N62'G6>$HF2X7E7L.N\:],
M3!JR)2YE<?<E4;(X.D IICQZV=U.P&2&E6V0 $X9\901(@GS70NO).C91U$W
ME[ON!-X ITRFRC$0E6AN9EXP[L1T9J"$NI"3H!6CZ4L%9L;,PR^ QR(%D;H*
MD#T48,4C2/:0@N[N(Q\";TRTSQ3;+A<!P?LUY0^#G>PB>U34.:B[4.FDJ01<
M'GK%KV<)HD]AJ*@LU#!QTA0?U3('1\ILR,NQ.QSHYKPX/+H$T<!<6.V*9"[
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M\EOV9YJ%$S36\#E((+U"J^6&P9*-'BP]<182UTZRI0T'((D)*AEA^KO"$:V
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M179[(QSN:8V4LVQ39.ZK9[YER;:#FV^O HUP!4[XZB4>NE6NPEUGKY\J\U_
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M4L2+J/5$DFFYAN<U9;8/&>#3QGJ,1(6+ [KD)7%LU.RU)YY&\-"MX#/8I/\
M9O+OAB$71*7W^2EW49E?<PSF<R'GA3)+%412\]U:'K[I&POMIR*4M6@OL&8
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M3]M@IFR8F&9"DL@:VN6C@JIX<DAE<C)3XBQ1+;UN !Z%\WGEF$9I Y/<&25
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MA[. :V\?L(Z2(78<W0=8;7^A'0"-F22M]AOLECCL Q1486F*$@P^^0?=HMM
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M!I@(V]4ZE;&AV,<4G&EA(>F,"!)+B4SU-:1A_#);T85[;T_1^OX2Y%^D-4(
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MKH]DH9#PG.U<S:E&T$DN&8M>>$D3SI(F;E3M+-.,^<[8N -J_%[-,</4P-"
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MQAS<&"=6..B<=AJ<XVF$-3*-XK4%<4WEZL5;?U_):[GR)!_^TJ&RN:;_6
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MO_M+;*-.Z[EC=2$SID<OD/.0R_MO@YX$!YZT(^"\!66#XD8Q(:K \:!X_"'
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MT[$L&0KF-B89&&IR)%;\O<,O#OM;&!K6$&O4HWY2]V^U<?TIKO1GTFHWQ\4
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M6)Y1)WZJW7H&A94;.?>&G(\941,;41/?D ?G&R][@@EA#0=?=@T/ 2<BP6/
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M(D]6VO'O?3D_]97%G<3H3F12%YK/1KT."4].W_T)[O[(UTZ+]-$D".",/NR
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M!)B ?5]/?3>F@*2_=K;( *+K.K7_Z '(<!?2@9>WT/TUL)8E].XI9<$.;Q9
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M^E\*NDHFS,N)3*97-),WB6\BK_;OBS; . 7O5+X)\EF RC1^%3ZUW[.+^QR
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M)O6'.O&M)@%F2]N[A)04/SNGBNW+7X96U7'I%0O42#:-1&2BGJGSN[9$E1.
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MA;W*'"VTNX7(A')\H_^N(W0A)=:A!4@;6!@&;1IH@-WM&QAAZ)PY\8SUEP!
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M>WF[O$,C6)^-U3.B>Q )_LP=KA!G ML'2-FG[SOT%%WX%^B36E_+SOCY&O1
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MGA))E/5B?J.3C\W\Q@9!=^^L?HT@ZG6;> >L]QR3EZE9HJ5U3LO>)Q0@MX\
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M1UX/#N(&*/#)3M.Y(1/*.:\M1&5FX@T-_0"M,/2>2G'(IC,%_FR6=Y?2OL&
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M_]V>?ZS5+-""I=$KAK _'EWYT\-_N,S.,Z6Q4^;^OSW*QM@I<1-:\,<#6(/
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M2%H(VYD')/5!;,<ZFS3U**5?YYFBYS"A@>O@CJ^!\N\-[P*!-LZ^BT> ,M0
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M).$Q%=MW!+"!JSQ9(H%Y9)F(P.CT5"UH=3O[X(0F%>D)MW+/>1;##V1(YZ@
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M3K&^;4O2$ 3[@16_59$37,A[!'1KS?G@O%K!" ]696S/[!53?E"SA#=5MM"
M//Q=CV#>-=2_Z*D)U+"X-2]:=))B["I"DIXQX6F^*.^F/]?N*6N<MFE7 4RN
M_:K3C7P;W]/@EVIB_AIBV"%TT?A<O[3GBQKAFJ[C/AE*MRRF#Q1<=/>Z>;>0
MSVDIC #FR'[MNC8AN(&'*Y.#CG\ZB,;($-B; 0>?/=ASGD'P^-3>SD?/=$U
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M])8:.Z.XTGA/:/2FYFI)K8LR^+%;<AZE,&50^:CKY60-=KR%1IEF)\&=SV,
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M9P4&?M:R+:(.#CWV;+:W:[)*%?^._.PHW: (LP#AOS:^V@V'$@=R6\0F6A^
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MO1X)TZAKF^8XWTF[*//)3:>G>RX:MH= %[ZJA_B73'I,=0C7,E35IO(? @I
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M]+'WR&HI?EGV=GRC-,J8:"W!_C9N#N*CPU6B*5RYD,BU+AU'L$SS8G&P8]]
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M"K,[?[FS<G-HM=_ZM=07_5DBX3EF*FOX[Z>3.5YB"V&X8P+#51;;RL\J9WF
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M30-=ST*4.CV ;)Y,]J[B[-$&O7\&ZBVCQ?+^\:S3]0PU+&>!1O"[/(V)[_<
M<9%;0[%U39+!8#)+[_K,0G:C37<YIL:?G54O-E2+C71/9$!XNG#"Y;1R%99
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M2E&1W7&?:19@EGWO1Q@%-^V]PQQ;QMGQM=4RVT6F2SB!L3*60%$#F;,6)+0
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M]95+\C8=7_J"S + #:B;,W$!5"![/;B<=W>9;#M)I?JV*OC%OWS$;F6PN0?
M !!!<&XAGY_(<48L>? W<-^8;S+/3EU?+2)(C=C2^^:-K:I%2]W)#&ZOBX'!
MQ+F7-Z0#)8G8<).0BGB6[@*7>U6Z-]UL$UBOC!C\W,S#4CH)AG,**>:$[&+)
M4#\XOW&5FS]C>2WM*-:0$O$,$V?H*KCSW0ARL^.8SQI6(T^EX<!7^+8A9TNJ
MD)3YQ'4-D=+5SZA)JCIT,W_. 'U%5E&=/)-\BJ'9SM@%!';N@,JWU< W;*?]
M?$<[D",*^-3B9?KSAC7^):4] )6DM/,F",2UFU=8EE@8Z#H57JMC.GQT"!R
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M6Z8]0KRVB/6+(:Q!S*<<FM7)P=6[Z6F67!];H)#]@X-1+2VV;"&FD\&<"L2
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M??54!.BBS7S,G?/OT.J1]VG)L.>PG#L9OH<R:<\H\^X(/+Q1JF*3C^=CRL/
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M]T&=1QG*PA#W\Y(:\'4?/WV\2V'K^ 07BMEA'M:=#)32ES0H4HB+^88OQ6J
M_+Y]BTWF7@N1Q3.\O@_N+-TZA><;*O%;SG36E9\97\F"J[:L0O:4Q')=LLGH
M@K!KR9SC(F?/A$C@K55WRC#US<! MX-VHC+/LE<52WFA2/_U6 W2V47S,Y3(
M7JM*NOT[R5DS%;)5JT2:"'"D;4VB<0T9H+"UB7S=X%: JHOJPR?2R5P,.S6Y
M-6X3X@0:OB'5UTZ^?2)_N3+RRG&5Z:!U0T2O:J:6<"*37]3,-L TY@<N!4<Z
M%?*Q!O(BOB(,^FQAWU!-T;2=B8WO.M)]TK7N6O1;':Y.GF!S%[A.,MB#5KG8
MG115177VM+^G:ZE=IKHP@HHSE@E[4_]%Q=I'<4(6FXS$[U$>;H$7V  WBLB6
M('$EL[3SLU);D\UH6\ (:!S7G7*;#V&O#BPM/-EP#Z.(-0_CQ@C1O@+%70+K
M]%KJZPUX":_AZL6SY@W2JU#OKW6%\5ZA#DJ\RX@#P6KHTPB#KAGYO3*!3%4-
MV ?S?$^CO+BS,LXDT%S;R1.77-!0 4[^G&=>7UI,7/1#J[;%C-%T M.^S2H=
MC>.0ZW,SNC,XQL!]>^NA(M]D4.IG%(7VI(;&L:68[S^WG!VAHW3XILJDV)VA
MZ5%[?)YO.&VGE]Q)PFRVA>T#JPVWH@:V[ (/'90U8'SW14Z0+Q?KAA MND?A
M F,O0LDF+KR*F>O<!*JIXF"XY7("D\450JU,[1'OQ;S0\[ILU1E[T'](!)&.
M?IBNH\3E&F,\Z&S:0T?X:OWY$U1D>CKAH(N+C5T"36 )]6?2/>O+*< ?%0@T
M]$AQVD60O='6$^+E(-8PBV9PI,=1P8X9)=[[T5](N9]8.,$^SBZ%DL8)![VA
MZOE/9O[.?!.]GN-+N4T]339Y$U4)('I2)%[9>:_??3?%['%P  3D)G[R^(4-
MH^D&?ZD3Y5ADM()1*_H(Y&B0;X3_UF/M<_C-Q^X/,$I J,TTRGLMK.R' ](^
M&7"Q%_9JS*[+&#T2[(OKNQB%G8H@*W6=(:OA']J:8=+D^X0@ ?4JJ/JFLG+[
M4KJ/:']YV6BZ%^4SZS/5>$4AYO4QC\X96<W@8.Y'I$4;9X9RBO,L19YD<=KQ
MBJ% 7V=YM"[A:*TC\YN5Y82#:_%G8H@/K\?$UDQO^'2.LX3K72?M&[U,VPR-
M]'#UHG WK_HW^E,%0<HD#7R4R[.ORYA<,B@YUL2M==#H-5F< /VLRV_><*UG
MH=0LIK!P6C)4: ]9^8&U\'(<U7?XSEM']1^XKIE%_)4*>/\DZ&7_Q)<C/0WY
M&9..TM$V'\ILWPU3]/>/W[PBRBYV\9\"WB)4Y?B1$742;$Q[25R0;Q(W07J&
M'-6E;G$<;5J/[O2>M:2M.NW$4=Y=>O<^+HJD2IBP@R<1-UPPYPG7?*.YGX:5
M3.)P) /\LJ^0OTZ_E\Q7!'._VJT2'T>4^B(T<(2!OVM^_ 4_K7<_KJ307\4N
M(/1I^=K8/M31>C\!'PJ+$CAF8V5IVB-1VP6?/8R@(U5]2_.YL7CV0M\S.*R(
MO;3[Y=AD7M<7,:))1LDW(=IE6HVPX2E-/4$0V\<Y&0\;]8&GAKQFQ\)&5$TE
MP6+NL$#(,2W&FB?'Y^:4^ I/2V%^2/?TTUA6)["17CBT+8"F=&5K;8)WWD("
MC]L^.55^2S4NS.\DX46GT*0;'%S;P'6D?-D](C?>?PM/GJ:=+I[/84,H81M)
M0^8F<C(>W.-DZ-@!S'ZZ@-QY]_XIK3O(,B7P:?(/8*(D,M=Y&Z!3XB!ZJCR"
MLH#"$=N WDUPE6AN?[ RM%:(=@&S?QOXP 1*7\Z6GR)[W\O"'=X&GK/2#VP8
MQ%&]LD=;0K236H%7H(]ABC"\,ZB^8F"T/D' W=?3YOW=V'EN/WJH-/!8M=IU
M:QFF S,A&5$N!BQC(A LG]%G!5#J&PTUDNL>=[3W5>CW(,?!T$VL7=:L36FU
M Z4%@"MO_H#$Q,[:O"=S; /'L3NAZF=;B;G-FK)\V*6%9WU-O=%;L\!FV9<\
M2,U.9J[J&L>,&0W!<&KK"$U\=<4J>$64.H64?FB-E>W$<6XE][%HK4BO@?U/
M+"Z7H+!PT4T54_?P%E([_3,W>HIR(V4%$42FGU)#;361OY(>V\%N:JUE+\.^
MZ-]7/ D=3 !=SRKJFS'GNL\?M;AQX?SGU\M<&#Y2 )']PI44!D&0XC3-R&&<
ML$I:P[$EX/T*)APA3%:7'VOD;BQ3<,Y"LI#=(<D.(@W'Y11#'IH=)6PM^$O3
MG<YY'P/DXK<!^K8\ZR#!ZL_VZINGOL">C&B&[FD,C<ORJP9Y)X:="N-#1"Y'
M>>.O.[EI"P&HBTH\,H5SO/N+IX7"6N5PA!9-#27._E!O^Q,G?+C81I$L.;W#
M_3>3>8UPUD?<7>;-0$3=F[V+U-]I',PE2>FRS_6(?K\-D,A!<V9&8^#U@[*;
M/;-HVFU@;!&<"WAB\2/K>VN6<^4_$A;(3V]O&,;]^X-\L9E60L"^J+!?7MO*
MK6.2D1;K!*W1I1IT/.=1A"Z>:T]*<XV3GCQ*"K)<G2=+LUC*M)"AJ58=U[[&
M7\'Y7G"[WU/Y#&' XG:MH]('*3*4A#YWZK-R?HO:EUA5"ALYRZ?!2^R3 R<Y
MNR I]+YR39<G2*:8Y$KSW:?/8H'+>E&=:LEUHVQ6QFX]QE*^[O7/S][HI[83
M9RA<2I__D!3TX-0.;]+CY!O)+AFQFB%E![$ZK]\V6VDD+N5.51>OU\)2;YO!
MA<QV"IET'[%\6'E;&^I["U&SF&WPJDY/,%W<KU$6?<!QIT2[6%^US-0:--7S
M.054A,C"TKKQ?=ZY;.S-UV<_'-L LP["3SZW8 8WO?T&8?NX0S_M62=1,V!!
MH<O2@Y\K0J[?3R=D7?<.,Y7E\R?=L?>59=@I1Y\J6V.22KTCVW6CH;-PT2+[
M];M0D4"M9U$?*V>C%[,WJAK$N1^0N)?>NVI[+\I.F*XFXF?F'2/Y<00BN-J?
M/P05 14A8,!N@A?8PO?3XTTNOWV!'WND=KNG[57>L3-AC(9#K:(I1)67A:_>
M<^;IP-8B/Q5"1%+<3]YI.7G>L]^67WN^VS<L,&'G97.WIHZ#C(2N:"+A&WHU
M,\)<3OH)^+1H.YS6\F0I:DXYRL^,FZ_3BB_]BY;?*.FXY!2DYVN_1'5QK]1'
MY<7LD?UD*&]^K3IU''<JZN#W47J/$4]5=5SY^D[$.RVE8V+#ON:\WDX=&*="
M*,BV;^<_%V+_"4^ZJX!9Y,?)MK3TIZE,?G+V7YJO^XDD$W+WERO:<*ALB>H&
M!KW+U7WFHO)#U[%K07IB!58=UL;"W(]2WWQG^RG64:K[4X:\C?:>SB[A94!'
M13H#L%872J#O^!=2$"@;8CD,)[04C%[-Q=.&+MXWYW-?QMRX=^B,];ZWJK-"
MM"T*T"\1^9%7E* 'ET-DP/R'L?R?DYS8Y//Z?R%G_P^EX=N_EWO4O1_U2@F4
M],+*\L^YFX<TU)3V65D)60/G-*ZF_WEIR'\$NM)BQQ/V349J\E@.*-$*W3NV
M+-TR9\:A01@Y!O5QZHX3HFU<@'!?[ORVZ =3[VXG@_G0QRX #5C7:(Z'/U1>
MR+UM-K?:GE\C1B?PJ(Z=\U*HJ&PMMZE1^QL1QCM%07CEM88IM6W@P+,C3'?!
M<7L4%NK03'?*Q']07L1(]$"8D]6UJ,_J!O^<&386>K97K&XH)=C=>*];?"PA
M2MIA)PTC$@_SS3<Y"Q8"59?NMQ<3L,LVZ7>IL.$#[B4PSM,JA]:QTNTI%8\,
MN)>K(B/S)O>ZW=XX1D#KW[36?]==V,4N_M7@1=>*.T5M&-54LB-=/84AV#4H
MBL,E@NHM6(S=6=>[ZMD"/$+0]]W!=K,XTK1XNA,P=5$MAY3=YF&OP82(QO19
M!4E.>^-5M&\E^\FBQ:KGH7'3M,OQ(_J%\6P.(L$HXR\X<;>HWA'E,&;^<&\S
M1E#]E&\=\O% ;WG;*'V]%5;%K39E:MA+(7QTV5N[-T7(<<GH'@&L%CZOP\N7
M5%R<DT9D3^#,?!"S8?(%\\1XL+I>P6E>B2]]*W31<E:2+#U&$2>\[C25.V@S
M6V;/A'K#/S]O.IGYY63)<_1.JDV$7M72-N#4[5>U-/8M9N,>@@=#7MH21N)-
M4>M3.ZL83U6S?-M,R[M!4G>^O1BSH426A5%WZ.?#Y0Z.S&X#ZL#BR#Z2M<J+
M1VD58,/VIAFQQ6V T5D>ZFW8\^1S8']O@;93$<UC;?JIA7H;PZ<;L,PT.%L/
M>Y]!D*/Y)-L0W(E0AJW]F#FXBCG4OI#6+BTVF,?M!=4NI\\SN6EY&"1Y46=N
MWK#\1JY)_W076%J-'R='@-67G/YJ*" .Y>XD&M7[E79^WEN!\@ F<9)N6;+E
MD0:;,4OH YG=6#J!US&CY'NC92$FN@\DC\6L@)[*\T;W:;\3EA/  IX"A**:
M>5X'F1'U#0XU'<8PX?-YY]Y3CK(7'BX<=# QGDS?BF4&QEAI.M:)VP!<WRCX
MK7$335NSF8%$:.&@[<A(;VD%R)32[L?SKEB;OK623\JH).P.AZ+-9-D%EO39
M]V_JN7%?22%XZ+RH._B^&^8%@M_-19-O4E6_'I0*/$96C; IV_**M-*K;YBH
M$]ER6[)8CM&SK<?B1_S?3?<%QNZP1#D0UNK3V45?/?9HI^_FDR?ZY!;&B1R@
M5X8=)EOTL!B41@A8G.@9X2-;1GE.GSP%69F,\H@8%BR?$BMNWX>NW@9 "C%O
M(2.CF'((U\>8:V&QH1#C]3F\Q9,F]T<OMS:,\FSZ2PB4L/='BXV!"J+HZ%WY
MF^7OU>GI*^ !8]M X#;0SZ'+W_(:;3Q%D8-?1[?%2T>L".2Z,<6.BL:9ZS3>
M>61).U0.O0]7=4O%V=;C8DE&A-9^Z4#5$$\/HU;HH4_]Z]=&<2\(;;5"!<UW
M;[X_K&A).V//>+U_QB4P 'M-U/ZC<H??%.R""=GD!B==]$I><PWEO&P=8H<:
M>N[XDVDK&[!&Y:9Z9JN-F9>P]0CQFTT519AYU1T1N<!=1'X<0Y (C,6UR2@R
M G#4&#VX/X2RXH%YO[J/ZHNXK05':<U?'B-E]R+H_#;ORAV=IOT&9:)ZHX+@
M5*M>"S_H. NHLV":IB!;K3#BT#]OM?P-%DV<6F'4=][@O=9V5O7AMH"8V$FQ
MOW!@9'R2;858@0)=;LUN8';'#%/6N&))(\NM0[W0__4Z:8)&M2OOR?&.XJQ(
M:=F%9J(S$BS@99<-HQ8T*ZI9S*EC</W!W!>+)K/SVP!,4-'F*6PE<ICTA4)1
M_Z*/.EOA_Q5Q/) B("$*3PJTM*/CR0I6U;ELV0*P\4QAU6)"7NJR@$'#;#,P
MI@$.'4^;ECO0,QA5D@>R,WFCN]'2]0ML06=UK>HSX M.P%AC&$@0I/..;XT9
M JL31>"J"S?,MP&+2QTJ;"_F=L;5_=W]#EPI TH,A8'&/S,HZZTL$_8.["PF
MUS..4PMNIX4&1OGR=B@U,$44/(UZ\N\8\0_\X8J4E1C4"L.=Y?^R9,E/X=^_
M*&'[CX.-=]$_^43[7HZ^;!NN$Z/EVT#MR.%PS9'-0?/AN#$D2]#YN^O$.G@Z
M46-4M'[1Y_G:@A)?)@9N?>6S'WJCCRT#;L6('J%@%U'^. %3Z1H:481S6V5H
M>OC.\@"EMMQ44F/4-G!SHTMOC/D[>00\ G<FKC*8XK1"?+ -#$O1K!23JM#K
MMAM=E7@[T/K\1E\CE!#=MC5)GD'B)8LIF]H"LS,4"1^J(SB2JY5*OK4DJ#/E
MNH)!813N.7@O8<T(?4'I83./YGN?H),@!XB?*S]O?IP:KDB^B-O\0=TQAO3N
M"Z7D9)7?Z<=&?7P'7S;:<YW"[KG0LYD4%0L>!*L[_UOB [ML]+O8Q;\8-!])
M\X4SFLL87XH,9=7*:T5Z=:%6=2"E:!-+&*G+#EG['E"?'!@YU.(.K]./M\DA
MM/F*S[L\SQ$M(H3ZL2<ZG4T8[RN8KF0:C6'CEUS7IO=OO.?1;DM3:FC*QXCK
M%K\\;AX^ ],9@(O=D-S,@T3VD)!X7I'9JP*+"2!.D@TA2?G$ P+E#BZ9(.&M
MIQD*#>=<S6UC)+&/7%/9"0TXO^EOV$^C LB?-Q P:+BH,9Y(8=9*\A+85$ .
MLGK&0[\=# L$4%^I9MY#G56W;:!81%V(YND)LT 1T4][>_.*YPV%00K:]$_)
M:@3ZU?28']Q;'QM]1)PEZ4GG+)Z]I J)W&!S3JEQ2CF[LIK'40=FLEU@\P^Y
MYIE!N]2IN6=3*]S2<$^:K<SJ-\5GDI@L^$5"//3,B\/D[ N:)%V<Y4=8*@ ?
M2"*+EG3;&_0+*FP8=8/I$=Q')1KO!QV]8)1(4L7?+#>YD:1#,DJ;P1TMZDK6
M#CRK2 <8=]D:]K9*T2;DL8SN#<X4[%\V7#?:4[S .I,V#PMNIV\KTM-:_9:^
M8)1%AD1^-F>\;L3'+.989N'Q#2Z0'*M9;LY*TV?-;7SS\^'+:FQ+F+I*OWW$
MD\)\'JN8]$BD"\UR3IQ)S1MKG>=-!Z1HUJ-'8;ZN+JXYS2PT:/70-HT*K-]]
M3@>8DULV7J5\\^4/4)$EC6W Y^#;Y_QC,TK@4T-NAFMZ)6!17K3Z"LH'R2"X
ME&S%K_@X<+4-1.8/2-5M#\5%SE$X2.[VZ9?3FW=>G-<3D-[16OFF:4R*HB$D
M;/J'!_?TZ1,QB)N*Q_VL _%P&+XCX_*7/$<E\"LP&YG'_7&&NHLDEV+V:X*%
M5WI1J2Z1#Q>YYAJ 8&KP%)5\!JXNF48PYJ:\NHZD.BAB8+7'%YRKGSL8BHN+
MC^(UC-Y)U$2I-$1O&+CCN-]-K2%3 7>[($^7KD-1<V8C!(K5RX;BF ]=")Z"
M1]X3E,B981;"JX+/BW>\%$]5?ZUG;7'.7E.Y91F%N&HM:3*6D'"P-,S.JR^4
M?*FC?Y8+,.TK:"T;XR_Q=%3A4+\\V$Y?&R]$X VW/E0-H41.CQQ0$%R5U0E[
MYCACALEPHQ%\610]TEFD((MGRW]QY>H=KPM;3% )S0#/K"UE"W#TGES-W]S]
M_0E4<\U1SY*FNR"BX!<'@@B[Q%+J_H&,M*[HU#_+A>?=!@*V@6YH)\Z"E%%G
M:+R!A#UK9O 4?8\3(#E\B[HJ;I,6&KP>//HZG=Y\%,EG>K;M5&_YNAWZ8\OC
MM1#(T3:%3F8N<K8/S&>-SVJK8V[&K/SNSA*[JCYG/K]#1;8%#ZT0O<.^%0<0
MG(.W$-,4_4I"CAUTZD76Y&6P'N;3T@*V FSCL0PE&<J"ESY0])'5^<54"TAU
M,;7E\$8<HB'>,W=6L!R^C+E"?83-';8!!=2$CFP-S^MM( L:R=O!4M7W]>&9
MFY*WS6()D_=M,G!8XQ%\2#U^I^ADLAL(O]R[QAS.-:>N9ZAXB)WI;5:L:M<V
M0,^YKKU%][ATJV,9 R;!4J1?.]R]4_$$,;UA%* W"G5NOC-V49#:2#?X,O[:
MZ*I[/RIFR!)0Z"AHK_B_*3;\ZZ>6%F,%FIS%_KI4;$:+@',B];'X)PTSMFB,
MUOB-_)DZ:T/ZX+-2O0V)": XQ&FWN,0;EQ>,USD:^L?,!J_(6L1LT(Z=^,9M
M7X^[T?MJ$G=+R^.@G$D(G\;,(HV<=&8Z&5I<#/A_HK!-0_83TE<C&A<M3AAU
M4!A(,D7:B6<L4.I[X>'VA/J)RHEPA($YA<VS'MHC.P%S,R8S:B:OT2YFBQ$@
M"LB,+2%F@@19E >U/CX2"2;DB$.GJ/)K160ATC8PY47.-/H"=]\&M*$B 'D;
M*"69/*K9TD,8N-94'A+G+]6]8T<=C(+1>\;LUUVW1#2TGDI6'8,HD3-H/U!8
M2)=,9/R$+DO"]$F0CU7VG )8\VDPR.C:@#\19;T@-03]FK5/,A#HW"G2Y)WZ
MEP[B=^BI_=3D>H^L#'^L1A,N%2;3TW)WQ+K1_G6A$*W)1YWA\%8MXU%[A=NL
M)[R/D><DRSWWH%>2EQ) :DOAO2@YJ@>'Q$.]*1ZHUG@<Y$GE1 9YFK:#7+>2
M;L>'K3(F=7+%!M"0;1*[L$ZE]3Q2-&4JTCR/O'^JT2C,]73E? )=VCNZ6>N0
MR7RZK-?%+8\VHD,2GJ&'0:U>%V#2GE8]4X=)J_O@[LE+>2@-HCX' /]"-;0[
M.W24'7GG(FY9&_]JXM@D68.2F]V6L@V@T/45]+65L_WE&UJD=;(E;0FA<LAX
M3C3\^\=?>F6[V,4N_@@:GE29UT/"!<#$C,:5BA\3UVC#27Y<X6JWH*4VH^!
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MW[7J]RJFW8?=X03.$)=(*M*]D;&G[G)7THKTQ]GXLS^V=)[ZYJAF^??6!5;
M6-4Y75'?:9N&9-(K.U/$,L*YW0IZ^-@KOX6=)O=3N?=IKG<M\$P-U+CS!ML&
M[W]V%,)&5Q=[$H#$AA;,4FT/F_-F:1DCUIG6Z:?8/LS&G_<=\E^BGU(ZVM;/
MTAO_=A]&IH!8:W0$.$%/S*M4ZZ'KW.F*CP*M>7.I8Y1P3I7':P.>^?L,TB?>
MM !F%@S=W4AK5&_Q3?.&WM5Q"A$I/W6"](K^%4H*X43S]<#92F4MC'@70F#@
MP_N=8JD-FD1]CD#(+20W,"V4,?KJOFEF>ON>#DWCO^T%X^\35\/NHA9DJ(Y5
M0Z1>9DZ(1FUOKS7"8;V/*XO\0U$ :L%H*0%T>=,44;#RRB01PPMFR26WK32O
M]^)BB=S#]VE;P'& AP];FU6\2%&IMJPWJ7?02.=CB6'"@8RDF(_,CSRT:3-S
M\!XQS;@^?(%>U)X21I-1QG(ZOYC*.,!U&Z"V?OS;[&7IL1:BS,C';<"T,NX!
M]5&>G[R]N3/YI.E<[W?U_U*NLT1+ZGVK_O909@L "=0:3?T=#(?_*(2%:*Q$
MN#!WJ/T\.[:G_)Z]=8J]#JF=_FK?_@K-8Z7!:Q@1'"G2GL>\!=::74>4&7SQ
MO2G>9/M.6_5,Q6C5,K@3J5OZ;IIC!H:%UGTM:0T#[WS M$^B?YS@CQ_WZ#RW
M5U=+?7(%<T35HNPT'> D]C!H^,G#D.'RZKE15F%!A8[UGOES]0Y#9VBJR):T
M'6S>>MD2&C@.]?URN>J_VA%%3QEVZA(YV5IMC ,!(I@'?EZC[M'.2_(I%"_\
M1'\G,\<,S&7HAJI3RMD^QE$M.A6W7/\JLA#M4E M&'0?>[_V+H*MVAK"5>(3
MRI:]L'"$+&SR]%/0,N9\#X[AVWV(UHQ26_"]#KN>4NESFX(+'=FS<YBG.9R4
ML>4L"8*5-S)S2XAY<6%5<R19O]W2U:YFPGK#&7+H';*99=W0!UVE5XP86TX
MO5Y&'AR\.B9DTP47([1JU%^M0U=7O%,FG9MX.PGNK#"I1AXRQXJ^S"=IT\>Z
M,> /!]?72W3BO FHIV-=8UK/#X'4IYW AVHLN"> .B?)^OQ@H3I Q<;ZS3'
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M$UGOIW:C>BZE+(.G/H-\P8QY9KPEASE>:[+)D6=:\$:G\SL0NSKJ+4:^Q*:
MZ<3\3/7"E?34;]HQH6!3).? S^R][8_?R'&11@=V/X ,('J[Z2IB%876%#WR
MU,28:G9H6.ZF&/X$*=[/_=S(H3:>>I0;([:_7(V(00(9I&>\5SB#*MB636,Q
MB@Y]4L$XS!T*;PD>;YJ<#>^G>?E3\WJ/>:<O;Y4*T)9;78XG.SN)W!/S1?D
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M":@2\ZJ6+R(?Y7)4/D*SWMYU%*@X/,O+%;9UY8%9^H7H1SU;C1N!\)8@.<2
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MB=[%B BCJ\T/6D%^T/@Z%<\DTU1UU &*?M/+S]5.RY]V54[XXX)2[$-%JQ5
M3R!#_" (64Z 1;@[/XB?<A096-4.K1 M; KWD,ZM(K^0J[S$\:VR5&FMBHDQ
M1*9%GK^P=S=<M^(>/:J+#[6=KLO :K-?7X/MG5[R$.O?SS78^H!]*I<CILZ$
M?/?K]]VDX55*OGY1DII-3]F(F'FR4*:X' Y8PA'LPS[(\MTHUW9!N]'WUHVT
MW9PA>X FR^NDX(#5*AYV1_*Y\[*W@B/N6__Z8>/((B600A@]I,'_PATKG7>3
M1>X,SR4VAIC'?UU+'D;QM?E0-%OR.96;89*N]".;8LN0B7\"%!/B4GM5%U<
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M#J3^T #?:B8"^6HCTI9]-VTR;X?#3KOD\-3-]OO5;\-_TKA(#,BBE1E*[KF
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MAH"NX\EN,KY)6U#Y:)])=VE@/"7@)JNG7+<CC UI7;]2D)H]':)Y,6]%^5P
MOIYVJN])W^7E#1X"K]DK95GLKEP0SWLE%D*JSGT[[QE1>SK6)6%LX#<O.<J!
M13H6"'22*7$4<XP9QFM>%LEA17YQ"#.J32@ZD9Z3P?/-3>1"PKAV'3C+KR$>
M(R%>6\T9"N"?(I*),TO"1P*H/Y0"U;TH>FKM(BZT7U7 :^ZGVY[S,.YQI-6S
MKUYG:+/KVCQYE@(OZ(\8-EZ^(D4MEF]]IROCK-S,1Z6:60#?IAT0+[F]%H:K
M+V[< ?&(9MQ62.P*@42^J<EB;C5W.UXF+#C+$_Y.]'7NY7=O7E=7\U)>*C&(
M?A6U+?]28F+:<GR(:274=B9&TUTD1X@&M-4C@N."9,3N3QA1?S!_<@,??UOI
MH/E#6_#[#BBBF(^VM@V?;#B&M';R&9:=M^U#WDSUI?9M_E!<M)&-]KKVQ:^A
M]/$%6,S;VK8NZ8EX,+&O)%PAIZO>J"F8[\5')MG=,>8X/')NCB4]O2Z\"7;\
M;=T-D=O:\?X^&>_S?[M=['(Y'K2G4^H>_Y-.D?X!>Z$\0[\ 6[T%><% :<.*
M"TVC4I5;P1[:UM1D$M]X.L86'TP"MEV8^C!<*.H5;7/8(]I)V,C>:9WX)N51
M;XY^Z&CP$='E!2*D*31[J$Y*9"#KO5OTW4*9&(_7I?KWF#AU3D)C$5M$!1N_
M$(-$;.B)M8T$4M5#S<;- 5T@6F!6<AXF!202>VPB&>WI:*@!D+EQ'20N2<E]
M^UL#)E3R&X3$&Q3,C;NUJ:,R-(7*.@)/(UNFZX>;ODWS..I8+;2=SJVM-;K;
MKJ9LN6)II/:P+1<E1TEMN;IP.5&. QMVK>T&Y8G/$_H*3Y<=TB3F='  %=\]
M=@XH457CI*.GAU);SPATB6MG,4%J@F/-BQT[MUTI-*OX1.JN?#V30;0=;L"!
MNUZ"HU>DV;X&7V  ^U@A]6(F$L<2NVJS5%N>CSK.=")/O*%9N_STEIVW+YW8
M <7&2N<JT"L8UEH4SWT[K%XDW8D\0WJ"N;*YDN._RFHS4&UV,5?W_9DS+G]X
M>YE]]MEGG_\&,$FWF&^^%(-VP/@J8/).&H'PN>WKV@H#$0C5UJ.2WR,MJLIS
M.<+K7/.WLQ>Z-'"0B,?K ?DS]?Z2+?6J[=7/2,+X9#&ZR<2,\ _%^1U06&WE
M]!/G7DQIWY*JZ^T9 $Y8"DO'_'S=X0_%"WI4- R2INF"!_RTL0LV'3&>&3B,
M+,6G= ;V5368)U">,FPU\NE./9Q4ZD8I&#C<%>0&6M4^X!H\Q"4IT(ZZ SL8
MW-+@TS66THKD[8/@E=0%IC'OGS;=GA7X28.\8 ,^M]6JE[NJM3ZHE>F)-3//
M7EO< 0E4*-Y?N>.%PP1663ZUV &%6AQ?5_TR>I4^DV-([3,:4)D-SQZ@\#6:
M7+UTIWT5523S>,U.<2GX*,@KAV^MI$UN=.^@YDNU6[HM=1NH-_1S\&R'CA5_
M? ==HGI+M\\[VY5MIN*H=E=_:MP*S)YVK-?GL(%(RDIPN%*X,E'8.9VZ1-"*
M0D>>UI-B^F6BLOEH0<D[3@8QTRH;%=9YS_S\A8VRXA;,*5YK.&AP$SXI&V>O
MZ">1QJRU]4-4%=O >;<V2?>6 0W>Y=1?IGPF@548QSAF4&1__+.Z\AR&@6S>
M+Q;WHLN%*?EI<Y7O90WKO-1FO$^SAA5T@,X'0))MBN2=$PV#H^C'Q.3DC[-G
MOV!8UO1/Z4H;><E?]KDIF%.BJEI7(1N##FZC'U01N7,#*_WU^T,K^PU^)88-
MYZ:&J,CY;T?/!PM2'9NI'V&W7H]F2Z^$$SQC!7&(BTAOF#-2D7*[%AWGV<W-
M\+M;X4VRK6E<W;5*E:45QT1K7+_RQ1,9*@'0KAT0GZ:;>Y(96%ADE8U(/X,T
MDJ]X_Y&.7GD:A7RLM= <>DH=@I9,0)I1(_K#@_S6RJ"&O>-FM<S)R3I\1)NL
MJY3J:50;(;;*=L%M#?9T!\1.__E)?KH^PQ2 )-DDCNY^J\/ NOO9Q39)-JD/
M%-VN++6#@[>I^#Z( F H,_'P=-ONTVB(HTD,N3<_JV[,=2ZB:0!9IXV.N9J:
MCV%* 6]2!";AY-UN$BS#'_*!>H\8WW(;WP=CKGMPZ[6%9*$_:*NLB^)QYX P
MQ?9I(M\VNVF^1J-_V[",V6(W-^:"1HGMEIDHB2,.-B]!@T]UNOO"P*6!!I2X
MH&6WS5@KV"IN5\46T$1/:T1YSTDO>#X=:K(>U/-UC-F=%@N_T$F*F0Z8L![D
MH\K*DWYI)%R(5FS;^#%>',[8($$+/B4;!>,4\<LWEPVV[@$B** 1_=/1VM;D
MHXYFJ>9U:@X/71C77Z-, A\\:)FDXKW)]";BXJ.OCK8SX77@\_D*G$\F\?W!
MK!#>YU/RL7UHD$\#*U)IR^$<)F55(L.ATN<DB9_G*4'[2%D&"S+M2UFR5?+O
MRG/,PF;,KY"Z%.@ZDO,.!<"W@SF#Q&N[ST;O2L-RFA-.X/IM(1SF'!#Z7K,J
M"=E6"K*OH]P=>M'"+"F)*W6MM>O*^Q)R#9Y"CJ^IJ['-7(%=H\F3[_,9\4X=
M"M$L0C+YG?88'$]QFA/A^(QN'VS"$/N"!*P-G#A>UFM)IU&@35N/X[]AM<^"
M@$B*QZ-U;81#)5*:6)P1\.+@H/>\?0Y).W+K;F Y/:5U$&!$>(0>S\:\8%AE
M;AKG-Y!]P9I.#6CR?UT3JN#=BGQ.GM')[KVZG ?MHQ^.)T7*N0C,>F7F*LTE
M<*P97=]O ;O//OOL\U\ HT;$N #/U [H6$6WPIB]AN":XM<R*%8P.,OY5)NC
M#O@@TKX/62.AMH;*?,PK-[Z;/WTI**.A/F%_?#OD]),VY(AOKG,I4A('Z5:"
MJ5R ]@WYQC*OFPGM@)[B,.?)U_+<[U[SLF]W)A(K3WHNS.O$Y/"C<]!^U??7
M4!E#HV7*.EZTFW/9*KCX>;G1],E'6K(+T#F?F730QGC(!=.ED]_P/U7\#2L3
MU.@LF\T3'M&3FY+N@<X%/\/S(]K(/Q0GP0G9X/;,B#54LK*)VK#;E5VY.ZXM
MJ"1_UMAGIA3I2G*7_8U/.E$]G9902$@H73<0%6@-&(%(@W\"X\,XC#FYZYV[
MA'DF-*^5F+QNZ[EP]>[X<72W]O?-XE:/NUNZ,RCE >"3M6(Q<@#KNC0SSD[[
MP5R*5.VAS;[5\(:9(2YU__9Q\TJ0;L4<GQ7Q?>&#__'!:CO5M$O#3#0:B"[E
M+Q4S&RTFC4=#N[T>2ZI/8U* #*2ENEX@?*I;P&#:]JII*9.\IK0GAF*PAGH/
MX;Y\(.C:;VB']8DO59F":SL@%@1I2]EB!BMU?,/YR=(YPB?;E%D3BLIKYW/G
M&.Q35@[E4'*'F_BZVDCF,*2+ZXM$5>WX@T+:7 NYK\2E$]:6=T QI99"A=+S
M]EE$SZ@<CW@Z<F:LSK?%OWM(S$%*K)^<_0Z'CU)UW%7!$^-1L>=TJO*1BGES
M[*EN>O[XOH9#RE6CQ]H7=,#V;ND%"^>>!4=B#('1$C6_$$]KJLC,=077 \DT
MY644MCBIMZ,3A!!?(-G"A#-7[",F-&XDN72PKTWK-O0=V2B;;Q;\4B[E'6>F
M.-\=21F^*'SO@_2P4KUAIX.9(;Z5RM?2\ &;:Y"(K85[QLN(,&=1?QRF:F"O
MWQJQQK"LHI(QTD--@@[598G7@?;UJ,,*,XG6R[)"0-_6Q;N;G](/^4'0\E48
M-:WY ?HQ^+4JL_C15D10?5"OG?/8YZ6("\FEDS#SBY*_-IKJ33L_Q4I^*/N,
MM?#L&YZUUR4_O>&$?IK=5*_:DBKBE!VT*\!A6/'-:52:<G,E!8-> V,9OH_'
M(\N)7+&5U!^'L.'O S-<.Q_-8(\*JW%0\>F-#[YF"B:0KB?SM^>R)UM1F,:N
MZOV>SB>/)7DN]C_/3">Y+Z8;1 ;">^LX'CSO% ET$80\ 2PFW@VWBS-[#*P5
MAB(5CY9^/!%RFV5SB2!#DYF,2QA8DXV8A'X4,G4[U)EB%@/BYTDABLDX :NE
M_L7O+L_8?%C/39X$QULF<:>%!.!;,>J5*9[@<%R#7M 9P'A,]SR7%IS4'37&
MA%@4]Y3%HT]E&Q&$&LJ[(JJG,;%  (7EA'8'V]Y!75X-Y<G&SR:.QQ1[[BHX
M=;D2/:W9J&WV'W0YF\ L:*=]-MI_ONUE;0P)H;Z!"EU%1>&]/HC @QZ/NN1P
M26CX&@9?T 5?&QT>=DL(FNTT+0!XQYP/G*;?G(2 @6<-YS>UK=? ;$B]2A^=
MN^ L1BWI9OK!!,:\DRC]GE4OM^+0&!)2D<0*STU[3)O_L;H%+!XWS.QC,E0>
MRK4HXDOAKCC\1Y_LM,\^^^SSCT]2".^GM7<'< I>0RB480S%U_JKUCNF2=GX
M(<NIG$1K +\K!5/]:;XH#$3>%?/(VVL>)HC8,EA>S--P8>I>[4C\V& +-<:<
ME/:,'RU^7KW=D7[GLWM:)\C-WNW0')(K?8'&E!]8,*>8L#:M<NY>+=-8_0I!
M+V/&Y(AH;]CSU88F&;[V!*Y*S-.^B6$G9K1?<+.=[+?*.!+:?ZTBX(ZYCN+7
MH+,N],=UA1X(98I^JY;L[PU.85_4CQRP*Q'.K+8 XZ(Y]?ITJ(I4'-[$:'1_
M&LGVZO1H*P-+"A6G#KR5&U7%O;%Y4XP+%4PORW6RZ%1MEG_EV3=_*^#[8-FG
M1D&_I$UVC1_, SD''Y7V7/$:A-:Y"7JF%B0G$E J@&3!0IB(!K36K=9C02E$
M.S(T!XRTM! R O#?@\ZJ9]'1:SE8$SFLTZXT3M:TQMAUA,_K_(PN_-)KL(R'
M%?SR]7XW*/BQ3IS%UNYLCC453J@*G>A_>2Y7/3>YU9&<_::CJ5X4H6^^& _S
M_M5P8*&L=*#N=5]O7AT =N> 7*6]8R(<T3P>+->H]]Z3C%UT_&ZR"1WQA;'>
M7_!.ZP_B21\[\B&^O-Q%@(+)(;^<=;*8 G^K[R8$A\R4N[1?DOYY7Y/G]O=J
MW;*E9OK1RHB+NM8''M2F%%O/BAU/?(FQ -HEG%(IJ$I-[[RH^W=9- 2!3R3Q
MHEL%)%QHCG95Y\,@=(_K2T73JMO*W:>)M/!Y^U;RTM68-2*;8CJH%4T>72U>
M+KY93M#2WRJ%W0!D"?&5KUG YX03#9=*Z<S#7W,W19=S.2)W0 3.?IOXTIL%
M0'#@ W9'MZW:^8E2='5[=/#9EEK ^Y[;5:F&%$8(9QV@_U@I9%-_N6R8L-'T
M.</H77M40J#T7")P:75[< C=A_!M]#D[=Y,W])7V44T-F8BZVT7\C)_'CYVQ
MTTQTFU7*X6CU/#;XYJ/F'<^I6PV]H6 Q&LQS;5>Y%1/U=D#&P:6!1I1HC&N#
MX*9%R]-M>4P%F]V%_I';#.D_$YL>7JOY::EYM&#[HPM6$781X4P8K*NP7%YI
MRP<A\:J18YT?H3R05TB<*LN%VW@,HIGPR;KINV@;P1Z,^H6Z\PB!/0H*2&U"
M"?!//>%;E/Z=^%3DK$VL2R-R$CJ-#U\C%8[DRL0)4C\35!.:#Z=^7UW2Z2X_
M]<K)-N;Y"[G&,EB3_Y?Z"';OUD?=I[$*)@<REZ*5N#'1&+.'THU!)Y%*?/9W
MCE/74;F/98]=/GSR P]VCCJ0U77Q7BY'M*8S^25,?KV5"DV= [-ZG'Z>^"+X
M[-:*6<_OQQ)J+-ZVVQO-0G"TN*-%CAL(N&#*U.T61'@WU!1POL4!TX&#' TK
ML03WUG6T[(".C!T=C%W-=0X)]ARYM>H@[7D9B/;R/$LG)P2Z=4?3.-<C,,;0
M@X^=<-=%^@]3$PE+K:JNHI8OUM9014$B0/.6GAH=29F'I=,Y*$PV8R='$P+A
MOW/"+JS8^H$J_2VDJ/1>4X51H:&"]Q<4/?O>0 ;\GY_Z$W3LV&>???;Y1X?1
M0G*:CWKC!5[H10R( HM.]\SBKO/'M^V N)1RSKM>DUYL$-K5=9Q>V>AE[=;M
MDVTSQS 5#,O9U0>\Y39*6MV;2^TI/D!9IF.]PZVO"T,AJH\T C=BUU#OZ$==
M [*Y8C8_-_EXRA"]QC!? ,F\G)%[+DRS2XRS1&DEM06[VOCW!^\B//HO.H)/
M%#N$R-/,.;(*&@2(&&V@)V_1-4$+_KO>6ENAO0V-[*$$Z*_P6E3A0M\2/+E=
MIZ4+U99L\YO] N?[D8$%2JJ<)^KGOSYV%5$_W,JHHM0SHX O1:KW(CO>=6G@
MGR%@R+Z3;?Y4(X)]PMTDT:K>T!QSY*D^6@:B^K?T\#2:\]9"&QF?CE3IHZ4Y
MD(2A)5*;.NNY'&E!R@ADA?<Q#)K"W!*HOE"63Q).WSX'O"90_-PE^-1Y_D=[
M=Q;4=)(& /P?\4 &Q$@B1($X@PB:X1)!HDAPN!1D!(^) B8B@P$R@(A"P 10
M+HT<@X@@R@10#N7(($00PY$$$@0C*$)$%$@"0D#D#PD8(.(RM36U6[6U;UNU
MNS5Y^+UU=W775UWU/7S]];19:^>J/7P+Z.=]I0BAOM9KC8J987'N0J=0.Z6@
M=L;!1C$Q[%VQ,]@:S+M_6N KQ&CSB]N:T#KY+I*O0+PBF&"5B]HCFZW0".5&
M>/0_UHN.%G &$'*68;FQ.D]:H4$4[\K\P3Y'-IOO4DT2B_(:"C(W0.2"C$%R
M4(K/^FUZ%&*+;>"TFF@QID]GR>J#I'S@%.[<\_,!QHO>',Q&.\$.R+:H67HT
MB+GVHF!3>*Z<( Q.?/_NI=;3"DH!V.1P:V] W^4Q8V@?Z9%@\I:I_3A*3$O%
MZ5*D>HV,SU8O:*->< ,&R:B5OII2C#YPJ,M *O#H?MO[Y9K.AX8UPJ_ U8W<
M -8OI[N7MLC=/X9L_=:"'\7<G1GXV>?GTUV6,A5A:+J)HC1^S]P4[O-]>?L+
MMXN&@I**F""YF0C6N]GR6V1J=.^=Z=OB.$V;I0N061Y500D,_<9W>0QI=TJ,
M*2?40.0Y+[A!*A'):CW-M;3D@FND>]QL;+6U7AIE#"HS4 2M%O]162?!K9#?
MF9LWV"RE1<M#G8C]$T4CZ5:R3M:DFB1W ^NIQYJW^HB>QO<A)6C1 [DPMNON
MHN=0WKZA&G<.PRPMJ5][P<-2C$\)EKKCOR?%:Y 'I[#=@XC;S&<3(ZD7!R='
MTV2JLJ] PMQUP]<^A P\46$-*B(WAJ7&@7NQK8.JB,:>=2YA^&@RTM.0N65!
M;36UT1K<Y'ZFQ:7_5>,!^;VA:L*N^]OVS-%?YN$/IHWW9(>0Z-EVNTB.P3D)
ML_D$-E9J=X<4U1^/8X TK@9L6L4HUDM*N^IE>ZOVAF]8_#'RY@?NOA=N;PW?
M;R1)9P_"MLY-^TMY%=&XDC)(T$EO!CD,S.2I%\+-) .-OW;/'GT@$:]!PR!L
MTB+WQ@F$^7",E6C3*#>2D7<Y9SGWZE[:'A#NKEZ>+^#AH;L6.X@/SNF$VW<6
M,"VF'X3X>W03IND70$)J!</)_46)W>P\O7 ">TM;Y7O.Z@9>,T9KI,HBZ=>4
M2UUKQG0]WPQX#4^BX2VDIYRY(\[RXW2#ETN[=WC'G9V<\"!B$'YUJ<EW:-PX
MFZ_ -2\3IET(,(6WEC]^[Y?!%E3*)WB%BS%(-!WQNA+I66>#>):OWJ3QMGWA
MBGCYUG?&/7YDL/_72]A.?0A(SL:&/7ZQE#6'97T%U!BY;%>_(H""S$\)//<%
M]<-#2<9\1!B=X?5O7[4H*2DI*?UGK39M.&-4&[,7RT=JVYJ?/?A[7MEXQU5%
M6QO=<KHDL77FV0PAW150B*;I5^X32UH(]*+3DH&UV>>^]"G*/J9#R:A%Q^?D
MNTOP;'\PFZCY;NDF1&2G#EI>3]AF*7C56"UW$W("JOS#3B[IR0-,AH^.^-%<
MY\S6RDDG'BKJ\M>-'D[O8*12'K;NA#ZV@BT 5$DDF_.6F2Q")B_UP&BFQ#<Y
M(4=0-,&NK/K4RXA\ FMP@^T&_M8$EP7L%>+R-B8U%JL%KYH<;'V'5M4/+C*7
MX,,+36S\SC-DVJO+2 OY;M9.2H$E8D*"/TI&@1D)CJ[1QW[3DQ^?BSHV;S/Z
MJJ&:U;A^8Q!M&T9M]<6!#=TQ?'5R1"6W5#)W155 ;;!/"84&%BZ\2R%00;.K
M@^L2Q]L=HSH9%..QK3Z;VGIL,?"/A)&579;2:BY-#;==[Y;!/#9GD&0MXAY-
M, #I+V/AY-W4D1/S#C/T[Z:UV59G?W%8\# 0O]1XWPBH;U\,W3;TB5YH9J=)
ML[P:ZVK2N%YO<#S65:U*^ARWL:YIZ-ZF<;(E6.Q]_:8?5%$V1OE&J);DPUG
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M[(4U0EQR\5A5GS/@H0'L=?O=^P2@HHO=*PX@]Z,!665'2$]SN<GY[DFH.3<
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M5!3M^/RY155"YR(A,]1,L4"&4",=!_=/X31)R#" RG/I9F>XL_CQK31]XO)
MD-*RB_1=2-XFL>]#[RL9#8+&6_6+/T6%+\4._9&5L*4HL63DTXE1SV<C%6]0
MA=I^;^HP@!?UNK5$'\2Q,>N)*%$2A.'.J>.=U(!O=THDP1!*8+6"V,_WNP5O
M7)7=0D9!WMS1KLL+W4;31IN:7M7U5YRWQ8?E"VLJXI>M+7J5IV]/ ;RI(Q&C
M/+T4AD5+ FA^O!%T;4N,YL[> ?"'('^!@0S!4<>E.^G64KWE<_L:5F\OE2%:
M_<+Y.)7O=3^F.1)[7?#CQW/):H?''>F?\S\AR#>]@OT!G #+(G!4>?$W86O)
M5G"]DPF@E&$[::=FX"MV'*(Z&.#+,S#'^F.#[+V21X_V+CS2.U[;W!=;:>I5
M7]_<;[=G3_F>9W=/G/ K_55]"?WQA_'/0V--!Z)3D>B#%\G1/X#+_*N;"YMJ
M^)@.0LJXLE"BDRC(.#,9@,TB$7@R1$J>45U.?_"Y7F)1>R3:R( ^9&?@<W?<
MM7:(\%@_-*>8U'N"41P==O;GT_JCR0L.B/\.)+;2,INBQ EP)U,=WM -]+=C
MM"V$:)=3Q+RXUU'XXFG]W)0FNV?H9)-J4._6C,4%VXPM7PZIN!F^[[$^1-,N
M-LD\@#V!X^CQSE#7DQS%Z):J]_&@53M.V8J\ZYQO7)R>?8"E#,'*1VKX0\&1
M9ZW6[*<5/T#Y,ND>"=:["_@<KUC-V@WTZ-Z.4]8VY5ADZI/@8N5+ODEF+\K,
MCC6>I!LKVRL1WP:XX77KCXPQ0O\(>^VX6MU\Y]N:PS5J>5ZB7Q>,45?;3VT5
M?/_13Z6W^M#<'UIK_S+KH]J9FKSU?3C7=4Q-'*GSH[U;^$CL.$DVESYMTN%3
M]%&*4(H("Y3<E_OJ[:&"'?T$TAZC;& N$)!.W)JGW7+0>2^):N%GK?P\&MY0
M4M PEKSXAPLM/+=!FV]YQ+8^^XW$60Y(#D#(HBD*<MX0R:,*/4"#-J8&6848
M(KK1+[$"^D7QX'AZDPMO+@FV&;":'U>9=K+K$UKRJ:WU#5^6(D?]SW&HN<_7
MAFAZXG7CAO=]03V-\4LAJ4F+R!KD7MRJVO%,E&K3X5A4RF)7E8EPMJ8TPDA_
MD&17!OF*?AX&SU[C"U5/UE?+K_"1*E-YB7 ^7\W4IZ[^=?^%F0FWXX45&5R<
M@@S!+:+6Z EU0 6R(5'K!/CA?MFTT=IA4C0P=Q*Z!DRT,Y$20S#[#4.O.1"I
M"?7SD&EH;.F)<(8],)N$_L.M+&C$;77/QT^C4^GGE\Z4$_<ZS18R3/LPW$)<
M]>(M)UT2"1I]3 KIM9M+PM2$9<1:I6"TFJ** L>G\K3)N_H*^\B]/)K*R9%
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MX0=Y<,-28L8_-K+E46=Z"Q-"423Y&]DW9_-9$M^>A<3XUJ%@AR$8Y91JE$4
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MDKTYOG]O8= YR1(D[FEI.)^SE#0Y-!>[F#;5T<$+$<O+IBKHVC:N0PFSNN5
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MNZ+7-#_?"&:;*OK>8Z@13YRZZ8&CBM1H$5.^F+F2/T;A2GD=%<B'KBNU2_,
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M+=##@A&/*($L<:#4$;@Z2+(Z=9(43"H'9\P\['.P)249'.=/ CVPZU/[+O'
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MO55>U-SG,\^WZF&F96PI-==\]K6B9:^04\@DW0M9<),?#']1&B+ZW-02.0_
MM&')R^.V;D_:\?_<?<3=16Z0E^^=<%AB'MABJZAOQ>MS+D;(C0XT\JRE-I[U
MLZ6"X:OO&L2!3-!U]'B1>'$LDH:*XQ_#!?<$:(KAT,P.; <M/E<')365$XT[
M0Y:T*'0$0=OI2U<V.60^+>+:EOUX2D[\TPM_$J0*X=9*&'X?8,/H?D90#- 0
M;:+(X7158N&'O#,OL7RVL 54*QVM]H+11O#8]/4JYS6:K20'CI6_^;OE=Z6"
MF_\#M7> ]T]R<T3LB1Y+JK;U-DMY0^SR^I=S';+I?:3C.%9-A.!&FP<;-0C3
M9]39L;]J:G6LH@I /3MQG!1>\# <IUU)'-C.AH_1'?",>'X/E5:?Y0P=8*'L
MPQ$%@S.<UFC D$X0W"E0!,Y/3X6[(H!(UMS%'IP*JXS:#Y31XO-!LYT$41O>
M8[;XY8\9N;T==QYM%!O>U[28:^QU)K'I6?RA,+K'/Y<PFB:&H_;CCP@.#B',
MO=?C6X=D4FWY+2R75:#@8FG"2=\-.2>TN,C7A:%#IU6B)X:O1?2ASE>J^T0<
M^5_ T;?/KXDIA8:KFY9MU3L.Y]>G&?!'DTO?+,NF#_U/X!X_@8-;B+Y6QP/,
MK9\/')S;5+;FV)4[3K.Q>T.##B<1!"\5E9_Y@O%R$MZ0]Q@ZBEP8K(%;@@Z=
MAI, B&^]I@Y2O) 1R:.[OD?22>&.T*:56+X,2S@E.8ZVJ'GXVZ.(Q\58VX"$
MG3*]"\_GV4%#JUU/G9*JH]7>=<NC4/AVPB_\4UC#5M1A.)R+K64N$63PYR>!
MP$"(&'#1KIJY$L;5I*F=7\(AWK4\FJ64!TI%T.(VZ&8Z%K,MI<$NL[=63;F2
MJ6PV+T%]6^@6)V:1&%M[LH*7B5/(1E-VNRJH-?M3XLK3H*VN\A\',/<R+8Z'
MOK3-PZ@_B+MA_[>RM>SQZE%\#A E^,%>7B1_'PX!F+..@_-344?C8"-!=EV.
MN ]W9HCR@>OP*%VM-^!KQ"3G6F5E28^O[_*QRNJ4<\H6%^4<GA:5N/D4FG9;
M-]]?%ML\T]*MUV@=(2><?%<[=DU=Y_Z FIL',6OC=:N-S+$\I)3EC3?9>35W
M%?NT'C1?1V]\MC5G2'C1,'ON\^6HDRHM=/^NXPR)?53;)J9MH-WYSK/?#U/O
M@R8L)WH]2>)Z"W)OW-^L 3]6YD7LIX#J2PN)WM>S7C)HFO4"KU7ZUVN?-@@!
MUJQ+;12%]0L'_P(7B_*090(-7QF E'95B5X//6M_<T!SV>=>^>$5C6/EU>DG
M3[B83/89:2_=N"TGW(P!3I&6$,Q,VEP3*3K= +0OS\F=P$36@L%P$\^?(],2
M%$6OU[R<I!9JN3HTU'TQG3UDJ)9'KWCC+<V.5WENM;_F^#=WTIT_V>."9U\%
MO9G/R)V"AQ_7FD,T"X:*'A6,])&7OW%47\R&(]'(YPW8J548(ESQ)#CVR_ %
M8&"B(RJUY=M4/H5&[IG;()2OW<M<I(R.W$6U@[;[.L*!E_IJ6\CS)I/?OS^,
MW]W*NYV&R+=C$[!6*&'N[R Q7_/!9:=!GJL*E#!(\5O2Q&G-N%K?S +NF6%"
M"<P.VZ#:7QZ5,':CMK*LM">GH3R^=>'W?XO':$@Q+Z.>(01C.HR&H6+"$3(X
M##BG>_E0G$_)0(5FA.R/7IA#$#3Z7H!72W&!OX^'Q]MN@F>2S%6-XMT9/IYT
M_Q+P$LKI,W_^\^COEDG\"8H>0A3J%@G"O^4J>!)F0JG*7,JW[,E;SELU6VM=
MB 0SU&U*64,1B'V8/_RY3#Y5E0U3)@WP^SI7B62"]ZR]Q-4=6Y-N282[=U&H
MQFOL5V^@;+SAHB281/<O\5?>->P#'O\3^O R.&VP]V&M4V#OH;2YUL4+R&L
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M.F]%I8LW7&UE.]G5K-T:;;B1[@NPBUL/2;J ]-\<);+K5\)ANL$%P246O+S
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M4(L4GRS.S#?3J4P8-\K$/FSR"\YSK7E)A22+G?E[E8:?)W<1QQC3'LU(:2?
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MLX5*%O%J2+,KJ"KZ\%2F1^&]]YZ6?!&:(=# %,&]MV8KL_1BV?O%*,B8Z7.
M1L4T>YS,1[A=>2CL4];)YN9/K+,5'G;D=SVCN,@G'B3'B$IO/"8@0/NXO:G9
MF'E-4&5XP]81DY0WE=\B]>E\#Z@A L4 VN$S2[_@Q<W[( 4H="N]_H+:E;'O
M[>LL*K_F^9YYPWGTE?AW-Z_N[1!.UB7DV'N)Z$HUCM9FX YZWFO0:O()U\6[
MBU05V4[,K@;>T[F9K+PZ55YA2/(Y\O#RJP\_'/V,T]<BC]=H1;J.^A?2][3$
M!6=V/DZ/S_,ZA:KN^=I19%J@U,E0%+NU]\3:])X'<])V'^QC("/_YYGXG&WJ
M'3N0I%"F)6YB!\(>QVW5JGCLKOOO8^F9@ZT\_^[5YF;"]C*(D*KP\&W+.?FI
MNSA6-$QM!U(M*K@#J>1*_"/F1.55X/?X],IPG L_L /9KB:L;.B>QBW!:>S6
MI7_W:G.O#2O.M](!S<[+6SO#ORF# 65KI@VP*ZBA([^GC__K^L%=+"(F=885
M!OPH!#9FX5T$(0Q7IWA@/,%SE=M;WHRN'B:">"#.WY:XUZ $..2M^3'H$'UO
M39'8L1&5V[WZ[9^)##6E--NN-9N5"W3Y+J0(F(<@"'." 0ER:1W!K4]#>*<+
M8=!;&>TBP4[E./RBDVRJU-/P-*<AI=6 DXZN\<>3* L7K9YP;R(9.=L9[+V8
M=<;T=A*!H@!X4;;-V3*3V+N-](G3?5ZBL6XTY /U*1-B><4DR>2 S??K4S5J
MID<$'3OJI^EK1ZSBPO"+6Z$13YW=\(OWK)ON913:O7=S+AQ_+UR>F9)9YL5;
M5UY>J_#D/?K/RT\[#EPN%E<H*8)P;_)!>^Y>=^C2++5NEA?'1%.6/JJ5GYQ5
M&"&ZO4G'Q-"+U_3\BQOMG_9L/"^AQ8:+^^>I?E,5T2;*]0-:]^]H2U;4BU>H
MGLC+F%D$3PS?V=R[FROK;@(BZN/WC^,7JP[':*\X*MPMH0ODL;N>SFFG5Y4_
M=Z'7X'U!QU;"L_7^,9#YOXW?<4K[-P.6[T+7?NU EON0V\<,\<FX#[,*8.RD
M@D#&HEC:@,F'Z\X,Z\4Q+H9)X98T"L=&A+\35LZ"^#N "1:3"0$@ 'SGT6SD
M-1M=FQW(L2]OV>_N9&\E7OGU9I9M8J8*AEU>%/R7=RSWB=RWB6G_V.,,P&<(
MK.RTU1K.EKR5;O ]LF-*U__]RSV]N&E?)%/<9 =B99NSX< 98(D0A*^$$W'+
M[V?4UCDS@O4I>O_3;.I2D']WX<>V0_IV(+FD,JL0 O"S"<R&(,)/^ZO7=+7!
MC@E/UY7]M_M=D'S_;IRQFMP.Y*FF)2AG+Q<[=U!WK'U@4YN% R.U4F@'LO1#
M4LC<(-B]_1]CFO_-%U2 PYAP7S^VGL.-BQ+A6UD8Z];1AAU((@:^'(?<^F.L
M TXS)V^>J4P@,_: N5:8)5Q9!Q:(V6G^K5E1]OVZ>0M0B'XM=L<+)!OOSC7I
M2OCZY4[#=NJ7D!U(B2IO=U%NS,^!Z/_5@NW24!^5E4KE*W>,5;Q]E'MM+M^L
M?V(JV.GZ)N[@S0=$[Q>[]LPJO7KH.:)_Q]T^B#0BDS3G_&RR2TTH>F%?IU#*
ML)JL]_&1>U8N)4:0IS$0MD+KT;!.N#!;$$/L/!3V&<2R5S@[N]H&]L%C YB5
M_%@437[E$9W B #0 93E;<_O7N=Q':1$$$EIQ;5*+FDQ^M.FCR7L0-KN7@_-
M-?J*RH\\S([#S3P+$P-"*8D3YTP?41*JF-)>60+#S5[4%KM.L)@>&0SHXYEY
MG[H68O4F(E2^/>P(7;K*=59;6E6UO7ZL(?6'_JF'6E7U;@KDE##X]C/X3!-4
MG.5*G223#*]M9[6>8JDWCP7X4: /"7QP%#F.4,/?QD1RF_C/&@UAO?F)_'_"
M$V$X/\8N<4]4!>8+JL'"2/W6AW>]E4PPH?X$ %7JP'U<35\DL?)P6#^Y)G&%
M6+3(EA^K6&6+@=BTH+P<JR4B&C'R:FPMP-%/C\8N+<(4VMQ\^FOR[;+1FGSJ
M8;=4!F7B.23,&/?^$DN5J;.(%%TGH%0CPK2!("HT'KH7YTF>*$&2/,E7Z1O1
M0XQJ6GV&5P4@TO,.MY?@%BO1\\8?MW^1K37TJV"XV92"48^=$J2*A..HSV?3
M0^T,W[S^#MT[ ?#QBV"% 7J^9WTU&(5ZO[<_/ 2B:0-489;=EW6Z]3(%.ZT)
M/,)C&BAFC9318=TOV?NQIVDZ1*).9D5DT(TFKLA5I=K,>UT?WC;9EU9^8[;#
M:]Q7F%1RK+0DL$K%/20?:+Y SVC3[$91LJ.W"(_4)78@$AY/].1$>IRI/!DG
M-?8Y?4!HC1__$4?"9:J.Y]__L%GEQH1A]PVUJGI"H2NZ_%CM&F"J9!$^'IS8
MX87C^G87P_AA?%)2&06/3OK@F5!]0<BZQH21J!MR.:\VW:8^_AA$BA_D16#K
M:FO=11<AT-Y2ON*$FP,+[3I4(UF[5&/5LW=W4<^E-CT\Z6W?H?/5$F5GF'+[
MA^/^-:J_'R3\TJ;0V$(:ZQ#\&MVLD:8VRZB93=QG2-N!= 97KG8S[:>!PG>O
M@8BNCBJ,H5T&-8 \J7Z"98[/#_9IK;^IRKJRXFJ"Z@V_ZL8;5O1_F+#\BF_W
M[$!'B^<DFUN?J?KM(":DS1U!4\F8[=N/'\9B2(&Q,+UL$9A6GKTICD+FYN?_
M(O>+$,[W4G9XI,X Y?S&5OC5.6N"G>(L-!:DCD1W]@?7!M:Q[%JX<Q;V-*7L
M1]P.9-_L^=(A @H=+WT4V$6K<00*\[!J+4!V(6 ][8UH)YEE4,L%V\:VPB*]
M!5"_)&P#/DR3+5+D3K<K'?4HN#/_%Z!7..5PVL#ZPXFO Q+(T]1>I=._%F\%
M1=A*PAG/:@[X&)I%["U][W;M]7.[9]]C^%*4[LF+6ETK79E6R6]9>ODB$>KB
MIR2B(C;/?[SG^P"?1T_DG>MQL<H#<W'M7Y?"=97*X_M1+GX)1[*T3B=H1=_]
M7FY_XOT<!NXJ,=3C8?'8V>0;MV(TX$=5/00TO'>"TJ&QS9+3N\9^A1P-":7(
MC_U<%])](A>H^5FW,;]+)!O[PVY35,G[B9+RZ?NIF(E$;Z?SGFK$T5*]0IGB
M2_F+IH.EQBVZP;YWTFHJ]0).C$:>P=9Y#&<J/*TM[C='M1191QR+ES2 >Q2/
MX<WJ-*Q3',Y;<3^U3*S-<1):_IRME'9>87AQI%"Q+5]&G1IS(K=:@QNP81P!
MR_,.9%*1/> 'EN"\'0C_\NJ4"=.0J0-Z668%1R*[-+%[V)_5XN%,PP_)*TBT
MYKLOL?#:3:2GYLS 5_3WR!?UK7+;B:V\88-DKKH=2((:Z_9H*]>R'7]'=G2K
M#$ L3 P?G=:N&_''"6-*SA\B6GQ&<\4(>*OX2SC"]1M2^Y>.BZZ'P'J4O+B+
M=9V4K[$_?YP3U_"TC.U@VKV.\?_VXY/YHZ(OR0Z#GWT[[=;=BC<<X$J2F',)
MBV.]U2P510&3R+R'[UR\^@]_:;N.';%I5Q(^,?A2(83[Y'#QJH*%D:W!1\0S
M9M8_,>)_;FFA(!)PW['0UX7;CP@HPK9UDUOH&)*;Y6>] XF8W@ZW1TUN9S--
MX\?/^8%L:^S*S$M76():.K/D7^'H-3?#+_1 5A2+ T<E0'I5R9^H]_M1-_ZQ
MI4<= -N$;""U:SL9(05FC7+)&'XL,FPP[%@KC?R.')UFY_ZPV8_.93G<+%>!
M"32E51(S(9BT#IWP'4C4S\ER\;YR]9I ETHOM%^0T-@&OV\TRJ/ZB^Y<W*.!
MF*0(48&33I]SK-X>GTHY>SO)FR";$2JP_%7(TT7M2VJXG*A%A5?:T,-G%#,5
MBXY!DW2\D=Y+&5Q,@/QA \>/1L?[91B2.Y!DG>WG.Y"5*!;H\6$O1&6)XM>!
M<=LZ 'Z3\$!'-(;%,YL8*2U/BR22^3!J[=*"0'AN5PXFAGB=UIGAG;]T2..9
M5MJG[D*'+Y/=FB]"A'OD5C,,M:]O"$%M1\\B6;&^V^([$.>VXWA1L>-%EJ;:
MW2<-"O,LC KSC+*R);O2XC$M?I;I.Q#;'PMB@Z5F=2<[;2L4S#,5AMUTK%#]
MRL;")_OOO+1[)DL=^HVX4OY_Q/6OB"N+,[$F421>@F%*WWA<#CM)Y^K4/0I$
M-)E%4OKD*>L/-<"BU\+(H)[G<7KCQ0P]-.U70.+AU:6D?J?G/L C3SKF'T5\
MT>6F:T3&L>0H9&'4/5)=5F;EHJ9=9F;%6[R31W#O08>V2DF[U*=%AL)KF9C[
MU!"3HD$/Y(FE?1I#GQVNT>J.)K;/.KJ=L"$ZOZ:_*O9M\N*%&1AHV9!T \^Z
M>$Z%:$_XRFZ/SOU\T[RQ/XJBE!&Q.)=R@EI=M@SK]YQ/A*XZQZ8&AG?3 DXM
MJV[EBTAK!Y\5X4K*[1CURV@W-C<ND[F<&Z-8N_GJ?[N$B2;(YLYA(MD3V=RZ
M*IA("ACA9'H7171E]156>?LE"\[\:UF0=0&PA'8@Q5F>0W6JL:<!02J$)AR1
M4XX2]\G.8?'3BAYU2JNECBH;7G,;+9-]:W+^Z/%&9 UN)G4'(LY6P*( >;HN
M&FQ2DLUR3$/,!H6PRD\WH7@O=/)'L 4_-<O1"!TD1'B%?Q?MU\9])=;YT))Q
M1Y2\P;!2?^'=[=*B'OZH#)O76A8&[@*5F8295TC)UA/C;) "\X?M\8 ?@CNK
M3G1=: 2DJ'!1L(<TK.90)) 22TAA#=5#RZ)9!X%'- (E(&4C!@MUQ:."5<-?
M#:ZU'LM/QX^,MA0"V<95WBJSI@E+E]E#8%0&8>XV0YG:'M-"D5W(ZLA$]?+=
M[4Y'JCZKXERA?Z+@_+K[/+:<WR10U)55B>*J4<V(0I*7=9J@PQ<OOXYBKJ:F
MMX(]:,FXWAFH+X<3_P\;%_[]GG/U7<L<VOOU)_PFG"D,]T!O&[#.VN] &A"L
M=-'5W3N0F^M6G-4&(YLU3 /<>\-6_F_0>O>V*?VV5BZ@DFY"A-9,-71F'V!=
MHZ<1P8+<6DZ9@EX=_GG^$-E>W'&R[Y!7%:!RSOH-_<KHH,&>.-^'2<91-]$M
M.$\D%&-"):R(T=VIJO<U,G " +P3N:\";%3\7B+VO5HD[YGZU+.P!JM4,1=B
M1P#ZC.QH38>Z6JZ18-%V1 ,/G<\DGI8&39\[_&6OH.!VLEX*UD#E<LDO[1KU
M7M2GLF1?XECI_0X*_5F1BXQQ^97S5M8'[UK<9;E$"M^9#WQ ?[3KF;NV)%$L
MDCW6/IP343H@'UG8)F9F:R-@,&$H&(E_?H.NK5-' QM[UK%D_-E.WX=IXUE@
M'WGJ3B0P_AB$_R2C[>LB*?=MB$[2UG^>^O3SR84_#QJ$OSGRZ,,1VH6OXE\J
M/RR#L=BP'5J\ \%_V([D9Z_KLYL'=R"#Q\#R<?/VO]N1C<V@/V(8T B=B#@D
M+UMS*5N(K07H=\"YRQ?J:6%I,U I?3!=N"<K\"HPO8TFI73E+;()U1MV/+:\
M6ZXM(_[XB=49YKG*3*2MN8&S"8]>^!4#NVO#"BXE"F^BY15'B@\KW'U909J_
M&G<CW60JSK76):W\N?N+>J_''^^(16A6*.Y_ZJQPPS=&6,;4<->CTJCBV.*(
M5Y1]/1,(8>OZHVV^28Q?I5;6F9Y)3PV$K!>2_J=MW\*;B4QMK"M@/HL 3FBM
MEN8 AE35QS"C<LZ'</<_=> ]2"/X7RO5&'U]NG0R-3]"6RK5G;96&.#E7"ZK
MLE[H^$5_SV"'S&KE4 RQBM854?NV6T-*C4B2SBPR7=@<&]4Q#<=_):">F/C-
M.]I/=IW;SKTJE^V7K?F7M&GOK@I))Y'Z8ZU(BTR[JQ'\HDJFU_M?+B@44^X>
M=N/VC;?SS# 1//G#6$/P;LQ<S>VM+.C &5:AXNP!$=7=\1U4[<3(;U_?*(S?
M]CZ@++G'.(AAFM4C')-GLR<F2_-0<=(G8HF0UXW\'+MR0]LW;<?G."N2>OZG
M3K#GO^[DNUZA2%6-"""+863:PT1I _&_*B/%U^H*Z[(R9A/Y2*C +7+$FOCU
M?/:G(6^-4J\^E9 'XK"C:.6"**5>2F#)J1?=G8+/;BP9GWZ69Z:B8(G2S!$]
M>VE_-Q,$FC$^WY-L;@%V_DO4U\.E+B<I)X8K+V4Z6'E8%YOPF@7(B%$5B+S&
MK<?\OW4T)8=S:Y0:G_9,44B^^VC3D+T?3+OCIC09]KNL8R#8F&P?V9#"OF?*
ML_LV"-5C1.U6$5S;%)W0D<B/"E2:%LWHTG22JA^&:16:*'>,=*9XPR-_3FD[
M30Z$!MZ]=ZO5R$<@N\<65O=':W:%9$&*IY@34E_ Z'.E_IZ('.N,E+-O^L,/
M6Z04&OL]3KXS'QN7W32RJHC_)7W$M7IE* %#T/AX^G6O;^]8U(^XL=UQA?JB
M$5:O&U-U6G624@YX'] \GF)L7E$T&FY\VKC\+//L-7RWA9N0N=.#[__O5B3_
M7S;+SJRSA.1G(CMN;E?5HDDR;<@:\@H_4Q]SC,RX,0Q3G)728E" /#=*-VNW
MZ\R F&?8R>%F=]J0P6@SS^QY*'%:NJYJ%*RZX2G4H*./IXC2X0?&-*-="![,
M(?;^OO)LH; ^<6A,.5LLK)O XX\^Y$6:!PNH/$.9'A$_6_F -!JO_L20*^HG
M0<!#5X06D>E73NX3HGG=*4B>GW0@[7//G+.^O .1A\]430L YGGLSUE_C+9J
MA8V0JW'O<(_)M89$Z!\L2> M5U>BP+(F5,Q_!_(HFT?WS 6Z5V<PUSME?M/J
M8?]5Q"5@ =,$!^MW#']E0:;KWFQGUS,.GFB!(</I;,[V3\!FJVMEF:Y(A1-Q
MT<@_6X]Y<#ZS0$%C=R"'2&,,3_9P\HPH<:*NQ>SCZ!AEG1B[C3#\9&.3J#^H
MOGH&)^RY=2_9N6 :Z-R!.&K6ORZ[>9!_]W9UL\;L-C^C!@B"MJF2<(QH>L/J
M(_ 18T1'- 7Q;N#/Y:N+Y#_"_@SKM=O;2.E!Q@6O=_'O'B<Y>(B2^7\1^$E
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M_G)B%$FC4E6\YK6%NQV=W;%.4KY4Q]7(E*60.K)2N0$I;RYL+>[GK51U;90
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MGBX!QHC!N"C>OF^6[C[J(2W&ROH#37P1T]":S60N4 ??K_]4P9RCPA5]QO.
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MQ=N8/<JS+ 5O=U*GS<>'!+GYWR--VY' T&K^0?HB?>1-C&:$:[;RI! F#<3
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M9Y][_!CX;1@[.C/2;3.U2+YNL(ZK\_#KPQM:8U6PUW7!<9,U?8MZW/,\,="
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ML3;A+&PA*G8POEW]FOW5\1DFR;'%?EL9]K)73!EUU/2NDY<:F$[#&K.SE'I
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M1$<&3IZ&]QTJ01_C_%)Q<9@?8O/6(0Z5*9P'?E'^E5"_2Z,?R7V&[@/8-,0
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MRKD29JD:_IV=:T<V V>H@IVAP##\'K&>0D/MQ[V71?W9IHY5YS]MD>3J8/>
MVE68#F.SY4M#N*/M[+EQQD0%$$Z[*Y9+=\\(U>P6(F,H M[9C AR?.KCT8:,
MH(BP9]^;4"X"X?[70;NA^WCF_$=X;PH]W H,7H>(4CF11,;[VC 6+(:-2:,R
M1FBP35AG]NI$,R/*YT(_UL&8T_@HP%E3D%6%":7)>@V71&VI&1V;LS\1(=.E
MWS+936%;-_<I8(PX/6P>14KR],@ZQ+>/+M..KB-TK$.D_";V6S8)Q,%Y1D,&
M^QOFN)6Y=6L;5R^ILAB0H8)58;Z;9]]$/9YKO'MKG^KX;>-(C@4_K^T(]BA
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M.SW(4,[95)P@UYVTONP%? 7JD:G<MX_-+3??RK[&IS-GX0A&V2'$&P_*]G_
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MP 5M*T$T=M4MU:NFJX9<8TA\X2N>?>6"4ZBHEHJAG2O_W9T@25L#; UH3OL
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M7!Y1J^!JR_/4[]':N"-_-5W^\Y;\YN2J-6IH0$R>K>9OQFP1[1LT=L;;@^*
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M$D:;E!7MZ2I;E.F MQ5(&^^]\V['7+WGCL=VA+N63SWM8:JIN:UN-P%PW4Y
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M&C;IUSWLJ!>9'1?P*U9DDRW4P6-F/Z%E)!+A'3CK3_EV"!'30HJ 0]UPONF
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MUSS<OCZ.N1(J:/;"]'&YBZO\[*\:2KQ2^^N2]PH_S*5UIZ%BB.\OZ/:'D/K
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M1VF<&"-JNJ7%4-3PDL,'\)1A^B>23FY51KX:P]<O?IQ7)."O0G:O?Y+)'BW
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MHP'.KZ4+RG9VS_5>,2<#'F>A<ER1#*(';W_SP6H@V--O6^(E28;I,F7PL<O
M01O!077"Q?-5*X&LR.M98]/E585ZW\5>-6IEL( &U4@%?-ZPP/?[N\JBZE>V
M;$P-M-P)U#$#5FL2E&J+I3L;M8XJHLI&HEI ^PI5H)DT0?^!S"S!1Z1@>*MX
M?D0.P><9Z$%SN E-@+E$C6PU*XG->E,:A4T3D[J:VDU2SNRVLO+*E03ZZ7//
M9)DE.Z4E,]I 3G'Q%S:>#ITD8V-C2K86K_4?AV QP-I[D-SQF0%>]UQW?IMT
M3L$ XF[LLH=.+_^F=U\_7,<YYJEZE&,MJ''3-$K)L+C7<GBO'!]?(NEO'(S\
MQ6J1=94HQ=D-I!FH8@GY#DD_0,4;QXQPT@2)7-KKB]>$>YVU)Q$K-)Y0K?(\
M=CY-)\+4S#N_-[C+4,6!>X4"NI%!R<'WD#W0/E]7!?B/NOEO,A N@HB#PT.A
M.'U\]4DP:_VBLUJEJ/YU;F13,M>7B<@ZB;[%B*EWOYREY4BI4O),H@9U!^05
M%DO,B[(NP(W%+-AF;&-M:=FJ.AE1_@2P;C887Y$"IU?]Q)-'@W244+R.<(3@
MH$IEP6<XVB0LSF%'"#23]E:$S/" VZ&]-@[43ISFH)V:_.T.P"YC3P#9O_"
MRZ"([%_'# 21HIY;5R&#-NX)^T$0E&S!.7M(;9,Z!D@(NA G;0E_LPXY77$D
M7C>2*NXSSB8&>]%.M&CUI4@&/;_7/AUW@!/1P+FK36DZI+/;;J[B("9]6& D
M2O)^#1C1_4$$*%OK30[/A,@UB12UCAO;C C_#[!]?)U^PHGLN-9\C5G_EP6K
MCL^,V^[=]L^:H\,MW[E#+5/6LZ B&>MU)%O/]^-?*;J(>ST088B,*UM!O6F:
M.10>07G5_&F?[.H4IQTJ\+"]S:!+@>83-#60_RPQFCCVZA8*TWTN.UG-)C!F
M'3SU#JGRN3W-@_-G'?9",86L@&&8ONXB=[8*;M9IQJ!O42/X2E(8&A3[N5H:
M+A'9VL.W<=##!F]AFA1S;^+.$!W<Y#__,QTA4^^PXY7.AJ\2NR;>^&Z,0E*H
MF)O9P:!"ORC-41>*0J,X$$]#-^B1O.O1YS4T^^\U0AL_:,3T4!1VS'>JEAK_
MN;:MV ?BHI2?)/+6'-M&SZXXZNR1\1MUGBHDC_JX= 0G&G0&]?:N,?WP-]N@
M7WHTT$V^('3\S#?(J!6YY%>T;ZRV(@JQ*W:X=NT/4ZW@&O?VY05O<:Z9SD@,
M;;@H<+ZNF5N' .][R0UKX,\>HG.^&/.7+<A0: VET\Q2312O_R,86$*Q#D%S
M(8(P6EYW;*8:CNB4PUP.RWEFHNIA>4&6)\8H&,4"?+'G#[K'S1@]V4,K38C"
M1G+!JH"PZK3[;KFIL"A$_X >'UFCV+S 5KMX>.;D- .CO@7V068=!8;I(NS
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M6K\A:=^<<L/8::X2[$7T5$R9Z*<:<D6(P8XG@C!.15@F;SWB/?GW&IR@7J-
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M0++U+M82\[,L8:PUEB+#M#7%(',AQ:!ME *'T#TE-ZJ,_"?(V!*X;ZZ*NLI
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M)KXQ7!0%&49S-<SQ4F-5VQ6/5P1C%W/_18PU"Z)*6-A57B1#- >T8C,*]72
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MVF]J#,1Q*Z@JXIESSKLP)(HR*]M_\)!\\,IV7-S6D!2 AW-Y3!#4^T;&:9I
MH5B:L[L%[S5IRD 666BYQ,<>H2I!H]<2M*NRHR$EX7BOZ'GBKX418-Q..H\D
MJT*[C8K.P*=%R08+_'U698-=&<<YKH7)PGX75"(ZQ68B!U<D+*0MD%3H![:
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M,#S?%SYMX.6H8"V9[N-@\0?B4K]N\M?+;W\N:\U^]\'^U2V[4<6O8L<A8/(
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M1'?/LOG"<[Z+P8+V3NX4&_].9UD=>9N#*XK#Q\%$A(\T""F#*7(>%/# N&\
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M:#'TC$WSZ$<1[\1LUW>RW:)=W3=8C4O*]9[LZJ"\"^5+IU;\R9$**CZBDSJ
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MAB5,JU1 ^DKS2XT,HT*^_?I.51O=UFZXWVBCD7?_.^>,NZY B1+2Z2S(M=A
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M*JYBX4\UP@)4-S,5>@<VU;>3(-[RS5/2?QS;%=]_MOQ T"LZ[7BLL4-H0)?
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M@MZNP14(#?$P/6,(D6JLFM\8K8I):8ZH_O6O@K)33X/^9;QJM&+]A"X2/:Z
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MZ1*9Q>'D_73[ZX/H2P GXFFP#$*8:/ >Z1YK1S./>#:IPHUKDQ\YQ8DMU3G
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MVF;F)2!2A;9<(+J(5, %*K,QU]&-S?(7T&R M#"^8]-57)"FA?:+5"0\1@A
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M35)*CP"@P0>UZN(J[F.%AW^.LA^#M/H@>^)//,K=^%\381.8=8HQ0J/<VLJ
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M'@'7 639SU&U.+ 5TF=*]8)IN07V7MJW>+STCA-8=YJ%<T\-$O:8.''M>38
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MS/ZHD"((3V5T=MPF8-'N7U<X5=2ZU1@P4]C)-D-8L=4]%C&G)G7JW?D5_KJ
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MY>\H1M+@JO2H^F_EC'GV&F,B%7FF4>2W(OXFRH"%2/5E1'4&^\K"BM@ZO F
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MR@.&0CKM/B\E4QU?$0.+4A'; T1E*[P<N;>DR<;![OXTLK9<M$G<RDJ'T:O
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MB*T1#&=6 -TAU^<:1Y6/1C_(V+IOJ_<%;'9BG,.J[X^U-K8:"A6NS*W'VGJ
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M$;.G!:QVS;G@5GS)MCT%$K?K0E:WO=G;A QSV=\PL&*NV!.[K?U I#HD-6(
M>1,41;V&B4$G("6N;)QO<)E&T(F8'Z2LVZN!)C[(2DC 6[/@7%[A.: SZ] 7
M'87"L)!$<-RK+] G?058Z"V(5)7K[V>RZ%_N7'XI$HT9RSI2OQ@?W;B6+?91
M+L Y' =8@R>3I%9R0W^<F38V+7-.0=W?V/7$G44N@:OB_7AS?ME]'*M+K\O)
MD*1082TJCBXI?%1-(V*\7VALQ5/LGKNTV]B6,JTI=:5#A(8?:&GX[=,W?\B1
MP"Y3,JLY0D%4?&S=JW5?P'>JL@7[IWK61*TRA!-D R5F"E1,[NJ9$6#)KR^>
M35N>1G00GS'$(T7#%%*[U61B%')5CP0;FSJ0-%P_&WHK_07U'QIZI]^DW^"4
M[*Z7=Q*)5/A2D@65)@K:O_F.C'XY=]=6,W?!'@5ET/GB%IO_4O CN<,F/DQX
MB@1>C;KR!,]@GQHKE\R7>]#DOKKU:Y*FPUQ1OS*_+T3_BO\9$#6H>)S\WD$O
M7J_E'-J1LL-T_^4*=L.;&\(X(I_'\%DXJ"5@ZHNJ:I6'D/.#C4S)K4F_L$%1
M%3T15NY * ;*')I?\=S.@XGHE(-W<[QE%S/:8O$A8)=>7GSHT".Q;]/6<5@V
MP=HO^9>W:^>WI.OIAH,3I<86"2Y;ZI-Q7V9@(1XRA-C4I_*(>E3"[2RTXL.A
MQ6>ZUQ?4/CHD>6,TM$9'JP56\G-'93-<3/W&C;8&='\'U;+B\-'H\\!5[\\>
M'XM_'.(BE\T^R_ _&\CZ:^2BJFXHW#F@TW3HELB2RIV(EW_:\$AGSI;Y\(__
MM4V.,?M_:'\;X^'0TLYJC%NA]:P)8/Q!=KJ*EH,(4&G!=-:L+43*"ATT<^[U
M:5=-KCR6TXC#V2K)R)]ZZ=-<CJM OO'^+OEISMJZHX=@LR9(94Q$J^4(VZ+)
MZ"_G?YN",N</CP>ORHVCK3VGB\CUAR)O;/+DU)AWY7^L<0"2W(2/3(Y^F_O,
M^GJ_AH17=<*=8]K"^&?X&Y$=X])N-&S5ZX.>O&_,RAXEE$4)BF=_'HSBX,[1
M;8W\RGJ&/U>&S5_ABWID-7L^?EN+[7G28KN[4:-W"K!@,T,I)5;J\Z&51N*
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M.\QPF)[#K4_VG2D.H.!2"'HSS<,Z0_!IV26%SU6H-2\IO"MK%RH)=CB9/:$
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MY)G$"H8H?+)7'GP.)X]P!>]1!^+0"ZM.5PM(U'!:O;O*+<,"6N,H!--@BE/
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MV1L74ZY#Y*G3TZ9QT;*BO>"(4,],A_P6LMH57CZ2?^8SA@EA?:F\VVR2%)<
M]A.UKS8;VG!I+JHE;8@L=;L]P=;6!;IMPV&AJK)A23G1ER^KP9_41/:N8G'O
M;X;6G<FC9#9/=')D,0Z>% ; ,Z.X_/^V13I@1L_<BF9GFNMV4K9#;GY!9(+P
MUOG^66_O9-#<L4?WEPZM332NN-GZ4/KJ.10K5;'I#4IS+:^0MVU/7#^LI2A"
MZ]JOW_3N6ZTTZ<^Q;V-[?O,I# X;X4IE^6YJ]P?#$[\N .KD><:9_@!Q8'FF
M]#*12XZ@V% QZNW5<J8QWC OKB(.&1IQM@8O)=9&Y&CYQJ%Z+">*MJ:\S*/>
M%;-@"R&54Z9R((=^HU(.I'NC\R;.EY!&K,-UV4T<^])M<474N17^9>?CG'DZ
M^RJ;3M<0KQR=:99O&:,_*VQD8XG(Z)86;!P/,X (#+-&VJ&=;0'\-JG?IR/4
M'74KMNV3H[68(%Q\Z2*]H<EQ\EN)JS?PF='0OH,8;+T66\OW]JQ)Y_H)W\#8
MS;:I0$\W7=X_=5YL;#^ES(1._QE..,\\\N5R\)414]>/%C;*6GP-#/80A-!F
M[!9%"8B+K2/=[E=.'77R/9*JJ3IXBLAC;)I8B"^OV=MGO&5KJFS _4Z]"-8T
MP)@A->Z&-8]@5L$!)'O:4E"6(V+M]NS5^E5/EZK2O)ZYB0G6=&XMGX.J.N_8
M$03RS,M!=*JFLJ5F9=91.99I6?E"L/YMY02WGU6YM76AO6!>)!\,_B2JOPE^
MN[J_M8QX9<R7$U>*\7RMTMD%KY5>ZF*UJ;>Y(AVV_D'^&979+WHI*=_]N>>K
M\5OPD_-K\BOGVH(P4Z*8;X5([UY -YBU0VPUM-K]]&I0$12?1-XEA6W353"+
M!@+7WB$FOC$9T&=Z5 R68YRV/B.:9B2_[!V'AE9F-%'VAID4;E,.9MI,K.?-
M[,_9+SLZ&$NO):G8_%(6IJ9Q!#(+\SW(=/;W=<M-I[ _G76<*/#<3?I2850B
M];[W'R13+1"%OHCU2'DX*2%9P)\VPA,P6E?9K9I6W-<*&^K:_!+S[G,;8!_6
M:B11\Q@HG#5_*)ZVC-Q#IQ2E=N:>G;WZ5^'_A# %_E&^G.@5-SBO*@,14Q9M
M=C,;-1VIG&^,* R3)99"RX@ @QE%^ >NDYX#ZNXU !.1'86^U5J4:'_^A"A0
M;6^WK$G(K^FC\6*&A2P?^L]F>8%>2W_0B(]7C!1U\]B)N+<#8(D P+3"?=:P
MQ<V]EQ2WG7+!*[17'J%&(1<2J'U].\N#<)P?[Q8W85A%TBVSWVI6PMNCP>W;
M]MX#!.AOH=X/^0G+]XGE:WMW%E!!7*.%X5BH,@KC?7Y]'DPGT9OU-$773]+<
MZ7'#@M>'Y>?[39GR]NSUGZ2D>+JY%I*!+1>%'5)X02+5JDUTH .OU"M>NGLI
MP"#(*QDV[\R/7E=$%.BD-;0\;-R$EVK[Z-(QZ7$N7 EAK=A/.;2K?DZDG7WW
M+Z%8.:%[RC;P(-PE)QQ!+<6=FL._R)M*Y@>BT8)C8$H'FKA*!C?[?#E@A7F"
M@)FI>4.:#,MB44[KDJH1T&LBI*LX3!DW:]* .T!A8I?E<'E=$%QFOX %T6!U
M&"JX':*/*%APZ.SK;WA=!I-;NJ1H?!:N-B3<53^99;1LYY%AZ[/@&7)DC0?\
MF O$4 -Q,\-8AA]C[S/.!#'72.K8"X,G>(9(WX[ ,MBD53HB,=CY>PI-YL01
M5!PK6A-O%)]KM2'E?W([I1/F$8<4L<-XH\%19"XT$;V_9N(D8]D0N77 /]I0
M?GN]A8^KZ8O6F$((HC?SSMGO__)VQ;YG&'ZCN1GJT2?S@=$;29TB\P& X,WL
MS8]KT^N++L9=4EQUN.@(0-\W"/F:PTV3<.N=?JY Q%=$<J]U5IA-GEO?^L52
M'Z*WY,8[U,MZF2&; E%EMY%03290R>RX\QDBM&EO?6<T/E#TG^IPEG_)ZNN6
M<B.#E*)R_40]\\&=O4W3=)52D2"=BN6PNT3P6NU-"+CAI!_S(7ILU6[F&7ZL
M-U%X_0\NKW2MBVM;J8VN*;LDUU;0OGI7628@H,;IK3]N?L&(KFL>:V5/Z&(A
MFO3D4VK=)U+V7%+0=T%DF""7%$RUKT;L,0/(^W49VFP0!JSV!W;"VJ,\[+*U
MMXF3\S[VGPTR_TE+GBQKPET'M([[%H_B9G 3F <I3!+(6] ELN/.?\"O*3B$
MJ_<&ZYJ&<@:"XY'W)])K7:=\C^/CL^4A+Q0%>*?0TEG__6MI^4[3DEY;VG$-
M-_PCGSF"EZB,TJ8ELRTLPA(1.^"[)--9DDEI<4GL:A?C5E# P@!]=B!//_#1
M!O?P6IF=KF^ 9@?8)8G[2]'3IO%GWDJM5B?G3E*XI2:",Z')*<@E^[WXJURO
M^C2QJ<KH?E4-1>_ROA:0;#E'V9-2X&C5ZKOX-#<18^K62D HB8EX<S4Y$BUH
M/=/<EAE+LO!O9MHAR^-O+IZ@1UOA<'X0/%@CU7"5[E<Y!_H--)+C_@T#KNK0
M9M/T+]_LEK;02JFEF&5D8;AKR;R]LQ?]@Y-F)0*^3W&2EI8SUR0GX=\H Z4I
M8N&,W+62GSM;;=UI-UUM-IV3F[,\(L7_K2KM:7J:2XI98HJ1Q$T6,YT/_]N'
MD60%0V&[]D9PH62:_[EC"KS([C6<KQ$1@P^YI#"=5@"SPASL)DSKO$O#U+(N
M*5;[ULD=&:C^B%N'FU&]0<Z\=4:7% B?ES)Q=%J/L#!M3^VG&#2<3*.#MR"\
MFPR[?_Z2/!C!253&T:_UY(EU3I&@1;!G1]D_PX"N3X5P_5\(*'QP_T.]<C!Y
MP[#K^Y]_%#2$;-\N, ,I_$I*^%_I.2<-U:MIT5V4=KV0F0ONQU!%<-N1O)$M
M$XT8QATM;=QW/.O5DS+,J,Q,->?*U2Y6(F6?$I=CRHX6;WVK%+TO*]25^E4=
M4 %TD-_ WCU&5+%X=/%-BW9'NQ&SQX#+[@,T]']9ZU0Z6).)4;A"@GC;-*+V
M^L#-N:DJA9UP[E6VV$I@H.2>YR!??A6D69)QMTVGU6&A:LOR6[4DC3?#[7^F
M 82M_KMMR3*MO[)/9&;U7YI;/3,KY7&)KU7V%#VGMP/:FVYI.3@-EE8L%)PN
MX6@(EGB9O?&K)3E=3;N8Q(8'[='AVU>#N\'T8=;$6*PO!Q&^"D^L;80Z])U@
M<-]+?I.$O@E-[X#1$/M;\0'A6K6!$%^7W\XTL*H4]>!7K3$3\)5T<&-7/\-\
MS"J Q%JZNMR\=L!(LKKBAUVP&Q;HO2H/ZR>?6*<"9QO5QYB(YG,.T@6:BS-H
MZ<HR]!87LKPXMN@-T%OD8UWL\Z6SY'.JB)Y\0)<'F"B:3V*1)^02TWU7/)&L
MY$DMT5E%^/L&6&C?3@TLPT'3 ,M%S)LC9C[D<BOX[:;V1$K2G7 R?&6W]"5!
M8\Z*Y[Q7V5/5XB>/D:6OEEH.:R8T75*\8WY,I#JWFB->4I@U3I&$L%MA9E5;
MEQ0,/L<,;-[HC88:B'66I+*]4D$A,>0TT%!JK[]<>V%/XW-AEF%/6QY_6KJ7
M?YH(T*R[[:6Q<J# [L6W9!MIY^?'\PX_GQ2:&>>DN7$&8%F*]JNI]9U'ALY$
M6^TJYYW'RD_GS]DC4'".*W,PU_"_7P(&>C%-'GO4W\C39(%)LA1QX<>LO6^"
M8.H/64@>;90%,S&T7XNW+6[%JRTX=KUNZM7@"\E\X.0K*:EJIN4A@J*LS!CX
M3A@0^_J*A!?AZ&"[[%ZR<+B[-CII2.4X",_7=-9XMSFV@Y^/!FI5FU1PLVYQ
M^UX<5J5)7B:#\JY3,DI4VW-L?H'PE#AVKA(F<16>G(ANN8B>LYE,/(/]9,0]
M73R5X;2V9^IJ)]BT-=4<%_-6B]M$,S-!0<IW@+';^]L2VLEV6XE@'UT0_+H$
MZ$H)% BIW14X!X1!+RJ[5MYBV+1H2,(3C;<U//!@0ORTANZ*[EKB*R)(=UI!
MA@86CP*5>YE['=J"3ZTGPB.W):A39F '-?<R5):,97GE,J4V55'SDD&\DXVO
MPW-%AX#ZP'XI_^K5 Y7MI59$OVQ7.X>1)<R^POE$65._?-FLL3C")V7<Q+"?
M$(3M6BE"S_;*GM-=)9\Z]0=9!2_ROL,-2Q-NVH/JG0DA5/H&TR-"2TBRC9.(
M<%//@[O'-I/2-<@%+B\Z?Z[_!*($%(.T&YMW3]<.B$)P$@N(0(D']"2C0]<&
M>CL-")'XO-Q"DILV2YA;:+7.&M 8P+RE)I/ MCVJ+?R+".[]O3.F6!(?[/LZ
MM'#D>F-(U4']?^?)A+JK^#J3I[LXX1Y=1,$3E/8-=)AL:I]V74T![UA_[XS6
M/>',DFX.OAMCI/NSFWHM?*+/KG321G$/JC1)JO6"N' $)K%2$>@NOG9Y)Z,S
M"2S$3IP_YD<#3)GP&K\W^X$L,(C%<-1&(V"-@QTVJYUN##%'J&),KM?FKIK5
M_ .:^,>/^>-?R[F]3.)/>04Y-XX8!?'NI:^Y%YO[%Q4MEZN7\IH'[TS:F95=
M%*6)C")+=[/,SV6+*@ZK\\6!)HA\5WPE^<[[<P>2%K'TBC=4\%>%?7#^-.S5
MQ5<M&G(_@*(Q._S.Y%5C;>A$%H9B\[EAAT[B0V?A( LNG_7&C+,#L\\EU>%N
M%;JE6R$ON*"=11;.P$"+_Q6G]DK1V5CW;?C*UTL*&B0;R9J8>/XHC)*HC:/L
MNZ3@N:1P@P:O.>>'NJZ!&3"PD'!UH)ITJUNEB5\@_><8I[CM<U,(7?HQ^4.S
MM36!T<M&5GD;OO?^DN+&^D5U(V@A_LE5W"/AW>H==CAW0*R6.FX.-]#G^Q[
MN^OJ>Q/V;L #6JJ%@/HI5D_)T%="7)\%E-M1OU!4#_>: MN"/PAG7#O -,!W
MN\X#PHR(3N>/8 SD.Q9X[A6/#V&*^.'NL\W(QJ[H2PK*,*JOML 5"=#=Z]('
MU6&AKJ40(-RC^!KU[T:)82=3'0WJ@'*O23EQM<#O&.M2@+_EQ16DL\L/^HO<
MJ,S-BLI55=M-LGRJ+ N%:YJ@%M5[)7N*,A"S_F]1D.Z!Q7<5:A7B$D6:J6EN
M'D$U<$#;%6?@)'J[;I!TSA^1="]:NZ#> *+8R$QM)0R%DBC8BA#VC4*;%MQ"
M"'@BV5MFH#6T4O3%I?]E1>ZPV;"%N$?Z?!WGUFN)&[(3ON"X"D_F%2Q9NB '
M1.%@$I/W6@\LU>:*M_LP'&'/\3/OL8DVJ,R3/(!RGCJN*19P%5K$1C*PM:DI
MQXL]"UKZP7EINLJE#9G.'_F@F&H!3*W]])*"*%6[^V6%ZB*CR_V2(DZ[;J,9
M!S# 2Q>\7@'%(S5_'[77QO&Q_@X$ND-=#D=G]6<:>?7H.I=^_5OT"@F_J*D3
M:^U <NE=I,GU"IPYD._X767S\*(&[CWV]I+B.R920P@+>+>L3<S' ;"(V22D
M K&>8 **TF*?F3GY;[)J7Y&!BNB#'K![;[NT8'(=<EZ]GL'ABLS%9FRMQ-NY
M/-COI!HSZE?T$!U#"Z\")U+^^!$4IE64UCQ;C8V-T4N#&V73!"O783-3RW*]
M@4\#>5X(I8VB[3$T*-WX,$& +7<":$?R.(>3E&>Z5I(PWR/JJ'X $L'<82;X
M6@*2&+]R0$TR)TZO75+P.L&B['![R"^KY[FN_<%@NFJM8<]E=K[[[>G3W".=
M,_S-6:NW*NHY:,&?FN"(KMWC\_NP80*,.'A^@SP+0(SUPN-^PPI1,YC&S;=D
M#4\U0BYN!\N7&#8#QZ4 B_7*'L_4V8Z\G V2]9PU]\IZYRU44NE6A=*L$SEG
MNLKJ%W(W.IC$PDUPSU_9=19NPFDGDV1KM_@TKG2T^K"=[ZL]@7XNJ:*9D@'[
MYJ@+82"58V.>B:9.M4YKI.VNKX#=S0:43 _@5L0->'?0<WQP3Q?-E30H.&>^
M8@ 3W+]S91,\((XDLP*@(Y[W ^Z2U$N*J[]PD>.5XCTGO ^W9IY)UC:>C]$M
MH(+]3^PCG>0^V:[B%7)IIM*$++(*:SE'+ B?UN-*L@B*/!-QZPDN:\,21@>!
MQ?;R5J^?<8J*ZIBG\6]L#1JI*EQ4*]Y:KD^;FLK(;-/2(\X6$S?)=P;^O_-R
M3W9CL?"$*RG-2AX&-,3T[&CS)%.3E/"T>9RS@5MTR5%_VJ8BEFYG3( 9O;D.
M$HX^7926S7M)%/Z=87*PLV]] A[K<AM[LRQX\>6J@6)];X5QSB(EB;-KIMFK
MH#<1ZK[7B;-8Q4L*0FTB%L=6C%,CGZ#R6&<1&F)3(KC<CNI"G3 VA;:FYCC;
MKTWZC")_P7NA5T#=N/A.4CX/T+V:(<U5%OQ@.ZONJ7B+/F?>_QW!S4+F#'/)
M<%+N/CL42D2F!I85_WHR1D?(K)R;GW/<5E,W<@V'5F[AG"&9XZ)/\J#GHE<,
MJ7Q%C<OT5V.5P&P(A(M*#3]<%%92;0S5!; E_3=-8L9R-IYV*-<0DW_8Q[S3
MD%E)IB)*;P+E'8E@E)E2;NE .1WP+I2T\]ZHU^T/JU=$=]E,2;D&;7E_?'U6
MKW]-N*IU?7#8XO(EA=QX9[*'MC>[N$6 ;=G(M,U+@L;0$&G,4*;!-]BW,6(]
M8A)P"-5N3+[(QO1?4EQ8+4O4K@'(U,#SQU>S=--BCA@,"7YW2?$,/*^-TN9$
MWKRDZ G  A_#QJQQ**_9?-P7YSE/$RROR)XWWKO;=>A[')UBBLPN^..BK'(P
M=QV T(S/[VGK2B+3DEQP,C$STR2=M>1W&"82Y]?JBY\-=5#?O@CJV5=T]WUK
M:?WCU07*MI5Z]O_VB38U_Q,^Q+BC2/GD$3C.]$I=NQ*,B& /7 P!3AS'":P.
MO'DZ+:/QB,Q=3XS!;3J]@459-=='676QDT6(!E7;SY>DWM=_1LX38+WW4+1N
MF" 53@L"ZS.1F(U R* !LY@^G>"L8N&!4O:DB7>MKN.C?$TQ/9OZQ/^6>444
M@X%%^UE&A\@QH)(V$,$0W]6<WR]#%$K>VZF!=S]$TFQI4Y*%(?ET$?Q;2#K<
M<G*14B*T@JC8<<\CW,4D"-^<%#8/;_R5T?^L#!U6QHCFH6;X 6A0S$]"@(GW
M0#V\-#W:B"Z4]ESS?S-(4=C0&%:Y'_ A$WE_\D $]Q OM-@6$T6ZZ[?ZP6-Z
MMM?^*)[SRXN/CL.E]L 7"4TG[/]=#.+@A!=7P$$1=PC!%TT13.3%?-8(#A)P
M6DN*1-N)T_[!K2G1QT>5#)S4\*V(_ZMHU*%31C19W7Q?/-&XDZTJQ:^<N5/1
MFVV+@G)'NY_J]L-Q>LGHR:O;XX-Y=<+K9KQV#X:>/ YHH.K7!I! 5\K:^5\?
MD[<VG<8S*'8G'O3=03MN;2(%+:5KS,9V\K*:D*A8P(RQ-T$464-=Q64[A&P8
M;N#3MF7<#B83PJ,:$CPJC8%ZK<*%$LVO/OB575Q2>-@#GQ5S6[7E%.\5P(:>
M^#6\W$A9]_,1'RPY(@JL!G^(8"'_ N,LX'.ZCRXBM;T : ]L3 \\(4\#)Q-)
M?K"=S\X0O]<ALC88IHNMA-,3D\EW7P<NR>M,=EBL=MKWK",XF# @I!;7U,RT
M?O5KA6>SO[572D/V*Z\D3K>AEEPMB<4+M  VN4B>X#8!SS=87&1U7!7V[<UW
M1R,W]UX=U'E9+&ZS99[1_?DW&O@,2Z<U+H#G09<WAZ8ES<5H0X@[9.K_F2P(
M<?+<B-R?C[BD&,AG)O]REL0/[!Y?Q2XX4_M6V+6JJSJA7$FF#%/#17<5P9),
MEFBLU)R.^(3QRO&*]RM&RNWUF_!VX5GC]S)N"YL81OR]J-#BOIH@Q&;-)D'Q
M8#X3"]Z-P8<2X'@6"P=BP,K)0/+->4]K,G-]6^*-[U[]AK7280;EW?<^"4R[
MS*PU=#1]I.F\+TB;7ED+6C!/*=?_/YR]:3S;VQ?_FYX.:BBE9D5;4U71UCSF
MM(JBI*4H*3E:<T1J#D):-=1<%*>FU%PE4D/,DIJ/*FHFIB1JEDJ*2(FX?O?U
MOP_N?7@?Y/L@#[[?O=?::ZWWY_7:>VW_0 4K_TQGAYWP^U/*;A9FG];%M(W-
MM1[#O'<8-B_SG'1K4ANB"X7,U[$>[OE:C_%V[.L5#:70TAHZ=BN15L<P.2I!
MD?(6<?L=P.C%1@A5YO ^0D"5SQMX$:ZOME3Y'_(LW8@TSN8:T4"+(%X\J*D?
M5\:U/U?E9:9OF]2.M5G>@,ROM<S9V3]VF%V;LJ_31^<= V@6[<"_CS).\O*_
MZ/HXEI!2)W$JM=H0B+"2OHP4HWE$ETY15YD&7J$4,.H<>&U!OHUVOR5 /6<R
M,[QR&$%,W/#ON>9 G#5[(>MN>0(L0-K)DRD'[U&=&8(0ERC#5+$3J8VFM:*@
M6$XFND,7'6O(ZV4$8GK1%N_3#<K*CSX>..5C<+'H #7O1L:^<+"N;0PNY4/Y
MTX@"CBP*>[URE3 -8G/:'WJQ%)BWZ<,,CJ/R(.#KENPM#;J6,7TK*_(JC;=&
M!4N/ DEM!A,UT#'(QW#)>4SZNF-PUL&Y_$JSXKF2]+XP^=?;.9P.]\/#%)^[
M4,=)FRX;9F8] 9W]]DDZ+J)#C"2?]!4SBY 0YR'XM-G(<GJ,9Z7\'XEEQIT,
M_]SDW(P)O!VU.A[91\ME<P;1E98(6Y(*+$&E'D@#FBHC34VEH&/9BD>%^@K5
M,\B_\0TTJPQX,=A[06ZL32^BO% \<<$[Q_?#SD:P;DQ,07QX8-8[+WOAX-;%
M5?BL#&.(67/HB.HX(0FWQ40I+;IP#9P.[I+&^5;2,GJEE$<U).9YMWMRL%%M
M6H*3SE?P$=?"0;J4?:O)P.+/_&]5-?3 E8MR/(?VVQ'<;,Z=DRAH8'K0I!V/
MHB(OLR*/<E0);@;6%SPZ=5$][<^=3(8I#:]I2]WV(:J5:^*1_\+DQF&!F[/0
MV:;JW6ZM[#3CH "7THW@!DL!A3+VM#3-)/6M%HIFN3TSQ9 ]2E=IDZ.@^)$W
MF'72W:F7F6B*:KP,31F;L&<) N4C093K<N+!GRL,>EA9C!SWM.7MAI&M+4K.
MAMGS=-.FJ:)*ZR"EQQ7L\7+C#O#,HV6O"OS33^6(OIF&K;&(#[R95F:?K"O/
MT3;4K$.";NS8>#]^-NH?!EJP;Y^L[ENQIQX>ZK&"3U(L<C'R)%>#.K=G.9;^
M=QC#<Y%HX:C+T8T61,SVI'NWW'>^-:ZO1YY_'EH/X?OC80XZWP&GQ.^BMB[8
M:CS)T=.N?DS-[+YX2.@^!KPJT#]Y(?0DPI\22'E$8%<J$;K4V#US#/#&"B/
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MBY:-S6,DW!WI3P12[F(#*(E](_*DI#V!SQ"LF9BEU,0%3N95&KS76>D(;:B
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MT%NC?C+U-F94C/*[^!)X0ROVWKV>E;/_G+[PJ>3=A5#+H=3#%Y&CV<34K6.
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MC6_[G\ZKG[K=KUR"45>;!9V=R!\<;*M41ICV+,ZNDN,Z0<E2<D<%%*8;_1A
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M^'7WXNP]4#FUR6S<VE#W(\YVTK?OC)'I.1B,?.^'Y[M7CLP1@HD%B/O.JP?
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M%E-G#![RE.F:O,UJB[K:=H.-%#>Y5H-9&+J#6YW"*$1K2FPOKLM-5$;AYP>
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MP!CUH T=-Z6",-P;*;&R!(UYJD4*/X:E*679W&1HP"C<>EQT.%)S%-9W5/L
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MEYGUH,@ ?,NT[N#QQL7Z0NP:5C'+TB6ECD,G/H6[^7WM++%@LUS'!2;DUKL
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ML&1::5.'+",:%L;41$[3=JDEMJZ]$[Q^).WK&3,S?'^]9_CN^U:[.!G!M[
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M0<<)?Q7!C%KJ\+5T8'B,\"V.1L:%5%T?@0XG*@%W'6NUC-&0;RI6,D5TR3H
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M1@,0/4[7SY];ZT?0F(3^$"#10$":SM\E2L58TC#>BA%5@L#M/55]MYO_>$_
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MCZ7JFMA39EI]31I..F^>+2%5.UJ-=1E>A@6UREH[*;NI;R_)DYC>RB@K)N2
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M:U.O:!.?9&0FFU2?7*V,WWA2]B!52*/J0=R,>T%D^W$N6^Q,1Z)C+Z>(/PW
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MR9 PTK@&G-JJ'D+PHYR@;.N;N+>,:K'XOZN Q?IE#@.#L:-R)<G279X*'XW
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MPJ=PICL<8#B*'W!,L^7U<>-^<1C=T0JHLDL <G<Q O.J%O00P?79BS4VC.%
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M+G5@T6G60)5SY9"0S][,=SC1?K<ZNJTYZHBMS)/IRS501XB%;JIAAHRO;[6
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M%QF+@<T"THGZ!3JV-<&F8$^-'B8-6A$5*Q5X$<N.,VDMZC,L$*X#"VH4(CN
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M#D^(7*9_=P\KB91#']39LPN*F#X8R]VDJ,0?M53I=''.%OL://V8V$3W-6=
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MG[O/QQ?B5ZZ4$/RLJA7BZ?JJEBNU[9JCJ5Y1F=HDR>5_[\SZOZ%JG8Z+L<8
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M)2G/*]PH!R<TO\&QBLN6TI1(3'):"ZG9R'J1;9N5X=(CG%\@)LMO[V2:42_
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M7'>6;]=N_]H]*IZ!78BY^CFBN0_1%+I$YD3<IMK-M<,J7.!HY[9F=N9LH93
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MM^E:8F]1+UST4V+^Q-IEAI0>5L\."2V;,2L-3*#YE$=!R,%%4.-$-6-4OB/
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M-G^+T]Y=>Z HFH^=OA;5UM#^<D ]Q\13_,?$HI8DN\P]D3&FALYS,9Q]YT?
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MP+2AN__+ GXSI_J_DV!949L12&\)OQDU;_Z#L#XIJ,CZ@^58\V#1!YO?A?
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M@"/K+#L(Z**;4;"]*8Z+6RD&ZL!!![I%5:T#(IN(.A---%":_ -[3I\?96C
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M4\A-%^O7W=4>B37* <6AOA\KS#)7Y]>QP94MT\.2^*0V&RPPXT)@*"9LF]7
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M5<L$\7_KVP--\:W_I=>;'_F"H/5H]^G#[SW/-FK(N?#//^=J\OS5"T=T6_]
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M0;88L$8G+\81"<\61'8QVY$\L&G4B?U?;H.&4F&)9#ZPU@1E5FW;EZ7"14G
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MMXS9ISV[7,Z/_3FO9T+O6]C4#[2.TLTX_*+NJ*64T/5?!]][(K]?=N62_'&
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M6(CE[JF.2/O5_T:IXKW3AQM)?=)1ML^?S[^-&'G:C'EC4%+\W/IFNM&"H2!
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M5(35]KT@_ZUB5$C\4#E7E_>B7=^5KF:A]=_2J*2[5P^WW,"= :K@H.%];['
M!5M[38Q/]R^?065HHX79<%@YJ,,J3=U[T?Y@_,V#+W-&=3:0A4)#YOM]2JP
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M2AP<28D4U[0^O/*=]<JY7;7-%SWD:TMX%/"-,><-6*/6%F:Q5:>7RR@!L5C
M3[=TA",:S';U28^]NK6)##BS_F56$?":8Z*^P8^2^.[IY)M)LJ*EV,3[#G^:
M'H=_/\AJMYD3OLGK.;H?O3-T!K@R#O?&/P5G_]YUQV?=)UJ79!GG)%^ WTG2
MN@%KZWFEE.4BC#'V9=X<7]O(J"[$I"H-6(K*@B3S_9(LTR77&J24!$R4CV F
MT[V#!,3>WPRC ?595?T4D$W5_%P>?08;X64:=,/?._,V.#AG;'-K/ 2,/(14
MP0;[KA@^?3Y4W\_]P,&03EC<+FKM\%KY@8^4_RV&D3 ,):]C)1>$1NPB"'08
M)C@-WDJ IS7%G"H(UT$C+A(YIT7]6K9)H!X&2$ H:Z6OWKA4T 7QKH]#C(B
M@@8N,JLQ@9&2;C-R!OBJ=>FO%@=L<+(X&<^ _<<,2$3M9='45+M/NZ89C2U\
M4^YKT?OPW)7;VO^*]]\4#K<XE5L/XZY:"3]^&,\N>RM!0I?=U2WQ/H!&]S$
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M_SY882GDN_#37#=(.+-_R*K2HJJYPM0RZY7Z_(!TZH'AOP='@N*?X@#_B3/
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M^=,/->&JU'_3@<XOD4^&PHW_)I$\^3^^8/]__%\)VK/9_P902P,$%     @
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MR%[OVUPF@]_JDI_E-C;U,3YWK[S+S='S4VWU_$Q977QO:A2\-4"*<(8#<[-
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MGH,@<>5(RGBF&PMW^2(M$#48YF*1J;^'>AY0]M$*=N;NX*BPEP+35;%,J;
M!A[4O&:1.,9D -[QGO7V@%XOPR_K9MM-[MHB\]JL&7K<I:LX(Q()D24"@%>
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M&=, I0&4"07I#:4 O*K(2E @X)O2]TL#ZPJIX@H8\!'+Q6)*B^"8_>E)TKF
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MI1"')2%3H2'FE%3@][V>PJT#*ET^1[<;NAHI3)Q2)Q(ESF&_&YOPG*@W1.O
M7!0^>=[;\%M?DR#68\0D#GY14)%$S< Q,N!R@R')B2Z>14V52Z:W,M=72O7
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M]EJ2/TRX':L"82\\I0(>0$N"6,XL49%2:Z+7@?4VEV>)G,X.IG:&"5%J\)_
M+FVJX[W:2DM!FNPI805M#6$%F(M<$\^$%L&S&/+:O>!O>WFUNK/I\/(.6V40
M$RS&9["X=Z"%)$/!F_&JZ-);YKSC L?G.TN9%7&CI&#[1F])*)AS2VDF@6)#
MHD0E"SS8('M;C6J5!%G>VCT<-6-\$BJLRSHBC.&I>V4*8_>'"\!1]3R1(EP!
M+L 2D[(XDKR+Q4AMA5[[GL3]"#!+9E2RF#O$!:R4"Q*<1"&(9DHS[6"Q2F]W
M;WH3A^G!+ISD-#ELM9-CB40:*8GG"O22M5J8$H/VO0W:?%.+EA<3H")F2,/
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MOMA%U]_E>#BL0<N<!XLOKS^KVRY[*J==WQZ^&(P^K>/PSP/."9*F>(7]QKC
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M$B%T2HD%3GUOFWQ\4T+"W&"]=U:JDIS'8A7Q04B"#B"QPCLBBK8N*Q&"ZJV
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MGAZ/VJYVX/9T?^IC?AI&GW%-\#UGLX1/EA3%:[GF*U0[D_GO$<=54[$^)[=
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MLRR:GY MY_?6LGWG(H/BL/#.G<(8M#@5"C:,$APJ-*^F)'>(;,<WZ62@S7I
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M+4W.QU.C&NO2_Z?4210K6"919B1:$D91;OL^;=WQKD_-5<C[DG=5S>%"325
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M)K09%DG=ZYET'ZJ(F^I=6E"1^[\?'Y]H?>"6KFM@>I99G*Z>P4!%/56?H=
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M4=(Z2?8W#?_]WT;'3TD1L6%[5WN6))2;2&!H.F5&6\\C_5NLZ+IJML)@U,?
MU0LJ)G0-EHG'G)=@,9>?]'#IAJ_$7S60E*,G?;^#897\X8L'-I/:N$G/L]R1
MTJL6@ UT&F)N)H8.GVTF.2"5O$#.)A_8[AUDPFPVUV@^U>7.)94N?KP^,_+
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MSLH\!,NMQ#6OC.V4?5.Q)6U9.W+Z=$9'.1L*&)TG';*K"S\PY8F7Y(=$P.H
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M;&2D[XF^@U;NPE:I0M0WS#6.8T;81DH<FEA:/?OFTK&$Y-OWSZ2O4_6>?MD
MOY-SB>!()2BUY#%9N,*46Y70.,#UZH &7=)Z9T7\-[-&P8IMS&>1THV\ N($
M+L-1,\S !>RG.S@JZ9)#U]S4,HE QVCI:!-(33P5[@M0$%\;P7P4I<T-(>Q
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M@0NGC[,Q[0D=-U=K\C29+QK4"ZT<R1N3_$7 M2!LXT3><?4JHKG1(8^ST1J
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MECISR\?R!@YS^\WM\='^TVK#IJ"KI'^PO&+WJB'.EB)>X*8Q(I5"^H6)4V]
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MB/0O(II1#5>EM+QC5F'.J2&4\GOA59HBK*RXJYP2_R#YUZDM'X45W4'E\O0
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MB\<Y9KI>]?25A*V+?P.TD84F89(J&O6B69\1.]EA8&H1[20_L2S"-2&9O&\
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M561', @!TD:Y!2@4$?9@B0RTZ%I4CMV^*#\"O5T[9 6$-:ZP176\4V!QA4S
M$$!75Y=UNDLEF/KCO5)IT35LFP*[G]CD'CXX_R)L:9/POJ)=7-?-&Y[U\%:9
M].04VC+.X;6_ 0L9@91=1*6R,/8^SJ_<INA4?$J: @C >+YX(>VX ;47WMF(
M9)&0G!\[J@P[2Q,[R233,O]K72)A9I&N V(M?A)-ZEB;X %EB:MT'AK#/DA#
MA0SSJJ'F">@X]*1V4ZC&GVU5)G;[OD.F;0'("9[9CNB>AT+ R:)?8LAZY^TK
M=1*B=VGU7T]ZFB,'X+C/:3MI0#)TD].92CS@M$=9%>EZ3I1]^_5SV6#S,K2"
M#'46.$5&^E9MOX0D!!LH?EPM?O#_MW8[%A-A)+L":$>7HH)=FV\X$[3M_0@/
M=U<MX84MJF^=4 N8FX!E2L2R[,@FGD)>>4,NH2$9(/.BC.$:@6SE+;)LP6NH
M!UY$VWGW HDM2C430K[EY[[QLFD#X(06A2"F:=0)R2O2%2.-"R0/X5 B)>G@
M[82+[]%N2$,EIL9)N51SE[$SWK)Y&^GJ#I6^E@G\^.Z!A^J(U 8R^JKU$DR&
M?%TZU?(%-&U<HI@LJ>9E\CCGBZ\<EYUDHZQZOX42A/D8RT?>MO6*1:VPA[UX
M]=J/J<L[56_#HR9NH=!D]95F<W-BQN"SQJ86.:6(XSP@>*(L2-AD_>?76Z?M
M6EGHEC#I8HBLJ2_,&4/C"/-L1Y<Z](4%I[J^31")G$YX*F[8H%3OD6DOJ++S
MY5UV> W*B!B,SD@.Y<RQ_X+'\+OC7P;(%=KSP1_Q^*\IL&AXIDPBB !X>8;3
MXXQNV7Y)7A1!7D;G3'R)"S[#[LS!<W'^Q:.+SY]\]O#1HZ<7#S___/,G?WWF
MG:,UXW2^?./<WC]G&89',#T8I1.C0FDG[WH^"7DG ^[A&S]\\."O@ZO>E>,W
MG+AI0_;%D89LW>DX N4=<#UU]'WW/Z_.+AZ:7%P*K)HM>+;@W\^"65ZMXIJ8
M&B[;*_E%8HLFJ70S\\"0QX!\JR&/@7@WAJ"@B+'X+2Q_1HC>#X3HDQDA>O\K
M0?/9,Y\]O[N5M<Z]4>%1[249AWMM<@KY\*+H4IR,TE.T@AQE6(8;QL+/%K,W
M-5OT^[5H GU#&IMR$U1_RJQ!5T#5>FM<]I(<WS2Y9DL=9_!,!2PM@&V0#P"6
M+D&=V?5C$B27CF2L]UM1"PV_](-6C>]DTB_M DPLQ)TZKYAYQ;SO%:-)IXQ2
M3-!A!@M14W?:,$ Y6>CJ]:P[3?6! S0P-G59U+.1SD;ZOHW4;]?8)OT<$754
MN;CR<0B)-*.CO=^#=7A8A]6J0)9FB4<9V<QLX9GJK-=7Q651#MN%-CY.!FQT
M-OK9Z-^WT8>.$-J"S[AWPP6U>S5BTQXRKM](SX-!J<^&.QON^W<IWO@PL#[D
M9><W5'\Q:I6IG&$-57"&4,V0GRW5;F/I@?U@-MK9:-^[T48$E<%I@#N#_N&O
MU1-3/X-J5OG>=$6VAY8,026S3$3Y#'^;;7>VW?=KNPPG<BPQL>^7?@?5_K_S
M8^;W<<.V$E0.!;G'6O@E=$C#!HD)@DMFDS?T@8*C@T>FL!#"04G_-/,?*F[#
M;CI'I4^^(3C0<:P.D"&"C[+72Y!-_NO_212^$WCIS# A'TEJ[:C3<S\ _ @Y
M@T5>TT,VD6#._V>Z@5+(1NV.M)&NBDX:'PGCTG1%*T I00L-8S[^<-D7Y5JN
MG0^N+E1\ZB#7S65>A5C/#GJ4L9'>=H,IBVE#I5D0@:!K%^?W)NS[<RO'<WT:
M*D@2N8(&1!>H]"%S,^6FK*]/=Z8P<^<M+@(\ZS97]4(R&OLP]'&&+F4FC] 6
M2FF.M!W!@AC6!F5<KF[>R E)W2<S[O[.[H _)P16XGT;TV'H6[$AI%^3&:I@
MAJNED%.&W<EF964+XKX(="C^FK:.F(4J*RE3/<VX6L*"DZ^T4P [++H$7A>9
MO ;+A6V?6W_3?I:).PPORX \<V ,?\LPU,F!PABNW=Z!C#>C&: ]#$$1H;A)
MV32>/P/&=KSN5*/+T3/AF10I:$E6CJY* )")S=V\+N-[U^K[ZJ%D?N/?=X54
M0JBV*!/P643T)EMR9C&24I>)@T1_%)TRDO_==TI8/SI8XZ9\4^GFR!F9%'&D
M@*-CP-YZDQ<M'U%$JE> ?,]'J8#",H2?+VZ:B] 5R+94=XK774C'>6@&4$U8
MFF3EW^!U8R;<_ZBM64-6&J3&/\X&E#!!2D[[\*>XMH7DPA($C?3E9GJ?.]N#
M?(>'YD<H,U";B.UGH-W$F!^MJ@2H[/?X?MD9T>B!$QY<$L0TW)#D_^:/F'O.
M#_]'&N]=\#M^<8F[J:$KBC=EL2LZ;F'B-M#H2MS<\IUTVQYO5]4SFC4X_;/Q
MKEF 7'WO+PA*.75WIIV#^./SQ5?:C@?B$VF6BOT]5.YOU=7NMFB]BJ$9G2PX
M'EFH@</#P1+AEL-W6!Z0R/R)Y#I?OLP6T-U]>AY;#I48)O3[?5VTJ[YM==2>
M^P<[M 4.D,@D\2)AB'L5SY@?PR)7<4T<6J<U03<L+A-O'(B']JQTBGBEZ:OK
M_"!M0.8OY'>@AY &++1#@KM,=(K@;-*1AR92[M187#<U#;4JUJ!+I9?P/9+5
M*-->;$5N:V_/Y)[E(!R2.2X/\K3GBW_XN2B%6L:OBT7>)FR%)#80+"AM6SH6
M.1K'VQLF;,CZ'R!LCYMKMVWJ_I(@+]X'6A95Z#.1P*P6-BKI0(0+ <+II<HQ
MQE1[E@CUE 7=KS79#L3739-7E_K]9=\=UQF1J<#8A-O'-IHPZO[E>K""M?Z!
M6M9$/1S7O+L+&]D<3MK1>*VY'KN[A0D'01HS4Z'](K)3L:- ?&F1ERJZUMIH
M!WJK*3)+LR5*0#3(_BB,ZVB(E+KB:HS***;[,YT'VM:&9N0UW[+,#Y%OT>]?
M=()5Z %FO:I) @-ZBLLFW[4I.=M)ML[HY0_X&XJ)IV=O2W8R$[M3U]BX8]S,
M&,5PIM]^YW*_CD.P1E4ZOV EW@JA'F5):[]+JH17L[N]^@^G'<R[_:S4='R,
MJTS1!%7;B2,07Y=V0]J:L'FNMC7)*M-5,'7^=>%T^'UGW>L5Z=?M])&+/@IF
MZ:N@P$:'FY'-F#:D$T^911;!$WK;_OD+*[BM6N0JM3,S>-_W_HRG<W_&GZD_
MXV[X 3-IV5V)OG\1EI8C5!#B8F!;5YH&;:@8)'DSDU156.)Q#/I&Z4_'6="Q
MBV0SK? IE'_'BJ4BERX.P D-9&Y /-5Y"%VB7;ZF2&9!-5CO'%*VE<14Z;&9
M6SKQ8J9/U^0K*%E@K$G2*X1XQSVV;.RR3? *!&]M43=C\*A6!S.MK(+]5IN2
MQ\SI]\1HY^#F1,X*R]EZS<'1MNTA;)L:FVLH[IWFAB/P44@>BAO9N%/%AMP&
MCYQ$\=.Q>W8B>#<RWIIO^]FL\=]'!#U9[&83]&'##4L?'X?U_WRUJI$J)N"
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M&!(VDS%1UEW=>.:SZ(-M4D'2&/6Y/'%UVBZ_=,H5*E'ZL#LXN#S5J$/WGHS
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M5&!6;_R%^)^KHEGU.\+M4&UIZ0ZUQ"T! 2=LPD0:19E%DM]K_/,>7-ZDG2X
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M3+M&5M$YU&,I0?'H3;DZ/R[-L[SHFK#M3&]@T1H6?VSPQ/-RNJO+Z2O'P/3
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M+_:<W'*(FX%/SPC[*13F@//.U(-H_RH7A+K*.*<^L"J!D2I<D:- (*VH7:U
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MNXR2.(?VS^O5G7OJOCO*2)8W=8WNY3RT)Z@3S% :UGZE-YDW 2[HYPF2#R:
MHX^>PG@=0$,[J%<Z-(9]H/<=DU@#\B%HF0$8QYB8IB=.GZ%]RXPQX/D6(*5S
MSKW-DY^2QT /:AP37LTIWQ8.:0;H=<X\%%=K\NC 1['.V](CY1RO[UL&YCKH
MW[)& I+&]W%T=Z"+-%46($9(AD6&*_[[V^:#<V@%[D91 MY..<1*344)MC]T
M0U@'M$%_DE;H-=,6Y:*DM.FQSJ8>'NAQ'N($'/&^:U0(KBXM,L/<_7\D(Q9>
MP!1<3_0J1AO(<"2(A-HIPJ=H78;=V),BWW>HC*N.A7N<KCQ)CP_3(9:5ZK8B
M,\0HR<[3?TWTER0/J&8JD]9[P-#:U!Q8W(C-$P-?"15:,Q9X"=)ZTS)?^M@8
MN*^&S1[R".,9?M"QY,=]*O_9J:)YMD1=8C"TH,@[7FSIZRDD+SWS!V\3Y(IU
M)1@37,(RTBO7,SWP,5^#F85IT7C7ELWV"H;C8JP/^A=W77SU!=/B7=[I.HZF
M@1MA2NN"F? 1D(,K\B8!G X>/-&?AM>"+Y^;DEDNAHG4Z%_XC0L 93LS@7&P
M$P.4 K/CB4C,4SNI,3W!Q'"]^G/?X+S)_&WOO0@R;3K:#Z<4^-LX5)F+H5ZV
MJ,6[25PLQ!(!/YJX[A6WFAJYK6Y4@4^K:R4 \DEJ>$;018>A8(S_:,>R%Q*\
MO'5L:AVJU <D/FZH&WL)DQ_Q@?SS+/6,K0A/,Q/755Q[HQ4VUPN@#29C1E%4
M)S<23-8!K9_V,'$0+@L4/0,)]=$]!S#91)+XLTI=YB0'_9;J*6YH2O./+5)(
ML.3O-A3T9"5?OUZ]9LK'?.,$(Q+R,#>>!'_;7<ZHI1V%;+$5#M@+.15\XJ-?
MI95N%88B7,[L-5CN00[XJJ9I[X9MM-Y$2&^*!LRNO][%:.*Z"[HG2P7#.7R3
M[EY^F;KJC.7;XO21+D>H$YI4ABY*\W8<ET02KL90E2N3^4X"BT-/<Q/$"U5I
M1H.XLM&&)&V'EGP"K@CJ.?_$V[(E'\OC.S@5,0R,E'S""U+-\)#-\Q#KG&76
M5S;LF%:OEUD#(;68BJXST1S9 =E^D2E?H=:!(<)W<5=..@1D"86>.3(=HV?D
M=CX44-<:N8KC[:KX>[2X5R>WH;B30WL&C\6^;(\ASS* F<M>$(7Y>$6\$V4N
MEOHR6-246@]G9&.$QK*<W*9!6'F]^OI^^3M^N*7=8T')?0PH.>FAF\HN94'Z
MRO5E4)3KR/?,/Y0C-)LY]Q:\_+*,W_<R#@>:T(M$K Y@+^T".5Y6X0<QIB5[
M,0<3C MLHBR^(0+<'D87/;.B^GM]623.)V?54:Y:5)H4OH2V66A/49G2:L*P
MI*.DUW=1YH9:74)0/7.]=;V]B!LL#$US49\2P &LR/XWLT)LK93'S/5PMIMR
M7[+\)X<-Y/X;B_V(I45OA]\?<U0,.>,JJ\H*B*6/U3F\;LLP,Y(WC_I+[U!;
M6E*HCV&;<)1_B:034FOC5=6FA'F.:TZT98:@72-)]-$[EY--\LL21N#OFZ@G
MQ"+'_,:[7OUY5))(<CWSI4Z15\*]\0B,@^#H/X&;KIE(CY6%>JD_UKTR(4<U
MS AN3W29N%;.9-+A>Q"_X<R'4-"+!YPINC:O!$LTSG=IO5W3(\*G%DGMJX3W
MSTC?C EDS!8XG'F7O74%%4NPS8_*>*'M8NXZ4V]BE.H23LB1?MY#-A,+KO?1
MX7K_N.!Z'W^![]?#]3X4R_-0G_M7J,<Y;^7=A"TF"SI.],.Y(>G5FL')11<Y
MF;BWG(Z^+)-244URE)#AL N5X,(['DT:(>@=+%72Q[Q]@[I49CIB"(W ?GBK
M(C\B*17105)*:1B86!4-V!K@<!L.T2_I5D [=.P(C"VWU2,4=T%$1[_I:JAA
M"P@%),T3[87(>6ZK>;)6*1L%K'T4"^32,!B$8C1BJ'K:)5 ,YAXXE;V<JT$*
MK!520<V%D:WR3P&W.I&C"3'>Z]5S1W%H4<EDO78H-NRY$>>KM495C!&I9N^@
M\AIXQ[GF/ I"8J=VQ7%1PG0DYF9*\M+9B.&%BF-;<!?X@,=PGG]1;VWSZD3L
MA*E/ZF[WG@0KZ(X1:8,;A2F/4<?,M^*2T^\^:.__XS9ISP=U7+H,=CC4OKAL
M;%N%;4(. W53'V^*M&BMZ&I'VDU7Q.EL5L@K#PSYPZ33@=5F 7U0+8,I"';4
METN1CL % _7=V4!]:T6K1.-]ZY$+LT5W)^<]DJ!W(E%C*LI5H**\7OTX8QLQ
M@3R[]"9@(J2M6O<71]+R3S' N$]DM%3E8.D<Z63*QYDYARD)[XXS-=N:]RZC
MUR?A-VW(,?!T 2II>SEU@R(W[=QY%3B(_4T=L/VM_3)W'(0)",X?4G/GT=RU
MC+U>[3$?E65"4N\00::9.@D.F+T#$"<*A9!2:,+^X=INZ$UHRF?>HYSV)TUS
M)+1WA'Q2N'Q?Z56VC\,,+Z'0,C6S4_/38=KKB*=7A,L%/W90 O+^4,[(HVK?
M'2Z96O1LP"QLTL'"+\M)946KX:KZUR #XW*V?35(G$X-_*[J4Y*SMNV<*MJ
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ML'12@0]A==R1(UB(<!<BW'^MJXTV1]7#<P'QR+;@I!^S-!?@.;VPI5&E4'3
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M_R8,E!KB!$A?3^6<KJSTT>:[ D7_K>*@-"#!! 4K*TUJ=&_TXW2*IQ.X6=I
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MA)\L\SA,M)H,GJ[2-DNB_C7'7H4A<C03[2NS\]\[<3;HJC3LB]H5'WYFLV5
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M5)X\"?ZG6]LNR;%!QQR?(^1"M:6D=_B,&J?\M<FA+;>SV1A)/*ZE/Y&W&I>
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M<H]@&WX/\'N" /F#HF!9>__='YU,V_D?]8O'TBE1R_/DFA,IK1X:WKX<1NC
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MPQQ7(K>#=G!L4RE1;&!FH7^G2TK ',<F6)&D-#T 2"F6%*U0AP 4@2S>%8A
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MI>;3!>6S77!G=2[U+, 1!8!DZE! <H^$F2RM.OR^'05&0C0NEL5W.I&?/)&
MM[V__.AO*2U^MHY>LOP+%P>]9;>U.W=RC&WV3C&[/KNE&TE[ _0KH=R4I<3I
MABTBYM):7,OY-8EMTMP46S:]*G]8 EG;:VT;5Z[SH[ODVL6@K6V)Z^SN8)68
M$[8-M/!'?T'438RVI" U^0(8@=J"BT+9?13O125:4)GMO6LMIZ0E\TUT%9JL
MPYT5X1"XRV=;54F=/-1IV/'U]:*&J&#+& 0E.-!R@C_>K\L;G1^PF+"(_4+(
M0J\H2=+E)PH&'GYN>7JK,[/(14Q/O ^V47TF1EW['RU$&]6'<\UYCC*42.12
MJARMY88>&8<[/A'>/9(C[+>?;:UH@#%;7@CH<2HAM=(N8S(G$.9%DQG1RS7&
M]#3?.HO+2S%Y(MP;-]0*%GC,8>%+X[=MM=;:3I8<NCX#/2MSYV6C L&=6&TR
MYD+)]BZ6Q%N&44O1'-"NGH#$(26L8Z$9\+FHX56&DY_ZO_[\;&Y$PF[RNX0Z
MCJ=Q//+<C<QRC..H!*36M"&'IT:'U<L>_WM@V?^^V2B#1]K-'$&"A\[9@?QP
MOBL_1?)E[9#RS1&7QOG)EFJQ^$\EV8Y\='8OST!L>2J*PM2>D:<:XE#N76LF
M+I(W-GPUXT#^9?MXHW:5=HGD=Z>$? FVT,I9A[#=,.:'[FR@Z2@8 R"I\LRR
MZ(/WYY.$657>]0A5N242T1-GY1]!4%$P4EP6EQIFW#_36-H_XLZ5['6#T1H1
M(4+C-Z]=:#APKL4S%W0=L8-IU@60#??D>'U,GPC6K5NP3.?_1A?$KX3+),1V
MJ$S-\QXQEYY?[\<1]'R0#CIIFC%2)#'\B W*0KF-Z9YV#)+*#>DD;^5.IQ5A
M%1F#ZBW 5Y)L^93^7!$T!Z5XZN8JG&*1S-[(X7SK]@-K:'7^S3">7VBQJ'*(
M/&SH O;=8%MZH;7D5M[F&BR(W=3(Y>B(E41S$;]FRL/*JB R]& $+.H$L8%L
M@FL&%GC%NYWX5.<J%;K;>L:_^#\S1V7"7!F*O-Z/Z )A4:=,EIG]O6&^M6Y^
M#.^)R40S4Y! ;7Z<$P5H0&/HRN* 0F,<F!D],.D=77Z@XG\EQ)6<EXU^!OEB
MX3:CD0<>5G^M1T_GPP;Z;V67;$8C+)&FCC\@0Q[10X?09/X\2+>$TAL))Z9#
MXM>%P4Z^I"ON=IKA FS"NGH^C#E.K[9PB\38TPT _[0*N)&<F6\KL5P4@LH.
M19(L,GK13-R1>4E!<^=OLN#N#!53I(7"TMXFAEM U8>JFM:?\(I,L\" [4.A
M/HBI/K(4^H,\34SY)XYEI-6[P!MDCQ&9W+\F= P?05PAIC!4;%\KO*;"1]"S
M&P40TH=<[O?6;>[]05-[<PIEM%"'C/6W48.B'@WAG4=5LZU@8R(QV0RJ.'(!
MA!@;XE$^=MW)W&-_N!/2IW :P)?A@.$-5-J;JV%F4FLZK[?EO,:[PK+CAJ-I
M(PIS'S:[CV-="H<.(7:,/;=.<9@$8B+ZC$")P#W$, MS\#$PG6697WEIV"89
M7%L>DR.O268&1,>+)]892)A7YTX'.F]<A^-!0V6)A?7G66Y+?<E;R0 QUT6Y
MLYJ6WG0HFMB]?AS.9JW7?6#UNN_ A!O@M)1V'DDNH.Q8;AFGOZ*D&2H0B&\"
M2I?1QMXK(.[5 -EB"%(RG30Z% 2"A"Y:>2AB.PS]F 3,EP7\<^'#K9H.![I$
M(.XQV#SA55RK?X\Y''C1,=FU]-Z8 P;'03ID$&#F6?"_H^DB?QE_NMR4- P>
MQBN:A0F,C-.!W8" /N(SO]DJO0L:I"-0^L*8CDP[!/'"C@>&8L=)^%\>\CFQ
M0CH?':3STQ72^?B#E@\2T@G2#AU@"ME9QUD-RN,4=U"A!<V $1M'6=/',#Y@
ME(PDW/$_YY[X'/':CA)-8Y\Y]MGQ %["@4VPG%V^^0ID/QUQ8@?@WH@K.V)W
M.+22@M9";/4XDH</,C3Y?H8'71 @E'?7PW'+V%"K"KT[Y!C^\,DFAE:5(#N_
M3>9UB3JIBU,?4M4"K#>?HX+G+HK&W:X(43+R;_EZ(...J?H_ SIS8J73^=W>
M[QOVT<3@S8)05%5_[ITM,;#[M_N$V:[PUV>?\VCA^"/4*M,/,.D<VE^HXY1!
M$8#+EMU!RQ$H[ !9*H]Q>R#JG-LF%+J75H4I[E'"V&/*N0^U7M1@=3\#!I1R
M/P>Y<$9:#5HDV#77Q)[GKW3=R( RUXSVL47)\EEZ.>D1 HQDL-$6#DVO#/U@
M;^G2W95OS(XL;P=O366[&XY41X*H$M?C1[RK5,0YD3-<OIA.VENJLCGKAC&Y
MNJ)YRR)%>\?RD)@LRY;3F%\4,1/_W,O0[_@:*.P4\1(I^S]9LS1IHO17;G=1
MLH-(SX&+@3*B?G%T';\:Y]?PBJKFEE"E-U(F\_$[+71![]F_&@RKC]HO/@5I
MXXC?XC?ICO>N@*:-\)]'/156,9@(M,%2L]&2R LWPG%!UNLFTC_FDWM-&MMR
M2O%G_*]#S4C9M+3%X%BG"Y1U8:^$'[G539I02Z5/@A2.K[D7P08P;PII$&FT
MES02ONNEMIL;H;^)(<*,.H)+\(QPPC46#]:'4K)@4C_;TW@[HK/'30ST048'
M25><5:?$L-NA@K^@PCX("-#\\G[R1=<U.R'EHVWY=5,Y5""(.>/ M82;J\W7
M9V\QQ>9OKG9]N?/F]56]N\HV?_GNY8MG3S;_*S^>/J?_?O[D+RC<_1>!DDLT
M,5[2.=%NOG=^\PD9Q]]-TX",[%M_6OCH>_.R:4]7]&M_)^F.[RTXEO\)!AP4
M$.=&FRR)<YC>H(>6L:ST\&)60^+#D\M%#@6%!D""PE[!!R/#C$X+>QXX =K>
MT06<5:6-8/7*168:PI?F>S-I;J8BP([#?2J5LE)A,?=S011NME0)L12=G*%I
M )V5(C.0V>*=R/&P; U.D)=-?=V"2RS\B0^3+/KS..45%$5]I/E$NMO;IA 6
MDI'P4::39/Q:1-()=W!-W:G:EKQD7 YQ+5TK83^D<%5%OO Y?L4+"P^5QX@&
M-9S:X$,E!A;[RU$1T^B( =<>ID3,"WP<OO*W7]%8VS +L.DIR4Q $2U1 :<\
MM9;GG/WS;=M ^[$Z,R250I5 A+K8 A[3U@0X2<K??/<O #KHQCSI892)?M&%
M*[8KJ=NC#GC$D/EM;@S;/$NU.=0G?,K0#%UUCEQ41)51\Q!:"NA*>R@$XTHY
MI$S')Z9]XT&?!20T#6<;!NZ>\RX?P@^MNWO7<28YO^T$YS=(^K%$T^OO*Y"$
M4]+07V BO[W+0]SR$.3/\!-$%4P :ZZ:ZBL 5_9T5R\TS.R WBQ_\<):9*,1
M:'V&@-<<NXEXQ1&Y5HQE=<&2M!I)6F%PA''4$K@1OXQ0S_5O@3_*;3Z9FE:X
MW@CE?,K!5S2#$^*W!A$#"ODD^KU \=>T$:>>Z1LU0=*!2E#F$ZI-R_!0'4U$
MP-/XD*U!05Q0.(&,U@S3&Q;MB+G*VT3*-5T+6;ED/0PLE7_+2J9'B!-GW5+B
MDEP_#P/V(^2^S/.J,:^1VQJY/<#C/\4"6.D74STR2;#2F_(P[*DJ,76"%/%&
MQ#VU%IG[[5TT/CNF2_AM="R[#JYR[ZC.?68<9-PJ4J!F5!UFB+CBS=D:"F11
M/OO:U;M LSU_JV-)78SL$52[1HI+)Q,-W(X?0_%T\6;6D.XQAW3?QSK"7P<Z
MK?+:6MW(H$*;9&P6MA<V9^$Y$>HM6+:B[DU'+,!/YUH^RJM"5&K$65GN>&>Z
M&O>S=SSO7[M;DG-VO WJ@8Y8_5]%V(Y\"\DF K% 4]L:! VBC @%6:B]&)ST
MBTYY&=H"7&BW/W-IEP8N83G:TXX<';*DW$4PIQYL"&&^A"1WT8>:\B"/;QC\
M@CSPQAI0=%W@Y.F>2:V*!FH[I6?@71Y7ZU:)&PD#K;>[+]NC%(^8Z!,2?O*/
M5&CRT<CT@KIDY%QL>U17@[L!TQ4,G[^XE _+/G\(RU;EMUBO$4GUWL'I4P9%
MT9^K3O02</-G34*83!%E9%'<#H&\O^RI"Y..NR&(OIV5L#8'$Q:>C*;L5+&.
M>7]9(:=IB\2]6Q*?=JA<(AX'V#<"R%"7C13)H_.";LO,-VW]XS2UME/XSE-*
MW5GR3M51X#DFS@3RZB&'BRN.[M'AZ/ZXXN@>?^[R0>+H9%2Q(GZ9JNEL,RV5
M%0C=(<M\AYX:]R9K;G1ED_I:H!$*4CI 6,1QN^QG=+W7O/]A[)TU[T\[^RF[
M-.;U0M8_Y8,+N?2>\":+0[M4?PNX)IGZ&]I^3: ?LP/FJG+I<S86&F1@LP6-
M:4TU!799->F   MV5E^@'^36/==L\SJ2V48N#CL9/KKPK#QUV06;E=PQL=NK
MS=^$\P"4I$%KW8#T(O5@'5J"5&E'LZ7Q^8;KM0%@LME^(.[9I)IDFPP^/15>
M@1M74?^AV:*WQ/)J4J!RX)BC[XYNL[8/(1(BS%!BJU]ZOZ*3H3.T] )D)-<_
M"5*C$7S,K"[],\@3PAEK^T#"\!?*+)@I+G!&EEWE<D;K4;+/B6<1R&/UYX!3
M'4LK$$ZSS:E]H_FI](N$728O,#O7MP@0#1!D6F*@U=JV35YD# *TVD8P]#<C
M.:3'<6I_D.[H%05S1T=8G;)#F8<),/R/)BI/$_ LEQN,H*UU864=9)=L^-AM
M?N^NKJ^LGI3]VA^N-J^$3GA$8!++ O['FUUHF(*P^RC(4DMI4FJ8"G"\NC>:
MS%?]FDMDWJN]/EA[_=[HZNZ;JFINX?EQB 9W+5I,X=QA]K^1<Y^J\OXP#\WC
M:RBI28;3@O;&J7)6VYHJ:@)"5'L+:J4!],R>.F#? P+XUHW(US>\^[R) B8Q
MU,1 X6:=/?&:F^,=GQ>55K#=@" U7:#I^HP.<2P1GHXQ>NA9^X?RYT_'LQ*9
M**BUA_P$1K"1O)[M'37U_8B29?_GX\QTTH9:2AJUE3W6A'XQ"7]P'L9X!*5H
M@$D/Y<DB,5E^7FE?K>S.^'VGX1HO&_B=DA])*'.ZI 8_ARYGAK=QC&CH,KE!
M+FN#X(3)-2[1YST.][8FT1]8$BWP<V9*#KRQ@4''LL4N:<;+QE<"+@WLPS4B
MJP[MB#61?NR1 -F*8L4BO% =J4%7F!X5M=8"F3;SC][BJ#9GES^U9;@PD-F/
MYGYEJ@J UDD[&1TOLC#P1!!;84C9A8$$O&4T$JI/\/RID'WRC""="*9#*'-Z
M2+[)]^=M5=+$!E(XXN4CN75M-U)+.G[^:O/7-ST=!106J;Y'F+U@*8[9\0L>
M)]2^<3JB6!=9JL=:B8ZF.:E+S*@V;0&>#9#ZT7+^K>2YL?%FC.Q6.GYF6)S\
MQ1V _IF=/N!: ";V*.OGP;U)\4-/6+TUS+HQSVQ0?$/)FM5 -!_V-]$=FK8'
M@1P5L,=?8B96(P;A'^[+)J8@@?G7^:T#^EX.'.5EF/"&; "Q%AW:''IVSKV.
MG^U&'U[(R_%:RGU\O=G,(,>20=.?OB!!PV]!6J44RSJ%*L[Y>S+7[T":Q99)
MHW?^YI[]Z;./*1@\PG+MO:9//)QXZM4[;>6V/3<2^-94 JGX->33LHFV#:(Q
M:8SN=XJW?51("]TQOQ<QG,C*;W/5^,$N?MLVZ0$4P32/WOT?$/NQI4CX%^:/
M:_.0D=-ME"F8\A9M[7-0AS8:.*RI.O-9SAETBC19H5!$&I.F$U87Y2-SM<Y_
MK:,17*ZM8=E5,=GV\2U>RU!4C]K]0@?=ST@1?_G%BY#1,#ACGC^!A7[/]N68
MW:T_<)Z=2%*JO1SZM,P#1/A8G^5TG2(:O&]G5 9M7[.C:&>:C:+#\9'VE8L=
MYAMIB2'PRO+G1*6#[=)^261Q:47]MD&VAJFQ9K<;VFZF?99*,*G$!8PTKZ(H
M56G$2$PF;,![QDRV>##(>0=(O#\AE&6(<L4GX0_>O>7X:Y4/]>X@^'-UK7SV
MM/Q@,EH5D.%;%WB9XI-J0HHG?BL.O1':F<].D"GZ,V18Q[?6/.8AAND_S&KA
MV-SE(N:_/[0TA-)(\'7;M%6Q9BJ/.5/Y$M%X%JMV&L?&.8IEJ^"N+Q]YL[81
M>U/^.X=R6PKML1%#453W1;NCDCFDZ,.OV;Y.&FD*@A R9'+8W8@$/%,7S1WV
MP@*[MX)1NT-#'Q>F7A%*P,'*T'F;4% TI9G*\EK)!Y*VPT3%62:9J;O(A63N
M5<1'EYDMW;27-ZR1C,)B]#2YKVP>X NGY^>?G%^8E_XF*4"HP6 U+Z:E)"XS
MU.0GS,WLHB$I9PN E%5UGW?*D2)=3=G-17ND34,-]"*9^'[FMYA0I9EO&G(
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MYYE!-K'7=7-;N>*:041T7/B(B-@B_&G=RH1>U'8(/U@/>'6DK*#FD!$W ;%
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M7)+98[;4JG)%&72,<08P"^M*>O8P]LW*2I$2M6XHXA3*5=I!?4. KF;HH=L
M 0=1>6A3-B@J\_L;);+$A&=)HIG:Y:WLI92I8I</G;-?6&;#()ZTMCE9[!KQ
M7M#6)QXFN^'!:P7]\5M7_3R:T97.XE?V3J_RR@$;D!NE<+'".3/1 BI@ 8%D
M3$C2T)HZJ=JU,3LTK^A_*UD>?K#R2^2F/QL904$?P7_- O=*,>SN9])7F_\R
MOT;TH&_00@8E^-6G&[]R%:B^EI\6YXV>/3M.8* H=INWQ$XN2N6,8B,6MNV/
M,E05Y7-B]21C#E"KM+VGG*=UUR6 H;@;&E5AM-V.^,F$&+ELPWVV(M%=#85+
M_\G?Y=*UK&@[?E08-?P2W\BP%U(V2VF8"8LZ8@#Y":([Q2=OB9)/_9(R)?I/
M^(.>DV]6IH 4Q;.//XZ<[*PC3PNV439CQWKA>1T4'^A? F3%6S'QG!Y9T%Y4
MMWO@M@*IG5PQOVZ=Z M)'C@P$@;/(,\%$CJF:F2J0EHRUSI6UHGFD/I'LX"
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M_2J$??+]P"C6W/KGJZ0 4=B3S+ U,,!)4%^"S#<8M^&ALC:LE#AQ5;YN6M>
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MLV_U D**U'D/U!\DL^.@5]H<>$U?T3V6*@QKWH!3W>885Q<4)=.=A+N@@OI
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MCU/6!E!3;8V/9VPZH?/6"%K37C8[319E3(S37&3 JD=#)OOW__O=D^?/GLK
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M2VGR _ +-;H5J0DA%"IOMG[E.5"D8,MSV;H9&MWDB#>>HW!'X0]&X76QZM^
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MES]QE/[ E)YX*H'S4X2^!O(^AU,$;1*(%]JAHKYX:?].NL%97<@?<QUNH$?
MI=C0Z <(1HP_&B1.ZM4/KWT*TRRNECGY\:A154907[5XM<0AI)1")FSG5_X"
M67*>9DL9M,TQ\'"9P':(G@W]!45(.$SA)SY\U_(-Z5_'5(ZI'EA]8+4OF%NQ
MTOS1)27 V8!O:S3(K5"&9$36X0OK6(0F-NAR@VN->6L6 ^ZY7\B<<)HD%X,*
MUY.0LTL_(=]=Y@V ]H]DA+&$D^UYPSAHCA) F1]1XLT C4FP6=];F=YX>Q2'
M^@]H<L<(]EM6$A'37ED!5D>4:M>!\-0XL:?\+& 0DQIH*()&$FZBG3@T,=,Z
MNIF>GK 2W&;4?)E 31M$\7.^+*\0)?$!-)^1026O!3F?\H04M4TPDG>M,(I-
M?HE^$][DFM6W'_:IAP_:8/AD+C+^9XZUK]L, ?4.*J+0PS3Y,>5"(&C;YGR:
M6:"$<!_'$L6.LJTF@+8MY/".4T$[&*OWN&#B)RH#Y*GJ_N5EIBZ1CR^SE$=_
M\Y!'?,;QN&<00HFBJT1Y+7#^T]%);V2@1.$;$U543^(FFU!IWC,;I,?#I*4>
MR1*8(9XRD5%_%^9O$^RJ6/A1R/#D[(O+#DWA&Q+LU6"!D-#?/OAYZ/_;^UN<
M3F$O?_>SKVIU5N2?"QK40H1B#62G^:<^GQ3^G)8%E9M;!\_JY1I-+W1S@+IG
MZ/6'0BGR-TJHP?%..J/146<XGFP<,=L\),?BM0)A%(' @$J8YBI+R\NK-5.O
M29RB/B$>MP@=*7L\'/<FAF()]RYA*6&/X( K65H -PU[ W,]E5 T^(7$<Z[G
MH/-<CU"I.;G &^BDX_UT>FQQ#\_7MOG'C%OEF:GP@4,]3@N(\8!: V84R9J"
M&KLYA">.CWM'VSQ1\KRCZGF=!C-ON'GM^."?AJ/>Z88GZ,B8C"4ZK_*),AC>
M#+<^@S/CI"Y-#1<?YF,671)4#(^=-Q>)/W,H(V:KW!N3Q:A#4G%R^S%>8HPP
MD1*4A#K <KSYI->__6;*3D9^\@M8';^!- :Q52V14YP_C;99!=<354.D:WKH
MQL]PND[5@<8*KP3"2@H0R6)T6/.3\RL5SVX?SCSR#LQ<YI/)X'AT*(-Y3?7
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MH5#'^_PY?MT*J0"Q!U=>A-$3V1,\LMISX)8U2Y)'HT;'*FG:)C"#"XIAD%;
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MFWL7W9%W\"'M>:/1J#L\.NX/^X>PQ[&-6WCQ]MQ -7(O(OROH$WIAW1DX*$
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MZ";4,: \S.1FXT5@P5>[DVGQ#2@,VLS)O%2)QPP JV7C^WH;[RN&O0&O>N
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MF$1F#PB3]<0E_$B[9FI;WY\YP-,H/D8MH_;)S _R&/-S(UL30.P\KCP41X_
MVRZB:$H)7O=,^7%OSTJB*\R9'&!^3V)*S'I^$Z\>7CU/:KS3B2T%ZYG./4!X
M QIQ"YFPB2D3&#Y4N2^D MS":G=S-9'?+$-,[#*I./!'L/0EK!ZPZ^&Y %10
M-G00+M%K2<ZD24C;<&W#[*4 _OT%FT6\1)YVB=R8A_F:$,R(9$0^#2*)L_,
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M:]=Z"WRD)_U+&"U>,//C)(4AP7P& :X@'!+^8444KB-(6E&<*FG@-5^R!2R
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M3);51RF3)9,EPY#ICW%W6+AC^F,85@"&3'^,.Z8_AN&1PI#ICW%7>_KKCOB
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MNGH_!ZX10:*&N! __$6VR*^,E5@H@F@"=[PN:[$N1[5<EV=J!Y 6HEJ7L+(
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M9!"I:?1BW!GRP\LHN%3GZ6,$#N#53[.I+ TL"_6D CS!>0J]("-;73D51=:
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M:9RZ-EDGVI=0]57[/SBVY;=HX-.>!)T6\A0&I'#T;C6_;S?:3R_]"8>$0[*
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M?WT#S1@W S])FR(08[A'-F4BXMGIM>40@&,XCO/VS/.32<"GI\- W)=%BL=
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MD03=LS<W88%YU">GPY)LH-+DP;A,\_[*_1_+-F?1I&S<1,4$PL- B/,!*!K
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M"]U9M5 H7/BY?\]G ;#5Y\"5?'49SL. &,S[0P%@\!KY$5T-)D_<F)UNAWY
M?H86-E.D:9"??>?R9#0+ TKA%J[+7$AW?A" =X"]5^>2R=.K'HAR(P](+O'G
M_HOT;0[@O[P,T3 ]U0K3RV<FAA$;J]/)8!3Z/7G^<*E3#PZ*&\L#S>18XU%N
M*WS=IT[6W(V+I?7Y1L\YA.OA.5>'.#IQ:[+=MBC1C)0.]5.''PEYTE^<CD#)
MYP=&H8F;';Z9*_=@+NNH/!8/< X*],Y_GQ\B"M<I4XH9(/)Z/AR"GR 9!_5M
MPGZ&\$2\+\,#'DIO O7&;^9JIBS*@U=*5?>+E^97A!R,!,9,W$S."[!D]%V!
M>ER^RELXAA1/!2Q>($_[2U<\0%Y9N@_^YMU3T]%G,8BEE;1[TJ2V&Z#M:!O5
MP;IW&,$!\/EX+(MG$$:7,/K 1"_C01EI.8AE*F[1C"O[&F<@]\+DYI;]ZM.%
MH4IFXZ\P%O*BQFJ ^T48I.3"<(E2Y5#(V0C&$N8%G @!Z,B_8XT5N"J)0,7@
M(WF?QVXC&=:;1'?8/3Q]%D^:E)R=_,Q@YY-) +! S03=P+4OAOU*K0%AP!SO
MX<38:3=Z/1,W^F\RDZY!IO33L*!,IH[%W5S\/%S=[\)'6]E^.7W#U*D4O[&N
MX27/L B_CD0@7RLG\]RJJ .'P33DJHKGF:H(J90@M"GWQ>#A8N$KM&\P?71,
M="I62T8]&,EG  I*?"Y,/#P47<";40Z@ A=Y;'?U7=)?FV0Q+,EG72Z)?9V\
M$'?J/&[5ZV5[4<U#[#I=H[NG$]Q@L;JO$]RL/;W(V<WQ=Y4[P6VK2>/5/>/M
M.S@Z:"J6O6$ZVN/ 1WM<S::W"S6]J6UU'\H3*HZ41^=5T%% &N>LD+W8C[VX
MG/F 9!"J<X!-!<ZOU:*0Q<-8(=Y_ZJ?P:/<Y.9QO<6GWWR!6P$?Y]/KU)^IM
MV8#I(ODZS8XDJ/H+BM20T*7)Y+V?ZN3Z#\EV"Y1C"!A/Z3Z?<SR22I*.[422
M*.?>K9](-O7KUPN]*Y"_^I0Y*A5!Y4I>5__:;G3;W4:[L^\"V(3$B@FJBD5+
M=)%=-4%61W/7-YQC+<_TTEIA;ZM4DK5JP[ K?_B[W''U(?:]&\'^"1=C$LTE
MC].P_L?R5%5!:9;09); ?4^]1LLZUIFBFD DG[A2LJLFR&IH[7I&_U@/?#FP
M2WSHW6UZ#L,N-J]Y[--LD_VOY4WVL]P;HI2(4B)!Z2NH?:BA'I-[-0%7<]E1
MO$N+>-<W'ON<7?* )W[28)<CXZ.A=S3+H6@6K>\.>UQ/UVRTVOL^HXY@6#%!
M42SKV$!60UMG0<^.%(.:Q++(W=TBG/_.8ZPL](?!_N _$QXTV#?M'=X6.;PT
M"1QV$FA8+7!YZ1RV2@&17-Y*R:Z:(*NCM3.ZQ[IWFW8T:C@,KX3S/V1ES M^
M"^\3L>:^;IM\7;+^A[7^O4ZC?[1;VJL)P]IYNIMQ\Z30FXCZ/_7 J!Z2U8C.
MI_CF#L#^PW='6 3[NR_&>)A9.;JYU:EL['M>('26JR93V3,%I8>9V"HF\;1,
MR]Y-6(=@6!L[2!Y5512:/"H]/2H*G^T [!<&'J3,OHDX]H<^EC37.X+6H0A:
ME29:/8S8=I-]^PV+,GTKA4)R]TB?R=VKF+M' ;0=@/T/@WV(N3<$&;*K,19^
MT=O=ZY*[5Z6)5@\CME6-:74;W5Z?4%@A%)*[1_I,[E[%W#V*[NT [-]YZ$[9
M5X-=A5-/Q#/.5'.OKT=>7Y7F6SULV7:#?&;#M-N$P@JAD+P^TF?R^BKF]5&0
M;R<I$=B6'P;[+1KXH=:NGL+2NSXY?%6::O4P8UO5&:?5:)M4\Z9**"2'C_29
M'+Z*.7P4YML!V,^#@+E9',-O3,SJ%D?ENL5>4;>8<?C+<% F[%T/S\%+HC!Y
M7P4OT3+)3:S2!*V'\=NJIMD-J]=OV+UCK:!032#6SE,DD.D'LAI:.\>PZ:2/
M+9:*@?_Y(!#RQUF'9$/\T(/[3_N&V>F^/5O?1\N&WS?OIKQ\2Y[HO#V/O?\9
M*S3V520)2T?0%.LMB^[PI+F1/T$'-1JRSV(09SR>,KO78+9IM\N)OB1 :,3O
M88 "#",\Q"]*1R*^\Q/1 (D*!EH4XY<@2 Z+@\!/\*(DC=R?HRCP<%7@)ZS5
M,]EYG(B0!^P//FW /V"W4AB*!OMVSDR[U;4-]HF[(WP0/G?A"?E31S!@210(
M=ANET&BYW/##6Y&D8UR03*([$:M#!J%)$UB%L#12#QMQ^(0-1"A@I>)#0Z<2
M!AX;3)??QK(UO4VRP?_FSW2C\3@+_73*)G$T@8Y,6<#O$G8'%X-()I, 3!#H
MWUHD:;;VVS9@KO,_2]WW_%OF!CQ)_OH&6C)NXK V12!P]&1K0)2S@%3>5>S6
MJ6,XCO/VS/.32<"GI\- W)=EUH&&_V^6I/YP6C1"7M-,4AZG9U(^37QC<CK@
MB0A\;/J2).==R5]6$FW^[,-)US%:K6[?ZENMMF5VG#X8GE)<XZ<0$VAI,)./
M'V(7FU),C\AEX9AW')O"HY3OM$SS[=(3=8'7918G&0_3IT,)3[2IM[4F;;#/
M:7_R 0O%V94[$EX&QM)R/IZ<LZ$?%">PHL&[^G3!HI!]%*X8#\#H61TY][4:
M&*=QQ43&=;[Z0[C2]47H0DN^<3#",?N<A5Z#?4T]@[W#B@2V>;9TB_S4.GL/
M5G@2Q7(Z0/OK%69;V6DTWOGGB#(9M($'J"^C6VR3U6AU9 Y<8<!A;D#3&X7*
M8)\M-/:*O3M_#RW[>K&R85=;:Q:LRGN-5JM#\%O=F'6#]8\H$9,1^^2) ![X
MZF&P&]UVM]'NV&O1@0\I0>#<N_43#$PB1';]=F/MFQ,1@\N"SB<J8LE_X>HJ
M=#"6-,I8 OI_7RJ<^^H9($U^@RT;+EYG+(N\?#WV=JR4?_&^A<:B)*2#A&[7
MRLOGS3'8KV6+8A<61>1NW<P;@+DF_W?)*YA -V!*CL$-DTB%-KY9F)K^+=WO
M^].F<R8G,A5LQF O@#T;AXLNPO*JSVC#$@]1FS,'IM'%3U9.D2+T5D22!]$]
MJ@NJ0-Y,^&3#5>,S%P3FZG6^#@IN68M1R<7Q',5++ESNCDBGXY1G:72V^ 6(
M6GVLAE^R-'P(_3WEP1V?)F=O3F9 61D+P$$L(>/A"&]W(/<4OMOVJ*T(8:U0
M07+,7^F8@_'T!WX B\/3D>]Y(MR.JUY%/_V7*(3FAS"QLLLH^\F#Z%9.*-^P
MN)H(V'F0JD2!8C[Z..<.TU534@,7]C#P,"\/XVC,HBQF'R*LTP;3R^QF@_VV
M&)B0<8IA%$L\@QD0&#8 0?I>Q@/%6N(7J2]DL,(]B5:_'.:X!FM;[!QF^)A=
M!B#!!K-,<*D_!U$4-Z20_E\4_YS_!%^;IF,\/?61WFFQ(+8KO2!FFZ_\_I&%
M@O6EB^8 7,$7'K$/L>_="/9/>&@6"W8),L%0*?MG\QS ;US.5WS?/_SS$C_>
MUIK*;MCM?L,QK;6^_%,M_+"ZA1^VM^JSS&[#Z9J/KC:>:.67E8W\LCTIMFVK
MT6VUUZY)5K9/FE]I<]@_'S;P&_MGT;Y&L8"0JX'_%M I'A3=PY<5L%"RR$=
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M&\7 +8^^N)_@O/U2'T+>88&#\-7_5^9[?A[9NN 3/P6/XH=(8"A=D3SI1SQ
M'BT>2C'D7(?9#WQ10HN'U4OXD)T#P /6E5.0O6H*^@[_C]CY6$@KHG;QX#(;
M?EDK9/;NS=KOWI0FI"7+C\OR9I2EN*+PE/*)H8CC8BM;96>BO K"\A2@MJ 4
M#XB5H![2 #=^DL:SV*:,SN4-S6W-4L6%!WX%/!S&/!1%]"Z7_L.YJ;' *"\"
M(508D.W_#JM#"QOX,G#D-G/I>8O^2B&5^62\P0)W@TH\"Z[.CW/H[*WLY .W
MQV#EVDI+;56"\L30ST.D,##Y0W_DXX7!15F19&;)<T)BO6 P@,MS6<([%=A5
MQ'+-OL]B)IV5,U_9I>+--&,\.F-X8AS. \JS8:'-7V4Q_2%4T9X%X^ OR6YF
MZ7)+6=2!73*0:%$?'"4F;652LI;(G 'B;U1%?J0$PQM9#U#2K^@HEUHP5>^:
MQ6S?J9,"9N;$Y8G:G^;'L]#K;6XCW-P%0X<Y>;^Z>855'F9!@"1A3D9.D)Q.
M4Z6''^&Y=VC]X;\%!G5)2LB_YKZDLNJH_C#Z<2BF,],^%+B9ZG\S[R:7Q5"2
MX+(JCTA3M54,!92AM.%EF9PO<W,PDP/\?=@77-Y@W'U&HN=NLB1/YNU>=PV^
M)))/D5,7]B?#P8K]!+^%B;QP555P>^898PS/=T5^3MRC;:3-2=7?G-2BS4G5
MC\P]*_^CUDY"D0!0&+>'6Z')87AZMSANSYYMZO(4IU^X"1=8E X6,;#T0Q(X
M@ 7='P9X]-P;8LV_*YAJ1[#&XZ$[95?A%!12%1,V/AH-]OG\XDI.CXM'U+-_
M92 ;\ ]X4GCJ_FPPTY*+CE&KV%O<$89)A6I7M?0YE&>#5?MXXO%_+6TO7EWS
M;VUGETLBYT4(2V4%H2]SFDW,J3#5(U^Q8>O[5(09O2PN;Y !!RB?AW$3U[I&
M9[.M0E/!87Z6:Y-9I7_'4I7^U?I628/Y91TI+9'RY0Q.^?!B/P];RCT\..&G
MN*N_[':HW(&R$Z/V>#1FV_MQP\= ",6NS\C^= 2.HVPN/ Z063B>8CP)HJD0
MQ;9VN"',MV,MO"64&T"F1?E$I0!Y34>%6Q'>P.0C_<I;\'8B=$&G$]6A0;$#
M;'%76Y8L;T(O;2#$(I9*=G$6H+NW9C3PW6.N-CID,\$5P,I=;^D.2W"5L##O
MG>IWM+!?$GIT#PC/XR*-8KF(.0DY7M;5L;R3F_ODEKDA'H UTYA9H%;NJ)NW
MHW!DI4_.XWA:>(HJU)%O8<<BZCE YOZA%."8_\P!F2SU?+W8U)[(/#[AJ:BL
M'+UYXL0L)K_D-RNL9+/\"4ROF,FWN&C.,Q=C+T/O4GUA.8&N\VW.T8?>DN 5
MCSV5>TO4>@0?GS/QT<(.&X/]G<<!&'2PA7_PGPD/E,E3'#G@D+-+#JZQ#Y*X
M',DO8$34AK#9 $A-Q9/*Y%<%N)?:)%=;N0HL+ME6N>C)CGGK#;9 U9ZQ+"6(
MMJXG8)-Q"U)PG6]BA8GA&M>)U\J@:^L\R011F"PNBPZP<]D!K3,I4;KL<S%M
M7.5+5SHI<DE,Z  ,HR"([J1]EN'/)!MCSMLL(U HD_[AXZ_L]ZMSL%+&A:&L
M=GF*4 %O&5R:9(/ =XN]VOC@H1^/&PPFB$#%2#,50Q>E\R,#Z03<@7$#4P\8
MDY[ \GCE#7Q8%D*N+1>C"JB0>'DSX%.8JM0ELY(&AOFVN!YD'_!)(DX3@7OA
MTUE%"'72K+SOC3JM-9VM>TNGAA3WYQ>5C\!5K^MTC'[?>5M>D.8CH%:D)VON
MLXR._8*[7G"+;?1ZCCG_\Y)G''O_BJ-\RRC)0Q18[&# W9\W,2B$U\R5?2C_
MK%;V4ED/%2S!#U8 ;,49RQL?J#P+BA21LTF*)<-]CQ5VZ!E'+O<TV.KS8%+9
MR 3"),$N0.MOHGCZ@B.MMR%NA033T47@ZT6</_\O%W#S(/;_TDAXF#1Q83A\
M79BJ+&P8;_SFKV_L-P?$^0H9[7 87A?]?1GR,0:@)>)U$/UZ86\#XEN0[I%*
MCHS#WHR#0\9AWQ!_Q(F4J[Z'7J0+DAJZKW$85W;F=6;H "3;IMJPT0"I+#@,
M'SP=Y,">-%M&I]<O_P$X/[6,[QA=N.@A;[EY,TO'P3]#17<PWBL59I<(D&_7
M9<HNOS>,ZJ ^FPOMSP3 '=F@5J_5L-OFD>)QSVI;*QB2'20[6!\[V+;-1K=+
M=G"?BXHB-/WR14694+/-=<[PTG",?<\+Q(N&HTP&R?>5&V ^0N;INPCY+<)M
MS>5%R&%MRQKT6_4-1.>MR$,5^4;4M0&B+5F>Q<"(;=CX1B_*D/E\ 3%3S=GR
M=2)_/N!?+/0:3K@;+CS6#=&#Z-T^].(E#)KV\[8V)OXPF^/)@I,%)PN^PR43
M6?!]K;S@?]R*=E2%<J[S/^M3 34[^<G!09AUYGC.?JKDT4^?HUCFL,CMO:I>
M I>DG=RNZJJ#H7!OJ?R]2*91ET3E2M58#T[6/L@3=55&@RS'G.],E7D2_GCE
M]45ZC,PJP8?^*P.QXJ%.>35+66L9&CMFEMG\'Y4$HS*B)W$T%++0##ZQR*V=
MI32LJ/X@RV2F43S-,Q*P[*K\%2LL8,X*;JF522ZR;:\X":JVF8"7\+K9X3%K
M3IBA/,"E#>++-6$7SVC)SU]9K*ZU+.7IK$R(S&1*1)JHHK\JT7Q^0HHJWQVJ
M?*MD12DPI<)X&;2[J7XK:T_YR ^82F3MRUF"4'G#NKPUKP^KJB(WBU*V>1&P
MA[U@-R(4L:Q).RL&HXYH$ZJF+>;M*!5\L$$^?U]C<2.]K(,MY%DT,F$?+\I-
M67-6$"WE]S*''].F$G56R(K.9V& 64RR-EF>(N@G1>ERK$@F[B<(^#0H%>U=
M4V.[*/:")\]@Z8.2>'@P&TNLU( EPQ:J2I2'3 WN_$X%ED+E2L.N"F4-E-U+
MUPB_:%0^""O;A ?[2#%PF=PG2^_DPL@Q4<H96QR)D4SN<X6/<EGU#G5>W[KF
M-9B?%LF!"5LIN'72!CG"-[)<&.B_K&ZA$A?7%5&7VA"-\S+X9;WTP)6ZR8OP
MXWR7CJ(8BY7!'3=8R6VA/0EF[$[G6C.#DK@OBD64U0)>E6"ZYJT(Y%PSR+P;
M(8U 7L="J@ \-IJ5^5@I!@,GQ/R\G"(!L_Q]8V6?Y</EQ(Z#L'!.T;PR12R*
MN5]6YBGR&J\^7?PE46F:.!\7JE_.>54ZO_*ELD</WKS.GH#.#;#&2+&QISAJ
M0A6[QKO&*$8Q'.:9H+)B"2;E^?B8O"^J()ZJ>#ZO,X)'0DJ3[G,YJK,.YL6?
M_C+/9FR N8@F> * FP58**513LA)I@FZP@UU7!>Z(GY>S5 Y)WCXA$P5E=6Z
M2STNE&DL:X>(<*0.^UAH E>),=AME0>)8,$I)8Z"_'RP& _,DJ<G*",FDZ+3
M*> 1JR9A;_,6S*K6%_(OBN(#_H.\;&$8R81A=0=+1C*[%3PGD((ZV6"PD'1Z
MNV:LP;SZD8<K6>F]H0NH[%39Z,^T(9'V>H:\=[,D42P1"4];KR;Y'#B;=];9
M(QQ<S+$=^C&ZLO(<#CEVJW0*<!'G!F&%=9'C\\BI#*L%HK);L4K;+)T>[W]H
M&LNF0S4#_ UI_^'_TLEC239(P##(S.:%).!7G<JXZT,8J7A-]8K7M*EXS9$5
MKWGU#F^9K(T'15S[M]HN7\]__*9UVC7[\D^]VW?@<Z+;U^)^Y _ C[N>A9.N
M9^&DZ\0=Z0H]50:@;;!/>0>D:R3/5-!ZQ&7 [JJ0,+O*CRAZG<NQ=YR^.&J.
M@:KV^JBY!/?KPN;FSH+F.Y"R8W0Z;;O=;IFV;9G.UH+H?"]!])W#[F/D9BJN
MC>M!N=+"&5&M&OSBA*;3-8%E JG>(-T/T[-SD,[/\9F9]:>YCJ,-WL^KNW@S
MY<8PV8RXPCI:',]S^]RTL I;E-V,X&>=5N2.HU-KL-HO1S>"84TN663=DR)=
M;3//Y2EV[(<ZW*[$!OZB^\E13VG!*Y9VU2WF\Y)"/MU7UH[97HF8YV1HZU1W
M9%<[*;>2L:Y%2OINJP%<P@SQDM22K2*W/(?+IR\-'5SW%([+CVC*9Q0W2,LS
MGR5V8WTY&\5B^-<W?U*.]'6)/[J>%U"[5@74L$[@^D%>5SE*OM43;J3*QIY*
MSA+]N1RKFX]Y,6,-V9<2S?5C7N?M4M5Y.Y_32I]]F-K>+56*^Q E*=9._08K
M Y@W,RR C\4N+\Y__<"^?#QEY<G];__EWV.SOH.K$L/#,73R^=IM.6:KU>TU
MS4ZOTVQQ[C3[GLV;[:'%':?5&?9;_3>28H+>_T )7URWS&&_S6VO.73ZPV;+
M]$2SUQKVFQ[ON\-NJ]-S.MTW\D2UO[[QA']ZKO@[[,(7[Y!RMUOSPAL+POC;
M$U[0[ILV+S? =V!@:[@3]W5^]&9P(;NL;P[?JK7JZ<X\%#T4Z&#%<78&:OME
MH"ZO::SEG-1#>A^XEP(M/VY6N![P /=P7"<C(=+DD!/?1:E9[(-J%KN2S:)Y
M1[MY9V5U,%+17:CH?+_Y=30[NOP:CVF-M='7^?R&*X;2">ORF%1LJAB),,$-
M;U^CA!1:/X5>60N4%'K'"@T+:2'&&-L$A0YOA8X*?86G5BX=7OKI7YF?3DF-
MM5/C-JGQ =38Y<GH>AA$=_IXT(LS\@4TD'W&!I+.:J>S'=+9'>IL&*4BN4ZC
MZP7E?;C_[I":^QW;B%OF%U1X5?B(U%<[]>WJFOM_8(9_5QO"3-H-]OK=8'9M
M=X.MV.1+V\(6YII5M0Q84DA-'14OC^A,LD%Q0KIP>:8RP::S(PIG9V'BX9OY
M9Z#5 <PUN+<'D]_FMRT<W3B[TU^LH2!/'%M5:"'/8@O5/*EV7CURS#AM0-70
MY#CU,#E?\T3((A/B%84V7CS;YX+6;,+79TO?VIJV#R#RK,U_1M?I[>7(NE;+
MZ+5?=*:>U7G^73W#[+^D7R]Z6<>PK?Y^SOUK&W;WR<V7VWF5:;2>%N'V]GD^
MG#SVL,^Q?OL:<Q->7K_5K(??,RPD\MPM)V6_N&>T'L:#7@"?4HV_=6$C]:IU
MI;L[.QV&JFX^KI]2?I3%@"9I?HK]"ATE"!.$M8:PS/&)XAK/*T6,A=22U+(R
MH#T"=V\A*$8:21JI-UX_R]*U["-/18VU4M;IN_IT0:I)JED9T )>&:AGG?5R
M?7#DD4A=9\<9V>M/05NU;V+%B&Q+0==P#%O=.L&V;A+7[%1Z5';[-W[/YF_V
M9_T(?X2_0^+O:0$^4F2AAL[)%A#W0&#D[1'>"&^$-QW$0W@CO%6Z5,#S4R7V
MM/U[N_G>AE4Q7_EPF^T.KMQ[ EN18C-*TTER>G)R=W=G),(U;J+;D_/8'?FW
M(CD1W@V/3SR>\A/+L;MVUSD!.%I6W['LMMVR.H[3;Y]X':ME=OJ>N'<L8Y2.
M#UOY2FX\]M@%"GL(XDZ%JH,%#Y_DS\</ODYCCD=GP.M%!L.2-/ :H\%4^LXW
M/F7M!AY/9\HT>'D,Q^(CS\<B].3VZ_RXI&V]^Q\9=-QRY-OGF=W/R!DBY=5[
M9M[Z 0@[G#MZS5^JY17N6+@$OCV"[S"."X&/P =/5M-P;VD:)A@2#/<*0_"W
MFTX?7.]-%\O:+)"W%8#0IMXT$4A:K8D)7X0O"J@>&G$4P">\$=X(;UJ*A_!&
M>"."L@($Y<JC$#3VE8^8X]"?H#3[;=/JFK9C=BVS[YP$TY@WQ;US?7!Z4G*&
M>-)<Z,WIP@_3@-\EZM0YD9_2$_,P)>JO2FI1O\@C47\$/J+^"'S'![Z/PA68
M7E;0?RNY%X(B09'H/Z)GB)XA^H_P565\U3I<J:^;4D.!$MX(;X0W;<1#>".\
M$?VG/?W7HOS$ZBBW_O1?D9]H6V:K9;=//,=VK);MB?O6P0G [WZ8CMA*&O!+
M"%U*HYC]0& F[/PF%O+\DR(OD$N.\'P2^P'KRKBDW6"#J7P*'T?AS;K$PED&
M8_&*A(5\+#QU&(L?$M%8)06L7XR3B$8"W\' =QCG@\!'X,/]0'(RSW/]#[$'
MCG!(.'P)RWCP@JK[YX2H>&6]W6W"&F&M$A-+10.G^GHR-10HX8WP1GC31CR$
M-\);G8C(Y_K*5>(B]Q:&.7#819M]C[IA:PO4HV.UN_U^[\1K6^UVNZ\%]3BO
M5_H],IB%54M?ST9BG51;%4IUJD=&D@8>=]ASC\0C0>VXH;9'FI&@=MQ0PSG9
ML?:;N$B8.V[,:96FJ!.34ZEPTV'#2]J(C^!$<-)T3JAHK)+01>@B=!&Z"%V$
M+D(7L7B[9_$H\E&M15-%6#S[T"S>YR@>(_%V"8_^G$G>[@\>8[G0!DNC&X$L
M&KOSTQ'C+'%'PLL"L?KZI,$$=T</Z+PB=-A@?I)D\-5@NI;+RT\^G%-YB4C9
M,(KA]1'()X/'%XT@7N_@.GDTT4CB]0AJ>^/U:+\008UX/<)<+3%'O)Y.**1P
M$_%Z!"==Q$?12T(7H8O01>@B=!&Z"%W$Z^V!UVOIK<JUCWP<'%N[X?4<;7B]
M#/K $[$AJ[=T-7%ZQZ:/1Q.))$Z/H+8W3H_X%8(:<7J$N5IBCC@]G5#X4BTN
M]86*+;X08H_*L-XR(MAI/9]4-.I)-? (;[J(A_!&>".\55B@A+?9:@S^YX-
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MH!]6\-B_(] UG;=K;-76]ZIVZ%_]_=JCP5[ULMH(?+4!'\[DCE7%A#8"86U
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MOY/D">$EA)? /FLMS@U!Z4[S!10QAS#TNV'H_[7U9%P=V$_YLK=S62  [6D
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M;/H530S'H^$XW]G,3I?]Y6Y_D$6]>'OQ^!MWUZ8\WE=V](?]4B\;K=W4@UL
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M9U<A\%EWX'-R-IG.4(:B\VHX_A27A3XAZ@&:[9UOMC/L6JB5&JT1,=$A+KE
M)LB(F/&"X4BHYZF-8*?!AM,,#4?7R/ T,DW#SS&@?\?II*B&IH2^!B+MDNU
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M+'(YZ_KH)5X(:W:"5[OMC.T,G4H9!.$4H\A#0OE_CZQ3"N4(1YK@!/-DI0[
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MG4[.#_+)RDW\?3@[.YC7611Q>OC9C^;E(>S7=<S_A?9J*)*!8)O=2-O3Y#K
M9L!FP.:-[G0ER>(0D(E"(DYX0#:'",AQHZ@.1GAL5K#995?>,X:L< %Q;RG2
M@0HDI9.<2..Q]YW"9J$!F]L)9C8RR=N= *:/<S\]%DB;DS_=0/1N*Q#("(P,
MA /:TO;DYD[X!JTZZ\>+%.+Q[U7\?!''V2=^!3H*;D,W00YD!$8&P@%MZ4@7
MT)LUK,B:BF61[2B6]3'6T4[]6;/;(L1/<32Y*'N88*H>INH[OK[3#:?C!6;H
M+5.!4J*1$\8B[KA FOJ(A+=!:"$U,:OU2IZT>KK @OUQ>'.-!(>+\*.M9MIL
MH.1FBU2!(6U>(("^?5>:W4'?I%,DBJ HI$!<AXR^,5&4*#%>)>J(7FD2]K3U
MT1= 7SW U #Z]B"O$V*8!S^UO\9QG-I1$\+8D+\UK&?3IJP)\"CP*/!H-WA4
M9+;$GB4D;0Y&N% )68HIBC:_Z;QF8;59RE.BF"4:9!K=OX4%[3(IT0.!"3!I
METP)\+>3,NJVTNP,_B8GC30Y')$X$L1)"L@J8TNSJAR2!$RT6,W!?T(<\T+X
M:P98*,!?6(W9IDCFZ/S"#J<E[J\FJ;J8ECIRLR]-8%,ZE,#*#' J<&J'.-5P
M:4A*$FG*,Z<R[)%-22.C)%-)N8 Q;R.FN<:%X_1N,O[]7>;34#9*S.K3R<_Q
MS;"^F-0Q'*?6=DQHS8!<NV13 ,2=E%&WE69G@#C#)E'&2&0YCXB;B)$U,B&<
MI+*46Q)X*\'-RP.Q,!2 &-9KMC?*:2 #31*:U[&RC2D!LP*S K-V@UD95C*6
M6AW4EV4;8A5RTA,DDL7>2BFQ3<\)<49?IO86K7XL SU.O]:QX=66B)320;XJ
M,&F7; B MY,RZK;2;"'P-DVH*:@5K%WTV:O_&.O9=.YG\VG^:K-D,9F=Q6G5
MM)B*H?)G^>8B^/:=HYBGEHOO/%J\5#O=[]21W1::NB>M2U/,%$[(>"H1UYPC
MHTE 5/% E..>$-K2YI1K>#E88$E;DVQXH$V7&J<_II7 #ELA@#N .X![;V.0
M+<8\J +^<G''Z61F1]5DI5P.<!%P$7!1'[GHGOQE*87$@B/FE46<>8,L9C0'
M#9R9&#7QVK<1:%P5WEHF++<591@UT'JS:_E;S+B [(#LO5(K0/8K9,<V!HE-
M0$K8C-(Z6:2MURC0:*)GSA*ZBNQ/2-Y:%[)+/9!JLP7&MQC97WS-9X=CJ7>3
MNJ[2=')^&4]-QA!'=8YM>VK(D!/P"*WZ\5*"+\S%.CFE12+(QTS#/+,KTE@S
M)#4/QBO*HUSM!O*<*.MH["?GL0#/P]FXSL\@O_I>P"4'C.]<WX^GMM?Y"7 >
M<!YP?E=PWEC-%,4<Y4"IQ$]&(V,=0QC'Q)36BC#9:LRU/IR7:D H!IQ_!LY#
M8X<7;.S09,4-&W. E@[0TJ&C!>A!1F!DH$!@9+V:NH5T_0<_M:.B;K&>+3T1
MB/Z[%OW#FBJLJ3X]OB=4V1S+,\2EX8@SGJ-VZIN2JRY'[D9@W$K/B*/QIPPB
M9>?N(L"_A)6VMNT.C("<F=X9(N [X#O@^SKQW3)%)-,2J< 4X@E+9*C0B#'-
MHHJ!1[^Z3O>4@D?KQ7<^X&:S_2BV&-]A%\*+[T*X,;<+C N,"XR[18RK$TU)
M&)1XS(S+J<[LR2T2/DD5O%2N1$?/CZC>3\:3VXNF[59.AY"JEY8(  \ #P"_
M3H /*CEG9<;IY C* 91&SEJ!HHW!$)N,4JUL0U@WP$-,U:F8"G8C/&LW@HM9
MV>,RIJIF]O/E!F^@WZ[1;T]-&O)5>Y"ORCC&(DB.9&0F1U^F%'A/ 44G&6;:
M2>U;B;ZNTU3?3B?G!_E\P_$\W_/QU7ZHGQM 6GSOU'Z.]>'GV=1F,!^.[?3+
MT2R>UYGARYU,)Z-1P_&/G3)]X/X&-F ;+ENU<8:!_0W %\ 7P!<K?.&,BH[H
M#/L.9[ZPAB,7%$4F,(F3=9YIV\[Z6&_X0M*!I#O7LK8C^R0@^GM\@B)$?%UG
M<)APA0G7+GL!)-I@&"9(&8L19Y0@DR1%5$1LHW<L,WU[46-F]^5,[L]Q'//]
MM32ARV V%P)!H!&@$:"1S="(Q")X[P2B/I8:]\(AQYA&.5;,H:$/UO)65@;7
M2R,":*1[\2&L#C[55-_'636:U%"?K'-T#F0-\[KKHF*5I1M9-$ARQA&WW.;H
MS!/DO2X9F)Y2NCJO^Y0LS#A;8V4R-N!,P$PL!&R \(#P@/"W*Y,E):67'FEE
M<[#E14(NN/RG\S8H%6G$L94TS'4B?%EKTU"3#&J2]2.66M0DR\:0CSV+XWKX
M*58_EN#J)RA4MLD:2ELG'! (" 3,![2E!8% <;'N^A._CK-@1_F>0W4V&97!
M7[H3O]OAN,J^?GTVF<Y0#I3.LX=Q66*B'E3C.*LFJ63]0-3?M:@?EFEAF;;+
M,P?<ZIB(C2@8)A$G,2#MC$4BDA0X<U@'WDKOBA(M'=P,EA83"=>H][<%Z/TU
M@UV973@>GT0_GPYGPUCO3X=U_NA-T\?\0YP.)^%]G!VG4_NY[4D(QF#!%Z:A
M@9" D':<D.[9(F(5YDP*Y 0ND\9:(),T039HDZ+3+MA6)IHW3Q??K@<#+-&9
M6@&P6^2I)G[+OB OJ =T3?=HL?4PF;M1W"1A/]4A_,]-,O?=TMM"[MY4,!F5
MQ8';A,I/Q&FF>T-#0D0KA;U-A(?5!EE/"";O< S6%0^6M"/9I3[%7RDQ1(5
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M(1Z<149@C:33C@N2W3K?2I+X/2-=NC4K W[F6*48$,(&^LX:7^"_] V;@/2
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MSQ1IMGTC9^L82@F*BSBN;5'P;F T. *]DATX AUQ!"#HZ9\: M;U2G;]5#+
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M6DVQFL_7(ZU!BI_3?@[H6A;+%JQX>BD\/[L$9RX0U4G050OK#[%&P=Q4BX6
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M$?.%(UB:\I3%<> &3I396;+=-.,./$ "Y7:[>V N\%28 )V9K3KKYGE+LN]
MQ5F1I#;'G+W  Q-3V#'CN1.S/$H3U_7=,!+W![CIJ?=3L5%H=B Z=MVC^(D0
M\A6,OK%"(O0((Y4-.M)*,.363\!;-CT5^Q$B8J,\3F.<#(V305+$[8)=5SL8
MI5-&^I][G_/FZ&,32'EN]CJG27^K+LH<7G<8BUKAMF*POD6U[I0"2J<[GS=(
M'^CFGJJT:PNC<2H+!)Z-87O\N5BUM#S2 U,MFFV-KU2=LE#K@S^HS \&'W0#
MJAKL((1JYEHJR_!(]'@N,'U#"U%2'@F;<'6^DLII+N 52Y*>Y%/]!LO< M\Q
MLO1VLK3(\CC+<X>EOFTSWT.-,/'0AQ3$F9^$CI^YF[*T".W(<T7$HM1/F!_X
M(4M%5K X 4EJ\R2,'&_;*I29K^\X3;4Y[O?R%[F5-Y>J2.'PUW4XK+;_9.1K
M:VU99./#)$-4NCR62AGP;QD9;,7VB=*&%/Q7-$)0@%T>V"/K>,?CQH[2,YZ;
M8W6?8Y7;F9WF8&@5W F8[[IP.K*H8"$<*"_C'$[.%ICQ78[56]Z<'2]R_,\[
ML(LOX, LVN:X?<OK&JNJ_X?/L?SE(/JJ;Q_MASJ8 EUTYPF3/V!%I,3"/T2_
M-G2N&D&23$:'K)J7\$6S2IL6D](Q@Z):I2W(Q&K57B<MN^-(J2@4C\;OJ"P&
M#R'F4Y!@Z[)F5.*CFL35I>X4GZ8"@GRZ&O564K:NQ'U>A?E*=44U];7KA+"6
M0]78"_7B3J=*['F7[4>F;/_%U:_?T(!_KJOS<6>Y]ZZ*:DOAQ:%I+RM?O]<2
M3A878G!T;_%HJ>$I*<^'7LA;UQ"_2$_*>U1[>G.^/:NKU>G9]0:(4LLH3L1/
M3]%[T9(OY@EH_UD,^Q^DV, D 4V>1V!>8WI3'H:N&]LY&-;IO1W4J/-_EDZ?
M_.?U>UUX<8P.V*M!UF^I]KM/QH[6-2?HG>K=4L/89J>$HTZMJX/0.@!EOD$?
M%:V<K'BI0)^?"["F:YDGV\Z&Q3V4R<UU>0Q<66:8?M1WOC.I'B-OZ@CKZWJ[
MYXQ?""L58H$%:3*'7G4GJ?.^V$IU*\$A88]AD"5LV"!?6E:!]5[6WQ=4^W:"
MSZ&4KV,R6;CUHTK=_-OQ\><^61-HY'S#80K/G<^O-/J4F[3%/#QZC,RD&Q6W
MJT @7MI@'4'!NZJK07<5/>L%'D]\Z*INB&"U8]:0V(C$=J;Y4>8_Z-:X11=<
MIL5WO %6E?8 JSK$:9G!+](E "L_1UU.._\W8@&W]?GWE02#6KF=%94-UN%U
M%$*X!7PPO\XE#X<IQ936#B=@1XHR"E$L:T%6GDOX!1AK"9\*& J=^JJS3WO&
M%U?F5.)ZD(5"[\D76"N ;TK.%6W8C#V6B [1XB%H5<YUH[($*;ERG#Q')=.2
M5<-VS*@:E))%&JS/@'L7XK1J2ZHU7%B"8VDTJ.GG:@%&HRE,!?H,@\TQHW \
M,QP]%2 <R2DZG!G=I.>"RU7PBZJ6E\'C&MJ-%E^ 4F;U7HY5%QP>5QWA%-0#
M=,'D7>9^]30, ]C% ,8\&C9 52S)'3X3/,]TZD67+4V, /=.1[K58< [NDQ\
M';VC!\@0'HFE_E!?F3&E;Z=J9\KIOU$LKJ+*\/("<YL_C,L.Y-&FN, 2I -*
M)(4?@"]W6E>70$^*?70ISS(.,,.Z:WH1JNO=5\3;K)98+"2/NUQ2_&48]?L=
MOIV/II4!/72QB6% LH;EP3V1=<FJ!AAY'JQ-65 <D.8E(XZHS]%<Q(9*UYD1
M?,@(![H<G)!<I&W_*@U6:L_G/-6@'YV>AK5*'7^%,T7%UI(<I$ZWE<-[-3>1
MWN3A<H)*2F>6? L(DD*5[&>*^?83 >H ?0=W0S+K*[@/S@!>K2<4Q6+P631?
M^0+# 2^KU3R7>A5'ADH^*$V&U>XH=*^:=>YRJ>[V#U9D-XH7Z_7<0; @%OJE
MVICT8+9CEIK1U%,A:Q TO Q?SSJ)!8NK:SRLICJG;P9R!F-@O,[.AM "L@RO
MKDYK?DXV@B1&)/8"=-,*A1^7Q7$PV-Z"!GVFY1QY#A3<8,!,XO]LQ-'KBC)D
MI%S?%!HC*NJXU[[P>G]RAW' 76<-#9GLK(1/. '@FFKW9-F< E]8X-&S<J#,
M:B14[N,TV<+#"47DAF'H,)&(G/EY4; T!0LYSJ,PL.TLC+9K@^Z$%R>1X8X[
MZ^ S;&BVEO_>AQ%G,H/& G52>&ZFWO]EVN!'UC'!$12B%C(O2$5..[1POEP"
M31#;/%V5<EY M^<"62#9-(4T6RCE=M6>57792MDWGLF.&>]^-<R&K,C-)%^H
M9S,XU")'.^SMH,]P]V+')V][WP+<O^/&QOI]26@H@YM^[VY2UN?[;K-VCB M
M07W_^^.3G[O5G)37[MH0,GT[]+R/G?E[9(P?Y&%NNTR$2<!\)\D9]V),Q,@\
MS^:N"]+C$#+FI)>T&W(&U)Z;XI#>9+(WQ2%]BJ+I1H3B'EDGJW/RJ, !&*S[
MD/SURC\=P-&#:E9I&+DN]V/F@O:,%.PR'@01BZ+(#H3(XC2[5\2ARS?JA 8<
M1Z-/W487^=Q+$$1P&2ZDT:J>LE9UO2*E&JQ+%40W6$=(DSVHNUS%L"[/*M1'
MJDM$:,7\M#(OD0UNW6>=R-C5&NBJP_P$W6D^)TS66@/Q$C*<C#5(!T'*Y]+=
MT>MZG2$]X8PS0W2W5.5!"YX+Y6Y4&K/VF*D*@9'K8*CX*L$J,1H0?SW5NGQ)
MX07IZ13S1ER>(420KFZ[W00)(ZB:- S@;AWUH&(\<[S0]SR/Y46*B0.>RQ)N
M1\SS0(8[;NZ :#Z$&/^]$9^*=TU+V=V-$=Q7$L'O,NC:+9>1UD^9<4I7QA!F
M?LOK?1.!CA=AF 5E+KE!T&L!;/;?J[*&V<D8*;F8*6+ZAX SINA'>M QMV"I
M@QGHUI?^8IDLH.#99(5P,XP'#](#9GUX5L::5&54V63SJE'1:FEPGA+4?I]T
M,$PRX&V?E:X6Y&;L>M<TNQD-*M;D=21+%.C=)XJ%*O0VT$&:LIGMW(G!,NH0
M7D.:4;>8VOVN52R$.<:<^3'4\6"@;NQ_K?)3^3(P;^TK1W0"$(,RJCLHJJ'P
M\(Y:[NV+1AL$0A X:MXMR\Q2T(F2^)HSF"I+*0:.L/2Y7MA1L@B^;XY>+ *2
MY-_4HX^L7Z1S'Q=N6.A7+E .+R@R27&FP6(A2!/7H<N&//]Y6:"'3&=&-0-*
M?6JR^(44(CP,HS8= O?/)C:E!L\OF=Z4&IA2@X<K-=A7-G!#E_^=(@7NJWWV
MZ'5R88\]*MP@"VP1L"Q-8^8+G[/4AX]NG G;$TX6Y\EAW,KGL%=GF&QS(;!Q
MS;DP(?O;FWJC9;1^K1ICJUZWW8$NXYR>M3K>3:SKUU9.0R@:],T 056FD\F6
M062B-BT<F3/8/B$1B,'LT?EQ9'*J!$:I^6]ZAA%FI#H'3H"64=N,,H4)"9VL
MWN$CCJSW ]2[1L+>W5^+.UQSRTF!&&P50-&JPQ_>3._D]OYK&'M*]%XMI*%X
MB$4^H)F&77B4EX&@*&82\J5 TU6HYA%HTC9G5=TRS&P$6KT FW,;(/4[>%P=
MQ\YYFB8LX$7(_-@.6))E&;-3UPOL.!<\NE>+MJN!&HQXNY5XTY@.],=@&8V4
M>\H>V3[+5U;J-)2Y>P;;,E];\Q*V.1]R"-TS\YRW,N1)3DMLF*+;3-94MB?3
MB9>K.CLC!YOL<+D-!_)V'U)(YU.D'\[$G,)>*5_\@8XTY?/47\.SQ5HW'Z.,
M;YE>.WX-RDGOZPS5PX?/1-\E^5ES=,QBU8#V< [P>!K](/0FBJ?FI=N;NE7D
M>1JGB<_R-$N9[SHAXT[*X5\V=WB1@:63/QPO)MSB$ON 7,6K#8N^OCD8+2*1
MMF',SX$Q(QI8W6\LL4.#NW?3R>R&"' *;KMADK PS6SFBRS$-BD>LWTG\),@
M]FQ_2^^\&^[>D*L="KGVR'X:@  H@9\ ,2 @A&L+E]DNH<5Y$4OR*&4QR+8D
M@<])S+<$7^1QSHN"V8[P@!CLA*4YCUG&;2=QX7]^%AZ(&/[J'/E/9+\IF'N5
M:3W"*%90<%T2'+4X(XV.-T..QW?7:?:1<;!XV[)=M0J$@C0\L?.>N6A;(=M'
M9;7(RY9 X@A.E6>RJ$Z6 D]7J_LN@C&<KE_NZXYM':1&:/#!8EY=]C;$IOPD
M(V8O2*&T73 989&IIF5GF)XY)9J S<*+,!]"YG6H+GSYX)N66OEI6ZDYHWX.
M*BNA7[*CD?*P)\'=#2.>!@%+BD0PT.LSQ@/A,R< )AFF/N?V06R#D^Q,Y*NY
M^%3LM@*^8J713<L[;C)I*N^8PGX>]_0VRHY"VIQM4>A,9:J,J;I+"4+R[GJ<
M#I*)%*L%4A"8BT1NZ&9UKM-8)+VH!S?8\'Y,.[N&W'_T5*G6G#[]2/=6JP;F
MW?STNF-HFR;J80HT=@3^;D@,=Z(A]Q6&'>4__]7*;KK;H)64=#!.?4$#!"]G
M<[ZN5NH221V.;1_9/^CKJ7A^V8C7C4R?$YI?4U*4O&\P"9A%EQ9Q43:EK#A^
MK4<970K7YEWTEAX=1D>>X_TPS%I0="K3%OYRY=W.47#G6^]\HWL4^W>?L7G5
MC1O_ZR]MO9N:5*9+#,<PY=D?IS668C+%- OZ9S?3Q-YR,MOFM<RYP2_V$N(H
MXZ9<O+G YFZ@'BM]1&HI6]E?<.$.I66'BRA^T"22>QHI.Q(;VOS0Z_2PZW*[
MS)##K0K0(?Y.-M1]5ZA+U-*9A4N0E2CV+*T<3('6[NS.N]&B_P.1L]]1(#FM
M_S(*FCXP?5ZQ^I++V-XDUO^!J=HPX@EOCF'$US-BUS#B0S!B=*,9CFL.M3G4
MS^M0>^903T*-(K_2MAZ5P0(5V3U5IIWOMK&#<.W-^<@DFIO<+F5LTW]Y-[*_
MR4K>EBD_4C7$@\NJX:,7U>17:DQV=\@U^)Z4M).=/>2*D9?W04_JGH;5KO!R
M+[*9X[D%%J"D+ Y$P#S?#7+7YK8=;X5]OG\?-6\4,/>N[:,V"Z)H;T#]69^R
M[\]Z#)M^5@1DV/04V721!I$?%AY+' =8;I(*EB""#1>^P^,\<8K8/D0"T_=D
MTZX[\P+/L.G',7RT ]D8/G<[IU_&F1E&CDY9CE[OBWK2/.#A2.Q63KSG+8*3
MS$ER[KLL=N*4^6G(69+&+HNBS NCA-N!B+YC0OGM9*TS2Y(IB-J;>"O-433<
MWG![P^T?E=N'CO"3"%AUZ'$PGI+,9[&71BQ,_"@J',Y=YR &UP-Q>R]Q#;>?
MKO%UD*C3L#K$09B5 UECPXQFIX-O40^RKZA F:ZQ]A73WHW0?CI"VSURD5GD
M%7:.?$RQ_:3<H3=9PY<CP6.0W)$?L2 /(^872<QX!I:;G15)GA<)#YRM7FAW
MC6Q=AW0P_F)PY:$B7NXLB/:7#$_D%#\/F6^$A1$61E@\,V'A>2+,G#1EW,U1
M6(#$2'GD,#LN;! :(DOC;1S..\;7'EM8N-XL\@,C++Z_@0B?L!9T;]^]:_"<
M[EKSBJBU^YYX4*P_/!".YSO,\QS$7/$2%F>IQPHWRXO"!Z4J.DAWE7>$L?F;
M:,^J_$,/7/;= *0.B&GZ""!,)STNY&#Q#)+4TP6R'6PC0>41=ITL4N^@\ CX
MCEHTE$4I"("%7_!R3L7I("\8-HD_LHZWOML<XUQP['V2;[0H::V"E[4$S+-6
MU-/]WZL*?UH"@Y!XN9QP8=3\&@)F:4IX=UZ/,/M^[W!7K\,Z142::R?<SQ$^
M6[J\GM!?85$7--Q^)-\C;,]\7JYD>WCL_2+Q$@AF%892;XP/XN?8AN5/"878
M RHB1 EU3+\0$KUW7A9=)Y@5$&L]IQY>_1VRL=R>YCG7OW!WA49]T#ACN.#8
M6@6[ZZQJ:F$R['Y^C.LC,8LWVL,/R*:;6#-^;M,-J=K@(*PQ 4*<GDFT"0FZ
M.$25I$;R<%S+BS+'KBF#\52_=M@@ CO&M8?518B6=0740&@M0Z@+:J^SN[7
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M[GAAH79";FS05*6UT5M\YU0PO5=SUMF>JM*5<C['YB5\4D6*0%8T/!XO5%K
M(#A9P9$$#@C$L]I?[8[4*(<NJ-H)JRXW6;9T"J/BE*+[0JABO\MR/I=>$24R
M8*Y8.K]=/YN7.1D!6RNP?P&Z .:.]YXNN9NR+E/6]5UGX]BFKNOY52Z9NBY3
MUS71NB[O;G5=_JL>8VPK()HX<9RYD<T*Q\F9[R4IC.![+//M,!&N&Z5Q<(B
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MI1X]7;/G96M_0W$-AZ92_4]Q*Q'U<EO'DQ7X/?'U!?)P\:GL"RMU-MT>V.@
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M9:6YDY9A,D.F\YA5L@/.E?DV&M,7'I])KJ:LM9GZ07\[Q%A&S]S6;8,+-L
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MCZ=;3U@+1$?0:H%)AF0S8WK&6.E;@DY5+19B3K8SM04MT"RO+Z@E);EF*/)
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M%JR;,&E;ST).C5,)Y/:VN+V#X*S.#%YKS^35606^/77_XZ'(^&&3!WR[3Q[
M+=/N-0IK2- G4BZV*T)DZ(]_T]*WPX87*F]ZD.N]"5J]6%##;,2,5I49/57L
M&T*B-F(8;A34QSOF_%(!.:M89M<33[NV=&Q(@2>76,%1:C\GA6/Z%V\4R"+(
MTO_I:GX08NA2)7;7!&4*4K%LSK"H9@PZ2FZF?)5)GVE7>M*]V0:.:]_LGN(V
M"B*2FLS+/&UTT<IJE4E1D>%TNSC= ,NJ!Y*3:(H=?6N?22.;DA(X&SII^^^I
MSF 7-72PE\VJ:0D5^$BWD_YS?(@V!B/'L(2+E_%"++QK1S2(6K$J\*;G!?8/
M^OE#8%15./6VQQ0?0EO!\5+/DBQB5ZF9B@!WQX_\YQ)*&K[3M1?2&SOAK)K;
M%!Y<1^E[%-4L2Z,DBPIFQR$HJFX"*CH8YPSL\"R,@Z@([?@0BNH[3B_??!8U
M1<V,OGH;0?\1>/JOF,@&A&W1^AFM]3GP\C.JID-3%2L**NHOJD#D1GTR\+I.
M,4%E* -UH)6YC4@2,M,B7<OH5:FBD-TE*N8N]UWDC",P.?#"Q8H@U:B(5P:Y
M<!Q5DO;O50FVO<RQ7+74741G9?<L5D*D8=?0;9C3KB";0JKS%266- )8+FE;
M8Q_(Z WI:OCOZ!V'4[0HQ&"=PMNJZHA14P',2-WY]-%K#A.<=%P672FK.J-Z
MOW'"W"651K=773)<IGS5]RF0PFB@G Y42Q5/93(:*C$=D5A@A]HNA0*F*KXA
M/:"3I1;;<E^G::&6V:]PGUR#H6V]"$?6SR+CJT9L14\[2M3KODV-,U5;WA?;
MCRF',@1D(AW\S/0S9Y)H9\K/)G=W@WK[6RDZ#-)CNH+YH"(X2=V$.Z'#G#P5
MS(\BC_'"MUD81T'!X]@+DH.(X!,$G%_-Q:=B4QC_C)N#H"MR9[ZB-^X&HOE%
MLF]:JQ$=[^#$EWR4F\@;E?+;6#^2AEJM&ABA/]:*J2WRP1B82//3Z\D>@;M1
MP7>-CEU'<?>(COT_EOKGOR@%<B-HCI.54?%Q<@:^$E[.YGP-PD)>(I_GV/:1
M_8.^GAKF+1OQ6O>8TTM#7=[E?:_Z2< LNK@]9L]*+]=K/<KH4K@V[Q:0'ATY
M1[;G_S ,JZLWEW'UOUQYMW,4N7>^]\XWVD=1^ B/?;;O^E]_:>O=]*22,6(X
M2RG/_L#4ND7.% LJZ)_=+.@22%DFA+R6:2'XQ5Y2'"6%E(LWJ/]@8J$Z_I(E
M;&4HP84[>,0.VS%^T#R'_8SHKK'W-C_T.CWLNMR./1]N58 .\??_\RI\=>\5
MZG*)=/8;"F8L.;.TJ)T"K=W9R+_1HO\#FR*\0]3M_TKKO_SU%Y%)U&W/F3TP
M?5ZQ^I++V-XDUO^!J=HPX@EOCF'$US-BUS#B0S!BUW9]PW'-H3:'^GD=:L\<
MZDFH4>28VM:C,EB@(OL.>A1\?7,^\J!>M)N2_,T"E>C9Q@XYKQ^%X3Z2NW&:
M''?G&7S(12/GY%.4WF:ES+$[V+%[IDMDEN50.H;VU=Q+G1A&W>@Y.U_V]DK'
M,()%XPX?9'^OR-YA=1(5G[T;@=]D75\2U=]TK1;5[5;J>OOPT77CFR_B?SP&
MK=W*PGY$/>>@A_O'^R1(W.@)*F?G?:U*T%2!5Q8$3A('S,Z]@OEQ[K D]#SF
M^%%L^YR[H>,=(FD'F)>L\L#TSU?6:E'*T7[_Y^\GOX"R H0!5\.C<I&5YWS>
M_)]7##YAZVCXZY4E(:?^SZOR6_MZL3IG>=4R=>FKOR;>S/<"G6:LW_"ODSK\
MG=?B"1W_GXRH,:+&B!HC:@XB:D('Q$/N"Y;YM@-BP[%9G.8Y\]PX$2)*@B3?
M[KZ7 M/,0![Q(,V9GW&7Q;D;L#!,0]\)D\S.LN\J:D)W%L:V$37?4=3<UP=^
M+_OT0.;H4[8W+=ZV=9FN9(:H[.#650N<57,@0V.3/B%%P3URD5GDU0KWTZ@*
MAUM#HRP<3%F(0]>.>!:S('$34!;BD/&BX"SQ@]@63I9Q^R"M>D?*PK&&\_U:
MO24>=S)@<50P\4(LUPWR?F8*A1%)1B09D61$TBU%4N 'OLM3EWDBQOK&-&'<
M#1.6QBD((SOU8KY=WWA?^_7[BZ2)6KC/6R3=-P9K\KSN=M)_$8N* -!-IM<$
M4DZF(:R>0A:*62ES[$RFEZ&<[YM-;C*]OH]6\O=-@*,1.(U"=D\W 3R,P\,X
M/&Z]FM]_X8R?XUY>B"2QHRPJ/);:0C#?"3/&?>&Q+,U"'@A/A*Y_",>XYD''
MD@5])(BU3P7A+#6?>H2P;1^$Y%)#YX-]C<MA]YNFB<_=Q"Y8GO*<^8$#_-#E
M+N-!D7 _R>WH,'W2][RI I':>N%[OFL8S!S'F\5!LL/%8GPN3YE/&6%HA*$1
MAM]3&/+4S]PB"$$$9C$(P[Q@<6['S/9]+Q"1F\=!< B7_.,+0]O- AY[">,A
MS^!-TX3%22*86^1>G(>IEWL/^:8/) S]9!;;_LR-/2,,'X5//6KME\FM&V)M
MWB#+SEC^1MEY]"BF275X_JD.2>'F7AH%+/#B%+0-VV%IEG@L*PK!XR!-A)\^
M1#>%'0D-\"?H'=A)I_E4'!/>-/\% 6'KAF[ITAWLH>+AWC3;8??[%UX4YF["
M69(DH%?:A<=B)Q2LL/T8U*V(.S9_B/=7:M9W70'GR#?:E\E(-&+:B&DCII^6
MF'8S/[(+WV61'PCF)UZ"[H^4>2+B@4B3(O8/4E$W53'MY7Z<17[&HK" =XG"
M&-XJREGBQ$7B9K8 8?T0[_\X8MH-C9B>4I8F?$);_:][VIN][,82!^[NYKBA
M[00V<U)L0YSG(4M21S X_]R/'"_*G0.WECD>=!HZZ3H1O?N&+8I$_KZNSM]2
MER?JU;3=B>;076<>Q9/U$!W#9/^8$MM&R88C0O:Z;65SPVMZ;<GVBWV'):'V
MPRI@0V1W1-6M1C79OJ*W3:J[1U6J\Q0UDCH?-YOJ.C^9!C;3Y#//J8%-&!XE
MN&MW;>KBA-^_J8MWY 5WG[)Y5]/ YFYLR$"L3\LA8QK8F 8VS^JL&T8\X<TQ
MC/B[% 891FP:V)A#;0[U<SS4IH'---0H ][W( %#@@FQ*FIV;]#Y)IUX\*03
MB!^.@)YAGL">.K?<RQP[Y(S'0<)\MR@83U*'<5L$H1MY;B&V@EMN8L<\C&(6
M%K;-?,\+6,)SE\6N'XM(>&EHIYO!K7N&M([/@3^WUR3\?_CX_KKZMYGG^+,@
M="80NS8G;RK+8ECW<R*@%\.ZDRSS8A\X<. Z ?,3/V-ID00LME/A">[S+-LJ
MQN9YZ@O@ZBRWX4H_*Q*6VH[/$B>)@M06#A?>-%EW,(OL9)9, ASN29\\4W7U
M.$;1%]&T=9EA0@B55=&!,-:1$;%&Q$Y6Q :.R".WB$&F)AGS<R]DB1='#$PC
M#L9/EN7;*"")X[JN[=HL]!(/1"RF_G$W9H'@()CSN""Q/$41Z\X<WYO%MFM$
M[%1/GF'=$UZIIT! +X9U<R=S@B#T65$X*?.%XS$>@^&3Y1ZW(^X&29%MLNY0
MA$7A^S$6943,]SV?I=Q)6!QQWPF%'^7!5M;V-%BW8P<SVX\-XS8!HZ=H&\F
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M/,9<0%Y9%+Q@W'A!A%TIY(&9TB8:CY(."G%/&-),1:2]-II&FXA@NR[D0<B
M2/7P2A[[9V6/#3S[:EP%M0MJ[RMJ)TLC9=0@&GU G.922HP!("LE?114NAA7
MRB]Y'V5T"BFB/-RC.3+)@#OL+8>/B).!%M0NJ-UOXRJH75"[_ZA]WR)&^Z=G
M!;<*;A7<*KBU;WK6C[U=9>YYDW//K\?-Z3B7,X&0PTVJ-OII4T_J6*:@^TDO
M-Y\_W6-@V![OW.G8[E-AIFOF08222KJ(4H@)<2,MLI@%9(B2%&,?'"$K\R#:
M:4U40E(JC3A6!%G*.7(Z&)R2#E2:7<^#Z('1>.?3(+<YUUPLM+>>8>&$YZ-Q
MA1,N:@S&Z$0T$7'/*.+6*F28,,@[:3V5Q(00KG*"T(0%$2(2C.954!R133HB
M8YAGQ 7.1'ID3DCUMQC0OV,S7@K+"B'LIWGVP_@*(3P?C2N$<$X(43EM@P:'
M7Q&/. -<=S1Z\+:)\RD1QH._2@C,)QL9I4AIPB%(D X9'C22GBJK)"/$ZA(D
M%$XHG% X86\T[EERPHZ6-)XX+.YLRWW7OWD]^.XM&YJGG\NQ*ZW>/7?Y1?,A
MV+-EDJ/QQ XKOX&#\ ^#G;(<<A_(H <T8T883W.MC!WRVAZMR-]&@D^0XJX)
M>ZQ(UC&(<PR1B"NCD),A(NX,YHQ%0HR^&O8X*1TU+*#H(4KB3#EDDPV(8BYE
MC%IS@W<=]E \('SW>T2_JVM/@>(+(11"*(3PA A!!Q]Y!!JP,2^6>TZ02T&A
MQ$.,AEFAL%DYZB5B% 9H@&%L$4\D("-P0%A9SJFFB9JX:T+HR:&!0@B%$ HA
M%$+8'T+P FM' T5422 $C3&R$KQ]SQ@FX.\G8(25A1&2A+9*(@74@+C@$AGB
M#%(JP%.(\Y[Z71-"'Q=&"A\4/BA\4/B@'WS0BT61)PB))=/OXR]S?#H>-Q,$
M9GE2U:,OL9V<9.]B$P5P^B.PDIIMCW8V%#D5.14;++I5Y+2'<BHV6'2KR*G8
MX+[)K,BIOWL6]RN5P*.D:OCS4S4!,;;3YJQR]7!84C3T<X9YC^?BGOK)C4=8
M(#0R)F=50%%X@[AR#FF')2(Z*FF$5]*GJPN$$1NO2.!(,$T1%UHC:VA"C'/+
MB,)647EU@;";PCN*S<F[BPF\#:T%*CDP1.]\,;#846_MJ.!RT:<]PV7.L'8R
M6.2PBHA;PY"A0J/ -6>::Q/X2OI?&1DU/CG$!/<Y-X)##JY$P@B-HU..);<]
M7.YC-H-B0[VUH8+)19_V#),)U3P0ZI%1P2'NA$&&>(:8)$;;2%G2*UD&M N)
M2TP092SD>^!NGP+"1D4BHZ62KVRF*[YRL:."RT6?GH0^/85-;7NL7B5Y<7]F
MQ"^2%_\R'H6VLJ-0_7GPZ:#Z^Q@$,\H\7QU^CB-_5GTJB8W[S3@E/TW)3_/
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MR>+P1#X[\8MMZTW5YE!RH#79>6V./4XQ7V"ZP'2!Z5W#M!2!>(H]$H[F,DD
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M]F$>/&)KO<&(8 [>E.0:::$LTDQ$0;G$7J_N\MJ<!Y:A]-U<-?/O&YKZ)OC
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M32B%D #"74 Z&HXP$2$YS6ADJP?!&$M<)(8HI19Q3RFR%NYVA%,O*"4:LYW
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M4'$EH8151BFA/+(XP#V.$^2\%2CRZ".3DCB\DDGVNX4T-[5P(P9$]")=>3'
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M>'*NPBN%5PJO%%ZY1;9\IXT.+"(>,D=$:I%5W"&M.#8I*6JLVVC<N3U>D6I
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M6T7BJH8 #$'^L.T%G#]IWL^T61/VTR=86;":CJKC1K5ZKN>H.6XS!UD#4A^
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MV?7R]'322FP>)PUM]$K$W2M=?+:+1@J[,YX]P]W)]??S:WQ87^.G7^Y_CW'
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M%:;MM=PO&U7;;!AO5*'DJ7#9AIS"C[6Y<EC@<*G\C^^4IG3%*W8]W*,ZM>,
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M0$;Y_QZ<2+HLJ&$(I:#Q3?:]KB^@?RNP7#8B"D@5D"K*\_#8M#MB54XQF6Q
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MF1D(/HU%UH+O*(66T@H= S=W!LM#V,@IK3P%R@N4/S[E&>*NC4R>,>,C$LW
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M4DIK&EP@UK+#4EQ-AJ^XG;HU.W;K+64S^B$-SO"<DV9V\4C563A/C4P1">\
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MHB&/-O!Y(A+C$8DHHG242(U[O*A*>R>=\;E]#V+EF""^EB)/]F)10T3*91B
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M2/SP>@EZ8AWT2'E%4)N.+@]G#X'Q,[A_C#N(E'=7$KL346VNP&4D1KD1ELI
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M/QQE'QI0O>![> C\ NNASS#VAY=\/$$Q-W&C05FJORV5&HQT+A-I+EW4S<W
M&&O].?8_S>9G80J/1==97'UXT@$4MY2Z#!(C#X8J 59G;HFLC"7!@;XO*\K,
M=K]&7@5=<BU(P4JXQP!82VXEH2X42FC0,3S?T']^ZY:F5]A_[1=M3X4">3$:
MN.FX7HQ2K[ED@25[ NH]JP= +Y4L*:@%0"_*&\)ESHAQ7H,"+*E3P8'.L!4#
M$#R7NBP\L1*%NZD\:-L.C$DOJB M=Z5T&_3295+]7(]].X,A]G33=H2#FO)O
M9V 5VI,:  V_ 4UZX9%^W6%<1V>?L)2OF9X?3]">7.)=%$_[HCY6'@KY ;B'
MN+ +B&JSV( )B*_W6>K5DL94D*6;WZU6%>M=%NNZ)4DZP7^ZV+AVE.%.[;@$
MN0$?!#\3<TZZGW X=;N)L M//[RYGHV[;@D+IADW7_K^I<0!2\VR:7.NQ[/:
M+R8&CYSX6=;"OD9D7Q-ST3_<@;M#Z)_6,*$:1[R _L6;L;RGF;3UPAC&.^VX
MGJ"]N[XPERS&]5Y[M"P6W9CXU,] _F8:?T3M+49NUAZ'7S3H4\H^^0:L]+.3
M.(7C-H9[KB',-B8+%-]T#JZ5SSN^%M_:F#B4RR>\&.$W9KE(7+WH<H\S*B@F
M#F&X*;.8YQ3]YDEU7-:&]#NE)Y-F/K&+["I8[?=VUD1]$2ML,4Y@%CE9JUXB
M<9OB73J&Y:;^!'8'F:B=@;H.[&>!V#[7,+ ^V&#F;0T<W':!N\7;NW2O.3!9
M7[\+ [3C^3+9J_6 -3%B$4"O;?VLJX+^4G>):Z[Y AQQYCL+H8WN(R0(@^WB
MOX!F'+F[TTE/.Q=(YY$Z :O%]U7-*Q:=>M N9XMW:\R/QAPYS&+.\)N>__ -
M.(+N]0C1G^M9W44<<? XLC ?!^"!!?3!HDRZBJ4,\WMCL-( 3?3C[EQA,;[Z
MM6YG^ "]8*INQL",;@[#L+"$2R"P\^D4KH!EBX-8PY'9%,;<K@*;N$=C/UOE
MW8%]@$] +_)J_BM: #+H(TM($[.XL&$^C= PQ1CNHE ;R7*QQ5^:Z>^ :#9J
M(IMEV25=]:3I[ C,9V^[_8''^3ZWKTL;7+RI^=SKTK:93UN_/>!V%DOK<8 X
M430N.H"#.T NX<$,9S%'=_GNB8\K.(VD4>.B]-"3Q:*Q\?GZSL(/[?P,=[[;
MFP"SZS S$A-.'4>W#/_A1=-%Z\ EQ?=&623>%8%TTUJW;^.RK,'9*'L]]SW$
M8=QOA92]3.NE[Z5QQZV'+Y:M1HJS?MJM5;O\?.%$:;OM7"P$D-$)B&"@7/][
M)$UX7PULBS(AKJ.V_YH#-"R>LQQ"C^ K1^^EDB,&--_!?I_VR,.S+W[3-M79
MI/G<34:O3-*3&K-.D4_KV1QI8?&*5Z"3P*ZBA%U\]+?_-\I^A-]C^F@]Z?2P
M&/\',L#0*DPPZXLX?JW;W[,?=8=VB_*O!U+#XI-?8$U ;6]2\Q+69AIK/F(D
M&'D>".?+4;?MNK<4 N[NI3L9*?G:N[?S9;.81HG\/^VJ0 !W3S-@Y"5C',6,
MXTD4]C"-1?8^*$@@$-JNM=42VI&) %%B:70[)'VXK_))*:'#U'/6*Y+T1(_/
M_]W#VR8^ZI6W.0(\XC5 ]Y<3'R41_'$>PZR(H[U&VEH@3Z32XP^O,DGE@Z5,
MW!(?-KSKV9I[?5#LM"RCZU=U441WU&-])T']JI8 )=)BFV(-PL96UI//S1BF
M^\^F1DVLPQ.484NM#5-M4!1TNE%,:_-]<QS<<*#ODX5ZM9'SML@N6SVH/[2H
M:3NS$O/+P-RU&.N<@CCI+IAZC"_C\&-F#@YJTBL#2\L'IH%:2K29XXS65$R0
M7[@R@@K4I.NVI]0H#>OUR?2I=\U\UMM/8:DJK*W0RK*U)_C9<EY+,[4>=[/#
M]#G0L18+M)C^ZE&=</T&6WV#=[KU1BI E>04#0*0R9GOU+,+-GQG22YK2=J>
M,A87+V9Y<22H0OG3;F_,-SFY-YZQ9=*2#J+2,/5AW+7FZ+()/\,6-E-BYRU@
M8%2-QYVX.JG/%A8XW .W#HK%+L9!M[J+II8BJ:7(G7/VJM12Y.DUS4@M15)+
MD?MK*7)9>Y!KIG/<*@ND&'86R+XWX#*U)RJ4J,"MJU'?LI$6BI&VMIG'QM/H
M:SF;3S'C++KXEW81S#JZ \^F6$R,\9;FTZ3SAIZ"XMZX"[7!T6%V=C;&4)%%
M);2=13?G4?;)3T"#1V^"Z<RYYM/YXE4X@V3W[K1[HXD0;0(T&-:T?_3_P?Y-
M7<SLC$["?BG[:,R&-[[3JKL34;)NUZ?1=;0,_$0GD\X6"O$H.YZMC!MXQ=(?
MOFDZ;.KW->Y4%RB,;DX@PN8+&FT+9Q(Z@DZQ;>"+[/O\AT5HZ%HI*4?9]\4/
M\*#)/."Q+M,+MF"4_9V)L!&70S?P^'PM^ ;/83]$G^2$^*^P2#'XL3:2U2M6
MZ3 XJI7;/[X$XP+!3R^,:.;MR:2)Q-WSJM5M;W/T0PFZ'L.SNT#?]_R'G3[@
MWAK4DU5QU$; [=*)?QHW!J;]2ZPX81?B"IMM7M;X=DDD-]L1O&,?.[((>3[V
MGF <"5O>3&(,">[%<KGUG5B]SGBKY^VJ<@TCY'%U7#;1Z][]Q7 WQP1\8'LW
MU=0OFHWT\[48S9FAI=MZ8-*XB+%#R4V6>VN5EXN\#.3N6E0 @6:"8:EEVG<=
M^EJ%B ^;Z]7)G;[("=TG[9I0VH2&#6+#QWW!/V9?@,YBW QP:?=*]U!Q<^)\
M4H2Y\*W!<IJXB+^L+=;[Y<M6/K<(+L5#@LMRC&N9-]AC:O&L;X]X@ K #:3[
M=[O3KW-IA<'J:..H(+PTAJB8*&5#)97SPK&MFL_;I%^_]D!<4^_Z'F*O?6NG
M=2S2&HA.\]MU0E%U'\J-YZ!@:!95SIB0B>S3)Y]U]<*]PGH#R.GEVV'F9FI.
M!<VY)E1H17B1<R*MT:2DBGI;4A'$5F^S8'A9^LH2EE.L9V&!*%?!W5+EVBGG
M<BF_G9NY4/7?3KHTO*[.K_W8?/"SV;C/MUMQ\K/,XNP<[O6I >M)=Z7N[5)/
MOERR1..H"WSW21W8I6]VOO* @^WD^A!J[_:N%QI]+RNVN4(O/>C8(\KOUM<[
MEWLLUP+MW*[#.TKC2X0P/KM3YT$>'P+'@*PH0Y$30W- 46XD,=H ]1O)O&>E
MYGZKC\I-#AZ.'+,0QFN2;>_L($?#+LU:<L,JH^];"LI>^O _1(<382B(;@1;
M@-#8AS_6N>:6"1,*QU2Q53AU8_I94Y16>M)]$A,;#;Q^]0(QW4B3C)E(/WHS
MC;6LV_4RRQ*- R _&I@S6EIB1<!SF')))/H_16E%60)-YJRZ2'ZY 34@B))0
MJ@HLS<9B#"^)"J4/\ 154#=$@7\P:?,Q._Y"9OPJ/WJ'(;5*?U\WI%R#GH68
MR=+=>0:KN<BBWBW8H[1V&%;M<AT.@(*ME=3G!=@ZAC'"M?;P4_"$,BNTIZ4-
M=,OT":8L@+HE"25#45T"Z#J1DZIT%>/!4:G+BZ9/;_+\.&U.%T<^_V\].WG5
M^S'??.W3-H][3^I'_?6YT>WST/ARGGONO"<>S!N0OHP25;""E&#^!!]R1;?K
MD6X,F0^A\;&!=ZI]HAJ?J2PMA0.1:RG03] 5*&[PDQ8L** D;ME6_P<=M"A5
M*4DI@71X03G14@)^4>]$P51.K7Y<C2\_,&*ZH<;W,9K?B[S]LP:?BJ[(I>1=
M5;@M74#+8-7N LSHEXZ^7K?N=[_,VDZ=MZ[=>:L30&M[HT\Q$MEV2Q[FXZZ*
M".N0NGST18)C##!,&S#@,:4Q.DG6U+!5&?E61MR=,.>[/P_/)3V(F/1D5:NQ
M:%?P[?8#ES4S:*)"\N4("0%+Q?J$;1A-NRI(G,7JEE@-B"HSEO=<$G^(R0=1
M2\X6)3)]H<UZ'2I.)0Z[BW5@I>/4Q]J)MDL97B82-]G$?VIF,?-A&9!95;
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MS3AK+#RU790@PP;-@+06;7EA/#'0#(_3G9!:<O,_Y^Y3'XA>JT4_];KMLWF
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M66IMDF'/68:EK,'A>"BODS7(DC)R@,K(4-;O(%2-YZ)(7'+^E@Q*6F.)9KP
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MU1JCE;#&?;[#HQBXFJ,)TWL:VYF>S6.H-'@,?8[7;XJ&S:S9-):F/HQAA[M
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M3C>0?;YJQG>+WW19E#&!;$=1<$3W324#)X27$U =FGE_2?>VG-(1_>/B>@"
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M<.+M,"&Z9)R0H?_XX>./'[Y#7I8EP=,^P]=QLKW$*V\?9G_];A_]<^^%P2K
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MQ[<S,U$ 7HV?=_P[W$2UY02-"M/3^I7?[IZ)SY%L!9+VDNS[91#NR5/P!6<
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M$V\-K&FCBG]DG$-#23W(H(,D4QP50PR]CWVEGHL<.%X6FI)_>UE<4RNB8VH
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M(M4(P;DG[V]Q"&87<.B!9+F(%/=?$D 5+S6NOD7\GFPX&_'9M2EFK<V-FS[
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MG<>=:69)3<K'H"R2.CKN?,!X"Y4FDP,3 ^$3P"SH^1[[F.T2VS19]EGG'1Y
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MFLS:/?J[N[QDH"]]+Y3PJQQCI2*>I&WFA[%49P#7RHMAI)K$+W:7/,:TPO$
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ME7:.([P*Z@W9PZG-X!A>P/P =<K42<P)SB=JI+HC7:-%:GK. CU;A(T3D:$
M?LE4:(J0M,3T-_I$FR'$3 >H5Q*ABF]*Z16J#5?O2<+]%7D3[8B*=(N?<?AC
MH[C1U&,F$8&Z"KWTCTU5@GN3<7Z;\#*=[7D%#1W<R;NE"K&M 3O:]C-P] @E
M:9&P,+@,4U/Q+F99@/TC!#I1G(MFWQRHKFEL'.P2+!_MV#BU[2P:?M+<6%.!
MZ>EK]VFD5<<3T$6OVY#\%*W_^AV.3K\^?%=@,\%IO$_TECB)*R'<K/\(GR2@
M8A*'F)TN<KA>7EY^H <,SM;']^]_? =_?D<)?O?ODA#Z%4@A2NO_^[=W^:#S
MG'X&'^RM"QYJ+XSS&*R<J[Q>.,45)P^7O!T'[D]A) 1#(3H6BE=(CH;D<.A7
M&!#1$2??1<C$_N)M>?;Q0 :!" (JZ%=&9^;35@^>G/O44[Y*DIB\/PGL-Z^R
M1W2L.&%WD))7"FY1_C&<'Y1_\(:1?[:%-P!"]P?N%YT*RN=R@AX)!^A7(#GY
MUE64,/$+ID8/9$D0080L8G1/D/PE(WUDG*FG5'*2,*ES\LL]C^BNK7Q6-@L,
MOB(+;\!^N_62 UR+@CY2W$V(_ ?Q5QJ$'_IOWA!Q!]_A=[,PXFWGX\&BJ"/^
M=\3&1##H2;Y>Y+MF Y-7A"Z2A;<DCX8[\WW2!OP>F1?^WV '-8R'WE&4(.(4
M3Q"CB0A1!%2/@Q?U=#MBJ$GPS2.[F'U(\7@RXU!1#*:Q.05$@S'K(0C!R5[2
M@5$*(]//>I?@TQ4='+WPT4]0A#-H'(B.2YC""6)<?!/K)P5^6"<V'\0FA-B,
M^&(@N;B+%6*S8K<'(O-"9&*(S2R_-\C<H*WL1Z?W3:RISR/462@67]N K:W/
MUG;'UC9E:QN8.;@_?!.K2Y2:I_C8OGF]>BCM1XOD8?^T%/]2C4EQ,KWB**<!
M[[TZ$:3,!*W(']UHE0P!0J)[,<O0P$5@M) DAGYEY(Z#"?7%XYRL]DE$@UOI
MJ5\%KS30=6INC%5U&KB-,#ZB$SA!<A"Z NHP7&JU(*J"3I;L8@8G1ZU/%Z!5
M)X?Q,FN!-+FK@#BB"C<=P)+\:I3!&D'6)9<RC 4BR/?+C+YP%^1-6..A,E6!
M%.*TCF'^64S4B-L&)D[0(S0Y"EZ48U;D!2Z*&(+.4,("F='R>+:H* 05&6-L
M3,V%B$"4?EF>]37T:V'T0#*3%)$@>32\J*<M9RB6#*6,[J1R^N?8IS@1+%>"
M.L1E-;B1FHQ*&ABCQ)&D?C1L\2/W>V%'/75EGF@N&/*FYLE4+H!BC&W*!1AJ
MY8"A3^G82)T?4B:(G@Y(;<<GB>@L3Q"?YXEJ-CY!8JZ(3U;\%2,ZW6]TU=5S
MV;)")T4S?(8N\9)J1^C'#R<(?/C3.Y_+QG<(QR$,,(CQ'5%KQMC62D9VT%@H
M=6Y$H_2/D,6B>,4X8O:7%,@)0PO9=RIN*:X7U5ACY?M0\XS&W!_DVU<HS7[J
MS-)X191SQL.Y%X+9:VJ#E^'Y$UTPR=QPH.#=R1__%I!++%EN#C3$<H3?/+=A
M($F3F3#._F[)>\[>@)O(QZ\ 7,1J+O'[ 9SX([ACI!&GC;*8>1B2_Y[*:]!B
MF, 4C!:,<=VXG=).PVN=0O#)P"WC%":-7Z$"\")9>Q%/Z3Z+? [W?T>Z"'UC
MD&VPI+&HH]#OZ@G&@6=IIXPTK>-D(D[%-Z9R"+XX2A\\;^H(4UM!IV2T\(W-
M@MNF>/N/HUP3JDV;$3U!E"SZ:,U+,5B;N!T;=3I6/;,;K6I]F0J134 :M:S5
M.5\KY'JMSA+L0>E>+[RBP8>B:L_01XJ0@SL<"")&$0F2Q\**NIF"G]W$/+25
MZQBX'3E%8"*AOF'RPQX,3T#V6-@IR0YM;$TK-1CDJQ C567J-%Z=2J:FC= Q
MR%0I#*3 UOWBZ[0G3UP&C]XKK_"@X(*/#GZ'@&-&%JET3^P&Q!OF33V$C0Q.
MS5<=ENWHH%I&]$3Q73&Z5F-DS'*F;A@C-?7\&S#J<TR8T1%0^2!4(2P,@_)Q
MK.[<M)RK.YF/5.7>7J1[P6$-6+<*E-@89;@4K4#(65%\+T%#BVE,5PX+IM2O
MS8'YABF')<%$&0YY<CR(*14#HEB..*V4,C7G?%]5CO-QD#(0RD>:7%&VPGDQ
M5Z<'^Y;S5<X/%/1CS%=+Z9P@2D=FI=BRX1ADIZ"?BRR;A>"'*..,0QLW$M%*
M?7(/JH>4@@SO5YX(/,JK10W-T61CH,)U1-Z4K3H,"Z^V\TE.RG3I#A;,^^W,
M3WL#3\IT(:U5L]V%L2QD>5"@.!9R7$(='>LKH,& 3 M&.TIZ8L> ,4Z$+X!R
MP"BB7QE-&^EZAKDI&/P5EJ8W[96+:'KU=3-'79N%NIT%<RU\3>J_&>_9QHM0
ML9,M$\#$"U+42\:NRN1!HG&T]-(- YIF:HL$ Z96=($#/#0 EM%'<@#*N1R"
M6>K1KV*4R3=_,GZ+"=J['8,O]T+DY\HWD0*C.#JE"[*22P +$N3+(R7AOTR.
MM+#=A?$!LT"I45^_H"2$7$L^/0,,%!(V!!<LUFM'1MY G.F.S,]J"EU-D0TH
M5KM.P)PP0;)</AZ2 Z)\1"M&(U;637P48[)^\\ME.;G8-F[")5&M-/%IQ;1Q
M,U<_&TOKK8_W!&@'<Z94CA=ATU Z&4M%34=@HS 3:9[L/A5[4.S\,<C "G$3
M^>15\_?>F+!"2HO.7B#531QC9XR!@IN(<D%$@9SDY(;X.@#;$1LA;5H"54:@
MJ5B*>2RCR1>QYC\E<9H6 >8'&VB?,I03/D%RX--5G)S"T"<H'PG!4,?+^\^,
M]PBOX='GIU7ACMQ%9-,CY!46(25S0*F<P*1O%E68<Z<XRS*\Y8%'0Z-N@"92
M/.V,JA)(-*W(8Y2GDD#!> MRWE@2Y62"A7S//&EY!M_W8J5HU:-B"("P8DNW
M9# PSTY!651YLI*E2TN)01D@\,J2_X#(\4QF$0%L>=UOQUF&0-NE(@?\H%"U
MMG\VF2Y8?W2<3XMH(UT_HJ(8X_LZC%\^XVP3^W$8KP_W8'I:K,@5L=^R?+EB
M49*Q.&R+%<K'9RL ,T#;? J(S@%:*K.PB,?F<KG*:$H*?)V?+QNS%)67C5H-
MH:67SV9BE"0WBU3K>B1\*_E%9Y$7'GCRP[T(9OP*"<_,7_ 5JI+6GT1EXM.C
MC%R0O4Z\D*;1_ <>&B+,(44X,9:4@PBYV<^_!A?%&A/"H5A3Z(&^N44)6JE5
M_34*#(+1B1D@F$(!>(Y),R5E(X><@X00.A4'X',.EZWJFF;+MX+E4['E>*"%
M#^N7*LJ: $>C3_ >)N4$8<[A$A:CB2=<P<D1@Z4IC*Q<6X9*JDM1,?X.J6(+
M%-)$041$%@\RWY<;TC%%GV,?3V[><;PZPEA2\'-UR7I*6]*>K F"U:BILI4E
M_TIO1Z:#=; I64EB*MQ-C_$Y7BR7 &T'UQ2KQER+?FGJ%L]B]$0."AN3W4@K
M.JH6-O3$SC4]W5*4Y8#'&)V3]Y\O 94*V&A:5-HC7X!2W-70@S#U+<#?X?'Z
M/Y/KQ",ZZVGSLRGL^;-/RN40/^1V7F&*$9K>1 RY=P8@2LJL0")@\_H]+V6M
MYT# RLA*B!8@(A:[((*$_)&BC("+X.2L^H(;"OE=>+L@\\*1$5EB /2]&.(/
M<$KS'"\^C,6@K.EX+IAC:<%>^DGR<%A0:\(<W7?R@"M91O,1+S=1\,\]KC.G
MC;B_Y0!(CG!2;_RR=<-/QW(AE:2.13GBI&+3/<[(34H8'&,;DD0LF'3&3;@D
MS^<3MV!)&3?S(JA;8=HV$B&YS)P7%L!#1155(Q!P82>\RL61<%+.W93U#932
M$=,SH\3VCP&35H/Y+6%(CYAY6)WTC&=;39J8%L^A:@F2,<8X>0Z66"-FA[14
M)T6]O<?+>!U!Q R3HD>G_]:J'+E<#R"CM)PZ#^QC A.,?X)8!3S[28<.%TV7
MKIB'J+,Y(3W6D)P7],MG)DH'7;#</SMK6A6-[Q*\\P)?5+KCFW\6^>,O!8UJ
MP$<4YXP>,YOWQ\1K4*N]"IXQ(YTJP/I+5DS8TDUTOD^#"*>I4C];@T(W4ND5
M R%E),KUN0 7+('1V=.)IU\#'1H?(!HKX LGZ%/,\D&C)4X:EL?")Q%OL2P&
M/-XD0*@AI;;PY*I_I7X@'7R1W"7Q<Q -QD*_*A4/E-56!-UCX:>I(J(UIMHK
MI.7%P!7-0#BR1U7MJZLL=\+U@Y,<9[U<(&UJ:[OE)>E<=*_'TC@LJ&=T;0J?
M2!O3MG"UV54*<??@/&- 1'NR"MR@&4?I.5[%"6;M'KU76!1RU<:)'T1><J!.
M7TA2)3T)ER&DI4:$4_(*C8O^@-BAO&0+Q/)_4XM1?.F^ASG]@7D;\VFA?%[H
MB4Z,%\1&=&HGJ#@5).;R#2UC 3X-\D'X.@5LG3+O54C,W]*B*,8@MXM2F^@U
MQO;0D.EE >^GEAVB[ 5LAQ5U8"Q[+SE[%#WT!':,#X/\?)PC9;<D1O1F>_*,
M(6[7 B_T(X[(E&ZV.R+<XM'UR@1A6N0UHZ0A(4K2/BK&PAJ>&%5T8X$G!G8;
M^?LEEM$#=X3(>/]=3I3'_MU-"+E@EHVP@0,[ &'&6"DC1><L>90EP,&8_":X
M2I(XN8B3!-/\.FK0,P#M 5113O9XN CK&3CA%E@K)XQH5\L]H!%=;+Q@)!^"
M%**TCF?^I8^CQ,>T.K6)^9>T977RLPU-$Q5,SWR?PCUX(5/BS_;9)D[ )^,N
MVB\OA)K/CML84#Z_;VAIB^\Y=R0%D5@3B1I I98UB)V3YT44TFO*(?U%E 2!
M*#)&]QL"%R&A3"Q%#MA8D]# <OP>UJ$(=ES*K=J7@#5VEAB_#2(PO](Z!=?>
M$D(?#XJ.Z67XPSA,_2QCU^*2E4)0%4I"_ C9X\<9* -?O,2#($[#+P2'EQ-R
MR)(T,/D#$4+6N0F=A6'Q"Y=<W_&6S&7IA>'A)KKREIO_Q-YH6& YJFI?YZ%:
MXJKWU*'AXL=D<'0@HT^<N&-G283NG2^%DIS#ED*^>H4AR:\1#(I@U-_#2A3,
M*^-.QO2U0\CX$*\STD%.Z9SPT@O6PN)'S[Y2[(1R,'F8.SUU3^U"Z5-[X>Z;
M*$N"* V6%.UAZ-4]685T.3V&1O'M+&RASMMZG=#8J?)RN"]_?J^OR$(N18CC
MHC\;J<L"L4"</OW,X'2P(>@_CY358M1\F5\6$)=PKAFZF$W U7%528NXI79,
M42;F/Q_8V/&FJ'SRTV>^4'#$>C@.<QGN=!"H>:G!VE"C4Z;=JFG8Y1\/8U./
M:7-A(6%[0B[5(]IG1R=E]7,0DALXCO#9<A-@[NP;_PE*LDBE>RR<A$U,V+G3
M#7)3NDQRKCR%]+37AD%NBA%HDO#D8O+^*<7_W)-Y7SV3_[D=6\!;DD.4GM4:
MTR#H)WA#9/W@F<<RL3HT9FKK%,CS:+<3Q&OL6*RU,S6[I81#A6<;F,U77A(1
M$0<*Z0EO3+ <XVD0!"$EB6FM)S0/86G)BV"$(7X$(3"56< )+]1T1%1%HD<^
M[3.J-V9QX87E,/FG3S#D4?"IGKT:9H^(DVI$\5PW3L(.0#+?"TAJ(E?LT7NE
M^6$,#>(F8BF2H_$6Y#@G2(P$4<,L0^XD-PWGF74B._/8ET+G]WV6:^.)@:<W
MF%9+13/3UV-\]9KA:&B\@*80MC +PE%G]-VB_Y\MB?2XI\:84B& 3UX0L7AH
MLNE3^G.5*2"F."D>7IC%B8B.)A/Y7:Z6^CV4>'=<'&(BAJNO@J<< L7/O;:Q
M!/(3Y4G!8PO8Y9^\(&C1 V2,F4)^J^1()#=/YA&"K,A+KM*>1='>"^_Q+DZ&
M[H4@A1@MQ(C-??*%,!"K'!03\N %9D^\>DTP?$>X+$:G:U*#F,<@)XKA7AS1
M$6K%'">OVCS,3CQ;RK@TS73!R>=R6W_QPFSC;:G,-=[>R:DQ$6[F\PYKIFS'
MJ#E^[J5O1O 0 L7I2Q!)+)KZZBYFBYU 6)B^S(U#'.LIF"]6NMUNO>1 JV_@
M91Q!3!Q3^OB2G%37@SG*14D>]G?V#I)_O039!E#4O9#>K \;C*=]'JMPA!(W
M$(0NF.+#_HD>VGLR?:'ACLQ69X21H(R M#023.M[L<6PD-D:H1G1-[$4I9OP
MLJ[ 3R:7!(LE2<624+@A$4XWG?M':I$,  O[]=D%7!>9&,WL.)FLP'^?TE@L
M,(3F46<3)X/3HYV;O1@P1@%I8[P,I=J]./(&DXE_L8&_,@%S84>^[ A?$S!8
MNH-R1K%@U!)*3!ZPEGE!A'WAF5"L4Y=X%2R#X6%YC#"27K+O5:LD)_Z'X^.O
MH(\I'/F,W!$RI+@T.^Z:)0<G)%%#K<\119)I CC0L%04><R4"R']8MZ3&S=7
M*R[F4RF?Y=60=Y?6$#(9Y$ &.N4CG=*A1 Z/&,QEQ,/TJU",?8B6M.X>0SE:
MR'2F^R#]C5::(_,I:E_T3Y-KK'@-CQ-3 R& >9S1GI-#DIY%F_W80AR+?99F
M1$<FLV9)NC-(>E#F)#*??_?+R'#U'C(OR6Z5%2VN1B6EX<=O9%VNHG*=%W55
M7.1Z,-3?"P;.._+^$&#NG)K%V\,(%X4;OX!6/'GNEQ)SS9'(V?FXQRE.GK$O
M'1+"86&D"((H6<,3,<5@U$E1JJEV] M0,#$P?LN@EXG*?ZF:VK2:^>-+_+B)
M]RFY!QY?R+$[T(5@5X\9J"ARE;SG.CG782?'BIJ&*7Z0"7$DJ"-&OLJ>':O#
M-'R6# _ ;R;XS1B_[-3&C-])4:88G XO!:"DR(VS&LG: C(3SEY"F3EFR@A'
MM4P=R\X4W"V"$S4]<_) I"]$F?/2#<7H]K%_?H *P4IEL[-E%CS3N*P1@=/4
MI2*& &G^>UZ'^ ]*K&(^TO'RK)J*@''J.-GSFLLYKK%GC=7!<CBX0K/#302Y
MM#2WA@*Y/6Z\J%J)\1<,J)S8/WLF#*[Q)[#, L;(M1<D-,5Z5!P$)XXX=43)
M4PP3! .()&X^GQF#63E=4G/J-F,#*7QPD+^,<%);7O0$==O$R;66W%)+9UR3
MQ@-Y-K2B_9"06N7C5XW";'7J<I@XPO<)^L+*U9-!+5F.)UZ*<.0J'#G[.A<(
MK\Q36(. 9[-%C/EL>N;SS /"XH67) >B@,&W/;A*6YYO *'T!9+'PTQ]\#%-
M'5K:Y(B()63T[ "Z3'86T6=C!_<L.8U#G3R<Y E5TS(:VR3)TN_NF)@J%6BG
M="E+.&<I.C*6E*?#(4MUF4FWO/+P0>!Y7^XQX'%=$T*F\Y3D6"?@\G_"1/0(
MB,0!PR$8[]CY+UF(_CP?16>D)7J DF?16CW],A1,V2)8CH-PU*E]DQNX'TDC
MJ%>I0"%=QELO&(J2"O18^*P*KO0KHSGY!DJMYS/Y(HE&0;_#>\@8@VF,@U=2
M5$A)T5K=<0T<EK'O4H_]Y>1#5+P.=UZR2&B).)^NOLCX-N)H(<2A6 @CSW8W
MQR X0B:UA:AWA-'G*55G%H!<RL1.ZU_( ?:R<LBQR$F'8D3,%:A6 Z-1QF$^
MVK16WNFXYF>VFH&?ED4BI(QRI,QJU*KR7DZ.+"%J/>?.(A-H0:H/;#(>E@?_
M'Q>')UA(FB1]@%BGSU[D,7N= /Y.%V#'V 99AJDC=T=^%1C('RH,S4*P\L$E
M%'J*:.4/,3Y2)F"U"F_QX-+B5(L5$?CHL9:U8Q<K#NGGA8(!"HU YWL;# ;;
MK*@T= *G\>KT*R N,YB-O((MD:CD/.1*HE_SJ:"KB%R0+!!N^J73F,+R#/R_
MQ2%$SD B/MA;%I&2MI\$*4B92C7-D=;#Q<4-P)3T@^?G,Z1 !M*PR+$<SOS_
MVJ<9TZ:]%0# 6S USF51-8 /&[Y>WX>TUB2 'R *CATGV2GILR4*W#-FJY;:
ML%+J:\RQ<JVC<(UD-129*,&('@LSXD;6U3L\.3)^NE?\8]6$IY7X6#A),;BD
M(#?<D9X;<JT;##.AD27E2!,L0@&XE,^'M1!T8F$)A$6!L5H.*I)1$$RR$L-9
MC2^:? DJD6)7#W=W#D +Q5LRTLK0V;5Y5@)>(_JQW;C5"=:@H-_4^/?XP\K<
M?-,7-<@%7)$L/-:&5)!697*T#;-1FF1DQR %.=EY2788F>JDDK*9\G0698$?
MA+2472[:P01&F615L@4)F;%FR31KFKF"Z[R)P\G=>WE)W%N\]L('G&6AN8*X
ME"92B!X1/\5J"[#+U*0C'&5HYP4^7._D-D2T<#FY)-#6B_8K#TS1;NJ+BU*"
M^3FZ\,(0O$%"%^ -!U\O>J$\USORT1$;'AQE4AD1/28_#)97J%X'$SG<7+:'
M$R,E71MH]7F1O;+M$YYQ<T9=7@3W.-BHB#/6)!865P@26AS!K33BI><ABCDM
M2R^]45X*L>%EAJ9$$[PBSVYV./-]TB;E_[D-HL%UK1@]Q"F=B!\0T$2+Z8#V
MC?)2V U'#%6!LVKQLL\B_Q*D)K@*#,.':1'=J6^9C^H42FS2%=%@BE57 )3>
M6P$Z3N=1T7U5CS4'';?E ^,Q (I3CZ=?CDPL.A4Y. IEF9UZ=,P5P@R] _E=
MR$+RRAE' I_V^#A4:S5TV4-;=1N$M0U#MD"T'(=*F5L4!3EKX3V&&"FYG"4;
M5A+$#/%0F^DF:1YOS@Y-9$EO(N:<&[>S"MPD,_SOHX#(KK0*_3'G-8U;HTIM
MQ^H*Q0JH0\J!'CY]VZLFA#=K^5Z?N"X?(39AJ\$PM+)>"K:MFV@5)UMR$,YC
M,GL9C[)('O9/2_$O)3:%=%F0KS %N\8$@3)\8M3D)Z>&Z-SR8!D:JZA,KQ [
M SWE#*U&TL!Y(=)L(A,;1CW#@EJ>>&+M&3;$2+DZ%^4FC5?9"RTJI&9K6*N6
M(Y%@1UA+E/) NUT20]5SZI"54*^6D.%T^32W(ROC-68_62V39Y[%VEPHQN:9
M,S9+E0TA=V#$\:P4-J2Y"';.Y)<XDO''S%T\#E98I2<=Y9SDY%"?QIA1]4:J
M$/+$5N;CMF?KJ?<]7KTNP[V/?:BRRZYI>KE534,F#6,:5R42DV&I0,ITZJUI
M3DUGKI938U6[BS/RM0=>&!Z87:UY:;UP"5G6?&GUAKA)8X?.ELMDCWU T?*2
M)=0TN"0J;AC3.UA41S((E,G'0V) 9H3,AY35H(Z>Z[ GPS9!4JTM0BEZ4"Q&
MHBZ&KRR&L$Q.7\=DJ!8L,_O.TG2_9;HD*$[7"<8W$*U#%/Y[+W,(=Y(G"")E
MCB=,O8-I(C%/!!/]YE:Z8)XA]$Y7L":!6)/$PIHTUQ.L*2(X96G)4C'%H^==
MDS<@$@6\PA) C2V4RN$GSW+&VUV<$'F!V:C@/L2L),$]]C$[Y.S,R\R/H='*
M8B1N#J,E1-E@X,S+AQ.YQ/F(Q[P(/[-%B/":>ISR-Q@+02LA8^ M%5J7<?1,
M]$]JM=HE(@[&2@C/39ZC<A/!)T">W\]>\ANF[E:V,$I63>1?D(F2$_R8>& T
M9O$R4/ FI(#F8Z4493I@$*7W!KS-^92$55619[^G9;G8O!"?&(\@^@/*YV;5
M!#B7=2VBR<K4)&5ZLWUW6^W\7V+*!?;- %VWNTA.T!5SE7  _6]\Z53L]"Z+
M=X[7012]K9\#'Y.<KRUX_ZO5"@-0!L\5>?1>040NUA DOV35*5*A^PT-5!"#
M"<L@A)#">*6BA2?T#VS,$ZD)GX 5:6DCT,;*FI2\OO7Z+?R;F1X!,&+)1IP^
MG/#O<;@G2GARN Y",LUQ89&2&&+49C_]FDA(FSR<D9WW8?>O0V\]U(HD:" @
M,MO9%BL;VYBR@H\)R5+DD7N =P]@#[_N?/*9?WS_X4_O/XYR!.>TD22.&'4$
MY$_??[3F&9Z$S\*V/5R@/__QHSL43.I/F #7DWLJ+,)Y&.&L'HW&'7NB6.LE
M9O]54.F*Z(.#-5%&%WTO1H!45"W,T.%H^9T)S)"&&R*X+L='(7-?JX:[@T3G
MX$,A6E4LGMP$:9SGZO53@0?-B4^>5D5DW#0+EC1[.#F,>OH$+2K _^]]$J0^
M438IY(^E!\\(-P63\ \//Z 5]LE6A>B_%):F#^I*P.R9E2S>(V/4.,TR[)#%
M4#6#7!4#UC2L32YB^3Y%M?)" /.]B7BY*04E<:@<*0E3F&!XUCCMDT)RS?$Q
M6! @<RXAK?J4<+ED UC%)H60LE%H!44D4H;F8@FB0/,^\9P6^Y!PRC,F\VKF
M"@GW!6=Y.82QU7  "66>$Y9^KDR9KB)H$5I6RA(-7^MB)HFMU6: Z;=,HD^7
M2< JPH_0.04V//]6%*JV5#*#/*D7.2/+]2T';-&7B*&TJ7""K#:C@HJ:7KWB
M9!FD@\'I3%;T%7.QD%=B;YT*!E1.I%(<,Q9+P 8^8JYK8PA$.5Y);K9.M"+?
M\*FZ=I:5OPZ8T['4NQZ]C-6ZLH5U<%+3N3'F<Y1"VA;F:K-0@6D6M1X^90 +
MF#E!!&<Y8N ,O(0L)%:#0W,=0:S;<"0@H(U4XE3Q.:&)VT?)FKIGG[V,;-AR
M0E;T:+,7$'<!V%3C7J$:/&!)^1B8Z@A =I1,=84&1DLQPK3(N.1#@N@*IG<3
M-EE\ T0\DSMQL5KQ8*"'#<;TMV9#_8NC4VF1CD_6(/V-Q4&L5J=/; XHA4G0
M/_VNUD1::0MKL5CQ6!@6D@]ICV1H$9R%Z. \&9MEA-@(H'2Q/$5S[[ UFCQX
MJ B,-LJD6 9%LV90-,)$$[S;E("Z]R"ICQ)*P589@!/)"Y%2D&ORY1\Y^X+F
M4,_"E)% E_Q"OPZBAVR;725)G%S$28*IMVQ$,),@K)B-<VLR'0;EXZ!?8:3)
MOY!/. *'(+EGSOQM$ 4IO8F>1V9/<ZKTN2O2%?K0D?&E'DF5.:] _-B84JS^
M[3MF"5*,F@J>VNT63Y48ZM==P%Y1YS@\<B:V+*&NUJQX4^?64,AG%4NPLP\R
M1!1>,BCDHY_1$&CL$QV'/!YQY#V%A]O@-QP>'N-RJWN\IH<^F@)>*!\,B3E1
MK4_."K%I08Y:I2W*IV8UJ>AZGT0!X("3&^<Z>(6?QH5M2(+TGA$DK=G&S/%3
M"&);K0(BFM?SYJK2'$.SPBDD#*\AFL0?(;BTU)438Z%\,$O2"Q2Y@/\'L?S9
M"S$M-BL2@^ /M%*K^@NEY=A:*H3:"2NSH1 ]04IF$FO"BKD6?JGVL%">@^JX
M=W&:?0Y",A&BN1BIB0043[>"Y+0&# .SY_M&9RU)V:E49&#V!?RH @L6L+!6
M038DU(&O.,0XE&H-D7^&>YK:>,="7RNHRQ W"A;Q. P9!!.#*9@OLX72"9:B
M.D;,MA3Q8VI_+&D)HH3"/7[&T1Z/0\66E2 X-6M(V&:X4 ^>9"5A)(^$ ^4P
M:C?#TLFZ$W@(5)]ACNM1)2 E05'SG-&<N/ZC>7:* (8%T @.Y<O+PUBX])88
M^RG@G)D,AQ)T&4Q9H5ZTO>@7X\R5<"<5#K$2T50(99I4%!+^6Y#,:8DB=AJ)
MSDNUB\N1P$:*[05(G>3^XFD/YU2\\;,IN0"'$*/-+Y 3),A3AH^-OY)*X9Q/
MI0@;2#K *@5O\\*Q^J*@R$RLG*8MY2_/(A$U4<_6"<9F()9EZ5=)\[AX$9;?
M/(FHRI$=/=$X:Z7/JY'%Z;$'FT)7M85[!Z,1TR>-#8<N>38+'5"(8">--8S=
M1O*:6P[U2X71:!Q!.8AY'_D ^&ZAN#$%A7K$R5:!A!JC+S"0J<<2R)0U9]5X
M9L(F/HZ! 0WD5V"1"XF,?!M'Z]O@&?L,T.QO./0YW.*H5!="]92293!O)P@(
M2RC)J1-#Z--PL]UY0<+2WQXWF,I&B]77%#-.1]T*DC3<"U +EL;KG<:KTSVY
M##TZP#$Q%U;X6C"^*.'3Q>KT:XHY8M\Q\55ZS9WR5Y^S.2YLI)* :2E8Q @/
MA2\J"@ /'8'#'3FP)(Y&=*A:X2SB.)CBI<DPZ@J"PQQSC3;3G*X]LREDO?-O
M!Z)F >V-74'CK/.<LDRD ?6900Z*HLV6K/43L%BRJ5(^!12\@IDGSNBT+W'G
MS+&T)76,2%PK3$,A9%&T7S"\3$0L@S*":RRLF7=)L)P2,3[MFJ"G3#E/8#U!
M8MJ(SUO:@1&=^;>^$^KQ;5FJ$TNI+5]P)JS<9RLROTNB&"QI'1VN^M)2G&-]
MNSMA2/=@#.2+0:B1F2K8RRDK?D[(:9@S*;T%E#R2])&T(DQ:UG1")DMR=(\=
MG3A+A_P&(MUYW6#*VSB8)$Y05D"F3-BQ99ICII)@5L?4L>Q,(?='<,+)VJD3
M7 R(&ZTJ5.+=[&D*ICC1%*Y=$J*3UX0@C18KY4D?47_O(@[)3S$/VU?CU:G+
M2?FW ME=[&2G6)\1IHM)=&,YGSQ2E:7<4G/^J%PZF5[+7!:V,NG&S[]X\:E,
M3"Y&B^+E]'K],-@]:+6:^\A)%XSR<N;32Z7<@?_X$H]_'D5V/"$VZSF'E>G:
MD;#&SKL^]@)E+_'DKN#"W:O<S^8J^^B?!$<5>B9D6?,4@BW$2D3&UX=/,;EB
M(OJ4KW&T/$""39S@8!U]\1@HYKD7_682)I7"V>;#(C8N?>]7;&04\:'1$QG;
M0K$SJVL1MBX#'Q2)41$,:Q,JU^IZE"ZS\KIXW8^'A<MONTOP!E!"16V6+Q@\
MA-[KX,M.H5B.Y?_"'!V$^DDEBO_.LZ&G&618=7L4N;:1;Z% !;,PG45>;VKX
MUDD Y#PP2:%[3#P5'R(EOH@'B,?'R5:U_%CKKCFH/F:>X[Q670=^[92JHV\*
MR[@]H[,#22<>BH]?>C1X)B\\$J&D/*UAT1@K_#KA+$#X=$[1SDMOC)6:Y&JO
MP(^%X&_J77N,SY;_W <)-A2K*.C"R\LI.PA:-,E=V(FQ8^*H-K"=B$\6PQF-
ML%,+H_C[8>BQ9INH13&U&H%*+SY:NUM-W!+.R<7J+@F>R73O0F^)AQ2U+N .
MP3"YHY+F<.T8?;03 QPKHZ'*H_0\PQBYNWFQ0GP8='?L_)8DC[J]#91@_<H^
M3Y^L41,9/C(#JC[$W4(*5&VA%/(/G#QCGHF5EUP?ZA\H$$><^HG(]+)89GX:
M+@NE;GCVVG%R4BS 4=RVT%9YO6)>]IV7+!**!>C_W0OW^ XG5,<RE7).Z /:
M%!L!T2$@QHTI<L?):D,Z^@G:$7Z?@;JM<-Y'[Y4%@MY$' [IOA:'?6PX-I2C
MXRDH-]$I'TI6EG8 RCXI]YU*2T]<3+HN,9]G(D.:)@3M,N&6L'KAA6&Z6)T]
M>T$(%E:>>I2;MD>BN+/T9^M"KM,ED%>:*AKEHY.[+1^?G@TZ UBD4OD\\A2+
M2<G,K<DKSL%7D:?I7)"+;HW'BE&4*%*2?SA9BX+4690%?A#NP969K_#5*X &
M81_.!]CF]TRZ7:RNO 0,H:FXZ\\/]01&Q#ZI! L^+BL!33-:CX*<5K\H5C$)
M^8- [H&;B'QV6\)WCAVX2,"P'&09QO!D[&)6.&\"_$WQ5)(I(#D1%<60@B^+
MN2!E,E:"! !W^HKL5G:@0%KD&R9;=NEEWKC<&482*30!/,.;.F/&-#<%@!<W
M+!41Y3_C;!/[BA++"@*,@\=G1(NJ,2^$8#%,Q2B#FM1PBZ9A'FKJ,VBC4:X5
MHGE"+6:X-Q[ ZT6KSW_=^6"7L16&.;BJ%]O6FPB47;KP-!#V<>-%/%7H[V1'
ML*_)$OH$@6$ NW--9 ZJMAE-%:+D*:P/@@&8@GJ"V)3>EG1ZP')V 2FLJ''2
M,DF.\=.8'U>[D[-& 380"V ("-A%R(#]E5-B"HRMFYW0 R>+%II=J]_5VJBN
M=2N><[4,U&V\9 _%<)VUK92X&.)$EG^:5IN597M&\E1;<FB^,W=8;HAZ&3][
M2>#=D1U.@_1N<VDDDHG21)PHNMN@RVG#F(SP$ I#9WGN=N*7C/!0M-@JC)P0
M3GZXG)2!7$&AVEJ T]L@PC?DCAEG1<KU'D$7_0J4$24][:88Y*FJQATU.Z4O
MOH:MR6,$BKA)D*AF"OC)1MW=\;,O!"I*%D(@-VFYW8)[(94*9)Y)-$:2$J@Z
MN?ZF9$Q9"E$TQEC8@:>C848];KFXZ''>5L";%:?WV*_=XC<^_-,NZQ86/^N*
MQE32D^I_.T)H+RN,S(U:*5-DPY-FCW<-Z(-V :8%BKR_^/'/'XV(_H04(K2F
ME??'S)<?NAMTC^A,$2,SV_D6@!W9XDY_;9%+'1<%E%L1FB8"02CH[%A7*1L)
MD-!*$I@<[@2"^I\PT6,"%82?8=[:]$Q96)2"*6"_W7H)#;=10V]*"R77:>J\
MXDIA$!&+K(;:7.\!ZPTB6T8I?%O0)) G"%.G^8J21NF$43,V^.3'OAA.Q'(4
M9;SU[Y+Q<NV^00LPN4:IQ^\>J_:7,;S3,H:W!1. X/(+W"=XL1)0HL,E-T8)
M[B4!CVI'3,L1U^MK#^<"%3W*!:L__<W7*"!B&\1OF'K):OV;N0NTX"MAV$DE
M7PG[)4P,HO;9S!P\<W-:6LU[6+MH<LW4ZH$?WW_\([I[^.H>M%;GQ?^R!YF0
M+W:JWK74E^W.*<\F1D&R6/+\6>%6IK/[5E:U@+\JUX6#"M2^5N(MF^T*M4:/
MT(72P?:Z"<BAOS[FB)R)U]3<Q]\Q(N<3+VTWMX@<6;T()\\!.,SK-O1+3,,
MR?H#SRFULJE_![/=ESC[3YS=XV6\CH)_D=VF;))KA/\*V@T&]&L3&.0$Q:[
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M-&F3SW>_9>:W*VY] T"VD4:H*VG(([2^G44P9^]7 I.5R;$"R'1A'[^IA2T
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M0"4$Z@R(5]/*HAHG2>2QY1<U<=,%1.QL@RS#&"H+[\BO O+J,^G@,3Z/ 8[
ML&]$3$)6YJ503OD\D#(1+J> HX3.Q=*;>Q%'3',CL[L!B6,-X6.C+CJ5)+7Q
M<J+60K5,\J0><1UCL_4>E,#T]^2=30!->$ZU">2D?O>K6+@MZRH03%UZ@.52
MQ@FY9\AK<!Y'?DITCJ\/GP T.Z+\1O[9&D=+HHO1FRS 9D DY*#H"4:ERL;7
M'QY^0&LY-/V=1P='J1Q]6JG/SEK(:U&L 1V-VN-A#?(1Z:_8F"@?U(XP:&<I
MBK=I<3WDF?A4/!.5!?D=K$,1T*++2EA;A?HBQZ6*%R!G0E3B/>BZ.%D.=U55
MR@=6D%3%6 @&HQ43EA84^:G9KP./E<4*?,$R'(K)W\623>XB]K<WD1\\!_[>
M"Q^#C(:\"@EVD7Q*XOU.D::_>%M\]9IA)L9>1>3>3\88WRMVNQ-TL;C\#,6A
MQ*00G17]3L2\$*UL1&:&8#[HUWQ&2)G2Y**G$D \ZK$HA)/;DIM'3UX7T#SU
MQ&M*9*<C4Q9J"WZG%E(8\O2@N_U3&"ROP_^?O3=M<AQ'TH3_"LUV;:;*3+E;
MF=T],]W]27'5Q$YD*BR.*NNW/K0Q1"C$+HI4DU1$JG[]"W<<!$B HD02A++:
M;&<[*P0ZX([+X<?C67ARW@7+"6*$ J3D]; -^4PNQBY/0A$Y2J(K=&2RZ"1<
M!5_(._YRM(-4O^I5+S#ZB69N*J^/PIHXL&6X+T  , ^PJ"K%ZW]!_B3KXRP9
M-;S<8L8N<][/G^CUE+*<+%D+==308&MAC^'KK0!3(#[^U$^2[-U%?;PA.&N"
M1VL 7 Z0I*F6]!*G6+^IB2X\T-.:]3 ):/0([,G7,F?+C _MZE$\.'OZ"[B5
MQ[%8*_+R[Y?KF*RNO]+7)#A[%JM5O"1YOPD#BH$D&7":HT_4P-QH\V-F:=0E
MIQ7S#A,]$$T S<%[+"<W6*R(_^WT<U]62X,N RQIO:B%%LI"%&"@HCT'K&L)
M#C=B52[70K%5._^7<!JA%5H=^#!IA$#-*M' 2WW;K*\UI3*(ORT$Y'B_NC<=
M-&#6A/<W?J$;9Q+0 ==Y!9MZB"LOVSDVLW<0K$308'=%BF4>;X< ^V%49\(^
MJ5!V&M8Z,',:?#229@Q.QU^5Q,Z3 'I:<#0X6@&U,+[]9GA^-)6DF?+_E_%7
M'ET7EUF*@P>3,,DW/=#_V3)3Z&&)BI$K (!YZHI?[5!PX-0W,B>!10M\':L6
M%>YBP!(B)_K'KBA%@EH+-%6/U:. 3CU".B=44 Z>MQ%XS]R4#M,<@N"5HWOP
MBKR4 [F)GQ\;;C]P D,/+IW"8W-[K"?8N?\3C4X5U/[E.LQ?^UD.%=S^)5+#
MH(]WR@[Y$&7OZ71H_L/P*G8H$ L49CFY\V!"-1G:.'&4HC(,0UUJ9[A==7"_
M\7V\__CI!7VYI\94HQ^8<O#QTW<OWXO3830PU2%&KJ6JNAV^C(\,"TB_A?^!
MG/TW^G:'2[F\I,]R*&B K\-3S8"02P[+"/^AD)\%(=U O ?V*CY+/K6+2S"[
MA'^0JH_SY$PY^HZ91A=5/MKL&,:<78/!"SQ(BU4OQ".[,U>S=UC,78Y]A#X)
MKE,FM"ZV U*#O_SO/\X^_?&/OP?Y'30T\E@5*=NZE=ILG"[0P4O;N@'K\DFB
M-4,_DQ+WZD=,LELF69;?&P^SV4>'X>=UM!_7A,BRUE?9)HQ/CL=3RW;?Q"FE
M#J4H9>"=H80WZ\^1252/U!1FM[U(;KK:D;^1,+^)WTY5:80!N!&J*ON:0=;.
M"U3,B*-9 -T%T-^Y\U]+XONS(T-CP5+ ^^;E\4E"+ J6X>T2F'T@7FKA MLL
M%>"1PHQ:C/9..Y!9]UB"R>85:J,P.PWL_;N>SI;6-#KPHK$^9WCJ5MTZ]53(
M Y%C3:ZS)**#'@0I6SML5>K_'C@#T5;MSS=QL0P3=D/?T+^=7-Q1V*$90:&T
M(,FSX,-H5'?(3.\LMIJCMQ!X@?AVNTU+JO$4\;+/TW^ ],!%5;Z<#[,""80$
M #Y*-^8#'T6MH2&_ON:(XT=E) 0CL6@TQ[LH6#A^O$$C:I/^XY+^=\Q,$ZLL
M!P$5 @1NR%!5^#?K*M#ZFDD(O#-G7D=[\E("K>!^IT.+51A^!@##L^*I!E1K
M!"<\+X84H^&AF7+D-QF4/]WB9YLR-\'^?2^D']$P(6XCK-#<3QR/'$<9"7N<
MP3\<_ZTEH5]_-V+@1[,(9RRS8$L'O ['.XV+<IO__?.\SWQ]#HLB7*YW]+(<
M;Z^>.$XNT,_SQ\?YY7\_/UX_/3V.:H45*<P$G4@W2?;^1);K-/[GCD XUJF*
MF:3*'$= -Y"$,=#KG+BJV8@5[M#AMP+N2LD=76N;<=-M!F9/<T5##-YW>WJ[
M%=^/#Y+'P@T $PPP%:Y%Q$&?LT@0G2'4&(..D(3ABLK&!^H9EC%5M>K"G2/U
M:E@FF8_EL0SS\BA6+\AKG*9@C.=>AW-D^SJ-CF+ZFI6O.$N.M</&Q3H%M*XL
MB2,&I9H-4096(SEEV=<A>:OAI:;+>)N0@L'+*[V,>K$]D!)@)[,47;F]XF<E
M*>;*=I,H.L3X:\I&Q<>X?N/!QJ^;-K1)&/U%M'LI"%6"Z"O_C0?-]W-Y2WH!
M$L3H>6=N[0="^]R1![+,7E/TL7^.Z8XLLY1\)N4ZBP9QC_)> J6;62 ["EA/
M$SA.1^9>@W+8;39AOL>C;@V/9W VE&O*+GTATZ<B!\%V@)"N)'<5PUQ56M9:
M,<4=-2!/>K):.&+=%@-DO=&4HN9.2G",>5'L-NQO RY2!=)> 262Y2/9((+K
MHHPW6#>:_L<5.(5H"[3T!,\%*HU)N/SU Z66P>W.OOH BQM^_)Q%5&!93O]!
M7Y?@/4BRX#'&4M0<[/0R9(F=PN;#;7Y@^[FD6B(]&)N9\M_X-"7-&6KQ;6H9
MP#,54J4:SP3G;246@>Q25&5A"KCX>F1K/5Y?!D(\L^#CIP\__'EF I,IU&HQ
M!;]NG61SZ;E,<X''>I/ED$L/68IQNLMVQ7.:DS !V%=(H1#!;Q\_P899%XO\
M+J/WQZDZ:RVY:Q;(<7Q89?D'&,DLJ,825(,),*%## =$'+ 1!5@F%\;T;4M0
M=XI2,1:*&"%V9E2]>9ZF.W#I+W.XE6[3&E2P(@L1JSHO.&!D^$H6Z:(J2LD^
MT0)?%RF$6R97X7ZQNMUL2!33<SW9W^=D2>"32PC)C\(<XOMZOC88(U!X 3F!
M S^MNS?,8,5!6$"@+&<);I]FI<TF($ :K("U( I1_8HK[B"6EK$7+#E_ 9@E
MQWT G>]$\B.$3Z#@@/Y#8&TO*JQM.8&4CRKD>UX$%2O!(@T49L2G]7!RV@I9
MHJK&'N/'E0F4; 6"+PR)_=?\'8[H&6P7KDR[\(0MN&(1;OL1YT_:M)*PH&+G
M$?Z+_ % <44,%;["Y(\%_[7XV-?NVD ;EA@FV",(1J9**&O$M2G6H6Q44_S)
MTG%NG7<B('[4ZD+X)CC3PSI.G/9O0A(:+K=@4H1/TH.1]C*#DY:=J6.SC(:H
M%1T2?9(]TK<1OM87*YF%H]3:AC=38?ZIERVTROA1"WN/;0OE!:HRO3K5#6VJ
M8C%N!T/1I%TUJI"M:&\ZJN9V?$3-,7G6/#T52:;P,))GRQM?K9]^^/1''4YS
MZZ*(J_%HNNN;"P-$E<,6GO1(V&VVR^ZEB*EBF.\9N"!+R>QA$N)(@>P=X<;(
M,Q@/FF%6961L#KZ0$D)^[O/L+8Y(=+%_+DATF]ZF;Z2 W+_YLHS?F &F7P(2
MY -CZ);H"C(VOH/>Z&OD^T!V&%0].@15&U\,#7@'"/+B()>Q9#Z4_8R.OF8Z
M6HH2+/P ^/GS.EZNZTH/UXE.J:-;S],GZ$OXMG@\=+S.F/\$I_P=^JZT7=%$
M(GA"_]/@ /7U6MC C9S6JQR8-0O:%IUC=F_2?] #@^?+N$7#N\[S++_,\IPL
M>V?D(ZV@(C:;)#X!MJ9 <?PY+M>7E-ML0_+KK\MD!^]!$#/]?Y .U3-& ;>B
MZ"MXIYT%HC=(%>3]!:)#2(3Z!H2@YWXG=  9JV(4Y*SSL7F\39>4%SKRJ@).
MWU.'D<1,M8JHTR-G2*:T\T9RYC(ZX7JU@C/@C4BVH"89!,_0-WL2XW(9W,DM
M.PV4Z81^ [WC";S9+B5CB]+H*I[Q"[LMZ>*.P"MZ<BDVI(#@HQZ/5IL(/N0(
M?,%5&93QMV2/X2MQ_JK$1X[G/P7>H^?C\F1TC]$?F"R]ILK?5M"[=7P=5"07
M*ZI&,BVR;TJ1FL>M=*J #27H"LRAWP_9ZL.N(+QPT<BY1@Z$P9=%!R$PM!NF
MQ2]<:/'CR^#/3 8I0C@(?V2':1^[XM%V1\_3QVQ5OH<Y4=,^ABI7A1T$H@=$
MII-].*OK-#"7XH#[-KFKHU#I+&JY2F/?LTI!&V:)^9*52MG/GA>4-/1@."*S
M]$ 'VF/%F;432Z@^$/"Z+4N$)!R@IJQ&SVUIV0%8:5:8=9-@LL[R$E)D02_K
M&Q,+M#Y@OBW7\MQ%NP["AUX-$Y@I=69<X>S(5!$U8^0W$IT:V"'U$$YQ%M22
M9'YS!Z T&&]Z6A9C)S]#=HSJTA0,M44[/_7P1W0( N<&%??'1+]L.O.!Y\A:
M/1 ODQ]Z(K;UBH@85UX*I[@/]SV6G8P8_DY0_A[B3@7Q@%,_._:TN%K!S/9<
MF5%,1!TGS!$:A/(NAABUH?%056N >&<X 4$=FS\MI;'&I-K+O_VO__KT\3__
MRAD?_74%Q8@6J]5B)2YN..!4G/6^JA7><AK:_"S 7K/5ZORXTZ)%L9 390-\
M ++.^(J%3T(VRY@/%17K]E[$N$,80U^\7HYM>PV(?B-&@@PV?B-.KR,F#D0I
MW8BE4$4IC1.D)3M2@K3.EV?U[@/&$7IKJS!>;;'0&;OB %$1^#".]@52?Q4L
MOD("\HLJH&GT)4N7[#]Z::%P2WS _B"SIX);)@SI$A]%.<@H+&2]T-%OD(D$
M4[]F-/QI-2E;'8%6P4%45H4+N!K'F.?=[7*5SW=17&;YO"Q)P4SD-TGX>JHJ
M?WGS$'"*@4(R )KGP8D643$%.V(=F\,'>#8S)&$P1TV6GGJ&=XT2F(GDS//E
M6#W!W51.I&..X@2Q*"J+"HO)(A&+V0(O!K*S6%V'.>2J04(H'A7S#;RD3D[$
MK?I6"[:*WD4PF^P?0T;X"&"NV7$U"]@HODE1:8DH&4)%A4FR#Z3<JB1^>INI
M<EN&R5* DH":#1_0WZ#44@)(",XRLS1?!@>N.!W@7/'(<%KG,/X:]G>3"7>
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MZXAJ B*R0NH/]R0-$U[1(C^AT#R?&ZVD$BA+HJ.9JFW)S@+>V[ESKX5)J2(
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MCH95B0$#XE<@!AG5%>"F@B=J*'L=7>G'S?MR6.EZ.1P*;@/QO\Q2=)COP@2
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MU&1]]!>O4MX2[N8K\E)6C\[Y!K#X?@.5LR@! .YTK-674GG,SBKXNP_TG/D
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MO3P"O9)6C!T.(3!^$/C)-PCS)]ZF5"%&'@K$?7]:ARF_6[Y *# <YS7[Y8_
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M6#:7)8+&X<U@<9N*0>6%F,/CX8JP_[U-[<60J^=&[TK7HMO@.]'Q]V#L:2^
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M_7HAX(9]C?[CDOYWS'20598C-H6([>IDHFLGX07;K;%JEE@I^P=>L-1WR>I
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ME1+C87X@C]7;].M*1 _A]HUX"#3D&H?YKZ0D6'MZ1Y_,]%=5DVTLJ1/I3"\
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MB0N";5 >!=-:;>301Y.?P/QAQ&I-@Z/9 LYI:^?%W*A1?@1SWA4# W_*1@N
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M".1 <.*8(5]#?+ MX*/>SHO9;ZT6+E;RU8Y G,K3>V9T=!U'P@NVFZ%OW!4
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MRR9+QJ?><4WJD#O,\H$7+'4UJWZA#ZVG=Y*\D<]96JZ-"NBIM+P0!%XSS&T
M)0);/.:FAM,K,X\Q5>4AC3 M'W?;;1*3O*VF9-=OO)@;)5>'^5CMMZ>EJ1=L
MB'QH -B @H&MODMKX^F7VAU]HB2/I"P3/-6JN\VB/Q]H[XE.HQ@[6L/.NWWA
MQ8)KIN3;TZNJ8[L]0:LO32\$8_654TUCM4ONXA7EKUCF\9992F 38G'M J(^
MKE/Z,FFB9PY.W M1W:8E(*(I%J(O6<FL2'2T;:K/X>^\8!"=_HM5+8"L2\6:
M;E]ZP63EDGN&< =N]JOC7,NG-;[$CPJ1/)GLY(;[I[A,$-XVHN^K:!<F %>"
M=7_A\;&.MT\9.^Z;:_V$S[U8#5WPL!1@?)&?WHA<'(+>].J,4E9]5:LS8E%H
M#G[AQ2S7"VIQ]/O;%!5DF"(P,5Q0-2;:*!>2<9^?1LH+,;151S#QVM;>"X84
MM=-J?JVW\63@"?T5$<3?B.J89V%X2\O/&-%&7T)PGMZU.<"&I#_YM73]E2PQ
M;H9#VYD=R^967LPVB+(06-2M"!;-=EXP<(M:"ZP09L9#C9:8JX[8VGK!B+G0
MI7235 E<QDW5]>/I+W+Z\%J1HD#= [ &=DG)8GP9H@['%D>MP^KI.Y*"%_-K
ML;BV&]RUIEZP4<NNJ^7>'7Z,'/.]%PS+372QY['IB-B7(Q+HTIH!W.$S+]AK
MY S:O3WFZ>S\N1?LMJ3(VC0T2W,OV*EYUT75M"N(YB51)V".(TEXP;;B$C&D
M%+;:0CI]Z0>3TFQ3?]@I+[J+/?^QHP7H*%+3*PNB+$)Z /M5-IA^R#?ADAO1
MP5M'I8R*"( DDFU.EK'%HW3LMWXLT=%C[9I(3J[[]D+079WV?1S^DS*ZW$=_
MO]Q3<1=,-]P_Q,6OG\,TY*__=9S32<S+_77Z2O_6P/ [Y7LO9M9R_3;NW;:X
MI6-I3'](BCQ(\;^P#7E).WD?F3@^^F,_YKC%6/DY+'&]7ED &KM^ZP6C+("8
M''[A&AM.ORQ_IH+,R^P]Q8%958YF(T^B(QXW89)<[ HPUEG*%VE-O%@T+2KI
M79LAN<MW/M]I"*Q%K^;B)L-(M:( )EAQNCTS:&%CJ ^]SDE8FE\VX_7BQ^JH
M/))7.\@]9K$**HH'V(Y8-HUYG1Q%P0NFGQ^?<C0:[2M3F3T(S=[:AQ,U*=?A
MYG'WDK0>J8967LQ$Z^*IP07CZ^(+@2+/V?_/WILU1XYC::)_9:SN<RV1655=
M>6WZP;5%:ZY"+I,4F=;W)8QRPN7LI)->(*D(SU\_ +@X%ZPD2( $S;JS0A(
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MSK;T'YS(%GI+\Y=$KKL2)#VC-3(_=9YR+KEHYSH9VY2T?+R!VA#\[[]>$'A
M_ZK]A?SA5*MQB?]>S*,!!YX0UGEX)Y"EP2[Y"Y*F$2P__?W33S]_^FOJ_8BC
M^'C^*P'H&?U'RDVI6C&.3_[//[7G\:?&7@&<?@"M\D^4O8V;VTK21\85O1R0
M!)1#^N=RQG_YD?C_3V]?+()D'U\N&EW*S!UO0H)V@1 DXDU_>8\__NJ#@.P
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MC%O'0Z$$;WTUB,%K^4J4T*T/!RIT3;^-$JSUP4 %J^M14@*V/A6H@'7]7$K
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MJB3N*2N*S%+S^A2G:#*!%X9G EKP 5[ +H.DM,/MCUV8^<"_0UMS[84[7+*
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M<!A^C;$EA^B4F)<XH[5V/0WU,V7B-/0[>KDQJ7X&=0-H7H<X] %,<DD:1[+
M!.3T?@J9(94R/<TNZSY),N#?$!^NW*R2G]]'\)W\B:W[D.IL;G%D(OD$T96[
M$QUW=GN#["O> > 33P$\,2_:H2=0[:@P.9>HG^93_QG&2=+X:H0$-2_,/7E+
M72OMW$OVM&H+9!:GWM_@/1(ACI3BQ)^T>SP_$5]/<90W3-CY5ON,9/H%W+3(
ME/?-Y:UQ[6&CP=6Y?! 5#96,50JCVGD7Y+\G62?A!V*-O>Z$[B VB$[UN<FJ
M#XK6^C,J5:RB A+SB\V'%X38B(ZPN\MPD#9^,M"?[VI#Z'[Q$.5<Y/^6$S6.
M@ND20RX]-]@#[E(<!.H#2<.P8ZST!KREER-=?@I]]2MB\'224NP\(H5=Y *)
MZ8AH36TP6U;U"-+MONS!S'&G<WC;N#LY-#T%_5;?,0Y8Q;UR)R]I-BC?>212
MQ"QJNT.$@>X[1#;Y!V4D^+ZCZ%X'@#OLJ4@*R[V_0^+*2I+%)Q3Q3ZJ+#4XN
M.,HP\ L_ZV>P SAB<QO5G%?$_BX28VC>#,1'2HK8[%, ;P".&<>>NR+6)=G3
M+A'\]@>BI" !Y U>_;&2D#^I"-["L;2G;J9.XA3 PBV85;%"M;<5[^%BHB7(
MK/N#V\6*A5QX:D> S'\!T!_5%2["P2S1BTL\@3@=K%K$-DN3U(M\GD*&WVMT
MS5B-/)IV0#GU&+N[=4>)NSS%SKISGR=I<,2VG%+]QKQ#&2VG(Q.!L"C9TS+B
M8#SW)3MI!K\6A?$:7^)YGKS OX^NO5.0X@05EX@?OK9BP&@&LY!C$H>!%[9\
ME1C[PVZO>6M*:$J!@:I/Z3:R(])NS("J1IU'F?BCI2=RE(A6:E2P'65OE@YR
MSUBJ*@&&,(S)B5R/P@"H.J%R0XV63F_R 4J7W*Q*@4*+IC=1=!'&3#&P9_$$
M)Q,$U+A'Z*$VBZ8KP=HI/*P;U+-H@!@10N5Y:T7I+!J*D@2X(3\-8595Q%@T
M?-3PHXIOUTELZ9R9'N7$**30?0$LFDHJ!$3!50VX)&2KI1.50N8.SN.Q$0'F
M!*%QH\<8-W\WE&#14/6*F+^\8IAA9(L&3>K1VX**&=WF!%**:B_!^\:).@=#
ME5@2P8M.X*BFG!&%2CH!F?2+N163Z00X?80*=DB?$Y!)<O_6*W*,XAA62?5#
M&3Q/5:PWWZ5M!"5]!D5APDZ@I2A\<>P^2R\0TI.NA.Q]X95IY-D[W<XS1N&/
M69(5,U;>B=(HBGR*H:MWHJZ'D*(4LAPX 9BJ H*MHAZCKL<LF954M@DWJL;T
M$K#:"(]2_L0VJ-2H2R+IQXI: S5V-I$QRL186.!40807NK&/4B%F=K2EE#IE
MG-(NL\.L1UX6O=5=YBQ8],KT,DJAESGSM\&)8TI$EZV\T".04#+/E/ M^\W>
MW\6B#.0L<5KV^U/NEE7.K5."M^SWE1QX6M+ZE( Z_IY0S1Y4PN;\ZV)H J,2
M2*UO#O> I.5,*FU]6I\F<X16,=M2B9O6A\D<<5/-^%0"MVSKLMI)5DDY5>+G
M^ -$+M55"=;ZW.B33JM$;WV$R"?R*C%;+6$]$X25 *YO#;649"5N6A\;LR0\
M?IJS$B?'[1=#4ZF5/ERK24.8E*V$:MGNS(.@:J1^*_%:7PB**>A*X!Q_&JBF
MMBMA<_R1P,VM5V*T/@7D\_V5F#ENAI!-)EC"M0K^P[(:ECAJ?0C,#T>)](@E
M4EJ? K-Z,K'R-):>]1-(]__[KQUTT%1_KS6@_KU81 ,JO!J<SL$[@2P-=LE?
M=O'QKV5>RK^FWH\XBH_G?#(W0;(+XR2#%[LG.D5U>WSEOKI!S.I(UIQ\1>C<
M1U=(=L!_1^,D7V(?A#<@]8+P@FR0XEFUI_RGQI:#'RG D>]_,EIC[<I#*\(Q
MK2!*"LJL(@>NSI<F3]Z9!!-\]Z#?H:0PWWV- YLM/-=G[G=> (F-J$8M#667
M;K#$'UR+FDOM^,5-7;05"6LO&D[M[0W6-K[90R$D8L-$I_D@G9"0 /Q?XQ -
M$^(H#B1$3'.$J5\V"^N;>'%O*HM[!?#(J@4RX@>709O/0?+['03@'L>,@B2=
MBC*IW[5#SM4GRG3"1D:2!9S(;Z24]F_HY;OT='?:Y10MI%X[0(O?@/&83),I
M+-M.- M>39?^QLB+8J'+WX@[-)(@.49"$;<V9ESA=+I$'8:TB<_H/]\45(JU
M7SZCF< /$B;5]/M,9JE5W)+MO$=S^(&.9TQ\(,I,"#@W23VC<>NU(M75V!M.
M-+MF/D#%I16=;5""L7(UL-5:G1X&*R47&5+KA@\.Q;';VU56E;,$=GN[EL ]
M'KP>II>1Q]5(S+[>T)SJ_7@*XS, C7H==/T[I>5J,5#&..?L\D@WVEM!VR)S
M'KVMN:E?1*?"$2)W(63*4:QE*8^CO=X\(_=Y8[K<IIIG5"-0'#.("^;! #^S
MR!](""%[CO*=-<\Z_^9K7&I8R??$F,ITL^/9IR)2UQ]VLA*K$[KHOKGVNY*D
M$W"M90[[^%AQJL[0Y#(G*&FM_32<PTO255,6=0*Y/IEV9,5&EP!<J_7HEB#D
MI#8G3'[J[$WU.>($C"I'5>I1Y 1JVNL\++;TBE![SDK7W!+U?_K+>A%()[:>
M(%;3>(1%3?8J6=!+=CQZ\%S+ '&) $:\OF!;&-)96D%7*XYE5ISFI'B&34X'
MO8M(8%I; /KI,GEJY>ABGLV_33\EJD:U_==)I_4EB.HEV3L3:_[=+DJ4-+ZP
M.MFUF$86!_GEU+L96U M5V)1#R9.P>4*$Y@F97MK-GWD%ZO8UD%M-^T9]7[P
MSVCC[[IAHE%=F9V%@A:G^>)M@-RL7?)P77I,,;]KK+##&=NEYW?IL306^NWO
MEBU)G/)-?IW"L:8\#8Q)*#(6N=$L6%=_)B <T(+5J;,0Z0'=/8[??K%(H*OQ
M2!PV("O)M;M9N: >B]%]Z#K?JH[W?93"($J"'0D6H)TOZ;Y6@O_%2W'"]?,-
M.Q!7NOO8FY)?)YP92W>S0Q>[^JD,0DJRVOSB0&%HLTH$6AJE19NWJ;K&!BF,
M"8,-Q*"FH!,R%%HN4ZV8G?(26ZD'4QL(J*<&38BC(W']*E9]NKYOT>Q)[?J2
MM^(OKJ"DZ$IK*F"=</V09^AB-;&[@/5T!G00*35V]-#Q!5FL9Y&.@]C-3JH'
MKE]RN")2.\BWGL844:NI-;4Z'"T!-06+RB@9+'(Y_C9:(GS2=7ZT)I2W]&6D
MD_T)C$X%JDZDG!\3S^YMXT1:^C$A[5Y%3F2H'YN3?ONEPE-K'ON%W$YB,V#Y
M7G%0?](;N0MJ#C[SV&Q1W@9:PN=$C2M-1->T6I8(.E'LJC<!TNR])7++3<>G
M%'JRV:7!!P9G#32Q9PEKH(D]B^BPFQG'*"0IYH&D,NPAV!T8SS[%75,8U!X'
MICG$-Y0H1_2H(WH;J^AMUM[/Q0=>O\="^"]M[*'P6;GHO:)&8BJOM[*+S@W&
M?JEX@=>^Q^;URMTM?BNLOI"R2 UP)G$+*&4=IHK0Y80ST^HJ-[I[2E=T=(*R
M1O%+69ROG"ECMUM \D]F[57AKL>87EVX@\8$ 8W5'U7N@J3.T6BFOM70(G*
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MJ[4:&58C@^G-F-A;TJEZJD-O,G4AT8F PM7DX X;D7AH.$'S$[-IVBO(D4K
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MK&9&G/L!C1[^GPP&B1_LF$98V5[3"C?>#[YPT_B[=HMP:T.[NUZ=*YP@+4K
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MS.7!/L0P?07P> />4D'-'WK;M0C55'4:!F\VMX1X:[/I;8U-_<H+\0OLY0!
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M,!)O1_*@<+/$BCMJ]HK;I*\'\,6#OP-ZUF]&(_,'8HW -.A6-\?PQ>PM"?S
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MPM714!J:NZ$ 1'SX^JG,0"E6]/%ZV'9W7=CRP+N+-Y"Y4U&4%'^--SLDCD*
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M"IBIH+(Y&4)X5U0O5BJI920>;3&;BK'A>_*D5?D6W\)L,\_3+-DB?/?A1WE
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MO#3B7 !'\""[#&,@PI$KHA95I#E#C=H#W:0*1T&_H&9)(XBB9T1*U\E#D54
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MJN&)E6J\!@!> P"O 8"@ P G#P)P.-#,20\V@+ ;5WWKU_B0D>)#KD$ UR
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M>;YF#/]2A_N A5S0O/E/B^7T^2DM#V(6W]2W:BSU<D 6\%WQ\7<9'"1ACG8
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M9&O Z5B(N8!I3(1$BB)CKRX]"N8# E%AOM4$5+X*S*0&*GU'29IC]$K-YOA
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MG]N575!;']\ASZ:OY<-UZFNE5&MNAN.QT]F=JG&)M@**@E&1$/HCY'N&%];
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M&YO?NI"5="XS19<P5'P\B4<1A(2W4MP46L'Q14WO%NT'S&5UB;2L@#YM2Q<
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M@5A]I14U?A;+S^,HP!@340!11ZP![!29JFIP76ZE;@#J!^%FJ9?$<.O(\/O
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M 7N<HV 5D^5BPY*.B(#J2OJ7Q?W:,5K@Q\.L% TC2Y*+"U31)GA/A!\@$^.
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M;5WLBMJR'3<?'.E</:HRU[E<U;.LM&/Y4 R<N@U'U7XWL&Y3D\A<\6[6V>E
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M9ELT;X0AY&0K)?@G0C\J+C_2O?"\(?BA_BRQJ_V0Z8&H^=Y(H8RV@*;OVQ5
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M3=&86I[WZ>[++ULVJ;];?INX@96#UEGS^/#\C\8?X)C><?/X>"ZQ*9R[*]E
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M!:S8L$:WA:MH8HM=1X^B25LF^P=02P,$%     @ NH%M6MTPX:]9"0  A4<
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MQ2"60'/0!+(, A8+!D1G^-^T_8@IEG>"$XBY%I D@5'(B)L!3%"G++ *8K]
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MK;F"8"QQNT4?J0A);QK$5(R H(J$*64LQQ\C&5(-! T#M'+)FMR3N3%H, E
M:A;-*B0;2S7&G(#HE"Q$8(%)'H%H% W33*-9B^*ED"$>JK3&4CFD I33GW*8
MD6Z@38\A7@7[J1V6S,BU2"?HY B\%3Z:E"3@5*D/.TB"Q.%,:0<X)& B"2%'
M_'9*VA0L,XPRG&T<[OHA4QFG,R_B,+W#V+_'ROA<$L *.4I3J7W+3<>H5-Z0
M*N#,T&:%Q;<T,A%RL+LYM&Y5#]H-]^#P?>NHT3QH'33:N_X$\S!G*(%>>]<
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M') 72)<[$-J\.9]MFP;12(/T*)_0F;+I4*=F7KXZ?M.IV=>V_@%02P,$%
M  @ NH%M6K$C[E+0!0  LB4   \   !L>7)A+65X,S)?,BYH=&WM6FU3VS@0
M_MY?H:-#!V;B),Y+ 3ME)@UACKL>Z9!TIO=1L>58ARSY)(4D_?6WDE](0J#
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M-K;?]U?@MDTGF:%</Y*TM;.=\3INZYDTR=C.W;T?(1*2T) $2Y"6M;_^G@<
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M14Y;5H4Q90K UA;EP!G>3Z]:Z?8%#>>&O*O.!3JK!RYXYU FMS'E?!WU'\#
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MO(A+:K#$E6=TP=L>&:H]TSB)[6*?3@8ZM^-. (2\)?G9<_XG0VF;+)OY/3_
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MSBS1=@Q+<MF1P>ANX;4\<3HQ9[&N_4+Z]P.;A'_3](XO+N**ZC'VT[!O%]V
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M[(=94^2__#]02P$"% ,4    " "Z@6U:)[/)H$W<  "6*0$ $@
M    @ $     :6UG,C(T,3DP,S(P7S N:G!G4$L! A0#%     @ NH%M6L64
MC\Z]AP$ ":$! !(              ( !?=P  &EM9S(R-#$Y,#,R,%\Q+FIP
M9U!+ 0(4 Q0    ( +J!;5IUPL)!SN<  .T7 0 2              "  6ID
M @!I;6<R,C0Q.3 S,C!?,BYJ<&=02P$"% ,4    " "Z@6U:R&X*BJR$! #Y
M"0D $@              @ %H3 , :6UG,C(T,3DP,S(P7S,N:G!G4$L! A0#
M%     @ NH%M6CX%JWH $@$ ]2\! !(              ( !1-$' &EM9S(R
M-#$Y,#,R,%\T+FIP9U!+ 0(4 Q0    ( +J!;5I#?;UBSX,#  NM P 2
M          "  73C" !I;6<R,C0Q.3 S,C!?-2YJ<&=02P$"% ,4    " "Z
M@6U:I>O-'SI.!0"<,D, $0              @ %S9PP ;'ER82TR,#(T,3(S
M,2YH=&U02P$"% ,4    " "Z@6U:9:075EJR 0#.N!D $0
M@ '<M1$ ;'ER82TR,#(T,3(S,2YX<V102P$"% ,4    " "Z@6U:"J'F61$2
M  #:K0  $               @ %E:!, ;'ER82UE>#$P7S(X+FAT;5!+ 0(4
M Q0    ( +J!;5JD<I$=5E8  !0* P /              "  :1Z$P!L>7)A
M+65X,3E?,2YH=&U02P$"% ,4    " "Z@6U:?/WW$M<#   M$P  #P
M        @ $GT1, ;'ER82UE>#(S7S$N:'1M4$L! A0#%     @ NH%M6MTP
MX:]9"0  A4<   \              ( !*]43 &QY<F$M97@S,5\Q+FAT;5!+
M 0(4 Q0    ( +J!;5JIO7A740D  '1'   /              "  ;'>$P!L
M>7)A+65X,S%?,BYH=&U02P$"% ,4    " "Z@6U:*8(; -<%  "])0  #P
M            @ $OZ!, ;'ER82UE>#,R7S$N:'1M4$L! A0#%     @ NH%M
M6K$C[E+0!0  LB4   \              ( !,^X3 &QY<F$M97@S,E\R+FAT
M;5!+ 0(4 Q0    ( +J!;5H$P*P^Q1H  %BA   .              "  3#T
F$P!L>7)A+65X-%\X+FAT;5!+!08     $  0 .8#   A#Q0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>lyra-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lyra="http://lyratherapeutics.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lyra-20241231.xsd" xlink:type="simple"/>
    <context id="C_81555852-032a-405b-bea2-d1c6de8074a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="C_852d2d00-74ce-4a20-9603-0c6650379dd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProfessionalConsultingAndPublicCompanyCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8550b4b7-6090-4399-a279-2b5260027481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lyra:DirectorsOrOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_87370fcb-d580-4410-a3e9-579a2b1905ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_878fce79-96fc-484b-9c23-1738cf8a0491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8902a605-b72c-4739-9074-c30c2e4cb614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8952cd7b-48b7-4b53-b987-499c3555124b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lyra:CorporateBondsAndUSGovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_89f8a662-2ae4-4167-b545-3e7a39f90636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="C_8aa217c6-fd0c-4938-960a-3d90887e55a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_8bdf4601-233d-4b5c-9cfd-097e16ea264c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d8c6d11-dc4c-4661-b6b8-cede22d16893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="C_8ee2d39b-2034-44ea-b1f5-705ee63ae9c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_8ee3e41f-03f7-4449-99b7-ef89d56d7c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8fdbc5a2-8bc0-4cc9-afb3-fd47c4ae421c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_90ccd445-a844-45e9-b76b-f02a4964792a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_91222020-6393-4cde-8a28-5ea0bed8fcc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_912b5ea1-01e3-4044-a2e8-d7c9eccbc5d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="C_92a8bd8f-ce57-4c0b-b9ef-52a50d85cf30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_940df23c-7acd-4b4c-a6d5-71d0b545b62d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_975bc4bf-e956-4689-baa6-6102f1379b64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_9780270b-2928-4f2c-b42b-5d857b4e3091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98b8817f-6678-4071-a244-b8d90ff8d269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9927410f-0750-4aef-8f2e-4c0203df94da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_998603de-c72b-41d7-8c9d-fb71a4c5e1ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9b8e7f3e-8fcd-405a-b6ca-6a57fd5e4161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="C_9c633c20-1b3c-4fcd-b70d-356063ad8dac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9cce6eb7-717c-4284-9f9d-cca47171b6d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9d4d7017-c77e-41be-bd4b-9129608b3d28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9dafe4ac-e499-43b9-b4cf-d9a535621146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e1ba78d-a7e7-44eb-af47-1f204e97c03c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e7ffac5-3543-48db-a285-11bbd13c936d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="C_9eeb8171-b971-4290-a284-8d735eff90bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9efb24d1-b674-4307-b0ea-d333f2bc6075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9efeb578-258e-4154-b77e-f69b4276c86d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="C_a0d4bd0f-380a-404f-bad2-a0ba8fbdde35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a1b363ff-1904-4c03-9f49-1ead948fba72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a26c186e-cfe1-4434-9835-0bc963d20468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:FacilitiesSupportCostsAndDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a2fba259-de87-46a2-af48-98b719cf4dc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="C_a43bd8f3-4538-44af-b61c-9114bcf4aa13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_a48e6107-bffc-483d-bc1d-dc2f272feed2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="C_a797757c-a0d8-4b41-bca5-e4ece3661b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ClinicalRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a8a81857-3883-412f-b823-244b5789543e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="C_a98e409f-d6f8-4b16-b04c-f09c481c5882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_aa987057-5b50-4f91-90e6-77882dbd1aa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-03</endDate>
        </period>
    </context>
    <context id="C_ab9d9d05-16a2-48db-a97a-38ad01878ef2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-10-02</endDate>
        </period>
    </context>
    <context id="C_ac38a720-8b0c-448e-b389-9c66f5e57c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ac5f170e-0fde-48cb-9c0b-b5694cb0083b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_adb4e732-d095-4cf9-b014-91975b0e1ae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aee49c45-4ce0-46b0-9eab-9386fa9c46b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_afa65958-5848-4204-a888-f0ed623910ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b0c1652c-3b2c-4e34-a9b2-16cba734c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b279e47d-9fb2-49d6-8595-a8c376f75802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3a5054d-64cd-44f8-a695-70cc465ba03f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b5cd3428-6f7e-489b-acb9-7fc886586ef5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_b66b293d-ec8e-437b-afad-20466ee88490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b738c303-1ab5-4ff7-a680-7afbc47dc33f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProductDevelopmentAndManufacturingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b75ec916-9f93-4a03-9cb4-7b9f5bdceb2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_b7855080-4b7e-4605-886c-ba8da30b5934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b7f4b320-3537-4193-801c-2cf634165bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="C_b8f88f49-0e89-489b-92ff-51d33224124a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b9710e1e-df0a-491d-918a-4327c625d8b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b980fa59-4978-4912-9bfb-143801b491d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b98307c7-4168-47d7-8b20-2ca01548fdde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bae57fb9-3c5f-471b-8356-fd251e1c7251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2020-05-05</instant>
        </period>
    </context>
    <context id="C_bd367419-34c7-4e6d-83a8-87b37d35c96d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_bed6c948-c9d7-4d57-84ac-6b989ca8e7ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bf0500da-2915-422d-95b0-080c64f50c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf748116-4ebf-40ac-bff9-35c1fb5ed691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c244cff9-72f9-43c0-88c4-5e6a576e390e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c3eef231-3463-425d-ba3f-d63c4ce2d6c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c5d324f4-4968-4ffb-aaf4-47d647da0f16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c78c329e-4f11-4535-afbf-fbe8ac79582c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c83768e3-f530-46bd-8293-57a4d5a51a00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c83cc782-1381-485a-9d57-319e02ec88af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c8d88912-cb32-4c79-b82d-9539702398aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_c9a482dc-f5d4-4994-8462-78e8c22a8165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-16</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c9aae08b-647b-4917-91f5-0e67b5b4eb3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cc81d85d-e11e-47ff-961c-df0bcedd5b2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_d20093d0-99e7-48dd-9fa7-66b19c3ada23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d2768b5c-c610-479e-8af2-6fa1c6059d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d72020a2-3023-4259-93b5-fa4a7d8ad386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_d910c3ca-d394-46d2-b9b9-f20df1877ad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_db5a6c2b-f92c-47a4-ab60-53c0ab05b473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lyra:ExecutiveChairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_dc75a67e-1185-42e1-9806-ae25f1f18a50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_def1fd73-fa5d-4a76-865c-950530caac65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e0489a50-b282-48d4-b174-d58246a172cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e06c0d9f-3e71-41ea-b315-fd20df7409c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_e09c71d4-5382-4588-a92f-344a3170a726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e2a3c196-b3fe-487a-9820-f84bfac368b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e4300f24-db1f-4970-b3ac-f88865d19c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e4a10c0f-30eb-47c6-8e2d-589710e6957f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lyra:RetentionCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e4f2d1ea-5751-43a3-bf6a-e61453470a6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="C_e71c57da-121c-464c-96b3-6536e9e26bf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="C_e7c9223a-fe0f-484a-a091-15fcc055e486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="C_e8ac4fa7-d460-485e-ae33-045deec8d365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ea185583-d49f-485e-8484-bcaef81144b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="C_ed18e4b7-9e3c-4404-ad65-960cbb74cdd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ed6610c5-7cef-4bd0-969d-825c8bae251e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_ef0c2d84-5760-4d06-a7b6-be126708a7ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_eff1908e-cf95-479e-8a29-8ae67fd4d38a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f24af48f-4786-4931-9dfc-97f5f94468c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f3bee2ff-cc2b-4188-9e55-bdfb437d68be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f60732e7-7b49-4546-becf-89f740a96713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f67b2471-5de2-454c-9767-81619473f71a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f6b0dc2d-d4c0-4391-b0ee-c716dc85497d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f8426778-65fb-4dfb-9474-719fbdef584a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f87955f6-4893-487d-8bee-6137b9aa2886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f8c3db8c-4348-48f7-88f6-6a511886b8fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">lyra:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f932f338-d1f5-448c-91af-c2103ea85652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fa285bde-8794-43cc-8482-2a6c0a625a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fa9efc50-d605-4083-8ab3-4094e47aab16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="C_fb455e7c-310e-4d3f-9d79-4891ad9dd188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fb525548-f539-4b57-ad61-75d734fd08a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPerformanceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fc7e6c54-5f68-4b31-8c26-243187e6b327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_fcf36a73-5344-415f-b95c-0bbadc656fc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_feffa18a-b969-4f5f-82cd-f03ad737e8a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_00c29fcf-7ef3-41c1-8925-61f5bbf063ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="C_00ea0f69-39f1-4cdd-88c1-1015ba40c9e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_027852d4-18db-4239-a7cd-a51806d8be2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_03789e9c-f8d7-4c13-837e-8c8982eaf153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_05ee597b-300a-4f1d-950d-07a44282f29e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_06ac994e-b8ce-41c9-80a2-2431128712fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProductDevelopmentAndManufacturingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_075aff53-3972-401b-9e57-6d6327e23180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_087ed0ac-1d0a-422c-a84f-3b93f915fd09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:OptionToExerciseStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0898fa9d-b760-4363-9f56-f980685e0512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_09a0cae9-fe57-4508-94a6-ac09c28407d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="C_0a039f52-1a66-4979-9a5e-3989a5131b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0a16c01a-3d42-4b14-9dcc-312ac1b87eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0a1ce932-422a-495f-ae97-fa5f565abba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_0b25fafa-9dbd-4d21-b6f2-54c2f0bc249a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0cf2e5c8-0ff5-4308-a0e2-b02e0055df23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0db4beff-330a-45de-8b43-98f81b33e6dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_0e5ac7b0-8d8f-42a9-ae36-22c91da28b12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_10cb439a-3f2a-42fe-9173-724723bcd311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_114bbe38-9e67-4a2b-8b86-6fa6b5de33e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="C_13349549-b2ec-4e54-b662-5d13b5935fbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lyra:MariaPalasisPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-18</instant>
        </period>
    </context>
    <context id="C_194bf10a-3e96-4e60-85a1-7fac540a46ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1afebb99-1342-4fb9-b854-e7c6117b6e01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="C_1b2977bb-aa44-4677-a4ee-e38cdd9f5f8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1b6f6f65-0092-4f48-84e8-9f5ef718920d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_1b70f3eb-a7d2-4546-8d83-3cc0e6a2bdef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1cdb38d7-d16f-4ad8-9875-be4af848c0cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1d3cffed-7156-4809-98e0-2a0d5179fc6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="C_1db39547-aa48-42b8-8c47-2ef94db71901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1e1030b6-cab3-4405-83f8-f89b4d6c3751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-10-02</endDate>
        </period>
    </context>
    <context id="C_1eedc30a-cbfb-49da-8177-e51404827448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="C_1ff01a7e-0054-4803-8549-b1cb6948ee4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_2053b9ce-487a-41c5-8660-4c6a0ff5d60c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_234874bf-c13c-4027-9389-b0792e0ac2ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:FacilitiesSupportCostsAndDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_240704ca-648b-4cb8-8da2-42d785c931ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_251f3b55-1dd2-4781-ac6d-0744e7ac38e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_2660b123-4ea6-43ac-8972-4157c6a3c040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="C_2801a74a-99e4-4308-a905-51778ab0e93c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:FinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_280682ef-880f-4702-8298-d09656436400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:LegalSettlementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_281acdc8-b177-4854-8880-10164275dc04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lyra:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="C_2908a678-6f00-4335-9ad2-8248e7e3b60b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2ea1e700-e522-466c-b768-f653aab494c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2f8edc3c-5429-4955-94db-7cf00859aeda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_31f58a76-705e-4546-91b9-77d2761bcc2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_32d5f8cc-4a3c-458b-8470-64a2b106b53b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="C_333d0a42-02ed-432e-82bf-5297563b9a25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3468569a-416b-4f26-96d4-911b0ce51a8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_346d080b-939c-4205-b5bb-6f8ce864f627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_37068379-d31d-4d98-a4d1-2e6f4f1ef031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_372a66a4-61dd-407b-a6a2-2b15c95d67ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_37541621-a0f6-46b9-a350-96d677fcfc2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3921f74d-c549-48e7-9cfe-f514102c6219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_397e0276-799b-4130-992e-a0f2da30c71c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3a120243-ed89-4f6b-be0c-34e7f9595719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="C_3a371107-2d9a-4f5c-8c37-b98e3086c62c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="C_3c311591-1876-4a38-97cd-e253457c022f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lyra:ImpairmentOfRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3cfae322-7814-406b-94d8-6c27a76311a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3d311cd5-55b8-42d3-8218-5c0087ca6b10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3db47ea0-1f9a-4383-be26-a1363ba1cbea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_3db95ee5-7b8d-409d-bb0f-d7092ea5f6f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_403a3ca8-bf23-400e-b0db-4d041b2b8b46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_40f95a2d-f39f-40de-84f9-da9cf7468367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4175d822-423f-49b4-b933-6156169f74f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_420d91c9-ecfc-4744-a255-788637fcb6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_433f45f3-222a-4c22-aadf-b142c5221803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4489b4bf-2198-4ebe-a1bf-695353f66282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="C_45126bd5-3587-4e96-98ac-59bdd46c63ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_45156f90-0a3a-42c8-9a1d-54c60279f926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_473aaaff-01e3-4509-bda8-ca01929294c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_478d5703-d418-4d23-b8de-ef04cf2df0c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_47fa54a6-2356-4b08-84c8-0df296adece4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_488bc5f4-10ce-45bb-95b7-d15c658c6b6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4969eb83-d672-422a-8e4f-a3bcb59d12f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">us-gaap:ErrorCorrectionOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_49c96c91-10ba-4114-a86d-ac6dc268373f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4a249401-3b7d-46fd-80ef-cb608151b1c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4b8292bd-93d8-4684-8cfe-8f2b9dd35c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ce73bf9-81de-427b-88a0-9148395b04ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d2b77e5-3c41-49f6-87a3-e99ca4394a5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_4dc62508-709f-473e-ba30-98fa0a06a2b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4e3aa3ed-daf5-453c-8203-7ffec41710a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ClinicalRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4fa89b2f-0fcf-42bb-8c6c-336ddd1b20ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5422cf85-ab34-4c8d-83a9-3f689e53bb52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57cb61d3-40d3-48d2-9f7a-c577d8ec047d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:EmployeeRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_57fb40b9-1300-49dd-abdb-a8199037cd9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5813d5de-532a-4e0e-af8e-993c31bd435f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5958571f-14a8-4ff8-a57a-1abe43eab75e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5a610f2d-1ed4-4ce1-9e6a-09068ac8d582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_605136ee-faca-4595-aa05-236b9cffe793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-02</instant>
        </period>
    </context>
    <context id="C_6137d41a-fa82-43b5-b6fb-bc98341150d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_61649002-24c3-41d8-9ae0-4fc54a732edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61c081e9-803b-4a01-830c-fe9cae97644d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_626e5a02-1411-4526-aa75-ce7297c15f35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_62e1129c-aef1-4103-970b-5c338ee35c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6418a52e-c88f-4b7e-b4d3-3e67f8c4d58d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_67686643-4752-4ca8-a5d1-4b5b2a07cb16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_68ef0c58-1c01-442d-9687-3c37bfae23d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lyra:MariaPalasisPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="C_69975709-688b-4d92-8cdc-d1d390a6e165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6c6217df-e212-4852-b745-042bc4d04033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6cd8d3f0-2e97-4106-9cea-1f0c4afe5e89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:ProfessionalConsultingAndPublicCompanyCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6cf8ced9-80e4-4607-86de-cb5d54cf5d13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6e329cfb-354c-4c3b-b489-59580eb7b3fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6e6920b6-a5cd-4c38-83d1-289485f945cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e6ff448-8d27-4434-ba19-87a416e47d57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7179b286-9afd-4afa-b79c-9e3a7b080f4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_71badc65-a44f-452a-aa75-c16093a3462e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_730f05ff-8e87-4546-b39e-fa70f5bfc2d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="C_73b2f5f2-5a24-429a-97e0-73eea6990ad7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_73dd090c-1ed2-47b8-9a90-b7e929765864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_74f98c49-91bf-4f2d-9c5b-151230a7e6b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lyra:EmployeeRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7610c97e-2aed-4d93-8ea6-f8005b036844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lyra:RetentionCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">lyra:TwentyTwentyFourRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_763123a3-30dd-4427-b10e-b4e51ac7debc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_76dcfeb5-6b92-4328-8676-8ad9414800c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="C_772f9e37-d7a0-4ed6-b29c-901e928669b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="C_776bd276-c2c1-4b3d-bf69-ffc77fd2d52e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_788a6a79-f3bb-44f9-a6a5-ec8d29c9b846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:MarketBasedConditionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_789b1913-2263-46dd-834b-d5389e9dab08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="C_78cb6b9c-1c43-4ef8-965e-5c3e825546d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:TwoThousandTwentyFourPerformanceOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>lyra:Segment</measure>
    </unit>
    <unit id="U_Rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Lease">
        <measure>lyra:Lease</measure>
    </unit>
    <unit id="U_Security">
        <measure>lyra:Security</measure>
    </unit>
    <unit id="U_Employee">
        <measure>lyra:Employee</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Vote">
        <measure>lyra:Vote</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_16068dac-d0e7-4be3-8b2f-a9aa30ceff5e">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_d0a29375-54d1-4720-8e50-c58732727f53">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_19335553-f48f-4a14-a18e-87c61cff5766">0001327273</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      id="F_3f0045f0-3fff-4e61-b86a-d3810d5684d8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      id="F_05ec1fb1-1dd3-4023-b23a-af84bcab4881"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      id="F_2511519b-36bc-46ee-8366-ebaa53d26f96"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      id="F_b343ec9f-148d-44d4-9d08-7d94b8644011"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_075aff53-3972-401b-9e57-6d6327e23180"
      id="F_9ae5f059-46cf-4fcf-b57c-b976764721ac">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627"
      id="F_12091721-daa6-4615-9374-7423de9475e8">http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627"
      id="F_d1514240-d93f-4827-833a-208926ab2d2a">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627"
      id="F_37e2bd47-4207-458b-957f-6e4048e1644e">http://fasb.org/us-gaap/2024#Liabilities</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_88da49e1-0053-471c-838d-493a47149bc4">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_7574a635-981a-4973-932d-d749f0f65056"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_f8426778-65fb-4dfb-9474-719fbdef584a"
      id="F_97b57973-2894-41e7-86a2-433229fcba95">2027-04-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_d910c3ca-d394-46d2-b9b9-f20df1877ad1"
      id="F_3543bcc5-79e8-4350-8931-cc3cab71a166">2028-05-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_9efeb578-258e-4154-b77e-f69b4276c86d"
      id="F_8e41f92a-aad6-47ad-8661-51315d4fb579">2026-02-28</us-gaap:LineOfCreditFacilityExpirationDate1>
    <dei:DocumentType
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0c052b22-1166-4212-bd51-c09eba22f45f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0d0c4abb-dfaf-4d09-81e7-47c1b52bf2fb">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_d14a0e82-cebe-493d-b787-537dbd1f9731">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c2a1a42c-cae8-42ee-909b-4ed29a98b363">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_cb6ce677-c4a9-4331-97b5-a2b6570d5e79">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0250c05b-d86d-4075-ad0d-baf9f9bf5ce9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_f861b0af-82b9-43f7-a87f-c5ae1f447b31">001-39273</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_f5ee8211-999c-4d9c-a5d3-293002f6aff9">Lyra Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_6927425e-e8e6-46a4-bc7c-e88eca410c6e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_9d5638be-86e3-4cc7-9afa-512030b61c73">84-1700838</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_940c9184-a368-4abf-8932-13771445a6f7">480 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_40d53846-298c-4b28-93a4-5d75d782741f">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_eef99c3d-a00b-49ac-b58a-03da9b1dda93">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_39e913e6-9b6a-466e-b8ce-1dc619638e75">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_315784c8-86be-49cd-aa36-2a4b94bb7b5f">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_710e1c55-bdcd-4006-a88e-fac0fb41bfa6">393-4600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c444e7a1-12c4-4787-a41a-14fd6e62329c">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_74119fab-8abb-4476-9c94-b2c3f45ddc93">LYRA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_a9434aed-4425-464f-ba93-859113210e7c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_047e1de6-a0ad-49ed-8382-8c5fd16a228c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_1a729ea7-2068-4b45-9b22-0aa8886f5b7c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_b2c307d8-4b94-471a-b33d-3082be6269d8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_e3d89a1e-257f-4f88-bf8f-40b2e0b352dc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_e9e85876-b2fe-42f1-83be-6e6d3bd03e58">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_ab484881-a587-4c8d-8c15-22c2838fd057">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0763eb1b-ab65-4d72-982a-201675d43bd3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_d082fbfc-f342-4c25-8fbf-1be729373caf">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_9c56ed74-ebc2-4ca1-9049-d1eb3c734bd9">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_710c584e-9f14-4a96-8131-111038717fc0">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_1e52d876-8624-4935-a3f2-a5e7447dfb2a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_251f3b55-1dd2-4781-ac6d-0744e7ac38e3"
      decimals="-3"
      id="F_19220a2f-f258-46f2-bb18-43359ec7bdd1"
      unitRef="U_USD">13803194000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_3db47ea0-1f9a-4383-be26-a1363ba1cbea"
      decimals="INF"
      id="F_8c7d7f2a-a86b-4095-8bee-30c23e338885"
      unitRef="U_shares">65880561</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_f961fd6f-9fac-4662-b0df-796c4ca48ea2">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_8f217861-4071-4df8-abe8-cc0c7b3c1f5b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We design and assess our program based on the core principles of the National Institute of Standards and Technology Cybersecurity Framework, or NIST CSF. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is integrated into our overall enterprise risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a lead IT person principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity awareness training of our employees, incident response personnel, and senior management; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a third-party risk management&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; process for service providers, suppliers, and vendors.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;See &#x201c;Risk Factors &#x2013; Our business, financial condition, and results of operations may suffer in the event of information technology system failures, cyberattacks, data security incidents, or deficiencies in our cybersecurity.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team&#x2019;s cybersecurity experience is limited.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;alerts and reports produced by security tools deployed in our IT environment&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0233e157-4a50-4649-a03b-d37d12ce88b7">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is integrated into our overall enterprise risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_00bf8bf0-432b-4ddb-a01d-40efafcbc9bf">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_e0c515cf-0144-41a5-9d23-88fcf4d3c4b6">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_86871cf6-f960-4e3d-8ce6-0c717f46e08a">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_999216cf-f680-4675-bf7c-f458b4d9d18f">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0ff9674c-81e6-4086-b438-11e5e08ddb83">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team&#x2019;s cybersecurity experience is limited.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;alerts and reports produced by security tools deployed in our IT environment&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_44c1fdf2-9014-4672-889b-ba222b76b0a7">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding significant cybersecurity incidents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_36b478a9-3fdb-4dc8-a863-fb254baad514">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_8a8e5372-c498-4611-8e89-bc30d99bf9ab">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team, including the Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team&#x2019;s cybersecurity experience is limited.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;alerts and reports produced by security tools deployed in our IT environment&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_887f710e-b826-4ce8-b419-1f90cb575e68">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_52b86cf8-caad-44b6-af67-571764ecf58d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CFO has primary responsibility for our overall cybersecurity risk management program and supervises both our internal information technology personnel and our retained external cybersecurity consultants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team&#x2019;s cybersecurity experience is limited.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_95040a32-56e9-459f-86fd-74833ed98e0c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team&#x2019;s cybersecurity experience is limited.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_90c28e3a-993a-42c1-b360-22629996b6aa">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team stays informed about and monitors efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include: briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;alerts and reports produced by security tools deployed in our IT environment&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0a92416b-667d-4882-a99b-a5b13eadf340">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_fcf36a73-5344-415f-b95c-0bbadc656fc2"
      id="F_6256b293-b445-4a78-ae5e-4d8bbe77d68a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a) On March 6, 2025, the Company&#x2019;s Board of Directors approved amendments to the employment agreements with each of Dr. Palasis, Dr. Waksal and Mr. Cavalier that modify the form of payment of any cash severance that such named executive officer becomes entitled to in the event of a qualifying termination of employment, in accordance with the terms of his or her respective employment agreement, from installments to a lump sum (and, in the case of Dr. Palasis, such modification is only to the extent permitted under Section 409A of the Internal Revenue Code).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;b) During the fiscal quarter ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, none of our directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) informed us of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;modification&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;termination&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as those terms are defined in Regulation S-K, Item 408.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_8550b4b7-6090-4399-a279-2b5260027481"
      id="F_a3f5be70-36e2-4b00-9f26-f5955c42124d">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_8550b4b7-6090-4399-a279-2b5260027481"
      id="F_409dbf14-dbe9-4a87-97b4-0aace3e8b7f3">false</ecd:NonRule10b51ArrAdoptedFlag>
    <lyra:Rule10B51Arrmodifiedflag
      contextRef="C_8550b4b7-6090-4399-a279-2b5260027481"
      id="F_14429c5a-b227-4464-aa4a-87de54a9e9c5">false</lyra:Rule10B51Arrmodifiedflag>
    <lyra:NonRule10B51ArrModifiedFlag
      contextRef="C_8550b4b7-6090-4399-a279-2b5260027481"
      id="F_3f3af547-0c31-4c31-a97e-a50d567076ce">false</lyra:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_8550b4b7-6090-4399-a279-2b5260027481"
      id="F_4a1dc695-81bf-4636-ac1c-89a56324d412">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_8550b4b7-6090-4399-a279-2b5260027481"
      id="F_e06650b9-1322-4d29-917c-90b8a486fd3d">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_68ebaf2b-7579-4bad-8102-790c58fbf20e">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_50d0b083-68f5-47ed-ac5e-913770341204">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We do not grant option awards in anticipation of the release of material nonpublic information and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we do not time the release of material nonpublic information based on option award grant dates or for the purpose of affecting the value of executive compensation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; we do not take material nonpublic information into account when determining the timing and terms of such awards.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In fiscal 2024, we granted stock options to Dr. Palasis within four business days before the filing of our Annual Report on Form 10-K for the year ended December 31, 2023. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table is being provided pursuant to Item 402(x) of Regulation S-K regarding such stock option grants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of securities underlying the award&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise price of the award&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant date fair value of the award&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maria Palasis, Ph.D.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 18, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maria Palasis, Ph.D.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 21, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;550,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:MnpiDiscTimedForCompValFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0d991940-623e-4369-98e1-4c22f28b9338">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:AwardTmgMnpiCnsdrdFlag
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c70129b2-8fa4-4b72-95d0-2276a524b643">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:AwardsCloseToMnpiDiscTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_2052ed7b-3003-4fed-94f5-90ef8baac295">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table is being provided pursuant to Item 402(x) of Regulation S-K regarding such stock option grants.&lt;/span&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of securities underlying the award&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise price of the award&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant date fair value of the award&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maria Palasis, Ph.D.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 18, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Maria Palasis, Ph.D.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 21, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;550,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ecd:AwardsCloseToMnpiDiscTableTextBlock>
    <ecd:AwardsCloseToMnpiDiscIndName
      contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc"
      id="F_37560b1c-ebc6-48db-a351-71e649d751c3">Maria Palasis, Ph.D.</ecd:AwardsCloseToMnpiDiscIndName>
    <ecd:AwardUndrlygSecuritiesAmt
      contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc"
      decimals="INF"
      id="F_5a5010cd-7f64-4ed0-a4a4-32a601c28bb9"
      unitRef="U_shares">500000</ecd:AwardUndrlygSecuritiesAmt>
    <ecd:AwardExrcPrice
      contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc"
      decimals="2"
      id="F_d3992648-1d6b-4e05-af5c-f43560dbfdc7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.77</ecd:AwardExrcPrice>
    <ecd:AwardGrantDateFairValue
      contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc"
      decimals="2"
      id="F_f23ec4b5-d0fa-4040-b2a0-00f5a5cd4390"
      unitRef="U_USD">4.02</ecd:AwardGrantDateFairValue>
    <ecd:UndrlygSecurityMktPriceChngPct
      contextRef="C_13349549-b2ec-4e54-b662-5d13b5935fbc"
      decimals="3"
      id="F_ab771e3c-767b-42a9-be63-6406956d9ae4"
      unitRef="U_Rate">0.015</ecd:UndrlygSecurityMktPriceChngPct>
    <ecd:AwardsCloseToMnpiDiscIndName
      contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0"
      id="F_15ba66d5-09cb-4421-9493-1c6a303b3183">Maria Palasis, Ph.D.</ecd:AwardsCloseToMnpiDiscIndName>
    <ecd:AwardUndrlygSecuritiesAmt
      contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0"
      decimals="INF"
      id="F_58003a3b-81cc-4cc6-822f-3e2be09632a8"
      unitRef="U_shares">550000</ecd:AwardUndrlygSecuritiesAmt>
    <ecd:AwardExrcPrice
      contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0"
      decimals="2"
      id="F_fdc8e692-0565-4c97-8506-f105a18ce303"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.07</ecd:AwardExrcPrice>
    <ecd:AwardGrantDateFairValue
      contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0"
      decimals="2"
      id="F_fae145d9-8ccd-4f2f-bc6f-01a3a83b944a"
      unitRef="U_USD">4.23</ecd:AwardGrantDateFairValue>
    <ecd:UndrlygSecurityMktPriceChngPct
      contextRef="C_68ef0c58-1c01-442d-9687-3c37bfae23d0"
      decimals="3"
      id="F_9dcf4682-6ade-458d-9e7d-ea85fd0755b0"
      unitRef="U_Rate">0.015</ecd:UndrlygSecurityMktPriceChngPct>
    <dei:AuditorFirmId
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c4304478-0686-4aa3-9d2a-5f1a3346f949">243</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_88944a0f-b0f5-4218-9082-649c092ee129">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_4074f077-bf5f-4137-846f-8a105c2d0fb1">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_a118b544-91cc-4701-b8fc-69b015bb221a">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_4bd7a42c-c4c3-4100-93c6-3f3d810db604"
      unitRef="U_USD">40577000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_46335d74-6fce-486c-94c1-622d21192f58"
      unitRef="U_USD">22353000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_35d72988-19eb-4645-9d6e-39c530e12c4f"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_c868ddef-5d12-4b71-b7b4-f2198d6282af"
      unitRef="U_USD">80400000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_3a80c7a3-7b49-4eae-bf03-f43535b456ee"
      unitRef="U_USD">2448000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_1a04a936-fa67-42b4-9f70-1b411803ab89"
      unitRef="U_USD">2068000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_a14cfee1-46f1-4fce-bb6f-d3f149aba020"
      unitRef="U_USD">43025000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_40554d04-a63b-4614-b32d-2791712e29db"
      unitRef="U_USD">104821000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_28d74e78-5238-4bfd-9c86-5f8817438aa5"
      unitRef="U_USD">1404000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_54f3c9a9-04c0-4894-a91a-16e18b46d639"
      unitRef="U_USD">2043000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_83a7ba89-0694-4a11-b9a9-535b28863f93"
      unitRef="U_USD">19924000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_f7fe00a8-bc9f-4381-8caf-b6d88dfe4cb8"
      unitRef="U_USD">33233000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_94e36d90-da31-4a9c-b9a3-73074ccafa16"
      unitRef="U_USD">1993000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_08a5eb1e-5818-4874-a748-31df611acf64"
      unitRef="U_USD">1392000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_16438f2f-8b54-4850-81de-1c6e7a87ad4b"
      unitRef="U_USD">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_c5be97b0-16a7-4466-881b-fe9aacd16739"
      unitRef="U_USD">1111000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_3cbdc23c-f8fd-4a40-ba5f-28c883c41f97"
      unitRef="U_USD">66346000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_35cf8ea6-3394-40bf-9324-fcfad54e813c"
      unitRef="U_USD">142600000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_4b1afbef-b8a1-4859-ad6d-8f6a9535fd27"
      unitRef="U_USD">1179000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_7c7c55af-86e2-40ce-b1ef-95ed4ef75c47"
      unitRef="U_USD">3131000</us-gaap:AccountsPayableCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_66d51420-e4df-4dfc-ab77-fbe69db53c14"
      unitRef="U_USD">4347000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_10333a18-f501-4d39-a2f5-908d51f1d791"
      unitRef="U_USD">2586000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_f48f3460-7e06-44e5-8370-b884dede9881"
      unitRef="U_USD">9374000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_31ca1f96-3024-4262-b56f-a5ab3f110642"
      unitRef="U_USD">4121000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_2fdcd5f2-a126-4054-8ca5-d7583a7e9f5a"
      unitRef="U_USD">5434000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_6306ab77-21fb-4444-8e47-c1688abe635f"
      unitRef="U_USD">398000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_54ca420f-e48b-4c83-9db9-6018f25947ac"
      unitRef="U_USD">1658000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_af135b73-eff2-4273-b307-53be9b69bc7b"
      unitRef="U_USD">12631000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_9c0924f3-9d4d-4f1d-b760-5756ee7b7d17"
      unitRef="U_USD">19597000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_abfec8d6-8037-4902-a6d1-84d698cdeb90"
      unitRef="U_USD">30259000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_071e11bb-e11f-4e6d-8cfe-5e71e066f9ed"
      unitRef="U_USD">21447000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_5370f6aa-83e4-4f87-a53d-271b5685e702"
      unitRef="U_USD">11862000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_08c247f4-4514-48ed-a651-6e0d16c04597"
      unitRef="U_USD">12136000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_1c033499-005a-4830-becf-c8e2b3f8cf58"
      unitRef="U_USD">54752000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_8e3551d9-52e6-4ddf-a1a8-aa611227adf0"
      unitRef="U_USD">53180000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_f3ba7100-9d0d-42ef-82e3-71315b81ae20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_219661ae-d571-4b75-a7d5-17f36cc8e281"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_2edb7341-8fc8-4878-b016-9e25087d35d9"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_3e06e9fa-8a79-4c6d-97be-148f6b61ab60"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_af521c56-f61e-4c5f-8f8b-7248a6518d6c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_40581430-cbe4-43e9-bf50-0e2ad8ffe713"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_990c9b70-4234-4b57-8bf1-8cec5ab096d2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_56a8abdb-2faa-4162-a148-aabf74aa19ef"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_444c2379-f2e7-4179-a1b8-a590381ae6d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_c916148a-32f6-4224-b2da-eae6f077acc2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_50c28ddd-cfb9-481b-a7b2-9ae4ac543dc5"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_eb58f0a7-cf15-4b44-983f-69d2b97ce1e1"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_66674cd2-ce5a-420b-86e2-c2edb0b9b793"
      unitRef="U_shares">65515440</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_43debed6-9e26-4e29-87ae-2a9de7318901"
      unitRef="U_shares">65515440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_87a9684b-cec4-4523-97c9-246b573ed73c"
      unitRef="U_shares">57214550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_cf1a1154-a3a1-4c18-9d35-6b84ef5cb2e3"
      unitRef="U_shares">57214550</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_3ce1fcef-c6d7-4fcb-be2d-3153ada87d2f"
      unitRef="U_USD">65000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_48e60a13-4b20-41fc-86a3-529003b49931"
      unitRef="U_USD">57000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_4eb79b7d-78a6-46ff-9925-87ee388c845f"
      unitRef="U_USD">416319000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_c3ccfe2e-597c-44c9-b08f-81389e84311a"
      unitRef="U_USD">400685000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_5158de1c-6c07-4042-b5d5-aff4fb5fe463"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_f5596692-a67c-4f63-9dc7-76303e836176"
      unitRef="U_USD">33000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_059e5cf8-67fb-4b85-b447-d52bd41f5c21"
      unitRef="U_USD">-404790000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_e490c277-cb74-43e4-a442-adf7da01015a"
      unitRef="U_USD">-311355000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_2a636f06-b2fd-4b21-9920-f66a7da999b0"
      unitRef="U_USD">11594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_8e7f8be3-7abc-4f7c-a56b-a912db317c6b"
      unitRef="U_USD">89420000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_1d5f954b-b61b-495c-8ae8-bf2abee2585a"
      unitRef="U_USD">66346000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_079eded6-67ea-4abe-8c12-ebe2059b4c53"
      unitRef="U_USD">142600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_ebfa6d88-ce3c-4878-b161-deeebd3a05e5"
      unitRef="U_USD">1534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_8e1fa0dd-9e56-414d-a023-b49728d95c09"
      unitRef="U_USD">1558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_a37d2218-b59a-4b45-82ce-5cad58568193"
      unitRef="U_USD">43766000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_af8fe171-e565-48d5-8ef2-f219c7f2b181"
      unitRef="U_USD">48029000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_59c70c3f-6ade-457f-a202-eac3fbc83db0"
      unitRef="U_USD">18501000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_fb6969bd-60e1-41fd-a79a-f66416d01855"
      unitRef="U_USD">19057000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_94691ff6-8241-430c-aff8-97637f7bd004"
      unitRef="U_USD">1883000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_46817996-a44e-49e0-a96f-0f67a24a1d45"
      unitRef="U_USD">1592000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <lyra:ImpairmentOfRightOfUseAsset
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_3076e161-2cde-41a7-b6c1-5fa0ca6660af"
      unitRef="U_USD">22836000</lyra:ImpairmentOfRightOfUseAsset>
    <us-gaap:RestructuringCharges
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_5820370f-9c26-4844-981d-274d17b4c112"
      unitRef="U_USD">10896000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_f6656054-3c7a-43c9-a032-da439ee81c8c"
      unitRef="U_USD">97882000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_0aed609d-75af-48fa-8ac8-d2e9ec3ba12c"
      unitRef="U_USD">68678000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_8fb785f1-cefa-4a5b-8083-684d9c724e69"
      unitRef="U_USD">-96348000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_9a837204-c0cd-4c98-9ab3-00ef37887136"
      unitRef="U_USD">-67120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_127a00e3-4694-4343-a2cf-a20b4ca95003"
      unitRef="U_USD">2952000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_a3716386-7d37-4f06-9258-3383e7ed4ec9"
      unitRef="U_USD">4499000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_a8f2ff59-f4e7-4428-8d4a-5cf67dc67b67"
      unitRef="U_USD">2952000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_d7fbba6f-4fb1-4ec8-baa5-eaed91af977c"
      unitRef="U_USD">4499000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_34005d64-6e39-4490-a9fd-eb63038b68c7"
      unitRef="U_USD">-93396000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_b97eb18f-4b09-4a94-bd72-9d360fabc38a"
      unitRef="U_USD">-62621000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_1ead9301-79a0-4321-9f62-25e0aecb3a5b"
      unitRef="U_USD">39000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_605dccb5-2ce6-485b-b338-c336b6cdaa4c"
      unitRef="U_USD">59000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_7adde3e9-6434-4a4a-84c1-cc867b6c222a"
      unitRef="U_USD">-93435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_9f766c6c-87a6-4c5f-bdbc-8bcad77e2e0e"
      unitRef="U_USD">-62680000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_4a8ef1ae-d936-41ed-8b9a-5e1fd43b08d4"
      unitRef="U_USD">-33000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_ba704365-b50d-4c85-9f81-ad89feb8bdae"
      unitRef="U_USD">23000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_e7a0d4af-0d4a-42bd-92df-18770caf14d6"
      unitRef="U_USD">-93468000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_30dfc59c-2c40-4b87-8a3c-c749852e27da"
      unitRef="U_USD">-62657000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_c4f5ab55-89e7-4258-a03b-8c56daebb24e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_eeae575b-b47f-472b-a070-17011e294f7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="2"
      id="F_1e10b7aa-7312-469e-bb75-e44167c2003d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="2"
      id="F_fae4b434-a5a5-48a3-8e5b-b2f2898fa01a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="0"
      id="F_3193d47d-255f-4a16-9ca1-5d1a0a82591d"
      unitRef="U_shares">65113859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="0"
      id="F_f5dea936-c6d3-4dba-9508-6b8b451e44c4"
      unitRef="U_shares">65113859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="0"
      id="F_2b8b8745-da9b-492b-aff7-ebab5646ccd5"
      unitRef="U_shares">49804283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="0"
      id="F_82647092-93fa-44c7-bac0-890564d585c8"
      unitRef="U_shares">49804283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_bf748116-4ebf-40ac-bff9-35c1fb5ed691"
      decimals="INF"
      id="F_045219b4-57a1-4b2c-b209-19371daa136d"
      unitRef="U_shares">31827659</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bf748116-4ebf-40ac-bff9-35c1fb5ed691"
      decimals="-3"
      id="F_9250e099-508a-4de6-ab91-b6984b9a20df"
      unitRef="U_USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_61649002-24c3-41d8-9ae0-4fc54a732edd"
      decimals="-3"
      id="F_8bf15ccf-ff25-45e6-9df2-b99d5e94bc4b"
      unitRef="U_USD">329387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a610f2d-1ed4-4ce1-9e6a-09068ac8d582"
      decimals="-3"
      id="F_7ec5401c-b3d8-4123-94d2-ecce87719c10"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57fb40b9-1300-49dd-abdb-a8199037cd9a"
      decimals="-3"
      id="F_67b7b14f-2dea-4152-9bed-de0ee755d422"
      unitRef="U_USD">-248675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_194bf10a-3e96-4e60-85a1-7fac540a46ce"
      decimals="-3"
      id="F_b971ed35-2911-4bde-9a84-90bfacac1936"
      unitRef="U_USD">80754000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="INF"
      id="F_0444bb47-8198-4951-b10c-97529f51cea1"
      unitRef="U_shares">57897</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd"
      decimals="-3"
      id="F_31e872de-9f7f-49a3-9f43-e71c773a9a6f"
      unitRef="U_USD">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_e0d8ba8b-2828-4cf3-9a1f-9067b3cadb82"
      unitRef="U_USD">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_0da16dc8-0d43-48b1-bb9f-662f90143eaf"
      unitRef="U_USD">3482000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="INF"
      id="F_7865dc44-2048-4600-be0c-eff2eee11105"
      unitRef="U_shares">17652962</lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="-3"
      id="F_345288c3-f55e-4b95-b596-42f176fd5824"
      unitRef="U_USD">18000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd"
      decimals="-3"
      id="F_d3a812d6-61bb-4724-8488-06e33257215f"
      unitRef="U_USD">46500000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_45d02e3f-4cc2-4666-960e-465b1c7c543d"
      unitRef="U_USD">46518000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="INF"
      id="F_2dc27005-3ed9-401f-b6fe-bd5185c656fc"
      unitRef="U_shares">7041</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_c9aae08b-647b-4917-91f5-0e67b5b4eb3a"
      decimals="-3"
      id="F_1c9db127-bb33-445e-b096-a948ea6586c6"
      unitRef="U_USD">172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="INF"
      id="F_264b5e2f-6304-4b38-a708-062ca524375d"
      unitRef="U_shares">6017568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="-3"
      id="F_0cfc204e-5209-4576-9e9c-d364801ac065"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd"
      decimals="-3"
      id="F_074a52c6-4ad0-42df-9ab6-6791b0087fe2"
      unitRef="U_USD">19062000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_34b60240-104c-4890-8216-e9895e3b4239"
      unitRef="U_USD">19068000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lyra:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="INF"
      id="F_bbbdafe6-b8d7-4dd1-b82b-42a0e04e270d"
      unitRef="U_shares">1651423</lyra:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
    <lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants
      contextRef="C_9780270b-2928-4f2c-b42b-5d857b4e3091"
      decimals="-3"
      id="F_efad70ed-14ce-4e18-accd-257cf8f1882c"
      unitRef="U_USD">1000</lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants>
    <lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants
      contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd"
      decimals="-3"
      id="F_2ebd8097-a67c-472b-a37f-31b99e3a2117"
      unitRef="U_USD">1000</lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants>
    <lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_1ff732bb-3450-4dc8-a94b-363c21bd9e0e"
      unitRef="U_USD">2000</lyra:StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_69975709-688b-4d92-8cdc-d1d390a6e165"
      decimals="-3"
      id="F_3b9a7494-23f5-4d63-9830-290b5ecaee15"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_107e7d85-47e8-4274-bec1-cf13bd295710"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bf9f91dc-7172-4932-b01a-d6ef4166edfd"
      decimals="-3"
      id="F_ae1d5370-b461-46b2-92b1-0ba22aa60c28"
      unitRef="U_USD">5632000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_547b0232-c34a-4d72-935a-f7bd9247e6c0"
      unitRef="U_USD">5632000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_4175d822-423f-49b4-b933-6156169f74f7"
      decimals="-3"
      id="F_08b2684e-12a3-4655-aa54-9bd75c167055"
      unitRef="U_USD">-62680000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_67519a8d-9be1-442e-8bc7-12c90826f4dc"
      unitRef="U_USD">-62680000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_f932f338-d1f5-448c-91af-c2103ea85652"
      decimals="INF"
      id="F_0053508b-82b8-4242-9be1-662da3a53dd5"
      unitRef="U_shares">57214550</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f932f338-d1f5-448c-91af-c2103ea85652"
      decimals="-3"
      id="F_7f3105a6-cf42-4ddd-bd41-305098a0a3b8"
      unitRef="U_USD">57000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45126bd5-3587-4e96-98ac-59bdd46c63ec"
      decimals="-3"
      id="F_3d9905c4-b2ef-4819-8f2d-c34acdd28d03"
      unitRef="U_USD">400685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3921f74d-c549-48e7-9cfe-f514102c6219"
      decimals="-3"
      id="F_9fd41176-3cef-46d7-aac4-6146f349150b"
      unitRef="U_USD">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2ea1e700-e522-466c-b768-f653aab494c5"
      decimals="-3"
      id="F_2ad9fc27-000c-4262-9ae8-ef06110ff971"
      unitRef="U_USD">-311355000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_193f02bf-9523-46af-ab64-963882d43523"
      unitRef="U_USD">89420000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="INF"
      id="F_f41bed95-801d-4b03-be86-cf202c4e01bb"
      unitRef="U_shares">1002</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e"
      decimals="-3"
      id="F_42bcdca0-20ae-4fdb-a06d-151af547439b"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_e1786513-d627-4c40-b319-245131c7946f"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="INF"
      id="F_d22cf200-5fa4-4797-953d-b4e86ac973d2"
      unitRef="U_shares">5746376</lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="-3"
      id="F_3b988732-aeab-4165-a093-c3ed46cbf36a"
      unitRef="U_USD">5000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e"
      decimals="-3"
      id="F_e37524b2-3aba-47a9-9fc7-d2e1641ada40"
      unitRef="U_USD">5000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_c3c57bac-5782-4be3-8284-53dc4b3f0748"
      unitRef="U_USD">10000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_b0c1652c-3b2c-4e34-a9b2-16cba734c265"
      decimals="-3"
      id="F_9855dd27-0928-42c3-b87e-1135291ad5e1"
      unitRef="U_USD">150000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="INF"
      id="F_436a7b21-bd31-4f8e-a979-a71147742eb0"
      unitRef="U_shares">1041666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="-3"
      id="F_c21ca04b-8ac5-48e2-a480-b481dbb5f430"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e"
      decimals="-3"
      id="F_a351ad4d-3729-42ec-9d58-5dbb3d8a4488"
      unitRef="U_USD">4849000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_3830e396-7d9d-4925-a174-5da802c045b6"
      unitRef="U_USD">4850000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="INF"
      id="F_fcb6fcd9-7a70-4538-b61d-233c6f23bf79"
      unitRef="U_shares">1000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <lyra:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="INF"
      id="F_82a377bd-ae18-40d8-9b6b-9e21aa9c72c4"
      unitRef="U_shares">1424272</lyra:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
    <lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="-3"
      id="F_a7df2a4b-4130-4d14-a913-931db9624926"
      unitRef="U_USD">2000</lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants>
    <lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e"
      decimals="-3"
      id="F_46a124fe-9545-4747-8d4a-70f7ecb915ce"
      unitRef="U_USD">3806000</lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants>
    <lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_2690be80-6fef-43a4-bcdf-614bf7edf4d7"
      unitRef="U_USD">3808000</lyra:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_56a2647b-37ed-4bc6-98b0-b635fcb57c9c"
      decimals="INF"
      id="F_90202df3-b91b-4ca5-94f2-762966f851b6"
      unitRef="U_shares">86574</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_6e6920b6-a5cd-4c38-83d1-289485f945cd"
      decimals="-3"
      id="F_b268c465-309f-4d3c-821a-97e1d8f2e5fe"
      unitRef="U_USD">33000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_c1f0533d-dd9e-48e0-b865-b1b26883a645"
      unitRef="U_USD">33000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5958571f-14a8-4ff8-a57a-1abe43eab75e"
      decimals="-3"
      id="F_e2e81e8c-75ef-473f-a3c6-a90ac0ff2034"
      unitRef="U_USD">6971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_871d9efe-d776-4644-ac93-01484e00116e"
      unitRef="U_USD">6971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0898fa9d-b760-4363-9f56-f980685e0512"
      decimals="-3"
      id="F_25ebda63-c5b6-4720-9ff0-434d5a9da56a"
      unitRef="U_USD">-93435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_c5abf9fa-70b5-4781-86ec-f0a5d0b3b55c"
      unitRef="U_USD">-93435000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_a1b363ff-1904-4c03-9f49-1ead948fba72"
      decimals="INF"
      id="F_a4244a66-016b-4b54-b2bc-0fe87660ca94"
      unitRef="U_shares">65515440</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a1b363ff-1904-4c03-9f49-1ead948fba72"
      decimals="-3"
      id="F_a753d58d-7b15-40d5-8f6e-c5e92da38230"
      unitRef="U_USD">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f87955f6-4893-487d-8bee-6137b9aa2886"
      decimals="-3"
      id="F_a1e97372-fcde-4772-acee-0839072b62ad"
      unitRef="U_USD">416319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_397e0276-799b-4130-992e-a0f2da30c71c"
      decimals="-3"
      id="F_d0647f41-c4fb-47b2-a6e0-378d33a1d214"
      unitRef="U_USD">-404790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_257ca228-5f1d-4b5d-99c7-0f9757a45454"
      unitRef="U_USD">11594000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_c3eda5b0-d26a-44a2-b8bd-8f14a525e11f"
      unitRef="U_USD">-93435000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_fff4a2ed-2e25-440b-9155-4a26540f4ad3"
      unitRef="U_USD">-62680000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_fe02415c-befe-4608-9e32-f10cb3ccfa9f"
      unitRef="U_USD">6716000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_1dfc3cfa-1b22-442f-af15-19a5476d4540"
      unitRef="U_USD">5887000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_9eeb518d-e0fb-4f69-b64e-b5f17238e0de"
      unitRef="U_USD">471000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_774e46c4-ecd3-4479-88eb-f7869fb1fc9a"
      unitRef="U_USD">278000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_20ad923c-edbf-4ef1-8310-9aecea0f3e30"
      unitRef="U_USD">1883000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_c9a086e1-6d78-4389-b94e-e7e81a6ef95c"
      unitRef="U_USD">1592000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_50fa1a97-ff5b-49b2-b31b-37d17e5d0dba"
      unitRef="U_USD">140000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <lyra:ImpairmentOfRightOfUseAsset
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_4b4ddf9a-265e-4b57-ab2d-3e23d0d7e260"
      unitRef="U_USD">22836000</lyra:ImpairmentOfRightOfUseAsset>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_ac2aad75-89ca-4ab0-9258-63c2333d11e7"
      unitRef="U_USD">2276000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_0b4164ae-127d-4951-ad49-a1ff2a868034"
      unitRef="U_USD">3496000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_e623f9e5-c404-42c6-90e7-59bfa79848cf"
      unitRef="U_USD">380000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_e2a40ce7-299c-495b-8b65-2f73f0eb358f"
      unitRef="U_USD">-867000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_58defadb-0c7f-4fb7-83aa-447a0a880103"
      unitRef="U_USD">-1353000</lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_bc2ec3a9-e2a6-467f-b025-05a336bdbabb"
      unitRef="U_USD">5137000</lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_38c3836e-1ad2-4310-be2f-c6edde76384a"
      unitRef="U_USD">-1111000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_1f0cde70-25ac-4490-b1ff-8a319f921323"
      unitRef="U_USD">-210000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_6ea982b7-5136-4c0f-9885-bc194dd14495"
      unitRef="U_USD">-1887000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_e74629fc-900d-40fc-b03d-0e5bf7c7face"
      unitRef="U_USD">450000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_ab680baf-a87a-49b5-94cb-2593eb320336"
      unitRef="U_USD">-5975000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_0ad5bfcf-2384-4816-97b2-e3c852df73bd"
      unitRef="U_USD">1491000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_fd026c66-f314-4e61-ab23-043fdca29336"
      unitRef="U_USD">4347000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_f3d7d2cf-cdb9-47fa-b97f-a0a3e35dbc07"
      unitRef="U_USD">-3381000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_8f6801cb-e105-40bf-aef7-702e47d0fc96"
      unitRef="U_USD">-1208000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_0d796d7a-c357-46d5-b750-c6961e0e9b96"
      unitRef="U_USD">-1534000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_294f773d-3e69-4bc2-9efa-650c90198566"
      unitRef="U_USD">-1558000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_906caf6d-3c76-434e-81fe-c642a8d8d31c"
      unitRef="U_USD">-70011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_9d5a9cb9-c60b-45a6-98b9-8bc309e54e06"
      unitRef="U_USD">-63304000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_5db2110d-cd1a-4c53-be39-1d1e799c2981"
      unitRef="U_USD">2338000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_f22af9bf-9a02-4f7c-9846-321f3829b243"
      unitRef="U_USD">1047000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_914ed25b-7cfe-4fec-a4a4-82d40c6abe07"
      unitRef="U_USD">47949000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_959e764b-4218-4fad-af3e-66fef170b35f"
      unitRef="U_USD">122423000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_599cfe6a-7d60-49af-a38e-9aa6474b6bde"
      unitRef="U_USD">130592000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_383998c9-180b-4f65-b329-2b4389d0ddfd"
      unitRef="U_USD">110886000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_1d099fed-915b-48be-9c46-08eeacfbad4b"
      unitRef="U_USD">80305000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_d4d8b89f-840e-4d24-a020-baf684ba4223"
      unitRef="U_USD">-12584000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <lyra:ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_33a72ef8-4e8a-43a0-92cf-64fb65d4f1a2"
      unitRef="U_USD">8818000</lyra:ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet>
    <lyra:ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_543403bd-2079-406a-aa97-7d3b9c1616d8"
      unitRef="U_USD">69242000</lyra:ProceedsFromSaleOfCommonStockWarrantsAndPreFundedWarrantNet>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_6ab151e7-c329-4353-9cb0-8a411364f9bc"
      unitRef="U_USD">290000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_267caf31-596a-406d-938b-6244ab63a854"
      unitRef="U_USD">3654000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_2a9e0539-7743-4f9e-b176-f2e9ae849e18"
      unitRef="U_USD">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_3cccd4f6-daf3-42bb-9b26-8b44203e74be"
      unitRef="U_USD">103000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_c2068171-a8fa-45d8-b7f5-1fd6d68e08e8"
      unitRef="U_USD">8531000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_bbd33cf1-df5e-43b2-a93d-300ba591724b"
      unitRef="U_USD">65691000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_27e84aa3-e887-4add-b0e1-9ef02592b606"
      unitRef="U_USD">18825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_a2e4585b-2917-46a4-967a-f2c0a0b8a361"
      unitRef="U_USD">-10197000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_c5f582e6-1eb9-4834-a164-6005208bc670"
      unitRef="U_USD">23745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_194bf10a-3e96-4e60-85a1-7fac540a46ce"
      decimals="-3"
      id="F_c4b3127c-1546-4cf2-8c8d-a5f46442af05"
      unitRef="U_USD">33942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_a335cb45-d5c6-45da-b5a7-6e2032fe814f"
      unitRef="U_USD">42570000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_abb36637-3be6-4250-acc5-7416920604ee"
      unitRef="U_USD">23745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_71ae9aab-7345-40a0-b252-2e842c2bd675"
      unitRef="U_USD">623000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <lyra:PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_74bc068f-d33f-4ddb-9470-a0697b1508ff"
      unitRef="U_USD">2786000</lyra:PrepaidExpensesForRightOfUseAssetIncludedInOperatingLeaseLiabilities>
    <lyra:ModificationOfLeaseAgreement
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_ec84e127-28ee-4b52-a313-5f9de351020e"
      unitRef="U_USD">4931000</lyra:ModificationOfLeaseAgreement>
    <lyra:OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_722d5188-0c83-412a-a9cb-9c1446ff97cf"
      unitRef="U_USD">13667000</lyra:OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_a74ed570-ebd7-490a-bd4c-3ab1af113296"
      unitRef="U_USD">18156000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_ca5bad57-9a4f-4605-bc34-8ac1ab3c7e58">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization, Restructuring, Going Concern and Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company&#x2019;s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#x2019;s product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 21, 2005&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 16, 2024, the Company reported that topline results from the Company&#x2019;s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant (7500&#xb5;g mometasone furoate), as a six-month treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210. The 52-week extension stage of the ENLIGHTEN 1 trial was completed in the fourth quarter of 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients who received a repeat dosing resulting in a 12-month treatment period. In the extension stage, LYR-210 was generally well tolerated, with no product-related serious AEs. The most commonly reported extension stage AEs in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results are expected in the second quarter of 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors of the Company (the &#x201c;Board of Directors&#x201d;) approved a reduction in the Company&#x2019;s workforce impacting &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; employees, which occurred during May and June 2024. In connection with the reduction in force, the Company stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. Furthermore, the Company is currently in the process of marketing all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of its leased properties for sub-leasing arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has recorded a restructuring charge in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, primarily related to severance and retention costs as further discussed in Note 5. The Company has also recorded an impairment charge for the write-down of property and equipment of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and right-of-use assets in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as further discussed in Notes 6 and 7, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The failure of the Company&#x2019;s Phase 3 ENLIGHTEN 1 trial to meet its primary endpoint, which resulted in the Company&#x2019;s restructuring during the second quarter of 2024, provides significant uncertainty regarding the Company&#x2019;s ability to meet its business plans and conduct its future operations. The Company has incurred recurring net operating losses every year since inception and has an accumulated deficit of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at December 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2024, the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash and cash equivalents. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From inception through December 31, 2024, the Company has raised an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;424.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to fund its operations, primarily from the issuance of equity securities and to a lesser extent, government contracts and a license agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) assuming the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board of Directors has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. The Company is attempting to sublease all of its leased locations, and, may also seek to negotiate an early termination of its leases with its landlords. The Company may be unable to sublease its locations on favorable terms or at all. In addition, the Company may not be able to obtain an early termination of its leases with its landlords on favorable terms or at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will continue to evaluate its headcount of employees and may further reduce its workforce, which will result in additional severance and retention costs, which may impact the Company&#x2019;s ability to meet objectives. If the Company decides to pursue any form of growth strategy in the future, it will need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to obtain funding as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_a1c5ec60-0f6e-4fe8-a5d1-ea0022fde5d3">2005-11-21</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_c9a482dc-f5d4-4994-8462-78e8c22a8165"
      decimals="INF"
      id="F_786f523d-eeec-462c-afd8-9019b4855808"
      unitRef="U_Employee">87</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_225c378b-e626-46d0-b884-9960506db706"
      unitRef="U_Lease">3</lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements>
    <us-gaap:RestructuringCharges
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_ba1a1da5-73e6-4247-ba87-676697d9fe0c"
      unitRef="U_USD">10900000</us-gaap:RestructuringCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_77aef211-4027-4e1e-bbab-8852517c0c95"
      unitRef="U_USD">1900000</us-gaap:AssetImpairmentCharges>
    <lyra:ImpairmentOfRightOfUseAsset
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_cf9b0a05-b53c-4e08-ad18-d7b9224267ef"
      unitRef="U_USD">22800000</lyra:ImpairmentOfRightOfUseAsset>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_fcd8cdd1-b400-431e-b934-9958c49614c2"
      unitRef="U_USD">-404800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_d0c0bd11-fa15-422f-8c7f-66143caa7b4e"
      unitRef="U_USD">40600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <lyra:CashProvidedByFinancingActivities
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_c8b3c5b2-a399-4a71-b2dc-d662280dc49b"
      unitRef="U_USD">424800000</lyra:CashProvidedByFinancingActivities>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_6e726661-e9ed-4dff-bb99-8d76500c6708">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_645d6d02-e695-419d-a381-fac330a2284f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, other comprehensive loss consisted of unrealized&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; gains and losses, net of taxes from its short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had restricted cash of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 and 2023, respectively. These balances were held as restricted at the Company&#x2019;s financial institution to secure the Company&#x2019;s letters of credit for its facility leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ginning-of-period and end-of-period total amounts shown on such statements. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#x2019; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#x2019;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company includes certain items within other assets on the consolidated balance sheets. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; balance in other assets as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company had other assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, primarily composed of long-term deposits for the Company's clinical trial agreements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant Suppliers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful life or remaining term of related lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the consolidated balance sheets and related gains or losses are reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment and right-of-use assets. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to loss on impairment of property and equipment for the periods ended December 31, 2024 and 2023, respectively, both related to specific facts and circumstances in the respective periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also assesses its right-of-use assets for impairment based on triggering events, and recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to impairment of right-of-use assets as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; indicators of impairment of the right-of-use assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_12091721-daa6-4615-9374-7423de9475e8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;right-of-use asse&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d1514240-d93f-4827-833a-208926ab2d2a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_37e2bd47-4207-458b-957f-6e4048e1644e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;finance leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the process of preparing the Company's consolidated financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing purchase orders and open contracts,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;communicating with the Company's personnel to identify services that have been performed on its behalf, and estimating the level of service performed and the associated cost incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company's service providers generally invoice the Company monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to the Company at that time. The Company confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company's accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which the Company has not yet been invoiced:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vendors in connection with preclinical development activities; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vendors in connection with the testing of preclinical and clinical trial materials; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CROs in connection with preclinical and clinical studies; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;investigative sites in connection with clinical trials. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company contracts with CROs to conduct clinical and other research and development services on its behalf. The Company bases its expenses related to CROs on its estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company's CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Although the Company does not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not recognized any product revenue to date since its product candidates are in development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 13 for further discussion of the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#x2019;s common stock, the expected volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#x2019;s stock options, and the Company&#x2019;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#x2019;s policy is to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expenses the fair value of its stoc&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares and equivalents outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,113,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,804,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,709,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,143,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,064,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,845,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements and are required to be applied on a retrospective basis. The Company adopted ASU 2023-07 on January 1, 2024 for its annual reporting, and the adoption did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. This ASU should be applied prospectively with the option to apply the standard retrospectively. In January 2025, the FASB issued ASU 2025-01: Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures - Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03. ASU 2024-03 is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of these standards on our disclosure of income statement expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_b6722a48-2ede-40d2-a557-77705eec8bcb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c1364333-dfb9-4a32-9a07-33eec12d1a9c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_e25c50e5-cbb8-4e4a-b4e5-28ce03e1c8d9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, other comprehensive loss consisted of unrealized&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; gains and losses, net of taxes from its short-term investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_110dabb9-5af6-4805-9ccc-0b23508dea73">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_fddb8b94-dbcb-4216-a1ba-a10a1afcc33d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had restricted cash of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 and 2023, respectively. These balances were held as restricted at the Company&#x2019;s financial institution to secure the Company&#x2019;s letters of credit for its facility leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ginning-of-period and end-of-period total amounts shown on such statements. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_1fa02699-6bc0-4ec6-afd3-041549583043"
      unitRef="U_USD">2000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-5"
      id="F_dc4920e2-0215-4237-9d7b-8f959942398a"
      unitRef="U_USD">1400000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_b267ab55-9f9e-468c-a5e4-158f96b4aa0d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows is as follows (in thousands):&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_72e3d370-132f-4e4b-85e5-3425d20a008d"
      unitRef="U_USD">40577000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_fb5746f3-9119-49be-9fb9-ae41a8d91f80"
      unitRef="U_USD">22353000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_9c19da42-818b-4b6a-9b82-77c3679a05e7"
      unitRef="U_USD">1993000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_61e497cf-63a3-49c4-83b7-69477f1aa210"
      unitRef="U_USD">1392000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_683a3747-5d67-4f98-ac8b-0cf9ddf9a518"
      unitRef="U_USD">42570000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_33e6c1bb-a2d7-4f67-ba71-08f0c8becb89"
      unitRef="U_USD">23745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_73aa1341-3310-4e39-8cb3-f2cdff47b47c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#x2019; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#x2019;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <lyra:OtherAssetsPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_d75f72c7-121e-43b3-a8f5-c21e0c2bd622">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company includes certain items within other assets on the consolidated balance sheets. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; balance in other assets as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company had other assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, primarily composed of long-term deposits for the Company's clinical trial agreements.&lt;/span&gt;&lt;/p&gt;</lyra:OtherAssetsPolicyTextBlock>
    <us-gaap:OtherAssets
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-6"
      id="F_6fb12bd0-23bb-4998-8886-a59ead14dc81"
      unitRef="U_USD">0</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-5"
      id="F_fedd6300-a454-49e7-87c3-df850db2c163"
      unitRef="U_USD">1100000</us-gaap:OtherAssets>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_57c881f1-2b2d-49a3-9b80-09c65c592d78">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <lyra:SignificantSuppliersPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_f08affeb-e719-4ba3-b4c5-db9ef457874a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant Suppliers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lyra:SignificantSuppliersPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_b2054b7e-584b-47f8-9afe-de3f7e201273">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_9188c270-f11d-439b-a343-c4069e227b85">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful life or remaining term of related lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the consolidated balance sheets and related gains or losses are reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_bc964cb4-a6f7-4786-8850-78cf0c340114">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_9ae5f059-46cf-4fcf-b57c-b976764721ac;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful life or remaining term of related lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.506%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_87370fcb-d580-4410-a3e9-579a2b1905ac"
      id="F_41598fb9-b21c-4e2f-95e0-c15c06f2a074">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4fa89b2f-0fcf-42bb-8c6c-336ddd1b20ad"
      id="F_a06d04af-bf9c-49bb-a43e-db62f012c19a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6137d41a-fa82-43b5-b6fb-bc98341150d3"
      id="F_fd490a88-7ef4-49c7-956a-99781c99d57e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_171885c0-2fb9-4ece-8bf2-1e4bf8762823">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment and right-of-use assets. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to loss on impairment of property and equipment for the periods ended December 31, 2024 and 2023, respectively, both related to specific facts and circumstances in the respective periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also assesses its right-of-use assets for impairment based on triggering events, and recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to impairment of right-of-use assets as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; indicators of impairment of the right-of-use assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_90910216-5c28-4f18-8f08-9416cf0e8b8a"
      unitRef="U_USD">1900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_e35f840d-9567-41bb-ad40-91cf75114e04"
      unitRef="U_USD">1600000</us-gaap:AssetImpairmentCharges>
    <lyra:ImpairmentOfTheRightOfUseAssets
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_1fc938a7-cd10-450d-b445-99a797636dd4"
      unitRef="U_USD">22800000</lyra:ImpairmentOfTheRightOfUseAssets>
    <lyra:ImpairmentOfTheRightOfUseAssets
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_5e9e7681-f1f7-4fcf-8302-2837279de5fe"
      unitRef="U_USD">0</lyra:ImpairmentOfTheRightOfUseAssets>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_3d5e47d4-9f5d-4422-8da9-c2051ace5293">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_12091721-daa6-4615-9374-7423de9475e8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;right-of-use asse&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d1514240-d93f-4827-833a-208926ab2d2a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_37e2bd47-4207-458b-957f-6e4048e1644e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;finance leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627"
      decimals="INF"
      id="F_379481e7-f87f-4444-90aa-0b2a32afb324"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627"
      decimals="INF"
      id="F_6ced48be-4525-4c70-8a47-39971cae9da1"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_346d080b-939c-4205-b5bb-6f8ce864f627"
      decimals="INF"
      id="F_d192a821-3bff-428c-a9b1-4f8c28ed9517"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiability>
    <lyra:AccruedResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_654c424b-9c36-4f40-943d-e16a8cea5471">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the process of preparing the Company's consolidated financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing purchase orders and open contracts,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;communicating with the Company's personnel to identify services that have been performed on its behalf, and estimating the level of service performed and the associated cost incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company's service providers generally invoice the Company monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known to the Company at that time. The Company confirms the accuracy of its estimates with the service providers and make adjustments if necessary. The significant estimates in the Company's accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which the Company has not yet been invoiced:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vendors in connection with preclinical development activities; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vendors in connection with the testing of preclinical and clinical trial materials; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CROs in connection with preclinical and clinical studies; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;investigative sites in connection with clinical trials. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company contracts with CROs to conduct clinical and other research and development services on its behalf. The Company bases its expenses related to CROs on its estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company's CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Although the Company does not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lyra:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_32f08600-c733-4839-89db-757ebf0e12c4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not recognized any product revenue to date since its product candidates are in development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 13 for further discussion of the arrangement.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_eacd5950-d4f9-4a98-ae95-ee64ad1bc7a9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_7cca8e6a-864a-47f5-bf41-74e2bd05498e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_899cf828-a4bf-4ad0-ba9c-94f80bc0969d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#x2019;s common stock, the expected volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#x2019;s stock options, and the Company&#x2019;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#x2019;s policy is to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expenses the fair value of its stoc&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_41225e0e-7449-4bb9-b5a6-72b9684db5fc">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_ccb79c7f-0869-429e-b5d6-330c6857f608">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares and equivalents outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,113,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,804,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,709,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,143,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,064,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,845,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_9b29a161-1dbe-4773-af40-6875fa883598">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,113,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,804,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_4c551985-0d3f-48d1-9633-147804aa2613"
      unitRef="U_USD">-93435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_619cfd4e-c401-4010-8bdd-3289ee7959d9"
      unitRef="U_USD">-62680000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_86207ac8-5929-4086-affa-94580e1cca09"
      unitRef="U_USD">-93435000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_54542ab2-3e8e-47b9-a269-b8ba090b38a8"
      unitRef="U_USD">-62680000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="0"
      id="F_9907c7f3-b0ee-416c-a4e3-cbc6a5e3e624"
      unitRef="U_shares">65113859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="0"
      id="F_b94a290f-dbad-451d-a2a2-a5f9a49d079d"
      unitRef="U_shares">65113859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="0"
      id="F_ab4c2f56-a4c8-41df-8d08-04435e72d855"
      unitRef="U_shares">49804283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="0"
      id="F_02c5a839-a6ac-41b9-899e-2fd38d6b3d35"
      unitRef="U_shares">49804283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_9f2d3b75-538b-4101-bc93-cffea85b9e4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_f376d29a-9998-40f3-816e-f04838d7a10a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="2"
      id="F_2c470f42-745e-4939-8d0b-3e7a5eb9f849"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="2"
      id="F_3d48c74c-76fd-4768-a57d-918f92c0e838"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c1260150-1b49-4dd6-9b1e-d48a47137d18">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,709,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,143,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,064,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,845,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2908a678-6f00-4335-9ad2-8248e7e3b60b"
      decimals="INF"
      id="F_bd3c106a-a859-42ff-a9b1-a0e562732fe8"
      unitRef="U_shares">6314561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_adb4e732-d095-4cf9-b014-91975b0e1ae3"
      decimals="INF"
      id="F_9cc38400-5215-494c-bf95-80be3ea4acc4"
      unitRef="U_shares">5709980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_91222020-6393-4cde-8a28-5ea0bed8fcc4"
      decimals="INF"
      id="F_51ed72f8-809c-4d36-9387-562a6f0ccd9d"
      unitRef="U_shares">2143802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6e6ff448-8d27-4434-ba19-87a416e47d57"
      decimals="INF"
      id="F_a1c15564-ff1b-4e13-a832-cd3a07a259fc"
      unitRef="U_shares">105048</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c244cff9-72f9-43c0-88c4-5e6a576e390e"
      decimals="INF"
      id="F_33aa2525-f402-43ef-816c-ce029e99116f"
      unitRef="U_shares">8606303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9c633c20-1b3c-4fcd-b70d-356063ad8dac"
      decimals="INF"
      id="F_5b9e33c3-608d-4fe8-b1b6-b058b30f1879"
      unitRef="U_shares">10030575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_3638c667-0499-427f-a2c7-9137310b6eb9"
      unitRef="U_shares">17064666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="INF"
      id="F_20e8f443-a1f8-4491-be5b-4c04fc1a7f16"
      unitRef="U_shares">15845603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_a0d62c19-1632-4ca4-a35f-74ee9d19b58c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements and are required to be applied on a retrospective basis. The Company adopted ASU 2023-07 on January 1, 2024 for its annual reporting, and the adoption did not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. This ASU should be applied prospectively with the option to apply the standard retrospectively. In January 2025, the FASB issued ASU 2025-01: Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures - Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03. ASU 2024-03 is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of these standards on our disclosure of income statement expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_b76729d4-a7ec-48ac-86a0-e7049c6e94c7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.609%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.609%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;US treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company&#x2019;s cash equivalents were invested in money market funds and U.S. treasury bills with maturity dates of less than 90 days, which were valued based on Level 1 inputs. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; short-term investments at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023, the Company&#x2019;s cash equivalents were invested in money market funds and U.S. treasury bills, which were valued based on Level 1 and Level 2 inputs, respectively. As of December 31, 2023, the Company's short-term investments consisted of U.S. treasury bills which were valued based on Level 2 inputs and U.S. Government Agency Securities and foreign national bank securities, which were valued based on Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining the fair value of its short-term investments at December 31, 2023, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities had contractual maturities of less than one year. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_36cad7e4-69e5-4b12-9b79-19de7eea8739">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.609%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.609%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;US treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4ce73bf9-81de-427b-88a0-9148395b04ab"
      decimals="-3"
      id="F_ea83bf7b-de9d-4f8f-854e-96fe5973145e"
      unitRef="U_USD">23214000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b3a5054d-64cd-44f8-a695-70cc465ba03f"
      decimals="-3"
      id="F_e14bea7a-9753-4401-98b6-c7f6fcae5300"
      unitRef="U_USD">23214000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e4300f24-db1f-4970-b3ac-f88865d19c63"
      decimals="-3"
      id="F_66735e31-f145-4e86-9e27-677c598789e7"
      unitRef="U_USD">6995000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ac38a720-8b0c-448e-b389-9c66f5e57c87"
      decimals="-3"
      id="F_fafa8bc5-ba0b-48a7-b2ec-5406278247d0"
      unitRef="U_USD">6995000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2053b9ce-487a-41c5-8660-4c6a0ff5d60c"
      decimals="-3"
      id="F_61bf8f16-d2dd-45c8-9567-702b73fc9534"
      unitRef="U_USD">30209000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4dc62508-709f-473e-ba30-98fa0a06a2b4"
      decimals="-3"
      id="F_16b5e25a-7b60-4f48-8917-937027ab2a3d"
      unitRef="U_USD">23214000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9dafe4ac-e499-43b9-b4cf-d9a535621146"
      decimals="-3"
      id="F_400b7516-4113-4b12-8d18-1ce506e6013b"
      unitRef="U_USD">6995000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_03789e9c-f8d7-4c13-837e-8c8982eaf153"
      decimals="-3"
      id="F_0d7a5c04-e01a-4ee9-9c7a-dc5349c515ab"
      unitRef="U_USD">11167000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9cce6eb7-717c-4284-9f9d-cca47171b6d2"
      decimals="-3"
      id="F_fa2e2329-2ecd-42b9-b33c-f776ce526bee"
      unitRef="U_USD">11167000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_98b8817f-6678-4071-a244-b8d90ff8d269"
      decimals="-3"
      id="F_f57676be-fdef-496a-a03d-9176200cdb11"
      unitRef="U_USD">8980000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5813d5de-532a-4e0e-af8e-993c31bd435f"
      decimals="-3"
      id="F_3eeb5e9e-4c32-4aa7-9359-cb6ac2619ddd"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3cfae322-7814-406b-94d8-6c27a76311a8"
      decimals="-3"
      id="F_e7b8ad8f-671c-438e-b2ec-de1bcff134dc"
      unitRef="U_USD">8980000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b66b293d-ec8e-437b-afad-20466ee88490"
      decimals="-3"
      id="F_ea5fab3c-d916-4797-b6de-4b90433e1198"
      unitRef="U_USD">20147000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_05ee597b-300a-4f1d-950d-07a44282f29e"
      decimals="-3"
      id="F_8dce4e97-aeef-4c41-bfd7-f4dee93a5709"
      unitRef="U_USD">11167000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_31f58a76-705e-4546-91b9-77d2761bcc2c"
      decimals="-3"
      id="F_c508b2d2-276f-4800-a6ad-c330166ef570"
      unitRef="U_USD">8980000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_e09c71d4-5382-4588-a92f-344a3170a726"
      decimals="-3"
      id="F_96efba7d-e5c9-47bb-8b06-18e7695c76cf"
      unitRef="U_USD">76918000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_6e329cfb-354c-4c3b-b489-59580eb7b3fb"
      decimals="-3"
      id="F_4308b6da-b07e-4a93-9258-d48438489d4e"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_8bdf4601-233d-4b5c-9cfd-097e16ea264c"
      decimals="-3"
      id="F_1284d12c-97db-4b59-91c3-36198ae23f8c"
      unitRef="U_USD">76918000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_e0489a50-b282-48d4-b174-d58246a172cf"
      decimals="-3"
      id="F_4410090c-bf93-4312-94c6-7d6651bb902b"
      unitRef="U_USD">3482000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0a16c01a-3d42-4b14-9dcc-312ac1b87eeb"
      decimals="-3"
      id="F_ae7fbea2-c506-45a3-b6a8-fa6dd7799dc4"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_dc75a67e-1185-42e1-9806-ae25f1f18a50"
      decimals="-3"
      id="F_efbed6e0-3e97-42e4-9b86-e6f0903dc5bf"
      unitRef="U_USD">3482000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_b66b293d-ec8e-437b-afad-20466ee88490"
      decimals="-3"
      id="F_4f78c0b3-d4b6-4f08-a75b-8eb39e998c21"
      unitRef="U_USD">80400000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_05ee597b-300a-4f1d-950d-07a44282f29e"
      decimals="-3"
      id="F_4c7fb26e-d0d2-48a6-b3cc-0dd5342e5823"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_31f58a76-705e-4546-91b9-77d2761bcc2c"
      decimals="-3"
      id="F_8c37c650-38ce-4683-b127-26a078493c7a"
      unitRef="U_USD">80400000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_2053b9ce-487a-41c5-8660-4c6a0ff5d60c"
      decimals="INF"
      id="F_595b0935-7158-417b-a09d-9f119d8a5494"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_ff73a11c-a1de-4dd0-8ab4-ecdb2d230b2e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_f9628151-a7c7-404f-a26f-0cec7fcf3465"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_3d7a3781-d86c-44b8-b2ee-6422cf0471ff">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; short-term investments and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; net accumulated unrealized gains or losses at December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of available-for-sale investments by type of security was as follows at December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.009999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.928%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; debt securities that were in an unrealized loss position as of December 31, 2023. The aggregated fair value of debt securities in an unrealized loss position was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of December 31, 2023, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t hold debt securities in a continuous unrealized loss position for more than 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded on the consolidated balance sheets, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss as a separate component of stockholders' equity. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the consolidated statements of operations and comprehensive loss. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. The unrealized losses at December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were attributable to changes in interest rates.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_44d0643b-875b-4c52-a3b4-f8aa586f95b4"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_62b0df74-a297-4f90-b0b1-a96295780b16"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_ea89b4f1-159e-4874-a43e-323766b39c57"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0e8af174-97ea-4344-af05-6a09ff5e9e6b">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of available-for-sale investments by type of security was as follows at December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.009999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.928%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28"
      decimals="-3"
      id="F_dc34edb8-d804-443c-917c-4b96264611a6"
      unitRef="U_USD">76881000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28"
      decimals="-3"
      id="F_65d1c20c-5b2e-46be-8f46-b9bbac833db6"
      unitRef="U_USD">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28"
      decimals="-3"
      id="F_45bb77f7-098e-427a-a8b2-78852bd3f530"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9d4d7017-c77e-41be-bd4b-9129608b3d28"
      decimals="-3"
      id="F_8caec86f-6274-4f75-a9ae-9c783de5a5fa"
      unitRef="U_USD">76918000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b"
      decimals="-3"
      id="F_51eaeca8-dad3-4685-a48f-65ceae2eddf4"
      unitRef="U_USD">3486000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b"
      decimals="-3"
      id="F_7777dcec-323a-41f3-9b26-79c7ded85bd6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b"
      decimals="-3"
      id="F_1d74418f-ccf2-4559-a5a6-bfff4129deab"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8952cd7b-48b7-4b53-b987-499c3555124b"
      decimals="-3"
      id="F_70aa0ad7-9f4c-4436-8705-c021efafee19"
      unitRef="U_USD">3482000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_c79f70c1-d6d2-4bd9-b2da-5c60c9371e3a"
      unitRef="U_USD">80367000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_5d60080b-f939-495b-aa56-aff7745fc04c"
      unitRef="U_USD">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_2b9f63cd-af0c-4b74-8f05-5998e62f7a80"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_0a1867eb-65ed-4fa3-bab7-60d24ab81c22"
      unitRef="U_USD">80400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_afa61780-c2d0-4fac-8624-4cf3688fb6de"
      unitRef="U_Security">2</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-5"
      id="F_2af86234-178e-4515-bde1-58100f830374"
      unitRef="U_USD">3500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_783520cf-922e-4bc7-b353-d134b3f7d66e"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_26e8541b-164b-4b06-87ce-236e7b2fb7b1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Restructuring and Other Related Charges&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors approved a reduction in the Company&#x2019;s workforce, impacting &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; employees, which occurred during May and June 2024. The Company incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through May 1, 2025. These amounts are recorded as restructuring and other related charges within our consolidated statements of operations and comprehensive loss as they are incurred. For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, restructuring and other related charges were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of severance costs, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of retention costs, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other costs.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restructuring liability activities du&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ring the year ended December 31, 2024 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.826%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;January 1,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024 Restructuring Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Severance Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Retention Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_c9a482dc-f5d4-4994-8462-78e8c22a8165"
      decimals="INF"
      id="F_90ce3301-1635-4b17-a016-890f439c48d9"
      unitRef="U_Employee">87</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_2e0aac90-104f-4648-857a-835e52460c82"
      unitRef="U_USD">10900000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:SeveranceCosts1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_ee754130-a599-473e-9070-af61e76d6174"
      unitRef="U_USD">6700000</us-gaap:SeveranceCosts1>
    <lyra:RetentionCosts
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_e328a6a0-e63a-41d8-8eec-fa1647c2084a"
      unitRef="U_USD">3200000</lyra:RetentionCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_194d879c-aa99-4afd-8ab8-74be2d407f63"
      unitRef="U_USD">1000000</us-gaap:OtherRestructuringCosts>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_22a9f3ae-b0cf-4e51-9e50-dad5bc9635ee">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restructuring liability activities du&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ring the year ended December 31, 2024 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.826%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;January 1,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024 Restructuring Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Severance Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Retention Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_c78c329e-4f11-4535-afbf-fbe8ac79582c"
      decimals="-3"
      id="F_b73f90f2-a6d6-41d7-9116-3148c5c25790"
      unitRef="U_USD">6713000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_c78c329e-4f11-4535-afbf-fbe8ac79582c"
      decimals="-3"
      id="F_45de6dfd-62ec-40e4-a0c5-708827722265"
      unitRef="U_USD">3953000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_b980fa59-4978-4912-9bfb-143801b491d8"
      decimals="-3"
      id="F_c8e74991-6c59-4eb9-90bb-926b678502c1"
      unitRef="U_USD">2760000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_e4a10c0f-30eb-47c6-8e2d-589710e6957f"
      decimals="-3"
      id="F_9073d2e2-7254-4abf-a522-9deeeb0be190"
      unitRef="U_USD">3174000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_e4a10c0f-30eb-47c6-8e2d-589710e6957f"
      decimals="-3"
      id="F_689f4695-fc3b-454d-8a8b-73cf82799688"
      unitRef="U_USD">1596000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_7610c97e-2aed-4d93-8ea6-f8005b036844"
      decimals="-3"
      id="F_84c7da59-bea9-415d-bfd2-3d8d05cf3ae3"
      unitRef="U_USD">1578000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_488bc5f4-10ce-45bb-95b7-d15c658c6b6b"
      decimals="-3"
      id="F_9545b195-0a41-4e3d-a12c-bcad4d72ed25"
      unitRef="U_USD">1009000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_488bc5f4-10ce-45bb-95b7-d15c658c6b6b"
      decimals="-3"
      id="F_2ad3b04f-6564-444c-ba7e-cd2c635b7984"
      unitRef="U_USD">1000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_b7855080-4b7e-4605-886c-ba8da30b5934"
      decimals="-3"
      id="F_10e2a3ec-a462-4e62-8c3a-8b5d75de90d9"
      unitRef="U_USD">9000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457"
      decimals="-3"
      id="F_8809a427-7ff1-4b73-b046-25b0b2a29069"
      unitRef="U_USD">10896000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_b5cce8a3-2067-4eec-a786-ceb5f6f2c457"
      decimals="-3"
      id="F_1084b308-c7d6-4020-9ebf-7ece3c8eedb5"
      unitRef="U_USD">6549000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_49c96c91-10ba-4114-a86d-ac6dc268373f"
      decimals="-3"
      id="F_d4f20850-6f8d-4ea5-88ec-d19212a717e9"
      unitRef="U_USD">4347000</us-gaap:RestructuringReserve>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_ef8c4ab9-ab0d-4bb3-aa01-a2dc864b71d6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Property and Equipment and Related Impairment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.506%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.006%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated depreciation includes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to loss on impairment of property and equipment described below for the years ended December 31, 2024 and 2023, respectively. In addition, the Company recognized approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of depreciation expense for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the second quarter of 2024 and as a result of the Company&#x2019;s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, the Company performed a recoverability test for its property and equipment. The Company concluded that the undiscounted cash flows associated with its property and equipment was less than the carrying value of the property and equipment. The Company compared the fair value of the property and equipment to the carrying value and recorded an impairment charge in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which is included as an impairment of property and equipment in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The Company determined fair market value of the equipment based on a third-party appraisal of the equipment through use of publicly available used equipment quotes. The equipment was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of December 31, 2024, and determined no additional impairment indicators existed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company recognized an impairment charge of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, related to specific facts and circumstances of a prior year agreement termination with a CMO. This impairment evaluation related to the net book value of leasehold improvement and laboratory equipment assets held at the CMO.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_87370fcb-d580-4410-a3e9-579a2b1905ac"
      decimals="-3"
      id="F_a1d35b1b-6656-4927-9514-f5c5aa8f210a"
      unitRef="U_USD">3927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_433f45f3-222a-4c22-aadf-b142c5221803"
      decimals="-3"
      id="F_f971e9af-fddf-44bd-8e94-015dfb832e39"
      unitRef="U_USD">2736000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b8292bd-93d8-4684-8cfe-8f2b9dd35c42"
      decimals="-3"
      id="F_451a3d70-ee27-43a3-84ea-d17cc507a2fa"
      unitRef="U_USD">159000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4a249401-3b7d-46fd-80ef-cb608151b1c7"
      decimals="-3"
      id="F_18244197-9e79-4c8b-9a56-da311b66fa65"
      unitRef="U_USD">105000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_420d91c9-ecfc-4744-a255-788637fcb6a9"
      decimals="-3"
      id="F_3f2c0af2-ea35-4133-a3a3-c19b7f60870a"
      unitRef="U_USD">961000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c3eef231-3463-425d-ba3f-d63c4ce2d6c3"
      decimals="-3"
      id="F_cb062059-76a9-48b9-baea-d618ae746e2c"
      unitRef="U_USD">662000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_075aff53-3972-401b-9e57-6d6327e23180"
      decimals="-3"
      id="F_4c121f36-e592-4f42-bd9c-de962a473bd3"
      unitRef="U_USD">486000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_027852d4-18db-4239-a7cd-a51806d8be2b"
      decimals="-3"
      id="F_0603f75e-1e20-457b-a0af-21a1af53c7db"
      unitRef="U_USD">461000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_b24dc46f-4839-482d-aec9-21a2caa84945"
      unitRef="U_USD">5533000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_de577d6a-3400-4f4b-9ca2-d06341521126"
      unitRef="U_USD">3964000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_0bc30e07-bad0-4ef9-bc3e-de995f34acd8"
      unitRef="U_USD">4129000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_a8a645be-fcd7-4542-885e-7eedfa8c7545"
      unitRef="U_USD">1921000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_275472f6-82b7-4d8a-a56e-914915c44742"
      unitRef="U_USD">1404000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_1682eaa4-c7f5-42df-87ce-ee616a6d938b"
      unitRef="U_USD">2043000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_2ef14ac1-89c4-4277-b932-bb0130b7b3e9"
      unitRef="U_USD">1900000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_475dad54-1752-40de-ba22-aba43b0c9416"
      unitRef="U_USD">1600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:Depreciation
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_2fec8c5d-2eb3-4932-83d6-adc7ee8b563a"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_f4368893-3e7e-42de-85c2-f008615bf90b"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_bdbf22d8-163c-4eae-aa10-4213a1497056"
      unitRef="U_USD">1900000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_8902a605-b72c-4739-9074-c30c2e4cb614"
      decimals="-5"
      id="F_4aaf229d-153b-4933-bb8a-3fd8e48486a0"
      unitRef="U_USD">1600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:AssetImpairmentChargesTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_4199b5dd-9958-40e1-a101-e1abba928353">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Impairment of Right-of-Use Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Company&#x2019;s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, the Company engaged a commercial real estate broker to market the Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; leased properties for sublease arrangements. Based upon these impairment indicators, the Company has performed a recoverability test over its right-of-use asset and concluded that the right-of-use assets are impaired. As a result, the Company has recorded an impairment charge in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the second quarter of 2024, which is included as an impairment of right-of-use asset in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The Company reassessed the need for any further impairment as of December 31, 2024, and determined no additional impairment indicators existed. As of December 31, 2024, the Company has not sublet any of its leased properties.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management conducted a fair value analysis of the Company's right-of-use assets using a discounted cash flow methodology as of May 15, 2024, which included the following range of assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.052%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.101%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:33.847%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.96&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected sublease rent increases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AssetImpairmentChargesTextBlock>
    <lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_fcb4463b-9045-4a0f-baac-e94cc6d38090"
      unitRef="U_Lease">3</lyra:NumberOfLeasedPropertiesMarketedForSubleaseArrangements>
    <lyra:ImpairmentOfRightOfUseAsset
      contextRef="C_3c311591-1876-4a38-97cd-e253457c022f"
      decimals="-5"
      id="F_357bbe6c-62d7-4bd7-aaeb-97e76441ea3a"
      unitRef="U_USD">22800000</lyra:ImpairmentOfRightOfUseAsset>
    <lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_e0a4c1f5-ac09-4741-97ad-8ca4e586a23d">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management conducted a fair value analysis of the Company's right-of-use assets using a discounted cash flow methodology as of May 15, 2024, which included the following range of assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.052%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.101%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:33.847%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.96&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected sublease rent increases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock>
    <lyra:DiscountedCashFlowTechniqueDiscountRate
      contextRef="C_478d5703-d418-4d23-b8de-ef04cf2df0c7"
      decimals="INF"
      id="F_5162e47c-cd41-477d-8936-aec75b4d98b3"
      unitRef="U_pure">0.095</lyra:DiscountedCashFlowTechniqueDiscountRate>
    <lyra:DiscountedCashFlowTechniqueDiscountRate
      contextRef="C_9efb24d1-b674-4307-b0ea-d333f2bc6075"
      decimals="INF"
      id="F_31bccdcc-d48b-4c5b-a4b0-15948810ae59"
      unitRef="U_pure">0.105</lyra:DiscountedCashFlowTechniqueDiscountRate>
    <lyra:DiscountedCashFlowTechniqueTerm
      contextRef="C_478d5703-d418-4d23-b8de-ef04cf2df0c7"
      id="F_042e8450-1902-4ee9-83b0-34d1544b0c25">P2Y11M15D</lyra:DiscountedCashFlowTechniqueTerm>
    <lyra:DiscountedCashFlowTechniqueTerm
      contextRef="C_9efb24d1-b674-4307-b0ea-d333f2bc6075"
      id="F_5636b567-1ab7-4816-8a54-4138835bf4b6">P9Y1M17D</lyra:DiscountedCashFlowTechniqueTerm>
    <lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases
      contextRef="C_62e1129c-aef1-4103-970b-5c338ee35c24"
      decimals="3"
      id="F_8de74ff0-925c-417e-b276-f60332ab63dc"
      unitRef="U_pure">0.03</lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_2894bee0-9d03-4a3a-8a34-ac1f756a9363">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Third-party research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_bd2f9881-e6db-44da-9b6c-37f1886fdaf6">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Third-party research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_5936fb57-c0a3-4007-baaf-9c55af16e169"
      unitRef="U_USD">529000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_82b4201c-8727-4103-82e2-bde6cd684777"
      unitRef="U_USD">4670000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_fbbc8c6b-4b78-48a6-8417-e676c2a8d331"
      unitRef="U_USD">1582000</lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent>
    <lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_248bf63d-7b93-4b6b-9fab-e0b378d1ddab"
      unitRef="U_USD">3473000</lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_e4189c72-188d-482c-b42d-aeff07dcedc9"
      unitRef="U_USD">475000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_cb876493-21ff-4982-9c42-67fedd86aea2"
      unitRef="U_USD">1231000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_06d597c2-b458-44df-9541-2ede054598bd"
      unitRef="U_USD">2586000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_148bc3ae-66ef-41db-ae3f-f1c32ef17b83"
      unitRef="U_USD">9374000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0192304b-fbe2-4d95-9921-0585d1570555">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s CODM, its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_88da49e1-0053-471c-838d-493a47149bc4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, regularly review the Company&#x2019;s operations and manage its business as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7574a635-981a-4973-932d-d749f0f65056;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases. Segment revenues represent collaboration revenue from the Company&#x2019;s consolidated statements of operations and is received from a single customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant segment expenses consist primarily of employee-related costs, clinical, facility and professional and consulting costs in connection with preclinical and clinical development activities. Segment expenses also include impairment charges, when and as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM evaluates and allocates resources within the segment based on the Company&#x2019;s net loss.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As the Company is a clinical-stage biotechnology company, the evaluation includes review of the actual and budget costs related to employee-related costs, clinical trials, facility, professional and consulting costs in connection with preclinical and clinical development activities, and the conduct of these pre-clinical and clinical trials and responses from government agencies in determining the probability of success of product candidates. Total segment assets are reported in the Company&#x2019;s consolidated balance sheets as total assets.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.751%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.503%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.503%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Product development and manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facilities, support costs and depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional, consulting and public company costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legal settlement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring and other related charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_644064ea-ca4e-4931-8550-b6bb0abbf17a">The Company&#x2019;s CODM evaluates and allocates resources within the segment based on the Company&#x2019;s net loss.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_66dafd5b-ed4b-49ea-8d7f-cf434ac9ca67">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.751%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.503%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.503%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Product development and manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facilities, support costs and depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional, consulting and public company costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legal settlement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impairment of right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring and other related charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_0b0d8942-9da9-4a13-9105-6b03356f4971"
      unitRef="U_USD">1534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_3d592dcb-ecf5-4e22-b3d9-c3c40ccda936"
      unitRef="U_USD">1558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a797757c-a0d8-4b41-bca5-e4ece3661b06"
      decimals="-3"
      id="F_a3daa2ee-a498-4a14-8cc1-233fb01e57e7"
      unitRef="U_USD">15156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4e3aa3ed-daf5-453c-8203-7ffec41710a2"
      decimals="-3"
      id="F_a3364aa1-d6db-4b9b-84e0-6a7c5daec37a"
      unitRef="U_USD">20682000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_74f98c49-91bf-4f2d-9c5b-151230a7e6b3"
      decimals="-3"
      id="F_6cc2f82d-85ac-427b-bfd0-531ab5efeda0"
      unitRef="U_USD">22828000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_57cb61d3-40d3-48d2-9f7a-c577d8ec047d"
      decimals="-3"
      id="F_b02ebb4b-2a61-453e-bee6-a8e21eaae96c"
      unitRef="U_USD">27124000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b738c303-1ab5-4ff7-a680-7afbc47dc33f"
      decimals="-3"
      id="F_8ca77d91-f668-42e8-b3cf-9e358c8b53b5"
      unitRef="U_USD">3304000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_06ac994e-b8ce-41c9-80a2-2431128712fd"
      decimals="-3"
      id="F_6f44d383-9827-4bff-af70-a657b7f9bdf8"
      unitRef="U_USD">4326000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_234874bf-c13c-4027-9389-b0792e0ac2ac"
      decimals="-3"
      id="F_2077972e-c3da-4b73-8913-a34547c5eb97"
      unitRef="U_USD">13579000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a26c186e-cfe1-4434-9835-0bc963d20468"
      decimals="-3"
      id="F_472a07fb-935c-4368-8253-0cca14d19771"
      unitRef="U_USD">7425000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6cd8d3f0-2e97-4106-9cea-1f0c4afe5e89"
      decimals="-3"
      id="F_f1dba068-6495-428a-bc0d-f0a81f7f143d"
      unitRef="U_USD">7400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_852d2d00-74ce-4a20-9603-0c6650379dd8"
      decimals="-3"
      id="F_17089a7a-a869-4e28-a3b1-9acfe0c55b37"
      unitRef="U_USD">7663000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_280682ef-880f-4702-8298-d09656436400"
      decimals="-3"
      id="F_d285e963-c97b-418e-a52e-a795dccd7e3f"
      unitRef="U_USD">-568000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2801a74a-99e4-4308-a905-51778ab0e93c"
      decimals="-3"
      id="F_c5dd44ae-1d56-4c25-9ceb-440a44ee7a5e"
      unitRef="U_USD">434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_0f45596a-12a9-4f1a-9667-a17f778d6e3c"
      unitRef="U_USD">1883000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_cedfeaa0-581f-45fa-be9e-ced413cce55d"
      unitRef="U_USD">1592000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <lyra:ImpairmentOfRightOfUseAsset
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_a0732172-180a-4dee-bd45-4bdd2ac1d5ce"
      unitRef="U_USD">22836000</lyra:ImpairmentOfRightOfUseAsset>
    <us-gaap:RestructuringCharges
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_b4ba8773-fa7e-4f4b-93b6-a419846b2207"
      unitRef="U_USD">10896000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_9dc2f159-95f5-4435-b37a-200235b9aae9"
      unitRef="U_USD">97882000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_b5d6c6cf-d4ca-49bc-b8f4-689c25631ea2"
      unitRef="U_USD">68678000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_965077d9-921b-4878-aeb4-ae74566a8148"
      unitRef="U_USD">-96348000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_1b898d3e-4d9f-4e2a-a74b-87409ff729ab"
      unitRef="U_USD">-67120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_dc60a7d3-9a16-4947-9755-d482e4ad71c1"
      unitRef="U_USD">2952000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_abb6b8d1-d519-4377-befb-bbc58109d028"
      unitRef="U_USD">4499000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_df619136-b7ac-414d-8e8e-989a00753d22"
      unitRef="U_USD">2952000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_e9ad775d-5fd1-4f1d-9619-236ebc59f480"
      unitRef="U_USD">4499000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_0ecdd561-5e0e-4494-8c5b-fa9c323287cc"
      unitRef="U_USD">-93396000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_9f78a17f-5c3d-4158-994f-4b1a55ffd3f7"
      unitRef="U_USD">-62621000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_c9c10ec9-96db-406b-a7d9-2ac2a89e8924"
      unitRef="U_USD">39000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_96ef8bea-868e-4c37-86a7-2015707c58b6"
      unitRef="U_USD">59000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_fb7e325c-e7f6-4d9c-a00e-c51ca49ec0d9"
      unitRef="U_USD">-93435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_14598e5e-b180-41ab-b8b3-fd3da8eab928"
      unitRef="U_USD">-62680000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_c966059a-2f06-4ff9-b844-5bfd9c9a1ed4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Preferred and Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of undesignated preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued or outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holders of common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote for each share held.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company currently has an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (&#x201c;Form S-3&#x201d;), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the aggregate. As of December 31, 2024, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,059,228&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares which generated proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million net of issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;September 2023 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 1, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp;amp; Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The offering and sale of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission ("SEC") on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023 (the "Prospectus Supplement").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell any of the shares under the Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Sales&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Sales Agreement, the Company has agreed to pay Cantor a commission equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate gross proceeds from any shares sold through it pursuant to the Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by Cantor in connection with the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 2, 2023, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,017,568&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock under the Sales Agreement, at a weighted average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which generated net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On November 15, 2023, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock under the Sales Agreement, at a weighted average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which generated net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On February 12, 2024, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,041,666&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock under the Sales Agreement, at a weighted average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which generated net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 22, 2024, the Company amended and restated the Controlled Equity Offering Sales Agreement (the &#x201c;Amended Sales Agreement&#x201d;) with Cantor pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The offering and sale of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the common shares has been registered under the Securities Act, pursuant to the Company's Registration Statement on Form S-3 (File No. 333-278163) (the "2024 Registration Statement"), which was originally filed with the SEC on March 22, 2024, the base prospectus contained within the 2024 Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on March 22, 2024. As of December 31, 2024, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in proceeds net of issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million generated from these agreements with $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million still available for future sale under the Amended Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;May 2023 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 25, 2023, the Company entered into the Purchase Agreement, with the purchasers, pursuant to which the Company agreed to sell securities to the Investors in a private placement (the &#x201c;Private Placement&#x201d;). The Purchase Agreement provided for the sale and issuance by the Company of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,652,962&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock and accompanying warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,826,481&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (&#x201c;Purchase Warrants&#x201d;), with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each Purchase Warrant became exercisable on November 30, 2023, and expire on November 30, 2028.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Additionally, the Company issued pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,408,188&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (&#x201c;Pre-Funded Warrants&#x201d;), with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and accompanying Purchase Warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,204,094&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In total &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Purchase Warrants were issued and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,408,188&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Pre-Funded Warrants were issued. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The closing of the Private Placement occurred on May 31, 2023. The Company filed a shelf registration statement on Form S-3 with the SEC on June 28, 2023, and it was declared effective on July 7, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company received an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in gross proceeds, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting issuance costs. The Company has allocated the net proceeds among the common stock, the Purchase Warrants and the Pre-Funded Warrants using the relative fair value method for each of the above transactions. The Company has allocated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the shares of common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Pre-Funded Warrants and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Purchase Warrants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the preparation of the Company&#x2019;s 2023 annual financial statements, the Company identified an immaterial error in the Company&#x2019;s historical financial statements whereby the Company omitted this disclosure in the interim financial statements for the quarter ended June 30, 2023 and incorrectly disclosed an allocation of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million instead of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Purchase Warrants and failed to disclose the allocation of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Pre-Funded Warrants in the interim financial statements for the quarter ended September 30, 2023.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These immaterial errors have been corrected within these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company has determined the fair value of the common shares based upon the Company&#x2019;s common stock price on the date of the transaction applied to the number of shares of common stock issued. The fair value of the Pre-Funded&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was determined based on the Company&#x2019;s common stock price on the date of the transaction, less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share exercise price of the warrants, applied to the number of Pre-Funded Warrants. The fair value of the Purchase Warrants was determined using the Black-Scholes model applied to the number of Purchase Warrants. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes model were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s outstanding warrants are freestanding instruments and are classified within stockholders&#x2019; equity since the warrants are indexed to the Company&#x2019;s common stock and meet the equity classification criteria.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,424,272&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Purchase Warrants were exercised related to the May 2023 financing as of December 31, 2024 at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;April 2022 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, Pre-Funded Warrants to purchase common stock), resulting in gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x201c;April 2022 Financing&#x201d;). The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net proceeds after deducting estimated offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,815,159&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for gross proceeds to the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and (ii) certain investors purchased Pre-Funded Warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, with the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Company. The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pre-Funded Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Pre-Funded Warrants, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the Pre-Funded Warrants and recorded as a component of additional paid-in capital. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,651,423&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Pre-Funded Warrants issued in the April 2022 Financing exercised as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has reserved for future issuances the following shares of common stock as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Option to exercise stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,018,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;723,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,348,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_bae57fb9-3c5f-471b-8356-fd251e1c7251"
      decimals="INF"
      id="F_11213277-b292-4def-8b26-7cdcddf396d9"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_bae57fb9-3c5f-471b-8356-fd251e1c7251"
      decimals="3"
      id="F_cc3f403a-d837-4a9d-9539-f6bb759ff250"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_c55fa726-f4d6-45c1-8fb4-09d78ecae1aa"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="0"
      id="F_da6b1245-db61-4110-a6ea-98518f573574"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="0"
      id="F_32a9445a-2e10-44b3-95f9-46c51739136e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="0"
      id="F_023535e5-64ec-4665-8e66-c29cb8d2c52d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_33437d60-13b8-4e79-bf35-c1891686610b">The holders of common stock are entitled to one vote for each share held.</us-gaap:CommonStockVotingRights>
    <lyra:CommonStockVotingRightsNumberOfVotes
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_217a5207-eeef-484f-b1a7-5517b779d91b"
      unitRef="U_Vote">1</lyra:CommonStockVotingRightsNumberOfVotes>
    <lyra:StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="C_09a0cae9-fe57-4508-94a6-ac09c28407d1"
      decimals="-5"
      id="F_08b9763d-d530-4930-b6a4-08da7eb87697"
      unitRef="U_USD">300000000</lyra:StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants>
    <lyra:StockDebtSecuritiesWarrantsAndUnitsIssued
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_58af51d8-d1ff-4224-8245-e6a4de9000ae"
      unitRef="U_shares">7059228</lyra:StockDebtSecuritiesWarrantsAndUnitsIssued>
    <lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_751b7ef2-04db-4731-bfe2-f6326a3610bc"
      unitRef="U_USD">23900000</lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits>
    <lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_a92f212b-9298-4338-a2c6-473d839692c1"
      unitRef="U_USD">900000</lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_281acdc8-b177-4854-8880-10164275dc04"
      decimals="INF"
      id="F_660cd571-34da-400b-a615-3c8c836f5b92"
      unitRef="U_USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock
      contextRef="C_281acdc8-b177-4854-8880-10164275dc04"
      decimals="INF"
      id="F_4b86478d-00ee-4037-99f6-651fff088e2c"
      unitRef="U_USD">50000000</lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock>
    <lyra:PercentageOfAggregateCommission
      contextRef="C_912b5ea1-01e3-4044-a2e8-d7c9eccbc5d7"
      decimals="3"
      id="F_cb15dbf5-cf2d-4290-ac7d-24c47eb11f5e"
      unitRef="U_pure">0.03</lyra:PercentageOfAggregateCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1e1030b6-cab3-4405-83f8-f89b4d6c3751"
      decimals="INF"
      id="F_e61f14eb-52c7-4114-80a0-4bbc2e6fdf18"
      unitRef="U_shares">3017568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_605136ee-faca-4595-aa05-236b9cffe793"
      decimals="2"
      id="F_e20bd3b1-a3bb-4636-a815-922db53f5157"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.71</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ab9d9d05-16a2-48db-a97a-38ad01878ef2"
      decimals="-5"
      id="F_20db55d5-34f7-4f4f-8bc4-ef405c15799b"
      unitRef="U_USD">10900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_789b1913-2263-46dd-834b-d5389e9dab08"
      decimals="INF"
      id="F_6b629fb6-8d95-474f-a4f4-1fc823c247f2"
      unitRef="U_shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_1afebb99-1342-4fb9-b854-e7c6117b6e01"
      decimals="2"
      id="F_ebb0ab1e-ad04-4237-9f0e-876d3116cb68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.88</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e7c9223a-fe0f-484a-a091-15fcc055e486"
      decimals="-5"
      id="F_b973fea9-5616-4944-8c21-39df5e5940b9"
      unitRef="U_USD">8200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3a120243-ed89-4f6b-be0c-34e7f9595719"
      decimals="INF"
      id="F_24073953-2406-4d69-90f7-e23683147d8d"
      unitRef="U_shares">1041666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_1d3cffed-7156-4809-98e0-2a0d5179fc6d"
      decimals="2"
      id="F_62bc1b0d-9c6c-4873-afbf-b8e558c15374"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.8</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_32d5f8cc-4a3c-458b-8470-64a2b106b53b"
      decimals="-5"
      id="F_6fc2da83-78bb-4095-b1a9-45c4ac68fbfe"
      unitRef="U_USD">4800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_9e7ffac5-3543-48db-a285-11bbd13c936d"
      decimals="-5"
      id="F_6fc5d7ff-3cda-4b58-9c3e-5ed052d62b0e"
      unitRef="U_USD">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock
      contextRef="C_9e7ffac5-3543-48db-a285-11bbd13c936d"
      decimals="-5"
      id="F_2aaabecc-3399-4a34-9b2f-f941417d81d0"
      unitRef="U_USD">75000000</lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock>
    <lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_41f989d6-9897-4a1f-a8c8-87a8af48eec3"
      unitRef="U_USD">23900000</lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnits>
    <lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_31a91196-b10a-4887-8494-1d3695dbe8c6"
      unitRef="U_USD">900000</lyra:ProceedsFromIssuanceOfStockDebtSecuritiesWarrantsAndUnitsNetOfIssuanceCosts>
    <lyra:StockIssuanceAmountAvailableForFutureSale
      contextRef="C_c83768e3-f530-46bd-8293-57a4d5a51a00"
      decimals="-5"
      id="F_d06c1460-61a6-4aa4-bd56-653a1fd62cd5"
      unitRef="U_USD">50200000</lyra:StockIssuanceAmountAvailableForFutureSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a43bd8f3-4538-44af-b61c-9114bcf4aa13"
      decimals="INF"
      id="F_b89ad25e-b82f-4061-a828-a2d08b30515d"
      unitRef="U_shares">17652962</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a48e6107-bffc-483d-bc1d-dc2f272feed2"
      decimals="INF"
      id="F_4dc54d81-a820-47c5-a9d1-0adad0d598f5"
      unitRef="U_shares">8826481</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a48e6107-bffc-483d-bc1d-dc2f272feed2"
      decimals="2"
      id="F_e2670d00-23e8-42c5-91e8-84da465595d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_0db4beff-330a-45de-8b43-98f81b33e6dc"
      decimals="-5"
      id="F_b4acdd2f-3279-41d7-ae4b-6808b4a7b680"
      unitRef="U_USD">44000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <lyra:ClassOfWarrantOrRightExpirationDescription
      contextRef="C_1b2977bb-aa44-4677-a4ee-e38cdd9f5f8a"
      id="F_6bd3499b-e962-4836-adb4-f2513125582e">Each Purchase Warrant became exercisable on November 30, 2023, and expire on November 30, 2028.</lyra:ClassOfWarrantOrRightExpirationDescription>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_00c29fcf-7ef3-41c1-8925-61f5bbf063ad"
      decimals="INF"
      id="F_53b46478-c0e9-4c60-b85c-0f00588d29c4"
      unitRef="U_shares">2408188</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_00c29fcf-7ef3-41c1-8925-61f5bbf063ad"
      decimals="3"
      id="F_63c48a99-3e1f-4280-8cb5-dd7e6daa9caf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_730f05ff-8e87-4546-b39e-fa70f5bfc2d0"
      decimals="INF"
      id="F_658d9449-4d87-4dbe-8a0f-023e788dddfd"
      unitRef="U_shares">1204094</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_730f05ff-8e87-4546-b39e-fa70f5bfc2d0"
      decimals="3"
      id="F_446462a8-5da2-4d03-a89e-b4cab6f70aca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.673</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_975bc4bf-e956-4689-baa6-6102f1379b64"
      decimals="-5"
      id="F_cbe99683-51ed-42bb-8b16-29bb646565e2"
      unitRef="U_USD">6000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_626e5a02-1411-4526-aa75-ce7297c15f35"
      decimals="INF"
      id="F_5c12fd8a-1989-4823-94b0-2ceafea4a420"
      unitRef="U_shares">10030575</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_c5d324f4-4968-4ffb-aaf4-47d647da0f16"
      decimals="INF"
      id="F_011ee329-63ec-45ad-9238-912429cd0ce6"
      unitRef="U_shares">2408188</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lyra:ClassOfWarrantOrRightExpirationDescription
      contextRef="C_0b25fafa-9dbd-4d21-b6f2-54c2f0bc249a"
      id="F_75a8efb9-a2ee-489c-8f6e-df8be32de612">The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028.</lyra:ClassOfWarrantOrRightExpirationDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0db4beff-330a-45de-8b43-98f81b33e6dc"
      decimals="-5"
      id="F_c3f23bb6-d532-4b8f-bde2-de03daeeb18c"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_0db4beff-330a-45de-8b43-98f81b33e6dc"
      decimals="-5"
      id="F_dddcbd13-27ca-4274-a00b-af0a0bf73c1e"
      unitRef="U_USD">46500000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e06c0d9f-3e71-41ea-b315-fd20df7409c5"
      decimals="-5"
      id="F_72a6c43a-d547-4cf0-a930-07893200f7e7"
      unitRef="U_USD">30500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_772f9e37-d7a0-4ed6-b29c-901e928669b6"
      decimals="-5"
      id="F_604061f3-9b03-481c-a272-ee1e1c5b432c"
      unitRef="U_USD">4200000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_fc7e6c54-5f68-4b31-8c26-243187e6b327"
      decimals="-6"
      id="F_db5379af-bef1-412e-877b-5d35cb3806dc"
      unitRef="U_USD">12000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ImmaterialErrorCorrection
      contextRef="C_f24af48f-4786-4931-9dfc-97f5f94468c5"
      id="F_d3509507-654d-48fe-aeb4-eea611a590ae">During the preparation of the Company&#x2019;s 2023 annual financial statements, the Company identified an immaterial error in the Company&#x2019;s historical financial statements whereby the Company omitted this disclosure in the interim financial statements for the quarter ended June 30, 2023 and incorrectly disclosed an allocation of $11.5 million instead of $12 million to the Purchase Warrants and failed to disclose the allocation of $4.2 million to the Pre-Funded Warrants in the interim financial statements for the quarter ended September 30, 2023.</us-gaap:ImmaterialErrorCorrection>
    <lyra:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants
      contextRef="C_b75ec916-9f93-4a03-9cb4-7b9f5bdceb2e"
      decimals="-5"
      id="F_2f2dc0ba-4be3-4210-94a8-9775eea9b215"
      unitRef="U_USD">11500000</lyra:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_4969eb83-d672-422a-8e4f-a3bcb59d12f2"
      decimals="-6"
      id="F_83571d30-97fa-4bc5-a842-6e62aa62b205"
      unitRef="U_USD">12000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_1ff01a7e-0054-4803-8549-b1cb6948ee4e"
      decimals="-5"
      id="F_75eac002-4169-489a-b196-3fa7ff880f85"
      unitRef="U_USD">4200000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e4f2d1ea-5751-43a3-bf6a-e61453470a6c"
      decimals="3"
      id="F_c8779b46-d518-44c1-baba-5b65b6653fcd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_97d57318-2825-4eea-87f2-bfaeb6f9c6c9">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes model were as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s outstanding warrants are freestanding instruments and are classified within stockholders&#x2019; equity since the warrants are indexed to the Company&#x2019;s common stock and meet the equity classification criteria.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,424,272&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Purchase Warrants were exercised related to the May 2023 financing as of December 31, 2024 at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_76dcfeb5-6b92-4328-8676-8ad9414800c8"
      decimals="2"
      id="F_380c52cf-00e4-4b63-a0c9-70726cc22ca0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="C_76dcfeb5-6b92-4328-8676-8ad9414800c8"
      decimals="2"
      id="F_f153afff-8f7f-4b0c-b4fa-cd34ef791260"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.57</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9927410f-0750-4aef-8f2e-4c0203df94da"
      decimals="4"
      id="F_31e7772b-f984-4d9f-a36e-bedca822bcbd"
      unitRef="U_pure">0.8193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9927410f-0750-4aef-8f2e-4c0203df94da"
      id="F_8d20a005-1261-4ea7-b31e-ac17091441ec">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9927410f-0750-4aef-8f2e-4c0203df94da"
      decimals="4"
      id="F_fc8aa4e5-2cc6-4cca-a1ba-738090fbd2b2"
      unitRef="U_pure">0.0374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <lyra:WarrantsExercised
      contextRef="C_1b2977bb-aa44-4677-a4ee-e38cdd9f5f8a"
      decimals="INF"
      id="F_b955b822-fd95-420d-b7bb-3661598c50bc"
      unitRef="U_shares">1424272</lyra:WarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_626e5a02-1411-4526-aa75-ce7297c15f35"
      decimals="3"
      id="F_cac645b0-35cf-4110-99e9-1e87fc9f5b1c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.673</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lyra:GrossProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe"
      decimals="-5"
      id="F_f62ab8ac-2d1c-422a-8a10-b19576cc05e4"
      unitRef="U_USD">100500000</lyra:GrossProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe"
      decimals="-5"
      id="F_42406630-907a-4571-8fd8-54a1c3421140"
      unitRef="U_USD">96300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lyra:EstimatedOfferingCosts
      contextRef="C_1f79f0e1-18b7-496b-ae78-df3ba09071fe"
      decimals="-5"
      id="F_09f3a217-8287-4ca9-9524-09959c17f50a"
      unitRef="U_USD">4200000</lyra:EstimatedOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_89f8a662-2ae4-4167-b545-3e7a39f90636"
      decimals="INF"
      id="F_88078956-b4ae-4ef7-b10e-94f58b944bca"
      unitRef="U_shares">18815159</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_fa9efc50-d605-4083-8ab3-4094e47aab16"
      decimals="2"
      id="F_4d8c51ad-4223-47b4-a339-b2fa381c46e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.22</us-gaap:SharesIssuedPricePerShare>
    <lyra:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_89f8a662-2ae4-4167-b545-3e7a39f90636"
      decimals="-5"
      id="F_60822cea-798b-4dd3-a6a1-7d0fa7f1a29e"
      unitRef="U_USD">79400000</lyra:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a2fba259-de87-46a2-af48-98b719cf4dc2"
      decimals="INF"
      id="F_11833bd0-0cd4-45be-b634-55fa7aff0ac8"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_81555852-032a-405b-bea2-d1c6de8074a4"
      decimals="3"
      id="F_a68bf6ef-98d2-4e56-93f7-e9794b7ed6a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_a2fba259-de87-46a2-af48-98b719cf4dc2"
      decimals="-5"
      id="F_253926c6-fb24-4325-b199-eb55d4a9dbae"
      unitRef="U_USD">21100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65"
      decimals="-5"
      id="F_c95ea9d9-afc5-4415-91d2-6cf975cf2d4d"
      unitRef="U_USD">19700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <lyra:WarrantsExercised
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="INF"
      id="F_12965119-840a-443e-b076-e1db05e573f9"
      unitRef="U_shares">1651423</lyra:WarrantsExercised>
    <lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_0949259e-6744-433f-a635-e4b35dea7011">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has reserved for future issuances the following shares of common stock as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Option to exercise stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,018,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;723,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,348,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_087ed0ac-1d0a-422c-a84f-3b93f915fd09"
      decimals="INF"
      id="F_e0533bf7-dcba-4e72-b5c7-3746c38a5160"
      unitRef="U_shares">8606303</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f8c3db8c-4348-48f7-88f6-6a511886b8fe"
      decimals="INF"
      id="F_f2d3c85a-aad0-42b6-8912-d245e8f43ecb"
      unitRef="U_shares">10018288</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9e1ba78d-a7e7-44eb-af47-1f204e97c03c"
      decimals="INF"
      id="F_249dc928-c699-4427-8379-109d82a2f169"
      unitRef="U_shares">723906</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_e94ca50e-8e62-4d33-9486-01579f969620"
      unitRef="U_shares">19348497</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lyra:CommonStockWarrantsDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_26211bdb-9013-4396-9f9a-717616265646">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table represents a summary of the warrants outstanding and exercisable as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, all of which are equity-classified:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.283%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.420999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.881%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.420999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.420999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.061%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Pre-funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 12, 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,408,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 31, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,651,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,756,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_97b57973-2894-41e7-86a2-433229fcba95;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_3543bcc5-79e8-4350-8931-cc3cab71a166;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,424,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,756,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</lyra:CommonStockWarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_9a4928cd-295c-4133-af35-2aa7bb9a63d9">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table represents a summary of the warrants outstanding and exercisable as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, all of which are equity-classified:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.283%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.420999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.881%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.420999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.361%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.420999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.061%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Pre-funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 12, 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,408,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 31, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,651,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,030,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,756,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_97b57973-2894-41e7-86a2-433229fcba95;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_3543bcc5-79e8-4350-8931-cc3cab71a166;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,424,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,756,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,606,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_998603de-c72b-41d7-8c9d-fb71a4c5e1ae"
      id="F_306ba07c-c95a-4109-8095-13950cfb52b8">2028-11-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901"
      decimals="INF"
      id="F_b786af54-010c-4cc9-b1a1-086cc89e5026"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901"
      id="F_7b736fad-97ee-40f3-8ee7-e2193a03ca99">P4Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901"
      decimals="-2"
      id="F_a8c75325-aaeb-4e85-b49f-f2981376b6b3"
      unitRef="U_USD">15700</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_1db39547-aa48-42b8-8c47-2ef94db71901"
      id="F_589d56eb-2313-4055-8b73-fe2c24d3fa2e">2027-04-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <lyra:ClassOfWarrantOrRightIssued
      contextRef="C_73dd090c-1ed2-47b8-9a90-b7e929765864"
      decimals="INF"
      id="F_d0f1daf7-3144-404c-b5de-93400e54e309"
      unitRef="U_shares">10030575</lyra:ClassOfWarrantOrRightIssued>
    <lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
      contextRef="C_73dd090c-1ed2-47b8-9a90-b7e929765864"
      decimals="3"
      id="F_34cef6d4-5891-4a53-8172-6ea057c4c6c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.673</lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued>
    <lyra:ClassOfWarrantOrRightIssued
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="INF"
      id="F_32d7902f-0809-4fbb-94bf-6c94bc2e8cdd"
      unitRef="U_shares">2408188</lyra:ClassOfWarrantOrRightIssued>
    <lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="3"
      id="F_82a60d2e-acf2-4a03-8ea2-6f9a8774c913"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued>
    <lyra:WarrantsAndRightsIssuedMaturityDate
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      id="F_8394d63d-f174-464e-979e-b69bd2a011a2">2028-05-31</lyra:WarrantsAndRightsIssuedMaturityDate>
    <lyra:ClassOfWarrantOrRightExercised
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="INF"
      id="F_85314e7c-2f63-4a02-a7b1-d3d9f74dbc4f"
      unitRef="U_shares">1651423</lyra:ClassOfWarrantOrRightExercised>
    <lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="3"
      id="F_499faba6-4ad5-4ca1-8272-fc753a1ac576"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <lyra:ClassOfWarrantOrRightCancelled
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="INF"
      id="F_c04e77ed-b4e2-496f-88ee-f2c3a26a2053"
      unitRef="U_shares">416</lyra:ClassOfWarrantOrRightCancelled>
    <lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled
      contextRef="C_b9710e1e-df0a-491d-918a-4327c625d8b9"
      decimals="3"
      id="F_8463ddca-152b-493a-a3b3-6a2534c80458"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af"
      decimals="INF"
      id="F_cc22ee4d-377b-4d7a-b47c-e2a213f20f7a"
      unitRef="U_shares">10030575</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af"
      decimals="3"
      id="F_a104de7f-3970-4f2e-ab67-568a8cca01bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.673</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af"
      id="F_1db8a4bd-78a6-41fa-a9ef-a6812e14897b">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af"
      decimals="-3"
      id="F_6ae43459-7ea3-49e0-95ec-1a5c903daec7"
      unitRef="U_USD">25700000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_c83cc782-1381-485a-9d57-319e02ec88af"
      id="F_3a6ccd82-c86b-47c2-bcfd-d5df296c9ad8">2028-11-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926"
      decimals="INF"
      id="F_ba65fb82-36c7-40b6-8d7e-e0a3ccde7b6a"
      unitRef="U_shares">5756349</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926"
      decimals="3"
      id="F_2078cf41-fa39-499a-aa5a-65866a58ed49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926"
      id="F_6fc339ce-5ba6-4bb2-9ec0-85b4eb424633">P3Y11M1D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_45156f90-0a3a-42c8-9a1d-54c60279f926"
      decimals="-3"
      id="F_8d90984b-9bfb-4f64-b1c7-2e14aeca0ffc"
      unitRef="U_USD">30200000</us-gaap:WarrantsAndRightsOutstanding>
    <lyra:ClassOfWarrantOrRightExercised
      contextRef="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72"
      decimals="INF"
      id="F_a2eb5ece-7e01-47e4-83f6-810d550d0960"
      unitRef="U_shares">1424272</lyra:ClassOfWarrantOrRightExercised>
    <lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72"
      decimals="3"
      id="F_120d7b0b-2a1e-444c-b61d-7c27e5534532"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.673</lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <lyra:WarrantsAndRightsExercisedIntrinsicValue
      contextRef="C_4aa1b1e6-9ac9-4530-b490-263e4c8d5b72"
      decimals="-3"
      id="F_f4324e1d-a181-4eed-b0b3-bd2d0a3dcd30"
      unitRef="U_USD">4297000</lyra:WarrantsAndRightsExercisedIntrinsicValue>
    <lyra:ClassOfWarrantOrRightExercised
      contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65"
      decimals="INF"
      id="F_9678911c-c682-4c30-bf7d-ad9b4fcdd83a"
      unitRef="U_shares">5756349</lyra:ClassOfWarrantOrRightExercised>
    <lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65"
      decimals="3"
      id="F_98a2b954-8099-44b1-add8-05934a50a5af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</lyra:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <lyra:WarrantsAndRightsExercisedIntrinsicValue
      contextRef="C_def1fd73-fa5d-4a76-865c-950530caac65"
      decimals="-3"
      id="F_f4595640-e085-4c73-b3aa-f0ae9afe0548"
      unitRef="U_USD">9715000</lyra:WarrantsAndRightsExercisedIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc"
      decimals="INF"
      id="F_1945060f-fc7c-422f-bd8a-eab50929824f"
      unitRef="U_shares">8606303</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc"
      decimals="3"
      id="F_92d10ea4-7362-46da-bf11-0bd7f30cdc6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.673</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc"
      id="F_88906caf-bbc8-4896-961f-506e3819b2b8">P3Y11M1D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_763123a3-30dd-4427-b10e-b4e51ac7debc"
      id="F_cfa7b3f2-8298-4738-8df3-49d44fec948b">2028-11-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_ed44678f-ad22-4231-9ff8-c160ba90f7de">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company currently grants equity-based awards under its 2020 Incentive Award Plan (&#x201c;2020 Plan&#x201d;) and the 2022 Employment Inducement Award Plan (&#x201c;Inducement Award Plan&#x201d;). The Company previously granted equity-based awards under its 2005 Equity Incentive Plan (&#x201c;2005 Plan&#x201d;) and 2016 Equity Incentive Plan ("2016 Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiary.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The initial number of shares of the Company&#x2019;s common stock that may be issued under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares plus the number of shares of the Company&#x2019;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#x2019;s Board of Directors. However, no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,800,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. On January 1, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the shares available for grant under the 2020 Plan was automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273,106&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On January 1, 2024, the shares available for grant under the 2020 Plan was automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,288,582&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;696,925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for issuance under the 2020 Plan. On January 1, 2025, the shares available for grant under the 2020 Plan was automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,620,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2022, the Company&#x2019;s Board of Directors adopted the Inducement Award Plan (and together with the 2020 Plan, 2016 Plan and 2005 Plan, the &#x201c;Plans&#x201d;), which was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#x201c;Rule 5635(c)(4)&#x201d;), and currently allows for the granting of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the Company's common stock. The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, performance units, restricted stock awards, restricted stock units and stock grants. In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#x2019;s entering into employment with the Company or its subsidiary. In June 2022, the Inducement Award Plan was amended to&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;increase &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the shares authorized for issuance thereunder to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,473,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and amended again in the same month to increase the shares authorized for issuance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,703,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In September 2022, the Inducement Award Plan was amended to increase the shares authorized for issuance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,813,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. On December 9, 2022, the Inducement Award Plan was amended and restated to increase the shares authorized for issuance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,413,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. The amended and restated Inducement Award Plan was amended in October 2023 to add another &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares to the shares authorized for issuance, for a current overall limit of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,763,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. During the year-ended December 31, 2024, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t grant options to purchase shares of common stock to executives under the amended and restated Inducement Award Plan, and during the year-ended December 31, 2023 the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;630,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares under this plan. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remaining available for issuance under the Inducement Award Plan as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All stock option grants are nonqualified stock options except for option grants to employees granted, under the 2020 Plan, 2016 Plan or 2005 Plan intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted under the 2020 Plan at less than the fair market value of the Company&#x2019;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024 &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock-based compensation expense was recorded to liabilities. For the year ended December 31, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the stock-based compensation expense was recorded to liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,648,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock that vest as to one-third of options, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to continued service on each applicable vesting date and certain exceptions in the context of a change in control transaction. The Company has accounted for these awards as market-based condition awards and therefore, stock-based compensation recorded during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;550,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share to its Chief Executive Officer (&#x201c;2024 Performance Options&#x201d;) and granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs to its Executive Chair (&#x201c;2024 PSUs&#x201d;), each with performance-based vesting conditions under the 2020 Plan. Vesting of the 2024 Performance Options and the 2024 PSUs are based on the achievement of various clinical and regulatory milestones during the specified periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the 2024 PSUs, the Company measures stock compensation expense based on the fair value of the award on the grant date and then once the Company determines the performance criteria is probable of achievement, recognizes such amount over the vesting term of the award, which is approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. The Company determined the fair value of the 2024 Performance Option using the Black-Scholes option-pricing model and using the following inputs: risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, expected dividend yield &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and expected term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the restricted stock unit activity, including 2024 PSUs, under the Plans for the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,332,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,143,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s unrecognized stock-based compensation as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrecognized Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Period of Recognition&lt;br/&gt;(years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to certain executive officers with market-performance grants, with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the stock option activity, including incentive options, under the Plans for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,709,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,605,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,999,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,822,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December 31, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024 and 2023 was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2020, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company initially reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock for issuance under the 2020 ESPP. In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#x2019;s Board of Directors, provided that no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock may be issued under the 2020 ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 1, 2023, the shares available for grant under the 2020 ESPP was automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159,138&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On January 1, 2024, the shares available for grant under the 2020 ESPP was automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;286,072&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. The purchase price of the shares, in the absence of a contrary designation, will be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the purchase date. In June 2024 the Company indefinitely suspended the offering of its 2020 ESPP. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been issued under the 2020 ESPP. As of December 31, 2024, there are a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;723,906&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for issuance under the 2020 ESPP. On January 1, 2025, the shares available for grant under the 2020 ESPP was automatically increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,594&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_372a66a4-61dd-407b-a6a2-2b15c95d67ae"
      decimals="INF"
      id="F_1dcac838-a101-4be3-9ec3-50d3f1b90be3"
      unitRef="U_shares">2100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear
      contextRef="C_cc81d85d-e11e-47ff-961c-df0bcedd5b2b"
      decimals="2"
      id="F_a0a377fb-1e10-45a0-8e96-95ed02ac2499"
      unitRef="U_pure">0.04</lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_cc81d85d-e11e-47ff-961c-df0bcedd5b2b"
      decimals="INF"
      id="F_02121687-aca4-4115-b3b8-9f95849c8289"
      unitRef="U_shares">8800000</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_ef0c2d84-5760-4d06-a7b6-be126708a7ea"
      decimals="INF"
      id="F_c38e6a29-e5f9-4364-a760-f9855784636c"
      unitRef="U_shares">1273106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_c8d88912-cb32-4c79-b82d-9539702398aa"
      decimals="INF"
      id="F_005814d6-0fef-4051-8983-3c9ab659638f"
      unitRef="U_shares">2288582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_feffa18a-b969-4f5f-82cd-f03ad737e8a5"
      decimals="INF"
      id="F_671847d3-82f4-47ca-b778-1f925e051447"
      unitRef="U_shares">696925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_3a371107-2d9a-4f5c-8c37-b98e3086c62c"
      decimals="INF"
      id="F_2e5d2abd-8868-4d06-8a1a-29a643ad768d"
      unitRef="U_shares">2620600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b5cd3428-6f7e-489b-acb9-7fc886586ef5"
      decimals="INF"
      id="F_9163f9a9-e963-49c8-8cc7-d33891b16e79"
      unitRef="U_shares">2763002</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_9b8e7f3e-8fcd-405a-b6ca-6a57fd5e4161"
      decimals="INF"
      id="F_65b7e5af-7dd7-4315-b1cc-6f3984328a9c"
      unitRef="U_shares">1473002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0e5ac7b0-8d8f-42a9-ae36-22c91da28b12"
      decimals="INF"
      id="F_8a4ffa2b-7605-45e0-abee-fbe08b709f62"
      unitRef="U_shares">1703002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_aa987057-5b50-4f91-90e6-77882dbd1aa3"
      decimals="INF"
      id="F_876b7507-9098-4135-871b-bd7eb73cc97f"
      unitRef="U_shares">1813002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_114bbe38-9e67-4a2b-8b86-6fa6b5de33e6"
      decimals="INF"
      id="F_5bc296fe-5cb5-4837-8c82-41fd68ebce27"
      unitRef="U_shares">2413002</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_4d2b77e5-3c41-49f6-87a3-e99ca4394a5f"
      decimals="INF"
      id="F_9d39c572-513c-496e-a4b4-6cf4cb912722"
      unitRef="U_shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_67686643-4752-4ca8-a5d1-4b5b2a07cb16"
      decimals="INF"
      id="F_5a3a2886-8e16-4b88-b905-5a9df3166489"
      unitRef="U_shares">2763002</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_bed6c948-c9d7-4d57-84ac-6b989ca8e7ce"
      decimals="INF"
      id="F_2f1285eb-6732-42d3-8348-4a3da7b0d585"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_61c081e9-803b-4a01-830c-fe9cae97644d"
      decimals="INF"
      id="F_96b05ce4-186e-4366-bd71-08b0a6cb5fe2"
      unitRef="U_shares">630000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_a98e409f-d6f8-4b16-b04c-f09c481c5882"
      decimals="INF"
      id="F_86997916-aa4d-45d7-ae4d-6d34daafcc8b"
      unitRef="U_shares">863000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_37068379-d31d-4d98-a4d1-2e6f4f1ef031"
      id="F_88d7ff6c-b61c-4e67-ad71-bd74341c7261">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_1cdb38d7-d16f-4ad8-9875-be4af848c0cf"
      id="F_7e7fd3bb-7061-4bdc-924f-3eb8aa4e8ae6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_dbbb8ad7-2fa8-4daa-a115-2f2fd234a8cb">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_00ea0f69-39f1-4cdd-88c1-1015ba40c9e8"
      decimals="-3"
      id="F_9e57dc29-a7ff-48f8-aee2-1c4eb4fae63c"
      unitRef="U_USD">1360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1b70f3eb-a7d2-4546-8d83-3cc0e6a2bdef"
      decimals="-3"
      id="F_501dab1f-499d-411f-b80d-7942a46616b8"
      unitRef="U_USD">1176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e2a3c196-b3fe-487a-9820-f84bfac368b0"
      decimals="-3"
      id="F_8578f012-c6bc-4e7c-b7a9-71b62f597ccb"
      unitRef="U_USD">5356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_10cb439a-3f2a-42fe-9173-724723bcd311"
      decimals="-3"
      id="F_f7878e84-3942-4772-b34f-9a241c88acf3"
      unitRef="U_USD">4711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_792bb737-25da-4fbd-8067-f964fa3117c9"
      unitRef="U_USD">6716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_bdf76943-4ba3-4452-9b05-204c9c267835"
      unitRef="U_USD">5887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_6ecc68af-e52f-4e4d-a8f7-2e83acb90bfe"
      unitRef="U_USD">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="0"
      id="F_ac5ba610-c5c1-49d8-90b4-f0cc063df9b5"
      unitRef="U_USD">255000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_788a6a79-f3bb-44f9-a6a5-ec8d29c9b846"
      decimals="0"
      id="F_7bd3e98f-8214-4ccc-8d73-1d0bf6c8b473"
      unitRef="U_shares">1648002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_788a6a79-f3bb-44f9-a6a5-ec8d29c9b846"
      decimals="-5"
      id="F_00f25969-d911-4615-9280-9cc6e4a5c384"
      unitRef="U_USD">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_78cb6b9c-1c43-4ef8-965e-5c3e825546d6"
      decimals="INF"
      id="F_8489bb54-2d3b-4c6e-a34e-5e5e6b216806"
      unitRef="U_shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_78cb6b9c-1c43-4ef8-965e-5c3e825546d6"
      decimals="2"
      id="F_74ad33a3-861e-49c2-b102-88718bc9efe6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_db5a6c2b-f92c-47a4-ab60-53c0ab05b473"
      decimals="INF"
      id="F_0b0cd2e6-a7eb-4b09-9871-8d8b52fde5da"
      unitRef="U_shares">385000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_fa285bde-8794-43cc-8482-2a6c0a625a7c"
      id="F_41dcba3c-9d47-4dda-a8e0-a9f0fc7637fb">P3Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4"
      decimals="4"
      id="F_7be7fd81-7f55-4d54-97b3-db6801261929"
      unitRef="U_pure">0.0426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4"
      decimals="4"
      id="F_f182d2b0-0ff3-4662-8bf1-d85e2b269637"
      unitRef="U_pure">0.7682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4"
      decimals="2"
      id="F_41090e18-a7d5-4b44-8094-fe3c0c2deb11"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fc24d230-7cd5-40a5-9d33-ea2022a2fdf4"
      id="F_db9f2fa5-cf7a-4f99-847e-8fc0630f2a52">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_a2d1d130-d51d-4e85-bc3a-f8e9bf69503b">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the restricted stock unit activity, including 2024 PSUs, under the Plans for the year ended December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,332,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,143,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_c5ef9b16-bba4-424a-b158-0bdfe7995917"
      unitRef="U_shares">105048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="2"
      id="F_1ef9a8d1-6e26-4ed3-866a-9e2a3f55ffec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_f010b9e3-5e08-4ce9-9c6d-4e0670598909"
      unitRef="U_shares">2332527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_7bc714f3-5f90-418c-ad2e-c2c58effdc14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_20cd2ce1-10ac-4c3e-8b86-0781b04e1836"
      unitRef="U_shares">86574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_5c6f59c4-b7d1-4c5d-8dbb-2c111aaab36c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_16abd4c4-0193-4ca3-9378-f954dc678cbc"
      unitRef="U_shares">207199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_c04a1e02-410e-4e0b-960e-b483d291e68b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_240d2b36-ba34-4e4f-8609-72da6dc79e6b"
      unitRef="U_shares">2143802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="2"
      id="F_6ca55d96-6a99-41aa-821a-a80f569ce2fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_015e8801-7b03-4179-94aa-ebd2a8d9678a">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s unrecognized stock-based compensation as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrecognized Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Period of Recognition&lt;br/&gt;(years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_333d0a42-02ed-432e-82bf-5297563b9a25"
      decimals="-3"
      id="F_96a9c43a-f789-4d50-8a68-b1edb0dcf4e2"
      unitRef="U_USD">2088000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f3bee2ff-cc2b-4188-9e55-bdfb437d68be"
      id="F_e3e661f4-3bfa-466b-a98f-a73ec582cb40">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_37541621-a0f6-46b9-a350-96d677fcfc2a"
      decimals="-3"
      id="F_ac0662c1-a82c-490e-aa4e-1a29a3a9f118"
      unitRef="U_USD">5743000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_eff1908e-cf95-479e-8a29-8ae67fd4d38a"
      id="F_c59adecc-34b8-4c52-b10b-e1967fd1a1ad">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_274a624e-c108-4f08-9b66-07a7763188cd"
      unitRef="U_USD">7831000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_1e07c509-71ad-4877-858e-416743f5b5d8">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to certain executive officers with market-performance grants, with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_0afd267b-0a4a-4931-b5a5-8d25db9f6530"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_08b17025-6b04-48c0-bfa7-531ed0186480"
      unitRef="U_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_55b4cf88-8d55-4508-b2bc-b64a9b31f7d3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      id="F_64983888-bb11-46e0-80e0-cb7fc9844ea4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_7d5abe7d-7434-4efa-9308-3c18314e6573"
      unitRef="U_pure">0.805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_e6d04c62-5171-4847-b190-5e57a163642d"
      unitRef="U_pure">0.827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_d9a4d35f-5782-4300-ae25-488e89fd7dce">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the stock option activity, including incentive options, under the Plans for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,709,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,605,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,999,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,822,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,314,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="INF"
      id="F_ac11134a-0344-4809-abc8-7aca2e334985"
      unitRef="U_shares">5709980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="2"
      id="F_7263ae0c-5da5-49f3-8409-d89c1da582ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      id="F_7f009e4a-50fd-446f-a3ae-452385bdd9ee">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_fd6d5100-65cf-4e4e-b2cb-48fd9602e16f"
      unitRef="U_USD">6334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_8a56d07e-e8a1-442f-9b4a-276b8bdd612a"
      unitRef="U_shares">2605002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_078ca3c1-b2c0-4e0b-a8a0-31cb7d60315d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_baafa410-3bf0-402d-b35a-ba92b152e39a"
      unitRef="U_shares">1002</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_7b51d857-d3eb-4a3d-83cc-0ae7fe39d57c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_8cbf10bb-4525-4f32-a48b-cd3fcc7aae35"
      unitRef="U_shares">1999419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_e40a3cc2-0088-48aa-aa5f-77ac3e8c30cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_1796e06e-fafa-4f6b-b67f-2bb39c4caa10"
      unitRef="U_shares">6314561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="2"
      id="F_da63e027-46be-4933-b459-e563973a63a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_24d794c6-19d5-43e1-9306-9df643e938d3">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_abf60443-2801-417b-99f3-c2e487b79eb2"
      unitRef="U_shares">2822175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="2"
      id="F_8941beac-1795-4b3c-81fb-14e2d4a82c4e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_73d03c9a-4c5b-4c40-a1f4-ce791c1449fd">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_868f18e2-fece-4870-ae05-314516fa78d1"
      unitRef="U_shares">6314561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="2"
      id="F_88aa7676-399e-495f-b78d-ebf742cc9d30"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_8148eaa0-d84d-4ecb-b9a0-4c73311ecf26">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="2"
      id="F_1d206e23-0898-4a67-964a-bb403e3400cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="2"
      id="F_796ddd70-e585-470e-8c47-021fd1115bd4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_bdd8f270-6cd0-4ef9-9a68-32d8af987fb3"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_04b6c08f-8af4-4b77-9783-0a01485be0bf"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_71badc65-a44f-452a-aa75-c16093a3462e"
      decimals="INF"
      id="F_359ed3ac-8b45-4cae-9294-a4d5c4f66fcc"
      unitRef="U_shares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear
      contextRef="C_d72020a2-3023-4259-93b5-fa4a7d8ad386"
      decimals="3"
      id="F_b3b93797-da03-48c6-821e-180239c5662e"
      unitRef="U_pure">0.005</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_d72020a2-3023-4259-93b5-fa4a7d8ad386"
      decimals="INF"
      id="F_b0219e65-3c44-454c-a31f-38a43070d5d3"
      unitRef="U_shares">987500</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_aee49c45-4ce0-46b0-9eab-9386fa9c46b5"
      decimals="INF"
      id="F_9a1259da-0b4b-41a6-9ff7-d62b9dd0c4d9"
      unitRef="U_shares">159138</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_8aa217c6-fd0c-4938-960a-3d90887e55a2"
      decimals="INF"
      id="F_ee5bf5dd-d7df-474d-8a28-3ce7bbe505c5"
      unitRef="U_shares">286072</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock
      contextRef="C_d72020a2-3023-4259-93b5-fa4a7d8ad386"
      decimals="2"
      id="F_70eb1f3f-5b45-480c-a115-49ca118301ee"
      unitRef="U_pure">0.85</lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ac5f170e-0fde-48cb-9c0b-b5694cb0083b"
      decimals="INF"
      id="F_88590010-e9a3-49a9-97e6-8f8842d0dbc6"
      unitRef="U_shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_9eeb8171-b971-4290-a284-8d735eff90bc"
      decimals="INF"
      id="F_934c7b73-3dd4-4f49-a044-066acb8cac4f"
      unitRef="U_shares">723906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_4489b4bf-2198-4ebe-a1bf-695353f66282"
      decimals="INF"
      id="F_4563781a-b4fe-4d9c-9145-fae19a7bfda4"
      unitRef="U_shares">262594</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_f17f9160-9b8f-4608-aeb9-14cede397ffd">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 31, 2021, and as amended on September 26, 2022, the Company entered into the LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the LianBio License Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, the Company will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and the Company will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to the Company&#x2019;s LYR-220 product candidate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;LianBio announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company&#x2019;s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBio&#x2019;s rights under the LianBio License Agreement. In November 2024 we entered into a novation agreement which substituted LianBio Cayman for LianBio HK. For more information, please see &#x201c;Risk Factors &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;If LianBio HK, as defined below, is unable to find a third party to acquire its rights under the LianBio License Agreement, as defined below, it may materially harm our business, financial condition, results of operations and prospects&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 808&#x201d;), which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities, or ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, the Company identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial. The Company determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, the Company determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure (&#x201c;Combined Performance Obligation&#x201d;), and (2) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial (&#x201c;Development Activities Performance Obligation&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Combined Performance Obligation and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Development Activities Performance Obligation. In February 2022, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which was allocated to the two performance obligations as follows: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Combined Performance Obligation and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as all milestone amounts were fully constrained based on the probability of achievement. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022. There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement until March 31, 2023. The amendment did not result in any change in the Company&#x2019;s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company determined that LianBio&#x2019;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#x2019;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#x2019;s consolidated balance sheets and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2022, the Company achieved a development milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for dosing the first patient in the U.S., and the related cash amount was received in April 2022. In accordance with ASC 606, the Company has updated its determination of the transaction price for this previously constrained amount from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;allocated the development milestones to each of the performance obligations previously identified in the agreement in accordance with&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;original revenue allocation percentages, and is recognizing the revenue under the revenue recognition model previously developed for each performance obligation. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reflects the change in the transaction price (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.975%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.916%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Pre-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Post-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.975%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.916%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months. As of December 31, 2024, the parties are not actively engaged in negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milestones achieved during the years ended December 31, 2024 or 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. No royalty revenue has been earned as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company&#x2019;s former directors are Managing Directors at Perceptive Advisors, LLC and one of these former directors is also the Executive Chairman of LianBio&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lyra:UpfrontPaymentReceived
      contextRef="C_47fa54a6-2356-4b08-84c8-0df296adece4"
      decimals="-5"
      id="F_5a5f89da-b096-491c-87bc-fd7b78703bd1"
      unitRef="U_USD">12000000</lyra:UpfrontPaymentReceived>
    <lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization
      contextRef="C_6418a52e-c88f-4b7e-b4d3-3e67f8c4d58d"
      decimals="-5"
      id="F_78504f9a-b9eb-4813-bdea-a180d9fd84f5"
      unitRef="U_USD">135000000</lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization>
    <us-gaap:DeferredRevenueDescription
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_18c6b74d-bd06-45bb-9813-bcf789de6d3e">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, 2024, as all milestone amounts were fully constrained based on the probability of achievement. </us-gaap:DeferredRevenueDescription>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_fb455e7c-310e-4d3f-9d79-4891ad9dd188"
      decimals="-5"
      id="F_a406014a-06a9-4214-8cba-5090ec506f6c"
      unitRef="U_USD">12000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:CombinedPerformanceObligation
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_a0675f21-b01f-44b8-bab9-4b83ee35a4e9"
      unitRef="U_USD">8400000</lyra:CombinedPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_e6b06b79-427c-4b77-a044-1c36bf2d392d"
      unitRef="U_USD">3600000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_1b6f6f65-0092-4f48-84e8-9f5ef718920d"
      decimals="-5"
      id="F_0f3dba8c-c6f5-4718-8eb9-65c655427137"
      unitRef="U_USD">5000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fb525548-f539-4b57-ad61-75d734fd08a5"
      decimals="-5"
      id="F_cc80e123-bb33-4aae-bbfe-03c6ae05cf0e"
      unitRef="U_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lyra:CombinedPerformanceObligation
      contextRef="C_1b6f6f65-0092-4f48-84e8-9f5ef718920d"
      decimals="-5"
      id="F_141e4dee-e1ad-4530-9232-510efef190f5"
      unitRef="U_USD">3500000</lyra:CombinedPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_afa65958-5848-4204-a888-f0ed623910ca"
      decimals="-5"
      id="F_b7c056dc-cc0d-4fa7-890d-a63f99234c34"
      unitRef="U_USD">1500000</lyra:DevelopmentActivitiesPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fb525548-f539-4b57-ad61-75d734fd08a5"
      decimals="-5"
      id="F_e048e1f8-b524-43d2-af17-6f1686f678df"
      unitRef="U_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_ed6610c5-7cef-4bd0-969d-825c8bae251e"
      decimals="-5"
      id="F_55292e8d-69de-4fad-893e-9d179992bb51"
      unitRef="U_USD">12000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_bd367419-34c7-4e6d-83a8-87b37d35c96d"
      decimals="-5"
      id="F_8d2f8243-ed0a-4c30-8a74-60af9019b73a"
      unitRef="U_USD">17000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_677da7e8-31cb-4e4b-811b-6c1ab85310e9">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reflects the change in the transaction price (in thousands):&lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.975%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.916%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Pre-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Post-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock>
    <lyra:CombinedPerformanceObligation
      contextRef="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f"
      decimals="-3"
      id="F_757f1f72-224e-468a-986a-de85c004235e"
      unitRef="U_USD">8373000</lyra:CombinedPerformanceObligation>
    <lyra:CombinedPerformanceObligation
      contextRef="C_afa65958-5848-4204-a888-f0ed623910ca"
      decimals="-3"
      id="F_27dd3fb1-8e34-4670-9a28-dc4cb18cbff4"
      unitRef="U_USD">3489000</lyra:CombinedPerformanceObligation>
    <lyra:CombinedPerformanceObligation
      contextRef="C_e8ac4fa7-d460-485e-ae33-045deec8d365"
      decimals="-3"
      id="F_c1ff8f9d-a0f3-4378-92dd-3b5499412060"
      unitRef="U_USD">11862000</lyra:CombinedPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f"
      decimals="-3"
      id="F_ca171f01-e5f7-4a68-952e-7b19420ef94b"
      unitRef="U_USD">3627000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_afa65958-5848-4204-a888-f0ed623910ca"
      decimals="-3"
      id="F_a943511e-9070-4a50-a8a3-4d4f4ee48c0e"
      unitRef="U_USD">1511000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_e8ac4fa7-d460-485e-ae33-045deec8d365"
      decimals="-3"
      id="F_2b8542c1-c689-4712-8f1d-cf5ba8c6deb4"
      unitRef="U_USD">5138000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_c53f0d72-43ff-4cd2-9777-6352f6bf306f"
      decimals="-3"
      id="F_90cede52-6268-4cb7-9c8e-41114eb1fa8a"
      unitRef="U_USD">12000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_afa65958-5848-4204-a888-f0ed623910ca"
      decimals="-3"
      id="F_e6e2ecd9-c239-4601-b1a1-b63b3cba4fb0"
      unitRef="U_USD">5000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_e8ac4fa7-d460-485e-ae33-045deec8d365"
      decimals="-3"
      id="F_f523232d-4a76-4764-a681-16d61d8ab0ce"
      unitRef="U_USD">17000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_7ae87ce1-ed49-4950-a7bb-ded6d39a2dfa">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.975%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.737%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.299%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.916%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="C_f6b0dc2d-d4c0-4391-b0ee-c716dc85497d"
      decimals="-3"
      id="F_161784dc-b5af-4707-a508-540ce543258f"
      unitRef="U_USD">11748000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_f67b2471-5de2-454c-9767-81619473f71a"
      decimals="-3"
      id="F_8c971d78-7bba-4119-be7c-f697cde0e934"
      unitRef="U_USD">3604000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_194bf10a-3e96-4e60-85a1-7fac540a46ce"
      decimals="-3"
      id="F_63befe6b-cb48-4b95-af7a-985714f5fb98"
      unitRef="U_USD">15352000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_b98307c7-4168-47d7-8b20-2ca01548fdde"
      decimals="-3"
      id="F_e5f468a7-535f-410a-b22e-5b18dbd57df6"
      unitRef="U_USD">1558000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_0e5e03c8-f595-4e11-ac65-ca669fd25609"
      unitRef="U_USD">1558000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue
      contextRef="C_2f8edc3c-5429-4955-94db-7cf00859aeda"
      decimals="-3"
      id="F_c8f98cbc-a342-4ea6-a2e7-99cffc1f93d6"
      unitRef="U_USD">11748000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_d20093d0-99e7-48dd-9fa7-66b19c3ada23"
      decimals="-3"
      id="F_ef57d73f-5384-45de-95d6-cd0fe6d7d5a8"
      unitRef="U_USD">2046000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_f99570b7-816f-4290-aae8-95b74780def1"
      unitRef="U_USD">13794000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_d2768b5c-c610-479e-8af2-6fa1c6059d7b"
      decimals="-3"
      id="F_1e5283a1-2e72-4d66-88b8-959d4903498e"
      unitRef="U_USD">1534000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_41635548-b29f-4f82-a89e-ac3aa468fd00"
      unitRef="U_USD">1534000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue
      contextRef="C_bf0500da-2915-422d-95b0-080c64f50c71"
      decimals="-3"
      id="F_4966f9ad-cc82-4c7a-a84e-833da2d0a687"
      unitRef="U_USD">11748000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0cf2e5c8-0ff5-4308-a0e2-b02e0055df23"
      decimals="-3"
      id="F_b6dbebaa-3173-4394-a495-7f9e5f457560"
      unitRef="U_USD">512000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_6573bdda-52f4-4b59-8d07-0c5ec10f81ea"
      unitRef="U_USD">12260000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_90ccd445-a844-45e9-b76b-f02a4964792a"
      decimals="INF"
      id="F_25511893-ee73-45f8-8b93-daa901ab7b1b"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3468569a-416b-4f26-96d4-911b0ce51a8e"
      decimals="INF"
      id="F_7fcb8461-29c8-41fc-99a2-616d261e80f4"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_454bd050-13f0-461a-81dd-06a7c70a1020">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2024 and 2023, the Company recorded net operating losses of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;62.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record an income tax benefit for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss of Attributes - IRC 382 Ownership Change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.094%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research &amp;amp; experimental expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had U.S. federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which may be able to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;offset future income tax liabilities and expire at various dates through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal net operating loss carryforwards that may be carried forward indefinitely. As a result of the IRC 382 study performed in 2022 the Company wrote off $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of state net operating losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of state research and development credits. The Company updated their IRC 382 study in 2023 given the changes to the Massachusetts apportionment to single sales resulting in a reduced amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, the Company had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which may be available to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;offset future income tax liabilities and expire at various dates through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2044&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company had federal research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, available to reduce future tax liabilities which expire at various dates through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2044. As of December 31, 2024 and 2023, the Company had state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, available to reduce future tax liabilities which expire at various dates through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company had performed an IRC 382 study during 2022 which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. The Company performed an update assessment to our IRC 382 analysis in conjunction with the December 31, 2023 annual audit noting no additional ownership change. For these reasons, in the event the Company experiences a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2024 and 2023 because the Company&#x2019;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, has been established at December 31, 2024 and 2023. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;during the year ended December 31, 2024 due primarily to the generation of net operating losses compared to the increase by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2023 due primarily to an increase in capitalized research and experimental expenditures and an increase in operating lease liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2024 and 2023. The Company&#x2019;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2024 and 2023, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In many cases, the Company&#x2019;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2021. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_4e13f44d-9d1e-4ee1-9cb2-7fbe03748f54"
      unitRef="U_USD">-93400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_31e2fe3b-078b-4f78-aa0d-dc538f2c92a0"
      unitRef="U_USD">-62700000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_776bd276-c2c1-4b3d-bf69-ffc77fd2d52e"
      decimals="INF"
      id="F_7aa07f29-8936-46ab-824c-e2fe1ce47782"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b8f88f49-0e89-489b-92ff-51d33224124a"
      decimals="INF"
      id="F_cc9875c3-b6f5-4095-bd5d-0bda8457c29a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_04a540d8-93fc-4494-af8d-8a300258a36a">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss of Attributes - IRC 382 Ownership Change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_4ef6dd34-d92f-4c99-b5c1-0b2b9304795e"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_2762fe5b-542c-44a4-897b-2494bafd2bee"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_19dcb2d5-4c33-42a4-a69a-57ec7d8c2616"
      unitRef="U_pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_32de7a8f-97d8-4ae4-b915-2862ef1cd380"
      unitRef="U_pure">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_05b799fb-6b85-4915-ac5d-298b80ec5d86"
      unitRef="U_pure">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_e00da095-afee-4e7a-90cb-66a5c8d261b7"
      unitRef="U_pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_6babc708-5bde-403d-8676-40110314c3fd"
      unitRef="U_pure">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_8c379912-a976-4963-8c5f-260c9ef7e1a9"
      unitRef="U_pure">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_fd0691e2-f190-4a4e-b436-d87b36f3d32f"
      unitRef="U_pure">0.266</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_39c8ec8a-a5e3-4346-8474-388cf2a40420"
      unitRef="U_pure">0.31</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_557c173d-e12f-4aa3-af62-a33d3d666df6"
      unitRef="U_pure">-0.003</lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange>
    <lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_34ba4b0d-67f0-47ed-af36-a46d0c725203"
      unitRef="U_pure">0.005</lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="3"
      id="F_bfbe1407-efd6-4fd4-a3aa-81f0129d6d2e"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="3"
      id="F_a4675544-0830-43d6-82bc-6cb090b76cac"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_e89f5d1a-89a1-40da-b4b4-0f762d3b8563">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.094%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research &amp;amp; experimental expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_568595a8-adf5-47c2-8274-2c50e951e152"
      unitRef="U_USD">41333000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_bcc8ddef-ac6c-4499-bad6-5892f7eb4d56"
      unitRef="U_USD">29999000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_c36f665d-ce0e-4201-ad5c-aaab522f4ece"
      unitRef="U_USD">7975000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_5ad206ca-6788-469a-922b-c72cb13627dd"
      unitRef="U_USD">5026000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_627295e1-4f48-43f8-923f-3183ed014aec"
      unitRef="U_USD">1062000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_3e40e833-d5b1-4203-87fb-81638f43924b"
      unitRef="U_USD">1132000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <lyra:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_3357fda8-4222-41e6-8b8e-5b1f0e432f28"
      unitRef="U_USD">9184000</lyra:DeferredTaxAssetsOperatingLeaseLiabilities>
    <lyra:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_2fc78a52-829d-4658-953e-0f1fb32858be"
      unitRef="U_USD">7466000</lyra:DeferredTaxAssetsOperatingLeaseLiabilities>
    <lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_c415e256-a63f-4d42-88c7-25d50a24194a"
      unitRef="U_USD">24975000</lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures>
    <lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_850b951c-7e6e-46e4-9857-50c312b54d85"
      unitRef="U_USD">19036000</lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_11d14317-c244-45ae-9b4c-d03ccda3275b"
      unitRef="U_USD">3234000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_ab76105f-d365-493a-9b97-20ac06359c03"
      unitRef="U_USD">3768000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_9066a12d-b76b-4561-adf6-395c13422356"
      unitRef="U_USD">785000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_b52a1809-5efe-48fe-9ccf-bdd18becf8db"
      unitRef="U_USD">920000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_08120976-98ba-4487-a6b7-d42c9dc8008b"
      unitRef="U_USD">88548000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_f59422da-d202-40e9-9c81-5733fc4dca17"
      unitRef="U_USD">67347000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_61bd3e18-d5be-4609-9195-7b9cbc44b4a7"
      unitRef="U_USD">84810000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_a4219dbc-6a0c-40d6-a9b8-bb6241bf9d2d"
      unitRef="U_USD">59956000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_70ab31ad-76d3-4480-b91f-9c6e2ffab47f"
      unitRef="U_USD">3738000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_9ef92d4c-72f9-4b5f-800b-d93af10cf94f"
      unitRef="U_USD">7391000</us-gaap:DeferredTaxAssetsNet>
    <lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_456f969b-c992-44dd-93f1-430588c2af11"
      unitRef="U_USD">3738000</lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_72a3b256-8fdb-4f39-8c8f-3ddc07bb5ac0"
      unitRef="U_USD">7391000</lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_193989b5-0207-4e1f-88a7-6576718d8dc3"
      unitRef="U_USD">3738000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-3"
      id="F_fae1a246-3a62-4f1a-9b44-8001102028f4"
      unitRef="U_USD">7391000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_1eedc30a-cbfb-49da-8177-e51404827448"
      decimals="-5"
      id="F_fdf361e0-d5de-4f2c-949d-1179b42b23d1"
      unitRef="U_USD">23700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_92a8bd8f-ce57-4c0b-b9ef-52a50d85cf30"
      id="F_867c0b86-c2e8-470a-9450-fa9994d7d8b7">offset future income tax liabilities and expire at various dates through 2037 </us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b279e47d-9fb2-49d6-8595-a8c376f75802"
      decimals="-5"
      id="F_70994e53-b509-4d6e-8798-75570049677f"
      unitRef="U_USD">147800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6cf8ced9-80e4-4607-86de-cb5d54cf5d13"
      decimals="-5"
      id="F_57e257fd-3fc7-49cf-8bde-343620831848"
      unitRef="U_USD">125800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6cf8ced9-80e4-4607-86de-cb5d54cf5d13"
      decimals="-5"
      id="F_566e6904-ca94-4134-bff9-56ec294380ef"
      unitRef="U_USD">2800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_73b2f5f2-5a24-429a-97e0-73eea6990ad7"
      decimals="-5"
      id="F_95d06bb7-4545-45c9-afa6-7bf8f23bb0a1"
      unitRef="U_USD">121200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ed18e4b7-9e3c-4404-ad65-960cbb74cdd5"
      decimals="-5"
      id="F_76eda843-b182-4a06-ae33-b0b1b1b9d845"
      unitRef="U_USD">84200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_878fce79-96fc-484b-9c23-1738cf8a0491"
      id="F_f6c606bb-3daf-47cf-a508-3bca7f8b376e">offset future income tax liabilities and expire at various dates through 2044</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_1eedc30a-cbfb-49da-8177-e51404827448"
      decimals="-5"
      id="F_86b026d5-2349-4847-a3bf-ba071f0db361"
      unitRef="U_USD">6400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_240704ca-648b-4cb8-8da2-42d785c931ba"
      decimals="-5"
      id="F_ee67d311-bec3-45b0-abf3-3fad74fb2e67"
      unitRef="U_USD">4200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ed18e4b7-9e3c-4404-ad65-960cbb74cdd5"
      decimals="-5"
      id="F_c2328807-c495-48bf-ae4b-f39969ead80b"
      unitRef="U_USD">2000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3d311cd5-55b8-42d3-8218-5c0087ca6b10"
      decimals="-5"
      id="F_b2a016ed-b329-43d7-88b5-011ede95dac3"
      unitRef="U_USD">1100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="INF"
      id="F_b8047659-dc9d-404f-ae30-4dbccf47ec7a"
      unitRef="U_USD">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-5"
      id="F_0346fc9a-efb6-479c-bfbc-71f54e77d42f"
      unitRef="U_USD">84800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="-5"
      id="F_8688ff1d-859f-4191-9901-4ff6e015da58"
      unitRef="U_USD">60000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_a24cce7d-0ebb-4bf9-81ea-c7c821e05542"
      unitRef="U_USD">24800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_fcd818e4-9289-49e9-ba16-ec17d2719ee3"
      unitRef="U_USD">-19500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_a225bde0-bee3-4e08-9cf5-c098a3bf2b98">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Watertown Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. The lease includes certain rent escalations. In July 2023, the Company amended the lease to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extend the expiration of the lease term&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from April 2024 to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Under the terms of the amended lease, the Company no longer has the right to terminate the lease after January 1, 2024. The Company has accounted for the amendment as a lease modification and changes to the right of use asset and liability was reflected within the consolidated balance sheets as of December 31, 2023. The impact to the right of use asset as of the lease amendment date was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains a letter of credit of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million securing its obligations under the operating lease which is secured by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Waltham Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2022, the Company executed a lease agreement located at 880 Winter Street in Waltham, Massachusetts. The leased premises comprise approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office and lab space, and the lease provides for base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per year, which will increase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per year over the noncancellable term ending on June 30, 2033. The Company has the option to extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one additional five-year term&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company did not include the option to extend the lease for the additional five-year term in its evaluation of the right-of-use asset and lease liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Upon lease commencement on December 21, 2023, following substantial completion of construction to prepare the premises for the Company&#x2019;s use, the Company recorded the lease as a component of its operating lease right-of-use asset and operating lease liabilities. The improvements to prepare the leased premises for the Company&#x2019;s intended use were funded by (i) the landlord, through a tenant allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and (ii) approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million funded by the Company. The Company recorded a right-of-use asset upon lease commencement in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deposits with the financial institution which is recorded as restricted cash.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; leases for two separate spaces in the same building at 880 Winter Street in Waltham, Massachusetts. The Company refers to the first lease as the &#x201c;Waltham Lease&#x201d; and the second lease arrangement as the &#x201c;Waltham Sublease&#x201d; as the Company, as a tenant, is subleasing space from under an existing lease arrangement whereby the lessee to the headlease has agreed to sublease the space to the Company under a sublease agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Waltham Sublease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Company executed a sublease agreement for additional laboratory and office space located at 880 Winter Street in Waltham, Massachusetts. The subleased premises comprise approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet, and the sublease provides for base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per year, which will increase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per year over the noncancellable term ending on November 30, 2032. The Company is also responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the subleased premises.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon sublease commencement on January 3, 2024, the Company recorded the sublease as a component of its operating lease right-of-use asset and operating lease liabilities. In connection with the sublease, a security deposit was delivered to the sublandlord in the form of an irrevocable standby letter of credit collateralized by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deposits with the financial institution which is recorded as restricted cash.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease cost recorded in the Company&#x2019;s consolidated financial statements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining lease term and discount rate related to the Company&#x2019;s operating leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.174%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.265%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.648%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturity of the Company&#x2019;s operating lease liabilities in accordance with ASC 842 as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total rent expense under the Company's leases amounted to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluated the above leases for impairment indicators and determined that the right-of-use assets were impaired. Additional details are included within Note 7 above.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0a039f52-1a66-4979-9a5e-3989a5131b95"
      id="F_ae3de6b1-0997-48c1-9931-41d54c8919cb">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <lyra:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_8ee2d39b-2034-44ea-b1f5-705ee63ae9c2"
      id="F_6f62ebe9-cce7-43cd-bb70-1bfc731c56cd">2027-04</lyra:LesseeOperatingLeaseExtendedLeaseTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3db95ee5-7b8d-409d-bb0f-d7092ea5f6f0"
      decimals="-5"
      id="F_b518d4f0-0a72-4c78-876d-3fb4eec680dd"
      unitRef="U_USD">4900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:SecuredDebt
      contextRef="C_403a3ca8-bf23-400e-b0db-4d041b2b8b46"
      decimals="-5"
      id="F_e1e74759-f8a9-4e00-857a-127c8fe628ae"
      unitRef="U_USD">300000</us-gaap:SecuredDebt>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_940df23c-7acd-4b4c-a6d5-71d0b545b62d"
      decimals="-5"
      id="F_948e01b4-c593-422e-92e7-4c5c4c3d47b3"
      unitRef="U_USD">300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_8fdbc5a2-8bc0-4cc9-afb3-fd47c4ae421c"
      decimals="INF"
      id="F_c7207173-0575-4381-b68d-e5d6b563ea9c"
      unitRef="U_sqft">29000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_7179b286-9afd-4afa-b79c-9e3a7b080f4b"
      decimals="-5"
      id="F_eef8a256-0a3f-4ef3-ac44-639dd0424b7a"
      unitRef="U_USD">2200000</us-gaap:OperatingLeaseExpense>
    <lyra:PercentageOfAnnualRentIncrement
      contextRef="C_8fdbc5a2-8bc0-4cc9-afb3-fd47c4ae421c"
      decimals="2"
      id="F_30a79ff5-c656-49e1-a126-4361509816d6"
      unitRef="U_pure">0.03</lyra:PercentageOfAnnualRentIncrement>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0a1ce932-422a-495f-ae97-fa5f565abba0"
      id="F_848453b4-6732-4d78-bcc2-56cd070a6de1">one additional five-year term</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_ea185583-d49f-485e-8484-bcaef81144b1"
      decimals="-5"
      id="F_9a9d048c-5d67-40db-b44d-76f1fee45e48"
      unitRef="U_USD">5900000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_2660b123-4ea6-43ac-8972-4157c6a3c040"
      decimals="-5"
      id="F_a0b50057-348a-40ed-9093-cbd939e9b853"
      unitRef="U_USD">8300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8d8c6d11-dc4c-4661-b6b8-cede22d16893"
      decimals="-5"
      id="F_1c242370-537b-49a7-ae67-280cb8ddef4e"
      unitRef="U_USD">27600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e71c57da-121c-464c-96b3-6536e9e26bf6"
      decimals="-5"
      id="F_c8231d45-3b2b-4302-8da2-279a2146603b"
      unitRef="U_USD">1100000</us-gaap:RestrictedCashNoncurrent>
    <lyra:NumberOfLeases
      contextRef="C_5422cf85-ab34-4c8d-83a9-3f689e53bb52"
      decimals="INF"
      id="F_1468a7a6-b6c9-4e6c-a8ee-dbc880c9447a"
      unitRef="U_Lease">2</lyra:NumberOfLeases>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_6c6217df-e212-4852-b745-042bc4d04033"
      decimals="INF"
      id="F_e60b0046-94e1-4edf-9917-c57a6752cdd6"
      unitRef="U_sqft">24000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_a0d4bd0f-380a-404f-bad2-a0ba8fbdde35"
      decimals="-5"
      id="F_0a71a68a-0e19-4755-8072-4c660dafd420"
      unitRef="U_USD">1800000</us-gaap:OperatingLeaseExpense>
    <lyra:PercentageOfAnnualRentIncrement
      contextRef="C_6c6217df-e212-4852-b745-042bc4d04033"
      decimals="2"
      id="F_489eae48-bad0-4835-983f-712ffbf9bb12"
      unitRef="U_pure">0.03</lyra:PercentageOfAnnualRentIncrement>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_8ee3e41f-03f7-4449-99b7-ef89d56d7c11"
      decimals="-5"
      id="F_5b00d793-1e76-49e6-a109-dd38136a8117"
      unitRef="U_USD">600000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_8a0f1ff6-f7cb-4903-a28f-803442454974">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease cost recorded in the Company&#x2019;s consolidated financial statements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.762%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_dc754ff7-321c-432f-8418-26be1cc5290d"
      unitRef="U_USD">6410000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_d5fdf26d-5073-4e0a-bd54-dd10a87b90a2"
      unitRef="U_USD">1966000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_ecb200ae-e134-48d7-9097-f8feafcadbbd"
      unitRef="U_USD">2514000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_2d1e01ef-8591-457f-8ae3-a41bdf71cec7"
      unitRef="U_USD">1202000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-3"
      id="F_1c4884b4-94cf-462a-904b-7d1eabf40068"
      unitRef="U_USD">8924000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-3"
      id="F_c29ed6d8-e4aa-445b-892c-ff8305ff3c98"
      unitRef="U_USD">3168000</us-gaap:LeaseCost>
    <lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_ff0a3092-c559-4d21-868d-b19ba0a1e322">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining lease term and discount rate related to the Company&#x2019;s operating leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.174%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.265%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.648%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      id="F_dfb9a898-afe4-49cc-bc05-1c614eb10547">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="3"
      id="F_27cb38ad-1ed2-42fd-acd2-be42a45ab85b"
      unitRef="U_pure">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      id="F_cb378a50-9ce5-42fd-a2d3-fecce4141d02">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_473aaaff-01e3-4509-bda8-ca01929294c6"
      decimals="3"
      id="F_ba95b972-d3e6-4427-87d8-604bbf5d97fb"
      unitRef="U_pure">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_1873a4af-ebbe-4012-ad4d-82d7afc5c45f">&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturity of the Company&#x2019;s operating lease liabilities in accordance with ASC 842 as of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:24.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_1ccd18cb-50b2-465c-9f4a-0dfe418e8232"
      unitRef="U_USD">6121000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_1f5e96c6-916d-4e2a-9d21-e2db1fbed3a1"
      unitRef="U_USD">6494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_5889010a-2333-4136-a7d3-ece0bc592387"
      unitRef="U_USD">5131000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_015bd54c-df68-48c0-9e79-0c0428d7f807"
      unitRef="U_USD">4507000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_ad365340-6042-4d29-b76a-0d84942228be"
      unitRef="U_USD">4642000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_d8052d86-ddcb-43b2-b20f-c69f17a4c161"
      unitRef="U_USD">16010000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_d5ac45cf-1395-4c7f-bb50-1a137a952ac5"
      unitRef="U_USD">42905000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_1bb7fd69-b862-4ea2-a1c0-8598ae540a59"
      unitRef="U_USD">8525000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_fff89bca-0871-4b74-b5dc-2bb4ee1b207d"
      unitRef="U_USD">34380000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_b86769f2-b870-4f04-b29f-c9b05e16382c"
      unitRef="U_USD">4121000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f60732e7-7b49-4546-becf-89f740a96713"
      decimals="-3"
      id="F_5bf0cecf-af0a-4826-91c3-eae9c47119bd"
      unitRef="U_USD">30259000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_92380d17-67e3-4685-97fb-5bd8905326e3"
      unitRef="U_USD">6400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_9a1dd639-0862-421a-a45f-f2753f607599"
      unitRef="U_USD">2000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_df4e974c-70bb-4f72-a0dc-edca33084f01">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Retirement Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (&#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company made a discretionary match that matches 50%, up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% employee contribution, and therefore a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of employees&#x2019; salary. Matching contributions are fully vested at the time of contribution. The Company matched &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of employee 401(k) contributions for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, which is included in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_a0050c29-a90c-44da-879d-cc0d815aa679"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="INF"
      id="F_18de8fe1-d751-43a8-b792-7b6a8b7b29fd"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="INF"
      id="F_5d540d60-60de-49d8-9316-8e5350fa9157"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="INF"
      id="F_b47847a3-9e81-431e-93f9-42be4d28ad94"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      decimals="-5"
      id="F_7b0886a7-1c4e-4f8e-9cfe-de56e84264a2"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_3c3f8783-297c-4713-bc47-5257e37ccac6"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_987cc757-ac7d-4783-a7e4-89474752d3ef">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;17. Commitment and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 10, 2023, the Company filed a complaint in the Superior Court of the State of Delaware against a former CMO alleging breach of contract. The Company alleged in its complaint that the former CMO breached the Master Clinical Supply Agreement (&#x201c;MCSA&#x201d;). The Company&#x2019;s complaint sought monetary damages and the return of equipment and materials that the Company owned. On July 20, 2023, the same former CMO filed an answer and amended counterclaims to the Company&#x2019;s May 10, 2023 complaint (the &#x201c;Litigation&#x201d;). Due to the legal proceeding and termination of agreement with this manufacturer, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million loss on impairment of long-lived assets during the year-ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 2, 2023, the Company entered into a settlement and release agreement, related to the Litigation, pursuant to which each of the Company and the former CMO provided broad mutual releases of all claims relating to or arising out of the MCSA, including without limitation, all claims brought in the Litigation or that could have been brought in the Litigation. The Company and the former CMO agreed to jointly file a Stipulation of Dismissal with prejudice relating to the Litigation. In the fourth quarter of 2024, the Company paid the remaining liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Stipulation of Dismissal with prejudice to the former CMO.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_4bfffc33-a5bd-4ca2-8d25-66b64169c0cc"
      decimals="-5"
      id="F_6a3bb8ec-47d2-46d1-b47e-c70be8567c54"
      unitRef="U_USD">1600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="C_fcf36a73-5344-415f-b95c-0bbadc656fc2"
      decimals="-5"
      id="F_1fdc135d-b17e-4a9b-b1a8-349e4cc422e4"
      unitRef="U_USD">400000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_40f95a2d-f39f-40de-84f9-da9cf7468367"
      id="F_78ade5ea-4088-4d16-850b-28ab95720b27">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 10, 2025, the Company replaced its letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to its Waltham lease, which is discussed in Note 15, with a new letter of credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8e41f92a-aad6-47ad-8661-51315d4fb579;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 14, 2025, options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,694,590&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an average per share price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, previously granted under the 2020 Stock Option Plan were voluntarily forfeited by certain executives and returned to the pool of options available for grant under the 2020 Stock Option Plan for future issuance. No replacement options were granted to those executives.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCredit
      contextRef="C_a8a81857-3883-412f-b823-244b5789543e"
      decimals="-5"
      id="F_daf4dad9-38c7-427a-9f91-411ba8598758"
      unitRef="U_USD">1100000</us-gaap:LineOfCredit>
    <us-gaap:LinesOfCreditCurrent
      contextRef="C_a8a81857-3883-412f-b823-244b5789543e"
      decimals="-5"
      id="F_3b49e990-492c-4acb-b7ad-576a8b24cd5c"
      unitRef="U_USD">1100000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b7f4b320-3537-4193-801c-2cf634165bb1"
      decimals="INF"
      id="F_8c707d5c-ebe5-4677-ba31-c483a5d3fba8"
      unitRef="U_shares">1694590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_b7f4b320-3537-4193-801c-2cf634165bb1"
      decimals="2"
      id="F_6f4b7fbd-5a3b-4f09-9130-ebb911e60966"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
